[
    {
        "instruction":"已知信息：\n'(2) If the application items are not within the scope of authority of drug regulatory department in accordance with the law, the relevant department shall make a decision of non-acceptance, issue a notification of non-acceptance, and inform the applicant to resubmit the application to the applicable administrative authority；'可被翻译为：（二）申请事项依法不属于药品监督管理部门职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；\n'Article 53 Where the applicant has an objection to the disapproval decision of the food and drug regulatory department, and has applied for an administrative reconsideration or administrative litigation, the food and drug regulatory department shall not accept its re-evaluation application.'可被翻译为：第五十三条 申请人对食品药品监督管理部门作出的不予注册的决定有异议，且已申请行政复议或者提起行政诉讼的，食品药品监督管理部门不受理其复审申请。\n'Article 44 Where the applicant has an objection to the disapproval decision of the food and drug regulatory department, and has applied for an administrative reconsideration or administrative litigation, the food and drug regulatory department shall not accept its re-evaluation application.'可被翻译为：第四十四条 申请人对食品药品监督管理部门作出的不予注册的决定有异议，且已申请行政复议或者提起行政诉讼的，食品药品监督管理部门不受理其复审申请。\n'Article 123 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers, and issue a acceptance notice of drug re-registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug re-registration application if requirements are not met.'可被翻译为：第一百二十三条 省、自治区、直辖市药品监督管理部门对申报资料进行审查，符合要求的，出具药品再注册申请受理通知书；不符合要求的，出具药品再注册申请不予受理通知书，并说明理由。\n\n根据上述已知信息，请将'Article 155 The written non-acceptance or unapproval decision made by drug regulatory departments by law shall provide the reasons thereof, and inform the applicant of the right to apply for administrative reconsideration or to bring an administrative suit by law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十五条 药品监督管理部门依法作出不予受理或者不予批准的书面决定，应当说明理由，并告知申请人享有依法提请行政复议或者提起行政诉讼的权利。"
    },
    {
        "instruction":"已知信息：\n'Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'可被翻译为：按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。\n'Article 48 For a in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'可被翻译为：第四十八条 对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，食品药品监督管理部门可以在批准该体外诊断试剂注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。\n'The production of samples for registration testing shall comply with relevant requirements of quality management system for medical devices. Clinical trials or registration application can be carried out only after the products passed the registration testing.'可被翻译为：注册检验样品的生产应当符合医疗器械质量管理体系的相关要求，注册检验合格的方可进行临床试验或者申请注册。\n'Article 23 When applying for class II and class III in-vitro diagnostic reagent registration, registration testing shall be conducted, and class III products shall conduct registration testing on samples in three continuous manufacture batches. The medical device testing institutions shall carry out relevant registration testing on the products in accordance with the product technical requirements.'可被翻译为：第二十三条 申请第二类、第三类体外诊断试剂注册，应当进行注册检验；第三类产品应当进行连续3个生产批次样品的注册检验。医疗器械检验机构应当依据产品技术要求对相关产品进行检验。\n\n根据上述已知信息，请将'Where applying for registration of a in-vitro diagnostic reagent subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品不得委托其他企业生产。"
    },
    {
        "instruction":"已知信息：\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'Article 42 If a medical device distributor finds that the medical devices involved in its distribution activities do not conform to mandatory standards, or to registered or filed technical specifications for the products, or have other defects, it shall suspend the distribution immediately, notify the registrant, filing entity and other relevant units of the medical devices, and record the conditions of distribution suspension and notification. If the registrant and filing entity of the medical devices deem that the products need to be recalled, recalls shall be performed immediately.'可被翻译为：第四十二条  医疗器械经营企业发现其经营的医疗器械不符合强制性标准、经注册或者备案的产品技术要求，或者存在其他缺陷的，应当立即停止经营，通知医疗器械注册人、备案人等有关单位，并记录停止经营和通知情况。医疗器械注册人、备案人认为需要召回的，应当立即召回。\n'Article 11 The medical device manufacturers shall, in a timely manner, report the collected information on adverse events of medical devices to the food and drug regulatory department in accordance with regulations, and the food and drug regulatory department may analyze and investigate the adverse events or possible defects of medical devices; the medical device manufacturers, distributors and using units shall provide cooperation.'可被翻译为：第十一条 医疗器械生产企业应当按照规定及时将收集的医疗器械不良事件信息向食品药品监督管理部门报告，食品药品监督管理部门可以对医疗器械不良事件或者可能存在的缺陷进行分析和调查，医疗器械生产企业、经营企业、使用单位应当予以配合。\n'Article 43 If a Class III medical device distributor has been suspended the distribution for more than one year, before resuming distribution, it shall make necessary verification and validation, and report to the local department in charge of drug supervision and administration at the level of a city divided into districts in writing. If the quality and safety might be influenced, the drug regulatory departments may organize inspection as needed.'可被翻译为：第四十三条  第三类医疗器械经营企业停业一年以上，恢复经营前，应当进行必要的验证和确认，并书面报告所在地设区的市级负责药品监督管理的部门。可能影响质量安全的，药品监督管理部门可以根据需要组织核查。\n\n根据上述已知信息，请将'Article 7 Upon finding that the medical device it sells and uses may be a detective product, the medical device distributor or using unit shall immediately suspend the sale or use of the medical device, notify the medical device manufacturer or supplier in a timely manner, and report the findings to the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where it is located; if the using unit is a medical institution, it shall also report the findings to the health administration department of the province, autonomous region, or municipality directly under the Central Government where it is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七条 医疗器械经营企业、使用单位发现其经营、使用的医疗器械可能为缺陷产品的，应当立即暂停销售或者使用该医疗器械，及时通知医疗器械生产企业或者供货商，并向所在地省、自治区、直辖市食品药品监督管理部门报告；使用单位为医疗机构的，还应当同时向所在地省、自治区、直辖市卫生行政部门报告。"
    },
    {
        "instruction":"已知信息：\n'A method of treating human diseases by using preparations made from extracts of the internal organs or tissues of certain animals.'可被翻译为：应用某些动物的内脏或组织器官提取物制成的制剂来防治人体疾病的方法。\n'A treatment that eliminates the primary disease-causing agent is a type of drug therapy.'可被翻译为：消除原发致病因子的治疗，是药物治疗作用的一种类型。\n'A method of calculating and providing an analysis of the costs and health outcomes of alternative medical interventions.'可被翻译为：计算并给出可供选择的医疗干预措施的成本和健康结果的分析方法。\n'Drugs developed in modern times that are screened and determined by the theories and methods of modern medicine and applied in accordance with the guidance of modern medical theories. Compared with traditional medicine.'可被翻译为：近代发展起来的用现代医学的理论和方法筛选确定，并按照现代医学理论指导应用的药物。相对于传统药物而言。\n\n根据上述已知信息，请将'A method of treating a disease, such as by directly combating or removing the cause of the disease itself. Is the theory and treatment method used in Western medicine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对造成疾病本身的原因直接对抗、移除等治疗疾病的方法。是西医所使用的理论和治疗方法。"
    },
    {
        "instruction":"已知信息：\n'I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test.'可被翻译为：一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。\n'For an in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, which requires cases number reduction or clinical trial exempt, the applicant shall apply for trial exempt and provide detailed reasons while submitting the application materials. The technical evaluation institution of food and drug regulatory departments shall perform comprehensive technical evaluation to the registration application materials, and inform the applicant by notice for supplements or corrections in the case that clinical trial is required.'可被翻译为：用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，要求减少临床试验病例数或者免做临床试验的，申请人应当在提交注册申报资料的同时，提出减免临床试验的申请，并详细说明理由。食品药品监督管理部门技术审评机构对注册申报资料进行全面的技术审评后予以确定，需要补充临床试验的，以补正资料的方式通知申请人。\n'Article 41 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'可被翻译为：第四十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。\n'III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.'可被翻译为：三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。\n\n根据上述已知信息，请将'II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。"
    },
    {
        "instruction":"已知信息：\n'Article 17 The following terms are defined as follows:'可被翻译为：第十七条 本规则下列用语的含义：\n'Article 4 The terms in the Provisions are defined as follows:'可被翻译为：第四条  本办法下列用语的含义：\n'Article 63 Terms used in these Provisions are defined as follows:'可被翻译为：第六十三条 本办法下列用语的含义：\n'Article 3 The terms used in the Rules are defined as follows:'可被翻译为：第三条 本规则有关用语的含义是：\n\n根据上述已知信息，请将'Article 178 The terms in this GSP are defined as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十八条 本规范下列术语的含义是："
    },
    {
        "instruction":"已知信息：\n'Article 53 After CDE notifies the applicant of registration inspection within the prescribed time limit, in principle, CFDI shall terminate the relevant registration inspection task, explain the reasons and basis, and inform the CED in case of the following circumstances.'可被翻译为：第五十三条 药品审评中心在规定时限内通知申请人进行注册核查后，原则上出现以下情形的，核查中心终止相关注册核查任务，说明原因及依据后告知药品审评中心。\n'If the problems found in the on-site inspection will affect the determination of the inspection conclusion, CFDI shall request the applicant in writing to provide feedback on the relevant issues within 20 days. If the problem only needs to be explained, the applicant shall be required in writing to submit dossiers within 5 days. After reviewing the feedback and explanations, CFDI shall inspect and review conclusion. If the applicant fails to submit feedback within the time limit, CFDI shall make the inspection and review conclusion based on the existing registration inspection status.'可被翻译为：认为现场核查发现的问题影响核查结论判定的，核查中心应当书面要求申请人于20日内对相关问题进行反馈，如涉及问题仅需进行解释说明的，书面要求申请人于5日内提交材料。核查中心对反馈及解释说明进行审核后，作出核查审核结论。申请人逾期未予反馈提交的，核查中心基于已有注册核查情况作出核查审核结论。\n'Article 52 If it is necessary to extend the time limit due to the variety characteristics or special circumstances of registration inspection, the applicant shall be informed in writing of the extension of the time limit, and CDE shall be notified, or other relevant professional and technical institutions shall be notified when necessary. The extension time limit shall not exceed one half of the original time limit.'可被翻译为：第五十二条 对于因品种特性或者注册核查工作遇到特殊情况，确需延长时限的，书面告知申请人延长时限，并通知药品审评中心，必要时通知其他相关专业技术机构。延长时限不超过原时限的二分之一。\n'Article 45 The CDE shall notify CFDI and the applicant to conduct registration inspection within 40 days after the acceptance of the drug registration application. In principle, CFDI shall complete the registration inspection and feed back to CDE 40 days before the expiration of the evaluation time limit.'可被翻译为：第四十五条 药品审评中心在药品注册申请受理后40日内通知核查中心和申请人进行注册核查，核查中心原则上在审评时限届满40日前完成注册核查并反馈药品审评中心。\n\n根据上述已知信息，请将'Article 51 The necessary feedback or explanation submitted by the applicant after the on-site inspection, the delay of the on-site inspection by the applicant due to force majeure, and the convening of the expert consultation meeting shall not be included in the time limit. Where relevant circumstances affect the time limit for registration inspection, CFDI shall notify CDE.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 申请人现场核查后进行的必要反馈或者提交解释说明、申请人因不可抗力原因延迟现场核查、召开专家咨询会等时间，不计入时限。相关情况影响注册核查时限的，核查中心应当通知药品审评中心。"
    },
    {
        "instruction":"已知信息：\n'The coordinates of the mass-charge ratio of the molecular ions ([M+H][M-H], [M+Na]+, etc.) and all the fragment ions obtained by the full scan and the relative intensity of their corresponding ion currents. According to the mass spectrometry to determine the structure of the analytical compound, the molecular formula.'可被翻译为：全扫描得到的分子离子([M+H][M-H]、[M+Na]+等)及所有碎片离子的质荷比与其对应的离子流的相对强度的坐标图。根据质谱图来决定解析化合物的结构、分子式。\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n'The main part of the mass spectrometer is to separate the ions formed in the ion source according to the difference of the mass charge ratio, and receive and amplify the weak ion flow signal and send it to the display unit and computer data processing system to obtain the mass spectrum and data of the analyzed sample.'可被翻译为：质谱仪主体组成部分，将离子源中形成的离子按质荷比的差异进行分离并将这些微弱的离子流信号接收并放大后送至显示单元及计算机数据处理系统，得到被分析样品的质谱图及数据。\n'The technique of bombarding the surface of the sample with primary ions to ionize some atoms on the surface of the sample to form secondary ions, and then measuring the mass-charge ratio of the secondary ions ejected from the target by mass spectrometer.'可被翻译为：利用初级离子轰击样品表面，使样品表面的部分原子离子化，形成次级离子，再利用质谱仪测量从靶上射出的次级离子质荷比的技术。\n\n根据上述已知信息，请将'The horizontal coordinate is the mass charge ratio (m\/z), the vertical coordinate is the relative strength of the ion, with the base peak of 100%, after computer processing of mass spectrum rod-like spectrum.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"横坐标是质荷比（m\/z）、纵坐标是离子的相对强度，以基峰为100%、经过计算机处理的质谱棒状谱图。"
    },
    {
        "instruction":"已知信息：\n'· Suitable storage and transport.'可被翻译为：适当的储存和运输。\n'· Adequate premises and space;'可被翻译为：适当的场所和空间；\n'i. Adequacy of equipment design, size, and location'可被翻译为：足够的设备设计、尺寸和位置\n'c. Adequacy of equipment and facility for intended use'可被翻译为：设备和设施是否满足既定用途\n\n根据上述已知信息，请将'(1) equipped with appropriate scale and sufficient capacity reserved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）具备适度规模和足够的产能储备；"
    },
    {
        "instruction":"已知信息：\n'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'可被翻译为：医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'V. Distribution Licensing and Filing Management of Medical Devices'可被翻译为：五、关于医疗器械经营许可、备案管理\n'If the product is not managed as medical device in the country (region) where the applicant or filing entity is registered or the manufacture is carried out, the applicant or filing entity shall provide relevant proof documents, including the permission for distribution of sold product in the country (region) where the applicant or filing entity is registered or the manufacture is carried out.'可被翻译为：申请人或者备案人注册地或者生产地址所在国家（地区）未将该产品作为医疗器械管理的，申请人或者备案人需提供相关证明文件，包括注册地或者生产地址所在国家（地区）准许该产品上市销售的证明文件。\n'Article 14 The Medical Device Distribution License shall be valid for 5 years, and indicated with the license number, enterprise name, unified social credit identifier, legal representative, person in charge of the enterprise, domicile, distribution premises, distribution mode, distribution scope, warehouse address, license issuing department, date of issuance, and valid term, etc.'可被翻译为：第十四条  医疗器械经营许可证有效期为5年，载明许可证编号、企业名称、统一社会信用代码、法定代表人、企业负责人、住所、经营场所、经营方式、经营范围、库房地址、发证部门、发证日期和有效期限等事项。\n\n根据上述已知信息，请将'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'absorbance ratio'可被翻译为：吸光度比值\n'absorbance'可被翻译为：吸光度\n'specific absorbance'可被翻译为：吸光系数\n'The length of the rotatory tube is 1dm, the concentration of the substance solution to be measured is 1g\/ml, and the rotatory power measured under this condition.'可被翻译为：旋光管的长度为1dm,待测物质溶液的浓度为1g\/ml,在此条件下测得的旋光度。\n\n根据上述已知信息，请将'Absorbance when the solution concentration is l%(g\/ml) and the liquid layer thickness is 1cm.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当溶液浓度为l%(g\/ml),液层厚度为1cm时的吸光度。"
    },
    {
        "instruction":"已知信息：\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of cosmetics, the NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品注册与备案工作，国家药监局制定了《化妆品注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of new cosmetic ingredients, the NMPA has developed the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients, which is hereby issued and shall take effect as of May 1,2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品新原料注册与备案工作，国家药监局制定了《化妆品新原料注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n'In order to guide registrants and filing applicants of cosmetics and new raw materials to carry out registration and notification and submit relevant documents in a standardized manner, according to the Regulations for the Supervision and Administration of Cosmetics, Provisions for Registration and Notification of Cosmetics, Provisions for Registration and Notification Dossier of Cosmetics, Provisions for Registration and Notification Dossier of New Cosmetic Raw Materials and other relevant provisions, NMPA has organized to formulate the Technical Guidelines for Submitting Registration and Notification Dossier of Cosmetics (Interim), which was issued on 2021, April 12.'可被翻译为：为指导化妆品和新原料注册人、备案人规范开展注册备案和提交注册备案资料，依据《化妆品监督管理条例》《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》《化妆品新原料注册备案资料管理规定》等相关规定，国家药监局组织制定了《化妆品注册备案资料提交技术指南（试行）》，于2021年4月12日予以发布。\n'The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021.'可被翻译为：《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'To implement the newly revised Regulationson the Supervision and Administration of Cosmetics (hereinafter referred to as the Regulations), reinforce the administration of cosmetics registration and notification, protect consumers' health rights, and standardize and promote the healthy development of the cosmetics industry, the NMPA drafted the Provisions for Registration and Notification of Cosmetics (hereinafter referred to as the Provisions).The Provisions has been adopted upon deliberation at the 14th Executive Meeting of the State Administration of Market Regulation on December 31, 2020, and shall go into effect as of May 1, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实新颁布的《化妆品监督管理条例》（以下简称《条例》），加强化妆品注册和备案管理，保障消费者健康权益，规范和促进化妆品行业健康发展，国家药监局起草了《化妆品注册备案管理办法》（以下简称《办法》）。2020年12月31日，国家市场监督管理总局2020年第14次局务会议审议通过《办法》，自2021年5月1日起实施。"
    },
    {
        "instruction":"已知信息：\n'repeat donor'可被翻译为：重复捐赠\n'A test in which the drug is re-administered, usually accidentally or intentionally, to see if the same adverse reaction occurs again.'可被翻译为：通常是偶然或有意地再次用药，以观察是否再次出现同样不良反应的试验。\n'An additional evaluation of a previously assayed sample. Also referred to as Repeat Analysis.'可被翻译为：对之前分析过的样品进行的额外评估。也称为重复分析。\n'An aseptic process should be subject to a repeat of the initial validation when:'可被翻译为：在下列情况下，无菌工艺应重复进行初始验证：\n\n根据上述已知信息，请将'A donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在筛选试验中发现具有反应性，使用相同的方法进行两次重新测试，并且至少有一次重复测试也是具有反应性的，则认为捐赠具有重复反应性。"
    },
    {
        "instruction":"已知信息：\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration department is located shall be adopted for domestic class II medical devices.'可被翻译为：境内第二类医疗器械为注册审批部门所在地省、自治区、直辖市简称；\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government combines the abbreviation of city divided into districts where filing department is located (if there is no corresponding city divided into districts, only use the abbreviation of province, autonomous region or municipality directly under the central government) shall be adopted for domestic class I in-vitro diagnostic reagent.'可被翻译为：境内第一类体外诊断试剂为备案部门所在地省、自治区、直辖市简称加所在地设区的市级行政区域的简称（无相应设区的市级行政区域时，仅为省、自治区、直辖市的简称）；\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government combines the abbreviation of city divided into districts where filing department is located (if there is no corresponding city divided into districts, only use the abbreviation of province, autonomous region or municipality directly under the central government) shall be adopted for domestic class I medical device.'可被翻译为：境内第一类医疗器械为备案部门所在地省、自治区、直辖市简称加所在地设区的市级行政区域的简称（无相应设区的市级行政区域时，仅为省、自治区、直辖市的简称）；\n'Class II in-vitro diagnostic reagents shall be reviewed by the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government, and the medical device registration certificate shall be issued after approval.'可被翻译为：境内第二类体外诊断试剂由省、自治区、直辖市食品药品监督管理部门审查，批准后发给医疗器械注册证。\n\n根据上述已知信息，请将'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration authority is located shall be adopted for domestic class II in-vitro diagnostic reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"境内第二类体外诊断试剂为注册审批部门所在地省、自治区、直辖市简称；"
    },
    {
        "instruction":"已知信息：\n'Article 35 After receiving the application for medical device clinical trial, the ethics committee shall hold a meeting to review and discuss it, issue written opinions affixed with the seal, and attach the list of attendants, specialties and their own signatures. The comments of the ethics committee may be:'可被翻译为：第三十五条 伦理委员会接到医疗器械临床试验的申请后应当召开会议，审阅讨论，签发书面意见、盖章，并附出席会议的人员名单、专业以及本人签名。伦理委员会的意见可以是：\n'The ethics committee refers to the independent institution which is set up by the clinical trial institution to examine the scientific and ethical nature of medical device clinical trial projects.'可被翻译为：伦理委员会，是指临床试验机构设置的对医疗器械临床试验项目的科学性和伦理性进行审查的独立的机构。\n'Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:'可被翻译为：第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：\n'Before the clinical trial institutions start the trial, the ethics committee of the leading unit shall be responsible for reviewing the trial protocol to ensure it is ethically rational and scientific. On the premise of accepting the review opinions of the ethics committee of the leading unit, the ethics committees of each clinical trial institutions participating in the trail can review the feasibility of the trial to be carried out in their own institution by meeting review or document review, including the qualification and experience of the investigators, equipment and conditions. Under normal circumstances, the ethics committees of clinical trial institutions shall not bring forward modification opinions to the design of the trial protocol, but shall have the right not to approve the trial in their own institution.'可被翻译为：各临床试验机构试验开始前应当由牵头单位伦理委员会负责审查试验方案的伦理合理性和科学性，参加试验的其他临床试验机构伦理委员会在接受牵头单位伦理委员会审查意见的前提下，可以采用会议审查或者文件审查的方式，审查该项试验在本临床试验机构的可行性，包括研究者的资格与经验、设备与条件等，一般情况下不再对试验方案设计提出修改意见，但是有权不批准在其临床试验机构进行试验。\n\n根据上述已知信息，请将'Article 30 The ethics committee of the medical device clinical trial institution shall consist of at least five members, including medical professionals and non-medical professionals, covering different sexes. In the non-medical professionals, at least one is a legal professional and one is independent of the clinical trial institution. The members of the ethics committee shall have the qualification or experience to assess and evaluate the scientific, medical and ethical aspects of the clinical trial. All members shall be familiar with the ethical guidelines and related regulations of medical device clinical trials and follow the articles of the ethics committee.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十条 医疗器械临床试验机构伦理委员会应当至少由5名委员组成，包括医学专业人员、非医学专业人员，其中应当有不同性别的委员。非医学专业委员中至少有1名为法律工作者，1名为该临床试验机构以外的人员。伦理委员会委员应当具有评估和评价该项临床试验的科学、医学和伦理学等方面的资格或者经验。所有委员应当熟悉医疗器械临床试验的伦理准则和相关规定，并遵守伦理委员会的章程。"
    },
    {
        "instruction":"已知信息：\n'Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.'可被翻译为：混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。\n'The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon.'可被翻译为：在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。\n'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'可被翻译为：如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。\n'flocculation'可被翻译为：絮凝\n\n根据上述已知信息，请将'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'Class 2: Modified new drugs that have not been marketed in China or overseas. They refer to drugs that have their structure, dosage form, formulation and process, route of administration and indications optimized on the basis of known active ingredients and have significant clinical advantages.'可被翻译为：2类：境内外均未上市的改良型新药。指在已知活性成份的基础上，对其结构、剂型、处方工艺、给药途径、适应症等进行优化，且具有明显临床优势的药品。\n'(1) Class 1 chemical drugs are innovative drugs that contain new compounds with clear structures and pharmacological effects and have clinical values. Class 2.1 drugs in modified new drugs are not included. New compound preparations containing new compounds with clear structures and pharmacological effects shall be applied in accordance with Class 1 chemical drugs.'可被翻译为：（一）化学药品1类为创新药，应含有新的结构明确的、具有药理作用的化合物，且具有临床价值，不包括改良型新药中2.1类的药品。含有新的结构明确的、具有药理作用的化合物的新复方制剂，应按照化学药品1类申报。\n'(1) Innovative drugs;'可被翻译为：（一）创新药；\n'5.1 Original drugs and modified drugs that have been marketed overseas and are underapplication for being marketed in China. Modified drugs shall have obvious clinical advantages.'可被翻译为：5.1境外上市的原研药品和改良型药品申请在境内上市。改良型药品应具有明显临床优势。\n\n根据上述已知信息，请将'Class 1: Innovative drugs that have not been marketed in China or overseas. They refer to drugs that contain new compounds with clear structures and pharmacological effects, and have clinical values.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1类：境内外均未上市的创新药。指含含有新的结构明确的、具有药理作用的化合物，且具有临床价值的药品。"
    },
    {
        "instruction":"已知信息：\n'Article 271: Operation procedures should be established to define the process of recording, evaluating, investigating, and handling of complaints. The measures for a complaint due to a possible product defect should also be defined. Consideration of the necessity of a recall from the market should be included.'可被翻译为：第二百七十一条 应当建立操作规程，规定投诉登记、评价、调查和处理的程序，并规定因可能的产品缺陷发生投诉时所采取的措施，包括考虑是否有必要从市场召回药品。\n'Article 195: Any deviation from master manufacturing documents or operation procedures should be avoided as far as possible. Once a deviation occurs, operation procedures for deviation handling should be followed.'可被翻译为：第一百九十五条 应当尽可能避免出现任何偏离工艺规程或操作规程的偏差。一旦出现偏差，应当按照偏差处理操作规程执行。\n'Article 228: Operation procedures for release of the materials and products should be respectively established with well defined criteria and responsibilities. Relevant records should be available.'可被翻译为：第二百二十八条 应当分别建立物料和产品批准放行的操作规程，明确批准放行的标准、职责，并有相应的记录。\n'Article 250: Any deviation from manufacturing process, material reconciliation, specifications, testing methods and operation procedures etc. should be recorded, and promptly reported to the person in charge and the quality management department with a clear description. Full investigation for major deviations should be carried out by the quality management department in conjunction with other departments, and a report should be filed. All deviation reports should be reviewed and signed by the designated personnel of the quality management department.'可被翻译为：第二百五十条 任何偏离生产工艺、物料平衡限度、质量标准、检验方法、操作规程等的情况均应当有记录，并立即报告主管人员及质量管理部门，应当有清楚的说明，重大偏差应当由质量管理部门会同其他部门进行彻底调查，并有调查报告。偏差调查报告应当由质量管理部门的指定人员审核并签字。\n\n根据上述已知信息，请将'Article 248: The manufacturer should establish operation procedures for deviation handling, define the reporting, recording, investigation, treatment and corrective actions adopted and all should be recorded accordingly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百四十八条 企业应当建立偏差处理的操作规程，规定偏差的报告、记录、调查、处理以及所采取的纠正措施，并有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'可被翻译为：境外已上市境内未上市药品临床技术要求\n'Notice of CDE of China NMPA on Issuing the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim)'可被翻译为：国家药监局药品监督管理总局关于印发《境外上市未在境内上市化学药品CMC研究评价技术要求(暂行)》的通知\n'The marketing or imitation of overseas marketed drugs is an important means to solve the availability and accessibility of drugs in urgent clinical needs of patients in China. In order to speed up the research& development and marketing processes of such drugs, strengthen the scientific regulation, according to the Provisions for Drug Registration (SAMR Order No.27)and supporting documents thereof, upon the approval by NMPA, CDE issued the Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China , which shall come into force as of the date of issuance.'可被翻译为：境外已上市药品境内上市或仿制，是解决我国患者对临床迫切需求领域药品的可获得性和可及性的重要手段。为加快此类药品研发上市进程，加强科学监管，依据《药品注册管理办法》（总局令第27号）及其配套文件，药审中心组织制定了《境外已上市境内未上市药品临床技术要求》。自发布之日起施行。\n'NMPA Issued the Announcement on the Requirements for Dossiers and Samples for Verification and Inspection of Specifications for Overseas New Drugs Urgently Needed in Clinical Settings'可被翻译为：关于发布临床急需境外新药标准复核检验用资料及样品要求的通告\n\n根据上述已知信息，请将'Center for Drug Evaluation, NMPA issued the Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局药审中心关于发布《境外已上市境内未上市药品临床技术要求》"
    },
    {
        "instruction":"已知信息：\n'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'可被翻译为：确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。\n'A widely accepted method, procedure, or measure used to measure an intervention.'可被翻译为：一种被广泛认可的用来衡量某种干预措施的方法、程序或者测量手段。\n'Statistical methods, such as significance tests and confidence intervals, which can be \ninterpreted in terms of the frequency of certain outcomes occurring in hypothetical \nrepeated realisations of the same experimental situation.'可被翻译为：是指在假设重现相同实验情境时，用某些结局的发生频\n率做出解释的统计方法，例如显著性检验和置信区间。\n'An experimental method of estimating the value of a good or service by asking a subject for their maximum willingness to pay or minimum willingness to receive by assuming a specific scenario and describing possible scenarios. This method is commonly used to measure the monetary interweaving of health outcomes.'可被翻译为：通过假定一个特定的情景和描述可能的情况，来询问受试者的最大支付意愿或最小接收意愿的一种为商品或服务估算价值的试验方法。这种方法常用来测量健康产出的货币交织。\n\n根据上述已知信息，请将'A method used to determine the reliability of an analytical outcome (e.g., cost-effectiveness analysis, decision analysis). The extent to which an important variable (e.g., cost, outcome, probability of an event, etc.) is affected by examining the possible range of variation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用来测定某种分析结果（如成本-效果分析、决策分析）可靠性的方法。通过检验重要变量（如成本、结果、事件的概率等）可能的变化范围来判断对分析结果产生影响的程度。"
    },
    {
        "instruction":"已知信息：\n'A technique for measuring the relationship between mass and temperature of a substance at a programmed temperature.'可被翻译为：在程序控制温度下，测量物质的质量与温度关系的一类技术。\n'A technique for measuring the relationship between the difference in energy lost to the substance to be measured and the reference substance in relation to temperature (or time) at a programmed temperature.'可被翻译为：在程序控制温度下，测量输给待测物质和参比物质之间的能量差与温度（或时间）关系的一种技术。\n'A method of artificially creating low temperatures by applying the principles of thermodynamics.'可被翻译为：应用热力学原理，用人工制造低温的方法。\n'According to the rate of heat release or heat absorption in the process of physical change or chemical change, the study of process dynamics, thermolysis chemistry and chemical dynamics in one branch of physical chemistry.'可被翻译为：根据物理变化或化学变化过程中，放热或吸热速率，研究过程动力学规律、融热化学与化学动力学于一体的物理化学分支学科。\n\n根据上述已知信息，请将'The amount of heat absorbed or emitted per unit mass of a substance by lowering its temperature by 1k or increasing it by 1 ° C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单位质量的某种物质，温度降低1k或升高1℃所吸收或放出的热量。"
    },
    {
        "instruction":"已知信息：\n'(2) Name, address, contacts of registrant or filing entity; for import medical devices, name, address and contacts of the agent shall be also specified.'可被翻译为：（二）注册人或者备案人的名称、住所、联系方式，进口医疗器械还应当载明代理人的名称、住所及联系方式；\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n'Article 45 The registrant, filing entity, and contract manufacturer of medical devices shall conduct annual self-inspection of the operation of its quality management system, and submit self-inspection reports to the drug regulatory department of the place where it is located before the next March 31. The registrant or filing entity of imported medical devices shall entrust its agent to submit self-inspection report to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the agent is located.'可被翻译为：第四十五条  医疗器械注册人、备案人、受托生产企业应当每年对质量管理体系的运行情况进行自查，并于次年3月31日前向所在地药品监督管理部门提交自查报告。进口医疗器械注册人、备案人由其代理人向代理人所在地省、自治区、直辖市药品监督管理部门提交自查报告。\n'Article 35 The registrant or filing entity of medical devices shall establish and implement the procedures for tracing products, to guarantee the traceability of the products. The contract manufacturer shall assist with the registrant and the filing entity in tracing the products.'可被翻译为：第三十五条  医疗器械注册人、备案人应当建立并实施产品追溯制度，保证产品可追溯。受托生产企业应当协助注册人、备案人实施产品追溯。\n\n根据上述已知信息，请将'Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。"
    },
    {
        "instruction":"已知信息：\n'12.20. Information on packaging to be transferred from the SU to the RU should include specifications for a suitable container and closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti- counterfeiting measures.'可被翻译为：准备从SU转给RU的包装信息应该包括有适当的容器和密闭器系统质量标准，以及其它设计、包装、处理或贴标要求和防拆封和防伪及措施信息。\n'12.18. The SU should provide to the RU information on any health, safety and environmental issues associated with the manufacturing processes to be transferred and the implications thereof (e.g. need for gowning or protective clothing).'可被翻译为：SU应该向RU提供所有与即将转移的工艺有关的安环卫资料及相关含义（例如需要更衣或防护服）。\n'12.23. During the transfer process, the RU should identify any differences in facilities, systems and capabilities and discuss these with the SU. The SU should cooperate with the RU to understand the potential impact and satisfactorily address this in order to assure equivalent product quality. based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop the relevant site operating procedures and documentation before the start of routine production.'可被翻译为：在转移过程中，RU应该找出设施、系统和能力方面的所有差异，并与SU进行讨论。SU应该与RU合作，了解潜在影响，并圆满解决这些问题，从而确保产品质量一致。基于从SU处收到的信息，RU应该考虑其自己生产和包装该产品达到所需标准的能力，应在开始常规生产之前建立相关的现场操作程序和文件。\n'A document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.'可被翻译为：一种或一组文件，规定原料及其数量和包装材料，以及生产规定数量的成品所需的程序和注意事项的说明，以及加工说明，包括过程控制。\n\n根据上述已知信息，请将'12.16. The SU should provide the product information including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations to the RU.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU应向RU提供产品信息，包括其定性和定量配方、物理描述、生产方法、中控、检测方法和质量标准、包装部件和参数，以及所有安全和处置注意事项。"
    },
    {
        "instruction":"已知信息：\n'Article 13 Where an unannounced inspection is organized by a higher level food and drug regulatory department, the local food and drug regulatory department may be notified at an appropriate time. The local food and drug regulatory department shall assign personnel to assist the inspection, and they shall follow the arrangements of the inspection team.'可被翻译为：第十三条 上级食品药品监督管理部门组织实施飞行检查的，可以适时通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当派员协助检查，协助检查的人员应当服从检查组的安排。\n'Article 20 Where any of the following circumstances exist, the inspection team shall report promptly to the food and drug regulatory department organizing the unannounced inspection for its timely decisions:'可被翻译为：第二十条 有下列情形之一的，检查组应当立即报组织实施飞行检查的食品药品监督管理部门及时作出决定：\n'Article 10 The inspection team assigned by a food and drug regulatory department shall consist of at least two inspectors, with the lead inspector taking responsibility. The inspectors shall be food and drug administration regulators, inspectors with legally accredited qualification, or other persons authorized for this inspection. Where necessary, the food and drug regulatory departments may invite experts in relevant fields to participate in the unannounced inspection.'可被翻译为：第十条 食品药品监督管理部门派出的检查组应当由2名以上检查人员组成，检查组实行组长负责制。检查人员应当是食品药品行政执法人员、依法取得检查员资格的人员或者取得本次检查授权的其他人员；根据检查工作需要，食品药品监督管理部门可以请相关领域专家参加检查工作。\n'Where an investigation is conducted by an inferior food and drug regulatory department, the food and drug regulatory department organizing the unannounced inspection shall follow, monitor and direct the investigation and sanction.'可被翻译为：由下级食品药品监督管理部门查处的，组织实施飞行检查的食品药品监督管理部门应当跟踪督导查处情况。\n\n根据上述已知信息，请将'Article 14 The food and drug regulatory department organizing the conduction of the unannounced inspection shall strengthen the leadership over the inspection team, timely adjust coping strategies according to the feedback of on-site inspection, initiate the coordination mechanisms when necessary, and assign relevant personnel to inspection sites for coordination and leadership.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 组织实施飞行检查的食品药品监督管理部门应当加强对检查组的指挥，根据现场检查反馈的情况及时调整应对策略，必要时启动协调机制，并可以派相关人员赴现场协调和指挥。"
    },
    {
        "instruction":"已知信息：\n'Article 191: At all times during processing, containers of all materials, intermediate or bulk products, major items of equipment, and where appropriate rooms used should be labeled or otherwise identified with an indication of the product or material being processed, its strength and batch number. Where applicable, this indication should also mention the stage of the manufacturing process.'可被翻译为：第一百九十一条 生产期间使用的所有物料、中间产品或待包装产品的容器及主要设备、必要的操作室应当贴签标识或以其他方式标明生产中的产品或物料名称、规格和批号，如有必要，还应当标明生产工序。\n'Article 192: Labels applied to containers, equipment or facilities should be clear, unambiguous and in the format approved by relevant departments of the manufacturer. In addition to the wording on the labels, different colors may be used to distinguish the status of these items (e.g. quarantined, accepted, rejected, or cleaned.).'可被翻译为：第一百九十二条 容器、设备或设施所用标识应当清晰明了，标识的格式应当经企业相关部门批准。除在标识上使用文字说明外，还可采用不同的颜色区分被标识物的状态（如待验、合格、不合格或已清洁等）。\n'Article 93: Weighing and measuring equipment, gauges, recording and control equipment should be clearly labeled to indicate the calibration validity date.'可被翻译为：第九十三条 衡器、量具、仪表、用于记录和控制的设备以及仪器应当有明显的标识，标明其校准有效期。\n'Article 119: Intermediate and bulk products should be clearly labeled, including at least the following information:'可被翻译为：第一百一十九条 中间产品和待包装产品应当有明确的标识，并至少标明下述内容：\n\n根据上述已知信息，请将'Article 87: Production equipment should be clearly labeled to indicate the equipment reference number and the contents (e.g. product name, strength, batch number, etc.). The equipment without contents should be labeled to indicate its cleaning status.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 生产设备应当有明显的状态标识，标明设备编号和内容物（如名称、规格、批号）；没有内容物的应当标明清洁状态。"
    },
    {
        "instruction":"已知信息：\n'The standard extracting, rinsing and soaking fluid for medical devices is pyrogen-free water. The analytical approach for testing medical devices is covered in USP. If the extraction fluid shows endotoxin interfering results, modification of testing may be necessary depending on the product configuration. Alternate diluents must be verified to not interfere with the endotoxin assay prior to use.'可被翻译为：医疗器械的标准萃取、淋洗和浸泡流体为无热源水。检测医疗器械的分析方法在USP 中写明。如果萃取流体显示出内毒素干扰结果，可能需要根据产品参数设置对检测进行 修改。替代稀释剂在使用前必须确认其不会干扰内毒素分析。\n'Test the sample eluate from the medical device extraction, using the bacterial endotoxins test (BET) assay parameters, procedures, standards, and controls for the gel-clot, kinetic chromogenic or turbidimetric, or endpoint assays, as directed in USP<85> and USP<161>.'可被翻译为：按USP<85>和 USP<161>所示，使用凝胶法、动力学显色或比浊，或终点分析法的 细菌内毒素测试（BET）分析参数、方法、标准和对照样品检测从医疗器械萃取的 样品洗脱液。\n'Question 1: Can FINISHED product units (vials, ampoules, pre-filled syringes, etc.) be \"Pooled\" into a composite and screened for bacterial endotoxin?'可被翻译为：问1：成品单元（西林瓶、安瓿、预充填注射针等）可“混合”至组合中并进行筛 选后执行细菌内毒素检测吗？\n'USP<161> Medical Devices – Bacterial Endotoxin and Pyrogen Tests, Current Version.'可被翻译为：USP<161> 医疗器械—细菌内毒素和热源测试，现行版本\n\n根据上述已知信息，请将'Finished medical devices may also be pooled into a composite sample and assayed for bacterial endotoxins. Testing for medical devices should be conducted using rinsing\/eluting and sampling techniques as described in ISO 10993-1 and ISO 10993-12, as also used for inhibition\/enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"成品组合器械可能亦会合并成组合样品进行细菌内毒素检测。器械的检测应该使用 ISO 10993-1 和 ISO 10993-12所述淋洗\/洗脱和取样技术，这也用于抑制\/增强。"
    },
    {
        "instruction":"已知信息：\n'An emerging discipline that uses chemical tools to study biological systems.'可被翻译为：利用化学工具来研究生物体系的-种新兴学科。\n'A discipline of proteomics that uses natural protein array analysis techniques for structural determination.'可被翻译为：一种应用天然蛋白质阵列分析技术进行结构测定的蛋白质组学学科。\n'combinatorial screening'可被翻译为：组合筛选\n'combinatorial chemistry'可被翻译为：组合化学\n\n根据上述已知信息，请将'A new discipline in the fields of combinatorial genomics, proteomics, combinatorial chemistry and cell screening.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组合基因组学、蛋白质组学、组合化学及细胞筛选等领域的新学科。"
    },
    {
        "instruction":"已知信息：\n'II. From May 1, 2022, electronic registration certificate will be issued to special cosmetics approved of change or renewal of registration.'可被翻译为：二、自2022年5月1日起，特殊化妆品获准注册证变更、延续的，开始发放电子注册证。\n'V. The time for official implementation of electronic registration certificate for cosmetics will be announced separately.'可被翻译为：五、正式实施化妆品电子注册证的时间，另行公告。\n'As of January 1 , 2023 , in case of registration or notification, registration or notification persons shall provide safety related information of all the ingredients in accordance with the Rules. For the cosmetics with registration or notification already completed , registration or notification persons shall supplement safety related information of all the ingredients in the product formula prior to May 1, 2023.'可被翻译为：自2023年1月1日起，注册人备案人申请注册或者进行备案时，应当按照《规定》的要求，提供全部原料的安全相关信息。此前已经取得注册或者完成备案的化妆品，注册人、备案人应当在2023年5月1日前补充提供产品配方中全部原料的安全相关信息。\n'As of January 1, 2022, in case of registration or notification, registration or notification persons shall provide safety-related information of the ingredients with functions of preservative, sunscreen, colorant, hair dye, spot corrector and whitening in accordance with the Rules.'可被翻译为：自2022年1月1日起，注册人备案人申请注册或者进行备案时，应当按照《规定》的要求，提供具有防腐、防晒、着色、染发、祛斑美白功能原料的安全相关信息。\n\n根据上述已知信息，请将'I. From January 1, 2022, electronic registration certificate will be issued to special cosmetics and new cosmetic ingredients with application submitted and approved for registration according to the Provisions for the Registration and Filing of Cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、自2022年1月1日起，按照《化妆品注册备案管理办法》提出申请并获准注册的特殊化妆品和化妆品新原料，开始发放电子注册证。"
    },
    {
        "instruction":"已知信息：\n'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'可被翻译为：（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。\n'Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:'可被翻译为：第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：\n'Article 80 Acceptance inspection records shall be taken for drugs under acceptance inspection, including adopted name, dosage form, strength, approval number, lot number, date of production, expiry date, manufacturer, supplier, quantity of arrival, date of arrival, quantity qualified in acceptance inspection and results of acceptance inspection of drugs, etc. The acceptance inspection personnel shall sign his\/her name and indicate the date on the acceptance inspection record.'可被翻译为：第八十条 验收药品应当做好验收记录，包括药品的通用名称、剂型、规格、批准文号、批号、生产日期、有效期、生产厂商、供货单位、到货数量、到货日期、验收合格数量、验收结果等内容。验收人员应当在验收记录上签署姓名和验收日期。\n'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'可被翻译为：第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。\n\n根据上述已知信息，请将'Article 78 Acceptance inspection personnel shall inspect and check the appearance, package, label, package insert and relevant supporting documents of the sampled drugs one by one; after the acceptance inspection, the intact samples taken shall be put back into the original packaging box, sealed and marked.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十八条 验收人员应当对抽样药品的外观、包装、标签、说明书以及相关的证明文件等逐一进行检查、核对；验收结束后，应当将抽取的完好样品放回原包装箱，加封并标示。"
    },
    {
        "instruction":"已知信息：\n'(13) Free treatment items and other related compensation that the subjects may obtain during the trial.'可被翻译为：（十三）受试者在试验期间可能获得的免费诊疗项目和其他相关补助。\n'(6) Whether the treatment and insurance measures to be given to the subjects who suffer from trial-related injuries and death are sufficient.'可被翻译为：（六）受试者若发生与临床试验相关的伤害或者死亡，给予的治疗和保险措施是否充分。\n'Article 48 The sponsor shall bear the treatment costs and corresponding economic compensation for the subjects who suffer injuries or death related to the clinical trial, except for the damage caused by the fault of the medical institutions and its medical personnel in the diagnosis and treatment activities.'可被翻译为：第四十八条 申办者应当为发生与临床试验相关的伤害或者死亡的受试者承担治疗的费用以及相应的经济补偿，但在诊疗活动中由医疗机构及其医务人员过错造成的损害除外。\n'(12) The subjects may know relevant information of their condition anytime in the trial period;'可被翻译为：（十二）受试者在试验期间可以随时了解与其有关的信息资料；\n\n根据上述已知信息，请将'(11) The subjects may receive treatment and economic compensation for any trial-related injuries.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如发生与试验相关的伤害，受试者可以获得治疗和经济补偿；"
    },
    {
        "instruction":"已知信息：\n'sampling inspector'可被翻译为：抽样检查\n'Person responsible for performing the sampling operations.'可被翻译为：负责执行抽样操作的人。\n'1) Person(s) authorized to take samples;'可被翻译为：1.经授权的取样人；\n'(VIII) Sampling shall be carried out by two or more professionals who have received special training, and the relevant personnel of the entity of which products are sampled must be present.'可被翻译为：（八）抽样应当由受过专门培训的专业人员（二人以上）进行，被抽样单位的有关人员必须在场。\n\n根据上述已知信息，请将'Person responsible for performing the sampling operations. The sampling inspector need not be a qualified analyst. However, everyone called upon to take samples should be trained in the practical aspects of sampling and should have sufficient knowledge of pharmaceutical substances to execute the work effectively and safely. A conscientious approach, with meticulous attention to detail and cleanliness, is essential. The sampling inspector must remain alert to any signs of contamination, deterioration or tampering. Any suspicious signs should be recorded in detail in the sampling record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责执行抽样操作的人员。抽样检验员不必是合格的分析员。然而，每个被要求取样的人都应该接受取样实践方面的培训，并且应该有足够的药物知识来有效和安全地执行工作。认真负责的方法，对细节和清洁的细致关注是必不可少的。抽样检查员必须对任何污染、变质或篡改的迹象保持警惕。任何可疑迹象都应详细记录在抽样记录中。"
    },
    {
        "instruction":"已知信息：\n'(1) Model or specifications;'可被翻译为：（一）型号、规格；\n'reference sample'可被翻译为：参考样品\n'example instance'可被翻译为：示例实例\n'The difference in content, size, shape, and arrangement of a point or line as manifested by an object.'可被翻译为：物体对某一点或直线在内容、大小、形状和排列上所表现出的差异性。\n\n根据上述已知信息，请将'The original type, form, style, or structure, or the typical example, reference, or standard of a class of things.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"泛指原始类型、形式，体例或结构，或代表某类别事物的典型个例、基准物或标准物。"
    },
    {
        "instruction":"已知信息：\n'(I)  Make major mistakes, causing serious consequences;'可被翻译为：（一）发生重大差错、造成严重后果的；\n'(I) makes major mistakes due to its own fault, causing serious consequences;'可被翻译为：（一）因主观原因发生重大差错，造成严重后果的；\n'(3) incompetence in the performance of duties which causes serious adverse effects or serious losses.'可被翻译为：（三）履行职责不力，造成严重不良影响或者重大损失。\n'(4) failing to perform drug supervision and administration duties, resulting in serious adverse impact or serious losses.'可被翻译为：（四）其他不履行药品监督管理职责，造成严重不良影响或者重大损失。\n\n根据上述已知信息，请将'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）履行职责不力，造成严重不良影响或者重大损失；"
    },
    {
        "instruction":"已知信息：\n'Upon receipt of the Report of Testing for Import Drugs, the local drug regulatory department at ports of entry shall promptly take administrative enforcement measures to seize and detain all such drugs, and make an administrative handling decision within 7 days. In the case of applying for verification test, an administrative handling decision must be made within 15 days since the day of issuing the testing report. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：所在地口岸药品监督管理局收到《进口药品检验报告书》后，应当及时采取对全部药品予以查封、扣押的行政强制措施,并在7日内作出行政处理决定。对申请复验的，必须自检验报告书发出之日起15日内作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n'If the drug meets relevant standards based on verification test, the drug regulatory department at ports of entry shall lift the administrative enforcement measures such as seizure and detention, and report the handling situation to the State Food and Drug Administration and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：经复验符合标准规定的，口岸药品监督管理局应当解除查封、扣押的行政强制措施，并将处理情况报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n'Article 29 Where an importer has objections to the testing result, it may, within seven days since the day of receiving such testing result, apply to the original drug control institute of port for a verification test, or directly apply to the National Institute for the Control of Pharmaceutical and Biological Products for a verification test. The verification test of biological products shall be directly applied to the National Institute for the Control of Pharmaceutical and Biological Products.'可被翻译为：第二十九条 进口单位对检验结果有异议的，可以自收到检验结果之日起7日内向原口岸药品检验所申请复验，也可以直接向中国药品生物制品检定所申请复验。生物制品的复验直接向中国药品生物制品检定所申请。\n'The drug control institute of port shall promptly notify the drug regulatory department at ports of entry, and shall, within 10 days after accepting the application for verification test, draw a conclusion on the verification test, notify the drug regulatory department at ports of entry and other drug control institutes of port, and submit it to the State Food and Drug Administration and the National Institute for the Control of Pharmaceutical and Biological Products.'可被翻译为：口岸药品检验所在受理复验申请后，应当及时通知口岸药品监督管理局，并自受理复验之日起10日内，作出复验结论，通知口岸药品监督管理局、其他口岸药品检验所，报国家食品药品监督管理局和中国药品生物制品检定所。\n\n根据上述已知信息，请将'Article 32 Where no application for verification testis submitted within the prescribed time or the drug still fails to meet relevant standards based on the verification test, drug regulatory department at ports of entry shall make an administrative handling decision in accordance with the Drug Administration Law and relevant regulations. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 未在规定时间内提出复验或者经复验仍不符合标准规定的，口岸药品监督管理局应当按照《药品管理法》以及有关规定作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'An investigation to determine the most probable root cause(s).'可被翻译为：进行调查，确定最可能的根本原因。\n'case-control study'可被翻译为：病例对照研究\n'A method of analyzing trial data on the relationship between time and health outcomes, such as death.'可被翻译为：对时间与健康产出（如死亡）之间的关系进行试验数据分析的一种方法。\n'non-interventional clinical study'可被翻译为：非干预性临床研究\n\n根据上述已知信息，请将'A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病"
    },
    {
        "instruction":"已知信息：\n'1) Name of the material or product, dosage form, strength, batch number or shipping batch number, where appropriate, the name of the manufacturer and\/or supplier;'可被翻译为：1.产品或物料的名称、剂型、规格、批号或供货批号，必要时注明供应商和生产商（如不同）的名称或来源；\n'packaging material'可被翻译为：包装材料\n'1. The appearance of the packages;'可被翻译为：（一）包装外观；\n'Article 19    The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.'可被翻译为：第十九条 用于运输、储藏的包装的标签，至少应当注明药品通用名称、规格、贮藏、生产日期、产品批号、有效期、批准文号、生产企业，也可以根据需要注明包装数量、运输注意事项或者其他标记等必要内容。\n\n根据上述已知信息，请将'1. The name of the material on the delivery note and the containers;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）交货单和包装容器上所注物料的名称；"
    },
    {
        "instruction":"已知信息：\n'Drug regulatory department shall supervise and inspect the approved clinical trials.'可被翻译为：药品监督管理部门应当对批准的临床试验进行监督检查。\n'The inspector refers to the person who is selected by the regulatory department to inspect the medical device clinical trial project.'可被翻译为：检查员，是指监管部门选派的对医疗器械临床试验项目进行检查的人员。\n'On-site inspection for drug registration (Drug Clinical Trials) is mainly aimed at evaluating whether the clinical trial execution, data recording and result reporting conform to the trial protocol and relevant regulations of drug clinical trial, verifying the authenticity and consistency of relevant application dossiers, and paying attention to subject protection, by checking and\/or on-site inspection of the original data and documents of the application dossier and clinical trials.'可被翻译为：药品注册现场核查(药物临床试验) 的目的主要是通过对注册申报资料与临床试验的原始记录和文件的核对和\/或实地确证， 评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规， 核实相关申报资料的真实性、一致性，同时关注受试者保护。\n'The on-site inspection of drug clinical trials is mainly to check the registration application dossiers and the original records and documents of clinical trials, evaluate whether the implementation of the trial, data records and result reports comply with the trial protocol and relevant laws and regulations of drug clinical trials, and pay attention to the protection of subjects. If necessary, random sample and test can be conducted on drugs used in clinical trials.'可被翻译为：药物临床试验现场核查主要是核对注册申报资料与临床试验的原始记录和文件，评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规，同时关注受试者保护。必要时可对临床试验用药物进行抽查检验。\n\n根据上述已知信息，请将'The inspection refers to the supervision and administration activities carried out by the regulatory department for inspecting relevant clinical trial documents, facilities, records and other aspects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"检查，是指监管部门对临床试验的有关文件、设施、记录和其他方面进行的监督管理活动。"
    },
    {
        "instruction":"已知信息：\n'(5) an applicant fails to provide supplementary data within the prescribed timeline;'可被翻译为：（五）未能在规定的时限内补充资料的；\n'(VI)  The lot release applicant fails to supplement and correct the dossiers within the prescribed timeline without rational reason;'可被翻译为：（六）批签发申请人无正当理由，未在规定时限内补正资料的；\n'(4) Where the dossier is incomplete or not in compliance with the defined format the applicant shall be informed on-site or within 5 days in a one-time notification of what to be supplemented or corrected. Where the dossier needs to be returned when the applicant is informed as per regulations, the dossier shall be returned. The applicant shall complete the supplementation and correction of the dossier within 30 days. Where the applicant fails to make the supplementation or correction within the specified timeline without justifiable reasons, the application shall be deemed to have been abandoned, and there’s no need to make a decision of rejection. Where the applicant is not informed of the need for supplementation and correction within the timeline, the application shall be regarded as- accepted on the date the dossier is received.'可被翻译为：（四）申报资料不齐全或者不符合法定形式的，应当当场或者在五日内一次告知申请人需要补正的全部内容。按照规定需要在告知时一并退回申请材料的，应当予以退回。申请人应当在三十日内完成补正资料。申请人无正当理由逾期不予补正的，视为放弃申请，无需作出不予受理的决定。逾期未告知申请人补正的，自收到申请材料之日起即为受理。\n'(4) Where the dossier is incomplete or not conformed with the defined format, the applicant shall be informed on-site or within five days at once of what to be supplemented or corrected; if it is not informed to the applicant within the timeline, the application is regarded as accepted on the date the dossier is received; and'可被翻译为：（四）申报资料不齐全或者不符合法定形式的，应当当场或者在5日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；\n\n根据上述已知信息，请将'(4) The applicant fails to submit supplementary dossier within the specified timeline;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请人未能在规定时限内补充资料的；"
    },
    {
        "instruction":"已知信息：\n'I. Applicants are required to carry out the study in accordance with the ICH Guidelines as early as possible based on current technical requirements. For relevant studies that start 6 months after the issuance date of this Announcement(based on the time point of the trial record), the above ICH Guidelines shall apply.'可被翻译为：1. 申请人需在现行技术要求基础上，尽早按照ICH指导原则的要求开展研究。本公告发布之日起6个月后开始的相关研究（以试验记录时间点为准），适用上述ICH指导原则。\n'1.Applicants must conduct research in accordance with the ICH guidelines ASAP based on the current technical requirements for pharmaceutical research; pharmaceutical research that begins 6 months after the issuance date of this Announcement (based on the time point of the trial record) shall apply the ICH guidelines.'可被翻译为：一、申请人需在现行药学研究技术要求基础上，尽早按照ICH指导原则的要求开展研究；本公告发布之日起6个月后开始的药学研究（以试验记录时间点为准），适用ICH指导原则。\n'Attachment: 13 ICH safety guidelines to be adopted'可被翻译为：附件：适用的13个ICH非临床指导原则\n'To align the technical standards for drug registration with international standards, the National Medical Products Administration has decided to adopt 13 ICH safety guidelines, including S1A: Need for Carcinogenicity Studies of Pharmaceuticals (see the attachment for further information). Items of the Announcement are as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用13个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n\n根据上述已知信息，请将'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'h2 receptor antagonist'可被翻译为：H2受体拮抗剂\n'a drug that covalently binds H+-K+ ATPase A subunit to inactivate the enzyme, thereby inhibiting the secretion of gastric acid and pepsin.'可被翻译为：与H+-K+ATP酶a亚单位的筑基以共价键结合而使酶失活，进而抑制胃酸、胃蛋白酶分泌的药物。\n'The physiological effect caused or enhanced by the binding of an agonist to a receptor.'可被翻译为：激动药与受体结合后，引起或增强的生理效应。\n'A drug that competes with histamine receptors and blocks allergic reactions caused by histamine. There are histamine H1 blockers such as diphenhydramine, promethazine, cetirizine, etc.; And H2 blockers such as cimetidine.'可被翻译为：竞争组胺受体，阻滞组胺所引起过敏反应的药物。有组胺H1阻滞剂，如苯海拉明、异丙嗪、西替利嗪等；H2受体阻滞剂，如西咪替丁。\n\n根据上述已知信息，请将'Competitively binds to the h2 receptor, antagonizing histamine compounds that promote gastric acid secretion, increase heart rate, and inhibit smooth muscle contractiles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"竞争性地与h2受体结合，拮抗组胺促进胃酸分泌，增加心率及抑制平滑肌收缩功能的化合物。"
    },
    {
        "instruction":"已知信息：\n'Article 7 People's governments at or above the county level shall incorporate the vaccine safety, immunization work into the national economic and social development plans of the corresponding level, enhance the capacity building of vaccine administration, and establish and improve the work mechanism for vaccine administration.'可被翻译为：第七条 县级以上人民政府应当将疫苗安全工作和预防接种工作纳入本级国民经济和社会发展规划，加强疫苗监督管理能力建设，建立健全疫苗监督管理工作机制。\n'The State gives support to the immunization in economically underdeveloped areas as required. People's governments of provinces, autonomous regions and municipalities directly under the Central Government as well as people's government of municipalities divided into districts shall grant necessary financial subsidies to the work related to immunization conducted by people's governments at county level in economically underdeveloped areas.'可被翻译为：国家根据需要对经济欠发达地区的预防接种工作给予支持。省、自治区、直辖市人民政府和设区的市级人民政府应当对经济欠发达地区的县级人民政府开展与预防接种相关的工作给予必要的经费补助。\n'Article 34 Disease prevention and control institutions at the provincial level shall, in accordance with the national immunization program and the need for disease prevention and control within their administrative regions, formulate plans for the use of immunization program vaccines within their administrative regions, report the plans to the vaccine procurement organizing departments as per relevant national regulations, and simultaneously file the record with the competent health departments under the people's governments of provinces, autonomous regions and municipalities directly under the Central Government.'可被翻译为：第三十四条 省级疾病预防控制机构应当根据国家免疫规划和本行政区域疾病预防、控制需要，制定本行政区域免疫规划疫苗使用计划，并按照国家有关规定向组织采购疫苗的部门报告，同时报省、自治区、直辖市人民政府卫生健康主管部门备案。\n'\"Immunization program vaccines\" are vaccines to be inoculated in citizens as per the government provisions, including vaccines confirmed in the national immunization program, vaccines added by people's governments of provinces, autonomous regions and municipalities directly under the Central Government while implementing the national immunization program, vaccines for emergency immunization or cluster immunization organized by the people's governments or their competent health departments at or above the county level.'可被翻译为：免疫规划疫苗，是指居民应当按照政府的规定接种的疫苗，包括国家免疫规划确定的疫苗，省、自治区、直辖市人民政府在执行国家免疫规划时增加的疫苗，以及县级以上人民政府或者其卫生健康主管部门组织的应急接种或者群体性预防接种所使用的疫苗。\n\n根据上述已知信息，请将'Article 63 To ensure the implementation of national immunization program, the people's government at or above the county level shall incorporate into the budget of the people's governments at the same level the funds needed for vaccine safety, procurement of immunization program vaccines, immunization and information-based construction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 县级以上人民政府应当将疫苗安全工作、购买免疫规划疫苗和预防接种工作以及信息化建设等所需经费纳入本级政府预算，保证免疫规划制度的实施。"
    },
    {
        "instruction":"已知信息：\n'The diameter of a spherical particle with the same settling velocity and density as the particle being measured when determined by sedimentation method.'可被翻译为：沉降法测定时，与被测粒子沉降速度和密度相同的球形微粒的直径。\n'The diameter of a spherical particle that has the same surface area, volume, or circumscribed circle as the particle under test.'可被翻译为：与被测粒子具有相同的表面积、体积或外接圆的球形粒子的直径。\n'The size of particles.'可被翻译为：颗粒的大小。\n'particle size'可被翻译为：粒度\n\n根据上述已知信息，请将'The diameter of a spherical particle with the same settling velocity as the particle calculated by the settling formula.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据沉降公式计算出的与粒子具有相同沉降速度的球形粒子的直径。"
    },
    {
        "instruction":"已知信息：\n'Article 65 In case of any major safety event related to drug quality, the drug MAH shall immediately take such control actions as sealing the drug product and related active drug ingredients, excipients and primary packaging materials and container in direct contact with the drug product and relevant manufacturing line and immediately report such events to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the MAH is located and other relevant agencies. The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall report the events to the provincial people's government as well as NMPA within 24 hours.'可被翻译为：第六十五条 发生与药品质量有关的重大安全事件，药品上市许可持有人应当立即对有关药品及其原料、辅料以及直接接触药品的包装材料和容器、相关生产线等采取封存等控制措施，并立即报告所在地省、自治区、直辖市药品监督管理部门和有关部门，省、自治区、直辖市药品监督管理部门应当在二十四小时内报告省级人民政府，同时报告国家药品监督管理局。\n'Where an MAH stops manufacture of drugs in shortage, it shall report to the drug regulatory department under the State Council or the drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the Central Government.'可被翻译为：药品上市许可持有人停止生产短缺药品的，应当按照规定向国务院药品监督管理部门或者省、自治区、直辖市人民政府药品监督管理部门报告。\n'Article 59 The NMPA and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall, if any deficiency in drug manufacturing or vaccine storage and transportation is found in the supervision and inspection or if evidence is available indicating the presence of potential safety risks, take corresponding actions according to law:'可被翻译为：第五十九条 国家药品监督管理局和省、自治区、直辖市药品监督管理部门通过监督检查发现药品生产管理或者疫苗储存、运输管理存在缺陷，有证据证明可能存在安全隐患的，应当依法采取相应措施：\n'Article 82 Where a drug has quality issues or other potential safety concerns, the MAH shall immediately stop selling the drug, notify relevant drug distributors and medical institutions to stop sales and use, recall the sold drugs, promptly announce recall information, stop manufacturing immediately if necessary, and report the situation on drug recall and handling to the drug regulatory departments and the competent health departments of the people's governments of the provinces, autonomous regions, or municipalities directly under the central government. The drug manufacturers, drug distributors, and medical institutions shall cooperate.'可被翻译为：第八十二条 药品存在质量问题或者其他安全隐患的，药品上市许可持有人应当立即停止销售，告知相关药品经营企业和医疗机构停止销售和使用，召回已销售的药品，及时公开召回信息，必要时应当立即停止生产，并将药品召回和处理情况向省、自治区、直辖市人民政府药品监督管理部门和卫生健康主管部门报告。药品生产企业、药品经营企业和医疗机构应当配合。\n\n根据上述已知信息，请将'Article 46 With respect to the drugs included in the list of drugs in shortage, the shutdown of which shall be reported to applicable authorities. If any drug MAH intends to shut down the manufacturing of such drugs, it shall report the shutdown to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the drug MAH is located 6 months ahead of the shutdown. In the event of unexpected shutdown, the drug MAH shall report it to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where it is located within 3 days. Where necessary, a report shall be made to the NMPA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十六条 列入国家实施停产报告的短缺药品清单的药品，药品上市许可持有人停止生产的，应当在计划停产实施六个月前向所在地省、自治区、直辖市药品监督管理部门报告；发生非预期停产的，在三日内报告所在地省、自治区、直辖市药品监督管理部门。必要时，向国家药品监督管理局报告。"
    },
    {
        "instruction":"已知信息：\n'A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.'可被翻译为：药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。\n'A solid preparation made of a drug and a suitable excipient in a round or shaped form.'可被翻译为：药物和适宜的辅料混匀压制而成的圆片状或异形片状的固体制剂。\n'A single or multilayer film-like preparation in which the drug is dissolved or dispersed or encased in a film-forming material.'可被翻译为：药物溶解或分散或包裹于成膜材料中而制成的单层或多层膜状制剂。\n'A preparation made of solid or liquid drugs heated and melted with a suitable matrix, dissolved, emulsified or suspended in the matrix, and then dropped into an immiscible, non-interacting condensate, and the droplet contracted into a ball due to surface tension.'可被翻译为：固体或液体药物与适宜的基质加热熔融后溶解、乳化或混悬于基质中后，再滴入不相混溶、互不作用的冷凝液中，因表面张力使液滴收缩成球状而制成的制剂。\n\n根据上述已知信息，请将'A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。"
    },
    {
        "instruction":"已知信息：\n'The speed of air supplied by unidirectional airflow systems should be clearly justified in the qualification protocol including the location for air speed measurement. Air speed should be designed, measured and maintained to ensure that appropriate unidirectional air movement provides protection of the product and open\ncomponents at the working position (e.g. where high-risk operations occur and where product and\/or components are exposed). Unidirectional airflow systems should provide a homogeneous air speed in a range of 0.36 - 0.54 m\/s (guidance value) at the working position, unless otherwise scientifically justified in the CCS. Airflow\nvisualization studies should correlate with the air speed measurement.'可被翻译为：单向流系统送风速度的合理性应在确认方案中明确论证，包括风速的测定位置。风速的设计、测定和维持应确保在工作区域（例如，在进行高风险操作的区域以及产品和\/或组分暴露的区域）有合适的单向气流为产品和开放组件提供保护。除非在 CCS 中另有科学论证，否则单向流系统应在工作区域提供 0.36-0.54m\/s（指导值）的均匀风速。气流可视化研究应与风速测定相关联。\n'Grade A: The critical zone for high-risk operations (e.g. aseptic processing line, filling zone, stopper bowl, open primary packaging or for making aseptic connections under the protection of first air). Normally, such conditions are provided by a localised airflow protection, such as unidirectional airflow workstations within RABS or isolators. The maintenance of unidirectional airflow should be demonstrated and qualified across the whole of the grade A area. Direct intervention (e.g. without the protection of barrier and glove port technology) into the grade\nA area by operators should be minimized by premises, equipment, process and procedural design.'可被翻译为：A 级：进行高风险操作的关键区域（例如，无菌生产线，灌装区，胶塞加料盘，敞口内包装或在初始气流保护下进行无菌连接）。通常情况下，这种条件是通过局部气流保护实现的，例如 RABS 或隔离器内的单向流操作台。应证明并确认整个 A 级区的单向流维护状态。应通过厂房、设备、工艺和程序性设计尽量减少操作人员对 A 级区的直接干预（例如，不使用隔离器和手套箱技术作为保护）。\n'Airflow tests - volume and velocity.'可被翻译为：气流测试——体积和流速。\n'Particle counters, including sampling tubing, should be qualified. The manufacturer's recommended specifications should be considered for tube diameter and bend radii. Tube length should typically be no longer than 1m unless justified and the number of bends should be minimized. Portable particle counters with a short\nlength of sample tubing should be used for classification purposes. Isokinetic sampling heads should be used in unidirectional airflow systems. They should be oriented appropriately and positioned as close as possible to the\ncritical location to ensure that samples are representative.'可被翻译为：粒子计数器，包括釆样管，应经确认。对于管径和弯曲半径，应考虑生产商建议的标准。除非另有正当理由，否则管长通常应不超过 1 米，并且应尽量减少弯曲。在测定房间级别时，应使用釆样管较短的便携式粒子计数器。在单向流系统中应使用等速釆样头。采样头应朝向适当并尽可能靠近关键位置，以确保样品具有代表性。\n\n根据上述已知信息，请将'Air velocity test (Note: For grade B, C and D the air velocity test should be performed according to a risk assessment documented as part of the CCS. However, it is required for filling zones supplied with unidirectional airflow (e.g. when filling terminally sterilised products or background to grade A and RABS). For grades with non-unidirectional airflow, a measurement of recovery testing should replace velocity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"风速测试（注：对于 B 级、C 级和 D 级，风速测试应按照风险评估的结果进行，并将该风险评估包含到CCS 中。但是，使用单向流的灌装区（例如，灌装最终灭菌产品时或 A 级和 RABS 的背景区）需要进行测试。对于非单向流的级别，应以自净测试代替风速测试）。"
    },
    {
        "instruction":"已知信息：\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n'A radioactive isotope of hydrogen. Its nucleus consists of a proton and two neutrons.'可被翻译为：氢的一种放射性同位素。其原子核由一个质子和两个中子组成。\n'A stable form isotope of hydrogen. Its nucleus consists of a proton and a neutron.'可被翻译为：氢的一种稳定形态同位素。其原子核由一个质子和一个中子组成。\n'The phenomenon of differences in the physical and chemical properties of isotopic atoms (or molecules) of the same element due to differences in nuclear properties, such as mass or spin.'可被翻译为：由于质量或自旋等核性质的不同而造成同一元素的同位素原子（或分子）之间物理和化学性质有差异的现象。\n\n根据上述已知信息，请将'An isotopic peak consisting of the most abundant nuclides in mass spectrometry. For example, the average atomic weight of the hydrogen atom is 1.00794, and the mass of the most abundant isotope,H, is 1.00783.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱分析中由丰度最高的核素组成的同位素峰。如氢原子的平均原子量为1.00794,丰度最高的同位素,H的质量为1.00783。"
    },
    {
        "instruction":"已知信息：\n'A class of biomacromolecules that bind to hormones, neurotransmitters, drugs, or intracellular signaling molecules and can cause changes in cell function.'可被翻译为：药物靶标中一类能够同激素、神经递质、药物或细胞内的信号分子结合并能引起细胞功能变化的生物大分子。\n'neurotransmitter'可被翻译为：神经递质\n'Any of various peptides in an organism that have a specific biological activity. Including various polypeptide hormones, kinins, neuropeptides, and peptides associated with behavior.'可被翻译为：生物体中具有特定生物活性的各种肽。包括各种多肽类激素、激肽、神经多肽和与行为有关的肽。\n'Glutamate receptors that regulate the production of intracellular second messengers through G protein coupling, resulting in metabolic alterations.'可被翻译为：通过G蛋白偶联，调节细胞内第二信使的产生而导致代谢改变的谷氨酸受体。\n\n根据上述已知信息，请将'Usually peptides, which can enhance or weaken the response of neurons to neurotransmitters and play a regulatory role.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一般为肽类，能增强或减弱神经元对神经递质反应，起调节作用。"
    },
    {
        "instruction":"已知信息：\n'Article 71 In any of the following circumstances for medical device distributing enterprises and user facility, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments and the health administrative departments above the county level according to their respective responsibilities should order to make correction and give warning, and a  fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production shall be ordered to stop until the relevant certificates are revoked by the original issuing authority:'可被翻译为：第七十一条  医疗器械经营企业、使用单位有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件：\n'Article 73 In any of the following circumstances for MAHs, the drug regulatory departments above county level should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction:'可被翻译为：第七十三条  持有人有下列情形之一的，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 74 In any of the following circumstances for medical device distributing enterprises and user facility, the drug regulatory departments and the health administrative departments above county level according to their respective responsibilities should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction.'可被翻译为：第七十四条  医疗器械经营企业、使用单位有下列情形之一的，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 72 Where MAHs fail to carry out re-evaluation as required, conceal re-evaluation results, or fail to submit an application for cancellation as required, the drug regulatory departments at provincial level or above shall order them to make rectification and give a warning, and may impose a fine between 10,000 and 30,000 RMB.'可被翻译为：第七十二条  持有人未按照要求开展再评价、隐匿再评价结果、应当提出注销申请而未提出的，由省级以上药品监督管理部门责令改正，给予警告，可以并处1万元以上3万元以下罚款。\n\n根据上述已知信息，请将'Article 70 In any of the following circumstances for MAHs, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments above the county level should order to make correction and give warning, and a fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production should be instructed to stop until the relevant certificates are revoked by the original issuing authority:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条  持有人有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件："
    },
    {
        "instruction":"已知信息：\n'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'可被翻译为：能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。\n'A class of drugs that have sympathetic excitatory effects similar to norepinephrine. Such as epinephrine, norepinephrine, dopamine, etc.'可被翻译为：具有去甲肾上腺素类似兴奋交感神经作用的一类药物。如肾上腺素、去甲肾上腺素、多巴胺等。\n'Drugs that inhibit recurrent episodes of brain dysfunction caused by abnormal firing of brain cells. According to its mechanism of action can be divided into: ① sodium channel regulator; ② gamma-aminobutyric acid regulator; ③ excitatory amino acid receptor antagonists and excitatory amino acid release regulators; ④ anti-absence seizure agents related to ethansuxamine (selective calcium channel blockers); ⑤ other drugs whose mechanisms are not well defined.'可被翻译为：抑制由脑细胞异常放电引起的脑功能障碍反复发作的药物。按其作用机制可分为：①钠通道调节剂；②γ-氨基丁酸调节剂；③兴奋性氨基酸受体拮抗剂和兴奋性氨基酸释放调节剂；④与乙琥胺有关的抗失神发作药（选择性钙通道阻滞剂）；⑤其他机制尚不明确的药物。\n'central nervous system stimulants'可被翻译为：中枢兴奋药\n\n根据上述已知信息，请将'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。"
    },
    {
        "instruction":"已知信息：\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'可被翻译为：治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。\n'Drugs that treat or prevent various parasitic infections. It can be divided into: (1) antigenic drugs, including anti-amoeba drugs, anti-sphaerozoon drugs, anti-leishmania (leishmania) drugs, anti-plasmodium drugs, anti-trichomoniasis drugs, etc.; ② Antihelminthic drugs, including roundworm repellents, hookworm repellents, tapeworm repellents and anti-filariasis drugs.'可被翻译为：治疗或预防各种寄生虫感染的药物。分为：①抗原虫药，包括抗阿米巴药、抗球抱子虫药、抗利什曼原虫（黑热病）药、抗疟原虫药、抗滴虫药等；②抗蠕虫药，包括驱蛔药、驱钩虫药、驱绦虫药及抗丝虫病药。\n'Drugs to prevent and treat urinary tract or vaginal infections caused by Trichomonas. It has a direct killing effect on trichomonas vaginalis, and commonly used drugs such as metronidazole.'可被翻译为：防治由毛滴虫引起的尿道或阴道感染的药物。对阴道滴虫具有直接杀灭作用，常用药物如甲硝唑。\n\n根据上述已知信息，请将'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。"
    },
    {
        "instruction":"已知信息：\n'An IVPT study can be sensitive and discriminating to differences in the rate and extent to which compounds applied on the skin from different formulations become available in and through it. Notably, unlike an IVRT study, differences in permeation that are observed in an IVPT study comparing a test versus reference product, if any, may correlate with and\/or be predictive of differences in bioavailability in vivo. The IVPT is routinely carried out to guide semi-solid topical formulation development.'可被翻译为：IVPT研究可以对不同配方的涂抹在皮肤上的化合物在皮肤内和通过皮肤获得的速率和程度的差异进行敏感和区分。值得注意的是，与IVRT研究不同的是，在IVPT研究中观察到的比较测试品与参考产品的渗透差异(如果有的话)可能与体内生物利用度差异相关和\/或预测了差异。IVPT通常用于指导半固体外用制剂的开发。\n'A separate and supplemental demonstration of the selectivity of an IVRT method, when feasible, independently validates the ability of the IVRT method to discriminate differences in release rates under the conditions of the pivotal IVRT study, in which the test and reference topical products are compared at the same strength. Thus, the supplemental demonstration of the selectivity of the IVRT method validates that it can detect differences in the release rate that are associated with aspects of the formulation other than the strength, and this is ideal, when feasible.'可被翻译为：对IVRT方法选择性的补充论证而言，在可行的情况下，在IVRT正式研究中，采用相同规格的自研制剂和对照外用制剂，单独确认IVRT方法区分释放速率差异的能力。因此，在可行的情况下，理想的情况是，IVRT方法选择性的补充论证是确认与配方相关的释放速率差异，而不是产品规格。\n'IVPT method development should encompass key aspects that influence the IVPT results (some of these aspects are discussed below), including the bioanalytical methodology used to quantify the amount of the drug in the IVPT study samples. The scope of the IVPT method development is dependent upon the purpose of the study. For example, a bioequivalence study is likely to require a larger number of skin donors in order to adequately power a statistical analysis, compared to a study intended to qualitatively evaluate different formulation prototypes. Further, whereas IVPT studies designed to support a demonstration of bioequivalence generally rely upon assessments of the rate and extent to which drugs permeate the skin based upon receptor solution results, the selection of new chemical entities or formulation prototypes may also employ assessments of tissue distributions. A comprehensive discussion on IVPT method validation is outside of the scope of this chapter.'可被翻译为：IVPT方法的开发应包括影响IVPT结果的关键方面(其中一些方面将在下文讨论)，包括用于量化IVPT研究样本中药物量的生物分析方法。IVPT方法开发的范围取决于研究的目的。例如，与旨在定性评估不同制剂原型的研究相比，生物等效性研究可能需要更多的皮肤供体，以便充分支持统计分析。此外，虽然IVPT研究旨在支持生物等效性的证明，通常依赖于基于受体溶液结果对药物渗透皮肤的速率和程度的评估，但选择新的化学实体或配方原型也可能采用组织分布的评估。关于IVPT方法验证的全面讨论超出了本章的范围。\n'The demonstration of IVRT selectivity (distinct from supplemental selectivity) validates the ability of the IVRT method to discriminate differences in release rates under conditions when the release rate is expected to differ in a predictable manner (i.e., when there are different concentrations of drug in the formulation).'可被翻译为：IVRT选择性论证（不同于补充选择性）是确认IVRT方法区分不同释放速率的能力，该释放速率经预测会存在不同（即，配方制剂中具有不同浓度的药物）。\n\n根据上述已知信息，请将'The selection between IVRT or IVPT should be based on the intended objective(s) of the formulation assessment, as described in Table 2. Intrinsic experimental differences between the two methodologies are further described in Table 3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IVRT或IVPT之间的选择应基于制剂评估的预期目标，如表2所示。表3进一步描述了两种方法内在的实验差异。"
    },
    {
        "instruction":"已知信息：\n'A description of the identified and unidentified impurities present in a new drug substance.'可被翻译为：对存在于某一新原料药中的已鉴定或未鉴定杂质的数量及含量。\n'A class of pharmaceutical impurities refers to impurities introduced during the production or storage of drugs. It includes residual solvents, starting materials, intermediates, and degradation products.'可被翻译为：药物杂质的一类，指药物生产或贮存过程引入的杂质。包括残留溶剂、起始物料、中间体和降解产物等。\n'potential impurity'可被翻译为：潜在杂质\n'An impurity that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug substance specification.'可被翻译为：在新原料药质量标准中，仅 对其限度进行统一控制而不单独一一进行控制的杂质。\n\n根据上述已知信息，请将'An impurity that theoretically can arise during manufacture or storage. It may or may not actually appear in the new drug substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照理论推测在生产或储存过程中可能产生的杂质。其在新原料药中可能存在，也可能不存在。"
    },
    {
        "instruction":"已知信息：\n'The China Food and Drug Administration shall supervise the management of medical device recall nationwide.'可被翻译为：国家食品药品监督管理总局监督全国医疗器械召回的管理工作。\n'(XIII) Being responsible for the management of drug recalls;'可被翻译为：（十三）负责药品召回的管理；\n'(XI) Management of drug recalls;'可被翻译为：（十一）药品召回的管理；\n'Article 9 The State Food and Drug Administration and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall establish the drug recall information disclosure system and publicize information about drugs with safety hazards and recall of drugs to the society in an effective way.'可被翻译为：第九条 国家食品药品监督管理局和省、自治区、直辖市药品监督管理部门应当建立药品召回信息公开制度，采用有效途径向社会公布存在安全隐患的药品信息和药品召回的情况。\n\n根据上述已知信息，请将'The State Food and Drug Administration shall supervise the management of recall of drugs across the country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家食品药品监督管理局监督全国药品召回的管理工作。"
    },
    {
        "instruction":"已知信息：\n'The minimum amount of energy required in a chemical reaction to travel from the ground state molecules of the reactants to the activated molecules. The difference between the average energy of the activated molecules and the average energy of all the reactant molecules.'可被翻译为：化学反应中由反应物基态分子到达活化分子所需的最小能量。即活化分子的平均能量与全部反应物分子平均能量之差。\n'transition state'可被翻译为：过渡态\n'The process by which a substance changes from its inactive state to an active state. The process by which the electrons of a particle, such as an atom or ion, transition from a lower ground state to a higher energy level after obtaining sufficient energy from the outside world.'可被翻译为：某一物质从其无活性状态转变为具有活性状态的过程。粒子（如原子或离子），从外界获得足够能量后，其电子由较低的基态能级跃迁到较高能级的过程。\n'A positive ion with an unpaired electron. Usually formed by an electrically neutral organic molecule that loses an electron and is an intermediate in an oxidation reaction.'可被翻译为：带有一个不成对电子的正离子。通常由一个电中性的有机分子失去一个电子生成，是氧化反应的中间体。\n\n根据上述已知信息，请将'An intermediate state occurring along a given reaction path. It is characterized by a higher potential energy than other states adjacent to it along that pathway.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"沿着一定反应途径所出现的一种中间状态。其特征是比该途径上与之相邻的其他状态有较高的势能。"
    },
    {
        "instruction":"已知信息：\n'The food and drug regulatory department shall issue a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the in-vitro diagnostic reagent registration application.'可被翻译为：食品药品监督管理部门受理或者不予受理体外诊断试剂注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。\n'For acceptance or non-acceptance of the application for Medical Device Manufacturing License, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall issue an acceptance or non-acceptance notice fixed with special seal of the administrative authority and indicated with date.'可被翻译为：省、自治区、直辖市药品监督管理部门受理或者不予受理医疗器械生产许可申请的，应当出具加盖本行政机关专用印章和注明日期的受理或者不予受理通知书。\n'For acceptance or non-acceptance of the application for Medical Device Distribution License, the department in charge of drug supervision and administration at the level of a city divided into districts shall issue an acceptance or non-acceptance notice fixed with special seal of the administrative authority and indicated with date.'可被翻译为：设区的市级负责药品监督管理的部门受理或者不予受理医疗器械经营许可申请的，应当出具加盖本行政机关专用印章和注明日期的受理或者不予受理通知书。\n'Article 39 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第三十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n\n根据上述已知信息，请将'The food and drug regulatory department shall grant a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the medical device registration application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"食品药品监督管理部门受理或者不予受理医疗器械注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。"
    },
    {
        "instruction":"已知信息：\n'In the process of the lot release of a specific product, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the product variety and previous lot release and dynamically adjust the testing items and testing frequency in the registration specification of the product variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall add the testing frequency on the corresponding item of the products of subsequent batches.'可被翻译为：批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种注册标准中的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。\n'Article 20 The lot release institution shall, in accordance with the previous quality management over the lot release applicant and the technical maturity and quality stability of corresponding product variety, carry out on-site inspection of different proportions for the product under application for lot release and may take sample for test as needed.'可被翻译为：第二十条 批签发机构应当根据批签发申请人既往质量管理情况、相应品种工艺成熟度和产品质量稳定情况等，对申请批签发的产品开展不同比例的现场核实，并可按需要抽取样品进行检验。\n'Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications.'可被翻译为：第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。\n'(VI) For the products with the same batch number which meet the testing requirements for lot release of relevant product variety in terms of quantity, test-related intermediate products, standard substances, reagents and other materials shall be provided when necessary;'可被翻译为：（六）数量满足相应品种批签发检验要求的同批号产品，必要时提供与检验相关的中间产品、标准物质、试剂等材料；\n\n根据上述已知信息，请将'In the process of the lot release of specific variety, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the variety and previous lot release and dynamically adjust the testing items and testing frequency of the variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall increase the testing frequency on the corresponding item of the products in subsequent batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。"
    },
    {
        "instruction":"已知信息：\n'Where an application for withdrawal of the lot release is required for such situations as that the test results fail to meet the provisions during the simultaneous lot release process, reasons shall be explained and the application may be withdrawn upon the approval of the lot release institution.'可被翻译为：同步批签发过程中出现检验结果不符合规定情况等需要申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回。\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。\n'Article 28 If the lot release applicant applies for withdrawal of its lot release application, it shall provide the explanation, and may withdraw the application only upon approval by the lot release institution; the lot release applicant shall report such withdrawal to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government. If the lot release institution has confirmed through review that the dossiers show defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'可被翻译为：第二十八条    批签发申请人申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回；批签发申请人应当向所在地省、自治区、直辖市药品监督管理部门报告批签发申请撤回情况。批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。\n\n根据上述已知信息，请将'If the lot release institution has confirmed through review that the dossier has defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。"
    },
    {
        "instruction":"已知信息：\n'An instrument in chromatographic analysis that accumulates the electrical signals generated by the system over time.'可被翻译为：色谱分析仪器中按时间累积检测系统所产生电信号的仪器。\n'chromatography'可被翻译为：色谱法\n'The use of multi-channel switch valve to change the connection between the injection valve and the column, or change the connection between the column, the use of a chromatograph, in a complete analysis process, the test product through a number of chromatographic conditions to obtain the analysis method of separation.'可被翻译为：利用多通路切换阀改变进样阀与色谱柱之间的连接关系，或改变色谱柱之间的连接关系，使用一台色谱仪，在一次完整的分析过程中，供试品经多个色谱条件获得分离的分析方法。\n'The sample is passed through the column and the detector, and the resulting signal-time curve is shown. A chromatogram is an image of the distribution of the detection signals of the separated components over time. The vertical coordinate of the chromatogram is the response signal of the detector, and the horizontal coordinate is time, volume, or distance.'可被翻译为：样品流经色谱柱和检测器，所得到的信号-时间曲线图。色谱图是被分离组分的检测信号随时间分布的图像。色谱图的纵坐标为检测器的响应信号，横坐标为时间、体积或距离。\n\n根据上述已知信息，请将'In the chromatographic instrument, after the completion of the separation of the components, according to the qualitative and quantitative requirements of the chromatography, the original chromatographic signals and data are collected and processed, and the computer system is used to control the operation of the chromatographic instrument.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在色谱仪器中，完成了组分的色谱分离后，按照色谱定性、定量要求，对原始色谱信号和数据进行采集、处理，并控制色谱仪器的操作的计算机系统。"
    },
    {
        "instruction":"已知信息：\n'(9) there are other circumstances not in conformity with relevant regulations.'可被翻译为：（九）其他不符合有关规定的情形。\n'(9) Other contents prohibited by relevant laws and regulations.'可被翻译为：（九）有关法律、法规禁止的其他内容。\n'(8) other circumstances in which applications shall not be approved according to laws and regulations.'可被翻译为：（八）法律法规规定的不应当批准的其他情形。\n'(VI) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（六）其他不符合法律法规要求的。\n\n根据上述已知信息，请将'9. Other circumstances that should not be passed as prescribed by laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9.法律法规规定的其他不应当通过的情形。"
    },
    {
        "instruction":"已知信息：\n'thin-layer chromatography'可被翻译为：薄层色谱法\n'A volumetric utensil for accurately removing a given volume of solution. It is a glass tube with two slender ends and an enlarged part in the middle. The bottom end of the tube is needle-shaped, and there is a ring mark in the upper part. The mark marks the volume of the liquid when the liquid is filled to the scale at the specified temperature and left to flow out naturally. The commonly used pipette has 50ml, 25ml, 20ml, 10ml, 5ml, 2ml, 1ml and other specifications.'可被翻译为：一种准确移取一定体积溶液的容量器皿。是一根两头细长而中间有膨大部分的玻璃管。管的最下端呈尖嘴状，在上部有一环形标线，该标线标示在指定的温度下把液体充满到刻度后，任其自然流出时流出液体的体积。常用的移液管有50ml、25ml、20ml、10ml、5ml、2ml、1ml等多种规格。\n'An instrument for the detection of separated components on a chromatographic column. For analysis, such as by capillary electrophoresis or capillary electrochromatography, the polyimide coating is removed at a certain position at the outlet of the capillary tube and used as a detection pool for detection.'可被翻译为：在色谱柱上对获得分离的组分进行检测的仪器。如采用毛细管电泳法或毛细管电色谱法进行分析时，就是在毛细管出口端的某个位置，除去聚酰亚胺涂层后作为检测池进行检测。\n'Pipettes'可被翻译为：移液管\n\n根据上述已知信息，请将'A tool used in thin layer chromatography to analyze point samples. Micropipette (total capacity 10μl) or microsyringe is generally used to point samples.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"薄层色谱分析中点样用的工具。一般采用微量吸管（总容量10μl）或微量注射器来点样。"
    },
    {
        "instruction":"已知信息：\n'deflection point'可被翻译为：拐点\n'azeotropic point'可被翻译为：共沸点\n'The phenomenon of the baseline changing slowly and continuously in a certain direction.'可被翻译为：基线朝一定方向缓慢连续变化的现象。\n'standard curve'可被翻译为：标准曲线\n\n根据上述已知信息，请将'The concave point on the curve changes, that is, the point from concave up (down) to concave down (up). If the function representing the curve has a second continuous derivative, the point at which the second derivative changes sign is the inflection point.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线上凹向改变的点，即由凹向上（下）变为凹向下（上）的点。若表示曲线的函数有二阶连续导数，则使二阶导数改变符号的点，就是拐点。"
    },
    {
        "instruction":"已知信息：\n'Usually refers to solid dosage forms of medicinal products such as tablets, capsules and powders to be taken orally.'可被翻译为：通常是指口服的片剂、胶囊、粉剂等药品的固体剂型。\n'oral solid dosage form'可被翻译为：口服固体剂型\n'Dosage forms present in solid form. Including powder, granule, tablet, capsule, dropping pill and film, etc.'可被翻译为：固体形态存在的剂型。包括散剂、颗粒剂、片剂、胶囊剂、滴丸剂和膜剂等。\n'Dosage forms whose drug-release characteristics of time course and\/or location are chosen to accomplish therapeutic or convenience objectives not offered by conventional dosage forms such as a solution or an immediate release dosage form. Modified release solid oral dosage forms include both delayed and extended release drug products.'可被翻译为：某种剂型，通过选择释药时间和\/或位置以达到治疗和方便用药的目的，这是常规剂型如溶液剂或普通释放剂型所不能做到的。固体口服调释释放制剂包括包括延迟和缓慢释放制剂。\n\n根据上述已知信息，请将'A solid dosage form that can be administered to patients in more than one manner, e.g. may be dispersed or taken orally as a whole.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可以一种以上方式给药给病人的固体剂型，例如，可分散或整体口服。"
    },
    {
        "instruction":"已知信息：\n'The hydroxide ion can be ionized in an aqueous solution, which can make the pH value of the solution greater than 7.'可被翻译为：在水溶液中能电离出氢氧根离子，可使溶液的pH值大于7的化合物。\n'A compound containing seven water molecules per molecule.'可被翻译为：每分子含七个水分子的化合物。\n'The amount of hydrogen ions required to neutralize alkaline substances in a 100g sample is expressed in millimoles.'可被翻译为：中和100g试样中的碱性物质所需要氢离子的物质的量用毫摩尔做单位的数值。\n'When a solute crystallizes out of a solution, a certain number of water molecules are bound to the crystal.'可被翻译为：溶质从溶液里结晶析出时，晶体里结合着的一定数目的水分子。\n\n根据上述已知信息，请将'In an aqueous solution, hydrogen ions can be ionized, which can make the pH value of the solution less than 7 compounds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水溶液中能电离出氢离子，可使溶液的pH值小于7的化合物。"
    },
    {
        "instruction":"已知信息：\n'The operators of cosmetic e-commerce platform shall assume the responsibility for managing cosmetic marketers within the platform according to law, make daily inspection of the marketing behavior of the cosmetic marketers within the platform, urge the cosmetic marketers within the platform to perform obligations specified in the Regulations on Supervision and Administration of Cosmetics and these Provisions according to law. In case of discovering illegal marketing of cosmetics, the inspectors shall stop timely by necessary means of deleting, shielding and unlinking, etc. in accordance with the laws or with service agreement and trading provisions of the platform, and report to the drug regulatory department of the province, autonomous region or municipality directly under the central government of the place where it is located.'可被翻译为：化妆品电子商务平台经营者应当依法承担平台内化妆品经营者管理责任，对平台内化妆品经营者的经营行为进行日常检查，督促平台内化妆品经营者依法履行化妆品监督管理条例以及本办法规定的义务。发现违法经营化妆品行为的，应当依法或者依据平台服务协议和交易规则采取删除、屏蔽、断开链接等必要措施及时制止，并报告所在地省、自治区、直辖市药品监督管理部门。\n'Article 46 The operator of cosmetic e-commerce platform shall establish cosmetics quality management institution or be staffed with full-time and part-time management personnel, establish and effectively implement the system for quality and safety of cosmetics management such as routine inspection of cosmetics, stopping and reporting of illegal acts, handling of complaints and reports, etc., and strengthen promotion of relevant laws and regulations to marketers of cosmetics in the platform. The operators of an e-commerce platform are encouraged to carry out sample testing.'可被翻译为：第四十六条 化妆品电子商务平台经营者应当设置化妆品质量管理机构或者配备专兼职管理人员，建立平台内化妆品日常检查、违法行为制止及报告、投诉举报处理等化妆品质量安全管理制度并有效实施，加强对平台内化妆品经营者相关法规知识宣传。鼓励化妆品电子商务平台经营者开展抽样检验。\n'Article 8 The department in charge of drug supervision and administration shall give full play to the role of the associations of cosmetics industry, the associations of consumers and other consumer organizations, news media, etc., promote the construction of industry integrity system, and advance social co-governance for cosmetics safety.'可被翻译为：第八条 负责药品监督管理的部门应当充分发挥行业协会、消费者协会和其他消费者组织、新闻媒体等的作用，推进诚信体系建设，促进化妆品安全社会共治。\n'Article 47 If the operators of cosmetic e-commerce platform receive adverse reaction information or complaint report information of cosmetics, they shall keep record and submit to the cosmetic marketers in the platform promptly for handling; in case of involving significant information on quality and safety of the products, they shall report to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located in a timely manner.'可被翻译为：第四十七条 化妆品电子商务平台经营者收到化妆品不良反应信息、投诉举报信息的，应当记录并及时转交平台内化妆品经营者处理；涉及产品质量安全的重大信息，应当及时报告所在地省、自治区、直辖市药品监督管理部门。\n\n根据上述已知信息，请将'If the department in charge of drug supervision and administration requires the operators of cosmetic e-commerce platform to provide relevant information according to law due to the needs for supervision and inspection and case investigation, etc., the operator of cosmetics e-commerce platform shall provide assistance and cooperation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责药品监督管理的部门因监督检查、案件调查等工作需要，要求化妆品电子商务平台经营者依法提供相关信息的，化妆品电子商务平台经营者应当予以协助、配合。"
    },
    {
        "instruction":"已知信息：\n'(10) A medical device with measuring function, its class shall not be lower than class II.'可被翻译为：（十）具有计量测试功能的医疗器械，其分类应不低于第二类。\n'(8) A medical device supplied in sterile state, its class shall not be lower than class II.'可被翻译为：（八）以无菌形式提供的医疗器械，其分类应不低于第二类。\n'(9) An orthopedic medical device which is used to actively apply a sustained action force to human body in such action modes as pulling, strutting, twisting, holding and bending and may dynamically adjust the fixed position of limb (not including a medical device with fixation and supporting function only, a medical device used in conjunction for temporary orthopedics in the surgery or a medical device used for limbs orthopedics after surgery or in other treatment), its class shall not be lower than class II.'可被翻译为：（九）通过牵拉、撑开、扭转、压握、弯曲等作用方式，主动施加持续作用力于人体、可动态调整肢体固定位置的矫形器械（不包括仅具有固定、支撑作用的医疗器械，也不包括配合外科手术中进行临时矫形的医疗器械或者外科手术后或其他治疗中进行四肢矫形的医疗器械），其分类应不低于第二类。\n'(2) For a medical device which may be used as an accessory, its classification shall be made with comprehensive consideration of the impact of the accessory to the safety and effectiveness of the major medical device used with. If the accessory has significant impact on the major medical device used with, the class of such an accessory shall not be lower than the major medical device used with.'可被翻译为：（二）可作为附件的医疗器械，其分类应当综合考虑该附件对配套主体医疗器械安全性、有效性的影响；如果附件对配套主体医疗器械有重要影响，附件的分类应不低于配套主体医疗器械的分类。\n\n根据上述已知信息，请将'(11) A medical device intended for the treatment of a certain disease, its class shall not be lower than class II.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如果医疗器械的预期目的是明确用于某种疾病的治疗，其分类应不低于第二类。"
    },
    {
        "instruction":"已知信息：\n'Article 26 Undertaking of drug manufacturing shall comply with the GMP. A quality management system shall be established and improved for drug manufacturing, which gives into consideration all factors influencing drug quality, to ensure that the whole process of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第二十六条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，涵盖影响药品质量的所有因素，保证药品生产全过程持续符合法定要求。\n'Article 43 The undertaking of drug manufacturing shall comply with the GMP.A quality management system shall be established and improved for drug manufacturing, to ensure that the whole chain of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第四十三条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，保证药品生产全过程持续符合法定要求。\n'Article 35 Drugs used for clinical trials shall be manufactured in facilities in compliance with the Good Manufacturing Practice for Pharmaceutical Products (GMP). The manufacturing process shall strictly meet the requirements of the GMP.'可被翻译为：第三十五条 临床试验用药物应当在符合《药品生产质量管理规范》的车间制备。制备过程应当严格执行《药品生产质量管理规范》的要求。\n'To build, rebuild or expand a workshop or manufacturing line at the original site or another site, relevant regulations and technical requirements shall be met, and relevant materials regarding the change shall be submitted to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for GMP compliance inspection. The manufacturer shall be notified of the inspection results. Products on which the inspection results comply with relevant regulations, meeting release requirements, can be sold and marketed. Related changes shall be specified in the duplicate of the Drug Manufacturing Certificate.'可被翻译为：原址或者异地新建、改建、扩建车间或者生产线的，应当符合相关规定和技术要求，提交涉及变更内容的有关材料，并报经所在地省、自治区、直辖市药品监督管理部门进行药品生产质量管理规范符合性检查，检查结果应当通知企业。检查结果符合规定，产品符合放行要求的可以上市销售。有关变更情况，应当在药品生产许可证副本中载明。\n\n根据上述已知信息，请将'Article 24 Engaging in drug manufacture activities shall comply with the GMP and the manufacturing process shall be in accordance with the national drug standards, drug registration specifications and the manufacturing process approved by drug regulatory departments. The site management file shall be submitted and continuously updated, the risk assessments and continuous improvements of the quality system operation shall be made to ensure a continuous compliance with statutory requirements throughout the whole process. Manufacturing and test records shall be complete and accurate. No fabrication or falsification is allowed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条 从事药品生产活动，应当遵守药品生产质量管理规范，按照国家药品标准、经药品监督管理部门核准的药品注册标准和生产工艺进行生产，按照规定提交并持续更新场地管理文件，对质量体系运行过程进行风险评估和持续改进，保证药品生产全过程持续符合法定要求。生产、检验等记录应当完整准确，不得编造和篡改。"
    },
    {
        "instruction":"已知信息：\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n'(IX) Dismantling sales: the method of dismantling drugs into the minimum package for sales;'可被翻译为：（九）拆零销售：将最小包装拆分销售的方式。\n'(VI) Dispensing tools and packaging supplies required for dismantling sales of drugs.'可被翻译为：（六）药品拆零销售所需的调配工具、包装用品。\n'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'可被翻译为：（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。\n\n根据上述已知信息，请将'(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；"
    },
    {
        "instruction":"已知信息：\n'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 40 If the drug regulatory departments, lot release institution, CFDI and their staff members constitute any of the following circumstances in the lot release work, sanctions shall be given to the directly responsible persons and  other directly responsible personnel by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条    药品监督管理部门、批签发机构、核查中心及其工作人员在批签发工作中有下列情形之一的，依法对直接负责的主管人员和其他直接责任人员给予处分；构成犯罪的，依法追究刑事责任：\n'Article 84 Where a lot release institution has one of the following circumstances in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give warnings until downgrade as punishment to the principal, director in charge and other directly responsible personnel:'可被翻译为：第八十四条 违反本法规定，批签发机构有下列情形之一的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至降级处分：\n\n根据上述已知信息，请将'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分："
    },
    {
        "instruction":"已知信息：\n'Article 91 The clinical trial institution shall keep clinical trial documents for 10 years after the completion of the clinical trial, and the sponsor shall keep the clinical trial data until the medical device is out of use.'可被翻译为：第九十一条 临床试验机构应当保存临床试验资料至临床试验结束后10年。申办者应当保存临床试验资料至无该医疗器械使用时。\n'Article 74 The clinical trial institution and the investigator shall ensure that the data, documents and records formed in the clinical trial are authentic, accurate, clear and secure.'可被翻译为：第七十四条 临床试验机构和研究者应当确保临床试验所形成数据、文件和记录的真实、准确、清晰、安全。\n'Article 90 The clinical trial institution, the investigator and the sponsor shall establish a basic document keeping system. The basic documents of the clinical trial are divided into three parts according to the clinical trial phases: documents in the preparation phase, documents in the implementation phase and documents after the termination or completion.'可被翻译为：第九十条 临床试验机构、研究者、申办者应当建立基本文件保存制度。临床试验基本文件按临床试验阶段分为三部分：准备阶段文件、进行阶段文件和终止或者完成后文件。\n'Article 82 The sponsor shall accurately and completely record the information related to the clinical trial, including:'可被翻译为：第八十二条 申办者应当准确、完整地记录与临床试验相关的信息，内容包括：\n\n根据上述已知信息，请将'Article 60 The clinical trial institutions shall properly keep the clinical trial records and basic documents as per the agreement with the sponsor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十条 临床试验机构应当按照与申办者的约定妥善保存临床试验记录和基本文件。"
    },
    {
        "instruction":"已知信息：\n'Article 8 Where any of the following circumstances exists, the food and drug regulatory departments can conduct an unannounced inspection for drugs and medical devices:'可被翻译为：第八条 有下列情形之一的，食品药品监督管理部门可以开展药品医疗器械飞行检查：\n'Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection.'可被翻译为：第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。\n'Article 5 The organization being inspected shall provide cooperation, and shall not refuse, delay, deny or limit the unannounced inspection of drugs and medical devices organized by the food and drug regulatory departments.'可被翻译为：第五条 被检查单位对食品药品监督管理部门组织实施的药品医疗器械飞行检查应当予以配合，不得拒绝、逃避或者阻碍。\n'Article 47 The drug regulatory department shall establish and improve a sound system for professional and specialized team of medical devices inspectors, and designate sufficient inspectors in accordance with the regulatory authority, industry scale and inspection task, etc., to guarantee the inspection needs effectively.'可被翻译为：第四十七条  药品监督管理部门应当建立健全职业化、专业化医疗器械检查员制度，根据监管事权、产业规模以及检查任务等，配备充足的检查员，有效保障检查工作需要。\n\n根据上述已知信息，请将'Article 34 The food and drug regulatory departments at all levels shall incorporate the costs for unannounced inspection of drugs and medical devices and related sampling and testing fees into annual budget, and shall provide sufficient guarantee as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 各级食品药品监督管理部门应当将药品医疗器械飞行检查所需费用及相关抽检费用纳入年度经费预算，并根据工作需要予以足额保障。"
    },
    {
        "instruction":"已知信息：\n'The limits for environmental monitoring of airborne particle concentration for each graded area are given in Table 5.'可被翻译为：各级别空气悬浮颗粒浓度环境监测限度见表 5。\n'Table 1: Maximum permitted total particle concentration for classification'可被翻译为：表 1：各级别允许的最大总微粒浓度\n'Environmental monitoring - total particle.'可被翻译为：环境监测——总粒子数。\n'Appropriate alert levels and action limits should be set for the results of viable and total particle monitoring. The maximum total particle action limits are described in Table 5 and the maximum viable particle action limits are described in Table 6. However, more stringent action limits may be applied based on data trending, the nature of the process or as determined within the CCS. Both viable and total particle alert levels should be established based on results of cleanroom qualification tests and periodically reviewed based on ongoing trend data.'可被翻译为：对活性粒子和总微粒监测的结果应设置适当的警戒限和行动限。最大粒子总数行动限见表 5 ，最大活性粒 子行动限见表 6。然而，基于数据趋势分析、工艺性质或按照 CCS 中的规定，可以应用更严格的行动限。应根据洁净室确认测试的结果确定活性粒子和总微粒警戒限，并根据持续趋势数据定期回顾。\n\n根据上述已知信息，请将'Table 5: Maximum permitted total particle concentration for monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表 5：监测最大允许的总粒子浓度。"
    },
    {
        "instruction":"已知信息：\n'An ingested liquid preparation containing one or more pharmaceutical ingredients in water as a solvent.'可被翻译为：以水为溶剂含有一种或-种以上的药物成分的内服液体制剂。\n'oral liquid preparation'可被翻译为：内服液体制剂\n'Usually refers to solid dosage forms of medicinal products such as tablets, capsules and powders to be taken orally.'可被翻译为：通常是指口服的片剂、胶囊、粉剂等药品的固体剂型。\n'A method of administration in which the drug is contained in the mouth or cheek membrane and slowly dissolved before being swallowed, rather than chewed or swallowed. Intended to exert a local or systemic effect.'可被翻译为：将药物含于口腔或颊膜内，缓缓溶解再咽下，而不要咀嚼或吞下的给药方法。意在发挥局部或全身作用。\n\n根据上述已知信息，请将'Also known as \"ingestion of liquid medicine\". A liquid preparation, such as a mixture, syrupy agent, or emulsion, for oral use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"内服液体药剂”。合剂、糖浆剂、乳剂等供口服的液体制剂。"
    },
    {
        "instruction":"已知信息：\n'A solution that allows the function and structure of red blood cells to remain normal when in contact with them.'可被翻译为：与红细胞接触时，可使红细胞功能和结构保持正常的溶液。\n'liposome'可被翻译为：脂质体\n'A liposome consisting of many non-concentric vesicles.'可被翻译为：由许多非同心囊泡组成的脂质体。\n'One of the methods for preparing liposomes. The phospholipids, cholesterol and other lipids and lipid-soluble drugs are dissolved in organic solvents, and then evaporated in a flask to form a film on the inner wall; Dissolve water-soluble drugs in phosphate buffer, add them to the flask and stir continuously to obtain liposomes.'可被翻译为：制备脂质体的方法之一。将磷脂、胆固醇等类脂质及脂溶性药物溶于有机溶剂中，然后在烧瓶中旋转蒸发，使其在内壁上形成一薄膜；将水溶性药物溶于磷酸盐缓冲液中，加入烧瓶中不断搅拌，即得脂质体。\n\n根据上述已知信息，请将'After proper surface modification, the liposomes can avoid phagocytosis of reticuloendothelial system and prolong the time of circulating system in the body.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表面经适当修饰后，可避免网状内皮系统吞噬，延长在体内循环系统时间的脂质体。"
    },
    {
        "instruction":"已知信息：\n'Article 129 Enterprises shall provide conditions for the personnel selling drugs under special management, drugs with special management requirements by the State, or refrigerated drugs to receive corresponding training, so that they can master relevant laws, regulations and professional knowledge.'可被翻译为：第一百二十九条 企业应当为销售特殊管理的药品、国家有专门管理要求的药品、冷藏药品的人员接受相应培训提供条件，使其掌握相关法律法规和专业知识。\n'Article 99 Specially-assigned personnel shall be responsible for the operations such as packaging and loading of refrigerated or frozen drugs, which shall conform to the following requirements:'可被翻译为：第九十九条 冷藏、冷冻药品的装箱、装车等项作业，应当由专人负责并符合以下要求：\n'Article 30 Personnel responsible for quality control, acceptance inspection, maintenance and storage and other posts in direct contact with drugs shall undergo pre-post and annual health examinations, and have health records established. Personnel suffering from infectious diseases or other diseases that could contaminate drugs shall not engage in the work in which they could directly contact the drugs. Personnel whose physical conditions do not meet the specific requirements of corresponding posts shall not be allowed to engage in relevant work.'可被翻译为：第三十条 质量管理、验收、养护、储存等直接接触药品岗位的人员应当进行岗前及年度健康检查，并建立健康档案。患有传染病或者其他可能污染药品的疾病的，不得从事直接接触药品的工作。身体条件不符合相应岗位特定要求的，不得从事相关工作。\n'Article 104 Enterprises shall take necessary measures for heat preservation, or refrigeration and freezing during transportation in accordance with the temperature control requirements of drugs.'可被翻译为：第一百零四条 企业应当根据药品的温度控制要求，在运输过程中采取必要的保温或者冷藏、冷冻措施。\n\n根据上述已知信息，请将'Article 28 Personnel engaged in the storage and transportation of drugs under special management and refrigerated and frozen drugs shall have received the training on relevant laws and regulations and professional knowledge, and shall not take up their posts until passing the assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十八条 从事特殊管理的药品和冷藏冷冻药品的储存、运输等工作的人员，应当接受相关法律法规和专业知识培训并经考核合格后方可上岗。"
    },
    {
        "instruction":"已知信息：\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n'The operation of coating the surface of the tablet with a suitable material.'可被翻译为：在片剂表面包裹上适宜材料的衣层的操作。\n'A layer of material coated during the coating process in order to smooth out the edges of the tablet and facilitate the coating operation.'可被翻译为：包衣过程中，为了消除片剂棱角并有利于包衣操作而包上的一层物质。\n'tablet coating'可被翻译为：片剂包衣\n\n根据上述已知信息，请将'The process of coating the surface of the tablet (core, plain) with a layer of enteric-soluble material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在片剂（片芯、素片）表面包裹肠溶性材料层的过程。"
    },
    {
        "instruction":"已知信息：\n'The ratio of absorbance of the sample solution under different wavelength conditions. Generally used for differential or derivative spectrometry for content determination.'可被翻译为：样品溶液在不同波长条件下的吸光度的比值。一般用于鉴别或导数光谱法进行含量测定。\n'The titration operation is combined with the absorbance, and the spectrophotometer is used to measure the ever-changing absorbance of the test liquid in the titration process in order to obtain the titration end point, and the method of calculating the content of the substance to be measured.'可被翻译为：将滴定操作与吸光度相结合，利用分光光度计按次序测量试液在滴定过程中不断变化的吸光度，以获得滴定终点，并由此计算出待测物含量的方法。\n'A method for simultaneous determination of multicomponent mixtures. When the absorption curves of components A and B have first order absorption points, the determination using the wavelength at which these absorption points are located simplifies the processing of the results.'可被翻译为：用于同时测定多组分混合物的一种方法。当组分A和B的吸收曲线有一等吸收点时,利用此等吸收点所处的波长进行测定，可简化结果处理。\n'The wavelength can be controlled by a user-set program, and an analysis can be measured at different wavelengths to obtain the best sensitivity of the detector.'可被翻译为：波长可以由用户设定程序进行控制，一次分析可在不同的波长进行测定，以获得最佳灵敏度的检测器。\n\n根据上述已知信息，请将'The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。"
    },
    {
        "instruction":"已知信息：\n'(V) Carrying out acceptance inspection of drugs, and guiding and supervising the quality management in drug purchase, storage, maintenance, sales, return and transportation;'可被翻译为：（五）负责药品的验收，指导并监督药品采购、储存、养护、销售、退货、运输等环节的质量管理工作；\n'(V) Carrying out acceptance inspection of drugs, and guiding and supervising the quality management in drug purchase, storage, display and sales;'可被翻译为：（五）负责药品的验收,指导并监督药品采购、储存、陈列、销售等环节的质量管理工作；\n'(V) Carrying out self-inspection on production quality management system and make rectification for the relevant issues;'可被翻译为：（五）对生产质量管理体系进行自查，并对相关问题进行整改；\n'1.11 The manufacturer and, where different, Marketing Authorisation holder should evaluate the results of the review and an assessment made as to whether corrective and preventive action or any revalidation should be undertaken, under the Pharmaceutical Quality System. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures verified during self-inspection. Quality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, sterile products, etc. where scientifically justified.'可被翻译为：1.11制造商和不同的上市许可持有人（MAH）应对回顾结果进行评估，确定是否需要采取纠正和预防措施或进行再验证。应有持续管理和回顾这些行动的管理程序，并在自检过程中验证这些程序的有效性。当有合理的科学依据时，质量回顾可按产品类型分组，如固体剂型、液体剂型、无菌产品等。\n\n根据上述已知信息，请将'1) To participate in quality management activities such as establishment of the quality system, self-inspection, external quality audit, validation, adverse drug reaction reporting and product recalls;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.参与企业质量体系建立、内部自检、外部质量审计、验证以及药品不良反应报告、产品召回等质量管理活动；"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department under the State Council and lot release institutions shall promptly publish the results of the lot release of marketed vaccines for public reference.'可被翻译为：国务院药品监督管理部门、批签发机构应当及时公布上市疫苗批签发结果，供公众查询。\n'Package inserts of approved drugs shall be disclosed to the public and promptly updated. For vaccines, the content of labels shall also be disclosed and promptly updated.'可被翻译为：批准上市药品的说明书应当向社会公开并及时更新。其中，疫苗还应当公开标签内容并及时更新。\n'The provision for vaccine storage and transportation shall be formulated by the drug regulatory department under the State Council in conjunction with the competent health department under the State Council.'可被翻译为：疫苗储存、运输管理规范由国务院药品监督管理部门、国务院卫生健康主管部门共同制定。\n'Article 21 The drug regulatory department under the State Council shall examine and approve the production process, quality control standards, package inserts and labels of vaccines during the approval process of the vaccine registration application.'可被翻译为：第二十一条 国务院药品监督管理部门在批准疫苗注册申请时，对疫苗的生产工艺、质量控制标准和说明书、标签予以核准。\n\n根据上述已知信息，请将'The drug regulatory department under the State Council shall publish the content of vaccine package inserts and labels on its websites in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院药品监督管理部门应当在其网站上及时公布疫苗说明书、标签内容。"
    },
    {
        "instruction":"已知信息：\n'Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.'可被翻译为：第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。\n'Registrants and filing persons of cosmetics and new cosmetic ingredients shall comply with the requirements of relevant laws, administrative regulations, mandatory national standards and technical specifications when applying for registration or filing for filing, and shall be responsible for the authenticity and scientificalness of the submitted dossiers.'可被翻译为：化妆品、化妆品新原料注册人、备案人申请注册或者进行备案时，应当遵守有关法律、行政法规、强制性国家标准和技术规范的要求，对所提交资料的真实性和科学性负责。\n'Article 29 The cosmetic registrant and filing person shall carry out cosmetic research and development, safety assessment, testing of registration and filing, etc. in accordance with laws, administrative regulations, mandatory national standards, technical specifications, and provisions for registration and filing administration etc., and submit registration and filing documents in accordance with the instructions for cosmetic registration and filing dossiers.'可被翻译为：第二十九条 化妆品注册人、备案人应当依照法律、行政法规、强制性国家标准、技术规范和注册备案管理等规定，开展化妆品研制、安全评估、注册备案检验等工作，并按照化妆品注册备案资料规范要求提交注册备案资料。\n'Article 7 The registrant and filing person of cosmetics and new cosmetic ingredients shall perform product registration and filing obligations in accordance with law and shall be responsible for the quality and safety of cosmetics and new cosmetic ingredients.'可被翻译为：第七条 化妆品、化妆品新原料注册人、备案人依法履行产品注册、备案义务，对化妆品、化妆品新原料的质量安全负责。\n\n根据上述已知信息，请将'Article 32 Cosmetic registrants and filing persons shall clarify the product standards that are implemented, and submit it to the drug regulatory department when applying for registration or filing for filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 化妆品注册人、备案人应当明确产品执行的标准，并在申请注册或者进行备案时提交药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'Article 40    Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.'可被翻译为：第四十条 药品生产、经营企业违反本办法第二十条规定的，限期改正，给予警告；逾期不改正或者情节严重的，处以赠送药品货值金额二倍以下的罚款，但是最高不超过三万元。\n'Article 30    In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:'可被翻译为：第三十条 有下列情形之一的，责令限期改正，给予警告；逾期不改正的，处以五千元以上二万元以下的罚款：\n'Article 42    Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.'可被翻译为：第四十二条 药品生产、经营企业违反本办法第二十一条、医疗机构违反本办法第二十八条规定，以邮售、互联网交易等方式直接向公众销售处方药的，责令改正，给予警告，并处销售药品货值金额二倍以下的罚款，但是最高不超过三万元。\n'Article 36 Drug distributors and users who violate the provisions in Article 6 of these Provisions shall be ordered to stop selling and using the drug and fined an amount more than 1,000 Yuan and less than 50 ,000Yuan; for those who have caused serious consequences, the original certificate-issuing department shall revoke their Drug Supply Certificate or other certificates.'可被翻译为：第三十六条 药品经营企业、使用单位违反本办法第六条规定的，责令停止销售和使用，并处1000元以上5万元以下罚款；造成严重后果的，由原发证部门吊销《药品经营许可证》或者其他许可证。\n\n根据上述已知信息，请将'Article 35    Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十五条 违反本办法第十三条规定，药品生产、经营企业知道或者应当知道他人从事无证生产、经营药品行为而为其提供药品的，给予警告，责令改正，并处一万元以下的罚款，情节严重的，处一万元以上三万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'With respect to vaccines that have serious adverse reactions or jeopardize human health due to other reasons, the drug regulatory department under the State Council shall revoke the drug registration certificates of such vaccines.'可被翻译为：对预防接种异常反应严重或者其他原因危害人体健康的疫苗，国务院药品监督管理部门应当注销该疫苗的药品注册证书。\n'Article 61 The drug regulatory department under the State Council may order vaccine MAHs to carry out post-marketing evaluation, or directly organize and carry out post-marketing evaluation.'可被翻译为：第六十一条 国务院药品监督管理部门可以根据实际情况，责令疫苗上市许可持有人开展上市后评价或者直接组织开展上市后评价。\n'Suspected adverse reactions of immunization that have significant influence on the society including any death or severe disability of the vaccine recipient caused by immunization and suspected cluster adverse reactions of immunization shall be investigated and handled by the competent health departments and the drug regulatory departments of the people's government of the municipalities divided into districts and above as per their respective responsibilities.'可被翻译为：因预防接种导致受种者死亡、严重残疾，或者群体性疑似预防接种异常反应等对社会有重大影响的疑似预防接种异常反应，由设区的市级以上人民政府卫生健康主管部门、药品监督管理部门按照各自职责组织调查、处理。\n'Article 62 The drug regulatory department under the State Council may organize post-marketing evaluation of vaccine varieties based on the demand for disease prevention and control as well as the development of the vaccine industry. Where a vaccine variety is found to be significantly inferior to other vaccine varieties used for the prevention and control of the same disease in terms of product design, production process, safety, effectiveness or quality management, the drug registration certificates of all vaccines of the inferior variety shall be revoked and the corresponding national drug standards shall be abolished.'可被翻译为：第六十二条 国务院药品监督管理部门可以根据疾病预防、控制需要和疫苗行业发展情况，组织对疫苗品种开展上市后评价，发现该疫苗品种的产品设计、生产工艺、安全性、有效性或者质量可控性明显劣于预防、控制同种疾病的其他疫苗品种的，应当注销该品种所有疫苗的药品注册证书并废止相应的国家药品标准。\n\n根据上述已知信息，请将'(5) Where, according to the provisions in Article 61 of the Vaccine Administration Law, vaccines have serious adverse events following immunization or are otherwise harmful to human health as indicated by post-marketing evaluation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）按照《疫苗管理法》第六十一条的规定，经上市后评价，预防接种异常反应严重或者其他原因危害人体健康的；"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products'可被翻译为：国家药监局关于发布《已上市生物制品变更事项及申报资料要求》的通告\n'NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers'可被翻译为：国家药监局关于发布《已上市中药变更事项及申报资料要求》的通告\n'To cooperate with the implementation of the Provisions for Drug Registration, the NMPA has organized to formulate the Requirements for Change Items of Marketed Chemicals and Application Dossier, which has been issued and implemented on February 3, 2021.'可被翻译为：为配合药品注册管理办法实施，国家药品监督管理局组织制定了《已上市化学药品变更事项及申报资料要求》，已于2021年2月3日发布实施。\n'NMPA Issues Requirements for Registration Classification and Application Dossiers of Chemical Drugs'可被翻译为：国家药监局关于发布化学药品注册分类及申报资料要求的通告\n\n根据上述已知信息，请将'NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布已上市化学药品变更事项及申报资料要求的通告"
    },
    {
        "instruction":"已知信息：\n'Article 26 The State implements lot release system for vaccines.'可被翻译为：第二十六条 国家实行疫苗批签发制度。\n'Warnings against vaccine safety risks, information on major vaccine safety accidents, investigation and handling as well as other vaccine safety information subject to unified release as confirmed by the State Council shall be released by the drug regulatory department under the State Council in collaboration with relevant departments. Reports of adverse reactions during immunization across the nation shall be published in a unified manner by the health department under the State Council jointly with drug regulatory department under the State Council. The release of such information without authorization is prohibited. The release of significant vaccine quality and safety information shall be timely, accurate and comprehensive, and scientific evaluation shall be carried out as required and necessary explanations shall be made.'可被翻译为：疫苗安全风险警示信息、重大疫苗安全事故及其调查处理信息和国务院确定需要统一公布的其他疫苗安全信息，由国务院药品监督管理部门会同有关部门公布。全国预防接种异常反应报告情况，由国务院卫生健康主管部门会同国务院药品监督管理部门统一公布。未经授权不得发布上述信息。公布重大疫苗安全信息，应当及时、准确、全面，并按照规定进行科学评估，作出必要的解释说明。\n'Article 6 The State implements immunization program system.'可被翻译为：第六条 国家实行免疫规划制度。\n'The drug regulatory department under the State Council and lot release institutions shall promptly publish the results of the lot release of marketed vaccines for public reference.'可被翻译为：国务院药品监督管理部门、批签发机构应当及时公布上市疫苗批签发结果，供公众查询。\n\n根据上述已知信息，请将'Article 76 The State implements the uniform release system for vaccine safety information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 国家实行疫苗安全信息统一公布制度。"
    },
    {
        "instruction":"已知信息：\n'As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can be performed outside the cleanroom. If maintenance has to be performed in the cleanroom, and the required standards of cleanliness and\/or asepsis cannot be maintained, then precautions such\nas restricting access to the work area to specified personnel, generation of clearly defined work protocols and maintenance procedures should be considered. Additional cleaning, disinfection and environmental monitoring should also be considered. If sterilisation of equipment is required, it should be carried out, wherever possible, after complete reassembly.'可被翻译为：设备及辅助装置和服务的设计和安装方式，应尽可能地使操作、维护和维修在洁净室外进行。如果必须在洁净室中进行维护，并且无法维持所要求的洁净和\/或无菌标准，则应当考虑预防措施，例如限制指定人员进入工作区，建立明确的工作方案和维护程序。还应考虑额外的清洁、消毒和环境监测。如果需要对设备进行灭菌，应尽可能在重新组装完成后灭菌\n'Article 85: Production equipment after cleaning should be stored in a clean and dry condition.'可被翻译为：第八十五条 已清洁的生产设备应当在清洁、干燥的条件下存放。\n'Article 47: The adequacy of the production area and storage area should ensure the orderly positioning of equipment, materials, intermediate, bulk and finished products, so as to avoid mixups, cross-contamination between different products and materials, and to avoid the omissions or errors of any of the manufacturing or quality control steps.'可被翻译为：第四十七条 生产区和贮存区应当有足够的空间，确保有序地存放设备、物料、中间产品、待包装产品和成品，避免不同产品或物料的混淆、交叉污染，避免生产或质量控制操作发生遗漏或差错。\n'Article 199: Before any new production is started, the equipment and work area should be checked to ensure that no product residues, documents or materials not required for the current operation are left, and the equipment is clean and ready to operate, and the check result should be recorded accordingly.'可被翻译为：第一百九十九条 生产开始前应当进行检查，确保设备和工作场所没有上批遗留的产品、文件或与本批产品生产无关的物料，设备处于已清洁及待用状态。检查结果应当有记录。\n\n根据上述已知信息，请将'Article 70: Maintenance workshops should as far as possible be separated from production areas. Whenever parts and tools are stored in the clean area, they should be kept in rooms or lockers reserved for that use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 维修间应当尽可能远离生产区。存放在洁净区内的维修用备件和工具，应当放置在专门的房间或工具柜中。"
    },
    {
        "instruction":"已知信息：\n'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number.'可被翻译为：（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。\n'(3) Registration certificate number or filing number of the medical device.'可被翻译为：（三）医疗器械注册证编号或者备案凭证编号；\n'(2) registration certificate number or filing number of the medical device;'可被翻译为：（二）医疗器械注册证编号或者备案编号；\n'(3) Name, residence, manufacturing address, contacts and production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.'可被翻译为：（三）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；\n\n根据上述已知信息，请将'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；"
    },
    {
        "instruction":"已知信息：\n'(3) For clinical trials with patients as subjects, relevant medical records shall be recorded in the outpatient or inpatient medical record system. The specific time and person who gives informed consent shall be recorded in the medical history record.'可被翻译为：(3) 以患者为受试者的临床试验，相关医疗记录载入门诊或住院病历。病历中记录受试者知情同意的具体时间和人员。\n'clinical trial'可被翻译为：临床试验\n'For a drug approved for marketing, where an indication is to be added and clinical trials are required, a new drug clinical trial application shall be filed.'可被翻译为：获准上市的药品增加适应症（或者功能主治）需要开展药物临床试验的，应当提出新的药物临床试验申请。\n'Where clinical trial is required, the clinical evaluation materials to be submitted shall include clinical trial protocol and clinical trial report.'可被翻译为：需要进行临床试验的，提交的临床评价资料应当包括临床试验方案和临床试验报告。\n\n根据上述已知信息，请将'(2) Where the electronic medical record has already been adopted in daily diagnosis and treatment, the clinical trials shall use electronic medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) 日常诊疗已使用电子病历系统的，临床试验应使用电子病历。"
    },
    {
        "instruction":"已知信息：\n'A solvent (non-solvent) that is insoluble to the material is added to the solution of the drug and the material, causing phase separation, and the drug is wrapped into a sac or co-precipitation into a ball method.'可被翻译为：药物和材料的溶液中加入一种对材料不溶的溶剂（非溶剂），引起相分离，而将药物包裹成囊或共沉淀成球的方法。\n'The process by which a surfactant increases the solubility of an insoluble drug in water and forms a clarified solution.'可被翻译为：表面活性剂增大难溶性药物在水中的溶解度并形成澄清溶液的过程。\n'A heterogeneous liquid dispersion system in which insoluble drug particles are dispersed in water.'可被翻译为：难溶性药物微粒分散在水中形成的非均相液体分散体系。\n'When appropriate amount of water is added to dissolve into a certain concentration of drug solution tablets.'可被翻译为：用时加适量水即溶解成一定浓度药物溶液的片剂。\n\n根据上述已知信息，请将'The insoluble drug is dispersed in the aqueous solution of the polymer material, and the coagulant is added to reduce the solubility of the polymer material to condense it into a sac.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"难溶性药物分散在高分子材料的水溶液中，加入凝聚剂以降低高分子材料溶解度使之凝聚成囊的方法。"
    },
    {
        "instruction":"已知信息：\n'1. Design qualification is to verify that the design of the premises, facilities and equipment is suitable for the intended use and in compliance with the Provisions;'可被翻译为：（一）设计确认应当证明厂房、设施、设备的设计符合预定用途和本规范要求；\n'General guidance on the design and operation of equipment.'可被翻译为：关于设备的设计和运行的一般性指导。\n'Guidance on the requirements for specific training, knowledge and skills. Also gives guidance regarding the qualification of personnel.'可被翻译为：关于具体培训、知识和技能要求，以及关于人员资质确认的指导。\n'Guidance regarding the special requirements of utilities such as water, gas and vacuum.'可被翻译为：关于水、气、真空等公用设施的特殊要求的指导。\n\n根据上述已知信息，请将'General guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有关具体厂房设计需求的一般性指导，以及关于厂房确认的指导（包括屏障技术的使用）。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'可被翻译为：第五十三条 省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告以及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。\n'Article 148 The drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall complete the check of drug development conditions and raw data, the review of application dossiers, sampling, the notice to drug testing institutes for conducting testing for drug registration, the submission of review opinions, inspection report and application dossiers to the State Food and Drug Administration, and the notice to the applicant of the review opinions within 30 days starting from the date an application is accepted.'可被翻译为：第一百四十八条 省、自治区、直辖市药品监督管理部门应当在受理申请后30日内完成对研制情况及原始资料的核查、对申报资料的审查、抽取样品、通知药品检验所进行注册检验、将审查意见和核查报告连同申请人的申报资料一并报送国家食品药品监督管理局等工作，同时将审查意见通知申请人。\n'Article 79 Drug testing institutes shall conduct sample testing, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and copy to the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government that notify them to conduct the verification, and the applicants.'可被翻译为：第七十九条 药品检验所应当对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送通知其检验的省、自治区、直辖市药品监督管理部门和申请人。\n'Article 78 Drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government shall review the submitted dossiers within the specified timeline and give review opinions. Where the regulations are conformed to, they shall provide for the Center for Drug Evaluation of the State Food and Drug Administration with the review opinions, the check report, the production site inspection report and the application dossiers, and inform the applicant. Where the regulations are not conformed to, they shall issue a Disapproval Notice with reasons, and notify the drug testing institute to terminate the testing for registration.'可被翻译为：第七十八条 省、自治区、直辖市药品监督管理部门应当在规定的时限内对申报资料进行审查，提出审查意见。符合规定的，将审查意见、核查报告、生产现场检查报告及申报资料送交国家食品药品监督管理局药品审评中心，同时通知申请人；不符合规定的，发给《审批意见通知件》，并说明理由，同时通知药品检验所停止该药品的注册检验。\n\n根据上述已知信息，请将'Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。"
    },
    {
        "instruction":"已知信息：\n'A sample of a batch of starting material, packaging material, product contained in its primary packaging, or finished product that is stored for the purpose of being analysed, should the need arise. This may include storage in a suitable bulk container.'可被翻译为：一批起始原料、包装材料、包含在其主要包装中的产品或成品的样品，如果需要，为分析目的而储存。这可能包括储存在合适的散装容器中。\n'4. Reference samples should be representative of the batch of materials or products from which they are taken. Other samples may also be taken to monitor the most stressed part of a process (e.g. the beginning or the end of a process).'可被翻译为：（四）留样应当能够代表被取样批次的产品或物料，也可抽取其他样品来监控生产过程中最重要的环节（如生产的开始或结束）。\n'2. The reference samples should be representative of the batch of material or product from which they are taken.'可被翻译为：（二）留样应当能够代表被取样批次的物料或产品。\n'1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.'可被翻译为：1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。\n\n根据上述已知信息，请将'9. Product sampling: a representative sample is selected based on lot size as per USP <71> guidelines; quantity per container & units per batch, sample storage (time and temperature), sampling port sanitization or sterilization problems; be aware of skip lot testing on raw material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"产品取样：按 USP<71>指南中的批量选择具有代表性的样品；每个包装&每批产品件数所取数量，样品存贮（时间和温度）、取样端口灭菌或消毒问题；了解原料的跳批检测"
    },
    {
        "instruction":"已知信息：\n'Medical costs directly related to the delivery of medical services. Such as the cost of diagnosis, treatment, and tests.'可被翻译为：与医疗服务的提供直接相关的医疗成本。如诊断、治疗、检查费。\n'The costs directly related to health care that are incurred specifically to provide a health care service.'可被翻译为：专为提供某医疗服务项目而发生的与医疗服务直接相关的成本。\n'direct non-medical cost'可被翻译为：直接非医疗成本\n'direct medical cost'可被翻译为：直接医疗成本\n\n根据上述已知信息，请将'Non-medical costs directly related to the provision of medical services. Such as transportation costs for patients to hospitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与医疗服务的提供直接相关的非医疗成本。比如患者去医院的交通费。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the results of adverse drug reaction assessment, to further guarantee the safety of people in the use of drug, the NMPA decided to revise such items as [Adverse reactions], [Contraindications]and [Precautions] in the package inserts of antiviral syrup, capsules, soft capsules, pills(concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid, and granules. The relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。现将有关事项公告如下：\n'NMPA Announcement on Revising the Package Inserts of 14 Drug Varieties Including Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution'可被翻译为：国家药监局关于修订氨酚麻美口服溶液等14个品种药品说明书的公告\n'NMPA Issued the Announcement on Revising the Package Inserts of Prescription and Over-the-counter Oral Preparations such as Huoxuezhitong Capsules'可被翻译为：国家药监局关于修订活血止痛胶囊等口服制剂处方药和非处方药说明书的公告\n'NMPA Revises Package Insert of Docusate Sodium and Dantron Capsules'可被翻译为：国家药监局关于修订多库酯钠丹蒽醌胶囊说明书的公告\n\n根据上述已知信息，请将'NMPA Announcement on Revising the Package Insert of Antiviral Syrup, Capsules, Soft Capsules, Pills (Concentrated Pills), Dropping Pills, Tablets, Effervescent Tablets, Chewable Tablet, Oral Liquid, And Granules'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于修订抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒药品说明书的公告"
    },
    {
        "instruction":"已知信息：\n'Article 64 Drugs shall be imported via the ports where drug importation is permitted, and drug importers shall file a record with the local drug regulatory department at the port. The drugs shall be released by customs on the basis of the Drug Import Note issued by the said departments and shall not release drugs for which no Drug Import Note has been issued.'可被翻译为：第六十四条 药品应当从允许药品进口的口岸进口，并由进口药品的企业向口岸所在地药品监督管理部门备案。海关凭药品监督管理部门出具的进口药品通关单办理通关手续。无进口药品通关单的，海关不得放行。\n'Provisions for Drug Importation'可被翻译为：药品进口管理办法\n'Article 16 In the case of drugs other than those specified in Article 10 of the Provisions, a drug regulatory department at ports of entry shall, if all the materials pass examination, approve the importation record filing and issue the Import Drug Note. At the same time, it shall issue the Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of the materials specified in Article 13 of the Provisions attached.'可被翻译为：第十六条 本办法第十条规定情形以外的药品，口岸药品监督管理局审查全部资料无误后，准予进口备案，发出《进口药品通关单》。同时向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份。\n'Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.'可被翻译为：第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：\n\n根据上述已知信息，请将'Article 11 An importer shall choose a port where drug importation is permitted as the port of delivery when signing a purchase contract. Drugs specified in Article 10 of the Provisions shall be imported via a port that is specially permitted by the State for such importation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十一条 进口单位签订购货合同时，货物到岸地应当从允许药品进口的口岸选择。其中本办法第十条规定情形的药品，必须经由国家特别批准的允许药品进口的口岸进口。"
    },
    {
        "instruction":"已知信息：\n'Machinery for the preparation of solid particles.'可被翻译为：可制备固体颗粒的机械。\n'The drug is mixed with a suitable filler, lubricant or dry adhesive, etc., pressed into a block or large sheet with suitable equipment, and then broken into particles of suitable size.'可被翻译为：将药物与适宜的填充剂、润滑剂或干燥黏合剂等混匀后，用适宜的设备压制成块状或大 片状，再将其破碎成大小适宜的颗粒。\n'The process of breaking up tissues, cells, or cell components and causing them to form a uniform suspension of small particles.'可被翻译为：使组织、细胞或细胞组分破裂并使它们成为均匀的小颗粒悬浮液的过程。\n'The operation in which two or more materials are dispersed to a uniform state by mechanical means.'可被翻译为：用机械方法使两种或多种物料相互分散而达到均匀状态的操作。\n\n根据上述已知信息，请将'The use of machinery to press the material powder into a certain diameter of the embryo sheet, and then broken into a certain size of particles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"利用机械将物料粉末压制成一定直径的胚片，再破碎成一定大小颗粒的方法。"
    },
    {
        "instruction":"已知信息：\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the Entries of [contraindications], [adverse reactions] and [precautions] on the package inserts of nicotinic acid injections (including nicotinic acid injection and nicotinic acid for injection).'可被翻译为：进一步保障公众用药安全，2020年3月17日，国家药监局发布公告决定对烟酸注射剂（包括烟酸注射液、注射用烟酸）说明书【不良反应】、【禁忌】、【注意事项】项进行修订。\n'To further protect drug safety for the people, on May 7, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions]and other Entries on the package inserts of Polyene Phosphatidylcholine Injection.'可被翻译为：为进一步保障公众用药安全，国家药品监督管理局于2020年5月7日发布对多烯磷脂酰胆碱注射液说明书【不良反应】、【注意事项】等项进行修订的决定。\n'To further protect drug safety for the people, on January 21, 2020, NMPA issued an announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of drugs containing pipemidic acid (including pipemidic acid tablets, capsules, and granules).'可被翻译为：为进一步保障公众用药安全，2020年1月21日，国家药监局发布公告，决定对含吡哌酸药品（包括吡哌酸片、吡哌酸胶囊和吡哌酸颗粒）说明书的【不良反应】、【禁忌】等项进行修订。\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of hydrocortisone injection and hydrocortisone sodium succinate for injection.'可被翻译为：为进一步保障人民群众用药安全，2020年3月17日，国家药监局发布《公告》，决定修改注射用氢化可的松注射液和琥珀酸氢化可的松钠说明书上的【不良反应】、【注意事项】等内容。\n\n根据上述已知信息，请将'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of probucol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步保障公众用药安全，2020年3月17日，国家药品监督管理局发布公告，决定对普罗布考说明书【不良反应】、【注意事项】等项进行修订。"
    },
    {
        "instruction":"已知信息：\n'According to the Provisions for Drug Importation, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing Principles and Standards for the Newly Establishment of Drug Import Ports, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing the Evaluation and Assessment Scheme for the Newly Establishment of Drug Import Ports, the Notice of the Comprehensive Department of National Medical Products Administration on Printing and Issuing the Evaluation Criteria for the Ports for the First Drug Importation and other relevant regulations, upon the on-site evaluation and assessment, the NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows:'可被翻译为：根据《药品进口规定》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸原则和标准的通知》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸评价考核方案的通知》，《国家药品监督管理局综合司关于印发《药品首次进口口岸评审标准》及其他有关规定的通知》经现场评审评估，国家药品监督管理局批准重庆市药品监督管理局关于增加化学品首次进口备案功能的申请，于2月2日发布本公告如下:\n'I. Chongqing Municipal Medical Products Administration is approved to add the filling function for the first import of chemicals. As of the date of printing and issuing this Announcement, the Chongqing Municipal Medical Products Administration can handle the filing of the first importation of chemicals.'可被翻译为：一、同意重庆市药品监督管理局增加化学药品首次药品进口备案职能。自本公告印发之日起，重庆市药品监督管理局可办理化学药品首次药品进口备案手续。\n'NMPA Issued the Announcement on Enabling the New Version of Management System for Import Filing of Drugs and Medicinal Materials'可被翻译为：国家药监局关于启用新版药品和药材进口备案管理系统的公告\n'To implement the Regulations on Optimizing the Business Environment in China, NMPA and the General Administration of Customs have collaboratively established a management system for import filing of pharmaceuticals and medicinal material imports (hereinafter referred to as the filing system), relying on the One-stop Window Public Platform for International Trade. On December 19, 2019, the Announcement on Enabling the New Version of Management System for Import Filing of Drugs and Medicinal Materials was issued to officially launch the filing system on the date of issuance, and the applicants for Inspection shall log in at http:\/\/www.singlewindow.cn  to submit Drug import filing application.'可被翻译为：为贯彻落实《优化营商环境条例》，国家药监局与海关总署依托国际贸易“单一窗口”公共平台，合作建设了药品和药材进口备案管理系统（以下称备案系统）。2019年12月19日，《关于启用新版药品和药材进口备案管理系统的公告》于发布之日正式启动备案制度，报验单位应登录http:\/\/www.singlewindow.cn 提交药品进口备案申请。\n\n根据上述已知信息，请将'NMPA Announcement on Approval of Adding the Filing Function for the First Importation of Chemicals to the Chongqing Municipal Medical Products Administration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于同意重庆市药品监督管理局增加化学药品首次药品进口备案职能的公告"
    },
    {
        "instruction":"已知信息：\n'When drugs are produced, packaged or prescribed, labels that meet the regulations should be affixed to the inner and outer packages of drugs; In order to guide patients to use the drug correctly, the pharmacist shall give written notification documents accompanying the drug.'可被翻译为：药品在生产、分装或处方调配时，将符合规定的标签贴在药品的内、外包装上；亦药师为指导患者正确使用药品，随药品所给予的书面告知文书。\n'Chapter III    Drug Labels'可被翻译为：第三章 药品的标签\n'A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information.'可被翻译为：贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。\n'A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.'可被翻译为：药品的标签应当以说明书为依据，其内容不得超出说明书的范围，不得印有暗示疗效、误导使用和不适当宣传产品的文字和标识。\n\n根据上述已知信息，请将'Article 16    Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十六条 药品的标签是指药品包装上印有或者贴有的内容，分为内标签和外标签。药品内标签指直接接触药品的包装的标签，外标签指内标签以外的其他包装的标签。"
    },
    {
        "instruction":"已知信息：\n'Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP) bags, glass or plastic ampoules, the critical parameters and variables that affect seal integrity should be evaluated, determined, effectively controlled and monitored during operations. Glass ampoules, BFS units and small volume containers (≤100 ml) closed by fusion should be subject to 100% integrity testing using validated methods. For large volume containers (>100 ml) closed by fusion, reduced sampling may be acceptable where scientifically justified and based on data demonstrating the consistency of the existing process, and a high level of process control. It should be noted that visual inspection is not considered as an acceptable integrity test method.'可被翻译为：当最终容器通过融合密封时，例如吹灌封（BFS）、成型-灌装-密封（FFS）、小容量注射剂和大容量注射剂（SVP&LVP）的袋子、玻璃或塑料安瓶瓶，应评估、确定影响密封完整性的关键参数和变量，并在操作过程中进行有效控制和监测。熔融密封的玻璃安瓿瓶、BFS 单元和小容量容器（≤100 ml）应使用经验证的方法进行 100%完整性测试。对于熔融密封的大容量容器（>100 ml），在经过科学论证并基于证明现有工艺可靠性和高水平工艺控制的数据的情况下，减少取样可能是可以接受的。值得注意的是，目检不被认为是可接受的完整性测试方法。\n'c. Guidance for Industry- Container and Closure system Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (2\/2008)'可被翻译为：行业指南—容器和密闭器系统完整性测试替代无菌检测，作为无菌药品的稳定性试验方案的一部分（2008 年 2 月）\n'Testing procedures should be established and validated to ensure the effective  sealing of components and moulded containers.'可被翻译为：应建立并验证检验程序， 以确保组分和成型容器的有效密封。\n'b. Testing or validation of supplier's test results for components, containers and closures'可被翻译为：组份、容器与密闭器供应商检测结果的测试或验证\n\n根据上述已知信息，请将'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。"
    },
    {
        "instruction":"已知信息：\n'Article 69 Where a drug MAH or drug manufacturer has failed to carry out manufacturing activities as per GMP requirements in any of the following circumstances and the circumstance belongs to the serious circumstances as specified in Article 126 under the Drug Administration Law, penalties shall be imposed according to law:'可被翻译为：第六十九条 药品上市许可持有人和药品生产企业未按照药品生产质量管理规范的要求生产，有下列情形之一，属于《药品管理法》第一百二十六条规定的情节严重情形的，依法予以处罚：\n'V. Provincial medical products regulatory authorities shall urge the drug marketing authorization holders of the product within their respective jurisdiction to revise the package inserts and replacement of the labels and package inserts as required and impose severe punishment in accordance with the law for violations of laws and regulations.'可被翻译为：五、省级药品监督管理部门应当及时督促行政区域内上述药品的药品上市许可持有人按要求做好相应说明书修订和标签、说明书更换工作，对违法违规行为依法严厉查处。\n'V. Provincial drug regulatory authorities shall urge the drug marketing authorization holders of the product within their respective jurisdiction to revise the package inserts and replacement of the labels and package inserts as required and impose severe punishment in accordance with the law for violations of laws and regulations.'可被翻译为：五、省级药品监督管理部门应当督促行政区域内上述药品的药品上市许可持有人按要求做好相应说明书修订和标签、说明书更换工作，对违法违规行为依法严厉查处。\n'Article 67 Where the drug regulatory department of the province, autonomous region or municipality directly under the Central Government has failed to promptly discover systematic drug safety risks in manufacturing and promptly eliminate drug safety risks within the supervision and administration region or the provincial people's government has failed to fulfill drug safety responsibilities and promptly eliminate major regional potential drug safety risks, the NMPA shall schedule a warning meeting with the principal persons responsible.'可被翻译为：第六十七条 省、自治区、直辖市药品监督管理部门未及时发现生产环节药品安全系统性风险，未及时消除监督管理区域内药品安全隐患的，或者省级人民政府未履行药品安全职责，未及时消除区域性重大药品安全隐患的，国家药品监督管理局应当对其主要负责人进行约谈。\n\n根据上述已知信息，请将'Article 70 Where manufacturers and suppliers of excipients or primary packaging materials and container in direct contact with drug products do not comply with the quality management standards or relevant requirements established by the NMPA and cannot ensure the quality management system persistently complies with regulatory requirements, the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government shall impose punishments in accordance with Article 126 under the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 辅料、直接接触药品的包装材料和容器的生产企业及供应商未遵守国家药品监督管理局制定的质量管理规范等相关要求，不能确保质量保证体系持续合规的，由所在地省、自治区、直辖市药品监督管理部门按照《药品管理法》第一百二十六条的规定给予处罚。"
    },
    {
        "instruction":"已知信息：\n'The branch of Chinese pharmacy in which modern scholars conduct documentary research on ancient materia medica. Materia medica is the special name for medicine in ancient China (now called traditional Chinese medicine).'可被翻译为：现代学者对古代本草进行文献研究的中药学分支学科。本草是中国古代对药物的特称（现称中药）。\n'Under the guidance of the basic theories of traditional Chinese medicine and the use of modern scientific methods, the study of the interaction and laws between traditional Chinese medicine and the body.'可被翻译为：以中医药基本理论为指导，运用现代科学方法，研究中药和机体相互作用及规律的学科。\n'Chinese traditional medicines'可被翻译为：中药\n'chinese materia medica'可被翻译为：中药学\n\n根据上述已知信息，请将'The general name of the Chinese medicine discipline. The discipline of studying the basic theory of traditional Chinese medicine and the source, extraction, performance, efficacy and clinical application of various herbal pieces and proprietary Chinese medicines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"中药学科的统称。研究中药基本理论和各种药材饮片、中成药的来源、采制、性能、功效、临床应用等知识的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 43 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第四十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n'Article 33 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第三十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n'The technical evaluation institution shall complete the technical evaluation within 40 workdays and China Food and Drug Administration shall make decisions within 20 workdays after technical evaluation. If the application of clinical trial is approved, the Approval Letter for Clinical Trial of Medical Device shall be issued. If the application is disapproved, the reasons shall be stated in written form.'可被翻译为：技术审评机构应当在40个工作日内完成技术审评。国家食品药品监督管理总局应当在技术审评结束后20个工作日内作出决定。准予开展临床试验的，发给医疗器械临床试验批件；不予批准的，应当书面说明理由。\n'Article 26 Where a clinical trial approval is required, the applicant shall submit the application documents to China Food and Drug Administration in accordance with related requirements.'可被翻译为：第二十六条 需进行医疗器械临床试验审批的，申请人应当按照相关要求向国家食品药品监督管理总局报送申报资料。\n\n根据上述已知信息，请将'Article 27 After accepting the application for approval of clinical trials, China Food and Drug Administration shall forward the application documents to technical evaluation institution within 3 workdays from the date of application acceptance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 国家食品药品监督管理总局受理医疗器械临床试验审批申请后，应当自受理申请之日起3个工作日内将申报资料转交医疗器械技术审评机构。"
    },
    {
        "instruction":"已知信息：\n'All operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage, and distribution of APIs and related controls.'可被翻译为：包括物料接收，生产，包装，再分装，标识，再标识，质量控制，放行，贮藏和 API 的分发及其他相关控制的所有操作。\n'A documented description of the operations to be performed, the precautions to be taken and measures to be applied directly or indirectly related to the manufacture of an intermediate or API.'可被翻译为：对所执行的操作，注意事项和与中间体或 API 生产直接或间接相关的文件化的说明。\n'All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.'可被翻译为：药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。\n'A documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.'可被翻译为：与中间体或API生产直接或间接相关的操作、预防措施和实施措施的文件化描述。\n\n根据上述已知信息，请将'All operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指从原料到 API 的生产和包装的所有操作。"
    },
    {
        "instruction":"已知信息：\n'It is referred to as \"total anesthetics\". A drug that acts on the central nervous system and can reversibly cause loss of consciousness, sensations (mainly pain), and reflexes, and relaxes skeletal muscles, thus enabling surgery to proceed smoothly. Categories include inhalant anesthetics nitrous oxide and enflurane; Intravenous anesthetics, such as ketamine, etomidate, etc.'可被翻译为：简称“全麻药”。作用于中枢神经系统，能可逆性地引起意识、感觉（主要是痛觉）和反射消失、松弛骨骼肌，而使外科手术能顺利进行的药物。分类有吸入性麻醉药氧化亚氮、恩氟烷;静脉麻醉药，如氯胺酮、依托米酯等。\n'Drugs that can produce varying degrees of inhibition on the central nervous system, causing sedation and hypnosis. Commonly used drugs are: barbiturates (e.g. Phenobarbital), benzodiazepines (e.g. Diazepam), and others (e.g. Methalamine).'可被翻译为：对中枢神经系统能产生不同程度的抑制作用，引起镇静和催眠的药物。常用的药物有：巴比妥类（如苯巴比妥）、苯二氮卓类（如地西泮）和其他类（如甲丙氨酯）。\n'Drugs for general anesthesia are administered intravenously. Such as propofol, etomidate, sodium thiopental, etc.'可被翻译为：通过静脉给药方式达到全身麻醉目的药物。如丙泊酚、依托咪酯、硫喷妥钠等。\n'inhalation anesthetics'可被翻译为：吸入麻醉药\n\n根据上述已知信息，请将'Any of a class of volatile liquids or gases inhaled through the airway that diffuse into the blood through the alveolar capillary membranes and reach the brain tissue, blocking synaptic transmission and causing general anesthesia. Commonly used drugs are: halothane, enflurane, isoflurane, nitrous oxide, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一类挥发性液体或气体，经气道吸入后由肺泡毛细血管膜弥散入血而到达脑组织，阻滞其突触传递功能，引起全身麻醉作用的药物。常用药物有：氟烷、恩氟烷、异氟烷、氧化亚氮等。"
    },
    {
        "instruction":"已知信息：\n'The receptor solution should be adequately mixed, typically by stirring at a constant and well-controlled speed throughout the experiment. The stirring speed or the flow rate should also be part of system qualification and is further described under Equipment.'可被翻译为：受体溶液应充分混合，通常在整个实验过程中以恒定和控制良好的速度搅拌。搅拌速度或流量也应是系统鉴定的一部分，并在设备中作进一步说明。\n'FDA recommends that pooled samples be a composite of aseptically removed aliquots (after at least 30 seconds of vigorous mixing) from each of the product containers. In this way, the original, individual containers will be available for possible retesting in the event the pooled sample displays an OOS result.'可被翻译为：FDA 建议混合样品是从每个产品容器中无菌取出的等分试样（剧烈混合至少 30 秒 后）的混合物。这样，如果合并样本显示 OOS 结果，原始的单个容器将可用于可 能的重新测试。\n'Sampling can be adjusted for special situations. After a suitable eluate\/extract pool is obtained from a finished production lot, this pooled extract should be kept under conditions appropriate for stability until it is tested in duplicate.'可被翻译为：取样可根据特殊情形进行调整。在经过适当的洗脱\/萃取之后，从一个成品生产批次 中获得混合样品，该混合萃取物应该保存在适合于稳定性的条件下，直到制备双样 进行检测。\n'First accurately add excess standard solution, so as to react with the measured substance or solid sample in the test solution, and then use another standard solution to titration the remaining standard solution method.'可被翻译为：先准确的加入过量标准溶液，使与试液中的待测物质或固体试样进行反应，再用另一种标准溶液滴定剩余的标准溶液的方法。\n\n根据上述已知信息，请将'The field laboratories are encouraged to mix the reconstituted CSE for at least 5 minutes and for at least 1 minute between dilutions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励现场实验室将调配的CSE混合至少5分钟，每次稀释之间混合至少1分钟。"
    },
    {
        "instruction":"已知信息：\n'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 123 of the Drug Administration Law.'可被翻译为：第四十二条    批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况，骗取生物制品批签发证明的，依照《药品管理法》第一百二十三条的规定予以处罚。\n'If the Certificate for Lot Release of Biological Products is forged, a penalty shall be imposed in accordance with Article 81 of the Drug Administration Law.'可被翻译为：伪造生物制品批签发证明的，依照《药品管理法》第八十一条的规定予以处罚。\n'If the Certificate for Lot Release of Biological Products is forged, a penalty shall be imposed in accordance with Article 122 of the Drug Administration Law.'可被翻译为：伪造生物制品批签发证明的，依照《药品管理法》第一百二十二条的规定予以处罚。\n'Article 41 If the lot release institution issues a false testing report when undertaking the lot release work, a penalty shall be imposed in accordance with Article 86 of the Drug Administration Law.'可被翻译为：第四十一条 批签发机构在承担批签发相关工作时，出具虚假检验报告的，依照《药品管理法》第八十六条的规定予以处罚。\n\n根据上述已知信息，请将'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 82 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十二条 批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况,骗取生物制品批签发证明的，依照《药品管理法》第八十二条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans for items critical to unit sealing, integrity and sterility.'可被翻译为：应根据风险建立适当的维护程序，并包括对单元密封、完整性和无菌性至关重要的物品的维护和检查计划。\n'Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans  for tooling  critical to the  effectiveness  of unit  sealing. Any issues  identified that  indicate  a potential product quality concern should be documented and investigated.'可被翻译为：应根据风险建立适当的维护程序，并包括对单元密封有效性至关重要的工具的维护和检查计划。发现的任何表明存在潜在产品质量问题的问题都应记录并进行调查。\n'Article 248: The manufacturer should establish operation procedures for deviation handling, define the reporting, recording, investigation, treatment and corrective actions adopted and all should be recorded accordingly.'可被翻译为：第二百四十八条 企业应当建立偏差处理的操作规程，规定偏差的报告、记录、调查、处理以及所采取的纠正措施，并有相应的记录。\n\n根据上述已知信息，请将'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'可被翻译为：治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A drug that kills or inhibits bacteria and is used to treat or prevent infections caused by bacteria. According to the different sources, it is divided into: ① antibiotics, such as cephalosporin; ② synthetic antimicrobials, such as quinolcopper; ③ antibacterial Chinese herbs, such as coptis, tanshinone, etc.; ④ Antifungal drugs, such as fluconazole, etc.'可被翻译为：对细菌有杀灭或抑制作用，用以治疗或预防细菌引起的感染的药物。根据来源的不同分为：①抗生素，如头孢氨卡等；②合成抗菌药，如喹诺铜类；③抗菌中草药，如黄连、丹参酮等；④抗真菌药，如氟康挫等。\n'antiinfective drug'可被翻译为：抗感染药\n\n根据上述已知信息，请将'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。"
    },
    {
        "instruction":"已知信息：\n'The highest amount of an analyte in a sample that can be quantitatively determined with pre_x0002_defined precision and accuracy'可被翻译为：样品中可通过预先定义的精密度和准确度进行定量测定的待测物最高浓度。\n'The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.'可被翻译为：某一分析方法的检测限度是样品中的被分析物能够被检测到的最低量，但不一定要准确定量。\n'The range of high-low limit concentrations or amounts for which the test method is applicable, with precision, accuracy, and linearity.'可被翻译为：能达到一定精密度、准确度和线性，测试方法适用的高低限浓度或量的区间。\n'The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.'可被翻译为：某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。\n\n根据上述已知信息，请将'The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。"
    },
    {
        "instruction":"已知信息：\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n'pharmacy ethics'可被翻译为：药学伦理学\n'The discipline that studies the specific problems of how to rationally select drugs and drug methods and formulate drug treatment plans in the prevention and treatment of diseases. Pharmacotherapeutics is the practice of pharmacological theory in clinical use of drugs.'可被翻译为：研究在疾病防治中如何合理地选择药物和用药方法及制定药物治疗方案等具体问题的学科。药物治疗学是药理学理论在临床用药的实践。\n'A science that uses basic medical knowledge such as physiology, pathology and biochemistry and pharmaceutical expertise such as pharmaceutical chemistry, pharmacy and pharmacology to study the principle of action of drugs on the human body, drug properties and clinical application, adverse reactions and medication precautions, and to provide support for clinical rational drug use.'可被翻译为：利用生理学、病理学、生物化学等基础医学知识和药物化学、药剂学、药理学等药学专业知识研究药物对人体的作用原理、药物性质及临床应用、不良反应和用药注意事项，为临床合理用药提供支持的一门科学。\n\n根据上述已知信息，请将'The subject that uses the theories and principles of ethics to explore and solve the problems of right and wrong, good and evil of human behavior in pharmaceutical work.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用伦理学的理论和原则探讨和解决药学工作中人类行为的是非、善恶问题的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.'可被翻译为：第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。\n'Article 20 The conduct of drug clinical trials shall comply with ethical principles, with a clinical trial protocol developed, and be subject to review and approval by the ethics committee.'可被翻译为：第二十条 开展药物临床试验，应当符合伦理原则，制定临床试验方案，经伦理委员会审查同意。\n'Article 27 For a drug approved for clinical trials, where an indication is to be added or the drug is to be used in combination with other drug(s), the applicant shall file a new drug clinical trial application to the CDE, and after approval shall the new drug clinical trial be conducted.'可被翻译为：第二十七条 获准开展药物临床试验的药物拟增加适应症（或者功能主治）以及增加与其他药物联合用药的，申请人应当提出新的药物临床试验申请，经批准后方可开展新的药物临床试验。\n'Article 23 Having completed the CMC, pharmacological and toxicological studies supporting drug clinical trials, to file a drug clinical trial application, the applicant shall submit relevant study data as per requirements on application dossiers. The application shall be accepted when the application dossiers pass preliminary review. The CDE shall organize CMC, medical and other technical personnel to evaluate the drug clinical trial application accepted. The decision on whether to approve the drug clinical trial shall be made within 60 days upon acceptance, and the applicant shall be informed of the review and approval result via the CDE website; where no notice has been issued within the specified timeline, the application shall be deemed approved, and the applicant may carry out the drug clinical trial as per the submitted protocol.'可被翻译为：第二十三条 申请人完成支持药物临床试验的药学、药理毒理学等研究后，提出药物临床试验申请的，应当按照申报资料要求提交相关研究资料。经形式审查，申报资料符合要求的，予以受理。药品审评中心应当组织药学、医学和其他技术人员对已受理的药物临床试验申请进行审评。对药物临床试验申请应当自受理之日起六十日内决定是否同意开展，并通过药品审评中心网站通知申请人审批结果；逾期未通知的，视为同意，申请人可以按照提交的方案开展药物临床试验。\n\n根据上述已知信息，请将'Article 26 When the drug clinical trial application is approved, the sponsor shall formulate the corresponding drug clinical trial protocols and have them reviewed and approved by the ethics committee before carrying out the subsequent phases of clinical trial, and submit the corresponding protocols and supporting dossiers on the CDE website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十六条 获准开展药物临床试验的，申办者在开展后续分期药物临床试验前，应当制定相应的药物临床试验方案，经伦理委员会审查同意后开展，并在药品审评中心网站提交相应的药物临床试验方案和支持性资料。"
    },
    {
        "instruction":"已知信息：\n'××××3 shall indicate the serial number of filing.'可被翻译为：××××3为备案流水号。\n'××××3 shall indicate the year of initial registration.'可被翻译为：××××3为首次注册年份；\n'The registration number shall be arranged in the following form:'可被翻译为：注册证编号的编排方式为：\n'×2 shall indicate the form of registration.'可被翻译为：×2为注册形式：\n\n根据上述已知信息，请将'××××6 shall indicate the serial number of initial registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"××××6为首次注册流水号。"
    },
    {
        "instruction":"已知信息：\n'An apparatus for injecting liquid medicine.'可被翻译为：用以注射药液的器具。\n'A cylindrical device with a cannula-like nozzle, with or without a fixed needle and a movable piston, used for the administration, usually parenteral, of an accurately measured quantity of a liquid pharmaceutical form. The syringe may be prefilled, and can be for single-dose or multi- dose use.'可被翻译为：注射器一种圆柱形装置，有类似套管的喷嘴，有或没有固定的针和可移动的活塞，通常用于注射精确测量的液体药物形式该注射器可预先填充，可用于单剂或多剂使用。\n'injection needle'可被翻译为：注射针\n'injection syringe'可被翻译为：喷射注射器\n\n根据上述已知信息，请将'A hollow needle with a locking device intended for the administration of liquid pharmaceutical dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"带有锁定装置的空心针，用于给药液体药物剂型。"
    },
    {
        "instruction":"已知信息：\n'Article 36 The registrant, filing entity or contract manufacturer of medical devices shall, in accordance with relevant requirements of the state for implementing Unique Device Identification (UDI) of medical devices, carry out code assignment, data uploading, maintenance and updating, to guarantee the authenticity, accuracy, integrity and traceability of the information.'可被翻译为：第三十六条  医疗器械注册人、备案人、受托生产企业应当按照国家实施医疗器械唯一标识的有关要求，开展赋码、数据上传和维护更新，保证信息真实、准确、完整和可追溯。\n'Article 1  The Rules are hereby formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, so as to regulate the establishment of unique device identification system (UDI system) and strengthen the whole-life cycle management of medical devices.'可被翻译为：第一条 为规范医疗器械唯一标识系统建设，加强医疗器械全生命周期管理，根据《医疗器械监督管理条例》，制定本规则。\n'Article 3  The UDI System of Medical Device mentioned in these Rules consists of the unique device identifier (UDI), UDI data carrier and unique device identification database (UDID).'可被翻译为：第三条 本规则所称医疗器械唯一标识系统，由医疗器械唯一标识、唯一标识数据载体和唯一标识数据库组成。\n'Uniqueness means that UDI shall comply with the requirements of device identification.'可被翻译为：唯一性，是指医疗器械唯一标识应当与医疗器械识别要求相一致。\n\n根据上述已知信息，请将'The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。"
    },
    {
        "instruction":"已知信息：\n'Male use to reduce the number of sperm until no sperm and achieve contraceptive purposes of the drug. Such as gossypol.'可被翻译为：男性应用后使精子数量减少直至无精子而达到避孕目的的药物。如棉酚。\n'spermatocides'可被翻译为：杀精子药\n'male contraceptives'可被翻译为：男性避孕药\n'condom'可被翻译为：避孕套\n\n根据上述已知信息，请将'Male contraceptive, applied topically to kill sperm. Such as commonly used surfactants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"男用避孕药，局部应用以杀灭精子。如常用的表面活性剂类药。"
    },
    {
        "instruction":"已知信息：\n'This guidance is intended to assist applicants who are submitting abbreviated new drug applications (ANDAs) for liquid-based and\/or other semisolid products applied to the skin, including integumentary and mucosal (e.g., vaginal) membranes, which are hereinafter called topical products.（注释2）Because of the complex route of delivery associated with these products, which are typically locally acting, and the potential complexity of certain formulations, topical products (other than topical solutions) are classified as complex products.（注释3）This guidance provides recommendations for in vitro release test (IVRT) studies that can be used to compare a proposed generic (test) topical product and its reference standard (RS) for the purpose of supporting a demonstration of bioequivalence (BE) to the reference listed drug (RLD). The reference standard ordinarily is the RLD.（注释4）'可被翻译为：本指南旨在帮助申请人提交用于皮肤的液体和\/或其他半固体产品的仿制药申请（ANDA），包括皮肤和粘膜（如阴道），以下简称“外用制剂”（注释2）。由于这些制剂通常局部起效，具有复杂递送途径和配方，外用制剂（外用溶液除外）通常称为复杂制剂（注释3）。本指南为拟申报的仿制药与其对照制剂（RS）的体外释放试验（IVRT）研究提供建议，以论证与参比制剂（RLD）的生物等效性（BE）。参比制剂通常简称为RLD。（注释4）\n'It is beyond the scope of this guidance to discuss specific topical products to which this guidance applies. FDA recommends that applicants consult this guidance and any relevant product-specific guidances (PSGs)（注释5） and any other relevant guidances for industry,（注释6） when considering the design and conduct of IVRT studies that, in conjunction with other studies, as deemed necessary, may be appropriate to support a demonstration that a proposed generic topical product and its RLD are bioequivalent. FDA also recommends that applicants routinely refer to FDA’s guidance web pages, because additional guidances may become available that could assist in the development of a generic topical product.'可被翻译为：本文不是讨论适用于该指南范围的特定外用制剂产品的指南。FDA建议申请人，在进行IVRT研究的设计和实施时，查阅特定产品开发指南（PSGs）（注释5）和其他行业指南（注释6），同时结合其他必要的研究，以支持拟申请的仿制药与RLD的生物等效性。此外，FDA建议申请人定期查阅FDA指南网站，及时获取最新的相关指南，以促进仿制药的开发。\n'The product technical requirements for class I in-vitro diagnostic reagents shall be submitted to the food and drug regulatory department at the time of filing by filing entity. The product technical requirements for class II and class III in-vitro diagnostic reagents shall be approved by the food and drug regulatory department at the time of registration approval.'可被翻译为：第一类体外诊断试剂的产品技术要求由备案人办理备案时提交食品药品监督管理部门。第二类、第三类体外诊断试剂的产品技术要求由食品药品监督管理部门在批准注册时予以核准。\n'(I) biological products specified by the State Food and Drug Administration;'可被翻译为：（一）国家食品药品监督管理局规定的生物制品；\n\n根据上述已知信息，请将'The Federal Food, Drug, and Cosmetic Act (FD&C Act) generally requires an ANDA to contain, among other things, information to show that the proposed generic drug product 1) is the same as the RLD with respect to the active ingredient(s), conditions of use, route of administration, dosage form, strength, and labeling (with certain permissible differences) and 2) is bioequivalent to the RLD.（注释9）Thus, an ANDA will not be approved if the information submitted in the ANDA is insufficient to show that the test product is bioequivalent to the RLD.（注释10）'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《联邦食品、药品和化妆品法案》（FD&C法案）要求ANDA申请中应包含合适的信息，说明：1）仿制药与RLD相比，具有相同的活性成分、使用条件、给药途径、剂型、规格和说明书（允许存在一些差异）；2）与RLD生物等效（注释9）。因此，如果ANDA中提交的信息不足以证明自制制剂与RLD具有生物等效性，则ANDA将不予批准。（注释10）"
    },
    {
        "instruction":"已知信息：\n'Article 67 A drug manufacturer shall investigate the manufacturing processes, quality, stability, therapeutic effect and adverse reactions, etc. of a new drug in the observation period, and report annually to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, where it is located. Where a drug manufacturer fails to perform its duties in the observation period, the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall order it to make rectifications.'可被翻译为：第六十七条 药品生产企业应当考察处于监测期内的新药的生产工艺、质量、稳定性、疗效及不良反应等情况，并每年向所在地省、自治区、直辖市药品监督管理部门报告。药品生产企业未履行监测期责任的，省、自治区、直辖市药品监督管理部门应当责令其改正。\n'Article 55 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall determine inspection frequency based on the drug varieties, dosage form, regulation categories, taking into account overall national situation of drug safety, drug safety risk warning information, major drug safety events and related investigations and handling information as well as the previous inspections, monitoring of adverse reactions, complaints and whistle-blowing.'可被翻译为：第五十五条 省、自治区、直辖市药品监督管理部门应当根据药品品种、剂型、管制类别等特点，结合国家药品安全总体情况、药品安全风险警示信息、重大药品安全事件及其调查处理信息等，以及既往检查、检验、不良反应监测、投诉举报等情况确定检查频次：\n'Article 78 Drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government shall review the submitted dossiers within the specified timeline and give review opinions. Where the regulations are conformed to, they shall provide for the Center for Drug Evaluation of the State Food and Drug Administration with the review opinions, the check report, the production site inspection report and the application dossiers, and inform the applicant. Where the regulations are not conformed to, they shall issue a Disapproval Notice with reasons, and notify the drug testing institute to terminate the testing for registration.'可被翻译为：第七十八条 省、自治区、直辖市药品监督管理部门应当在规定的时限内对申报资料进行审查，提出审查意见。符合规定的，将审查意见、核查报告、生产现场检查报告及申报资料送交国家食品药品监督管理局药品审评中心，同时通知申请人；不符合规定的，发给《审批意见通知件》，并说明理由，同时通知药品检验所停止该药品的注册检验。\n'Article 62 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall, pursuant to applicable laws, file the information obtained while supervising and inspecting the drug MAHs and manufacturers within its administrative region in drug safety credit archives and keep relevant data updated dynamically. Regulatory information includes the information on drug manufacturing authorization, routine supervision and inspection results, investigation and handling of illegal acts, spot checks for product quality, misconduct records, complaints and whistle-blowing.'可被翻译为：第六十二条 省、自治区、直辖市药品监督管理部门应当依法将本行政区域内药品上市许可持有人和药品生产企业的监管信息归入到药品安全信用档案管理，并保持相关数据的动态更新。监管信息包括药品生产许可、日常监督检查结果、违法行为查处、药品质量抽查检验、不良行为记录和投诉举报等内容。\n\n根据上述已知信息，请将'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'2. The storage conditions of the test\/control articles should be in conformity with those specified in the study protocol or other supporting documents (such as instructions for use, certificates of analysis, etc.); records of monitoring storage conditions and handling unexpected events of the test\/control articles and their formulations during the study period should be retained completely;'可被翻译为：2.受试物\/对照品保存条件应符合试验方案或相关证明 性文件(如使用说明书、质检报告等)要求；应完整保留研 究期间受试物\/对照品及其制剂保存条件监测及异常情况处理记录；\n'(2) Records of receipt, formulating, analysis (such as homogeneity, concentration, stability, etc.), use and return of the test\/control articles should be retained completely and traceably and should be consistent with those in the application dossiers. For example:'可被翻译为：(2)应完整保存可追溯的受试物和对照品的接收、配制、分析(如均一性、浓度、稳定性等)、使用、返还等记录，并与申报资料一致。如：\n'3. Records of formulating the test\/control articles, storage and use of their formulations, and the residuals for disposal should be retained completely; the amount of each requisition should be in line with that in dispensing record of the test articles, and the amount of formulating, use and residual for disposal should be in reconciliation;'可被翻译为：3.受试物\/对照品的配制、配制后保存、使用、使用剩余后的处理应有完整的记录；每次领用量应与受试物领用记录一致，配制量、使用量、使用后剩余处置量应符合物料平衡；\n'1. The applicant and the testing facility under inspection should ensure that the original study materials retained are complete and can be provided for inspection in a timely manner, including an original copy of protocol, raw data, specimens, relevant testing reports, reserve samples of test\/control articles, an original copy of the final study report and other documentation related to the study;'可被翻译为：1.现场核查期间，申请人及被核查研究机构应确保研究 原始资料保存完整并能够及时提供、接受核查，包括试验方案的原件、原始数据、标本、相关检测报告、留样受试物和对照品、总结报告的原件以及研究有关的各种文件；\n\n根据上述已知信息，请将'3. The storage conditions of the test\/control articles and their formulations, biological samples, study files and specimens, etc. should be in conformity with those specified in the study protocol, SOPs or other operational instructions; records of corresponding environmental monitoring and handling of unexpected events in the course of the study should be retained completely.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.受试物\/对照品及其配制制剂、生物样本、研究档案和 标本等储存保管条件应符合试验方案及机构 SOP或其他试验操作文件要求；应完整保存研究开展期间相应环境控制数据以及异常情况处理等记录。"
    },
    {
        "instruction":"已知信息：\n'The applicant shall be subject to inspection within the specified timeline.'可被翻译为：申请人应当在规定时限内接受核查。\n'Article 47 During the process of registration technical evaluation, the technical assessment agency may notify the inspection agency to carry out on-site inspection as needed. Domestic on-site inspections should be completed within 45 working days, and overseas on-site inspections should be implemented in accordance with relevant provisions on overseas inspections. The time for on-site inspection is not included in the time limit of technical evaluation.'可被翻译为：第四十七条 技术审评机构在注册技术审评过程中，可以根据需要通知审核查验机构开展现场核查。境内现场核查应当在45个工作日内完成，境外现场核查应当按照境外核查相关规定执行。现场核查所用时间不计算在审评时限之内。\n'Chapter IV Review, Test, Inspection and Release'可被翻译为：第四章  审核、检验、检查与签发\n'Section 1 Inspection tasks initiation'可被翻译为：第一节核查任务的接收\n\n根据上述已知信息，请将'(4) Time occupied during overseas inspection where overseas inspection is initiated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）启动境外核查的，境外核查所占用的时间。"
    },
    {
        "instruction":"已知信息：\n'The site where an enzyme molecule binds to a substrate and participates in a catalytic reaction.'可被翻译为：酶分子与底物结合并参与催化反应的部位。\n'A substance that changes an enzyme from inactive to active or increases its activity.'可被翻译为：使酶从无活性变为有活性或使酶活性增加的物质。\n'Any of several enzymes that catalyze the cleavage of peptide bonds within a polypeptide or protein molecule. Molecular weight is generally 20 ~ 30kDa, widely distributed in animals, plants and bacteria, a wide variety of metabolism and biological regulation of the body plays an important role.'可被翻译为：催化多肽或蛋白质分子内肽键裂解的酶的统称。分子量一般在20〜30kDa,广泛分布于动物、植物以及细菌中，种类繁多，对机体的新陈代谢以及生物调控起重要作用。\n'A non-protein component of an enzyme required for its activity. It can promote the activation of enzymes and reactants, and can be divided into coenzymes and coenzymes.'可被翻译为：一种酶的活性所需要的一种非蛋白质成分。能促进酶及反应物进入活化状态，分辅基和辅酶。\n\n根据上述已知信息，请将'Any of several organic substances of small molecular weight that are loosely bound to enzyme proteins and are essential for catalytic activity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某些为催化活性所必需的、与酶蛋白疏松结合的小分子量的有机物质。"
    },
    {
        "instruction":"已知信息：\n'Disease prevention and control institutions shall supply vaccines to immunization entities as required.'可被翻译为：疾病预防控制机构应当按照规定向接种单位供应疫苗。\n'Vaccine MAHs and disease prevention and control institutions shall operate under the vaccine cold-chain storage and transportation conditions when delivering vaccines on their own, or they may also entrust qualified vaccine distribution entities to distribute vaccines.'可被翻译为：疫苗上市许可持有人、疾病预防控制机构自行配送疫苗应当具备疫苗冷链储存、运输条件，也可以委托符合条件的疫苗配送单位配送疫苗。\n'Article 36 Vaccine MAHs shall deliver vaccines to disease prevention and control institutions or immunization entities designated by disease prevention and control institutions in accordance with the procurement contract.'可被翻译为：第三十六条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构或者疾病预防控制机构指定的接种单位配送疫苗。\n'Article 43 Disease prevention and control institutions at all levels shall, as per their respective duties, carry out tasks related to immunization including publicity, training, technical guidance, monitoring, assessment, epidemiology surveys, emergency response, etc.'可被翻译为：第四十三条 各级疾病预防控制机构应当按照各自职责，开展与预防接种相关的宣传、培训、技术指导、监测、评价、流行病学调查、应急处置等工作。\n\n根据上述已知信息，请将'(3) distributing vaccine to immunization entities by any institution or individual other than disease prevention and control institutions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）疾病预防控制机构以外的单位或者个人向接种单位供应疫苗；"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where a drug included into the special review and approval procedure is considered to no longer meet the inclusion conditions, the special review and approval procedure for the drug shall be terminated, and the applicant shall be informed.'可被翻译为：第七十五条 对纳入特别审批程序的药品，发现其不再符合纳入条件的，应当终止该药品的特别审批程序，并告知申请人。\n'Article 65 During review, where it is found that a drug registration application included into the conditional approval procedure does not meet the requirements for conditional approval, the CDE shall terminate the conditional approval procedure and inform the applicant to apply as per the normal review procedure.'可被翻译为：第六十五条 审评过程中，发现纳入附条件批准程序的药品注册申请不能满足附条件批准条件的，药品审评中心应当终止该品种附条件批准程序，并告知申请人按照正常程序研究申报。\n'Article 71 During review, where it is found that a drug registration application included into the priority review and approval procedure does not meet the conditions for priority review and approval, the CDE shall terminate the priority review and approval procedure for the application, evaluate the application as per the normal review procedure and inform the applicant.'可被翻译为：第七十一条 审评过程中，发现纳入优先审评审批程序的药品注册申请不能满足优先审评审批条件的，药品审评中心应当终止该品种优先审评审批程序，按照正常审评程序审评，并告知申请人。\n'After the drug registration application is accepted, where it is necessary to pay fees, the applicant shall pay the fees as required. If the applicant fails to pay the fees within the specified timeline, review and approval of the drug registration shall be terminated.'可被翻译为：药品注册申请受理后，需要申请人缴纳费用的，申请人应当按规定缴纳费用。申请人未在规定期限内缴纳费用的，终止药品注册审评审批。\n\n根据上述已知信息，请将'Where an application is recalled by the applicant in the process of drug registration, the review and approval procedure is terminated henceforth.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册过程中申请人自行提出撤回申请的，其审批程序自行终止。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of medical device distribution within their administrative areas.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域的医疗器械经营监督管理工作。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall organize and implement graded supervision and administration, in accordance with the list of products under key regulation and the management condition of manufacturing quality of medical devices, as well as in combination with medical device adverse events, product complaint reports and enterprise credit status, etc.'可被翻译为：省、自治区、直辖市药品监督管理部门依据重点监管产品目录以及医疗器械生产质量管理状况，结合医疗器械不良事件、产品投诉举报以及企业信用状况等因素，组织实施分级监督管理工作。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of Class II and Class III medical device manufacturing within their administrative areas, be responsible for the supervision and administration of Class I medical device manufacturing within their administrative areas in accordance with their duties according to law, and strengthen guidance for the supervision and administration of Class I medical device manufacturing within their administrative areas.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域第二类、第三类医疗器械生产监督管理，依法按照职责负责本行政区域第一类医疗器械生产监督管理，并加强对本行政区域第一类医疗器械生产监督管理工作的指导。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device manufacturing within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device manufacturing as required by NMPA.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械生产监督管理信息化建设和管理工作，按照国家药品监督管理局的要求统筹推进医疗器械生产监督管理信息共享。\n\n根据上述已知信息，请将'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or contract manufacturer of the medical devices is located shall implement local supervision and administration responsibility, establish coordinated supervision and administration mechanism to strengthen communication on regulatory information and realize effective cohesion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当分别落实属地监管责任，建立协同监管机制，加强监管信息沟通，实现监管有效衔接。"
    },
    {
        "instruction":"已知信息：\n'The time it takes for the plasma drug concentration to decrease by half after the distribution of the drug in the body reaches equilibrium.'可被翻译为：药物在体内分布达到平衡状态后血浆药物浓度降低一半所需的时间。\n'The time it takes for half the drug to be eliminated from the body is also the time it takes for the blood concentration to drop by half.'可被翻译为：药物从体内消除一半所需的时间，也是血药浓度下降一半的时间。\n'The time required for the concentration of the reactant to decrease to half of the initial concentration. In pharmacokinetics mainly refers to the time required for half of the drug to be absorbed or eliminated.'可被翻译为：反应物浓度降低至初浓度一半所需要的时间。在药动学中主要指药物吸收或消除一半所需的时间。\n'The period of time during which the drug has fallen below its effective concentration but has not been completely eliminated from the body.'可被翻译为：体内药物已降到有效浓度以下，但又未从体内完全消除的时段。\n\n根据上述已知信息，请将'The time it takes for the concentration of the drug in the plasma to drop by half.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆中药物浓度下降一半所需的时间。"
    },
    {
        "instruction":"已知信息：\n'Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:'可被翻译为：第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：\n'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'可被翻译为：第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。\n'Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.'可被翻译为：第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。\n'Article 57 During the supervision and inspection, drug MAHs and manufacturers shall provide relevant explanations and the following materials according to the inspection need:'可被翻译为：第五十七条 监督检查时，药品上市许可持有人和药品生产企业应当根据检查需要说明情况、提供有关材料：\n\n根据上述已知信息，请将'Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。"
    },
    {
        "instruction":"已知信息：\n'In molecular orbitals, the highest occupied orbital and the lowest unoccupied orbital are collectively called.'可被翻译为：分子轨道中，最高占据轨道和最低未占轨道的统称。\n'In molecular orbitals that are not occupied by electrons, the ones with the lowest energy.'可被翻译为：在电子未占有的分子轨道中，能量最低的分子轨道。\n'The delocalization of electrons by the interaction of more than two non-bonding orbitals.'可被翻译为：两个以上非成键轨道因相互作用所发生的电子离域作用。\n'A low energy orbital in an atom or molecule that exists before the electrons are excited.'可被翻译为：原子或分子中电子激发前存在的低能量轨道。\n\n根据上述已知信息，请将'The highest energy orbital of the electron occupied molecular orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在电子占有的分子轨道中，能量最高的分子轨道。"
    },
    {
        "instruction":"已知信息：\n'Article 82 Where, in violation of the Provisions, a registration alteration of permission items for an in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第八十二条 违反本办法规定，未依法办理体外诊断试剂注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。\n'Article 81 Where, in violation of the Provisions, a change of filing for a class I in-vitro diagnostic reagent is not performed, or a registration alteration of registry items for a class II or class III in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第八十一条 违反本办法规定，未依法办理第一类体外诊断试剂变更备案或者第二类、第三类体外诊断试剂注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。\n'Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.'可被翻译为：药品生产、批发企业违反本办法第十九条规定，未在药品说明书规定的低温、冷藏条件下储存药品的，按照《药品管理法》第七十九条的规定予以处罚；有关药品经依法确认属于假劣药品的，按照《药品管理法》有关规定予以处罚。\n'Article 59 If it is found in the supervision and inspection that the registrant, the filing entity and the contract manufacturer of cosmetics violates the key inspection points of the Good Manufacturing Practice for Cosmetics, and fails to organize manufacturing in accordance with requirements of the Good Manufacturing Practice for Cosmetics, the department in charge of drug supervision and administration shall impose punishment in accordance with the Paragraph 3 of Article 60 of the Regulations on Supervision and Administration of Cosmetics.'可被翻译为：第五十九条 监督检查中发现化妆品注册人、备案人、受托生产企业违反化妆品生产质量管理规范检查要点，未按照化妆品生产质量管理规范的要求组织生产的，由负责药品监督管理的部门依照化妆品监督管理条例第六十条第三项的规定处罚。\n\n根据上述已知信息，请将'Article 165 Where the Good Laboratory Practice for Non-Clinical Laboratory Studies or the Good Clinical Practice is not executed in the process of drug registration according to regulations, punishments shall be given in accordance with the provisions in Article 79 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十五条 在药品注册中未按照规定实施《药物非临床研究质量管理规范》或者《药物临床试验质量管理规范》的，依照《药品管理法》第七十九条的规定处罚。"
    },
    {
        "instruction":"已知信息：\n'The drug is placed in a closed screen with a screen cover and a receiver, and the device for grading the material is shaken and vibrated on the machine for a certain time.'可被翻译为：将药物置于具有筛盖和接受器的密闭筛中，在机器上摇动和振动一定时间以完成物料分级的装置。\n'Medium used in the dissolution (release) test item of drug standards.'可被翻译为：药品标准中溶出度（释放度）试验项下所用的介质。\n'An examination system shall be applied for storing and releasing drugs from storage.'可被翻译为：药品入库和出库应当执行检查制度。\n'The work of screening suitable dosage forms for drugs.'可被翻译为：为药物筛选合适剂型的工作。\n\n根据上述已知信息，请将'Under certain conditions, all drug dosage forms (tablets, pills, etc.) were disintegrated and passed the screen with the testing device prescribed by pharmacopeia'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以药典规定的检测装置在一定条件下测得药物剂型（片剂、丸剂等）全部崩解并通过筛"
    },
    {
        "instruction":"已知信息：\n'The Plate Method is the most commonly used USP <81> test. The Plate Method uses a solid \nmedium (agar) to demonstrate antibiotic activity (i.e. zones of inhibitions (ZOIs)). This method \nrequires the use of a five-point standard curve [S1] – [S5], median reference standard [S3], test \nantibiotic\/ unknown sample [U3], verified inoculum, stainless steel penicylinders and petri_x0002_plates containing growth agar. See Diagram 1 for an example of one independent test run for the \nPlate Method and placement of the standard curve and unknown sample onto triplicate agar \nplates.'可被翻译为：管碟法是最常使用的 USP<81>测试方法。管碟法使用固体培养基（琼脂）证明抗生素活性（即抑菌圈（ZOI））。该方法需要使用 5 点标准曲线【S1】-【S5】、中值标准品【S3】、供试抗生素\/未知样品【U3】、经过确认的接种物、不锈钢小管和含有生长琼脂的培养碟。参见图 1 中一次独立碟法测试及一式三份标准曲线和未知样品琼脂平板的放置示例。\n'The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.'可被翻译为：浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。\n'An internal quality control is built into each plate and tube tested. Since antibiotics have different listed dosages per label, the test antibiotic\/unknown sample is diluted to a known sample concentration ([U3]). The unknown sample [U3] has an equivalent concentration of the median reference standard ([S3]). The median reference standard ([S3]) is the median concentration (i.e. mid-point) of the five-point standard curve ([S1], [S2], [S4] and [S5]). The five- point standard functions as the testable detection range and is prepared from a traceable and within expiry USP Reference Standard (RS).'可被翻译为：内部质量控制来源于每个测试平板和试管。由于抗生素在每个标签上都标明不同剂量， 检测抗生素\/未知样品被稀释为已知样品浓度（【U3】）。未知样品【U3】与中间对照 （【S3】）的浓度相同。中值标准品（【S3】）浓度处于5点标准浓度曲线（【S1】， 【S2】，【S4】和【S5】）中间（即，中点）。5点标准的作用是建立检测范围，它们采用可追溯的在效期内的USP标准品（RS）制备。\n'Antibiotic potency testing is performed either by the plate (cylinder-plate or diffusion) or tube (turbidimetric) method. Both plate and tube methods demonstrate measurable levels of growth inhibition. For example, zones of inhibition (ZOIs) are observed and measured during cylinder plate testing. And, turbidity is observed and measured during tube testing. Growth inhibition measurements are tabulated and integrated into a linear regression curve, resulting in extrapolated antibiotic potency values.'可被翻译为：抗生素效价采用碟法（管碟或扩散）或浊度法（浊度计）法测定。碟法和浊度法均会显 示出可测量的生长抑制性。例如，在管碟法测试中可观察到抑菌圈（ZOI）。浊度法测 定中，观察并测量混浊度。将生长抑制测量结果制表，作线性回归曲线，外推得到抗生 素效价值。\n\n根据上述已知信息，请将'USP <81> states the following criteria for both the Plate and Tube Methods: 1) The calculated \npotency of the test antibiotic [U3] must be 80% to 125% of the median reference standard [S3] \n2) Relative standard deviation for all measured and calculated data is NMT 10% and 3) Testing \nis performed in triplicate over a period of three independent test runs. The Plate Method further \nstates: 1) The percentage coefficient of determinations (%R2) for each standard curve will be \nNLT 95% (i.e. correlation coefficient of NLT 0.9750) and 2) ZOIs for all media reference standard (S3 will measure between 14-16 mm). Refer to USP <81> for testing parameters and acceptable data requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"USP<81>要求管碟法和浊度法符合以下标准：（1）测试抗生素【U3】的计算效价必须为中值标准品【S3】的 80-125%，（2）所有测量数据和计算数据的相对标准偏差 NMT 10%，且（3）进行三次独立检测，每次测试一式三份样品。管碟法还要求：（1）每条标准曲线的测试百分比系数（%R2）NLT 95%（即相关系数 NLT 0.9750），且（2）所有中值标准品（S3）的 ZOI 应在 14-16mm。参见 USP<81>中检测参数和可接受数据要求。"
    },
    {
        "instruction":"已知信息：\n'(3) Class 3 chemical drugs are drugs manufactured by domestic applicants by imitating the original drugs that have been marketed overseas but not yet in China. They have identical active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage with those of the reference formulations, and have proven consistency of quality and efficacy with those of the reference formulations.'可被翻译为：（三）化学药品3类为境内生产的仿制境外已上市境内未上市原研药品的药品，具有与参比制剂相同的活性成份、剂型、规格、适应症、给药途径和用法用量，并证明质量和疗效与参比制剂一致。\n'(4) Class 4 chemical drugs are drugs manufactured by domestic applicants by imitating the original drugs that have been marketed in China. They have identical active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage with those of the reference formulations, and have proven consistency of quality and efficacy with those of the reference formulations.'可被翻译为：（四）化学药品4类为境内生产的仿制境内已上市原研药品的药品，具有与参比制剂相同的活性成份、剂型、规格、适应症、给药途径和用法用量，并证明质量和疗效与参比制剂一致。\n'The registration classification of chemical drugs covers innovative drugs, modified new drugs, generic drugs and chemical drugs marketed overseas but not in China, which fall into the following 5 categories:'可被翻译为：化学药品注册分类分为创新药、改良型新药、仿制药、境外已上市境内未上市化学药品，分为以下5个类别：\n'Class 5: Drugs that have been marketed overseas and are under application for being marketed in China.'可被翻译为：5类：境外上市的药品申请在境内上市。\n\n根据上述已知信息，请将'(5) Class 5 chemical drugs are drugs that have been marketed overseas and are under application for being marketed in China. Drugs manufactured in China and overseas are included. Among them, Class5.1 chemical drugs are original drugs and modified drugs, and the latter are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Class 5.2 chemical drugs are generic drugs, whose quality and efficacy shall be proven to be consistent with those of the reference formulations, and whose technical requirements are the same as those of Class 3 and Class 4 chemical drugs. Generic drugs developed simultaneously at home and abroad but produced overseas shall be applied in accordance with Class5.2 chemical drugs. If clinical trials for such drugs are applied, the supporting documents for approval of marketing and sales can be exempted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）化学药品5类为境外上市的药品申请在境内上市，包括境内外生产的药品。其中化学药品5.1类为原研药品和改良型药品，后者在已知活性成份基础上进行优化，应比改良前具有明显临床优势；化学药品5.2类为仿制药，应证明与参比制剂质量和疗效一致，技术要求与化学药品3类、4类相同。境内外同步研发的境外生产仿制药，应按照化学药品5.2类申报，如申报临床试验，不要求提供允许药品上市销售证明文件。"
    },
    {
        "instruction":"已知信息：\n'Isokinetic  sampling head - A sampling head designed to disturb the air as little as possible  so that the  same particles go into the nozzle as would have passed the area if the nozzle had not been there (i.e. the  sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (±20 percent) as the mean velocity of the airflow at that location).'可被翻译为：等速采样头：一种几乎不会扰乱空气的采样头、使进入管口的粒子与管口不存在时通过该区域的微粒相同，即，采样条件为进入样品探针入口处的空气流速与该位置气流的平均流速几乎相同(±20%）。\n'Particle counters, including sampling tubing, should be qualified. The manufacturer's recommended specifications should be considered for tube diameter and bend radii. Tube length should typically be no longer than 1m unless justified and the number of bends should be minimized. Portable particle counters with a short\nlength of sample tubing should be used for classification purposes. Isokinetic sampling heads should be used in unidirectional airflow systems. They should be oriented appropriately and positioned as close as possible to the\ncritical location to ensure that samples are representative.'可被翻译为：粒子计数器，包括釆样管，应经确认。对于管径和弯曲半径，应考虑生产商建议的标准。除非另有正当理由，否则管长通常应不超过 1 米，并且应尽量减少弯曲。在测定房间级别时，应使用釆样管较短的便携式粒子计数器。在单向流系统中应使用等速釆样头。采样头应朝向适当并尽可能靠近关键位置，以确保样品具有代表性。\n'isokinetic sampling head'可被翻译为：等速采样头\n'Article 62: There should normally be a separate sampling area for materials, which air-cleanliness levels should be the same as the corresponding production area. If sampling is performed in other areas or with other methods, it should be conducted in such a way as to prevent contamination or cross-contamination.'可被翻译为：第六十二条 通常应当有单独的物料取样区。取样区的空气洁净度级别应当与生产要求一致。如在其他区域或采用其他方式取样，应当能够防止污染或交叉污染。\n\n根据上述已知信息，请将'A sampling head designed to disturb the air as little as possible so that the same particles go into the nozzle as would have passed the area if the nozzle had not been there (that is, the sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (± 20%) as the mean velocity of the airflow at that location).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种采样头，其设计目的是尽可能少地干扰空气，使进入喷嘴的颗粒与没有喷嘴时通过该区域的颗粒相同(即进入样品探头入口的空气的平均速度与该位置气流的平均速度几乎相同(±20%)的采样条件)。"
    },
    {
        "instruction":"已知信息：\n'(VI) Failing to take corresponding control measures according to the situation of adverse events and release to the public;'可被翻译为：（六）未根据不良事件情况采取相应控制措施并向社会公布的；\n'(2) failing to promptly investigate and deal with drug safety violation upon discovery;'可被翻译为：（二）对发现的药品安全违法行为未及时查处；\n'(V)  In case the safety and effectiveness of the product cannot be guaranteed due to failure to collect the safety-related information of product through adverse event monitoring as required, or failure to conduct post-market study and re-evaluation as required.'可被翻译为：（五）未按照要求通过不良事件监测收集产品安全性信息，或者未按照要求开展上市后研究、再评价，无法保证产品安全有效的。\n'(3) fail to promptly discover systemic risks of drug safety, or fail to promptly eliminate drug safety hazards within their supervision and administration region, resulting in serious effects; or'可被翻译为：（三）未及时发现药品安全系统性风险，或者未及时消除监督管理区域内药品安全隐患，造成严重影响；\n\n根据上述已知信息，请将'(6) fails to formulate a risk management plan after a drug goes to market; or'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）未制定药品上市后风险管理计划；"
    },
    {
        "instruction":"已知信息：\n'Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties.'可被翻译为：第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。\n'Article 60 The department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update credit files of the medical device distributors within their administrative areas. The credit files shall include information such as a medical device distributor’s licensing or filing, supervision and inspection results, investigation and punishment of illegal acts, sample testing of quality, self-inspection report, records of misconducts, and compliant reporting, etc.'可被翻译为：第六十条  设区的市级负责药品监督管理的部门应当建立并及时更新辖区内医疗器械经营企业信用档案。信用档案中应当包括医疗器械经营企业许可备案、监督检查结果、违法行为查处、质量抽查检验、自查报告、不良行为记录和投诉举报等信息。\n'The credit file shall include manufacturing licensing filing and manufactured product variety, entrusted manufacturing, supervision and inspection results, investigation of illegal acts, sample testing of quality, records of dishonest behaviors and complaint report, etc.'可被翻译为：信用档案中应当包括生产许可备案和生产产品品种、委托生产、监督检查结果、违法行为查处、质量抽查检验、不良行为记录和投诉举报等信息。\n'Article 42 The medical device manufacturer shall report the variety of the manufactured products to the drug regulatory department.'可被翻译为：第四十二条  医疗器械生产企业应当向药品监督管理部门报告所生产的产品品种情况。\n\n根据上述已知信息，请将'Article 68 The drug regulatory department shall record the varieties of the products manufactured by the enterprise in the credit file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条  药品监督管理部门应当在信用档案中记录企业生产产品品种情况。"
    },
    {
        "instruction":"已知信息：\n'The molecule contains groups that can absorb UV-visible light and produce electronic transition structures.'可被翻译为：分子中含有能吸收紫外-可见光而产生电子跃迁结构的基团。\n'A state description of a molecular vibrational transition process; Sometimes the transition may also occur between excited states, where the lower energy level is not the ground state, and the resulting absorption band is called a thermal band. This peak is weak and is often masked by the fundamental frequency peak.'可被翻译为：分子振动跃迁过程的一种状态描述；有时跃进也可能发生在激发态之间，低能级不是基态，此时产生的吸收谱带称为热谱带。此峰很弱，常被基频峰所掩盖。\n'The property of chemicals to react with another molecule as a consequence of absorption of photons.'可被翻译为：化合物吸收光后与其他分子反应的性质。\n'The phenomenon of enhanced absorption at the short wavelength end of the ultraviolet absorption spectrum. It is produced when the molecules are excited by ultraviolet light, and the electrons in the molecular orbit absorb the photons from the ground state to the excited state, generally located between 180 and 220nm.'可被翻译为：紫外吸收光谱中位于短波末端所出现的吸收增强的现象。是分子在紫外光激发下，分子轨道上的电子吸收了光子后由基态激发到激发态上而产生的，一般位于180~220nm之间。\n\n根据上述已知信息，请将'After absorbing a certain wavelength of infrared light, molecules transition from the ground state to the second or even the third excited state to produce infrared absorption bands.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子吸收一定波长的红外光后，从基态跃迁到第二激发态甚至第三激发态产生的红外吸收带。"
    },
    {
        "instruction":"已知信息：\n'(1) name, model, specification, and quantity of the medical device;'可被翻译为：（一）医疗器械的名称、型号、规格、数量；\n'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;'可被翻译为：（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；\n'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number.'可被翻译为：（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。\n'(2) registration certificate number or filing number of the medical device;'可被翻译为：（二）医疗器械注册证编号或者备案编号；\n\n根据上述已知信息，请将'(1) name, model, specification, registration certificate number or filing number, quantity, unit price and amount of the medical devices;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）医疗器械的名称、型号、规格、注册证编号或者备案编号、数量、单价、金额；"
    },
    {
        "instruction":"已知信息：\n'(I) to verify, item by item, whether the materials submitted are complete and true;'可被翻译为：（一）逐项核查所报资料是否完整、真实；\n'Examine all units visually for container closure integrity, for the presence of any foreign matter in the product and other container closure defects. Note findings on analyst's worksheet.'可被翻译为：目视检查所有装置的容器密封完整性、产品中是否存在任何异物以及其他容器 密封缺陷。在化验员工作表上记录检查结果。\n'analytical worksheet'可被翻译为：分析工作表\n'7. Method description, modifications, and verification along with recording of sample results and appropriate review and evaluation by management'可被翻译为：方法描述、修改和确认，以及样品结果的记录和管理人员的适当审核与评价\n\n根据上述已知信息，请将'7. Worksheets - Review possible falsification or incorrect entry onto worksheets or Laboratory LIM system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工作表—审核是否存在伪造或不正确录入记录或实验室 LIMS 系统的可能性"
    },
    {
        "instruction":"已知信息：\n'(1) failing to supply, receive, and purchase vaccines as required;'可被翻译为：（一）未按照规定供应、接收、采购疫苗；\n'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'可被翻译为：（一）履行职责不力，造成严重不良影响或者重大损失；\n'(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;'可被翻译为：（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；\n'(5) Where, according to the provisions in Article 61 of the Vaccine Administration Law, vaccines have serious adverse events following immunization or are otherwise harmful to human health as indicated by post-marketing evaluation;'可被翻译为：（五）按照《疫苗管理法》第六十一条的规定，经上市后评价，预防接种异常反应严重或者其他原因危害人体健康的；\n\n根据上述已知信息，请将'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。"
    },
    {
        "instruction":"已知信息：\n'The process of putting a new label on the material (see also labelling).'可被翻译为：将新标签贴在材料上的过程(参见标签)。\n'Revision'可被翻译为：版本\n'Revision'可被翻译为：版本号\n'(VII) Improving production process, design and product technical requirements etc.;'可被翻译为：（七）改进生产工艺、设计、产品技术要求等；\n\n根据上述已知信息，请将'(VI) Revising the instructions, labels and operating manual, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）修改说明书、标签、操作手册等；"
    },
    {
        "instruction":"已知信息：\n'The applicant shall be subject to inspection within the specified timeline.'可被翻译为：申请人应当在规定时限内接受核查。\n'(V)  carrying out a verification test when the testing result is objected; and'可被翻译为：（五）对有异议的检验结果进行复验；\n'The applicant for testing refers to the actual owner or the domestic distributor of that batch of imported drugs who is specifically responsible for going through the formalities of importation record filing and port testing.'可被翻译为：报验单位，是指该批进口药品的实际货主或者境内经销商，并具体负责办理进口备案和口岸检验手续。\n'I. Users who have previously passed the test'可被翻译为：一、原通过测试用户\n\n根据上述已知信息，请将'The consignee and the applicant for testing may be the same.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"收货单位和报验单位可以为同一单位。"
    },
    {
        "instruction":"已知信息：\n'Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product.'可被翻译为：任何引入的非原液或成品生产工艺预期部分的外源性物质(如化学、生化物质或微生物)。\n'A medium containing only the minimum combination of components necessary for the growth of a wild-type strain of a microbe.'可被翻译为：仅能满足某微生物的野生型菌株生长需要的最低成分组合的培养基。\n'Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product. (ICH Q6B)'可被翻译为：引入的任何外源性物质(如化学、生化物质或微生物)，而不是原料药或制剂生产过程中的一部分。(ICH Q6B)\n'Medium designed to improve the separation efficiency of desired microorganisms, according to the specific nutritional requirements of a class or microorganism.'可被翻译为：为提高所需微生物的分离效率、根据某・类或某种微生物的特殊营养要求而设计的培养基。\n\n根据上述已知信息，请将'1. Microorganism culture medium (not applicable to microorganism identification and drug sensitivity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.微生物培养基（不用于微生物鉴别和药敏试验）；"
    },
    {
        "instruction":"已知信息：\n'A thin-layer chromatography technique developed on the basis of the high separation efficiency obtained by using a homogeneous stationary phase of fine particles in the high performance liquid chromatography.'可被翻译为：参考高效液相色谱仪使用均一的微细颗粒固定相而得到高分离效率的基础上发展起来的一种薄层色谱技术。\n'thin-layer chromatography'可被翻译为：薄层色谱法\n'In thin layer chromatography, a certain amount of adhesive is added to the fixed phase in advance, spread on the glass plate, and made of thin layer chromatography plate.'可被翻译为：在薄层色谱法中，预先在固定相中加入一定量的黏合剂，铺展在玻璃板上，烘干制成的薄层色谱板。\n'In the distribution chromatography, the fixed liquid is coated on the surface of the carrier by mechanical coating or physical coating, and the separated substance is distributed in two phases to separate the components.'可被翻译为：分配色谱中采用机械涂布或物理涂布把固定液涂在载体表面上，利用被分离物质在两相分配使组分分离的操作。\n\n根据上述已知信息，请将'The stationary phase is spread on the solid in a uniform thin layer for separation and analysis method of chromatography.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将固定相在固体上铺成均匀薄层进行色谱的分离、分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level.'可被翻译为：第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。\n'Article 26 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第二十六条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 18 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第十八条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 58 The drug regulatory departments shall, in accordance with the conditions of supervision and inspection, sample testing of products, monitoring of adverse events, complaint reporting and administrative penalty, etc., carry out risk analysis and assessment through consultation regularly, and make proper investigation and prevention and control of potential medical device quality and safety hazards.'可被翻译为：第五十八条  药品监督管理部门应当根据监督检查、产品抽检、不良事件监测、投诉举报、行政处罚等情况，定期开展风险会商研判，做好医疗器械质量安全隐患排查和防控处置工作。\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments and health administrative departments at all levels may entrust medical device inspection agencies with corresponding qualification to inspect the products involved in medical device adverse events when necessary. A medical device testing institution shall perform the test promptly and issue the test report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条  各级药品监督管理部门和卫生行政部门必要时可以将医疗器械不良事件所涉及的产品委托具有相应资质的医疗器械检验机构进行检验。医疗器械检验机构应当及时开展相关检验，并出具检验报告。"
    },
    {
        "instruction":"已知信息：\n'For imported medical devices, overseas registration applicants (filing applicants)shall apply for registration (handle the filling). For medical devices manufactured in China by overseas enterprises, domestic manufacturing enterprises shall apply for registration (handle the filing) as the registration applicants (filing applicants).'可被翻译为：进口医疗器械，应当由境外注册申请人（备案人）申请注册（办理备案）；境外企业在境内生产的医疗器械，应当由境内生产的企业作为注册申请人（备案人）申请注册（办理备案）。\n'The production of Class II and Class III medical devices with imported medical device registration certificates in China by overseas registrants invested by domestic enterprises in China can be implemented with reference to this Announcement. The domestic enterprises in China that invest the overseas registrants should apply for product registration as the registration applicants.'可被翻译为：中国境内企业投资的境外注册人在境内生产已获进口医疗器械注册证的第二类、第三类医疗器械产品的，参照本公告执行，由投资境外注册人的中国境内企业作为注册申请人申请该产品注册。\n'This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China.'可被翻译为：进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。\n'(I) The foreign-invested enterprise established by an imported medical device registrant in China shall, asthe registration applicant, submit the application for medical device registration in China to the corresponding drug regulatory authority. The content of the registration application, except the name, domicile and production address of the registrant, shall, in principle, be consistent with relevant items specified in the corresponding imported medical device registration certificate and its attachments.'可被翻译为：（一）进口医疗器械注册人在中国境内设立的外商投资企业作为注册申请人，向药品监督管理部门提交境内医疗器械注册申请。注册申请内容，除注册人名称、住所、生产地址外，原则上应当与所对应的进口医疗器械注册证及其附件载明的相关事项保持一致。\n\n根据上述已知信息，请将'The medical device manufacturers mentioned in the preceding paragraph refer to the registrants or filing entities of the domestic medical device products, and the agents appointed by the overseas manufacturer of imported medical devices within the territory of China.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"前款所述医疗器械生产企业，是指境内医疗器械产品注册人或者备案人、进口医疗器械的境外制造厂商在中国境内指定的代理人。"
    },
    {
        "instruction":"已知信息：\n'Analytical equipment and tools used in sterility analysis and suitability should be cleaned and sterilized using a validated sterilization procedure. Commercially purchased equipment and tools should be labeled sterile and accompanied by a certificate of analysis for sterility.'可被翻译为：无菌分析和适用性中所用的分析仪器和工具应使用经验证的灭菌程序进行清洁和灭 菌。商业购买的设备和工具应贴上无菌标签，并附有无菌分析证书。\n'An uninoculated media and rinse fluid control are analyzed to ensure sterility at time of use.'可被翻译为：对未接种培养基和淋洗液控制进行分析，以确保使用时的无菌性。\n'5. Equipment and Instrumentation- (Steritest, manifold, automated\/molecular identification system, Vitek, isolator and bio- decontamination system) review calibration, maintenance, validation (IQ, OQ, PQ)'可被翻译为：设备和仪器（Steritest 无菌检验系统、歧管试验、自动\/分子识别系统、Vitek 系统等、隔离器和生物除污染系统），查看校验、维护、验证（IQ、OQ、PQ）\n'All sterilisation processes should be validated. Validation studies should take into account the product\ncomposition, storage conditions and maximum time between the start of the preparation of a product or material to\nbe sterilised and its sterilisation. Before any sterilisation process is adopted, its suitability for the product and\nequipment, and its efficacy in consistently achieving the desired sterilising conditions in all parts of each type of\nload to be processed should be validated notably by physical measurements and where appropriate by Biological Indicators (BI). For effective sterilisation, the whole of the product, and surfaces of equipment and components\nshould be subject to the required treatment and the process should be designed to ensure that this is achieved.'可被翻译为：所有灭菌工艺均应经过验证。验证研究应考虑产品成分、储存条件以及从待灭菌产品或物料的准备到其灭菌之间的最长时间。在釆用任何灭菌工艺之前，应验证该工艺与其产品和设备的适用性，以及该工艺的效能（即每种装载模式下的所有部位始终达到预期的灭菌效果），验证应主要通过物理测定，在适当情况下通过生物指示剂（BI）。为进行有效的灭菌，产品、设备和部件的表面都应进行必要的灭菌处理，灭菌过程的设计应确保实现有效灭菌。\n\n根据上述已知信息，请将'a. Review QC records for proper\/validated sterilization of all equipment and media used during the sterility test method: manifold\/ Steritest; rinse fluid, culture media, canister kits, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审核 QC 记录，查看无菌检测中所用的所有设备和培养基是否均有经过恰当\/经验证的灭菌：歧管\/ Steritest 检验系统；冲洗液、培养基、灌装配套工具等"
    },
    {
        "instruction":"已知信息：\n'The administrative department that examines and approves, supervises and penalizes the research, production, distribution and use of drugs according to law.'可被翻译为：依法对药品的研制、生产、经营、使用进行审批、监督及违法处罚的行政部门。\n'Article 72 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, strictly enforce the discipline of clean government, and shall not ask for or accept property, seek for other interests, or hinder normal manufacturing activities of the enterprises.'可被翻译为：第七十二条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常生产活动。\n'Article 64 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, and strictly enforce the discipline of clean government, shall not ask for or accept property, seek for other interests, or hinder normal distribution activities of the enterprises.'可被翻译为：第六十四条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常经营活动。\n'Article 61 On-site control actions shall be promptly taken, and evidence collection shall be performed as specified in case of any suspected violation of drug laws, regulations and rules found during drug production supervision and inspection. The drug regulatory department shall, in accordance with its duties and authorities, investigate and handle the case according to laws, and transfer the suspects to the public security authorities for handling.'可被翻译为：第六十一条 开展药品生产监督检查过程中，发现存在涉嫌违反药品法律、法规、规章的行为，应当及时采取现场控制措施，按照规定做好证据收集工作。药品监督管理部门应当按照职责和权限依法查处，涉嫌犯罪的移送公安机关处理。\n\n根据上述已知信息，请将'The administrative body of drug supervision and administration. Supervision and inspection of the other party's compliance with laws, administrative regulations, administrative orders, decisions and measures in accordance with its statutory functions and powers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理的行政主体。依照法定职权，对行政相对方是否遵守法律、行政法规、行政命令、决定和措施所进行的监督检查。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。\n'Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。\n'Article 2 These Provisions shall apply to medical device manufacturing activities and its supervision and administration within the territory of the People’s Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械生产活动及其监督管理，应当遵守本办法。\n'Article 2 These Provisions shall apply to medical device distribution activities and their supervision and administration within the territory of the People's Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械经营活动及其监督管理，应当遵守本办法。\n\n根据上述已知信息，请将'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。"
    },
    {
        "instruction":"已知信息：\n'The action of chemical or biological materials that can trigger the development of cancer.'可被翻译为：化学或生物材料可引发癌症发生的作用。\n'The ability of a substance to cause alteration in a living organism, tissue, cell, or active molecule.'可被翻译为：某物质能引起活体、活组织、活细胞或活性分子发生改变的能力。\n'Carcinogens which produce cancer by affecting genes or chromosomes.'可被翻译为：指通过影响基因或染色体而致癌的物质。\n'The alteration of an organism's chromosomes or genes by physical or chemical mutagens.'可被翻译为：通过物理或化学诱变剂造成生物染色体或基因的改变而产生遗传性状的变异。\n\n根据上述已知信息，请将'A substance that does not react with DNA and may indirectly affect DNA and alter the genome to cause cells to become cancerous or cause cancer by promoting growth or enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不与DNA反应，可能间接影响DNA并改变基因组导致细胞癌变或通过促长，增强作用导致癌产生的物质。"
    },
    {
        "instruction":"已知信息：\n'1.Analysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n2.A regime of testing to verify that a lot complies with the specification.'可被翻译为：1.活性药物成分(api)、药用辅料、包装材料或药品根据药典各论的要求或已批准上市许可的规范进行分析。\n2.一套测试制度，以验证产品是否符合规格。\n'1.An officially conducted examination (i.e. review of the conduct of the trial, including quality assurance, personnel involved, any delegation of authority and audit) by relevant authorities at the site of investigation and\/or at the site of the sponsor in order to verify adherence to GCP and GLP as set out in this document.\n2.An official examination, normally conducted on site, of the compliance with WHO good manufacturing practices as referred to in this document. In some cases, an off-site review of documentation may be done in lieu of the on-site examination.\n3.An on-site evaluation by a regulatory authority of a manufacturing facility to determine whether such manufacturing facility is operating in compliance with regulatory requirements and or commitments made as part of the approval to market a product (11).'可被翻译为：1.由调查现场和\/或申办者现场的相关部门进行的正式检查(即对试验进行的审查，包括质量保证、相关人员、任何授权和审计)，以验证本文件中规定的GCP和GLP的遵守情况。\n2.通常在现场进行的符合本文件所述WHO良好生产规范的官方检查。在某些情况下，可以对文件进行非现场审查，以代替现场检查。\n3.监管机构对生产设施的现场评估，以确定该生产设施的运营是否符合监管要求和\/或作为产品上市批准一部分的承诺(11)。\n'good manufacturing practices (GMP). That part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.'可被翻译为：优良生产规范（GMP）：质量保证中确保药品被持续生产和检测达到其既定用途所需的合适质量标准并符合上市许可要求的一部分\n'(vi) Records are made of the results of inspection and that testing of materials, intermediate, bulk, and finished products is formally assessed against specification. Product assessment includes a review and evaluation of relevant production documentation and an assessment of deviations from specified procedures;'可被翻译为：(vi)应当记录检验结果和根据质量标准对物料、中间、散装和成品的正式评估。产品评估包括对相关生产文件的审查和评估以及不符合规定程序的偏差的评估；\n\n根据上述已知信息，请将'The evaluation of documentary evidence by a competent regulatory authority recognized by the national regulatory authority, for compliance with the required good practices (good manufacturing practices (GMP), good laboratory practices and good clinical practices) in support of marketing authorization and other regulatory decisions. Desk assessment may be performed in support of a new marketing authorization, or for routine GMP inspection (including in the frame of specified product(s) life-cycle management as required).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由国家监管机构认可的主管监管机构对文件证据的评估，以证明符合所需的良好规范(良好生产规范(GMP)、良好实验室规范和良好临床规范)，以支持上市许可和其他监管决定。案头评估可用于支持新的上市许可，或用于常规GMP检查(包括在所要求的指定产品生命周期管理框架内)。"
    },
    {
        "instruction":"已知信息：\n'CDE accepted 5,979 applications for registration of chemical drugs, of which107 were for NDAs, an increase of 43%compared with 2017; and 982 applications were for ANDAs (generic drugs), an increase of 79% compared with 2017. The details of the acceptance of registration application for various classes of chemical drugs are shown in Figure 2. The 2015-2018 acceptance of registration applications for clinical trial,marketing and consistency evaluation of chemical drugs is detailed in Figure 3.'可被翻译为：药审中心受理化药注册申请共5979件，其中受理化药NDA申请107件，较2017年增长了43%；受理仿制药上市申请（ANDA）982件，较2017年增长了79%。化药各类注册申请受理情况详见图2。2018年化药临床、上市和一致性评价注册申请受理情况与近三年比较详见图3。\n'CDE completed the review of registration applications for 6,624 chemical drugs, including 843 clinical applications (IND and confirmatory trial), 206 NDAs, and 2,353 ANDAs. See Figure 14 for details of the various registration applications for chemical drugs that have been reviewed.'可被翻译为：药审中心完成审评的化药注册申请6624件，其中完成化药临床申请（IND和验证性临床）共843件，完成化药NDA 206件，完成化药ANDA 2353件。完成审评的化药各类注册申请情况详见图14。\n'In 2019, CDE accepted a total of 8,082 new registration applications (including 5 drug-device combination products, counted by acceptance numbers, the same below), of which 6,199 applications are subject to technical review (including 4,907 applications subject to technical review and administrative approval of CDE), and the rest of 1,878 applications are subject to direct administrative approval (not requiring technical review, the same below).'可被翻译为：2019年，药审中心受理新注册申请8082件（含器械组合产品5件，以受理号计，下同），其中需技术审评的注册申请6199件（含4907件需药审中心技术审评和行政审批的注册申请），直接行政审批（无需技术审评，下同）的注册申请1878件。\n'In 2018, CDE accepted a total of 7,336new registration applications (counted by acceptance numbers, the same below), of which 5,574 are subject to technical review,the rest to direct administrative examination and approval (dispense with technical review,the same below). Compared with 2017, the number of registration applications requiring technical review by CDE saw a substantial increase (up by 47%) in 2018, whereof the numbers of applications for registration of TCMs, chemicals and biologicals all saw a significant increase (up by 30%, 50% and42%, respectively).'可被翻译为：2018年，药审中心受理新注册申请共7336件（以受理号计，下同），其中需技术审评的注册申请5574件，直接行政审批（无需技术审评，下同）的注册申请1762件。与2017年相比，2018年药审中心需技术审评的注册申请任务受理量大幅增长（较2017年增长了47%），且中药、化药和生物制品各类药品注册申请任务受理量均有较大幅度增长（较2017年分别增长了30%、50%和42%）。\n\n根据上述已知信息，请将'Of the 8,077 drug registration applications accepted by CDE, 80.2% (6,475) of the total are chemical drugs applications in 2019. See Figure 1 for the acceptance of registration applications for various classes of drugs in 2016-2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心受理的8077件药品注册申请中，化学药注册申请受理量为6475件，占2019年全部注册申请受理量的80.2%，2016-2019年各类药品注册申请受理情况详见图1。"
    },
    {
        "instruction":"已知信息：\n'The genetic information carried by the nucleotide sequence. A set of 64 triplet codons that encode the start and end of 20 amino acid and polypeptide chains.'可被翻译为：核昔酸序列所携带的遗传信息。编码20种氨基酸和多肽链起始及终止的一套64个三联体密码子。\n'genetic information'可被翻译为：遗传信息\n'The DNA sequence corresponding to mature mRNA, rRNA, or tRNA molecules in eukaryotic genes. Is the coding sequence.'可被翻译为：真核生物基因中与成熟mRNA、rRNA或tRNA分子相对应的DNA序列。为编码序列。\n'The nucleotide sequence containing specific genetic information is the smallest functional unit of genetic information.'可被翻译为：含特定遗传信息的核昔酸序列，是遗传信息的最小功能单位。\n\n根据上述已知信息，请将'The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。"
    },
    {
        "instruction":"已知信息：\n'ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet the appropriate specifications in order to ensure the requirements of the method or specification are met;'可被翻译为：确保QC具备所需的仪器，并经过确认。分析方法转移期间RU所用仪器应符合适当的标准，以确保满足方法要求或标准要求；\n'12.23. During the transfer process, the RU should identify any differences in facilities, systems and capabilities and discuss these with the SU. The SU should cooperate with the RU to understand the potential impact and satisfactorily address this in order to assure equivalent product quality. based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop the relevant site operating procedures and documentation before the start of routine production.'可被翻译为：在转移过程中，RU应该找出设施、系统和能力方面的所有差异，并与SU进行讨论。SU应该与RU合作，了解潜在影响，并圆满解决这些问题，从而确保产品质量一致。基于从SU处收到的信息，RU应该考虑其自己生产和包装该产品达到所需标准的能力，应在开始常规生产之前建立相关的现场操作程序和文件。\n'4.2. The suitability and degree of preparedness of the RU should be assessed prior to the start of the transfer. The procedure to be followed should be documented.'可被翻译为：在转移开始之前，应对RU的适用性和准备程度进行评估。应记录准备遵守的程序。\n'5.5. The SU should provide criteria and information on inherent risks, hazards and critical steps associated with the process, product or procedure to be transferred. This may serve as a basis for the risk assessment exercise.'可被翻译为：SU应提供准备转移的工艺、产品或方法相关的固有风险、危害和关键步骤的标准和信息。这可作为风险评估活动的基础。\n\n根据上述已知信息，请将'5.12. The SU should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms and pharmaceutical quality system - QC procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"转移前SU应评估RU的在设施、设备和支持服务（例如采购和库存控制机制和药物质量体系—QC程序、文件、计算机验证、场所验证、设备确认、制药生产用水和三废管理）方面的适合度和准备就绪程度。"
    },
    {
        "instruction":"已知信息：\n'The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.'可被翻译为：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。\n'Within the design range, the degree to which the test result (response value) is directly proportional to the concentration or amount of the tested substance in the sample, or the change in the concentration of the tested substance is linearly related to the test result. Regression equations, correlation coefficients and linear graphs should be listed for data requirements.'可被翻译为：在设计的范围内，测试结果（响应值）与试样中被测物的浓度或量直接呈正比关系的程度，或说供试物浓度的变化与试验结果成线性关系。数据要求应列出回归方程、相关系数和线性图。\n'The interval between the upper and lower concentration (amounts) of analyte in the calibration standards (including these concentrations)'可被翻译为：校正标样中待测物的高、低浓度区间（包括两端浓度）。\n'A matrix to which a known amount of analyte has been added or spiked. Calibration standards are used to construct calibration curves.'可被翻译为：加入已知量待测物的基质。校正标样被用于构建校正曲线。\n\n根据上述已知信息，请将'A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。"
    },
    {
        "instruction":"已知信息：\n'The potential to induce direct DNA damage through chemical reaction with DNA.'可被翻译为：通过与DNA发生化学反应直接诱导DNA损伤的潜在能力。\n'dna adduct'可被翻译为：DNA 加合物\n'In nucleic acid molecules, bases that can be paired with each other by hydrogen bonding.'可被翻译为：在核酸分子中，可以通过氢键相互配对的碱基。\n'chemical biology'可被翻译为：化学生物学\n\n根据上述已知信息，请将'Electrophilic compounds and their metabolites form covalent conjugates with DNA in living organisms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"亲电性化合物及其代谢产物和生物体内的DNA形成的共价结合物。"
    },
    {
        "instruction":"已知信息：\n'A reference stringent regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers, does not object to sharing of these documents with national medicines regulatory authorities and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'可被翻译为：参考严格监管机构同意向申请人\/授权持有人或被检查制造商提供其监管专业知识的结果(特别是评估和检查报告)，不反对与国家药品监管机构共享这些文件，并在符合程序原则的规定条件下向程序涉及的其他各方提供支持。\n'For the purpose of this document, a national or regional authority or a trusted institution such as WHO prequalification (WHO PQ) whose regulatory decisions and\/or regulatory work products are relied upon by another regulatory authority to inform its own regulatory decisions.'可被翻译为：为本文件的目的，国家或区域主管部门或WHO资格预审(WHO资格预审)等值得信赖的机构，其监管决定和\/或监管工作产品是另一个监管机构赖以为其自身监管决定提供信息的依据。\n'A system of shared regulatory responsibilities in which an industry association or professional group assumes some regulatory functions, such as surveillance and enforcement or setting regulatory standards.'可被翻译为：一种共同监管责任的制度，由行业协会或专业团体承担一些监管职能，如监督和执行或制定监管标准。\n'participating stringent regulatory authority'可被翻译为：参与的严格监管机构\n\n根据上述已知信息，请将'A regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers; agrees to sharing of these documents with national regulatory authorities; and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"同意向申请人\/授权持有人或被检查制造商提供其监管专业知识结果(特别是评估和检查报告)的监管机构;同意与国家监管机构共享这些文件;并在符合程序原则的特定条件下，向参与程序的其他各方提供支持。"
    },
    {
        "instruction":"已知信息：\n'Raw material controls - including in-process controls'可被翻译为：原辅料控制——包括过程控制\n'A \"system control\" is used to demonstrate maintenance of sample integrity during all analytical manipulations. Any piece of equipment that comes in contact with the product under analysis, along with any manipulations by the analysts, must be controlled. Thus, all equipment, fluids, and culture media for the \"system control\" must be handled in a manner which duplicates, as closely as possible, the manipulations of the actual sample being analyzed. All materials used as system controls must be sterilized by the analyzing laboratory. However, the method of sterilization need not be the same as for the product, but they must render the material sterile.'可被翻译为：在所有分析操作过程中，“系统控制”用于证明样品完整性的维护。在分析中与产 品接触的任何设备，以及分析人员的任何操作都必须加以控制。因此，用于“系统 控制”的所有设备、液体和培养基必须与被分析的实际样品尽可能接近的方式进行 处理。用于系统控制的所有物料必须通过分析实验室进行灭菌。物料灭菌的方法不 必与产品相同，但是必须使物料无菌。\n'A series of operations to circulate materials, intermediate products, bulk products, documents, production molds, etc. within the manufacturer.'可被翻译为：指生产过程中物料、中间产品、待包装产品、文件、生产用模具等在企业内部流转的一系列操作。\n'Equipment Controls'可被翻译为：设备控制\n\n根据上述已知信息，请将'Alternatively, controls for these materials are accomplished as part of the \"system control\" for each manifold. This will also include membrane cutters, and other items that contact the product but cannot be individually controlled.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"或者，完成对这些材料的控制，作为每个歧管的“系统控制”的一部分。这还将 包括薄膜切割器和其他接触产品但无法单独控制的物品。"
    },
    {
        "instruction":"已知信息：\n'The extent to which the results of a particular study or systematic review can be extrapolated to other Settings.'可被翻译为：某种研究或者系统综述的结果能够外推于其他环境的程度。\n'(1) There shall be source data to confirm that all the subjects actually participate in the clinical trial.'可被翻译为：(1) 有源数据支持以证实所有受试者确实参与了临床试验。\n'A clinical study in which patients are not restricted to a clinical site.'可被翻译为：受试人群不局限于临床研究地点的临床研究。\n'A precise description of the treatment effect reflecting the clinical question posed by the trial objective. It summarises at a population-level what the outcomes would be in the same patients\nunder different treatment conditions being compared.'可被翻译为：对治疗效应的精确描述，反映了针对临床试验目的提出的临床问题。它在群体水平上汇总比较相同患者在不同治疗条件下的结局。\n\n根据上述已知信息，请将'The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指将临床试验的发现从参与试验的受试者可靠地外推到更广泛的患者人群和临床环境的程度。"
    },
    {
        "instruction":"已知信息：\n'A method of assessing the level of air cleanliness against a specification for a cleanroom or clean air equipment by measuring the total particle concentration.'可被翻译为：根据洁净室或洁净空气设备的规格，通过测量总颗粒浓度来评估空气洁净度水平的一种方法。\n'particulate matter monitoring'可被翻译为：微粒监测\n'A purification measure for the purpose of producing clean air.'可被翻译为：以制造洁净空气为目的净化措施。\n'A method of assessing the level of compliance of a classified cleanroom or clean air equipment with its intended use.'可被翻译为：评估分类洁净室或洁净空气设备与其预期用途的符合性水平的方法。\n\n根据上述已知信息，请将'It mainly measures the size of dust particles in the air and counts the concentration, which is used to monitor the cleanliness of the air.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要测量空气中尘埃粒子的大小以及计数浓度，用于监测空气洁净度。"
    },
    {
        "instruction":"已知信息：\n'enzyme'可被翻译为：酶\n'Enzymes used in the prevention, treatment, and diagnosis of certain diseases.'可被翻译为：用于某些疾病的预防、治疗和诊断的酶。\n'An enzyme that catalyzes the joining of two molecules into one or the end of a molecule.'可被翻译为：能催化两个分子连接成一个分子或把一个分子的首尾相连接的酶。\n'A class of stable compounds. It mimics the transition state structure of a substrate to a product in an enzyme-catalyzed reaction.'可被翻译为：一类稳定的化合物。它模拟酶催化反应中底物转变成产物过程中的过渡态结构。\n\n根据上述已知信息，请将'A group of enzymes that catalyze the same chemical reaction but differ in molecular structure, physicochemical properties, and even immunological properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"催化作用的化学反应相同而分子结构、理化性质乃至免疫学性质不同的-组酶。"
    },
    {
        "instruction":"已知信息：\n'transformation'可被翻译为：转化\n'linearity'可被翻译为：线性\n'When the geometric shape of particles is quantitatively described by mathematical means, various dimensionless combinations of particles are used.'可被翻译为：以数学方式定量描述粒子的几何形状时，粒子的各种无因次组合。\n'linear dynamics'可被翻译为：线性动力学\n\n根据上述已知信息，请将'For a given set of variables, a new set of variables is generated by mathematical transformation. These new variables are linear functions of the original set of variables, but the two new variables are unrelated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对给定的一组变量，通过数学变换生成新一组的变量，这些新变量是原来一组变量的线性函数，两个新变量之间却是互不关联的。"
    },
    {
        "instruction":"已知信息：\n'The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon.'可被翻译为：在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。\n'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'可被翻译为：混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。\n'Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.'可被翻译为：混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。\n'flocculation'可被翻译为：絮凝\n\n根据上述已知信息，请将'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'ophthalmic preparation'可被翻译为：眼用制剂\n'The semi-solid ophthalmic preparation is made of a sterile solution or a suspended paste, which is evenly mixed with a suitable substrate.'可被翻译为：由药物与适宜基质均匀混合，制成无菌溶液型或混悬型膏状的眼用半固体制剂。\n'The drug is an ophthalmic preparation with a certain shape and slow release in the conjunctiva capsule with a polymer film-forming material as the carrier.'可被翻译为：药物以高分子成膜材料为载体，制成一定形状，在结膜囊内缓慢释药的眼用制剂。\n'ophthalmic solution'可被翻译为：洗眼剂\n\n根据上述已知信息，请将'A pasteurized preparation for ophthalmic use made of medicine and a suitable substrate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物与适宜基质制成的供眼用的膏状灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 7: The manufacturer should be adequately resourced with competent personnel, suitable and sufficient premises, equipment and facilities for achieving its quality objective.'可被翻译为：第七条 企业应当配备足够的、符合要求的人员、厂房、设施和设备，为实现质量目标提供必要的条件。\n'The manufacturer should ensure that there are sufficient appropriate personnel, suitably qualified, trained and experienced in the manufacture and testing of sterile products, and any of the specific manufacturing technologies\nused in the site's manufacturing operations, to ensure compliance with GMP applicable to the manufacture and handling of sterile products.'可被翻译为：生产商应确保具有足够数量的合适人员，这些人员在无菌产品生产和检验以及该场地生产操作所用的任何\n具体生产技术方面经过适当的资质确认、培训并富有经验，以确保符合无菌产品生产和处理相关 GMP 要\n求。\n'A manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.'可被翻译为：代原制造商从事某些生产活动的制造商。\n'A system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.'可被翻译为：预期对产品质量有直接影响的系统。这些系统的设计和调试符合良好工程实践(GEP)，此外，还受资格认证实践的约束。\n\n根据上述已知信息，请将'The manufacturer has sufficient knowledge and expertise in relation to the products manufactured and the equipment, engineering and manufacturing methods employed that have an impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产商对所生产的产品以及对产品质量有影响的设备、工程和制造方法具备充分的知识和专业技能。"
    },
    {
        "instruction":"已知信息：\n'A certified, homogeneous substance used for specific chemical and physical tests. One or more properties of the chemical reference required in the test to be compared with the sample to be tested, and the chemical reference should be of an appropriate purity for its purpose.'可被翻译为：用于特定化学和物理检测的经过检定、性质均匀的物质。在检测中需要化学对照品的一个或多个性质与待测样品进行比较，化学对照品应具有满足其用途的适当纯度。\n'Primary chemical reference substances are substances that are widely acknowledged to have the appropriate qualities within a specified context, and whose assigned content when used as a (mostly as an assay) standard is accepted without requiring comparison to another chemical substance (7).'可被翻译为：主要化学标准物质是在特定环境中被广泛认可具有适当质量的物质，其指定含量在用作(主要是作为分析)标准时被接受，而无需与另一种化学物质进行比较(7)。\n'Secondary chemical reference substances (also called working standards) are substances whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than for a primary chemical reference substance (7).'可被翻译为：二级化学标准物质(也称为工作标准品)是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质(7)。\n'A secondary chemical reference substance is a substance whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than  for a primary chemical reference substance. Although this definition may apply inter alia to some substances termed “working standards”, part B of these guidelines is intended to apply to secondary reference substances supplied as “official”, e.g. regional\/national standards, and not to manufacturers’ or other laboratories’ working standards.'可被翻译为：二级化学标准物质是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质。虽然该定义可特别适用于一些被称为“工作标准”的物质，但本指南B部分旨在适用于作为“官方”提供的二级标准物质，例如区域\/国家标准，而不适用于制造商或其他实验室的工作标准。\n\n根据上述已知信息，请将'1.The term chemical reference substances, as used in this text, refers to an authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.\n2.An authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.本文所用的“化学对照物质”一词是指一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有足以满足其预期用途的纯度。\n2.一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有适合其预期用途的纯度。"
    },
    {
        "instruction":"已知信息：\n'Article 41 The undertaking of drug manufacturing shall be subject to approval by the local drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the central government, and shall obtain a Drug Manufacturing Certificate. No one may manufacture drugs without the certificate.'可被翻译为：第四十一条 从事药品生产活动，应当经所在地省、自治区、直辖市人民政府药品监督管理部门批准，取得药品生产许可证。无药品生产许可证的，不得生产药品。\n'Article 21 The National Institute for the Control of Pharmaceutical and Biological Products shall be responsible for guiding and coordinating the port testing for drugs to be imported. The biological reference standard and chemical reference substance required for port testing shall be reviewed and characterized by the National Institute for the Control of Pharmaceutical and Biological Products.'可被翻译为：第二十一条 中国药品生物制品检定所负责进口药品口岸检验工作的指导和协调。口岸检验所需标准品、对照品由中国药品生物制品检定所负责审核、标定。\n'Article 9 Applicants shall be enterprises or drug R&D institutions that can undertake corresponding legal liability. Overseas applicants shall designate an enterprise legal person within the territory of the People's Republic of China to handle matters relating to drug registration.'可被翻译为：第九条 申请人应当为能够承担相应法律责任的企业或者药品研制机构等。境外申请人应当指定中国境内的企业法人办理相关药品注册事项。\n'Article 117 For supplementary applications of drug manufacturing technology transfer, altering formula or manufacturing process that may affect product quality, etc., the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall organize production site inspection, according to the attachment of the Letter of Approval for Drug Registration or the verified manufacturing process. Drug testing institutes shall conduct testing on samples of three batches of product.'可被翻译为：第一百一十七条 对药品生产技术转让、变更处方和生产工艺可能影响产品质量等的补充申请，省、自治区、直辖市药品监督管理部门应当根据其《药品注册批件》附件或者核定的生产工艺，组织进行生产现场检查，药品检验所应当对抽取的3批样品进行检验。\n\n根据上述已知信息，请将'Article 9 An entity which applies for port testing shall be an independent legal entity and hold the Drug Supply Certificate. A drug manufacturer shall hold the Drug Manufacturing Certificate to import the active pharmaceutical ingredients and intermediate (including pharmaceutical preparations for re-packaging within China) used for its own manufacture.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 报验单位应当是持有《药品经营许可证》的独立法人。药品生产企业进口本企业所需原料药和制剂中间体（包括境内分包装用制剂），应当持有《药品生产许可证》。"
    },
    {
        "instruction":"已知信息：\n'The infusion of nutrients into the patient's body by a completely non-gastrointestinal route. It is of great significance for the treatment of certain diseases, especially for critically ill patients who cannot be taken orally, playing a life-saving role.'可被翻译为：完全由非胃肠途径输入病人体内的营养。它对于某些疾病的治疗有着重要的意义，特别对于不能口服的危重病人，起到挽救生命的作用。\n'A method of standard infusion of an organ with artificial blood or nutrient solution.'可被翻译为：将器官进行人工血液或营养液标准灌注的方法。\n'A method of administration in which a drug injection (liquid) with water as the solvent is injected directly into a vein.'可被翻译为：将以水为溶媒的药物注射液(药液)直接注射入静脉的给药方法。\n'intravenous injection'可被翻译为：静脉注射\n\n根据上述已知信息，请将'A type of intravenous infusion. Clinical according to the needs of special conditions, the injection containing essential nutrients - amino acids, fats, carbohydrates, vitamins, trace elements, etc., is directly injected into the vein administration method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"静脉输液的一种。临床针对特殊病情需要，将含有人体必需的营养素--氨基酸、脂肪、碳水化合物、维生素、微量元素等的注射液直接注射入静脉的给药方法。"
    },
    {
        "instruction":"已知信息：\n'(IX) Break-bulk drugs whose outer packages have been removed shall be stored in a centralized manner;'可被翻译为：（九）拆除外包装的零货药品应当集中存放；\n'(VIII) LCL shipping: the method of packing break-bulk drugs into the same packaging box for shipping;'可被翻译为：（八）拼箱发货：将零货药品集中拼装至同一包装箱内发货的方式。\n'drug substance (bulk material)'可被翻译为：原液\n'(3) Sub-packaging of drugs;'可被翻译为：（三）药品分包装；\n\n根据上述已知信息，请将'(VII) Break-bulk drugs: drugs with their packaging for transportation and storage removed;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）零货：拆除了用于运输、储藏包装的药品。"
    },
    {
        "instruction":"已知信息：\n'biochemical engineering'可被翻译为：生化工程\n'The use of engineering means to make use of certain functions of living organisms (mainly microorganisms) and active in vitro enzymes to produce useful biological products for human beings, or a technology in which microorganisms are directly involved in controlling certain industrial production processes.'可被翻译为：采用工程技术手段，利用生物（主要是微生物）和有活性的离体酶的某些功能，为人类生产有用的生物产品，或直接用微生物参与控制某些工业生产过程的一种技术。\n'Using traditional methods such as biochemistry and biophysics and modern biotechnology such as gene engineering, cell engineering, protein separation and purification technology and bioreactor, the preparation of biological materials such as animals, plants and microorganisms, from which bioactive substances are separated and extracted.'可被翻译为：采用生物化学、生物物理学等传统方法及基因工程、细胞工程、蛋白质分离纯化技术和生物反应器等现代生物技术，将动物、植物和微生物等生物材料加以制备，从中分离提取出具有生物活性物质的一门学科。\n'fermentation engineering'可被翻译为：发酵工程\n\n根据上述已知信息，请将'An important part of bioengineering, including substrate or nutrient solution preparation, pretreatment, transformation and product separation, refining and other engineering and technology. Generally, fermentation engineering, large-scale culture of plant and animal cells, enzyme engineering, biochemical reaction engineering, biological separation engineering (downstream engineering), biological functional components (such as enzyme electrodes, etc.) and the control and optimization of biological processes are included in biochemical engineering.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生物工程的重要组成部分，包括底物或营养液的准备、预处理、转化以及产品的分离、精制等工程和工艺。一般把发酵工程、动植物细胞的大规模培养、酶工程、生化反应工程、生物分离工程（下游工程）、生物功能元件（如酶电极等）以及生物过程中的控制和优化都包括在生化工程之内。"
    },
    {
        "instruction":"已知信息：\n'Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)'可被翻译为：为消除已发现的违规或其他非期望状况的原因(所采取)的措施。注:采取纠正措施是为了防止(事情)再次发生，而采取预防措施是为了防止(事情)发生。 (ISO 9000:2005)\n'1.Steps taken to eliminate the cause of existing nonconformities in order to prevent recurrence. The corrective action process tries to make sure that existing nonconformities and potentially undesirable situations do not happen again.\n2.Steps that are taken to eliminate the causes of existing nonconformities in order to prevent recurrence. The corrective action process tries to ensure that existing nonconformities and potentially undesirable situations do not happen again.'可被翻译为：1.为消除现有不合格的原因而采取的步骤，以防止不合格的再次发生。纠正措施过程试图确保已存在的不符合和潜在的不良情况不再发生。\n2.为消除现有不符合的原因，防止不符合再次发生而采取的步骤。纠正措施过程试图确保已存在的不符合和潜在的不期望情况不再发生。\n'corrective action'可被翻译为：纠正措施\n'Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. (ISO 9000:2005)'可被翻译为：为消除潜在的违规或其他潜在的非期望状况的原因(所采取)的措施。注:采取预防措施是为了防止(事情)发生，而采取纠正措施是为了防止(事情)再次发生。(ISO 9000:2005)\n\n根据上述已知信息，请将'Any action that is taken to eliminate a nonconformity. However, corrections do not address causes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为消除不符合而采取的任何措施。然而，纠正不解决原因。"
    },
    {
        "instruction":"已知信息：\n'Article 39 After completion of a clinical trial, the applicant shall submit a clinical trial final report, a statistical analysis report and its database to the State Food and Drug Administration.'可被翻译为：第三十九条 申请人完成临床试验后，应当向国家食品药品监督管理局提交临床试验总结报告、统计分析报告以及数据库。\n'Article 37 Prior to conducting a clinical trial, the applicant shall report to the State Food and Drug Administration for record while copying to the drug regulatory department of the seat of the clinical trial institution and that of the province, autonomous region or municipality directly under the Central Government to receive the application a confirmed clinical trial protocol, the name of the principal investigator at the institution in charge of the clinical trial, a list of participating institutions and names of investigators where from, an ethic committee approval letter, and a template of the informed consent form, etc.'可被翻译为：第三十七条 申请人在药物临床试验实施前，应当将已确定的临床试验方案和临床试验负责单位的主要研究者姓名、参加研究单位及其研究者名单、伦理委员会审核同意书、知情同意书样本等报送国家食品药品监督管理局备案，并抄送临床试验单位所在地和受理该申请的省、自治区、直辖市药品监督管理部门。\n'After a clinical trial is completed, the applicant shall fill the Application Form for Drug Registration, submit the clinical trial data, other altered and supplementary data in accordance with regulations, give in detail the basis and reasons, and provide relevant approved documents.'可被翻译为：临床试验结束后，申请人应当填写《药品注册申请表》，按照规定报送临床试验资料及其他变更和补充的资料，并详细说明依据和理由，提供相关证明文件。\n'Article 82 After completing drug clinical trials, applicants shall submit clinical trial data to the Center for Drug Evaluation of the State Food and Drug Administration. The State Food and Drug Administration shall issue a drug approval number or a Disapproval Notice based on the technical review opinions.'可被翻译为：第八十二条 申请人完成临床试验后，应当向国家食品药品监督管理局药品审评中心报送临床试验资料。国家食品药品监督管理局依据技术意见，发给药品批准文号或者《审批意见通知件》。\n\n根据上述已知信息，请将'(4) the applicant shall submit a complete clinical trial report to the State Food and Drug Administration after the completion of a clinical trial; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）临床试验结束后，申请人应当将完整的临床试验报告报送国家食品药品监督管理局；"
    },
    {
        "instruction":"已知信息：\n'Article 41 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'可被翻译为：第四十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。\n'Article 39 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第三十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n'Article 49 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第四十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n'Article 50 For an accepted registration application, the applicant may, prior to the administrative permission decision is made, withdraw the registration application and relevant materials, and give reasons to the food and drug regulatory department which accepted the application.'可被翻译为：第五十条 对于已受理的注册申请，申请人可以在行政许可决定作出前，向受理该申请的食品药品监督管理部门申请撤回注册申请及相关资料，并说明理由。\n\n根据上述已知信息，请将'Article 51 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。"
    },
    {
        "instruction":"已知信息：\n'The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world.'可被翻译为：任何公司的任何含有活性物质的药品在世界上任何国家\/区域被首次批准上市销售的日期。\n'interventional clinical trial'可被翻译为：干预性临床试 验\n'Article 30 Clinical trials of medical devices shall be conducted within 3 years after approval. Where it is not conducted in due time, the original approval document shall be invalid automatically. Where the clinical trial still needs to be conducted, a new application shall be submitted.'可被翻译为：第三十条 医疗器械临床试验应当在批准后3年内实施；逾期未实施的，原批准文件自行废止，仍需进行临床试验的，应当重新申请。\n'Article 40 A clinical trial shall be conducted within three years after approval. If overdue, the original approval documents shall be invalid. If the clinical trial is still needed, the application shall be reapplied for.'可被翻译为：第四十条 药物临床试验应当在批准后3年内实施。逾期未实施的，原批准证明文件自行废止；仍需进行临床试验的，应当重新申请。\n\n根据上述已知信息，请将'Date of first approval (or authorisation) for conducting an interventional clinical trial in any country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"干预性临床试验在任何国家首次获准（或许可的）的日期。"
    },
    {
        "instruction":"已知信息：\n'Article 79 The investigator may, according to the needs of the clinical trial, authorize corresponding personnel to recruit subjects, communicate with the subjects, record the clinical data and manage the investigational medical device. The investigator shall carry out relevant training and form the corresponding document for the personnel authorized.'可被翻译为：第七十九条 研究者可以根据临床试验的需要，授权相应人员进行受试者招募、与受试者持续沟通、临床试验数据记录、试验用医疗器械管理等。研究者应当对其授权的人员进行相关的培训并形成相应的文件。\n'Article 63 The investigator shall ensure that the relevant working personnel involved in the trial are familiar with the principles, scope of application, product performance, operating methods, installation requirements and technical specifications of the investigational medical device, understand the pre-clinical study data and safety data of the investigational medical device, and master the prevention and emergency treatment methods for possible risks in the clinical trial.'可被翻译为：第六十三条 研究者应当确保参与试验的有关工作人员熟悉试验用医疗器械的原理、适用范围、产品性能、操作方法、安装要求以及技术指标，了解该试验用医疗器械的临床前研究资料和安全性资料，掌握临床试验可能产生风险的防范以及紧急处理方法。\n'Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.'可被翻译为：第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。\n'Article 21 Before a subject is to be involved in the clinical trial, the investigator shall adequately explain the details of the clinical trial to the subject or the guardians of the subject who is without capacity for civil conduct or with limited capacity for civil conduct, including known and foreseeable risks and possible adverse events. After a full and detailed explanation, the subject or the guardians shall sign and date the informed consent form, and the investigator shall also sign and date the informed consent form.'可被翻译为：第二十一条 在受试者参与临床试验前，研究者应当充分向受试者或者无民事行为能力人、限制民事行为能力人的监护人说明临床试验的详细情况，包括已知的、可以预见的风险和可能发生的不良事件等。经充分和详细解释后由受试者或者其监护人在知情同意书上签署姓名和日期，研究者也需在知情同意书上签署姓名和日期。\n\n根据上述已知信息，请将'Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。"
    },
    {
        "instruction":"已知信息：\n'The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (7).'可被翻译为：评估和分析与医疗器械有关的临床数据，以验证器械在按制造商预期使用时的临床安全性和性能(7)。\n'(3) Where safety and effectiveness of the medical device can be demonstrated through the analysis and assessment made on the basis of the data obtained from clinical trial or application of a medical device of the same variety.'可被翻译为：（三）通过对同品种医疗器械临床试验或者临床使用获得的数据进行分析评价，能够证明该医疗器械安全、有效的。\n'Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'可被翻译为：第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。\n'The source data refers to the original records of clinical findings, observations and other activities in the clinical trial and all information of approved copies, which can be used for clinical trial reconstruction and evaluation.'可被翻译为：源数据，是指临床试验中的临床发现、观察和其他活动的原始记录以及其经核准的副本中的所有信息，可以用于临床试验重建和评价。\n\n根据上述已知信息，请将'The clinical data refers to the safety and performance information which is obtained from relevant literature or in the clinical use of medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"临床数据，是指在有关文献或者医疗器械的临床使用中获得的安全性、性能的信息。"
    },
    {
        "instruction":"已知信息：\n'(VIII) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（八）其他不符合法律法规要求的。\n'(9) there are other circumstances not in conformity with relevant regulations.'可被翻译为：（九）其他不符合有关规定的情形。\n'9. Other circumstances that should not be passed as prescribed by laws and regulations.'可被翻译为：9.法律法规规定的其他不应当通过的情形。\n'(XII) Other violations of the Provisions.'可被翻译为：（十二）其他违反本办法规定的。\n\n根据上述已知信息，请将'(VI) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'As of June 1, 2021, prior to the issuance and implementation of relevant provisions on registration and filing supporting the new Regulations, medical device registrants and filing applicants shall continue to apply for registration and conduct filing in accordance with the current provisions. The requirements for clinical evaluation of medical devices shall be implemented in accordance with Article III of this Announcement. Medical products administration shall carry out the registration and filing in accordance with the currently specified procedures and time limits.'可被翻译为：自2021年6月1日起，在新《条例》配套的注册、备案相关规定发布实施前，医疗器械注册申请人、备案人继续按照现行规定申请注册和进行备案。有关医疗器械临床评价要求，按照本公告第三条执行。药品监督管理部门按照现行规定的程序和时限开展注册、备案相关工作。\n'Article 15 The applicant or filing entity shall prepare the product technical requirements for medical device to be registered or filed. The product technical requirements for class I medical devices shall be submitted to the food and drug regulatory department at the time of filing. The product technical requirements for class II and class III medical devices shall be approved by the food and drug regulatory department at the time of registration approval.'可被翻译为：第十五条 申请人或者备案人应当编制拟注册或者备案医疗器械的产品技术要求。第一类医疗器械的产品技术要求由备案人办理备案时提交食品药品监督管理部门。第二类、第三类医疗器械的产品技术要求由食品药品监督管理部门在批准注册时予以核准。\n'In order to strengthen the supervision and guidance on the registration of medical devices and further improve the quality of registration review, the National Medical Products Administration formulated the Guidance for the Registration Review of Disposable High Pressure Contrast Syringes and Accessories, Guidance for the Registration Review of Internal Fixation System Products of Metal Plates (2021 Revision), Guidance for Registration Review of Magnesium Or thopaedicImplants, Guidance for the Registration Review of Microcatheters, Guidance for the Registration Review of Disposable Endoscopic Injection Needles, and Guidance for the Registration Review of Intraocular Lens, which were issued on January 11,2022.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《一次性使用高压造影注射器及附件产品注册审查指导原则》《金属接骨板内固定系统产品注册审查指导原则（2021年修订）》《可降解镁金属骨科植入物注册审查指导原则》《微导管注册审查指导原则》《一次性使用内窥镜注射针注册审查指导原则》《人工晶状体注册审查指导原则》，并于2022年1月11日发布。\n'In order to strengthen the supervision over medical device production, guarantee the safety and effectiveness of medical devices, and guide registrants, filing entities and contract manufacturers of medical devices to jointly manage the quality of contract manufacturing of medical devices, according to Paragraph 2 of Article 34 in the Regulations on Supervision and Administration of Medical Devices, the National Medical Products Administration organized to revise the Guidance for Preparation of Contract Manufacturing Quality Agreement of Medical Devices, which was issued on March 22, 2022.'可被翻译为：为加强医疗器械生产监管，保障医疗器械安全有效，指导医疗器械注册人、备案人与受托生产企业共同做好医疗器械委托生产质量管理工作，根据《医疗器械监督管理条例》第三十四条第二款规定，国家药品监督管理局组织制定了《医疗器械委托生产质量协议编制指南》，于2022年3月22日发布。\n\n根据上述已知信息，请将'In order to improve the normalization and scientificity of technical evaluation of medical devices and guide medical device registrants\/filing entities to prepare product technical requirements,in accordance with the Regulations on Supervision and Administration of Medical Devices, Provisions for Medical Device Registration and Filing and Provisions for Registration and Filing of In-vitro Diagnostic Reagents, the National Medical Products Administration has organized the revision of the Guidance for Compiling the Product Technical Requirements for Medical Devices, which was issued on February 8,2022.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为提高医疗器械技术审评的规范性和科学性，指导医疗器械注册人\/备案人编写产品技术要求，根据《医疗器械监督管理条例》及《医疗器械注册与备案管理办法》《体外诊断试剂注册与备案管理办法》的规定，国家药品监督管理局组织修订了《医疗器械产品技术要求编写指导原则》，并于2022年2月8日发布。"
    },
    {
        "instruction":"已知信息：\n'e. Sterile Whirl-pak® bags'可被翻译为：无菌 Whirl-pak®袋\n'e. Place the swab (or sponge) back into the carrier container (if it came with one) and place into the additional sterile Whirl-pak® bag. Be sure to break off the handle portion of the sponge applicator stick.'可被翻译为：将棉签（或海绵）重新放回装载容器（如果有）并放置在另一个 Whirl-pak®无菌袋中。确认已将海绵手柄折断去除。\n'b. Swab\/Sponge Sterility Control: Place an intact unus ed swab (or sponge) unit into a sterile Whirl-pak® bag.'可被翻译为：棉签\/海绵无菌控制：将完整的未使用的棉签（或海绵）单元放入无菌 Whirl-pak®袋中。\n'1. Approximately 100 ml of sterile media, MLB or other suitable media, should be aseptically added to each plastic bag containing a square sponge swab. Mix or swirl thoroughly.'可被翻译为：取约 100ml 无菌培养基，MLB 或其它适当培养基，加至每个装有方形海绵拭子的塑料袋中，充分混合或旋转搅拌。\n\n根据上述已知信息，请将'5. Place the EM sample into a sterile Whirl-pak® bag and identify the bag immediately after.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将 EM 样品放入 Whirl-pak®无菌袋，然后立即对袋子进行标示。"
    },
    {
        "instruction":"已知信息：\n'For shuttle type equipment used for aseptic filling, the parison is open to the environment and therefore the areas where parison  extrusion, blow-moulding and  sealing take place  should meet grade A  conditions  at the critical zones. The filling environment should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'可被翻译为：对于用于无菌灌装的往复式设备，模具在环境中是开放的，因此进行模具挤出、吹塑和密封的关键区域应 符合 A 级条件。灌装环境应进行设计和维护，从而在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。\n'It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).'可被翻译为：确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。\n'Blow-Fill-Seal equipment used for the manufacture of products which are terminally sterilised should be installed  in  at  least  a  grade  D  environment.  The  conditions  at  the  point  of  fill   should  comply  with  the environmental requirements of paragraphs 8.3 and 8.4.'可被翻译为：用于生产最终灭菌产品的吹灌装设备应至少安装在 D 级环境中。灌装点的条件应符合第 8.3 和 8.4 节的环境要求。\n'The background environment in which closed systems are located should be based on their design and the processes  undertaken.  For  aseptic  processing  and  where  there  are  any  risks  that  system  integrity  may  be compromised, the system should be located in grade A. If the system can be shown to remain integral at every usage (e.g. via pressure testing and\/or monitoring) then a lower classified area may be used. Any transfer between classified  areas  should be thoroughly  assessed (see paragraph 4.10). If the closed  system  is  opened (e.g.  for maintenance of a bulk manufacturing line) then this should be performed in a classified area appropriate to the materials (e.g. grade C for terminal sterilisation processes, or grade A for aseptic processing) or be subject to further cleaning and disinfection (and sterilisation in case of aseptic processes).'可被翻译为：密闭系统所处的环境应基于其设计和所釆取的工艺。对于无菌工艺，如果存在可能损害系统完整性的任何 风险，应将系统放置在 A 级区。如果证明系统每次使用时都保持完整性（例如通过压力测试和\/或监测）， 那么可以将其放置在较低级别的环境中。应彻底评估分级区域之间的任何转移（参见第 4.10 节）。如果需 开启密闭系统（例如生产线的维护），则应在适合于物料的分级区域内进行（例如，最终灭菌工艺的 C 级，或无菌工艺的 A 级）或进行进一步清洁和消毒（以及灭菌（针对无菌工艺） ）。\n\n根据上述已知信息，请将'For rotary-type equipment used for aseptic filling, the parison is generally closed to the environment once formed, the filling environment within the parison should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于用于无菌灌装的旋转式设备，包材通常在成型后密闭于环境，包材内灌装环境的设计和维护应在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。"
    },
    {
        "instruction":"已知信息：\n'orthogonal design'可被翻译为：正交设计\n'Experimental Design'可被翻译为：试验设计\n'A structured, organized method for determining the relationship between factors affecting a process and the output of that process. Also known as “Design of Experiments”.'可被翻译为：一种确定工艺的影响因素与工艺输出之间相互关系 的、系统的、有序的方法，也称为“实验设计”。\n'define experimental design, sampling methods and acceptance criteria;'可被翻译为：界定实验设计、取样方法和可接受标准；\n\n根据上述已知信息，请将'A design method to study multi-factors and multi-levels. It is to select some representative points from the comprehensive test according to the orthogonality, these representative points have the characteristics of \"uniform dispersion, uniform comparison\", orthogonal experimental design is the main method of fractional factorial design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究多因素多水平的一种设计方法。它是根据正交性从全面试验中挑选出部分有代表性的点进行试验，这些有代表性的点具备了\"均匀分散，齐整可比”的特点，正交试验 设计是分式析因设计的主要方法。"
    },
    {
        "instruction":"已知信息：\n'Article 45 Drug registration inspection refers to the inspection of drug R&D and manufacturing site in order to verify the authenticity and consistency of the application dossiers and the conditions for commercial manufacturing of the drug to be marketed, and to check the compliance and data integrity of drug R&D; when necessary, inspection may be extended to the manufacturers, suppliers or other contracted organizations for chemical active drug ingredients, excipient and primary packaging materials and containers involved in the drug application dossiers.'可被翻译为：第四十五条 药品注册核查，是指为核实申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。\n'Article 4 If the Center for Drug Evaluation of NMPA (hereinafter referred to as the CDE) decides to initiate a registration inspection during the review of a drug registration application, it shall notify the CFDI to conduct an inspection, provide relevant information required for the inspection, and at the same time inform the applicant and the relevant provincial authority where the applicant or the manufacturing site is located.'可被翻译为：第四条 国家药品监督管理局药品审评中心(以下简称药品审评中心) 在药品注册申请审评期间，决定启动注册核查的，通知核查中心组织实施核查，提供核查所需的相关材料，同时告知申请人以及申请人或者生产企业所在地省级局。\n'Article 2 This Procedure is applicable to the domestic registration inspection of drug development site and manufacturing site organized by the National Medical Products Administration (NMPA). The Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) organizes the implementation of registration inspection work.'可被翻译为：第二条 国家药品监督管理局组织的在境内开展的药品研制、生产现场注册核查适用本程序。国家药品监督管理局食品药品审核查验中心(以下简称核查中心)组织实施注册核查工作。\n'(I) It is applicable to the on-site inspection of drug clinical trials under the on-site inspection of drug registration development initiated by the Center for Drug Evaluation, NMPA and organized and implemented by Center for Food and Drug Inspection of NMPA. Which institutions to be inspected shall be determined based on registration requirements and risk principles. On-site inspection of phase IV and other drug clinical trials initiated by CDE shall be implemented by referring to the inspection points.'可被翻译为：(一) 适用于由国家药品监督管理局药品审评中心启动、由国家药品监督管理局食品药品审核查验中心组织实施的药品注册研制现场核查中的药物临床试验现场核查。被核查机构基于注册需要和风险原则确定。药品审评中心发起的Ⅳ期等药物临床试验现场核查参考本核查要点执行。\n\n根据上述已知信息，请将'Article 3 Registration inspection is the inspection activity initiated by the Center for Drug Evaluation of NMPA (hereinafter referred to as CDE) to verify the authenticity and consistency of the drug registration application dossiers, and the commercial production conditions of the drug ,check the compliance, data  integrity, etc. on the development site and manufacturing site focusing on the development and manufacturing involved in the application dossiers of relevant registration applications; and, if necessary, extended inspection activities may be carried out to the manufacturers, suppliers or other contracted institutions of chemical active pharmaceutical ingredient, traditional Chinese medicine (TCM) materials, TCM decoction pieces and extracts, excipients, and packaging materials and containers that directly contact the drugs involved in drug registration applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 注册核查是由国家药品监督管理局药品审评中心(以下简称药品审评中心)启动，为核实药品注册申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，围绕相关注册申请事项申报资料中涉及的研制和生产情况，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、中药材、中药饮片和提取物、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。"
    },
    {
        "instruction":"已知信息：\n'4. Qualification of Stirring\/Agitation\/Flow Rate: The stirring rate should be verified with a suitable device, such as a photo tachometer. For VDC, stirring rates in the range of 400–600 rpm are common. The stirring rate measured is typically applicable to the specific location where the stirring impeller is (e.g., a specific position in a rack that holds multiple VDC, or a specific stir plate). Stirring rate can be measured using a surrogate stir bar if the stir bar used in the diffusion cell is too small to obtain an accurate measurement. The paddle stirring rate for immersion cells of 50 or 100 rpm is common and should be verified and maintained during the test.'可被翻译为：4.（桨法）搅拌\/（搅拌子）搅拌\/流速的确认:搅拌速率应使用合适的设备进行验证，例如光转速计。对于VDC，搅拌速率范围在400-600 rpm是常见的。测量的搅拌速率通常适用于搅拌叶轮所在的特定位置(例如，在容纳多个VDC的机架中的特定位置，或特定的搅拌板)。如果扩散池中使用的搅拌子太小而无法获得准确的测量，则可以使用替代搅拌子来测量搅拌速率。浸没池的桨叶搅拌速率通常为50或100转\/分，在试验期间应加以验证和保持。\n'Stirring rates are relevant for VDC, but not necessarily for FDC or immersion cells. In case of FDC, the flow rate of the receptor solution should be set at a specific value and maintained throughout the test. The flow rate (typically expressed in units of milliliters per minute) can be determined by setting the desired flow rate and collecting a sample into a tared vial for a specific duration. A suitable flow rate allows for a sample of sufficient size to ensure an accurate weighing and should not be substantially impacted by normal variability that may arise due to a drop that fails to fall from the tip of the dispensing tube. It is essential that the lengths of all the dispensing tubes are exactly the same, because differences in dispensing tube lengths can alter the void volume and lag time for samples to be dispensed into collection tubes.'可被翻译为：搅拌速率与VDC有关，但不一定与FDC或浸没池有关。在FDC的情况下，受体溶液的流速应设定在一个特定的值，并在整个测试过程中保持。流速(通常以毫升\/分钟为单位表示)可以通过设置所需的流速并在特定时间内将样品收集到带刻度的小瓶中来确定。合适的流量允许足够大小的样品以确保准确称重，并且不应受到由于未能从分配管尖端落下的液滴可能产生的正常变异性的实质性影响。所有分配管的长度必须完全相同，因为管长度的差异会改变样品被分配到收集管中的空隙体积和滞后时间。\n'Any stirring device that is not stirring properly with the receptor solution present should be repaired or replaced. Since direct measurement of the stirring device used for testing is not always feasible, the stirring system (e.g., the rotating magnetic impeller) can be evaluated with a surrogate. For example, if stirring within a VDC is done with a 5 mm stir bar, the VDC can be temporarily removed, and a 25 mm stir bar can be placed in the cell block which can be measured to determine the stirring speed.'可被翻译为：任何在受体溶液存在的情况下不能正确搅拌的搅拌装置都应修理或更换。由于用于测试的搅拌装置的直接测量并不总是可行的，因此搅拌系统(例如，磁力搅拌子)可以用替代品进行评估。例如，如果用5mm的搅拌棒进行VDC内的搅拌，则可以暂时移除VDC，并在单元块中放置25mm的搅拌棒，可以测量搅拌速度。\n'The VDC, immersion cells, and FDC should match the general descriptions provided below and may have design variations of the types shown among specific examples illustrated in Figures 1–5 for VDCs, Figures 6 and 7 for immersion cells, or Figures 8–10 for FDCs. The VDC, immersion cell, and FDC components should be manufactured with inert materials that do not adsorb, absorb, bind, or react with the analyte. The diffusion cell and its components should not alter the amount of diffusing drug that is measured, either by adsorbing, absorbing, binding, or reacting with the drug, or by releasing drug that was adsorbed, absorbed, bound, or reacted with in a previous experiment.'可被翻译为：VDC、浸没池和FDC应符合下面提供的一般描述，并且可以在图1-5所示的VDC、图6和图7所示的浸没池或图8-10所示的FDC的具体示例中具有不同的设计类型。VDC、浸没池和FDC组件应使用惰性材料制造，这些材料不会吸附、吸收、结合或与分析物发生反应。扩散池及其组件不应通过吸附、吸收、结合或与药物反应，或通过释放先前实验中吸附、吸收、结合或与之反应的药物来改变所测量的扩散药物的量。\n\n根据上述已知信息，请将'4. Rate of stirring or agitation for VDCs or immersion cells, or the flow rate for FDCs, as applicable'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDCs或浸没池的搅拌或搅拌速率，或FDCs的流量，视情况而定"
    },
    {
        "instruction":"已知信息：\n'Article 99: Purified water and water for injection should be produced, stored and distributed in a manner that prevents microbial growth. Purified water can be circulated, and water for injection can be circulated at a temperature above 70℃.'可被翻译为：第九十九条 纯化水、注射用水的制备、贮存和分配应当能够防止微生物的滋生。纯化水可采用循环，注射用水可采用70℃以上保温循环。\n'Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures.'可被翻译为：第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。\n'Where WFI storage tanks are equipped with hydrophobic bacteria retentive vent filters, the filters should not be a source of contamination and the integrity of the filter tested before installation and after use. Controls should\nbe in place to prevent condensation formation on the filter (e.g. by heating).'可被翻译为：如果 WFI 储罐配有疏水性除菌过滤器，过滤器不应成为污染的来源，并应在安装前和使用后进行过滤器的完整性测试。应采取控制措施，防止在过滤器上形成冷凝水（例如加热）。\n'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'可被翻译为：水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。\n\n根据上述已知信息，请将'Article 98: The materials of storage tanks and pipes for transport of purified water and water for injection should be non-toxical and corrosion resistant. The vent of storage tanks should be installed with non-fiber releasing hydrophobic microorganism retention filter. Dead legs should be avoided in the design and installation of pipelines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十八条 纯化水、注射用水储罐和输送管道所用材料应当无毒、耐腐蚀；储罐的通气口应当安装不脱落纤维的疏水性除菌滤器；管道的设计和安装应当避免死角、盲管。"
    },
    {
        "instruction":"已知信息：\n'Maximum operating pressure.'可被翻译为：最大工作压力。\n'Closed systems'可被翻译为：密闭系统\n'Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations.'可被翻译为：密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。\n'thermodynamics'可被翻译为：热力学\n\n根据上述已知信息，请将'The maximum useful work that a closed system can perform under isothermal and isobaric conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"封闭系统在等温等压条件下可能做出的最大有用功。"
    },
    {
        "instruction":"已知信息：\n'(VI) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（六）其他不符合法律法规要求的。\n'(8) other circumstances in which applications shall not be approved according to laws and regulations.'可被翻译为：（八）法律法规规定的不应当批准的其他情形。\n'(9) there are other circumstances not in conformity with relevant regulations.'可被翻译为：（九）其他不符合有关规定的情形。\n'(VII)  Other violations of the Provisions.'可被翻译为：（七）其他违反本办法规定的。\n\n根据上述已知信息，请将'(VIII) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'Article 41 If the lot release institution issues a false testing report when undertaking the lot release work, a penalty shall be imposed in accordance with Article 138 of the Drug Administration Law.'可被翻译为：第四十一条    批签发机构在承担批签发相关工作时，出具虚假检验报告的，依照《药品管理法》第一百三十八条的规定予以处罚。\n'Article 163 When undertaking testing for drug review and approval, a drug testing institute that issues a false certificate of analysis shall be punished in accordance with the provisions in Article 87 of the Drug Administration Law.'可被翻译为：第一百六十三条 药品检验所在承担药品审批所需要的检验工作时，出具虚假检验报告的，依照《药品管理法》第八十七条的规定处罚。\n'Article 138 Where a drug control institution issues a false Certificate of Analysis (CoA), it shall be ordered to make correction and be given a disciplinary warning, and be subject to a fine of not less than RMB 200,000 but not more than RMB 1,000,000. The persons directly in charge and other directly responsible persons shall be demoted, removed, or dismissed in accordance with the law, illegal income shall be confiscated, and a fine of not more than RMB 50,000 shall be imposed. In serious circumstances, the qualification for testing shall be annulled. Where the drug control institution issues false testing conclusions and causes damages, it shall bear the corresponding liability of compensation for losses.'可被翻译为：第一百三十八条 药品检验机构出具虚假检验报告的，责令改正，给予警告，对单位并处二十万元以上一百万元以下的罚款；对直接负责的主管人员和其他直接责任人员依法给予降级、撤职、开除处分，没收违法所得，并处五万元以下的罚款；情节严重的，撤销其检验资格。药品检验机构出具的检验结果不实，造成损失的，应当承担相应的赔偿责任。\n'Article 43 Where the applicant, the inspected institution, and the person directly responsible are found to provide false certificates, data, materials, samples and other illegal acts that do not meet the requirements of the relevant quality management standards, the drug regulatory authorities at or above the provincial level shall deal with them in accordance with the Drug Administration Law of the People's Republic of China and other relevant regulations.'可被翻译为：第四十三条 对核查发现申请人、被核查单位及其直接责任人提供虚假的证明、数据、资料、样品以及不符合相关质量管理规范要求等违法违规行为的，由省级以上药品监督管理部门按程序依《中华人民共和国药品管理法》等有关规定处理。\n\n根据上述已知信息，请将'Article 117 Where a drug testing institution undertaking testing for drug registration issues false testing reports, the case shall be handled according to Article 138 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 药品检验机构在承担药品注册所需要的检验工作时，出具虚假检验报告的，按照《药品管理法》第一百三十八条处理。"
    },
    {
        "instruction":"已知信息：\n'The medium density of plasma lipoprotein is 0.95 ~ 1.006g\/cn? Is a lipoprotein. Is a very low density of plasma lipoproteins - lipoproteins, which can be determined by class separation of plasma lipoproteins by ultracentrifugation or electrophoresis.'可被翻译为：血浆脂蛋白中密度为0.95〜1.006g\/cn?的脂蛋白。是血浆脂蛋白中密度极低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n'Plasma lipoproteins have a density of 1.063-1.21g\/cm3. Is the higher density of the plasma lipoprotein - lipoprotein, light by ultracentrifugation or electrophoresis of plasma lipoprotein category separation to determine.'可被翻译为：血浆脂蛋白中密度为1.063-1.21g\/cm3的脂蛋白。是血浆脂蛋白中密度较高的-类脂蛋白，灯用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n'low density lipoprotein'可被翻译为：低密度脂蛋白\n'high density lipoprotein'可被翻译为：高密度脂蛋白\n\n根据上述已知信息，请将'The medium density of plasma lipoprotein is 1.006-1.063g\/cn? Is a lipoprotein. Is a lower density of plasma lipoprotein - lipoprotein, can be determined by ultra-fast centrifugation or electrophoresis of plasma lipoprotein class separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆脂蛋白中密度为1.006-1.063g\/cn?的脂蛋白。是血浆脂蛋白中密度较低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。"
    },
    {
        "instruction":"已知信息：\n'Article 29 Upon knowing of any ADE cluster, a drug manufacturer shall immediately carry out investigation to have a detailed understanding of the occurrence of ADE cluster, information of drug use, diagnosis and treatment of patients involved, and production, storage, distribution and previous similar adverse events of the drug, etc., complete the investigation report within 7 days, and submit it to the provincial drug regulatory department and the ADR monitoring institution where the manufacturer is located. At the same time, the drug manufacturer shall rapidly conduct self-inspection, analyze the cause of the events, suspend production, sales and use, recall relevant drugs when necessary, and report to the provincial drug regulatory department where it is located.'可被翻译为：第二十九条 药品生产企业获知药品群体不良事件后应当立即开展调查，详细了解药品群体不良事件的发生、药品使用、患者诊治以及药品生产、储存、流通、既往类似不良事件等情况，在7日内完成调查报告，报所在地省级药品监督管理部门和药品不良反应监测机构；同时迅速开展自查，分析事件发生的原因，必要时应当暂停生产、销售、使用和召回相关药品，并报所在地省级药品监督管理部门。\n'Article 19 Drug manufacturers, distributors and medical institutions shall spontaneously collect ADRs. When an ADR is known or discovered, it shall be recorded, analyzed and handled in detail, and a Form for ADR\/ADE Report (see Attached Table 1) shall be filled out and submitted.'可被翻译为：第十九条 药品生产、经营企业和医疗机构应当主动收集药品不良反应，获知或者发现药品不良反应后应当详细记录、分析和处理，填写《药品不良反应\/事件报告表》（见附表1）并报告。\n'Article 17 Drug manufacturers, distributors and medical institutions shall cooperate with drug regulatory departments, health administrative departments and ADR monitoring institutions in investigating ADRs or ADE clusters and provide materials necessary for the investigation.'可被翻译为：第十七条 药品生产、经营企业和医疗机构应当配合药品监督管理部门、卫生行政部门和药品不良反应监测机构对药品不良反应或者群体不良事件的调查，并提供调查所需的资料。\n'Article 13 Drug manufacturers, distributors and medical institutions shall establish ADR reporting and monitoring management systems. To undertake the task of ADR reporting and monitoring within the enterprises or institutions, drug manufacturers shall establish specialized departments and allocate full-time personnel while drug distributors and medical institutions shall establish or designate departments and allocate full-time or part-time personnel.'可被翻译为：第十三条 药品生产、经营企业和医疗机构应当建立药品不良反应报告和监测管理制度。药品生产企业应当设立专门机构并配备专职人员，药品经营企业和医疗机构应当设立或者指定机构并配备专（兼）职人员，承担本单位的药品不良反应报告和监测工作。\n\n根据上述已知信息，请将'Article 27 Drug manufacturers, distributors and medical institutions shall, upon knowing or discovering ADE clusters, immediately report to the county-level drug regulatory departments, health administrative departments and ADR monitoring institutions where they are located by telephone or by fax; when necessary, they may report directly to authorities at a higher level; at the same time, a Form for Basic Information of ADE Clusters (see Attached Table 2) and a Form for ADR\/ADE Report for each case shall be filled out promptly and submitted via the national ADR monitoring information network.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 药品生产、经营企业和医疗机构获知或者发现药品群体不良事件后，应当立即通过电话或者传真等方式报所在地的县级药品监督管理部门、卫生行政部门和药品不良反应监测机构，必要时可以越级报告；同时填写《药品群体不良事件基本信息表》（见附表2），对每一病例还应当及时填写《药品不良反应\/事件报告表》，通过国家药品不良反应监测信息网络报告。"
    },
    {
        "instruction":"已知信息：\n'Article 21 The technical committee on medical device standardization that undertakes the medical device standards plan project shall be responsible for organizing the technical review of the proposed draft of the medical device standard. After the proposed draft passes the technical review, the draft for approval, implementation suggestions and relevant materials for medical device standards shall be submitted to the Center for Medical Device Standardization Administration for examination.'可被翻译为：第二十一条 承担医疗器械标准计划项目的医疗器械标准化技术委员会负责组织对医疗器械标准送审稿进行技术审查。审查通过后，将医疗器械标准报批稿、实施建议及相关资料报送医疗器械标准管理中心进行审核。\n'(5) Be responsible for the follow-up assessment of the implementation of medical device standards in each specialized field;'可被翻译为：（五）负责本专业领域医疗器械标准实施情况的跟踪评价;\n'Article 24 The technical committees on medical device standardization shall reexamine medical device standards that have been issued and implemented. The committees shall organize timely reexamination of the effectiveness, applicability and advancement of medical device standards in keeping with scientific progress, industry development and regulatory demands and put forward the reexamination conclusion. The reexamination conclusion include “Remain in force\", \"To be revised\" and \"Abolished\". The reexamination cycle shall not exceed five years in principle.'可被翻译为：第二十四条 医疗器械标准化技术委员会应当对已发布实施的医疗器械标准开展复审工作，根据科学技术进步、产业发展以及监管需要对其有效性、适用性和先进性及时组织复审，提出复审结论。复审结论分为继续有效、修订或者废止。复审周期原则上不超过5年。\n'The technical committees on medical device standardization shall perform the following responsibilities:'可被翻译为：医疗器械标准化技术委员会履行下列职责：\n\n根据上述已知信息，请将'Article 32 The technical committees on medical device standardization shall conduct follow-up assessment on standards implementation. The Center for Medical Device Standardization Administration shall make statistical analysis on the implementation of mandatory standards based on the follow-up assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 医疗器械标准化技术委员会对标准的实施情况进行跟踪评价。医疗器械标准管理中心根据跟踪评价情况对强制性标准实施情况进行统计分析。"
    },
    {
        "instruction":"已知信息：\n'A list of coded values that are used to structure the xml coding within a message. These values do not carry source data that is being transmitted by \nthe message, i.e. they do not represent data contained in the content of a message, but instead are used to identify components of an xml file for \nparsing by an IT system receiving transmitted message. Usually they are not entered by an end user (for instance through a drop-down pick list such as \nused for coded elements), but are instead used by an implementing IT system to construct an xml message for export and transmission.'可被翻译为：在消息中构建XML编码的编码值列表。这些值不携带消息发送的源数据，即不表示包含在消息内容中的数据，而旨在标识 XML 文件的组件，以供接收传输消息的 IT 系统进行解析。通常，它们不是由最终用户输入的（例如，借助用于编码元素的下拉选择列表等），而是被实施应用的IT系统构建的用于导出和传输的XML消息。\n'namespace'可被翻译为：命名空间\n'An Object Identifier: An OID is a name used to identify an object. In the context of IT standards OIDs are globally unique identifiers. Most \ninternational standards, including ICH, use the ISO ASN.1 data type which consists of a sequence of one or more non-negative integers, often referred \nto as arcs, which define a hierarchy, or tree, of object identifier values.These are represented using a form that consists only of numbers and dots \n(e.g., \"2.16.840.1.113883.3.989\"). OIDs are paths in a tree structure, with the left-most number representing the root and the right-most number \nrepresenting a leaf.'可被翻译为：对象标识符：OID 是一种用来标识特定对象的名称。在 IT 标准语义中，OID 是全球唯一标识符。包括 ICH在内的大多数国际标准使用 ISO ASN.1 数据类型，它由一个或多个非负整数的序列组成，通常称为弧，它定义对象标识符值的层次结构或树。仅使用由数字和点组成的形式（例如，“2.16.840.1.113883.3.989”）来表示这些对象标识符。OID 是树结构中的路径，最左边的数字表示根，最右边的数字代表一个叶。\n'An XML format for interchange, documentation and management of code lists (a.k.a. controlled vocabularies or coded value enumerations) in any \nprocessing context. Genericode is a project of OASIS (Organization for the Advancement of Structured Information Standards), a not-for-profit \nconsortium that drives the development, convergence and adoption of open standards for the global information society.'可被翻译为：用于在任何处理环境中交换、记录和管理编码列表的XML 格式（也被称为受控词汇或编码值枚举）。Genericode 是 OASIS（结构化信息标准推动组织）的项目，OASIS 是一个非营利组织，旨在推动全球信息社会开发、统一和采用开放标准。https:\/\/www.oasisopen.org\/committees\/codelist\/faq.php\n\n根据上述已知信息，请将'A technical identifier that allows the transmission of coded values for which there is no ICH accessible master list of values. Namespaces identify the \nsource or domain of a coded value without providing the list of values to allow the code to be interpreted, i.e. namespaces identify the domain of an \nidentifier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种技术识别符，允许在无 ICH 可访问的主编码值列表时，传输编码值。命名空间对编码值的源或域进行标识，但不提供解读编码值的列表，即命名空间确认 \n标识符的域。"
    },
    {
        "instruction":"已知信息：\n'Article 39 MAHs shall, from the date of the first approval for registration or filing, complete the post-market periodic risk evaluation report in the previous year within 60 days after one full year. For those approved by the NMPA to be registered , the report shall be submitted to national monitoring agencies; for those approved to be registered at  drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government, the report shall be submitted to local provincial monitoring agencies. Periodic risk evaluation report of Class I medical devices shall be kept by MAHs for future reference.'可被翻译为：第三十九条  持有人应当自产品首次批准注册或者备案之日起，每满一年后的60日内完成上年度产品上市后定期风险评价报告。其中，经国家药品监督管理局注册的，应当提交至国家监测机构；经省、自治区、直辖市药品监督管理部门注册的，应当提交至所在地省级监测机构。第一类医疗器械的定期风险评价报告由持有人留存备查。\n'Article 30 Local provincial monitoring agencies where MAHs locate shall complete the review of evaluation results within 10 days upon the receipt of evaluation results from MAHs, and if necessary, may carry out on-site investigation on the adverse events that cause or possibly cause severe injuries or death by entrusting or cooperating with the provincial monitoring agencies where adverse events occur. For the medical devices approved by the NMPA to be registered, national monitoring agencies shall also re-check the evaluation review results by provincial monitoring agencies, and if necessary, may organize investigation on the adverse events causing death.'可被翻译为：第三十条  持有人所在地省级监测机构应当在收到持有人评价结果10日内完成对评价结果的审核，必要时可以委托或者会同不良事件发生地省级监测机构对导致或者可能导致严重伤害或者死亡的不良事件开展现场调查。其中，对于国家药品监督管理局批准注册的医疗器械，国家监测机构还应当对省级监测机构作出的评价审核结果进行复核，必要时可以组织对导致死亡的不良事件开展调查。\n'Article 29 After reporting medical device adverse events or knowing relevant medical device adverse events through the National Medical Device Adverse Events Monitoring Information System, MAHs shall carry out subsequent investigation, analysis and evaluation as required. The evaluation results of the events causing death shall be reported to local provincial monitoring agencies where MAHs locate within 30 days and the evaluation results of the events causing severe injuries or possibly causing severe injuries or death shall be reported to local provincial monitoring agencies where MAHs locate within 45 days. If the MAH has any new identification or notification of event information and evaluation results, it shall submit a supplementary report as required.'可被翻译为：第二十九条  持有人在报告医疗器械不良事件后或者通过国家医疗器械不良事件监测信息系统获知相关医疗器械不良事件后，应当按要求开展后续调查、分析和评价，导致死亡的事件应当在30日内，导致严重伤害、可能导致严重伤害或者死亡的事件应当在45日内向持有人所在地省级监测机构报告评价结果。对于事件情况和评价结果有新的发现或者认知的，应当补充报告。\n'Article 59 Where drug regulatory departments at provincial level or above order to carry out re-evaluation, MAHs shall submit the re-evaluation plan and re-evaluation report to the corresponding drug regulatory departments and monitoring agencies before implementation of re-evaluation and within 30 days upon the completion of re-evaluation.'可被翻译为：第五十九条  省级以上药品监督管理部门责令开展再评价的，持有人应当在再评价实施前和再评价结束后30日内向相应药品监督管理部门及监测机构提交再评价方案和再评价报告。\n\n根据上述已知信息，请将'Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products'可被翻译为：国家药监局关于发布人工智能医用软件产品分类界定指导原则的通告\n'The detailed classification of TCMs, chemical drugs, biological products and other drugs, as well as the corresponding requirements on application dossiers, shall be formulated by the National Medical Products Administration (hereinafter referred to as “NMPA”) according to the product characteristics, innovativeness and review management needs of the drugs to be registered, and shall be made public.'可被翻译为：中药、化学药和生物制品等药品的细化分类和相应的申报资料要求，由国家药品监督管理局根据注册药品的产品特性、创新程度和审评管理需要组织制定，并向社会公布。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Fundamental Principles for Medical Device Safety and Performance.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定，并于2020年3月10日发布了《医疗器械安全和性能的基本原则》。\n'In order to strengthen the classification management of medical devices and standardize the dynamic adjustment of the Classification Catalogue for Medical Devices, according to the Regulations for the Supervision and Administration of Medical Devices and the Classification Rules for Medical Devices, NMPA has organized to formulate the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices, which was issued on April 27.'可被翻译为：为加强医疗器械分类管理，规范《医疗器械分类目录》动态调整工作，根据《医疗器械监督管理条例》《医疗器械分类规则》，国家药监局组织制定了《医疗器械分类目录动态调整工作程序》，并于4月27日发布。\n\n根据上述已知信息，请将'In order to strengthen the supervision and administration of AI-based medical software products and promote the high-quality development of the industry, the NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步加强人工智能医用软件类产品监督管理，推动产业高质量发展，国家药监局组织制定了《人工智能医用软件产品分类界定指导原则》，并于7月1日发布。"
    },
    {
        "instruction":"已知信息：\n'A drug that corrects various low blood cells, resulting in different types of anemia. It can be divided into: ① to correct low red blood cells, such as iron, folic acid, vitamins or epotin; ② promote leukocyte proliferation, such as recombinant human granulocyte macrophage colony factors.'可被翻译为：纠正各种血细胞低下，所致不同类型贫血的药物。分为：①纠正红细胞低下，如铁剂、叶酸、维生素或依泊汀类；②促进白细胞增生，如重组人粒细胞巨噬细胞集落因子等。\n'Drugs used to treat polycythemia caused by neoplastic hyperplasia of genuine erythrocytic cells. Such as hydroxyurea.'可被翻译为：治疗真性红细胞系细胞的肿瘤性增生所造成的红细胞增多症的药物。如羟基脲等。\n'constituents with known therapeutic activity'可被翻译为：具有已知治疗活性的成分\n'Drugs that inhibit proliferative cells. Often used as anticancer drugs. This class of drugs can be divided into two categories according to the different cell cycle of drug action: (1) Cycle non-specific drugs: including alkylation agents and most anticancer antibiotics; ② cell cycle specific drugs, which can also be divided into drugs that mainly act on the S phase, such as anti-metabolic drugs; Mainly in the M phase of the drug, such as colchicine, colchicine and so on.'可被翻译为：能抑制增殖期细胞的药物。多为抗癌药。本类药物依药物作用细胞周期不同时相，又可分为两类：①周期非特异性药物：包括烃化剂和大部分抗癌抗生素类；②细胞周期特异性药,又可分为主要作用于S期的药物,如抗代谢药;主要作用于M期的药物,如长春新碱、秋水仙碱等。\n\n根据上述已知信息，请将'A class of drugs used to treat agranulocytosis. Includes drugs that promote leukocyte proliferation and metabolism, such as inosine, madder bisester, anisene, berberine, etc.; Some cytokines, such as mixostim, sargasstim, etc., can stimulate bone marrow to produce white blood cells for the adjuvant treatment of tumors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于治疗粒细胞缺乏症的一类药物。包括促进白细胞增生和代谢的药物，如肌苷、茜草双酯、茴香烯、小檗胺等；一些细胞因子，如米格司亭、沙格司亭等可刺激骨髓生成白细胞，用于肿瘤的辅助治疗。"
    },
    {
        "instruction":"已知信息：\n'A uniform, stable mixture formed by the separation of one or more substances into another.'可被翻译为：一种或几种物质分散到另-种物质里，形成的均一的、稳定的混合物。\n'When one substance is present inside another, the latter acts as a mediator for the former.'可被翻译为：一种物质存在于另一种物质内部时，后者是前者的介质。\n'The property of interaction between two or more substances combined to form a compound.'可被翻译为：两种以上物质结合成化合物时互相作用的性质。\n'A substrate for mixing two liquids that are insoluble to each other.'可被翻译为：可使不能互相溶解的两种液体能够混到一起的基质。\n\n根据上述已知信息，请将'When two or more substances are mixed, there is no repulsive separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种或两种以上物质混合时，不产生相斥分离的现象。"
    },
    {
        "instruction":"已知信息：\n'The action of changing the packaging of the material.'可被翻译为：改变材料包装的动作。\n'Article 216: Upon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed, and the destruction recorded. An operation procedure should be followed if un-printed packaging materials are returned to stock.'可被翻译为：第二百一十六条 包装结束时，已打印批号的剩余包装材料应当由专人负责全部计数销毁，并有记录。如将未打印批号的印刷包装材料退库，应当按照操作规程执行。\n'Article 127: Outdated or obsolete printed packaging materials should be destroyed and its disposal recorded.'可被翻译为：第一百二十七条 过期或废弃的印刷包装材料应当予以销毁并记录。\n'Article 124: Printed packaging materials should be properly stored in specific area so as to exclude unauthorized access. Cut labels and other loose printed packaging materials should be stored and transported in separate closed containers so as to avoid mixups.'可被翻译为：第一百二十四条 印刷包装材料应当设置专门区域妥善存放，未经批准人员不得进入。切割式标签或其他散装印刷包装材料应当分别置于密闭容器内储运，以防混淆。\n\n根据上述已知信息，请将'Article 123: When the version of a printed packaging material is changed, actions should be taken to ensure that the correct version is used for production. It is recommended that the obsolete stencil plates be withdrawn and destroyed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百二十三条 印刷包装材料的版本变更时，应当采取措施，确保产品所用印刷包装材料的版本正确无误。宜收回作废的旧版印刷模版并予以销毁。"
    },
    {
        "instruction":"已知信息：\n'Article 38 For a medical device which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'可被翻译为：第三十八条 对用于治疗罕见疾病以及应对突发公共卫生事件急需的医疗器械，食品药品监督管理部门可以在批准该医疗器械注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。\n'Article 4 In-vitro diagnostic reagent registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.'可被翻译为：第四条 体外诊断试剂注册是食品药品监督管理部门根据注册申请人的申请，依照法定程序，对其拟上市体外诊断试剂的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。\n'(3) For an in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the registrant fails to complete items stated in medical device registration certificate within specified time as required by registration department upon approving such registration.'可被翻译为：（三）对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，批准注册部门在批准上市时提出要求，注册人未在规定期限内完成医疗器械注册证载明事项的。\n'Article 55 Where the in-vitro diagnostic reagent is put on market, the technical requirements and product instructions must be consistent with the contents approved by the food and drug regulatory department. The registrant and filling entity shall track the safety and effectiveness of post-market product, and timely provide application for modifying the technical requirements or instructions when necessary.'可被翻译为：第五十五条 体外诊断试剂上市后，其产品技术要求和说明书应当与食品药品监督管理部门核准的内容一致。注册人或者备案人应当对上市后产品的安全性和有效性进行跟踪，必要时及时提出产品技术要求、说明书的变更申请。\n\n根据上述已知信息，请将'Article 48 For a in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，食品药品监督管理部门可以在批准该体外诊断试剂注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。"
    },
    {
        "instruction":"已知信息：\n'Maximum filtration time\/total time filter is in contact with the fluid.'可被翻译为：最长过滤时间\/过滤器与液体的总接触时间。\n'Routine process  controls  should be  implemented to  ensure  adherence to validated  filtration parameters. Results of critical process parameters should be included in the batch record, including but not limited to the minimum time taken to filter a known volume of bulk  solution and pressure difference across the filter. Any significant difference from critical parameters during manufacturing should be documented and investigated.'可被翻译为：应实施常规工艺控制以确保符合经验证的过滤参数。关键工艺参数的结果应包含在批记录中，包括但不限 于过滤已知体积的待包装溶液所需的最短时间和过滤器两端的压差。生产过程中与关键参数的任何显着差异都应记录并调查。\n'Processing of the bulk solution should include a filtration step with a microorganism retaining filter, where\npossible, to reduce bioburden levels and particles prior to filling into the final product containers and there should\nbe a maximum permissible time between preparation and filling.'可被翻译为：待包装溶液的加工应包括在可能的情况下使用微生物截留过滤器的过滤步骤，以在灌装入最终产品容器之前降低生物负载水平和微粒，并且配制和灌装之间应规定最长允许时间。\n'The clarification of a liquid through a filtering medium.'可被翻译为：透过过滤介质的澄清液体。\n\n根据上述已知信息，请将'The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"过滤已知体积的待包装溶液所需时间以及过滤器两端的压差。"
    },
    {
        "instruction":"已知信息：\n'If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.'可被翻译为：2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。\n'4. If the products within one package are less than 1 kg, take 1 product for sampling for every 20 kg, and the odd less than 20 kg shall be counted as 20 kg (taking samples from original package).'可被翻译为：4．1公斤以下的，每20公斤抽样1件，不足20公斤者以20公斤计（原装抽样）。\n'If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;'可被翻译为：10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；\n'If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.'可被翻译为：100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。\n\n根据上述已知信息，请将'Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。"
    },
    {
        "instruction":"已知信息：\n'(1) appoint a dedicated quality responsible person to independently undertake responsibilities for drug quality management;'可被翻译为：（一）配备专门质量负责人独立负责药品质量管理；\n'(1) failing to appoint a dedicated person in charge of quality to independently undertake drug quality management and supervise GMP implementation;'可被翻译为：（一）未配备专门质量负责人独立负责药品质量管理、监督质量管理规范执行；\n'(2) appoint a qualified dedicated person to be responsible for the drug release on manufacturing site;'可被翻译为：（二）配备专门质量受权人履行药品出厂放行责任；\n'Article 26 Undertaking of drug manufacturing shall comply with the GMP. A quality management system shall be established and improved for drug manufacturing, which gives into consideration all factors influencing drug quality, to ensure that the whole process of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第二十六条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，涵盖影响药品质量的所有因素，保证药品生产全过程持续符合法定要求。\n\n根据上述已知信息，请将'(1) appoint a qualified dedicated person who is independently in charge of drug quality management, to supervise the implementation of the GMP, ensure suitable in-process control and quality control and guarantee the compliance of drugs with national drug standards and drug registration specifications;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）配备专门质量负责人独立负责药品质量管理，监督质量管理规范执行，确保适当的生产过程控制和质量控制，保证药品符合国家药品标准和药品注册标准；"
    },
    {
        "instruction":"已知信息：\n'Drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the vaccine administration within their respective administrative regions. Departments undertaking responsibilities for drug administration (hereinafter referred to as drug regulatory departments) of the people's governments of municipalities divided into districts and at county level shall undertake the administrative duties on vaccines within their respective administrative regions. The competent health departments of people's governments at or above the county level shall undertake the administration of immunization within their respective administrative regions. Other relevant departments of the people's governments at or above the county level shall undertake the administrative duties on vaccines within the scope of their respective responsibilities.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域疫苗监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域疫苗监督管理工作。县级以上地方人民政府卫生健康主管部门负责本行政区域预防接种监督管理工作。县级以上地方人民政府其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。\n'Article 70 The drug regulatory departments and health departments shall conduct administration on the whole process of vaccine development, manufacture, distribution and immunization according to their respective responsibilities and supervise vaccine MAHs, disease prevention and control institutions, and immunization entities to fulfill their obligations according to law.'可被翻译为：第七十条 药品监督管理部门、卫生健康主管部门按照各自职责对疫苗研制、生产、流通和预防接种全过程进行监督管理，监督疫苗上市许可持有人、疾病预防控制机构、接种单位等依法履行义务。\n'Article 9 The State Council and people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall establish a coordination mechanism to comprehensively coordinate relevant work of vaccine administration, regularly analyze the safety situations of vaccines, enhance vaccine administration and ensure vaccine supply.'可被翻译为：第九条 国务院和省、自治区、直辖市人民政府建立部门协调机制，统筹协调疫苗监督管理有关工作，定期分析疫苗安全形势，加强疫苗监督管理，保障疫苗供应。\n'Article 8 The drug regulatory department under the State Council shall be responsible for drug administration nationwide. The relevant departments under the State Council shall be responsible for the related administrative work within the scope of their duties. The drug regulatory department under the State Council shall cooperate with relevant departments under the State Council in implementing national drug development programs and policies.'可被翻译为：第八条 国务院药品监督管理部门主管全国药品监督管理工作。国务院有关部门在各自职责范围内负责与药品有关的监督管理工作。国务院药品监督管理部门配合国务院有关部门，执行国家药品行业发展规划和产业政策。\n\n根据上述已知信息，请将'Article 8 The drug regulatory department under the State Council shall be responsible for the administration of vaccines nationwide. The competent health department under the State Council shall be responsible for the administration of immunization nationwide. Other relevant departments under the State Council shall be responsible for the administration of vaccines within the scope of their respective responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国务院药品监督管理部门负责全国疫苗监督管理工作。国务院卫生健康主管部门负责全国预防接种监督管理工作。国务院其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。"
    },
    {
        "instruction":"已知信息：\n'6.4. The quality system should ensure that:'可被翻译为：质量体系应确保：\n'quality system'可被翻译为：质量体系\n'6.2. The quality system should be adequately resourced, implemented and maintained.'可被翻译为：质量体系应配备有充足的资源，并得到实施和维护。\n'a description of the objective, scope and responsibilities of the SU and the RU;'可被翻译为：目的、范围和SU和RU职责说明；\n\n根据上述已知信息，请将'6.1. The SU and RU should each have an appropriately designed, clearly defined and documented quality system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU与RU应分别具备经过恰当设计、清楚规定和文件化的质量体系。"
    },
    {
        "instruction":"已知信息：\n'A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.'可被翻译为：药品的标签应当以说明书为依据，其内容不得超出说明书的范围，不得印有暗示疗效、误导使用和不适当宣传产品的文字和标识。\n'The descriptions in drug package inserts and labels shall be scientific, standardized and accurate; texts shall be clear and legible. Any modification or supplement by means of pasting, cutting, or erasing made to the package inserts and labels is not allowed.'可被翻译为：药品说明书和标签中的表述应当科学、规范、准确，文字应当清晰易辨，不得以粘贴、剪切、涂改等方式进行修改或者补充。\n'When drugs are produced, packaged or prescribed, labels that meet the regulations should be affixed to the inner and outer packages of drugs; In order to guide patients to use the drug correctly, the pharmacist shall give written notification documents accompanying the drug.'可被翻译为：药品在生产、分装或处方调配时，将符合规定的标签贴在药品的内、外包装上；亦药师为指导患者正确使用药品，随药品所给予的书面告知文书。\n'A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information.'可被翻译为：贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。\n\n根据上述已知信息，请将'Article 4    A drug label shall be printed on or affixed to the drug package, and no other written words, audio and\/or visual materials or other information are attached to introduce or publicize the product or the enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 药品包装必须按照规定印有或者贴有标签，不得夹带其他任何介绍或者宣传产品、企业的文字、音像及其他资料。"
    },
    {
        "instruction":"已知信息：\n'(IV) Post-marketing change approval documents;'可被翻译为：（四）上市后变更的批准证明性文件；\n'(2) Administration of filing and reporting for drug post-marketing changes;'可被翻译为：（二）药品上市后变更的备案、报告事项管理；\n'(II) Drug approval documents;'可被翻译为：（二）药品批准证明文件；\n'Chapter V Post-marketing Changes and Registration Renewal of Drugs'可被翻译为：第五章 药品上市后变更和再注册\n\n根据上述已知信息，请将'(IV)  Post-marketing change approval documents\/filing documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）上市后变更的批准或者备案文件；"
    },
    {
        "instruction":"已知信息：\n'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market.'可被翻译为：（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；\n'(3) the design and performance of the research project are not able to support to evaluate the safety, efficacy and quality of the drug applied for registration ;'可被翻译为：（三）研究项目设计和实施不能支持对其申请药品的安全性、有效性、质量可控性进行评价的；\n'(3) The application dossier cannot demonstrate the safety, efficacy and quality of the drug or it is considered upon evaluation that the drug’s risks outweigh its benefits;'可被翻译为：（三）申报资料不能证明药品安全性、有效性、质量可控性，或者经评估认为药品风险大于获益的；\n'(1) Study data in the drug clinical trial application are inadequate to support the conduct of drug clinical trials or cannot guarantee subjects’ safety;'可被翻译为：（一）药物临床试验申请的研究资料不足以支持开展药物临床试验或者不能保障受试者安全的；\n\n根据上述已知信息，请将'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the medical device to be sold on the market.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）申请人对拟上市销售医疗器械的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；"
    },
    {
        "instruction":"已知信息：\n'2. Swab corner crevices inside the HEPA Filtered work station.'可被翻译为：擦拭取样有 HEPA 过滤的工作站内的角落缝隙\n'1. Swab the frequently utilized surfaces within the controlled work station such as:'可被翻译为：擦拭受控工作站内频繁使用的表面，如\n'Inside the clean room preparation area located outside the ISO 5 area (if available) remove all outer packaging from subsample units that will be tested without compromising the sterile integrity of the product. Remove sample units and place them on a tray or cart disinfected with an effective antimicrobial agent.'可被翻译为：在ISO 5区域外的洁净室准备区域内（如有），移除将要测试的子样品单元的 所有外包装，同时不影响产品的无菌完整性。取下样本单元并将其放置在用有 效抗菌剂消毒的托盘或推车上。\n'1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected'可被翻译为：拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。\n\n根据上述已知信息，请将'5. Swab tables or benches within the controlled room where product container(s) or post sterilized product may be held outside of the HEPA filtered workstation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"擦拭取样控制室内但不在 HEPA 过滤工作台内，可能会放置产品容器或消毒后的产品的桌子或长凳"
    },
    {
        "instruction":"已知信息：\n'Cleanroom - A room designed, maintained, and controlled to prevent particle and microbial contamination of drug\nproducts. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'可被翻译为：洁净室：一种经设计、维护和控制以防止微粒和微生物污染药品的房间。这样的房间是指定的，可持续性地符合适当的空气洁净水平。\n'A room (or an area) with defined environmental control of particulate and microbial contamination, constructed, outfitted and used in such a way as to reduce the introduction, generation and retention of contaminants within the room or area.'可被翻译为：需要对环境中尘粒及微生物数量进行控制的房间（区域），其建筑结构、装备及其使用应当能够减少该区域内污染物的引入、产生和滞留。\n'1.An area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n2.An area within the facility in which specific procedures and environmental parameters, including viable and nonviable particles, are defined, controlled and monitored to prevent degradation, contamination or cross-contamination of the product.'可被翻译为：1.设施内的一个区域，在该区域内，特定的环境设施条件和程序被定义、控制和监测，以防止产品的降解或交叉污染。\n2.设施内特定程序和环境参数(包括活的和非活的颗粒)被定义、控制和监测以防止产品降解、污染或交叉污染的区域。\n'The handling of sterile product, containers or devices in a controlled environment in which the air supply, materials and personnel are regulated to prevent microbial, endotoxin\/pyrogen and particle contamination.'可被翻译为：在受控环境中处理无菌产品、容器或设备，其中空气供应、材料和人员受到调节，以防止微生物、内毒素\/热原和颗粒污染。\n\n根据上述已知信息，请将'1.A room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n2.A room designed, maintained and controlled to prevent particle and microbial contamination of drug products. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.对微粒和微生物污染有明确环境控制的房间或区域，其建造和使用方式可减少该区域内污染物的引入、产生和滞留。\n2.为防止药品被颗粒和微生物污染而设计、维护和控制的房间。这样的房间是指定的，并且可重复地满足适当的空气洁净度水平。"
    },
    {
        "instruction":"已知信息：\n'3. Dedicated facilities (e.g. a dedicated air handling system) and equipment must be used in production of β-lactam products and sex hormonal contraceptives, and their production areas must be strictly segregated from those of other products.'可被翻译为：（三）生产β－内酰胺结构类药品、性激素类避孕药品必须使用专用设施（如独立的空气净化系统）和设备，并与其他药品生产区严格分开。\n'2. Dedicated and self-contained premises, facilities and equipment must be used for the production of products with particular properties such as highly sensitizing products (e.g. penicillins) or biological preparations (e.g. Bacillus Calmette Guerin vaccine or any other products derived from live microorganisms). Dust generating operation areas in penicillin production should maintain relatively negative pressure, the exhaust air should be decontaminated as required, and the air outlet should be far away from the air inlet of other air-handling systems.'可被翻译为：（二）生产特殊性质的药品，如高致敏性药品（如青霉素类）或生物制品（如卡介苗或其他用活性微生物制备而成的药品），必须采用专用和独立的厂房、生产设施和设备。青霉素类药品产尘量大的操作区域应当保持相对负压，排至室外的废气应当经过净化处理并符合要求，排风口应当远离其他空气净化系统的进风口。\n'(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施、设备和卫生环境；\n'(2) have the premises, facilities, and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施和卫生环境；\n\n根据上述已知信息，请将'4. Dedicated facilities (e.g. a dedicated air handling system) and equipment should be used for some hormonal, cytotoxic and highly potent chemical products. In exceptional cases, the principle of campaign working in the same facilities and equipment can be accepted provided that specific precautions are taken and the necessary validations are made.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）生产某些激素类、细胞毒性类、高活性化学药品应当使用专用设施（如独立的空气净化系统）和设备；特殊情况下，如采取特别防护措施并经过必要的验证，上述药品制剂则可通过阶段性生产方式共用同一生产设施和设备。"
    },
    {
        "instruction":"已知信息：\n'A class of pharmaceutical preparations that use certain physical or chemical methods to kill all living microbial propagules and buds.'可被翻译为：采用某种物理或化学方法杀灭所有活的微生物繁殖体和芽抱的一类药物制剂。\n'aseptic preparation'可被翻译为：无菌制剂\n'Aseptic preparation and processing'可被翻译为：无菌制备和加工\n'Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product.'可被翻译为：任何引入的非原液或成品生产工艺预期部分的外源性物质(如化学、生化物质或微生物)。\n\n根据上述已知信息，请将'A class of pharmaceutical preparations prepared by aseptic manipulation or aseptic techniques that do not contain any living microbial propagules or buds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用无菌操作法或无菌技术制备的不含任何活的微生物繁殖体和芽抱的一类药物制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where, for a registered in-vitro diagnostic reagent, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'可被翻译为：第七十五条 已注册的体外诊断试剂有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。\n'Except for the situations specified in Article 65, the food and drug regulatory department receiving the application for registration renewal shall make a decision for the renewal before the expiration of period of validity of the medical device registration certificate. If the decision is not made within the specified time, the renewal is considered approved.'可被翻译为：除有本办法第六十五条规定情形外，接到延续注册申请的食品药品监督管理部门应当在医疗器械注册证有效期届满前作出准予延续的决定。逾期未作决定的，视为准予延续。\n'Article 67 Where a food and drug regulatory department of a province, autonomous region or municipality directly under the central government conducts a medical device registration by violating the Provisions, China Food and Drug Administration shall order it to correct within a deadline. Where it fails to correct before the deadline, China Food and Drug Administration may directly announce a revocation of the medical device registration certificate.'可被翻译为：第六十七条 省、自治区、直辖市食品药品监督管理部门违反本办法规定实施医疗器械注册的，由国家食品药品监督管理总局责令限期改正；逾期不改正的，国家食品药品监督管理总局可以直接公告撤销该医疗器械注册证。\n'Article 66 Where, for a registered medical device, the management classification is adjusted from a higher class to a lower one, the registration certificate within its period of validity shall remain valid. Where a renewal is needed, the registrant shall apply for registration renewal or filing on changed classification to corresponding food and drug regulatory department six months prior to the expiration of period of validity of the registration certificate.'可被翻译为：第六十六条 已注册的医疗器械，其管理类别由高类别调整为低类别的，在有效期内的医疗器械注册证继续有效。如需延续的，注册人应当在医疗器械注册证有效期届满6个月前，按照改变后的类别向食品药品监督管理部门申请延续注册或者办理备案。\n\n根据上述已知信息，请将'Article 65 Where, for a registered medical device, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十五条 已注册的医疗器械有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。"
    },
    {
        "instruction":"已知信息：\n'A multidimensional measure of health status. These include physical changes, functional changes, social activity, cognition, emotion, sleep and rest, energy and vitality, health awareness, and overall life satisfaction.'可被翻译为：健康状态的一种多维测量指标。包括生理变化、功能变化、社会活动、认知、情感、睡眠与休息、精力与活力、健康意识以及总的生活满意度等。\n'A standardized tool for measuring health status in five dimensions: mobility, self-care, daily activities, pain and discomfort, and anxiety and depression. Each dimension is measured at 3 or 5 levels.'可被翻译为：用行动能力、自我照顾、日常活动、疼痛与不适、焦虑与抑郁5个维度，测量健康状态的一种标准化工具。每个维度用3个或5个水平来测量。\n'A multi-dimensional health-related quality of life scale used to measure health status and quality of life in the general population or in people with various diseases.'可被翻译为：一种多维度的健康相关生存质量量表，用于测量一般人群或各种疾病人群的健康状态和生存质量。\n'A standardized tool for measuring health status using multiple dimensions such as sensory and communication skills, well-being, self-care ability, pain and discomfort, learning ability, and physical activity ability.'可被翻译为：用感官和沟通能力、幸福感、自我照顾能力、疼痛与不适、学习能力、身体活动能力等多个维度测量健康状态的一种标准化工具。\n\n根据上述已知信息，请将'A measure of a patient's health outcome. The measurement extends beyond traditional mortality and morbidity to include measures of multiple dimensions such as physiology, functioning, social activity, cognition, emotion, sleep and rest, energy and activity, perceived health, and overall survival satisfaction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种测量患者健康结果的指标。其测量范围超越了传统的死亡率和患病率，还包括生理、功能、社会活动、认知、情感、睡眠和休息、精力和活动、健康感知和总体生存满意度等多个维度的测量。"
    },
    {
        "instruction":"已知信息：\n'Article 32    In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated,  and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:'可被翻译为：第三十二条 有下列情形之一的，依照《药品管理法》第七十三条规定，没收违法销售的药品和违法所得，并处违法销售的药品货值金额二倍以上五倍以下的罚款：\n'Article 37    Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.'可被翻译为：第三十七条 违反本办法第十六条规定，药品经营企业购进或者销售医疗机构配制的制剂的，按照《药品管理法》第八十条规定予以处罚。\n'Article 68 In case of any following circumstances, penalties shall be imposed in accordance with Article 115 under the Drug Administration Law:'可被翻译为：第六十八条 有下列情形之一的，按照《药品管理法》第一百一十五条给予处罚：\n'Article 33    Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments，shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.'可被翻译为：第三十三条 药品生产、经营企业违反本办法第八条规定，在经药品监督管理部门核准的地址以外的场所储存药品的，按照《药品管理法实施条例》第七十四条的规定予以处罚。\n\n根据上述已知信息，请将'Article 43    Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十三条 违反本办法第二十二条规定非法收购药品的，按照《药品管理法》第七十三条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'The DNA sequence corresponding to mature mRNA, rRNA, or tRNA molecules in eukaryotic genes. Is the coding sequence.'可被翻译为：真核生物基因中与成熟mRNA、rRNA或tRNA分子相对应的DNA序列。为编码序列。\n'DNA sequences that are far from the transcription start site (l~30kb), determine the specific expression of genes in time and space, and enhance the transcriptional activity of promoters.'可被翻译为：远离转录起始点（l~30kb）、决定基因的时间、空间特异性表达、增强启动子转录活性的DNA序列。\n'The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).'可被翻译为：编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。\n'A nucleotide triad sequence from start codon to stop codon. In general, the readable frame is the code sequence of a gene.'可被翻译为：自起始密码子到终止密码子之间的核昔酸三联体序列。一般情况下，可读框即指某个基因的编码序列。\n\n根据上述已知信息，请将'Non-coding nucleotide sequences that are adjacent to the 5' and 3' end of the coding sequence of the product which contain important elements that affect the transcription, translation, or stability of the coding sequence. These regions include, e.g., promoter, enhancer, and splicing sequences and do not include origins of replication and antibiotic resistance genes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是与产品编码序列的5'和3'末端相邻的非编码核苷酸序列,含有影响编码序列转录、翻译和稳定性的重要元件,包括启动子、增强子和剪接序列等区域,但不包括复制起点和抗生素耐药基因区域。"
    },
    {
        "instruction":"已知信息：\n'If the results do not meet this criterion, 4 additional tests (2 reference and 2 test) of 6 cells each should be performed, resulting in 12 additional slope determinations for each product tested. The T\/R slope ratios for all 18 slopes for each product tested are determined. All 324 individual T\/R slope ratios are ordered from the lowest to the highest. To pass this second stage testing, the 110th and 215th slope ratios, representing the 90% confidence interval, must be within the range of 75%–133.33%.'可被翻译为：如果结果不符合此标准，则应执行4个额外的测试(2个参考和2个测试)，每个测试6个单元，从而为每个测试产品进行12个额外的斜率测定。确认了每个测试样品的所有18个T\/R斜率比率。所有324个单独的T\/R斜率比从低到高排序。为了通过第二阶段的测试，代表90%置信区间的第110和215斜率比率必须在75%-133.33%的范围内。\n'The T\/R slope ratios are calculated for each test-to-reference combination of all pairs of T\/R slopes. This procedure is facilitated with a table where the values for the slopes for T are listed down the left side of the table and the slopes for R are listed across the top of the table. The T\/R slope ratios are then determined. See Table 1.'可被翻译为：计算每次试验相对于参考坡度的T\/R斜率比。该程序通过一个表格来实现，其中测试批次和参考批次的斜率值分别列在表格的左侧和顶部。然后确定T\/R斜率。见表1。\n'The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.'可被翻译为：浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。\n'IVRT is commonly used to assess the sameness of a drug product after postapproval changes. Because common testing artifacts, such as air bubbles and membrane defects, yield measurements that are not normally distributed, a nonparametric statistical technique is used to evaluate the test results. The Mann-Whitney U test is used to calculate the 90% confidence interval for the ratio of the slopes between the test and the reference batches. This is illustrated by the following example in which the initial drug product batch is referred to as the reference batch (R) and the changed or subsequent batch is referred to as the test batch (T). The individual amounts of drug released from R are plotted versus the square root of time, and the resulting slopes are determined. Those are the reference slopes. The process is repeated for the test batch (T).'可被翻译为：IVRT通常用于评估药品批准后变更后的一致性。由于常见的测试工件，如气泡和膜缺陷，产生的测量结果不是正态分布的，因此使用非参数统计技术来评估测试结果。Mann-Whitney U检验用于计算试验批次与参考批次之间斜率之比的90%置信区间。下面的例子说明了这一点，其中初始药品批次被称为参考批次(R)，改变或后续批次被称为测试批次(T)。从R中释放的单个药物量与时间的平方根相对应，并确定了结果斜率。这些是参考斜率。对测试批次(T)重复此过程。\n\n根据上述已知信息，请将'After the T\/R ratios have been calculated, they are ordered from the lowest to the highest. The 8th and 29th T\/R ratios are identified and converted to percent (multiplied by 100). These values represent the 90% confidence interval for the ratio of test to reference release rates. To pass first stage testing, those ratios must be within the range of 75%–133.33%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计算出T\/R比后，它们按从低到高的顺序排列。识别第8和第29个T\/R比率并将其转换为百分比（乘以100）。这些值代表试验与参考释放率之比的90%置信区间。要通过第一阶段测试，这些比率必须在75%-133.33%的范围内。"
    },
    {
        "instruction":"已知信息：\n'Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.'可被翻译为：第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。\n'Article 117 In case of identifying a sold drug with serious quality issues an enterprise shall immediately notify the purchaser to stop the sale, retrieve the drug, take records and report to the food and drug regulatory department.'可被翻译为：第一百一十七条 企业发现已售出药品有严重质量问题，应当立即通知购货单位停售、追回并做好记录，同时向食品药品监督管理部门报告。\n'Article 162 Enterprises shall regularly inspect the drugs on display or in storage, with the focus on dismantled drugs, perishable drugs, drugs approaching the expiry date, drugs that have been displayed for a long time and Prepared Slices. Any drugs identified with suspected quality issues shall be promptly withdrawn, the sales shall be discontinued, and quality management personnel shall confirm and take corresponding measures, and also keep the relevant records.'可被翻译为：第一百六十二条 企业应当定期对陈列、存放的药品进行检查，重点检查拆零药品和易变质、近效期、摆放时间较长的药品以及中药饮片。发现有质量疑问的药品应当及时撤柜，停止销售，由质量管理人员确认和处理，并保留相关记录。\n'Article 82 Where a drug has quality issues or other potential safety concerns, the MAH shall immediately stop selling the drug, notify relevant drug distributors and medical institutions to stop sales and use, recall the sold drugs, promptly announce recall information, stop manufacturing immediately if necessary, and report the situation on drug recall and handling to the drug regulatory departments and the competent health departments of the people's governments of the provinces, autonomous regions, or municipalities directly under the central government. The drug manufacturers, drug distributors, and medical institutions shall cooperate.'可被翻译为：第八十二条 药品存在质量问题或者其他安全隐患的，药品上市许可持有人应当立即停止销售，告知相关药品经营企业和医疗机构停止销售和使用，召回已销售的药品，及时公开召回信息，必要时应当立即停止生产，并将药品召回和处理情况向省、自治区、直辖市人民政府药品监督管理部门和卫生健康主管部门报告。药品生产企业、药品经营企业和医疗机构应当配合。\n\n根据上述已知信息，请将'Article 87 For drugs likely to have quality issues, measures of suspending the sales shall be taken immediately, and the drugs shall be locked in the computer system and reported to the quality management department for confirmation. With respect to drugs with quality issues, the following measures shall be taken:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 对质量可疑的药品应当立即采取停售措施，并在计算机系统中锁定，同时报告质量管理部门确认。对存在质量问题的药品应当采取以下措施："
    },
    {
        "instruction":"已知信息：\n'An enclosure capable of being subject to reproducible interior biodecontamination, with an internal work zone meeting grade A conditions that provide uncompromised continuous isolation of its interior from the external environment (for example, surrounding cleanroom air and personnel). There are two major types of isolators:\n•□Closed isolator systems exclude external contamination of the isolator’s interior by accomplishing material transfer via aseptic connection to auxiliary equipment rather than use of openings to the surrounding environment. Closed systems remain sealed throughout operations.\n•□Open isolator systems are designed to allow for the continuous or semicontinuous ingress or egress of materials during operations through one or more openings. Openings are engineered (for example, using continuous overpressure) to exclude the entry of external contaminant into the isolator.'可被翻译为：能够进行可重复的内部生物净化的外壳，其内部工作区域满足A级条件，可将其内部与外部环境(例如，周围洁净室空气和人员)不受损害地连续隔离。隔离器主要有两种类型:\n•□闭式隔离器系统通过与辅助设备的无菌连接来完成物料转移，而不是使用对周围环境的开口，从而排除隔离器内部的外部污染。封闭系统在整个操作过程中保持密封。\n•□开放式隔离系统的设计允许物料在操作期间通过一个或多个开口连续或半连续地进入或流出。开口设计(例如，使用连续超压)以排除外部污染物进入隔离器。\n'Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations.'可被翻译为：密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。\n'Isolators or RABS, which are different technologies, and the associated processes, should be designed to provide protection through separation of the grade A environment from the environment of the surrounding room.\nThe hazards introduced from entry or removal of items during processing should be minimized and supported by high capability transfer technologies or validated systems that robustly prevent contamination and are appropriate\nfor the respective technology.'可被翻译为：隔离器或 RABS（两种不同的技术）及其相关工艺的设计中，应通过将 A 级环境与周围房间环境分隔来提供保护。应尽量减少工艺过程中物品进出所带来的危害，并通过高性能转移技术或经过验证的系统提供支持，其能有效防止污染且适合于各自的技术。\n'The design of closed isolators should ensure grade A conditions with adequate protection for exposed products during processing. Airflow may not be fully unidirectional in closed isolators where simple operations are conducted. However, any turbulent airflow should not increase risk of contamination of the exposed product.\nWhere processing lines are included in closed isolators, grade A conditions should be ensured with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：封闭式隔离器的设计通过工艺过程中充分保护暴露产品保证 A 级条件。在进行简单操作的封闭式隔离器中，气流可能不是完全单向的。然而，任何湍流不应增加暴露产品的污染风险。当生产线包含在封闭式隔离器中时，应通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A 级条件。\n\n根据上述已知信息，请将'Open isolator systems are designed to allow for the continuous or semi-continuous ingress and\/or egress of materials  during  operations  through  one  or  more  openings.  Openings  are  engineered  (e.g.  using  continuous overpressure) to exclude the entry of external contaminant into the isolator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"开放隔离器系统的设计允许操作过程中物料通过一个或多个开口连续或半连续进出。开口的设计（如使用连续过压）可以阻断外部污染进入隔离器。"
    },
    {
        "instruction":"已知信息：\n'An establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.'可被翻译为：将特定的工作或服务分包给另一个机构，并订立合同规定双方的义务和责任的机构或机构。\n'contract'可被翻译为：合同\n'(1) They shall be enterprises or organizations that are established according to law;'可被翻译为：（一）是依法设立的企业或者其他组织；\n'The involved disciplines at an organization from where a designated product, process or method is expected to be transferred.'可被翻译为：指定的产品、过程或方法预计将从该组织转移，该组织所涉及的学科。\n\n根据上述已知信息，请将'An establishment or institution that performs particular work or services under a contract for a different institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据合同为另一机构提供特定工作或服务的机构或机构。"
    },
    {
        "instruction":"已知信息：\n'good manufacturing practices (gmp)'可被翻译为：良好生产规范(GMP)\n'good manufacturing practices (GMP). That part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.'可被翻译为：优良生产规范（GMP）：质量保证中确保药品被持续生产和检测达到其既定用途所需的合适质量标准并符合上市许可要求的一部分\n'GMP good manufacturing practices'可被翻译为：优良生产规范\n'Good Manufacturing Practice (GMP) for Drugs'可被翻译为：药品生产质量管理规范（2010年修订）\n\n根据上述已知信息，请将'Commercial-scale production process verification batches and on-site inspection dynamic production batches if needs should be organized on the planned commercial production line in accordance with the requirements of Good Manufacturing Practice of Medical Products (GMP); in principle, the batches should be consistent with the planned commercial production batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"商业规模生产工艺验证批次和必要的现场核查动态生产批次，应当在拟定的商业化生产线上按照药品生产质量管理规范的要求组织生产；其批量原则上应当与拟定的商业化生产批量一致。"
    },
    {
        "instruction":"已知信息：\n'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.'可被翻译为：一种物理、化学、生物或微生物性质或特性，应在适当的限制、范围或分布范围内，以确保所需的产品质量。\n'Critical Quality Attribute – a physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to assure the desired product quality. (Q8(R2))'可被翻译为：关键质量属性——一种物理、化学、生物学或微生物学属性或特征，其应在一个合适的限度、范围或分布内，以确保 符合预期 的产品质量。（Q8 R2）\n'A substance that is produced by or extracted from a biological source and for which a combination of physicochemical-biological testing and the production process and its control is needed for its characterization and the determination of its quality.'可被翻译为：由生物源生产或从生物源中提取的物质，对其进行物化生物学试验、生产过程及其控制相结合，以表征和确定其质量。\n'A characterised range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria.'可被翻译为：一个确定的工艺参数范围，在保持其它参数不变的前提下，在该参数范围内的任何运行均可生产出符合相关质量标准的产品。\n\n根据上述已知信息，请将'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指产品的物理、化学、生物或微生物性质或特征，应在适当的限度、范围或分布之内，以确保预期的产品质量。"
    },
    {
        "instruction":"已知信息：\n'Article 70 Personnel of the drug regulatory departments that abuse their powers, neglect their duties, engage in malpractice for personal gains in violation of these Provisions shall receive disciplinary punishment according to law.'可被翻译为：第七十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。\n'Article 150 Where drug supervision and administration officers abuse their powers, engage in malpractice for personal gains, or neglect their duties, they shall be punished in accordance with the law.'可被翻译为：第一百五十条 药品监督管理人员滥用职权、徇私舞弊、玩忽职守的，依法给予处分。\n'Article 41 If the drug regulatory department and its personnel fail to perform their duties or abuse their powers, neglect their duties, commit malpractices for personal gains, they shall be investigated for legal responsibility according to law; if such act constitutes a crime, corresponding criminal liabilities shall be pursued according to law.'可被翻译为：第四十一条 药品监督管理部门及其工作人员不履行职责或者滥用职权、玩忽职守、徇私舞弊，依法追究法律责任；构成犯罪的，依法追究刑事责任。\n'Where the persons directly in charge and other directly responsible persons of a drug regulatory department fail to discharge their duties or commit misconduct in the investigation and punishment of illegal acts involving counterfeit or inferior drugs, they shall be subject to heavier punishment in accordance with the law.'可被翻译为：查处假药、劣药违法行为有失职、渎职行为的，对药品监督管理部门直接负责的主管人员和其他直接责任人员依法从重给予处分。\n\n根据上述已知信息，请将'Article 80 Officers from the drug regulatory department who abuse their powers, neglect their duties, or engage in malpractice for personal gains violating provisions of these Provisions, shall be given sanctions in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'expert knowledge'可被翻译为：专家知识\n'expert judgment'可被翻译为：专家判断法\n'A method used to determine the reliability of an analytical outcome (e.g., cost-effectiveness analysis, decision analysis). The extent to which an important variable (e.g., cost, outcome, probability of an event, etc.) is affected by examining the possible range of variation.'可被翻译为：用来测定某种分析结果（如成本-效果分析、决策分析）可靠性的方法。通过检验重要变量（如成本、结果、事件的概率等）可能的变化范围来判断对分析结果产生影响的程度。\n'A widely accepted method, procedure, or measure used to measure an intervention.'可被翻译为：一种被广泛认可的用来衡量某种干预措施的方法、程序或者测量手段。\n\n根据上述已知信息，请将'A method of soliciting opinions from people with specific expertise. Often in a group setting, the aim is to use expert experience to make a quick assessment when certain variables are difficult to obtain.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"向具有特定专业知识的人征求意见的方法。通常采用小组座谈的方式,其目的在于当某些变量难以获得时,利用专家经验做出快速评估。"
    },
    {
        "instruction":"已知信息：\n'A tablet having a two - or multi-layer structure. Each layer may contain different drugs or excipients, may perform different functions, or avoid changes in compatibility between different drugs, etc.'可被翻译为：具有两层或多层结构的片剂。各层可含不同的药物或辅料，可发挥不同的功能，或避免不同药物间的配伍变化等。\n'The extent to which the tablet is broken or splintered by abrasion or vibration.'可被翻译为：片剂因磨损或震动引起碎片、裂片的程度。\n'mutilayer tablet'可被翻译为：多层片\n'A layer of material coated during the coating process in order to smooth out the edges of the tablet and facilitate the coating operation.'可被翻译为：包衣过程中，为了消除片剂棱角并有利于包衣操作而包上的一层物质。\n\n根据上述已知信息，请将'Also known as \"scratch tablet\". A tablet in which dividing lines are marked on the surface of the tablet during production. In order to facilitate the patient to cut into half or even 1\/4 pieces.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"划痕片”。生产过程中在片剂表面划出分割线的片剂。以方便患者切割成半片乃至1\/4片。"
    },
    {
        "instruction":"已知信息：\n'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n'(II) Failing to be equipped with the organization and personnel corresponding to the products to carry out the relevant medical device adverse event monitoring work as required;'可被翻译为：（二）未按照要求配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作的；\n'(I)  Establishing a medical device quality management system that incorporates medical device adverse event monitoring and re-evaluation working mechanism;'可被翻译为：（一）建立包括医疗器械不良事件监测和再评价工作制度的医疗器械质量管理体系；\n\n根据上述已知信息，请将'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Where it is specified in laws, regulations and guidelines as a major change or determined by MAHs as a major change, it shall be implemented after being approved in accordance with relevant provisions. For the change to lower the category after communicating with and reaching an agreement with the drug regulatory department, the application for filing or reporting shall be filed according to the agreed category of change management. For the changes of filing and reporting categories specified in laws, regulations and technical guidelines or defined by MAHs, those shall be submitted in accordance with relevant provisions.'可被翻译为：法律、法规、指导原则中明确为重大变更或持有人确定为重大变更的，应当按照有关规定批准后实施。与药品监管部门沟通并达成一致后降低变更管理类别的变更，应当按照达成一致的变更管理类别申报备案或报告。法律、法规、技术指导原则中明确为备案、报告管理的变更或持有人确定为备案、报告管理的变更，应当按照有关规定提出备案或报告。\n'Where the change management category of circumstances of change has not been specified in laws, regulations or technical guidelines, MAHs shall determine the change management category on the basis of sufficient study, evaluation and necessary verification according to the internal change classification principle, working procedures and risk management criteria, by referring to relevant technical guidelines in combination with product characteristics.'可被翻译为：变更情形在法律、法规或技术指导原则中未明确变更管理类别的，持有人应当根据内部变更分类原则、工作程序和风险管理标准，结合产品特点，参考有关技术指导原则，在充分研究、评估和必要验证的基础上确定变更管理类别。\n'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'可被翻译为：第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。\n\n根据上述已知信息，请将'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。"
    },
    {
        "instruction":"已知信息：\n'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, and laboratory supplies, etc.'可被翻译为：超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、实验用品等\n'Substances used for the prevention, treatment and diagnosis of human diseases, the purposeful regulation of human physiological functions, and the regulation of indications or functional indications, usage and dosage. Including Chinese medicinal materials, Chinese herbal decoction pieces, proprietary Chinese medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, radiopharmaceuticals, serum, vaccines, blood products and diagnostic drugs.'可被翻译为：用于预防、治疗、诊断人的疾病，有目的地调节人的生理机能并规定有适应证或者功能主治、用法和用量的物质。包括中药材、中药饮片、中成药、化学原料药及其制剂、抗生素、生化药品、放射性药品、血清、疫苗、血液制品和诊断药品等。\n'(1) active ingredients extracted from plants, animals and minerals, etc. and their preparations not yet marketed in China, and newly discovered Chinese crude drugs and their preparations;'可被翻译为：（一）未在国内上市销售的从植物、动物、矿物等物质中提取的有效成份及其制剂，新发现的药材及其制剂；\n'For example, the raw materials for chemical drug preparations are referred to as active pharmaceutical ingredients (APIs); those for biological products are referred to as raw ingredients; those for traditional Chinese medicine preparations are referred to as Chinese crude drugs, prepared slices of Chinese crude drugs and outsourced traditional Chinese medicine extracts; and the raw materials for the APIs are referred to any substances used in the manufacture of APIs excluding packaging materials.'可被翻译为：例如：化学药品制剂的原料是指原料药；生物制品的原料是指原材料；中药制剂的原料是指中药材、中药饮片和外购中药提取物；原料药的原料是指用于原料药生产的除包装材料以外的其他物料。\n\n根据上述已知信息，请将'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, cell strains for assay, bacterial strains, and laboratory supplies, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、检定用细胞株和菌毒种、实验用品等。"
    },
    {
        "instruction":"已知信息：\n'If the cosmetics manufactured by the cosmetic manufacturer do not belong to the classification units of the licensed items stated on the License for manufacturing of cosmetics, but the manufacturer relocates the premises without licensing, or fails to obtain renewal of the license for manufacturing of cosmetics at the expiration of the validity period, it shall be deemed that the manufacturer engages in manufacturing of cosmetics without licensing.'可被翻译为：化妆品生产企业生产的化妆品不属于化妆品生产许可证上载明的许可项目划分单元，未经许可擅自迁址，或者化妆品生产许可有效期届满且未获得延续许可的，视为未经许可从事化妆品生产活动。\n'(4) Cosmetics Manufacturing License is withdrawn or canceled according to law, or the license for production of cosmetics is revoked according to law;'可被翻译为：（四）化妆品生产许可依法被撤回、撤销或者化妆品生产许可证依法被吊销的；\n'Article 20 If renewal of the Cosmetics Manufacturing License is needed at the expiration of the validity, the applicant shall submit an application for renewal of license to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located within 30-90 working days before expiry date, and commit that it conforms to the conditions for the cosmetics manufacturing license as specified in these Provisions. The applicant shall be responsible for authenticity and legality of the documents submitted and the commitment made.'可被翻译为：第二十条 化妆品生产许可证有效期届满需要延续的，申请人应当在生产许可证有效期届满前90个工作日至30个工作日期间向所在地省、自治区、直辖市药品监督管理部门提出延续许可申请，并承诺其符合本办法规定的化妆品生产许可条件。申请人应当对提交资料和作出承诺的真实性、合法性负责。\n'(2) the License is not renewed upon expiration of the valid term;'可被翻译为：（二）有效期届满未延续的；\n\n根据上述已知信息，请将'(3) Cosmetics Manufacturing License is not renewed upon expiration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）化妆品生产许可证有效期届满未申请延续的；"
    },
    {
        "instruction":"已知信息：\n'Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and controls shall include the following:'可被翻译为：使用封闭系统来生成、修改、维护或传送电子记录的人员应采用能够保证真实性、完整性、以及必要时的机密性的规程和管理方式，以确保签名者不能轻易否认签名的非真实记录。规程和管理的内容应包括：\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n'a) The regulations in this part set forth the criteria under which the agency considers electronic records, electronic signatures, and handwritten signatures executed to electronic records to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.'可被翻译为：本法规条例制订了相应标准供主管部门判断电子记录、电子签名以及电子记录上的手写签名的确实性、可靠性并大体上等效于纸质记录及纸质材料的手写签名。\n'(e) Use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Record changes shall not obscure previously recorded information. Such audit trail documentation shall be retained for a period at least as long as that required for the subject electronic records and shall be available for agency review and copying.'可被翻译为：使用计算机生成的可靠、时间戳记的审计跟踪，以独立记录操作者登录和生成、修改、或删除电子记录的日期和时间。记录更改不应覆盖之前记录的信息。审计跟踪文档将至少与目标电子记录保存形同的时限，并便于主管部门审核与复制。\n\n根据上述已知信息，请将'Persons who use open systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, as appropriate, the confidentiality of electronic records from the point of their creation to the point of their receipt. Such procedures and controls shall include those identified in 11.10, as appropriate, and additional measures such as document encryption and use of appropriate digital signature standards to ensure, as necessary under the circumstances, record authenticity, integrity, and confidentiality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用开放式系统来生成、修改、维护或传送电子记录的人员应采用能够保证记录从创建点至接收点的真实性、完整性以及必要时的机密性的规程和个人管理方式，必要时应包括11.10中明确的内容，以及额外的措施，例如文档加密和运用相应的数字签名标准以确保记录必要的真实性、完整性和保密性。"
    },
    {
        "instruction":"已知信息：\n'Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays.'可被翻译为：第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。\n'Article 64 Where it is required to extend the period of validity of the medical device registration certificate, the registrant shall submit application for registration renewal to the food and drug regulatory department six months before the expiration of period of validity and submit application documents according to corresponding requirements.'可被翻译为：第六十四条 医疗器械注册证有效期届满需要延续注册的，注册人应当在医疗器械注册证有效期届满6个月前，向食品药品监督管理部门申请延续注册，并按照相关要求提交申报资料。\n'Article 54 Where it is required to extend the period of validity of the medical device registration certificate, the registrant shall submit application for registration renewal to the food and drug regulatory department six months before the expiration of period of validity and submit application documents according to corresponding requirements.'可被翻译为：第五十四条 医疗器械注册证有效期届满需要延续注册的，注册人应当在医疗器械注册证有效期届满6个月前，向食品药品监督管理部门申请延续注册，并按照相关要求提交申报资料。\n'Article 66 Where, for a registered medical device, the management classification is adjusted from a higher class to a lower one, the registration certificate within its period of validity shall remain valid. Where a renewal is needed, the registrant shall apply for registration renewal or filing on changed classification to corresponding food and drug regulatory department six months prior to the expiration of period of validity of the registration certificate.'可被翻译为：第六十六条 已注册的医疗器械，其管理类别由高类别调整为低类别的，在有效期内的医疗器械注册证继续有效。如需延续的，注册人应当在医疗器械注册证有效期届满6个月前，按照改变后的类别向食品药品监督管理部门申请延续注册或者办理备案。\n\n根据上述已知信息，请将'Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issues 5 Technical Review Guidances for the Registration of Tendon and Ligament Fixation Systems and Others'可被翻译为：国家药监局关于发布肌腱韧带固定系统等5项注册技术审查指导原则的通告\n'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'可被翻译为：国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing Six Registration Technical Review Guidelines on Products such as Disposable High Pressure Contrast Syringes and Accessories'可被翻译为：国家药监局关于发布一次性使用高压造影注射器及附件产品等6项注册审查指导原则的通告\n'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'可被翻译为：国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 5 Technical Review Guidances for Registration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布5项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'e. Validation and security of computerized or automated processes'可被翻译为：计算机化或自动化流程的验证和安全保护\n'Process validation'可被翻译为：工艺验证\n'5. Process validation is to verify that a manufacturing process, operated within established parameters, can consistently produce products that are suitable for their intended use and in accordance with the registration requirements.'可被翻译为：（五）工艺验证应当证明一个生产工艺按照规定的工艺参数能够持续生产出符合预定用途和注册要求的产品。\n'process validation. The collection and evaluation of data, from the process design stage through to commercial production, which establishes scientific evidence that a process is capable of continuously delivering the finished pharmaceutical product meeting its predetermined specifications and quality attributes.'可被翻译为：工艺验证：从工艺设计阶段到商业化生产过程中建立科学证据证明工艺有能力持续生产出满足既定标准和质量属性的数据集合与评估\n\n根据上述已知信息，请将'h. Process validation, including validation and security of computerized or automated processes (i.e. simulation studies)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工艺验证，包括计算机化或自动化工艺的验证和安全保护（即模拟研究）"
    },
    {
        "instruction":"已知信息：\n'The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be\nassessed for any impact on the CCS before and after implementation.'可被翻译为：CCS 应考虑污染控制的所有方面，并进行持续、定期的回顾，酌情更新药品质量体系。现行体系如有变更，应在实施前后评估对 CCS 的任何影响。\n'Contamination Control Strategy (CCS) - A planned set of controls for microorganisms, endotoxin\/pyrogen and particles, derived from current product and process understanding that assures process performance and product quality. The controls can include parameters and attributes related to active substance, excipient and drug product materials  and  components,  facility  and  equipment  operating  conditions,  in-process  controls,  finished  product specifications, and the associated methods and frequency of monitoring and control.'可被翻译为：污染控制策略（CCS）：源于现有产品和工艺的理解得出的针对微生物、内毒素\/热原和微粒的一系列有计 划的控制措施，以确保工艺性能和产品质量。控制措施可包括，原料药和制剂的物料和组分相关的参数和属性，厂房设施设备的操作条件，过程控制，成品质量标准， 以及相关方法和监控频次。\n'contamination control strategy'可被翻译为：污染控制策略\n'The site's environmental and process monitoring programme forms part of the overall CCS and is used to monitor the controls designed to minimize the risk of microbial and particle contamination. It should be noted that the reliability of each of the  elements of the monitoring  system (viable, non- viable and APS) when taken in isolation is limited and should not be considered individually to be an indicator of asepsis. When considered together, the results help confirm the reliability of the design, validation and operation of the system that they are monitoring.'可被翻译为：场所的环境监测和工艺监测计划构成整体 CCS 的一部分，用于监测旨在最大程度降低微生物和微粒污染风 险的控制措施。需要注意的是，监测系统的每个要素（活性粒子，非活性粒子和 APS）的可靠性在单独使 用时的可靠性都是有限的，不应单独视为无菌的指标。当综合考虑时，这些结果有助于确认所监测系统的设计、验证和操作的可靠性。\n\n根据上述已知信息，请将'A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety. The\ncombined strategy of the CCS should establish robust assurance of contamination prevention. The CCS should be actively reviewed and, where appropriate, updated and should drive continual improvement of the manufacturing and control methods. Its effectiveness should form part of the periodic management review. Where existing control systems are in place and are appropriately managed, these may not require replacement but should be referenced in the CCS and the associated interactions between systems should be understood.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"污染控制策略（CCS）应在整个设施内实施，从而明确所有关键控制点，并评估所有用于管理药品质量和安全风险的控制措施（设计，程序性、技术性和组织性措施）和监测措施的有效性。CCS 的综合策略应建立起强有力的污染预防保障。应积极回顾并适当更新 CCS，并应推动生产和控制方法的持续改进。CCS 的有效性应成为定期管理回顾的一部分。如果控制系统已经建立并得到了妥善管理，则这些系统可能不需要更换，但应在 CCS 中提及，并应了解系统之间在相关方面的相互作用。"
    },
    {
        "instruction":"已知信息：\n'Article 24    The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.'可被翻译为：第二十四条 药品说明书和标签中标注的药品名称必须符合国家食品药品监督管理局公布的药品通用名称和商品名称的命名原则，并与药品批准证明文件的相应内容一致。\n'(V) The package, label and package insert of drugs shall comply with relevant provisions;'可被翻译为：（五）药品包装、标签、说明书符合有关规定；\n'Article 108 For the registration application of a non-prescription drug, the insert sheet and package label shall comply with the relevant regulations on non-prescription drugs.'可被翻译为：第一百零八条 非处方药的注册申请，其药品说明书和包装标签应当符合非处方药的有关规定。\n'Article 102 The insert sheets and labels of a repackaged import drug shall be in conformity with those of the import drug, and shall be indicated with the approval number of the repackaging drug and the name of drug manufacturer.'可被翻译为：第一百零二条 进口分包装药品的说明书和标签必须与进口药品的说明书和标签一致，并且应当标注分包装药品的批准文号和分包装药品生产企业的名称。\n\n根据上述已知信息，请将'Article 142 The name, insert sheet and label of any drug for which the registration is applied, shall comply with the provisions of the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十二条 申请注册药品的名称、说明书和标签应当符合国家食品药品监督管理局的规定。"
    },
    {
        "instruction":"已知信息：\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.'可被翻译为：在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。\n'The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.'可被翻译为：A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。\n'Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。\n'3. Qualification of Temperature Control: The temperature of each cell should be equilibrated to provide the target temperature at the membrane, and the initial qualification of the equipment should verify that the temperature can be maintained for the duration of the test when using the relevant equipment and method parameters. Depending on the VDC or FDC equipment design, a measurement of the membrane temperature can often be made conveniently using an infrared thermometer, or using a thermocouple mounted with the membrane; for immersion cells, the temperature at the membrane may be assumed to be the same as the bulk volume of the receptor solution in the dissolution vessel, once equilibrated and stabilized. The temperature of each cell should typically remain within ±1° of the target temperature (typically 32° or 37°) during the test.'可被翻译为：温度控制的确认:应平衡每个池体的温度使膜达到目标温度，并且设备的初始确认应验证在使用相关设备和方法参数时，该温度可在测试期间保持。根据VDC或FDC设备的设计，膜温度的测量通常可以方便地使用红外温度计，或使用安装在膜上的热电偶;对于浸没池，可以假设膜上的温度与溶解容器中受体溶液的体积相同，一旦达到平衡和稳定。在测试过程中，每个池体的温度通常应保持在目标温度(通常为32°或37°)的±1°内。\n\n根据上述已知信息，请将'The system should be equilibrated, and the temperature should be measured at the membrane. The membrane should be within ±1° of the target temperature (typically 32° or 37°) prior to applying the dosage form. The stirrers should be turned on during the equilibration period.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"系统应平衡，并在膜处测量温度。在上样之前，膜应在目标温度(通常为32°或37°)的±1°范围内。在平衡期间应打开搅拌子搅拌。"
    },
    {
        "instruction":"已知信息：\n'The legal representative and the principal responsible person of a drug manufacturer shall be fully responsible for the drug manufacturing activities.'可被翻译为：药品生产企业的法定代表人、主要负责人对本企业的药品生产活动全面负责。\n'Article 28 The legal representative and the principal of a drug MAH shall be fully responsible for drug quality and fulfill the following responsibilities:'可被翻译为：第二十八条 药品上市许可持有人的法定代表人、主要负责人应当对药品质量全面负责，履行以下职责：\n'Article 5    Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.'可被翻译为：第五条 药品生产、经营企业对其药品购销行为负责，对其销售人员或设立的办事机构以本企业名义从事的药品购销行为承担法律责任。\n'The legal representative and the principal responsible person of a drug distributor shall be fully responsible for the drug distribution activities.'可被翻译为：药品经营企业的法定代表人、主要负责人对本企业的药品经营活动全面负责。\n\n根据上述已知信息，请将'Article 29 The legal representative and principal of a drug manufacturer shall be responsible for drug manufacturing of the company in all aspects and perform the following duties:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 药品生产企业的法定代表人、主要负责人应当对本企业的药品生产活动全面负责，履行以下职责："
    },
    {
        "instruction":"已知信息：\n'drug synthesis'可被翻译为：药物合成\n'organic synthesis'可被翻译为：有机合成\n'Combining chemical synthesis, combination theory, computer-aided design, etc., and repeatedly connecting different building blocks in a short time to produce a large number of diverse molecular groups to form a compound library, and then using the combination principle to screen and optimize the components of the library to obtain possible compound structures with targeted properties.'可被翻译为：将化学合成、组合理论、计算机辅助设计等相结合，并在短时间内将不同构建模块反复连接，从而产生大批多样性的分子群体，形成化合物库，然后运用组合原理，对库成分进行筛选优化，得到可能的有目标性能的化合物结构的学科。\n'Organic synthesis reaction in which reactants or reagents are covalently bonded to solid phase carriers.'可被翻译为：反应物或试剂共价键合于固相载体上所进行的有机合成反应。\n\n根据上述已知信息，请将'In designing the synthetic route of the target molecule, a logical reasoning analysis method conforming to the principle of organic synthesis is adopted. The target molecule is converted reasonably (including functional group tautometry, functional group addition, functional group removal, connection, etc.) or divided to produce molecular fragments and new target molecules. The latter is then repeatedly converted or segmented until readily available reagents are obtained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在设计目标分子的合成路线时，采用的一种符合有机合成原理的逻辑推理分析法。将目标分子经过合理的转换（包括官能团互变，官能团加成，官能团脱去、连接等）或分割，产生分子碎片和新的目标分子。后者再重复进行转换或分割，直至得到易得的试剂为止。"
    },
    {
        "instruction":"已知信息：\n'Article 4 The generic names of medical devices shall be in Chinese and conform to the norms of the standard spoken and written Chinese language.'可被翻译为：第四条 医疗器械通用名称应当使用中文，符合国家语言文字规范。\n'Provisions for Instructions and Labels of Medical Devices'可被翻译为：医疗器械说明书和标签管理规定\n'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。\n'Article 7    Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.'可被翻译为：第七条 药品说明书和标签应当使用国家语言文字工作委员会公布的规范化汉字，增加其他文字对照的，应当以汉字表述为准。\n\n根据上述已知信息，请将'Article 9 Text in the instructions and labels of medical devices shall be in Chinese, and the use of Chinese shall meet the national general rules for language and words. Other languages are optional in the instructions and labels of medical devices, but the Chinese version shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 医疗器械说明书和标签文字内容应当使用中文，中文的使用应当符合国家通用的语言文字规范。医疗器械说明书和标签可以附加其他文种，但应当以中文表述为准。"
    },
    {
        "instruction":"已知信息：\n'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'可被翻译为：这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。\n'pharmacy-only drugs'可被翻译为：药店药品\n'prescription-only drugs'可被翻译为：处方类药物\n'Drugs that can be purchased, dispensed and used only on the prescription of a medical practitioner or assistant medical practitioner.'可被翻译为：凭执业医师和执业助理医师处方方可购买、调配和使用的药品。\n\n根据上述已知信息，请将'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。"
    },
    {
        "instruction":"已知信息：\n'Article 148 The drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall complete the check of drug development conditions and raw data, the review of application dossiers, sampling, the notice to drug testing institutes for conducting testing for drug registration, the submission of review opinions, inspection report and application dossiers to the State Food and Drug Administration, and the notice to the applicant of the review opinions within 30 days starting from the date an application is accepted.'可被翻译为：第一百四十八条 省、自治区、直辖市药品监督管理部门应当在受理申请后30日内完成对研制情况及原始资料的核查、对申报资料的审查、抽取样品、通知药品检验所进行注册检验、将审查意见和核查报告连同申请人的申报资料一并报送国家食品药品监督管理局等工作，同时将审查意见通知申请人。\n'Article 11 Provincial drug control institutions shall, within 30 days upon the receipt of test samples and related materials, complete the sample testing, issue the testing report of imported drugs to the applicants, and submit it to the provincial drug regulatory department. Where it is necessary to extend the testing time due to characteristics of varieties or testing items, the duration and reasons of the extension shall be reported to provincial drug regulatory department in written form and notified to the applicants.'可被翻译为：第十一条 省级药品检验机构收到检验样品和相关资料后，应当在30日内完成样品检验，向申请人出具进口药材检验报告书，并报送省级药品监督管理部门。因品种特性或者检验项目等原因确需延长检验时间的，应当将延期的时限、理由书面报告省级药品监督管理部门并告知申请人。\n'Article 30 Where there is evidence to prove that potential safety hazards may exist, the drug regulatory department shall, based on supervision and inspection findings, adopt measures such as issuing a warning, scheduling a warning meeting, ordering a rectification within a stipulated period, or suspending manufacture, distribution, use, and importation, and shall promptly announce the inspection outcome.'可被翻译为：第三十条 对有证据证明可能存在安全隐患的，药品监督管理部门应当根据监督检查情况，对药品网络销售企业或者第三方平台等采取告诫、约谈、限期整改以及暂停生产、销售、使用、进口等措施，并及时公布检查处理结果。\n'Article 22 When necessary, within 3 months upon completion of filing, the department in charge of drug supervision and administration at the level of a city divided into districts shall carry out on-site inspection of the submitted materials and the implementation of the Good Supply Practice for medical devices.'可被翻译为：第二十二条  必要时，设区的市级负责药品监督管理的部门在完成备案之日起3个月内，对提交的资料以及执行医疗器械经营质量管理规范情况开展现场检查。\n\n根据上述已知信息，请将'Provincial drug regulatory departments shall strengthen the supervision and administration, complete the review on the notified materials within 30 days upon the completion of filing according to the risk characteristics and safety credit of the filing change items, and may carry out inspection and testing when necessary.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省级药品监管部门应当加强监管，根据备案变更事项的风险特点和安全信用情况，自备案完成之日起30日内完成对备案资料的审查，必要时可实施检查与检验。"
    },
    {
        "instruction":"已知信息：\n'A substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:—obtained from an officially recognized source;\n—prepared by independent synthesis;\n—obtained from existing production material of high purity; or\n—prepared by further purification of existing production material.'可被翻译为：经大量分析试验证明为真实材料的物质，应具有高纯度。该标准可以是:-从官方认可的来源获得;\n-独立合成制备;\n-从现有的高纯度生产材料中获得;或\n-通过进一步提纯现有生产材料制备。\n'A substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be: (1) obtained from an officially recognised source, or (2) prepared by independent synthesis, or (3) obtained from existing production material of high purity, or (4) prepared by further purification of existing production material.'可被翻译为：通过一系列分析试验表明其真实性的高纯度物质。可由以下方式得到: (1)来自于认可的官方(2)单独合成(3)来自于现有的高纯度的生产产品(4)对现有生产产品进行进一步纯化。\n'A substance other than a starting material, intermediate, or solvent that is used in the manufacture of a new drug substance.'可被翻译为：一种与起始物、中间体或溶剂不同的物质，在新原料药的生产中使用。\n'A reference substance used as a physical or chemical reference for drug identification, inspection, and content determination.'可被翻译为：用于物理或化学方法进行药品鉴别、检查、含量测定对照的标准物质。\n\n根据上述已知信息，请将'A high-purity non-standard substance provided by a pharmaceutical reference substance development institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由药品标准物质研制机构提供的高纯度非标准物质。"
    },
    {
        "instruction":"已知信息：\n'electrophoretogram'可被翻译为：电泳图\n'Method for electrophoretic analysis using paper as a support.'可被翻译为：以纸为支持物进行电泳的分析方法。\n'zone electrophoresis'可被翻译为：区带电泳\n'paper electrophoresis'可被翻译为：纸电泳法\n\n根据上述已知信息，请将'Recording of zoned electrophoretic patterns. The form or the electrophoretic carrier itself or a scan of it.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"区带电泳图形的记录。其形式或电泳载体本身或为对它的扫描图。"
    },
    {
        "instruction":"已知信息：\n'An auxiliary material used to reduce friction between particles and improve material flow.'可被翻译为：降低颗粒间摩擦、改善物料流动性的辅料。\n'The degree of adhesion to the die when the solid material is pressed.'可被翻译为：固体物料压片时对冲模的黏着程度。\n'When pressing the tablet, the auxiliary material is added to accurately add the material, reduce the adhesive punch, reduce the friction between the particles and the tablet and the die hole.'可被翻译为：压片时为准确加料，减少黏冲，减低颗粒之间和药片与模孔间摩擦力而加入的辅料。\n'lubricant'可被翻译为：润滑剂\n\n根据上述已知信息，请将'An additive used to reduce the adhesion of raw materials to the die. It is a kind of lubricant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于减轻原料对冲模的黏附作用的添加剂。为润滑剂的一种。"
    },
    {
        "instruction":"已知信息：\n'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'可被翻译为：第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。\n'(I) The internal and external environment of the warehouse is clean without pollutant source; and the ground of warehouse area is hardened or covered by vegetation;'可被翻译为：（一）库房内外环境整洁，无污染源，库区地面硬化或者绿化；\n'(III) Effectively monitoring and controlling the temperature and humidity in the warehouse;'可被翻译为：（三）对库房温湿度进行有效监测、调控。\n'warehousing'可被翻译为：入库\n\n根据上述已知信息，请将'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）库房内墙、顶光洁，地面平整，门窗结构严密；"
    },
    {
        "instruction":"已知信息：\n'first-time donor'可被翻译为：第一次捐赠\n'A person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.'可被翻译为：在同一血库按最低时间间隔定期捐献血液、血液成分或血浆的人。\n'The procedure whereby a single donation of blood is collected in an anticoagulant and\/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and\/or coagulation activation of the resulting blood donation.'可被翻译为：单次献血的血液在抗凝和\/或稳定溶液中收集的过程，在设计的条件下尽量减少微生物污染、细胞损伤和\/或由此产生的献血的凝血激活。\n'blood collection'可被翻译为：血液采集\n\n根据上述已知信息，请将'A donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"首次在血液机构进行血液或血浆传染病标志物检测的献血者。"
    },
    {
        "instruction":"已知信息：\n'Where pre-marketing GMP inspection is necessary, the CFDI shall coordinate the relevant drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government to implement the inspection concurrently with the drug registration inspection of the manufacturing site. The administrative requirements for pre-marketing GMP inspection shall be stipulated by the Provisions for Drug Manufacturing Supervision and Administration.'可被翻译为：需要上市前药品生产质量管理规范检查的，由药品核查中心协调相关省、自治区、直辖市药品监督管理部门与药品注册生产现场核查同步实施。上市前药品生产质量管理规范检查的管理要求，按照药品生产监督管理办法的有关规定执行。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the contract manufacturer is located shall be responsible for carrying out supervision and inspection of the contract manufacturer’s manufacturing activities, and if involving relevant conditions of the registrant, the drug regulatory department of the place where the registrant is located shall carry out supervision and inspection on the registrant.'可被翻译为：受托生产企业所在地省、自治区、直辖市药品监督管理部门负责对受托生产企业生产活动开展监督检查，涉及注册人相关情况的，应当由注册人所在地药品监督管理部门对注册人开展监督检查。\n'Article 12 If the drug regulatory authorities of a province, autonomous region, or municipality directly under the Central Government determine that it is necessary to conduct Pre-market inspection of Good Manufacturing Practice of Medical Products (GMP) during the Manufacturing Site Inspection period, CFDI shall coordinate the drug regulatory authorities of the relevant province, autonomous region, or municipality directly under the Central Government to implement the inspection simultaneously with Manufacturing Site Inspection.'可被翻译为：第十二条 对于省、自治区、直辖市药品监督管理部门确定需要在生产现场核查期间开展上市前药品生产质量管理规范符合性检查的，核查中心协调相关省、自治区、直辖市药品监督管理部门与生产现场核查同步实施。\n'Where pre-marketing GMP compliance inspection is carried out, after completion of the inspection, the inspection conduct and inspection results shall be included into a written report as an important basis for marketing supervision of the drug. Where the pre-marketing GMP compliance inspection involves changes to items in the Drug Manufacturing Certificate, the drug regulatory department of the province, autonomous region or municipality directly under the Central Government issuing the license shall make decisions according to the procedure for making changes.'可被翻译为：开展上市前的药品生产质量管理规范符合性检查的，在检查结束后，应当将检查情况、检查结果等形成书面报告，作为对药品上市监管的重要依据。上市前的药品生产质量管理规范符合性检查涉及药品生产许可证事项变更的，由原发证的省、自治区、直辖市药品监督管理部门依变更程序作出决定。\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may, as needed for supervision and administration, carry out pre-marketing GMP compliance inspection on drug marketing authorization applicants holding Drug Manufacturing Certificate and its contract manufacturer as required below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 省、自治区、直辖市药品监督管理部门根据监管需要，对持有药品生产许可证的药品上市许可申请人及其受托生产企业，按以下要求进行上市前的药品生产质量管理规范符合性检查："
    },
    {
        "instruction":"已知信息：\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'可被翻译为：销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。\n'Article 21 The medical device manufacturer shall keep detailed records on the handling of recalled medical devices, and report to the food and drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the medical device manufacturer is located. The records shall be kept up to 5 years after the expiration of the Medical Device Registration Certificate, and the handling records of the recall of Class I medical devices shall be kept for 5 years. Where product defects can be eliminated by warning, checking, repairing, relabeling, modifying and improving the instructions for use, software upgrade, replacement, and destruction, the above actions may be completed at the location of the product. The medical devices that need to be destroyed shall be destroyed under the supervision of the food and drug regulatory department.'可被翻译为：第二十一条 医疗器械生产企业对召回医疗器械的处理应当有详细的记录，并向医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门报告，记录应当保存至医疗器械注册证失效后5年，第一类医疗器械召回的处理记录应当保存5年。对通过警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、销毁等方式能够消除产品缺陷的，可以在产品所在地完成上述行为。需要销毁的，应当在食品药品监督管理部门监督下销毁。\n'Article 19 MAHs, distributing enterprises and secondary medical institutions or above shall register as the users of the National Medical Device Adverse Events Monitoring Information System, voluntarily maintain the user information and report medical device adverse events. MAHs shall continuously track and handle monitoring information; in case of any change in product registration information, MAHs shall update the information in the system immediately.'可被翻译为：第十九条  持有人、经营企业和二级以上医疗机构应当注册为国家医疗器械不良事件监测信息系统用户，主动维护其用户信息，报告医疗器械不良事件。持有人应当持续跟踪和处理监测信息；产品注册信息发生变化的，应当在系统中立即更新。\n\n根据上述已知信息，请将'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。"
    },
    {
        "instruction":"已知信息：\n'Prior to beginning a test procedure an environment blank must be prepared and tested according to ORA-LAB.019. After passing results have been obtained the instrument can now be used to perform the test procedure.'可被翻译为：在开始检测程序之前，必须根据ORA-LAB.019制备和检测一份环境空白。在得 到合格结果之后，可使用该仪器执行检测程序。\n'Sample ready for the application of the test procedure.'可被翻译为：样品准备好应用测试程序。\n'l. Required testing is performed on the correct samples'可被翻译为：使用正确的样品执行所需检测\n'2. Management of test sample and blank matrix'可被翻译为：2.试验样品和空白基质的管理\n\n根据上述已知信息，请将'Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。"
    },
    {
        "instruction":"已知信息：\n'Article 105: Materials and products should be transported in a manner to protect their quality. Where special requirements are needed, the transportation conditions should be verified.'可被翻译为：第一百零五条 物料和产品的运输应当能够满足其保证质量的要求，对运输有特殊要求的，其运输条件应当予以确认。\n'8.1. The RU should have appropriate premises with the layout, construction and finishing to suitable for the intended operations. Utilities such as heating, ventilation and air conditioning, as well as gas and water systems, should have sufficient capacity and should be appropriate for the intended process, product or procedure to be transferred.'可被翻译为：RU应具备有恰当的设施，有平面布局图，其建筑和装修适合于既定操作。公用设施如HVAC和水气系统，均应具备足够能力，适合于准备转移的工艺、产品或方法。\n'c. Adequacy of equipment and facility for intended use'可被翻译为：设备和设施是否满足既定用途\n'If there are special requirements for temperature, humidity and other environmental conditions of the medical devices, the enterprise shall take corresponding measures to guarantee safety and effectiveness of the medical devices.'可被翻译为：对温度、湿度等环境条件有特殊要求的，应当采取相应措施，保证医疗器械的安全、有效。\n\n根据上述已知信息，请将'environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"准备转移的产品特性所决定的设施或设备所需的环境条件和所有特殊要求。"
    },
    {
        "instruction":"已知信息：\n'Exposure during gestation to physical and chemical factors that can cause offspring malformations.'可被翻译为：在妊娠期接触能引起子代畸形的物理化学因素。\n'Prenatal factors cause serious anatomical morphological and structural defects in developing organisms.'可被翻译为：出生前因素引起发育生物体的严重的解剖学上形态结构的缺陷。\n'The occurrence of structural malformations in a developing fetus when a substance is administered during pregnancy.'可被翻译为：在怀孕期间使用某物质时造成胎儿发育产生结构性畸形的现象。\n'Abnormalities in fetal morphology and structure.'可被翻译为：胎儿形态、结构的异常。\n\n根据上述已知信息，请将'Exposure to exogenous physical and chemical factors during gestation (before birth) causes structural deformities in offspring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在妊娠期（出生前）接触外源性物理化学因素，引起后代结构畸形的作用。"
    },
    {
        "instruction":"已知信息：\n'In chromatographic analysis, a quantitative method is performed by comparing the chromatographic peak area or peak height of the reference and the test.'可被翻译为：在色谱分析中，一种通过对照品和供试品色谱峰面积或峰高的比较进行定量的方法。\n'When performing chromatographic analysis, a quantitative method of adding a certain amount of reference substance to the solution of the test product and the control product.'可被翻译为：进行色谱分析时，在供试品与对照品溶液中添加一定量参比物的定量方法。\n'Different types of chromatographic analysis techniques are combined to form a combined system to achieve the separation and analysis of multi-component methods in complex samples.'可被翻译为：将不同类型的色谱分析技术组合构成联用系统，以实现复杂样品中多组分的分离和分析的方法。\n'chromatogram'可被翻译为：色谱图\n\n根据上述已知信息，请将'The method uses the percentage of the chromatographic peak area of each component in the total peak area of a multi-component sample for chromatographic quantification. Usually used only for the examination of the substance in question.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种利用多组分样品中各组分的色谱峰面积占总峰面积的百分比进行色谱定量的方法。通常仅用于有关物质检查。"
    },
    {
        "instruction":"已知信息：\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'可被翻译为：第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。\n'Article 16 The State supports innovation in drug development which is guided by clinical value and has clear or specific therapeutic effect on human diseases, encourages research and development of new drugs with new therapeutic mechanisms, treats serious life-threatening or rare diseases, makes use of targeted and systemic regulatory interventions for humans, and promotes technological advancement in drug development.'可被翻译为：第十六条 国家支持以临床价值为导向、对人的疾病具有明确或者特殊疗效的药物创新，鼓励具有新的治疗机理、治疗严重危及生命的疾病或者罕见病、对人体具有多靶向系统性调节干预功能等的新药研制，推动药品技术进步。\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n\n根据上述已知信息，请将'Article 8 The State encourages the research and innovation of medical devices, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of medical devices and promotes the development of medical device industry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国家鼓励医疗器械的研究与创新，对创新医疗器械实行特别审批，促进医疗器械新技术的推广与应用，推动医疗器械产业的发展。"
    },
    {
        "instruction":"已知信息：\n'(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.'可被翻译为：(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。\n'(3) Extract part of the electronic chromatograms of the test sample, accompanying standard curves and QC samples as well as method validation sample, which are consist with the application dossier.'可被翻译为：(3) 抽取工作站中的试验样品、随行标准曲线和 QC 样品以及方法学验证样品的部分电子图谱， 与申报资料一致。\n'(5) All samples introduced into the instruments are recorded in the original records, and investigation and analysis is conducted for abnormal circumstances occurred during the process of method validation, which are consist with those in the application dossier.'可被翻译为：(5) 所有在仪器中进样的样品均记录在原始记录中， 并对方法学验证过程中出现的异常情况进行调查和分析， 与申报资料一致。\n'(2) Records of receipt, formulating, analysis (such as homogeneity, concentration, stability, etc.), use and return of the test\/control articles should be retained completely and traceably and should be consistent with those in the application dossiers. For example:'可被翻译为：(2)应完整保存可追溯的受试物和对照品的接收、配制、分析(如均一性、浓度、稳定性等)、使用、返还等记录，并与申报资料一致。如：\n\n根据上述已知信息，请将'(5) If there is residual during the process of test sample analysis, evaluate the impact on the concentration of the test sample and carry out specific measures, consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) 试验样品分析过程中如有残留， 对试验样品浓度的影响进行评估并采取具体措施， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'1. All changes of starting materials used for the product, especially those materials from new suppliers;'可被翻译为：（一）产品所用原辅料的所有变更，尤其是来自新供应商的原辅料；\n'(ii) Samples of starting materials, packaging materials, intermediate products, bulk products and finished products are taken by approved personnel and methods;'可被翻译为：(ii)原材料、包装材料、中间产品、散装产品、成品的取样人员和方法应经过批准；\n'Raw materials and excipients packaging materials, and etc.'可被翻译为：指原料、辅料和包装材料等。\n'information on starting materials, applicable Material Safety Data Sheet (MSDS) where required, storage and distribution requirements for raw materials and finished products;'可被翻译为：起始物料信息，适用的MSDS（如需要），原料和成品存贮和运输要求\n\n根据上述已知信息，请将'(i) A review of starting materials including packaging materials used in the product, especially those from new sources and in particular the review of supply chain traceability of active substances;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(i) 对产品中使用的原材料包括包装材料进行回顾，特别是新供应商的包装材料，以及贵活性物质的供应链追溯性的回顾；"
    },
    {
        "instruction":"已知信息：\n'Article 51 ADR monitoring institutions at all levels shall conduct statistical analysis on the ADR reporting and monitoring data received and provide feedback in appropriate forms.'可被翻译为：第五十一条 各级药品不良反应监测机构应当对收到的药品不良反应报告和监测资料进行统计和分析，并以适当形式反馈。\n'Article 48 The National Center for ADR Monitoring shall conduct comprehensive analysis on serious ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to the SFDA and the Ministry of Health.'可被翻译为：第四十八条 国家药品不良反应监测中心应当每季度对收到的严重药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报国家食品药品监督管理局和卫生部。\n'Article 34 The National Center for ADR Monitoring shall analyze and evaluate ADR reports received and report to the SFDA and the Ministry of Health semiannually; once information indicating potential drug safety risks is identified, reports shall be submitted in a timely manner.'可被翻译为：第三十四条 国家药品不良反应监测中心应当对收到的药品不良反应报告进行分析、评价，每半年向国家食品药品监督管理局和卫生部报告，发现提示药品可能存在安全隐患的信息应当及时报告。\n'(IV) Release ADR warning information;'可被翻译为：（四）发布药品不良反应警示信息；\n\n根据上述已知信息，请将'Article 52 The National Center for ADR Monitoring shall release ADR warning information in a timely manner based on results of comprehensive analysis and evaluation on ADR reporting and monitoring data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 国家药品不良反应监测中心应当根据对药品不良反应报告和监测资料的综合分析和评价结果，及时发布药品不良反应警示信息。"
    },
    {
        "instruction":"已知信息：\n'Article 26 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第二十六条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 18 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第十八条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 52 The drug regulatory departments and health administrative departments at all levels may entrust medical device inspection agencies with corresponding qualification to inspect the products involved in medical device adverse events when necessary. A medical device testing institution shall perform the test promptly and issue the test report.'可被翻译为：第五十二条  各级药品监督管理部门和卫生行政部门必要时可以将医疗器械不良事件所涉及的产品委托具有相应资质的医疗器械检验机构进行检验。医疗器械检验机构应当及时开展相关检验，并出具检验报告。\n'Article 16 When applying for class II and class III medical device registration, registration testing shall be conducted. The medical device testing institutions shall carry out relevant registration testing on the products in accordance with the product technical requirements.'可被翻译为：第十六条 申请第二类、第三类医疗器械注册，应当进行注册检验。医疗器械检验机构应当依据产品技术要求对相关产品进行注册检验。\n\n根据上述已知信息，请将'For the medical devices having not included in the testing scope of any medical device testing institutions, the corresponding registration department shall designate a testing institution which has the capability to conduct the testing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尚未列入医疗器械检验机构承检范围的医疗器械，由相应的注册审批部门指定有能力的检验机构进行检验。"
    },
    {
        "instruction":"已知信息：\n'A class of stability tests designed to accelerate the chemical degradation or physical change of an active drug substance or preparation through the use of exceptional storage conditions.'可被翻译为：通过使用超常的贮存条件来加速活性原料药或制剂的化学降解或物理变化的一类稳定性试验。\n'1.The purpose of stability tests is to obtain information in order to define the shelf-life of the pharmaceutical product in its original container and to specify storage conditions.\n2.A series of tests designed to obtain information on the stability of a pharmaceutical product in order to define its shelf-life and utilization period under specified packaging and storage conditions.'可被翻译为：1.稳定性试验的目的是获取信息，以便确定药品在原容器中的保质期，并规定储存条件。\n2.为了在规定的包装和储存条件下确定药品的保质期和使用期限，为获得药品稳定性信息而设计的一系列试验。\n'The period of time within which the quality of drugs can be guaranteed under certain storage conditions.'可被翻译为：药品在一定的贮存条件下，能够保证质量的期限。\n'Studies undertaken to elucidate the intrinsic stability of the drug substance. Such testing is part of the development strategy and is normally carried out under more severe conditions than those used for accelerated testing.'可被翻译为：为了揭示原料药内在稳定性而进行的研究，它是开发研究的一部分。这些试验通常是在比加速试验更剧烈的条件下进行。\n\n根据上述已知信息，请将'A stability test performed under conditions close to the actual storage of the drug to provide a basis for establishing the expiration date of the drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在接近药品实际贮存条件下进行的，为制定药物的有效期提供依据的稳定性试验。"
    },
    {
        "instruction":"已知信息：\n'National medical device varieties under intensive surveillance shall be determined according to the medical device registration, adverse event monitoring, supervisory inspection and testing and based on risk degree and product use.'可被翻译为：国家医疗器械重点监测品种应当根据医疗器械注册、不良事件监测、监督检查、检验等情况，结合产品风险程度和使用情况确定。\n'Article 5 According to the factors which may influence the degree of risk of medical devices, medical devices are divided as follows:'可被翻译为：第五条 依据影响医疗器械风险程度的因素，医疗器械可以分为以下几种情形：\n'(4) The status of use or the effects generated of medical devices, according to their different structural characteristics, whether are in contact with human body and patterns of use, include:'可被翻译为：（四）根据不同的结构特征、是否接触人体以及使用形式，医疗器械的使用状态或者其产生的影响包括以下情形：\n'(3) Patterns of use of medical devices, according to their different structural characteristics and whether are in contact with human body, include:'可被翻译为：（三）根据不同的结构特征和是否接触人体，医疗器械的使用形式包括：\n\n根据上述已知信息，请将'The risk degree of a medical device shall be determined comprehensively according to the intended purpose, structural characteristics, pattern of use, status of use as well as whether the device is body contacting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械风险程度，应当根据医疗器械的预期目的，通过结构特征、使用形式、使用状态、是否接触人体等因素综合判定。"
    },
    {
        "instruction":"已知信息：\n'Article 60 Where the management classification of a filed medical device is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III medical device, the filing entity shall apply for registration in accordance with the Provisions.'可被翻译为：第六十条 已备案的医疗器械管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类医疗器械的，按照本办法规定申请注册。\n'Article 76 Where, for a registered in-vitro diagnostic reagent, the management classification is adjusted from a higher class to a lower one, the registration certificate within its period of validity shall remain valid. Where a renewal is needed, the registrant shall apply for registration renewal or filing on changed classification to corresponding food and drug regulatory department six months prior to the expiration of period of validity of the registration certificate.'可被翻译为：第七十六条 已注册的体外诊断试剂，其管理类别由高类别调整为低类别的，在有效期内的医疗器械注册证继续有效。如需延续的，注册人应当在医疗器械注册证有效期届满6个月前，按照改变后的类别向食品药品监督管理部门申请延续注册或者办理备案。\n'Where, the in-vitro diagnostic reagent classification is adjusted from a lower class to a higher one, the registrant shall apply for registration on changed classification to the corresponding food and drug regulatory department in accordance with the provisions in Chapter VI hereof. China Food and Drug Administration shall specify a time limit for completing the adjustment in the notice on adjusting management classification.'可被翻译为：体外诊断试剂管理类别由低类别调整为高类别的，注册人应当依照本办法第六章的规定，按照改变后的类别向食品药品监督管理部门申请注册。国家食品药品监督管理总局在管理类别调整通知中应当对完成调整的时限作出规定。\n'Article 69 For a filed in-vitro diagnostic reagent, where the contents set forth in the filing information form for in-vitro diagnostic reagent changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing materials meet the formal requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第六十九条 已备案的体外诊断试剂，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n\n根据上述已知信息，请将'Article 70 Where the management classification of a filed in-vitro diagnostic reagent is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III in-vitro diagnostic reagent, the filing entity shall apply for registration in accordance with the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 已备案的体外诊断试剂管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类体外诊断试剂的，按照本办法规定申请注册。"
    },
    {
        "instruction":"已知信息：\n'For all product types, follow current USP methodology in , with the following additional instructions.'可被翻译为：所有产品类型应遵循中现行USP方法和以下附加说明。\n'Follow the current edition of the USP for the amount of sample to be tested.'可被翻译为：样本量执行USP现行版本要求。\n'Follow the current edition of the USP to determine the correct number of units to be tested and the amount of product to be analyzed from each unit. It is preferable to test the entire contents of each unit if possible. Follow laboratory policy if it requires testing more units than the USP requires.'可被翻译为：按照现行版本的USP确定要测试的正确件数以及每件要分析的产品数量。如 果可能，最好测试每件的全部内容。如果实验室政策要求测试的单元数超过 USP要求，则遵循实验室政策。\n'USP<62> Chapter describes specific enrichment procedures depending on the target specified microorganism that must be absent, as required by a product monograph. Products which are  insoluble or immiscible in water must be appropriately treated to obtain a suspension suitable for the test procedures. USP<1111> is used to identify organism recommendations for various drug dosage forms. use—are of concern.'可被翻译为：USP<62> 描述了根据产品专论的要求不得检出的指定目标微生物特定的富集程序。 不溶于 水或不溶于水的产品必须经过适当处理以获得适合测试程序的悬液。USP 用于确定 不同用途的各种药物剂型的检测微生物建议。（译注：上述最后一句英文貌似文理不通，未能理解是何含义。USP<1111>内容为“非无菌\n药品的微生物检查：原料药和制剂的可接受标准”。）\n\n根据上述已知信息，请将'For all product types, follow current USP<51> methodology in chapter , with the following additional instructions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有的产品类型均需遵守现行USP<51>的方法，和以下附加说明。"
    },
    {
        "instruction":"已知信息：\n'The selection of the monitoring system should take into account any risk presented by the materials used in the manufacturing operation (e.g. those involving live organisms, powdery products or radiopharmaceuticals) that may give rise to biological, chemical or radiation hazards.'可被翻译为：监测系统的选择应考虑生产操作中使用的可能导致生物、化学或放射性危害的物料所带来的任何风险（例如涉及活微生物的物料，粉末物料或放射性物料）。\n'The basic standards for drug production and quality control shall apply to the whole process of the production of pharmaceutical preparations and the key processes affecting the quality of finished products in the production of raw materials.'可被翻译为：药品生产和质量管理的基本准则，适用于药品制剂生产的全过程、原料药生产中影响成品质量的关键工序。\n'A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）\n'A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle. (ICH Q9)'可被翻译为：贯穿产品生命周期的对药品质量风险进行评估、控制、沟通和回顾分析的系统化过程。(ICH Q9)\n\n根据上述已知信息，请将'The determination of key materials should comprehensively take into account of the quality risk of the drugs produced by the manufacturer, the materials consumption and the impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要物料的确定应当综合考虑企业所生产的药品质量风险、物料用量以及物料对药品质量的影响程度等因素。"
    },
    {
        "instruction":"已知信息：\n'Design compounds with expected pharmacological effects, improve the screening hit rate, and find new effective structure types by using the law of drug structure-activity relationship under the premise of reducing the workload of synthesis and screening, and obtain new drugs with high efficiency, low toxicity and easy to administer.'可被翻译为：设计预期药理作用的化合物，提高筛选命中率，在减少合成及筛选工作量的前提下，运用药物构效关系规律，寻找新的显效结构类型，获得高效低毒便于给药的新药的途径和方法。\n'In vivo or in vitro screening models were used to identify compounds with specific biological activities.'可被翻译为：利用体内或体外筛选模型，确定具有特定生物学活性的化合物。\n'For the first time a new chemical structure for a drug.'可被翻译为：首次成为药品的新化学结构。\n'Studies conducted to scale-up, optimise, and validate the manufacturing process for a new drug substance.'可被翻译为：对新原料药合成工艺进行放大、优化以及验证的研究。\n\n根据上述已知信息，请将'Through chemical structure modification and in vitro and in vivo pharmacological and toxicological evaluation, the process of further discovering the derivative of the lead compound series with excellent efficacy, safety and pharmacokinetic properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学结构改造，并经体外和体内药理毒理方法评价，进一步发现先导化合物系列中，其药效、安全性、药动学特性优良的衍生物的过程。"
    },
    {
        "instruction":"已知信息：\n'x-ray diffraction of powder'可被翻译为：X 射线粉末衍射\n'x-ray diffraction of single crystal'可被翻译为：X 射线单晶衍射\n'When a crystal is illuminated with X-rays, the scattered X-rays of the atoms in the crystal add up. When the X-ray is monochromatic, the scattered X-ray of each atom interferes, producing strong X-ray diffraction lines in a specific direction. The structure of the crystal can be determined by the diffraction effect of the X-ray of a single crystal.'可被翻译为：当晶体被X射线照射时，晶体中各原子的散射X射线会叠加起来。当X射线为单色时，各原子的散射X射线发生干涉，在特定的方向上产生强的X射线衍射线，利用单晶体的X射线的衍射效应可测定晶体的结构。\n'The degree to which a substance is ordered in its solid state. The periodic, regular arrangement of atoms and molecules during crystallization. A sample can be determined by polarizing microscopy or X-ray powder diffraction to determine whether it is crystalline.'可被翻译为：物质在固体状态下有序排列的程度。在结晶时原子和分子是处于周期的、有规则的排列状态。可以通过偏光显微镜法或X射线粉末衍射法测定样品是否是结晶质。\n\n根据上述已知信息，请将'The X-ray diffraction method using powder crystal or polycrystal as the sample.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用粉末状晶体或多晶体为试样的X射线衍射法。"
    },
    {
        "instruction":"已知信息：\n'For the registrant, filing entity and distributor of medical devices with bad credit records, the drug regulatory departments shall increase the supervision and inspection frequency, and impose heavier punishment on dishonest behaviors according to law.'可被翻译为：对有不良信用记录的医疗器械注册人、备案人和经营企业，药品监督管理部门应当增加监督检查频次，依法加强失信惩戒。\n'Article 105 Drug regulatory departments establish drug safety credit record for MAHs, drug manufacturers, drug distributors, drug non-clinical safety evaluation research institutions, drug clinical trial organizations, and medical institutions to record issuance of permits, regular supervision and inspection findings, and investigations and handling of illegal acts, and shall make the records available to the public in accordance with the law and promptly update them. They may increase the frequency of supervision and inspection for entities with poor credit records and may implement joint punishment in accordance with the provisions of the State.'可被翻译为：第一百零五条 药品监督管理部门建立药品上市许可持有人、药品生产企业、药品经营企业、药物非临床安全性评价研究机构、药物临床试验机构和医疗机构药品安全信用档案，记录许可颁发、日常监督检查结果、违法行为查处等情况，依法向社会公布并及时更新；对有不良信用记录的，增加监督检查频次，并可以按照国家规定实施联合惩戒。\n'Disease prevention and control institutions and immunization entities shall truthfully record conditions including vaccine distribution and immunization in accordance with law, and provide traceability information to the national coordination platform for vaccine electronic traceability as required.'可被翻译为：疾病预防控制机构、接种单位应当依法如实记录疫苗流通、预防接种等情况，并按照规定向全国疫苗电子追溯协同平台提供追溯信息。\n'For registrant, filing entity or contract manufacturer of medical devices with bad credit records, the drug regulatory department shall increase supervision and inspection frequency, and impose heavier punishment on dishonest behaviors.'可被翻译为：对有不良信用记录的医疗器械注册人、备案人和受托生产企业，药品监督管理部门应当增加监督检查频次，依法加强失信惩戒。\n\n根据上述已知信息，请将'Drug regulatory departments shall establish a credit record system for the vaccine MAHs and their responsible persons and include them into the national credit information sharing platform, release information of their serious loss of honesty according to regulations and impose joint punishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门应当建立疫苗上市许可持有人及其相关人员信用记录制度，纳入全国信用信息共享平台，按照规定公示其严重失信信息，实施联合惩戒。"
    },
    {
        "instruction":"已知信息：\n'In the DNA double strand, the strand that is not used to transcribe mRNA.'可被翻译为：DNA双链中，不用于转录mRNA的那条链。\n'DNA Double-stranded DNA synthesized from an mRNA template by reverse transcriptase.'可被翻译为：DNA通过逆转录酶由mRNA模板合成的双链DNA。\n'A single strand in a double-stranded DNA molecule in which the sequence of bases is identical to that of the transcript.'可被翻译为：双链DNA分子中，碱基序列与转录产物一致的那条单链。\n'Also known as \"reverse transcription\". The process of using RNA as a template and transcribing it into double-stranded DNA with the help of reverse transcriptase.'可被翻译为：又称\"反转录”。以RNA为模板，在逆转录酶催化下转录为双链DNA的过程。\n\n根据上述已知信息，请将'The strand of a DNA double that is used to transcribe mRNA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"DNA双链中，用于转录mRNA的那条链。"
    },
    {
        "instruction":"已知信息：\n'Some product types should not be pooled. Two examples are drug products that have an initial low MVD (see discussion above of “adjusted MVD”) and products that are manufactured as a suspension, because sample aliquot homogeneity may present significant interference issues.'可被翻译为：有些产品类型不可混合取样。2个例子是初始MVD较低（参见上述“调整后的 MVD”）的药品和作为混悬液生产的药品，因为样品等分均匀性可能呈现出重大 干扰问题。\n'Samples taken away from the packaging line should not be returned to prevent the products from mixups or contamination.'可被翻译为：样品从包装生产线取走后不应当再返还，以防止产品混淆或污染。\n'Sampling methods should not pose a risk of contamination to the manufacturing operations.'可被翻译为：釆样方法不应给生产操作带来污染风险。\n'Article 188: Operations on different products should not be carried out simultaneously in the same room unless there is no risk of mixups or cross-contamination.'可被翻译为：第一百八十八条 不得在同一生产操作间同时进行不同品种和规格药品的生产操作，除非没有发生混淆或交叉污染的可能。\n\n根据上述已知信息，请将'FDA does not recommend pooling in-process samples from different in- process stages of the manufacturing process because it may be difficult to ensure the homogeneity of these materials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA不建议对生产工艺中不同中控步骤的中控样品进行合并，因为可能难以确保这 些物料的均一性。"
    },
    {
        "instruction":"已知信息：\n'Annexes: 1. Requirements for registration of medical excipients (Interim)(omitted)'可被翻译为：附件：1.药用辅料登记资料要求（试行）（略）\n'2. Requirements for registration of medical packaging materials (Interim) (omitted)'可被翻译为：2.药包材登记资料要求（试行）（略）\n'The active drug ingredients and excipients for the manufacture of drug products shall meet the requirements for pharmaceutical use and relevant requirements in the corresponding GMP. The primary packaging materials and container in direct contact with drug products shall meet the requirements for pharmaceutical use and the standards for ensuring human health and safety.'可被翻译为：生产药品所需的原料、辅料，应当符合药用要求以及相应的生产质量管理规范的有关要求。直接接触药品的包装材料和容器，应当符合药用要求，符合保障人体健康、安全的标准。\n'Raw materials and excipients packaging materials, and etc.'可被翻译为：指原料、辅料和包装材料等。\n\n根据上述已知信息，请将'4. Basic requirements for the annual report of medicinal raw materials, excipients and pharmaceutical packaging materials (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.药用原辅料、药包材年度报告基本要求（略）"
    },
    {
        "instruction":"已知信息：\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'Upon the receipt of the notice for supplementing and correcting dossiers, the lot release applicant shall submit the dossiers within 10 days. Failure to submit within the time limit without any justifiable reason shall be deemed as a waiver of the application and the decision of non-acceptance is not necessary to be made.'可被翻译为：批签发申请人收到补正资料通知后，应当在10日内补正资料，逾期未补正且无正当理由的，视为放弃申请，无需作出不予受理的决定。\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected one-off on site or within 5 working days. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容。逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申请资料之日起即为受理；\n\n根据上述已知信息，请将'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。"
    },
    {
        "instruction":"已知信息：\n'Person(s) who direct and control an organization at the highest levels and who have the authority and responsibility to mobilize resources within the organization. In NRAs, the terms “senior management” or “top management” can be used interchangeably.'可被翻译为：在组织最高层指导和控制组织的人，他们有权力和责任在组织内调动资源。在国家注册机构中，术语“高级管理人员”或“最高管理人员”可以互换使用。\n'Management system to direct and control a pharmaceutical company with regard to quality. (ICH Q10 based upon ISO 9000:2005)'可被翻译为：为在质量方面指导和控制制药公司而建立的管理体系。(ICH Q10 依据 ISO 9000:2005)\n'An organization currently engaged in establishing, populating on an initial basis or maintaining controlled vocabularies (ISO). For example, EDQM, ICH, \nIHTSDO.'可被翻译为：目前参与建立、在初步基础上填入或维护受控词汇（ISO）的组织。 例如，EDQM、ICH、IHTSDO。\n'A member of staff who has a defined responsibility and authority for ensuring that the management system related to quality is implemented and followed at all times (see Part one, section 1.3(j)).'可被翻译为：具有明确职责和权限的员工，以确保始终实施和遵循与质量相关的管理体系(见第一部分，第1.3(j)节)。\n\n根据上述已知信息，请将'Person(s) who direct and control a company or site at the highest levels with the authority and responsibility to mobilise resources within the company or site. (ICH Q10 based in part on ISO 9000:2005)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在最高级别上指导和控制一个公司或工厂、具有权力和责任在公司或工厂内部调动资源 的人员。 (ICH Q10 部分依据 ISO 9000:2005)"
    },
    {
        "instruction":"已知信息：\n'Prior to use in the test, the labeled LAL reagent sensitivity must be confirmed. Prepare a control standard endotoxin dilution series having at least four concentrations equivalent to 2 λ, λ, 0.5 λ, and 0.25 λ. Inoculate four replicates from each control standard endotoxin tube with equal amounts of reconstituted lysate per manufacturer’s recommendation. Multiple dilution series are not required. The geometric mean of the endpoints must be within the limits of labeled claim. The acceptable variation is one half (0.5 λ) to two times (2 λ) the labeled sensitivity (λ).'可被翻译为：LAL试剂用于检测之前，必须确认其灵敏度。制备一套标准内毒素对照稀释液，至 少有4个等同于2 λ、λ、0.5 λ和0.25 λ的浓度。根据生产商的建议从每个标准内毒 素对照管接种出4个相同等数量的复溶裂解液。不需要多个稀释系列。终点的等比 中数（几何平均数）必须在标称的限度内。可接受变异为标示灵敏度（λ）的0.5-2 倍（0.5 λ-2 λ）\n'Endotoxin Calculation'可被翻译为：内毒素计算\n'Perform medical device extractions and final endotoxin concentration calculations per USP and USP Guidelines on the Endotoxins Test.'可被翻译为：根据USP 和USP 内毒素测试指南实施医疗器械萃取和最终内毒素浓 缩计算。\n'NOTE: The rinse or extract volume may be adjusted for the size and configuration of the device. The device or components may be cut into smaller pieces using sterile, nonpyrogenic equipment such as forceps, scissors, wire cutters, etc. prior to the extraction.'可被翻译为：注：淋洗或萃取容积可根据医疗器械的尺寸和参数设置进行调整。医疗器械或组份可在 萃取前使用无菌无热源设备如镊子、剪刀、剪线钳等切为更小块。\n\n根据上述已知信息，请将'NOTE: Adjust the final endotoxin value taking into account the volume of the rinse solution used in the extraction procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注：调整最终内毒素值时要考虑提取程序所用淋洗溶液的体积。"
    },
    {
        "instruction":"已知信息：\n'The period in which the bacteria are inoculated into the fermentation medium and begin to grow and reproduce under suitable culture conditions.'可被翻译为：产生菌接种至发酵培养基后，在合适的培养条件下，开始生长和繁殖的时期。\n'The liquid in which the microorganisms are inoculated into the liquid medium for a period of time and then metabolized to synthesize the bacteria and secrete the products.'可被翻译为：微生物接种到液体培养基培养一段时间后，经微生物代谢合成菌体及分泌产物的液体。\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n'A substance provided by a culture medium that can be metabolized in part or in whole to form an end product.'可被翻译为：由培养基提供的，能被部分或整体代谢形成某种终产物的物质。\n\n根据上述已知信息，请将'The period in which the seeds or bacteria grown on the solid medium are transferred to the liquid medium for culture, so that they can multiply into a large number of mycelia or bacteria.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将在固体培养基上培养出的抱子或菌体转入到液体培养基中培养，使其繁殖成大量菌丝或菌体的时期。"
    },
    {
        "instruction":"已知信息：\n'Article 7 Where units and individuals discover any medical device adverse event, they have the right to report to authorities of drug supervision and administration (hereinafter referred to as drug regulatory departments) or monitoring agencies.'可被翻译为：第七条  任何单位和个人发现医疗器械不良事件，有权向负责药品监督管理的部门（以下简称药品监督管理部门）或者监测机构报告。\n'Article 11 The medical device manufacturers shall, in a timely manner, report the collected information on adverse events of medical devices to the food and drug regulatory department in accordance with regulations, and the food and drug regulatory department may analyze and investigate the adverse events or possible defects of medical devices; the medical device manufacturers, distributors and using units shall provide cooperation.'可被翻译为：第十一条 医疗器械生产企业应当按照规定及时将收集的医疗器械不良事件信息向食品药品监督管理部门报告，食品药品监督管理部门可以对医疗器械不良事件或者可能存在的缺陷进行分析和调查，医疗器械生产企业、经营企业、使用单位应当予以配合。\n'Article 28 The food and drug regulatory departments shall supervise and inspect the implementation of medical device mandatory standards and the registered or filed product technical requirements by medical device enterprises.'可被翻译为：第二十八条 食品药品监督管理部门对医疗器械企业实施医疗器械强制性标准以及经注册或者备案的产品技术要求的情况进行监督检查。\n'Article 27 The medical device manufacturers shall report the relevant situation of medical device recall to the food and drug regulatory department, and carry out subsequent handling of recalled medical devices in accordance with Article 19, 20, 21 and 22 of these Provisions.'可被翻译为：第二十七条 医疗器械生产企业应当按照本办法第十九条、第二十条、第二十一条、第二十二条的规定向食品药品监督管理部门报告医疗器械召回的相关情况，进行召回医疗器械的后续处理。\n\n根据上述已知信息，请将'Article 29 Any unit or individual have the right to report to the food and drug regulatory departments misbehaviors that violate the medical device mandatory standards and registered or filed product technical requirements. Departments receiving such reports shall take proper actions in accordance with regulations in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 任何单位和个人有权向食品药品监督管理部门举报或者反映违反医疗器械强制性标准以及经注册或者备案的产品技术要求的行为。收到举报或者反映的部门，应当及时按规定作出处理。"
    },
    {
        "instruction":"已知信息：\n'(2) not publicizing at the acceptance place the information that shall be publicized by la]w;'可被翻译为：（二）不在受理场所公示依法应当公示的材料的；\n'Without consent of the applicant, the drug regulatory department, professional technical institutions and their staff shall not disclose the commercial secrets, undisclosed information or confidential business information submitted by the applicant, unless otherwise specified by law or where national security or major social and public interests are involved.'可被翻译为：未经申请人同意，药品监督管理部门、专业技术机构及其工作人员不得披露申请人提交的商业秘密、未披露信息或者保密商务信息，法律另有规定或者涉及国家安全、重大社会公共利益的除外。\n'Without consent from the applicant, drug regulatory departments, specialized technical institutions and their staff, and participants in expert review shall not disclose the commercial secrets, undisclosed information or confidential business information submitted by the applicant, except as otherwise provided by law or those involving national security and major social and public interests.'可被翻译为：未经申请人同意，药品监督管理部门、专业技术机构及其工作人员、参与专家评审等的人员不得披露申请人提交的商业秘密、未披露信息或者保密商务信息，法律另有规定或者涉及国家安全、重大社会公共利益的除外。\n'Article 55 Without the consent of the registrant and the filing person, the drug regulatory departments, professional technical institutions and their staff, and those who involved in the evaluation shall not disclose the business secrets, undisclosed information or confidential business information submitted by the registrant or filing person, except as otherwise provided by law or involving national security or major public interests.'可被翻译为：第五十五条 未经注册人、备案人同意，药品监督管理部门、专业技术机构及其工作人员、参与审评的人员不得披露注册人、备案人提交的商业秘密、未披露信息或者保密商务信息，法律另有规定或者涉及国家安全、重大社会公共利益的除外。\n\n根据上述已知信息，请将'(II) Not publicizing on the institution's website or at the acceptance place the information that should be publicized according to law;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）不在本机构网站或者申请受理场所公示依法应当公示的材料的；"
    },
    {
        "instruction":"已知信息：\n'Article 93 Anyone who fabricates or spreads false information about vaccine safety, or picks quarrels and provokes troubles in immunization entities, thus constituting an act violating public security regulations shall be subject to public security punishment by the public security departments according to law.'可被翻译为：第九十三条 编造、散布虚假疫苗安全信息，或者在接种单位寻衅滋事，构成违反治安管理行为的，由公安机关依法给予治安管理处罚。\n'All entities or individuals are entitled to report any vaccine illegal behaviors to the competent health departments, the drug regulatory departments etc.; if the competent health departments or the drug regulatory departments etc. fail to perform their administration duties according to law, entities or individuals may report them to the relevant departments of people's governments at the same level or the superior level as well as relevant supervisory departments. Relevant departments shall verify and handle the report in a timely manner; if the reports are verified to be true, give rewards to the informants according to relevant regulations; and give substantial rewards to the informants who report serious illegal behaviors committed in the entities where they work if the reports are verified to be true.'可被翻译为：任何单位和个人有权向卫生健康主管部门、药品监督管理部门等部门举报疫苗违法行为，对卫生健康主管部门、药品监督管理部门等部门及其工作人员未依法履行监督管理职责的情况有权向本级或者上级人民政府及其有关部门、监察机关举报。有关部门、机关应当及时核实、处理；对查证属实的举报，按照规定给予举报人奖励；举报人举报所在单位严重违法行为，查证属实的，给予重奖。\n'News media shall, for the public welfare, carry out publicity on vaccine safety laws and regulations, and knowledge of immunization, and supervise illegal behaviors related to vaccines through public opinions. Publicity reports on vaccines shall be comprehensive, scientific, objective and impartial.'可被翻译为：新闻媒体应当开展疫苗安全法律、法规以及预防接种知识等的公益宣传，并对疫苗违法行为进行舆论监督。有关疫苗的宣传报道应当全面、科学、客观、公正。\n'Drug regulatory departments of people's governments at or above county level discovering any vaccine quality and safety information likely to mislead the public and affect social opinions shall immediate perform verification and analysis in conjunction with the competent health departments and other relevant departments, professional institutions and relevant MAHs, and release the results in a timely manner.'可被翻译为：县级以上人民政府药品监督管理部门发现可能误导公众和社会舆论的疫苗安全信息，应当立即会同卫生健康主管部门及其他有关部门、专业机构、相关疫苗上市许可持有人等进行核实、分析，并及时公布结果。\n\n根据上述已知信息，请将'Relevant competent departments shall impose sanctions according to law on a newspaper, journal, radio, television, internet website or any other media where they fabricate or disseminate any false information about vaccine safety, and on the main responsible person, executive in charge and other directly responsible personnel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"报纸、期刊、广播、电视、互联网站等传播媒介编造、散布虚假疫苗安全信息的，由有关部门依法给予处罚，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'Article 84 The registration shall not be renewed in any of the following circumstances:'可被翻译为：第八十四条 有下列情形之一的，不予再注册：\n'Article 65 The registration renewal shall not be approved in any of the following circumstances:'可被翻译为：第六十五条 有下列情形之一的，不予延续注册：\n'(5) Other circumstances where registration renewal shall be disapproved as per laws and administrative regulations.'可被翻译为：（五）法律、行政法规规定的其他不予再注册情形。\n'Article 55 The registration renewal shall not be approved in any of the following circumstances:'可被翻译为：第五十五条 有下列情形之一的，不予延续注册：\n\n根据上述已知信息，请将'(2) Where registration shall not be renewed according to these Provisions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）按照本办法规定不予再注册的；"
    },
    {
        "instruction":"已知信息：\n'In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.'可被翻译为：在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。\n'a class of biological macromolecules widely present in living organisms, consisting of a peptide chain formed by a peptide bond between A amino acid encoded by nucleic acid through A amino group and A carboxyl group, and an active macromolecule with a specific three-dimensional structure generated by post-translational processing.'可被翻译为：生物体中广泛存在的一类生物大分子，由核酸编码的a氨基酸之间通过a氨基和a竣基形成的肽键连接而成的肽链，经翻译后加工而生成的具有特定立体结构的、有活性的大分子。\n'Proteins or glycoproteins of non-immune origin. Able to bind specifically to sugar-containing macromolecules, causing cell agglutination and\/or glycoconjugates to precipitate. It is widely distributed in a variety of organisms and may be involved in a variety of important physiological recognition responses.'可被翻译为：非免疫来源的蛋白质或糖蛋白。能与含糖大分子特异性结合，使细胞凝集和\/或含糖缀合物沉淀。广泛地分布于多种生物体中，可能与多种重要的生理识别反应有关。\n'Natural products or synthetic polymers with high molecular weight above 10000Da or even millions of high molecular weight. Proteins, nucleic acids, polysaccharides, synthetic fibers, etc. are macromolecular compounds. They consist of structural units (equivalent to a covalent small molecule) bound together in covalent bonds. The structure is linear, reticular, or three-dimensional.'可被翻译为：分子量在10000Da以上甚至达数百万的高分子量的天然产物或合成高聚物。蛋白质、核酸、多糖、合成纤维等为大分子化合物。它们由结构单元（相当于一个共价小分子）以共价键结合而成。结构为线形、网状或三维体形。\n\n根据上述已知信息，请将'A protein compound consisting of a non-protein group of cogroups bound to an amino acid sequence. The non-protein portion of which is nucleic acid is called riboprotein, lipid compound is called lipoprotein, polysaccharide is called glycoprotein, and flavin riboxylic acid is called flavin protein.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由非蛋白质基团的辅基结合于氨基酸序列上组成的蛋白质类化合物。其非蛋白质部分是核酸的称为核蛋白，是类脂化合物的称为脂蛋白，是多糖的称为糖蛋白，是黄素核昔酸的称为黄素蛋白。"
    },
    {
        "instruction":"已知信息：\n'The online drug sales enterprises shall keep complete records of qualification documents and electronic transactions of the suppliers. The online drug retailers selling prescription drugs shall also keep records of prescriptions, online pharmaceutical services, etc. The relevant records shall be kept for not less than 5 years, and not less than 1 year after the expiration of the drug.'可被翻译为：药品网络销售企业应当完整保存供货企业资质文件、电子交易等记录。销售处方药的药品网络零售企业还应当保存处方、在线药学服务等记录。相关记录保存期限不少于5年，且不少于药品有效期满后1年。\n'The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.'可被翻译为：药品生产、经营企业按照本条前款规定留存的资料和销售凭证，应当保存至超过药品有效期1年，但不得少于3年。\n'Article 20 The third-party platform shall audit the qualifications, and the quality and safety assurance capabilities of the online drug sales enterprises that apply for settlement, establish registration record for online drug sales enterprises, and check and update such information at least every six months to ensure that the settled online drug sales enterprises meet the legal requirements.'可被翻译为：第二十条 第三方平台应当对申请入驻的药品网络销售企业资质、质量安全保证能力等进行审核，对药品网络销售企业建立登记档案，至少每六个月核验更新一次，确保入驻的药品网络销售企业符合法定要求。\n'Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.'可被翻译为：药品购进记录必须保存至超过药品有效期1年，但不得少于3年。\n\n根据上述已知信息，请将'Article 21 The third-party platform shall keep the information on drug display, transaction records, complaints and reports, and other relevant information. The storage period shall not be less than 5 years, and not less than 1 year after the expiration of the drug. The third-party platform shall ensure the authenticity and integrity of relevant materials, information, and data, and provide convenience for the settled online drug sales enterprises to save their own data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 第三方平台应当保存药品展示、交易记录与投诉举报等信息。保存期限不少于5年，且不少于药品有效期满后1年。第三方平台应当确保有关资料、信息和数据的真实、完整，并为入驻的药品网络销售企业自行保存数据提供便利。"
    },
    {
        "instruction":"已知信息：\n'Article 48 The National Center for ADR Monitoring shall conduct comprehensive analysis on serious ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to the SFDA and the Ministry of Health.'可被翻译为：第四十八条 国家药品不良反应监测中心应当每季度对收到的严重药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报国家食品药品监督管理局和卫生部。\n'For death cases, the provincial ADR monitoring institutions where the event occurs and where the drug manufacturer is located shall analyze and evaluate the event based on the investigation report in a timely manner, conduct on-site investigation when necessary, and report the evaluation results to the provincial drug regulatory departments and health administrative departments and the National Center for ADR Monitoring.'可被翻译为：对死亡病例，事件发生地和药品生产企业所在地的省级药品不良反应监测机构均应当及时根据调查报告进行分析、评价，必要时进行现场调查，并将评价结果报省级药品监督管理部门和卫生行政部门，以及国家药品不良反应监测中心。\n'Article 34 The National Center for ADR Monitoring shall analyze and evaluate ADR reports received and report to the SFDA and the Ministry of Health semiannually; once information indicating potential drug safety risks is identified, reports shall be submitted in a timely manner.'可被翻译为：第三十四条 国家药品不良反应监测中心应当对收到的药品不良反应报告进行分析、评价，每半年向国家食品药品监督管理局和卫生部报告，发现提示药品可能存在安全隐患的信息应当及时报告。\n'Article 43 ADR monitoring institutions at or above the provincial level shall be responsible for the supervision and inspection of intensive surveillance carried out by drug manufacturers, and conducting technical evaluation of the monitoring reports.'可被翻译为：第四十三条 省级以上药品不良反应监测机构负责对药品生产企业开展的重点监测进行监督、检查，并对监测报告进行技术评价。\n\n根据上述已知信息，请将'Article 47 Provincial ADR monitoring institutions shall conduct comprehensive analysis on ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to drug regulatory departments and health administrative departments at the provincial level and the National Center for ADR Monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条 省级药品不良反应监测机构应当每季度对收到的药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报省级药品监督管理部门、卫生行政部门和国家药品不良反应监测中心。"
    },
    {
        "instruction":"已知信息：\n'Article 46 Where major interest relationship between the applicant and others is directly involved in the application for medical device registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for medical device registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'可被翻译为：第四十六条 医疗器械注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人可以依照法律、法规以及国家食品药品监督管理总局的其他规定享有申请听证的权利；对医疗器械注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。\n'Article 8 The food and drug regulatory department shall publicize relevant information on in-vitro diagnostic reagent registration and filing promptly in accordance with laws. The applicant can look up the approval progress and relevant results as well as the public can look up the result of approval.'可被翻译为：第八条 食品药品监督管理部门依法及时公布体外诊断试剂注册、备案相关信息。申请人可以查询审批进度和结果，公众可以查阅审批结果。\n'Where a class III in-vitro diagnostic reagent registration is directly applied for, China Food and Drug Administration shall determine the class based on its risk degree. Where a domestic in-vitro diagnostic reagent is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region, or municipality directly under the central government where the applicant is located for evaluation and approval. Where a domestic in-vitro diagnostic reagent is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consisting of districts where the applicant is located.'可被翻译为：直接申请第三类体外诊断试剂注册的，国家食品药品监督管理总局按照风险程度确定类别。境内体外诊断试剂确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内体外诊断试剂确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。\n'Article 88 China Food and Drug Administration may, according to necessity, authorize the food and drug regulatory departments or technical organizations of provinces, autonomous regions and municipalities directly under the central government and relevant social organizations to conduct the specific work related to the registration of in-vitro diagnostic reagents.'可被翻译为：第八十八条 根据工作需要，国家食品药品监督管理总局可以委托省、自治区、直辖市食品药品监督管理部门或者技术机构、相关社会组织承担体外诊断试剂注册有关的具体工作。\n\n根据上述已知信息，请将'Article 56 Where major interest relationship between the applicant and others is directly involved in the application for in-vitro diagnostic reagent registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for in-vitro diagnostic reagent registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十六条 体外诊断试剂注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人依照法律、法规以及国家食品药品监督管理总局的有关规定享有申请听证的权利；对体外诊断试剂注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。"
    },
    {
        "instruction":"已知信息：\n'An antibiotic whose molecule contains three common double bonds.'可被翻译为：分子中含有三个共瓶双键的抗生素。\n'An antibiotic with a 14-membered lactone ring in the molecule.'可被翻译为：分子中含有十四元内酯环的抗生素。\n'An antibiotic with four common stem double bonds in the molecule.'可被翻译为：分子中含有四个共柄双键的抗生素。\n'An antibiotic that contains a large lactone ring in the molecule.'可被翻译为：分子中含有大内酯环的抗生素。\n\n根据上述已知信息，请将'The 3-position of the tetradecyclic macrolide is converted into a keto-based antibiotic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"十四元环大环内酯的3-位转变为酮基的抗生素。"
    },
    {
        "instruction":"已知信息：\n'Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).'可被翻译为：所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。\n'Integrity testing of the product filling lines and filtration systems (as relevant).'可被翻译为：产品灌装线和过滤系统的完整性测试（如相关）。\n'Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP) bags, glass or plastic ampoules, the critical parameters and variables that affect seal integrity should be evaluated, determined, effectively controlled and monitored during operations. Glass ampoules, BFS units and small volume containers (≤100 ml) closed by fusion should be subject to 100% integrity testing using validated methods. For large volume containers (>100 ml) closed by fusion, reduced sampling may be acceptable where scientifically justified and based on data demonstrating the consistency of the existing process, and a high level of process control. It should be noted that visual inspection is not considered as an acceptable integrity test method.'可被翻译为：当最终容器通过融合密封时，例如吹灌封（BFS）、成型-灌装-密封（FFS）、小容量注射剂和大容量注射剂（SVP&LVP）的袋子、玻璃或塑料安瓶瓶，应评估、确定影响密封完整性的关键参数和变量，并在操作过程中进行有效控制和监测。熔融密封的玻璃安瓿瓶、BFS 单元和小容量容器（≤100 ml）应使用经验证的方法进行 100%完整性测试。对于熔融密封的大容量容器（>100 ml），在经过科学论证并基于证明现有工艺可靠性和高水平工艺控制的数据的情况下，减少取样可能是可以接受的。值得注意的是，目检不被认为是可接受的完整性测试方法。\n'c. Guidance for Industry- Container and Closure system Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (2\/2008)'可被翻译为：行业指南—容器和密闭器系统完整性测试替代无菌检测，作为无菌药品的稳定性试验方案的一部分（2008 年 2 月）\n\n根据上述已知信息，请将'Methods and parameters for integrity testing of filled containers (see paragraph 8.22).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已灌装容器完整性测试的方法和参数（参见第 8.22 节）。"
    },
    {
        "instruction":"已知信息：\n'Article 55 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall determine inspection frequency based on the drug varieties, dosage form, regulation categories, taking into account overall national situation of drug safety, drug safety risk warning information, major drug safety events and related investigations and handling information as well as the previous inspections, monitoring of adverse reactions, complaints and whistle-blowing.'可被翻译为：第五十五条 省、自治区、直辖市药品监督管理部门应当根据药品品种、剂型、管制类别等特点，结合国家药品安全总体情况、药品安全风险警示信息、重大药品安全事件及其调查处理信息等，以及既往检查、检验、不良反应监测、投诉举报等情况确定检查频次：\n'The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out routine supervision and inspection of suppliers and manufacturers of active drug ingredients, pharmaceutical excipients and primary packaging materials and container in direct contact with drug products and, when necessary, carry out extended inspection.'可被翻译为：省、自治区、直辖市药品监督管理部门应当对原料、辅料、直接接触药品的包装材料和容器等供应商、生产企业开展日常监督检查，必要时开展延伸检查。\n'The drug regulatory department of the province, autonomous region or municipality directly under the Central Government is responsible for regulating the drug manufacture within its administrative area and shall undertake licensing, inspection and punishment in drug manufacturing.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域内的药品生产监督管理，承担药品生产环节的许可、检查和处罚等工作。\n'Specialized technical institutions for drugs set up or designated by drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall undertake the review, testing, inspection, monitoring and evaluation and other tasks required for drug supervision and administration in accordance with the law.'可被翻译为：省、自治区、直辖市药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。\n\n根据上述已知信息，请将'The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may adjust the inspection frequency depending on the practical situation of drug manufacturing supervision within respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门可以结合本行政区域内药品生产监管工作实际情况，调整检查频次。"
    },
    {
        "instruction":"已知信息：\n'(20) The drug regulatory authorities of the provinces (autonomous regions and municipalities) shall strengthen the supervision and inspection of drug\/preparation enterprises (Drug Marketing Authorization Holder) within their respective administrative regions, supervise and urge drug\/preparation enterprises(Drug Marketing Authorization Holder)to perform supplier audit responsibility for APIs, pharmaceutical excipients and pharmaceutical packaging materials.'可被翻译为：（二十）各省（区、市）药品监督管理局应加强对本行政区域内药品制剂生产企业（药品上市许可持有人）的监督检查，督促药品制剂生产企业（药品上市许可持有人）履行原料药、药用辅料和药包材的供应商审计责任。\n'II. Drug marketing authorization holders and drug registration applicants shall actively prepare for the implementation of the Good Pharmacovigilance Practice, establish and continuously improve the pharmacovigilance system and conduct pharmacovigilance activities in a standardized manner.'可被翻译为：二、药品上市许可持有人和药品注册申请人应当积极做好执行《药物警戒质量管理规范》的准备工作，按要求建立并持续完善药物警戒体系，规范开展药物警戒活动。\n'The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out routine supervision and inspection of suppliers and manufacturers of active drug ingredients, pharmaceutical excipients and primary packaging materials and container in direct contact with drug products and, when necessary, carry out extended inspection.'可被翻译为：省、自治区、直辖市药品监督管理部门应当对原料、辅料、直接接触药品的包装材料和容器等供应商、生产企业开展日常监督检查，必要时开展延伸检查。\n'8. Drug administration departments at all levels should strengthen leadership, make overall arrangements, conduct effective publicizing and training concerning the Production Provisions in light of the actual work in the administrative region. It is necessary to fully implement the Four Strictest requirements of drug administration, strictly implement the laws and regulations, and reinforce the supervision of production links in accordance with the principle of territorial supervision, beef up crossprovincial production supervision and information notification, and make overall arrangements for 2020 Drug Manufacturing Certificate reexaminations, renewals and reissuances, to ensure that there is no reduction in administration efforts, standards, and continuous supervision, to ensure the quality and safety of medicines.'可被翻译为：八、各级药品监督管理部门要加强领导、统筹部署，结合本行政区域的工作实际，做好《生产办法》的宣贯和培训。要全面贯彻药品监管“四个最严”要求，严格落实药品管理法律法规规章等规定，按照属地监管原则，加大生产环节的监管力度，加强跨省委托生产监管和信息通报，统筹安排2020年《药品生产许可证》重新审查发证工作，确保监管力度不减、标准不降、监管不断，保证药品质量安全。\n\n根据上述已知信息，请将'IV. All the provincial medical products administration shall supervise and urge the drug marketing authorization holders within their respective administrative areas to actively make preparations, cooperate with relevant publicity and interpretation, supervise and guide drug marketing authorization holders to implement the Good Pharmacovigilance Practice as required by strengthening routine inspection and other activities, and in a timely manner collect and feedback relevant questions and comments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、各省级药品监督管理部门应当督促本行政区域内的药品上市许可持有人积极做好相关准备工作，配合做好有关宣贯和解读，通过加强日常检查等工作监督和指导药品上市许可持有人按要求执行《药物警戒质量管理规范》，及时收集和反馈相关问题和意见。"
    },
    {
        "instruction":"已知信息：\n'Article138 An applicant shall select representative samples for drug registration specifications study.'可被翻译为：第一百三十八条 申请人应当选取有代表性的样品进行标准的研究工作。\n'Except for special regulations and requirements, the quantity of drug samples required for sampling generally shall be three times of the quantity required for testing. The remaining samples after testing, except for the retained samples for future reference, shall be returned to the applicant for testing.'可被翻译为：除特殊规定与要求外，一般为检验用量的三倍。检验后剩余样品除留样备查外，应当退回报验单位。\n'To apply for drug registration, authentic, sufficient and reliable data, documents and samples shall be provided to demonstrate the safety, efficacy and quality of the drugs.'可被翻译为：申请药品注册，应当提供真实、充分、可靠的数据、资料和样品，证明药品的安全性、有效性和质量可控性。\n'Article 6 The applicant for drug registration (hereinafter referred to as the applicant) shall ensure that the information in the entire process of development and registration activities is true, accurate, complete, and traceable, and shall provide true, sufficient, and reliable data and samples when file an application for drug marketing authorization and shall possess the conditions for commercial production of drugs marketing. The applicant and the inspected institution shall cooperate with the registration inspection work.'可被翻译为：第六条 药品注册申请人(以下简称申请人)应当保证研制和注册活动全过程信息真实、准确、完整和可追溯，提出药品上市许可申请还应当提供真实、充分、可靠的数据资料和样品，具备药品上市商业化生产条件。申请人和被核查单位应当配合注册核查工作。\n\n根据上述已知信息，请将'Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。"
    },
    {
        "instruction":"已知信息：\n'a. Carefully remove the lid of RODAC plate or loosen the cap on the Hycheck slide tube. \nTake care not to touch the agar surface.\nNote: Examine agar for contamination and or dehydration'可被翻译为：小心取下 RODAC 碟的盖子或松开 Hycheck 滑管的盖子。小心不要接触琼脂培养基表面\n注：检查琼脂是否被污染或脱水\n'4. Hycheck slides and RODAC plates should promptly be incubated at 30-35ºC for 2 days and then 20 ºC -25 ºC for 5 days. Longer incubation times may be required when contaminants are suspected to be slow growing. Check plates daily for colony formation to minimize obscuring visualization of smaller colonies by over growth.'可被翻译为：立即将 Hycheck 条和 RODAC 碟在 30-35ºC 充分培养 2 天，然后在 20 ºC -25 ºC 培养5 天。如果容器可能导致生长缓慢，则可能需要更长时间。每天检查培养碟中菌群污染物情况，以减少较小菌落过分生长难以看清。\n'b. Gently but firmly touch the RODAC agar surface against the area being sampled, exert moderate, even, vertical pressure and then carefully replace lid. Avoid using rubbing motions of the plate at the sample site as this may break the agar.'可被翻译为：将 RODAC 碟用于取样的琼脂表面轻轻但牢固地接触被取样的表面，垂直均匀按压，取下，小心地重新盖上盖子。避免碟表面与取样面摩擦，因为可能会使琼脂裂开。\n's. Hycheck slides'可被翻译为：Hycheck 培养条\n\n根据上述已知信息，请将'c. When using Hycheck press down on the spike to bend the paddle at the hinge line gently lowering the slide and press the agar to the surface with firm and even pressure. Repeat this step using the 2nd agar surface on an area adjacent to the initial test site. \nReplace slide in container and close tightly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用 Hycheck 取样条时，以尖头为着力点，手持盖按压，让取样条在折线处向下弯曲，垂直均匀地将培养基表面压在被取样表面。翻转，将反面培养基同样操作，从第一个取样点的邻近表面取样。将培养基条放回瓶中，盖紧。"
    },
    {
        "instruction":"已知信息：\n'The active drug ingredients and excipients for the manufacture of drug products shall meet the requirements for pharmaceutical use and relevant requirements in the corresponding GMP. The primary packaging materials and container in direct contact with drug products shall meet the requirements for pharmaceutical use and the standards for ensuring human health and safety.'可被翻译为：生产药品所需的原料、辅料，应当符合药用要求以及相应的生产质量管理规范的有关要求。直接接触药品的包装材料和容器，应当符合药用要求，符合保障人体健康、安全的标准。\n'Manufacturers of active drug ingredients shall organize manufacturing according to approved manufacturing processes and strictly abide by good manufacturing practice to ensure the drug manufacturing continuously complies with statutory requirements.'可被翻译为：原料药生产企业应当按照核准的生产工艺组织生产，严格遵守药品生产质量管理规范，确保生产过程持续符合法定要求。\n'Article 184: The production and packaging of all drugs should follow approved manufacturing formula and processing instructions and operation procedures with records retained, in order to ensure the drugs meet defined quality specifications and conform to drug manufacturing licensing and registration approval requirements.'可被翻译为：第一百八十四条 所有药品的生产和包装均应当按照批准的工艺规程和操作规程进行操作并有相关记录，以确保药品达到规定的质量标准，并符合药品生产许可和注册批准的要求。\n'Article 75 Medical institutions engaged in preparing drug preparations shall have facilities, management system, inspection equipment and hygienic environment for ensuring drug quality.'可被翻译为：第七十五条 医疗机构配制制剂，应当有能够保证制剂质量的设施、管理制度、检验仪器和卫生环境。\n\n根据上述已知信息，请将'When preparing drug preparations, medical institutions shall perform their duties in accordance with the approved process, and the required active drug ingredients, excipients, and packaging materials shall comply with medicinal requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗机构配制制剂，应当按照经核准的工艺进行，所需的原料、辅料和包装材料等应当符合药用要求。"
    },
    {
        "instruction":"已知信息：\n'Article 287: A contract should be drawn up between the contract giver and the contract acceptor which specifies their respective responsibilities relating to the manufacture and control of the product. Technical aspects of the contract should be drawn up by competent persons with suitable knowledge in the pharmaceutical technology, analysis and the provisions. All arrangements for manufacture and analysis must be in accordance with the drug registration requirements and agreed by both parties.'可被翻译为：第二百八十七条 委托方与受托方之间签订的合同应当详细规定各自的产品生产和控制职责，其中的技术性条款应当由具有制药技术、检验专业知识和熟悉本规范的主管人员拟订。委托生产及检验的各项工作必须符合药品生产许可和药品注册的有关要求并经双方同意。\n'Article 184: The production and packaging of all drugs should follow approved manufacturing formula and processing instructions and operation procedures with records retained, in order to ensure the drugs meet defined quality specifications and conform to drug manufacturing licensing and registration approval requirements.'可被翻译为：第一百八十四条 所有药品的生产和包装均应当按照批准的工艺规程和操作规程进行操作并有相关记录，以确保药品达到规定的质量标准，并符合药品生产许可和注册批准的要求。\n'The contract manufacturer shall organize manufacturing in accordance with laws, regulations and provisions, the Good Manufacturing Practice for medical devices, mandatory standards, technical specifications for the products and entrusted manufacturing quality agreement, etc., and shall be responsible for the manufacturing acts and accept the supervision of the registrant and filing entity of the medical devices.'可被翻译为：受托生产企业应当按照法律、法规、规章、医疗器械生产质量管理规范、强制性标准、产品技术要求、委托生产质量协议等要求组织生产，对生产行为负责，并接受医疗器械注册人、备案人的监督。\n'Article 278: To ensure the product quality of contract manufacture, and the accuracy and reliability of contract analysis, there must be a written contract between the contract giver and the contract acceptor, which clearly establishes the duties of each party, and covers the manufacture and\/or analysis arranged under contract and any technical arrangements made in connection with it.'可被翻译为：第二百七十八条 为确保委托生产产品的质量和委托检验的准确性和可靠性，委托方和受托方必须签订书面合同，明确规定各方责任、委托生产或委托检验的内容及相关的技术事项。\n\n根据上述已知信息，请将'Article 279: All arrangements for contract manufacture and analysis including any proposed changes in technical or other arrangements should be in accordance with the drug manufacturing licensing and registration requirements for the product concerned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百七十九条 委托生产或委托检验的所有活动，包括在技术或其他方面拟采取的任何变更，均应当符合药品生产许可和注册的有关要求。"
    },
    {
        "instruction":"已知信息：\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n'A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.'可被翻译为：20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。\n'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'可被翻译为：确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。\n'The application of multivariate statistical techniques to analyse complex process data with potentially correlated variables. (Ph. Eur.)'可被翻译为：应用多变量统计技术分析具有潜在相关变量的复杂工艺数据。\n\n根据上述已知信息，请将'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'The phenomenon in which the aqueous solubility of some insoluble drugs can be increased without reducing their biological activity when a third substance is added.'可被翻译为：当加入第三种物质时可增加一些难溶性药物的水中溶解度而不降低其生物活性的现象。\n'The proportion of the concentration in which a drug is distributed between two adjacent liquid media that are not mutually soluble.'可被翻译为：药物分配在互不相溶的两种相邻液态介质中的浓度比例。\n'An auxiliary solvent that increases the solubility of the drug in the main solvent.'可被翻译为：能提高药物在主溶剂中溶解度的辅助溶剂。\n'The combination of two drugs shows an effect significantly greater than the sum of the two.'可被翻译为：两药联合应用所显示的效应明显超过两者之和。\n\n根据上述已知信息，请将'The phenomenon in which the solubility of a drug in a mixture of two solvents in a certain ratio is greater than that in any single solvent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在混合溶剂中两溶剂在某一比例时，药物的溶解度比在任一单纯溶剂中的溶解度均大的现象。"
    },
    {
        "instruction":"已知信息：\n'(1) products with unreasonable risks that may cause hazards to human health and life safety under normal use;'可被翻译为：（一）正常使用情况下存在可能危及人体健康和生命安全的不合理风险的产品；\n'A physical injury or damage to the health of people or damage to property or the environment (15).'可被翻译为：人身伤害或对人的健康的损害或对财产或环境的损害(15)。\n'The relative ability of foreign chemicals to cause damaging effects when they come into contact with the body or enter a susceptible site in the body.'可被翻译为：外源化学物与机体接触或进入体内的易感部位后，能引起损害作用的相对能力。\n'An identified risk or potential risk that could impact on the risk-benefit profile of the product or have implications for public health. What constitutes an important risk will depend upon several factors, including the impact on the individual, the seriousness of the risk, and the impact on public health. Normally, any risk that is likely to be included in the contraindications or warnings and precautions section of the product labelling should be considered important.'可被翻译为：可能会影响产品的风险-利益特征或对公众健康产生影响的已确定风险或潜在风险。是否属于重要风险将取决于多个因素，包括对个人的影响、风险的严重性以及对公众健康的影响。通常，有可能被纳入产品标签中的禁忌，警告和注意事项章节的任何风险都应该被认为是重要的风险。\n\n根据上述已知信息，请将'A product or substance that may present a substantial risk of injury, to health or to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可能对健康或环境造成重大伤害风险的产品或物质。"
    },
    {
        "instruction":"已知信息：\n'I. On June 24, 2020, the government website of NMPA has released a new version of drug registration application software for applicants.'可被翻译为：一、2020年6月24日，国家药监局政府网站将发布供申请人使用的新版药品注册申报软件。\n'To support the implementation of the newly revised Provisions for Drug Registration,NMPA is currently stepping up the upgrade of related systems for drug registration. The related issues were announced as follows:'可被翻译为：为保障新修订《药品注册管理办法》顺利实施，目前国家药监局正在抓紧对药品注册相关系统进行升级改造。现将相关事宜公告如下：\n'Applicants for drug registration shall complete user registration and authorization based binding of the drug business application system through the Online Service Hall of the NMPA (https:\/\/zwfw.nmpa.gov.cn\/) as per the Operation Guidelines for Enterprises on Pharmaceutical Related Application System. As of January 1, 2021, drug registration can be applied online.'可被翻译为：药品注册申请人应当按照《药品业务应用系统企业操作指南》（见附件）通过国家药品监督管理局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn\/）完成用户注册及药品业务应用系统授权绑定操作，自2021年1月1日起可在网上办理药品注册业务。\n'NMPA Issues the Announcement on Upgrading Related Systems for Drug Registration'可被翻译为：国家药监局关于药品注册相关系统升级改造的公告\n\n根据上述已知信息，请将'III. From July 1, 2020, NMPA will enable a new version of related system for drug registration. Drug registrants are advised to download the latest version of the application software, and submit registration application as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"三、2020年7月1日起，国家药监局将启用新版药品注册相关系统，请药品注册申请人注意下载最新版申报软件，按要求提交注册申请。"
    },
    {
        "instruction":"已知信息：\n'NMPA Notice on Launching the Cosmetic Ingredient Safety Information Registration Platform'可被翻译为：国家药监局关于化妆品原料安全信息登记平台上线通知\n'In order to facilitate enterprises to makegood preparation for the registration and notification of cosmetics in advance, as of April 1, 2021, domestic cosmetic registration persons, notification persons, domestic responsible persons and cosmetic manufacturers may submit relevant documents and apply for the user account for registration and notification at the Information Service Platform of Cosmetics Registration and Notification(hereinafter referred to as the new platform) according to the requirements in the Rules through the NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn), a national integrated online government service platform. As of May 1, 2021, cosmetic registration persons, notification persons and domestic responsible persons shall apply for the registration of special cosmetics or file notification of the general cosmetics through the new platform.'可被翻译为：为方便企业提前做好化妆品注册备案准备工作，自2021年4月1日起，境内的化妆品注册人、备案人、境内责任人和化妆品生产企业，可以通过全国一体化在线政务服务平台国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn），按照《规定》的要求在化妆品注册备案信息服务平台（以下简称新注册备案平台）提交相关资料，办理注册备案用户账号；自2021年5月1日起，化妆品注册人、备案人、境内责任人，应当通过新注册备案平台申请特殊化妆品注册或者进行普通化妆品备案。\n'After the launch of the Cosmetic Ingredient Safety Information Registration Platform, cosmetics registrants, filing applicants and persons in charge within the territory of China can still fill out and submit the safety information document of ingredients issued by raw material manufacturers through the Information Service Platform for Registration and Filing of Cosmetics, or fill in the safety information document of ingredients associated with the ingredients submission code generated by the platform.'可被翻译为：化妆品原料安全信息登记平台上线后，化妆品注册人、备案人、境内责任人仍可以通过化妆品注册备案信息服务平台填报原料生产商出具的原料安全信息文件，也可以填写化妆品原料安全信息登记平台生成的原料报送码关联原料安全信息文件。\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of new cosmetic ingredients, the NMPA has developed the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients, which is hereby issued and shall take effect as of May 1,2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品新原料注册与备案工作，国家药监局制定了《化妆品新原料注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'In order to implement the Provisions for the Registration and Filing of Cosmetics, Provisions for the Registration or Filing Dossier of Cosmetics and other regulatory documents, NMPA organized to establish the Cosmetic Ingredient Safety Information Registration Platform. Since 9 A.M. on December 31, 2021, cosmetic ingredient manufacturers or their authorized enterprises can log in to this platform to report information related to the safety of ingredients. Domestic users may log in to the platform directly through the \"Cosmetic Ingredient Safety Information Registration Platform\" module at NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn); and overseas users need to set up an account at the \"Cosmetic Ingredient Safety Information Registration Platform” (http:\/\/ciip.nifdc.org.cn) before login.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》等法规文件，国家药监局组织建立了化妆品原料安全信息登记平台，自2021年12月31日上午9时起，化妆品原料生产商或其授权企业可以登陆该平台报送原料安全相关信息。境内用户直接通过国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn）的“化妆品原料安全信息登记平台”模块进行登陆；境外用户需在“化妆品原料安全信息登记平台”（http:\/\/ciip.nifdc.org.cn）开通账号后登陆。"
    },
    {
        "instruction":"已知信息：\n'The range of blood concentrations within which drug efficacy can be produced without unacceptable toxicity, or the range of dosage and frequency of administration that should be considered in the course of prolonged treatment.'可被翻译为：能产生药效而不出现不可接受毒性的血药浓度范围，或进行长时间治疗时应考虑的给药剂量和频度范围。\n'The ratio of minimum toxic dose (LD5) to maximum therapeutic dose (ED95).'可被翻译为：最小中毒剂量（LD5）与最大治疗剂量（ED95）的比值。\n'The ratio of the highest dose with no observed effect to the lowest dose with no observed harmful effect.'可被翻译为：未观察到作用的最高剂量与未观察到有害作用的最低剂量的比值。\n'In the course of medical treatment, according to the efficacy and condition, according to a certain law to increase or reduce the drug dose to achieve effective and safe medical behavior.'可被翻译为：在医疗过程中，根据疗效和病情，按照一定规律增加或减少药物剂量使达到有效和安全的医疗行为。\n\n根据上述已知信息，请将'The ratio of median lethal dose to median effective dose. A large therapeutic index indicates high curative effect and relatively safe drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"半数致死量与半数有效量的比值。治疗指数大表示疗效高、用药比较安全。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the National ADR Monitoring Network received 1.514 million copies of ADR\/ADE Report Form. From 1999 to 2019, the National ADR Monitoring Network received an accumulative total of 15.19 million copies of the ADR\/ADE Report Form (See Figure 1).'可被翻译为：2019年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》151.4万份。1999年至2019年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,519万份（图1）。\n'In 2018, the National ADR Monitoring Network received 495,000 new and serious ADR\/ADE reports, accounting for 33.1% of the total number reported in the same period.The steady growth of the proportion of new and serious ADR\/ADE reports indicates a constant upclimbing of the availability of ADR reports in China.'可被翻译为：2018年全国药品不良反应监测网络收到新的和严重药品不良反应\/事件报告49.5万份；新的和严重药品不良反应\/事件报告占同期报告总数的33.1%。新的和严重药品不良反应\/事件报告比例持续增加，显示我国药品不良反应报告可利用性持续增加。\n'In 2018, the National ADR Monitoring Network received 1.499 million copies of the Report on Adverse Drug Reactions\/Events. From 1999 to 2018, the National ADR Monitoring Network received a total of 13.68 million copies of the ADRs \/ ADEs Report Forms (Figure 1).'可被翻译为：2018年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》149.9万份。1999年至2018年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1368万份（图1）。\n'In 2020, the National ADR Monitoring Network received a total of 830,000 ADR\/ADE reports of the varieties included in the National Essential Drugs List (2018 Edition), of which 88,000 were reports of serious ADRs\/ADEs, accounting for 10.6%. Reports involving chemical drugs and biological products account for 88.1% and those involving traditional Chinese medicines account for 11.9%.'可被翻译为：2020年全国药品不良反应监测网络共收到《国家基本药物目录（2018年版）》收载品种的不良反应\/事件报告83.0万份，其中严重报告8.8万份，占10.6%。报告涉及化学药品和生物制品占88.1%，中成药占11.9%。\n\n根据上述已知信息，请将'In 2020, the China National ADR Monitoring Network received 1.676 million copies of ADR\/ADE Reports. From 1999 to 2020, the National ADR Monitoring Network received a total of 16.87 million copies of ADR\/ADE Reports.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》167.6万份。1999年至2020年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,687万份。"
    },
    {
        "instruction":"已知信息：\n'(V)  Production is approved to resume after ordered production suspension for violation of relevant laws and regulations;'可被翻译为：（五）因违反相关法律法规被责令停产后经批准恢复生产的；\n'During the investigation and handling of the above issues, the acceptance of lot release application or issuance of lot release for corresponding variety of the applicant may be suspended.'可被翻译为：在上述问题调查处理期间，对批签发申请人相应品种可以暂停受理或者签发。\n'(3) in the process of acceptance, review and approval, not fulfilling the regulatory informing obligation to the applicant or interest party;'可被翻译为：（三）在受理、审评、审批过程中，未向申请人、利害关系人履行法定告知义务的；\n'The time for the testing for drug registration and for the review shall be kept in accordance with the Provisions. Where there is a need for time extension in particular situation, it, with reasons provided, shall be reported to the State Food and Drug Administration for approval, and the applicant shall be informed thereof.'可被翻译为：药品注册检验、审评工作时间应当按照本办法的规定执行。有特殊原因需要延长时间的，应当说明理由，报国家食品药品监督管理局批准并告知申请人。\n\n根据上述已知信息，请将'(3) Time occupied during suspension of the review and approval procedures where the review and approval procedures are suspended in accordance with laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）根据法律法规的规定中止审评审批程序的，中止审评审批程序期间所占用的时间；"
    },
    {
        "instruction":"已知信息：\n'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'可被翻译为：2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。\n'(II) Number of registered grassroots users nationwide'可被翻译为：（二）全国注册基层用户数量\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n'As of December 31, 2020, there were a total of 350,973 grassroots users (incl. registrants, distributors and using units) registered in the National Medical Device Adverse Event Monitoring Information System, covering 27,195 registrants (7.75%); 198,833 distributors (56.65%); and 124,945 using units (35.60%).'可被翻译为：截至2020年12月31日，在国家医疗器械不良事件监测信息系统中注册的基层用户（包括注册人、经营企业和使用单位）共350,973家，其中注册人27,195家，占用户总数的7.75%；经营企业198,833家，占用户总数的56.65%；使用单位124,945家，占用户总数的35.60%。\n\n根据上述已知信息，请将'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。"
    },
    {
        "instruction":"已知信息：\n'Review and approval for drug registration applications'可被翻译为：药品注册申请审评审批情况\n'Key Points and Determination Principles of Drug Registration Inspection'可被翻译为：药品注册核查要点与判定原则\n'II. Review & approval of drug registration applications'可被翻译为：二、药品注册申请审评审批情况\n'The process in which the drug regulatory department inspects and evaluates the implementation of the corresponding quality control standards by the drug research, production, distribution and user, and decides whether to issue the corresponding certification.'可被翻译为：药品监督管理部门对药品研制、生产、经营、使用单位实施相应质量管理规范进行检查、评价并决定是否发给相应认证证书的过程。\n\n根据上述已知信息，请将'A technical evaluation of the reasonableness and controllability of drug registration criteria. Such as the review of imported drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对药品注册标准的合理性和可控性进行的技术评价。比如进口药品复核。"
    },
    {
        "instruction":"已知信息：\n'Article 45 The sponsor shall be responsible for the safety of investigational medical device in clinical trial. When finding it may affect the safety of the subjects or the implementation of the trial may change the approval of the ethics committee for the continuation of the trial, the sponsor shall immediately notify all clinical trial institutions and investigators and make corresponding handling.'可被翻译为：第四十五条 申办者对试验用医疗器械在临床试验中的安全性负责。当发现可能影响受试者安全或者试验实施可能改变伦理委员会对继续试验的批准情况时，申办者应当立即通知所有临床试验机构和研究者，并作出相应处理。\n'Article 22 Drug clinical trials shall be conducted in qualified and filed clinical trial institutions. Vaccine clinical trials shall be carried out or organized by Class III medical institutions or disease prevention and control institutions above the provincial level that meet the requirements prescribed by the NMPA and the National Health Commission.'可被翻译为：第二十二条 药物临床试验应当在具备相应条件并按规定备案的药物临床试验机构开展。其中，疫苗临床试验应当由符合国家药品监督管理局和国家卫生健康委员会规定条件的三级医疗机构或者省级以上疾病预防控制机构实施或者组织实施。\n'Vaccine clinical trials shall be carried out or organized by Class III medical institutions or disease prevention and control institutions at or above the provincial level that meet the requirements prescribed by the drug regulatory department under the State Council and the competent health department under the State Council.'可被翻译为：疫苗临床试验应当由符合国务院药品监督管理部门和国务院卫生健康主管部门规定条件的三级医疗机构或者省级以上疾病预防控制机构实施或者组织实施。\n'Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:'可被翻译为：第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：\n\n根据上述已知信息，请将'Article 17 The sponsor of vaccine clinical trials shall design the clinical trial protocol, establish the safety monitoring and evaluation system for clinical trials, prudently select subjects, appropriately set up subject population and age groups, and take effective measures based on risk levels to protect legal interests of subjects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 疫苗临床试验申办者应当制定临床试验方案，建立临床试验安全监测与评价制度，审慎选择受试者，合理设置受试者群体和年龄组，并根据风险程度采取有效措施，保护受试者合法权益。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China (2019 No. 103), which reads as follows:'可被翻译为：2019年11月29日，国家药监局发布了关于贯彻实施《中华人民共和国药品管理法》有关事项的公告（2019No.103），其内容如下：\n'NMPA Issued the Announcement on Issues Pertaining to the Current Administration on Drug Distribution'可被翻译为：国家药监局关于当前药品经营监督管理有关事宜的通告\n'NMPA Issues the Announcement on Implementing the 2020 Edition of the Pharmacopoeia of the People's Republic of China'可被翻译为：国家药监局关于实施2020年版《中华人民共和国药典》有关事宜的公告\n'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Newly Revised Provisions for the Supervision and Administration of Drug Production'可被翻译为：国家药监局关于实施新修订《药品生产监督管理办法》有关事项的公告\n\n根据上述已知信息，请将'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于贯彻实施《中华人民共和国药品管理法》有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'(1) site master files and the materials in connection with any change;'可被翻译为：（一）药品生产场地管理文件以及变更材料；\n'(IV)  Post-marketing change approval documents\/filing documents;'可被翻译为：（四）上市后变更的批准或者备案文件；\n'Portable Document Format -- A document management format and current de-facto standard for the electronic transfer of documents. Although it \nbegan as a proprietary format from the Adobe corporation the current M2 recommendation is to use the public standard PDF described in ISO 32000-\n1:2008.'可被翻译为：可移植文档格式 – 一种文件管理格式和文件电子传输的事实标准。虽然它开始是 Adobe 公司的专有格式，但是目前 M2 推荐使用 ISO 32000-1: 2008 中描述的公开的标准 PDF。\n'(IV) Post-marketing change approval documents;'可被翻译为：（四）上市后变更的批准证明性文件；\n\n根据上述已知信息，请将'New document format introduced to replace the product dossier and site master file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"引入新的文档格式，以取代产品档案和站点主文件。"
    },
    {
        "instruction":"已知信息：\n'The technique of manipulating genes at the molecular level to alter the genetic characteristics of a species. For example, the operation of introducing the foreign gene into the recipient cell after recombination in vitro, so that the gene can be copied, transcribed, translated and expressed in the recipient cell.'可被翻译为：在分子水平上对基因进行操作，以达到改变物种遗传特征的技术总称。如将外源基因通过体外重组后导入受体细胞内，使这个基因能在受体细胞内复制、转录、翻译表达的操作。\n'An experimental technique that alters or destroys the structure of a target gene at the genomic level, resulting in a complete loss of function.'可被翻译为：在基因组水平上改变或破坏靶基因的结构，使其功能完全丧失的实验技术。\n'The technique of introducing artificially isolated and modified genes into the genome of an organism and causing heritable modification of the traits of the organism due to the expression of the imported genes.'可被翻译为：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，引起生物体性状的可遗传性修饰的技术。\n'The process of artificially manipulating the genetic material of an organism so that it is modified or altered.'可被翻译为：对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。\n\n根据上述已知信息，请将'An experimental technique in which a specific gene in the genome is altered by site-specific homologous recombination of DNA in order to study the function of the gene in vivo. It builds on the achievements of embryonic stem cell technology and homologous recombination technology, and promotes the further development of related technologies. It is widely used in the research of gene function, the development of animal models of human diseases and the improvement of genetic material of economic animals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过DNA定点同源重组，改变基因组中的某一特定基因，从而在生物活体内研究此基因功能的实验技术。它建立在胚胎干细胞技术和同源重组技术成就的基础上，并促进了相关技术的进一步发展。广泛应用于基因功能研究、人类疾病动物模型的研制以及经济动物遗传物质的改良等方面。"
    },
    {
        "instruction":"已知信息：\n'(IV) A copy of the packing list, bill of lading and shipping invoice;'可被翻译为：（四）装箱单、提运单和货运发票复印件；\n'The above information must be provided with both a paper version (with the official seal of the applicant) and corresponding electronic version.'可被翻译为：以上资料需同时提供纸质版（加盖申请人公章）和相应电子版。\n'The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.'可被翻译为：随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n\n根据上述已知信息，请将'(IV) Model of relevant seal and the accompanying sheet (bill);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）相关印章、随货同行单（票）样式；"
    },
    {
        "instruction":"已知信息：\n'The transfer of partially closed containers to a lyophilizer should be undertaken under grade A conditions at all times and handled in a manner designed to minimize direct operator intervention. Technologies such as conveyor systems or portable transfer systems (e.g. clean air transfer carts, portable unidirectional airflow workstations) should be used to ensure that the cleanliness of the  system used to transfer the partially closed containers is maintained. Alternatively, where supported by validation, trays closed in grade A and not reopened whilst in the grade B area may be used to protect partially stoppered vials (e.g. appropriately closed boxes).'可被翻译为：将半封闭容器转移到冻干机时，应始终在 A 级条件下进行，并且采用可以最大程度减少操作员直接干预的 传递方式。应使用诸如传送带系统或便携式转移系统（例如，洁净空气传输车，便携式单向流工作台）等 技术，以确保维持用于转移部分密闭容器的系统的洁净度。或者，在经过验证的情况下，在 A 级密封且在B 级区时不再重新打开的托盘可用于保护半压塞的西林瓶（例如，适当密封的箱子）。\n'The  sterilisation  of the  lyophilizer  and  associated  equipment  (e.g.  trays, vial  support rings)  should  be validated and the holding time between the sterilisation cycle and use appropriately challenged during APS (see paragraph 9.33). The lyophilizer should be sterilised regularly, based on system design. Re-sterilisation should be performed  following  maintenance  or  cleaning.   Sterilised   lyophilizers  and  associated  equipment  should  be protected from contamination after sterilisation.'可被翻译为：冻干机和相关设备（例如托盘、西林瓶支撑环）的灭菌应经过验证，应在 APS 期间适当挑战灭菌循环和使 用之间的保持时间（参见第 9.33 节）。冻干机应根据系统设计定期灭菌。在维护或清洁后应进行再灭菌。应保护灭菌后的冻干机和相关设备，防止污染。\n'Loading of a lyophilizer.'可被翻译为：冻干机的装载。\n'Lyophilizers and associated product transfer and loading\/unloading areas should be designed to minimize operator intervention as far as possible. The frequency of lyophilizer sterilisation should be determined based on the  design  and  risks  related  to  system  contamination  during  use.  Lyophilizers  that  are  manually  loaded  or unloaded with no barrier technology separation should be sterilised before each load. For lyophilizers loaded and unloaded by automated systems or protected by closed barrier systems, the frequency of sterilisation should be justified and documented as part of the CCS.'可被翻译为：冻干机和相关产品转移和装载\/卸载区域应经过设计，尽可能减少操作人员的干预。冻干机灭菌的频率应根 据设计和使用过程中与系统污染相关的风险来确定。没有屏障技术隔离的手动装载或卸载的冻干机应在每 次装载前进行灭菌。对于通过自动化系统装载和卸载或由密闭的屏障系统保护的冻干机，应对灭菌频率进行论证并，作为 CCS 的一部分记录在案。\n\n根据上述已知信息，请将'Utensils used during loading and unloading of the lyophilizer (e.g. trays, bags, placing devices, tweezers) should be sterile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"冻干机装载和卸载过程中使用的器具（例如托盘、袋子、定位装置、镶子）应为无菌状态。"
    },
    {
        "instruction":"已知信息：\n'This programme is typically comprised of the following elements:'可被翻译为：本计划通常包括以下内容：\n'1.4. A technology transfer requires a planned approach by trained, knowledgeable personnel working within a quality system, with appropriate documentation, data and information covering all aspects of development, production and quality control (QC), as applicable, and considering the stage of the product life cycle.'可被翻译为：技术转移要求由经过培训的具备丰富知识并在质量体系内工作的人员进行规划，有适当的文件记录、有包括所有开发、生产和质量控制（QC）（适用时）的数据和信息。同时还要考虑产品所处生命周期阶段。\n'Article 27: Training should be provided for all personnel in production and quality activities. The content of the training should be appropriate to the responsibilities assigned to them. Besides the training on the theory and practice of the Provisions, there should be training on relevant laws and regulations, and job related responsibilities and skills. The practical effectiveness of the training should be periodically assessed.'可被翻译为：第二十七条 与药品生产、质量有关的所有人员都应当经过培训，培训的内容应当与岗位的要求相适应。除进行本规范理论和实践的培训外，还应当有相关法规、相应岗位的职责、技能的培训，并定期评估培训的实际效果。\n'5.8. The SU should make all the necessary information and knowledge with regard to the product, process or procedure available in relevant documents in order to ensure a successful transfer.'可被翻译为：SU应在相关文件中提供关于产品、工艺或程序的所有必要信息和知识，以确保转移成功。\n\n根据上述已知信息，请将'5.14. A training programme should be implemented covering various topics, including those specific to the process, product or procedure to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应针对准备转移的工艺、产品和程序执行专门的不同主题培训。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'可被翻译为：国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over medical device registration, and further improve the quality of registration review, NMPA has organized to formulate the Technical Review Guidance for the Registration of Disposable Breast localization Wire, Technical Review Guidance for the Registration of Dural(Spinal) Patches, Technical Review Guidance for the Registration of Customized and Personalized Equivalent Models of Bone Implants, Technical Review Guidance for the Registration of Finite Element Analysis Data of Orthopedic Metal Implants, Guidance for Clinical Trials of Hernia Repair Meshes, and Guidance for Animal Study of Bioabsorbable Coronary Artery Drug-Eluting Stents, and they were issued on July 7, 2020.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《一次性使用乳腺定位丝注册技术审查指导原则》《硬脑（脊）膜补片注册技术审查指导原则》《定制式个性化骨植入物等效性模型注册技术审查指导原则》《骨科金属植入物有限元分析资料注册技术审查指导原则》《疝修补补片临床试验指导原则》《生物可吸收冠状动脉药物洗脱支架动物实验研究指导原则》，现予发布。\n'NMPA Announcement on Issuing Six Registration Technical Review Guidelines on Products such as Disposable High Pressure Contrast Syringes and Accessories'可被翻译为：国家药监局关于发布一次性使用高压造影注射器及附件产品等6项注册审查指导原则的通告\n'NMPA Announcement on Issuing 5 Technical Review Guidances for Registration'可被翻译为：国家药监局关于发布5项注册技术审查指导原则的通告\n\n根据上述已知信息，请将'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'drug advertisement'可被翻译为：药品广告\n'Non-drug advertisements may not involve drug promotion.'可被翻译为：非药品广告不得有涉及药品的宣传。\n'No organization or individual shall fabricate or disseminate false drug safety information.'可被翻译为：任何单位和个人不得编造、散布虚假药品安全信息。\n'Article 4    A drug label shall be printed on or affixed to the drug package, and no other written words, audio and\/or visual materials or other information are attached to introduce or publicize the product or the enterprise.'可被翻译为：第四条 药品包装必须按照规定印有或者贴有标签，不得夹带其他任何介绍或者宣传产品、企业的文字、音像及其他资料。\n\n根据上述已知信息，请将'No unscientific, categorical assertion, or guarantee of described function or safety may be included in drug advertisements. No names or images of government departments, research institutions, and academic institutions, or of experts, scholars, physicians, pharmacists and patients may be used as evidence for drug advertising.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品广告不得含有表示功效、安全性的断言或者保证；不得利用国家机关、科研单位、学术机构、行业协会或者专家、学者、医师、药师、患者等的名义或者形象作推荐、证明。"
    },
    {
        "instruction":"已知信息：\n'The term applied to third party attestation related to a conformity assessment body conveying formal demonstration of its competence to carry out specific conformity assessment tasks (2).'可被翻译为：该术语适用于与合格评定机构有关的第三方认证，该机构正式证明了其执行特定合格评定任务的能力(2)。\n'b. Validation: status of required validation\/revalidation (e.g., computer, manufacturing process, laboratory methods).'可被翻译为：验证：验证\/再验证所需的状态（例如，计算机，生产工艺，实验室方法）\n'Revalidation of a validated process, component, system, or analytical determination method for changes that may affect the final result.'可被翻译为：对经过验证的工艺、组分、系统或分析测定方法的可能影响最终结果的变更，再次进行的验证。\n'1.The processes and procedures to manage system changes.\n2.A formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n3.A formal system by which qualiﬁed representatives of appropriate disciplines review proposed or actual changes that might affect the registration and validated status. The intent is to determine the need for action that would ensure that the system is maintained in a regulatory compliant and validated state.\n4.A formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.'可被翻译为：1.管理系统变更的过程和程序。\n2.一个正式的系统，由适当学科的合格代表审查可能影响已确认状态的提议或实际变化。目的是确定采取行动的需要，以确保系统维持在已验证的状态。\n3.一个正式的系统，由适当学科的合格代表审查可能影响注册和验证状态的建议或实际变化。目的是确定采取行动的必要性，以确保系统保持在符合法规和经过验证的状态。\n4.一种正式的系统，由适当学科的合格代表审查可能影响已确认状态的提议或实际变化。目的是确定采取行动的需要，以确保系统维持在已验证的状态。\n\n根据上述已知信息，请将'1.The final review and formal approval of a validation or revalidation, followed by approval of a process for routine use.\n2.The term applied to third party attestation related to products, processes, systems or persons (2).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.确认或再确认的最终审查和正式批准，随后批准常规使用的过程\n2.该术语适用于与产品、过程、体系或人员相关的第三方认证(2)。"
    },
    {
        "instruction":"已知信息：\n'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'可被翻译为：使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。\n'h. <1207> Sterile Product Packaging—Integrity Evaluation'可被翻译为：<1207>无菌产品包装—完整性评估\n'Where materials, equipment, components and ancillary items are sterilised in sealed packaging or containers, the packaging should be qualified for minimizing the risk of particulate, microbial, endotoxin\/pyrogen or chemical contamination, and for compatibility with the selected sterilisation method. The packaging sealing process should be validated. The validation should consider the integrity of the sterile protective barrier system, the maximum hold time before sterilisation and the maximum shelf life assigned to the sterilised items. The integrity of the sterile protective barrier system for each of the sterilised items should be checked prior to use.'可被翻译为：如果物料、设备、组分和辅助用品在密封包装或容器中灭菌，包装应经过确认，以最大限度减少微粒、微生物、内毒素\/热原或化学污染的风险，并与所选灭菌方法兼容。包装密封工艺应经过验证。验证应考虑无菌保护屏障系统的完整性、灭菌前的最长保持时间以及被灭菌物品的最长有效期。应在使用前检查每种被灭菌物品的无菌保护屏障系统的完整性。\n'Appropriate measures should be in place to ensure the integrity of components used in aseptic connections. The means by which this is achieved should be determined and captured in the CCS. Appropriate system integrity tests should be considered when there is a risk of compromising product sterility.  Supplier assessment should include the collation of data in relation to potential failure modes that may lead to a loss of system sterility.'可被翻译为：应釆取适当的措施确保无菌连接所用组件的完整性。应在 CCS 中确定并记录实现方式。如果存在影响产品 无菌性的风险，应考虑适当的系统完整性测试。供应商评价应包括收集整理与可能导致系统丧失无菌性的潜在失效模式相关的数据。\n\n根据上述已知信息，请将'c. Guidance for Industry- Container and Closure system Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (2\/2008)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"行业指南—容器和密闭器系统完整性测试替代无菌检测，作为无菌药品的稳定性试验方案的一部分（2008 年 2 月）"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products'可被翻译为：国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance of medical device registration and further improve the quality of registration review, the NMPA organized to formulate the Guidance (Revision 2020) for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems which was issued on January 27, 2021.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》，并于2021年1月27日发布。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and  the Guidelines for  Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》，\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and the Guidelines for Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》。\n\n根据上述已知信息，请将'In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。"
    },
    {
        "instruction":"已知信息：\n'The substance is dissolved in the solvent, the combination of solvent molecules and solute molecules or ions, etc., makes the solute change its original state and generate solvent compounds.'可被翻译为：物质在溶剂中溶解，溶剂分子与溶质分子或离子等的相互结合，使溶质改变了原来的状态而生成的溶剂化合物。\n'Two or more organic molecules interact with each other to covalently bond to form a large molecule, and are often accompanied by the loss of small molecules (such as water, hydrogen chloride, alcohol, etc.). A similar reaction that takes place inside the molecules of multifunctional compounds is called intramolecular condensation.'可被翻译为：两个或两个以上有机分子相互作用后以共价键结合成一个大分子，并常伴有失去小分子(如水、氯化氢、醇等)的反应。在多官能团化合物的分子内部发生的类似反应则称为分子内缩合反应。\n'Larger molecules are formed when smaller molecules are released by condensation.'可被翻译为：经缩合反应释放出小分子后生成的大分子。\n'When a solute crystallizes out of a solution, a certain number of water molecules are bound to the crystal.'可被翻译为：溶质从溶液里结晶析出时，晶体里结合着的一定数目的水分子。\n\n根据上述已知信息，请将'The solvation layer of the colloidal particles is heated or other soluble compounds are added! 1 (it and the original loss of solvent has a strong binding force) under the conditions, the solvation layer is weakened, resulting in the phenomenon of colloidal condensation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"溶胶胶粒的溶剂化层在受热或加入其他溶齐!1（它和原失溶剂有较强的结合力）的条件下，溶剂化层被削弱，导致胶体聚沉的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 58 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions and raw data, make preliminary review of the submitted dossiers, and provide review opinions within five days from the date it accepts an application. For the other drugs except biological products, samples of three production batches shall also be collected for testing, and a notice of specifications verification shall be issued to the drug testing institute.'可被翻译为：第五十八条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对临床试验情况及有关原始资料进行现场核查，对申报资料进行初步审查，提出审查意见。除生物制品外的其他药品，还需抽取3批样品，向药品检验所发出标准复核的通知。\n'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'可被翻译为：第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。\n'Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required.'可被翻译为：第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。\n'Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection.'可被翻译为：第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。\n\n根据上述已知信息，请将'Article 63 When carrying out on-site inspection, the drug regulatory department can make sample testing as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条  药品监督管理部门开展现场检查时，可以根据需要进行抽查检验。"
    },
    {
        "instruction":"已知信息：\n'Pharmaceutical professional and technical personnel who have passed the national unified examination, obtained the Qualification Certificate of Licensed Pharmacists and have been registered to practice in the units that produce, distribute and use drugs.'可被翻译为：经全国统一考试合格，取得《执业药师资格证书》并经注册登记，在药品生产、经营、使用单位中执业的药学专业技术人员。\n'(1) have legally qualified pharmacists or other pharmaceutical professionals;'可被翻译为：（一）有依法经过资格认定的药师或者其他药学技术人员；\n'Pharmacy professionals who have obtained the qualifications for pharmaceutical technical positions within healthcare institutions provide technical services throughout the entire medication process, including prescription issuance and transmission, prescription review, prescription compounding, medication dispensing, drug management, and drug utilization monitoring. They ensure the quality and safety of medications throughout the entire medication process.'可被翻译为：医疗机构取得药学专业技术职务任职资格的药学专业技术人员在处方（医嘱）开具与传递、处方\n审核、处方调剂、药品发放、药品管理、药品使用与监测等用药全过程的保障药品质量和用药安全的\n技术服务。\n'In accordance with the \"Regulations on the Trial Implementation of Professional Titles for Health Technical Personnel,\" individuals who have obtained qualifications for pharmaceutical technical positions include Chief Pharmacist, Deputy Chief Pharmacist, Supervising Pharmacist, Pharmacist, and Pharmacy Technician.'可被翻译为：按照《卫生技术人员职务试行条例》规定，取得药学专业技术职务任职资格人员，包括主任药师、\n副主任药师、主管药师、药师和药士。\n\n根据上述已知信息，请将'Pharmaceutical professional and technical personnel who have received academic education in pharmacy and are engaged in drug dispensing, preparation, testing, production and other work, and have been recognized as qualified according to law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受过药学专业学历教育，从事药物调剂、制备、检定、生产等工作，并依法经资格认定的药学专业技术人员。"
    },
    {
        "instruction":"已知信息：\n'Article 71 If any serious adverse event in the clinical trial occurs, the investigator shall immediately give appropriate treatment measures to the subjects, at the same time report in writing to the relevant medical device clinical trial management department of the clinical trial institution, and notify the sponsor through the department by a written notice. The medical device clinical trial management department shall report in writing to the corresponding ethics committee and the local food and drug administration department and the competent health and family planning department of the province, autonomous region or municipality where the clinical trial institution is located within 24 hours. For death events, the clinical trial institution and the investigator shall provide the ethics committee and the sponsor with all the information needed.'可被翻译为：第七十一条 在临床试验中出现严重不良事件的，研究者应当立即对受试者采取适当的治疗措施，同时书面报告所属的临床试验机构医疗器械临床试验管理部门，并经其书面通知申办者。医疗器械临床试验管理部门应当在24小时内书面报告相应的伦理委员会以及临床试验机构所在地省、自治区、直辖市食品药品监督管理部门和卫生计生主管部门。对于死亡事件，临床试验机构和研究者应当向伦理委员会和申办者提供所需要的全部资料。\n'Article 38 Where the applicant finds a clinical trial institution violating relevant regulations or failing to implement the clinical trial protocol, it shall urge the institution to make corrections; if the circumstances are serious, the applicant may demand suspension or termination of the clinical trial, and shall report the matter to the State Food and Drug Administration and the drug regulatory departments of the relevant provinces, autonomous regions or municipalities directly under the Central Government.'可被翻译为：第三十八条 申请人发现药物临床试验机构违反有关规定或者未按照临床试验方案执行的，应当督促其改正；情节严重的，可以要求暂停或者终止临床试验，并将情况报告国家食品药品监督管理局和有关省、自治区、直辖市药品监督管理部门。\n'Article 37 Prior to conducting a clinical trial, the applicant shall report to the State Food and Drug Administration for record while copying to the drug regulatory department of the seat of the clinical trial institution and that of the province, autonomous region or municipality directly under the Central Government to receive the application a confirmed clinical trial protocol, the name of the principal investigator at the institution in charge of the clinical trial, a list of participating institutions and names of investigators where from, an ethic committee approval letter, and a template of the informed consent form, etc.'可被翻译为：第三十七条 申请人在药物临床试验实施前，应当将已确定的临床试验方案和临床试验负责单位的主要研究者姓名、参加研究单位及其研究者名单、伦理委员会审核同意书、知情同意书样本等报送国家食品药品监督管理局备案，并抄送临床试验单位所在地和受理该申请的省、自治区、直辖市药品监督管理部门。\n'Article 38 Where the applicant finds that the clinical trial institution violates relevant regulations or fails to performs the clinical trial protocol, it shall supervise and urge the clinical trial institution to correct; In case of severe conditions, the applicant can require suspending or terminating the clinical trial, and report to the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government where the clinical trial institution is located and China Food and Drug Administration.'可被翻译为：第三十八条 申请人发现临床试验机构违反有关规定或者未执行临床试验方案的，应当督促其改正；情节严重的，可以要求暂停或者终止临床试验，并向临床试验机构所在地省、自治区、直辖市食品药品监督管理部门和国家食品药品监督管理总局报告。\n\n根据上述已知信息，请将'Article 41 If any serious adverse event occurs during the clinical trial, the investigators shall report to the drug regulatory departments of the relevant provinces, autonomous regions or municipalities directly under the Central Government and the State Food and Drug Administration and notify the applicant within 24 hours, and report to the ethic committee in time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十一条 临床试验过程中发生严重不良事件的，研究者应当在24小时内报告有关省、自治区、直辖市药品监督管理部门和国家食品药品监督管理局，通知申请人，并及时向伦理委员会报告。"
    },
    {
        "instruction":"已知信息：\n'Tablets coated with sucrose as the main coating material.'可被翻译为：以蔗糖为主要包衣材料进行包衣的片剂。\n'sugar coated tablet'可被翻译为：糖衣片\n'The process of coating the surface of the tablet (core, plain) with a layer of enteric-soluble material.'可被翻译为：在片剂（片芯、素片）表面包裹肠溶性材料层的过程。\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n\n根据上述已知信息，请将'The core material of medicated tablets is coated with sucrose as the main material. To protect the drug or cover up the bad odor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以蔗糖为主要材料对含药片剂芯材进行包覆的操作。以保护药物或掩盖不良嗅味。"
    },
    {
        "instruction":"已知信息：\n'Article 123 The quality management department or quality management personnel of enterprises shall fulfill the following responsibilities:'可被翻译为：第一百二十三条 企业应当设置质量管理部门或者配备质量管理人员，履行以下职责：\n'Article 16 Enterprises shall set up a quality management department to effectively carry out quality management. The responsibilities of quality management department shall not be performed by other departments or personnel.'可被翻译为：第十六条 企业应当设立质量管理部门，有效开展质量管理工作。质量管理部门的职责不得由其他部门及人员履行。\n'Article 134 Enterprises shall take measures to ensure that the personnel at all the posts can correctly understand the quality management documents to ensure their effective implementation.'可被翻译为：第一百三十四条 企业应当采取措施确保各岗位人员正确理解质量管理文件的内容，保证质量管理文件有效执行。\n'Article 13 Enterprises shall set up an organization or posts corresponding to their distribution activities and quality management and clearly define their duties, authorities and relations with each other.'可被翻译为：第十三条 企业应当设立与其经营活动和质量管理相适应的组织机构或者岗位，明确规定其职责、权限及相互关系。\n\n根据上述已知信息，请将'Article 12 Enterprises shall have all their employees involved in quality management. Personnel of all departments and posts shall correctly understand and perform their duties and assume corresponding quality responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 企业应当全员参与质量管理。各部门、岗位人员应当正确理解并履行职责，承担相应质量责任。"
    },
    {
        "instruction":"已知信息：\n'The work area for opening the unit container should be either a HEPA filtered laminar flow hood or an alternate controlled environment to safeguard the exposure of open media and product to either environmental or personnel contamination.'可被翻译为：打开单元容器的工作区应该是一个 HEPA 过滤层流罩或一个替代的受控环境，以保 护打开的介质和产品暴露在环境或人员污染中。\n'Repeat disinfection procedure using appropriate disinfectant\/sporicidal immediately prior to placing product primary containers in a working certified laminar flow hood. Allow all disinfected containers to completely air dry in the laminar flow hood prior to opening for analysis. Alternatively, if conducting the testing in an isolator, place the disinfected items into the isolator and proceed with the local procedures for the proper decontamination of the interior of the isolator.'可被翻译为：使用适当的消毒剂\/杀孢子重复消毒程序，然后立即在将产品内包容器放入经过认证的工作层流罩中。在打开进行分析之前，让所有已消毒的容器在层流罩中完全晾干。或者，如果在隔离器中进行测试，则将已消毒的物品放入隔离器中，并按照当地程序对隔离器内部进行适当的净化。\n'An aseptic process whereby the operator manually compounds, fills, places or seals an open container with sterile product.'可被翻译为：操作人员用无菌产品手动配制、填充、放置或密封一个开放容器的无菌过程。\n'weighing room, dispensing room'可被翻译为：称量室\n\n根据上述已知信息，请将'Aseptically open containers and perform weighing procedures in a laminar flow hood or biological safety cabinet if possible.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如可能的话，在无菌条件下打开容器，在层流罩中或生物安全柜中称重。"
    },
    {
        "instruction":"已知信息：\n'Filled APS units should be incubated without unnecessary delay to achieve the best possible recovery of potential contamination. The selection of the incubation conditions and duration should be scientifically justified and validated to provide an appropriate level of sensitivity of detection of microbial contamination.'可被翻译为：培养已灌装 APS 单元应避免延迟，以尽确保达到潜在微生物的最高回收率。培养条件和培养时长的选择应经过科学论证，并进行验证以提供适当水平的微生物污染检测灵敏度。\n'Filled APS units should be incubated in a clear container to ensure visual detection of microbial growth. Where  the  product  container  is  not  clear  (e.g.  amber  glass,  opaque  plastic),  clear  containers  of  identical configuration may be substituted to aid in the detection of contamination. When a clear container of identical configuration cannot be substituted, a suitable method for the detection of microbial growth should be developed and validated. Microorganisms isolated from contaminated units should be identified to the species level when practical, to assist in the determination of the likely source of the contaminant.'可被翻译为：已灌装的 APS 单元应在透明的容器中培养，以确保目测微生物生长。如果产品容器不透明（例如褐色玻璃、不透明塑料），可用相同构造的透明容器替代， 以方便检测污染。当不能用相同构造的透明容器替代时， 应开发并验证合适的微生物生长检测方法。从被污染单元中分离的微生物应在可行的情况下鉴定至种，以帮助确定污染物的可能来源。\n'Interventions and stoppages should be recorded in the batch record. Each line stoppage or intervention should\nbe sufficiently documented in batch records with the associated time, duration of the event, and operators involved\n(ref to paragraph 9.34).'可被翻译为：干预和停工应记录在批记录中。每次生产线的停工或干预都应在批记录中充分记录，包括相关的时间、持\n续时间和操作人员（参见 9.34 节）\n'Filled APS units should be inspected by personnel who have been appropriately trained and qualified for the detection of microbiological contamination. Inspection should be conducted under conditions that facilitate the identification of any microbial contamination.'可被翻译为：已灌装的 APS 单元应由接受过适当的微生物污染检测培训和资质确认的人员进行检查。检查应在便于识别任何微生物污染的条件下进行。\n\n根据上述已知信息，请将'All APS runs should be fully documented and include a reconciliation of units processed (e.g. units filled, incubated  and  not   incubated).  Justification   for  filled  and  non-incubated  units   should  be   included  in  the documentation. All interventions performed during the APS should be recorded, including the start and end time of each intervention and the involved person. All microbial monitoring data as well as other testing data should be recorded in the APS batch record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有 APS 运行应完整记录，并包括已处理单元的物料平衡（例如已灌装、已培养和未培养的单元）。已灌 装和未培养的单元的说明应包含在文件中。在 APS 过程中进行的所有干预操作都应进行记录，包括每次干预的开始和结束时间以及涉及的人员。所有微生物监测数据以及其它检测数据应记录在 APS 批记录中。"
    },
    {
        "instruction":"已知信息：\n'(3) Where safety and effectiveness of the medical device can be demonstrated through the analysis and assessment made on the basis of the data obtained from clinical trial or application of a medical device of the same variety.'可被翻译为：（三）通过对同品种医疗器械临床试验或者临床使用获得的数据进行分析评价，能够证明该医疗器械安全、有效的。\n'The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (7).'可被翻译为：评估和分析与医疗器械有关的临床数据，以验证器械在按制造商预期使用时的临床安全性和性能(7)。\n'(V)  Conducting continuous study on the safety of medical devices once they are on the market, and write periodic risk evaluation reports as required;'可被翻译为：（五）对上市医疗器械安全性进行持续研究，按要求撰写定期风险评价报告；\n'Article 38 MAHs shall conduct continuous research on the safety of medical devices once they are on the market, summarize and analyze the adverse event reports, monitoring data and domestic and overseas risk profile of products, evaluate its  risks and benefits, record the risk control measures taken and completepost-market periodic risk evaluation report.'可被翻译为：第三十八条  持有人应当对上市医疗器械安全性进行持续研究，对产品的不良事件报告、监测资料和国内外风险信息进行汇总、分析，评价该产品的风险与受益，记录采取的风险控制措施，撰写上市后定期风险评价报告。\n\n根据上述已知信息，请将'(II) The analysis and evaluation of monitoring data are reinforced for product risks mining and promoting the safety of medical devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(二）夯实监测数据分析评价，挖掘产品风险促进用械安全"
    },
    {
        "instruction":"已知信息：\n'A group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.'可被翻译为：旨在执行一种特定功能或一组特定功能的一组软硬件组合。\n'1.A process or operation integrated with a computer system.\n2.A system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n3.A computerized system collectively controls the performance and execution of one or more automated processes and\/or functions. It includes computer hardware, software, peripheral devices, networks and documentation, for example, manuals and standard operating procedures, as well as personnel interacting with hardware and software.'可被翻译为：1.计算机系统:与计算机系统集成的过程或操作\n2.一种包括数据输入、电子处理和信息输出的系统，用于报告或自动控制。\n3.计算机化系统集中控制一个或多个自动化过程和\/或功能的性能和执行。它包括计算机硬件、软件、外围设备、网络和文件，例如手册和标准操作程序，以及与硬件和软件交互的人员。\n'A comprehensive discipline that studies and explores the structure of biological systems, the characteristics and mechanisms of energy conversion, information control processes, etc., in order to transform and create new machinery, instruments, architectural configurations, processes, automatic devices, and other engineering and technical systems.'可被翻译为：一门通过研究和探索生物系统的结构、能量转换、信息控制过程的特性、机制等，以用来改造和创造新的机械、仪器、建筑构型、工艺过程、自动装置等工程技术系统的综合性学科。\n'A process or operation integrated with a computer system.'可被翻译为：由计算机系统参预的工艺或操作。\n\n根据上述已知信息，请将'A general term for the design and construction of computer systems, including technical infrastructure, information (data), and applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"计算机系统设计和构建的一般术语，包括技术基础设备、信息（数据）和应用程序。"
    },
    {
        "instruction":"已知信息：\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n'(3) Using records of the investigational medical device by each subject, including the date and time of each use and the state of the investigational medical device;'可被翻译为：（三）每个受试者使用试验用医疗器械的记录，包括每次使用的日期、时间、试验用医疗器械的状态等；\n'3. Records of formulating the test\/control articles, storage and use of their formulations, and the residuals for disposal should be retained completely; the amount of each requisition should be in line with that in dispensing record of the test articles, and the amount of formulating, use and residual for disposal should be in reconciliation;'可被翻译为：3.受试物\/对照品的配制、配制后保存、使用、使用剩余后的处理应有完整的记录；每次领用量应与受试物领用记录一致，配制量、使用量、使用后剩余处置量应符合物料平衡；\n'Article 39 Enterprises shall establish records related to drug purchase, acceptance inspection, maintenance, sales, ex-warehousing check, return after sales and return after purchase, transportation, temperature and humidity monitoring during storage and transportation, and disposal of unqualified drugs and make them authentic, complete, accurate, effective and traceable.'可被翻译为：第三十九条 企业应当建立药品采购、验收、养护、销售、出库复核、销后退回和购进退出、运输、储运温湿度监测、不合格药品处理等相关记录，做到真实、完整、准确、有效和可追溯。\n\n根据上述已知信息，请将'3. There are records retained for the receipt, storage, distribution, use, recovery, return and unused disposal of investigational medicinal products (such as authorized destruction).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.试验用药品的接收、贮存、分发、使用、回收、退还及未使用药品的处置(如授权销毁) 等环节留有记录。"
    },
    {
        "instruction":"已知信息：\n'One of the two substances with a high specific affinity between each other is used as the stationary phase, using different degrees of affinity with the stationary phase, so that the composition and impurities are separated by chromatography.'可被翻译为：将相互间具有高度特异亲和性的两种物质之一作为固定相，利用与固定相不同程度的亲和性，使成分与杂质分离的色谱法。\n'Different types of chromatographic analysis techniques are combined to form a combined system to achieve the separation and analysis of multi-component methods in complex samples.'可被翻译为：将不同类型的色谱分析技术组合构成联用系统，以实现复杂样品中多组分的分离和分析的方法。\n'multiple column chromatography'可被翻译为：多柱色谱法\n'A granular stationary phase used to fill liquid chromatographic columns.'可被翻译为：用于填充液相色谱柱的粒状固定相。\n\n根据上述已知信息，请将'In the analysis of complex component samples containing different functional groups by column chromatography, often a single component of the stationary phase can not achieve the purpose of complete separation, and must use a multi-component stationary phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在用柱色谱分析含有不同功能团的复杂组分样品时，往往单一组分的固定相不能达到全分离的目的，而必须采用多组分的固定相。"
    },
    {
        "instruction":"已知信息：\n'Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.'可被翻译为：第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。\n'An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency). The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator.'可被翻译为：单独或与其他人一起，发起并实施一项临床试验的个人。在他\n（们）的直接指示下，给受试者服用、发给受试者或由受试者使\n用试验药。该术语并不包括除了个人以外的任何人（如不包括一\n个公司和一个机构）。申办者－研究者同时履行申办者义务和研\n究者义务。\n'1.The person responsible for the trial and for protecting the rights, health and welfare of the subjects in the trial. The investigator must be an appropriately qualified person legally allowed to practice medicine\/dentistry.\n2.A person responsible for the trial and for the rights, health and welfare of the subjects in the trial. The investigator should have qualifications and competence in accordance with local laws and regulations as evidenced by an up-to-date curriculum vitae and other credentials. Decisions relating to, and the provision of, medical or dental care must always be the responsibility of a clinically competent person legally allowed to practise medicine or dentistry.'可被翻译为：1.对试验负责并对保护试验对象的权利、健康和福利负责的人。研究者必须是法律允许执业医学\/牙科的适当合格人员。\n2.对试验和对试验对象的权利、健康和福利负责的人。研究者应具有符合当地法律法规的资格和能力，并有最新的简历和其他证书作为证明。与医疗或牙科护理相关的决定和提供必须始终由法律允许执业医学或牙科的临床胜任人员负责。\n'1.An individual, company, institution or organization which takes responsibility for the initiation, management and\/or financing of a clinical trial. When an investigator independently initiates and takes full responsibility for a trial, the investigator then also assumes the role of the sponsor.\n2.An individual, company, institution or organization that takes responsibility for the initiation, management and financing of a clinical trial. When an investigator independently initiates and takes full responsibility for a trial, the investigator also then assumes the role of the sponsor.'可被翻译为：1.负责启动、管理和\/或资助临床试验的个人、公司、机构或组织。当研究者独立发起并对一项试验承担全部责任时，研究者也承担了发起人的角色。\n2.负责启动、管理和资助临床试验的个人、公司、机构或组织。当研究者独立发起并对一项试验承担全部责任时，研究者随后也承担了发起人的角色。\n\n根据上述已知信息，请将'The investigator refers to the person who is responsible for implementing the clinical trial in a clinical trial institution. Where the trial is carried out by a group of personnel in a clinical trial institution, the investigator shall be the person who is in charge of the group, also known as the principal investigator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者，是指在临床试验机构中负责实施临床试验的人。如果在临床试验机构中是由一组人员实施试验的，则研究者是指该组的负责人，也称主要研究者。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。\n'Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。\n'Article 2 These Provisions shall apply to medical device distribution activities and their supervision and administration within the territory of the People's Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械经营活动及其监督管理，应当遵守本办法。\n'Article 2 These Provisions shall apply to the recall, supervision and administration of marketed medical devices within the territory of the People's Republic of China.'可被翻译为：第二条 中华人民共和国境内已上市医疗器械的召回及其监督管理，适用本办法。\n\n根据上述已知信息，请将'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。"
    },
    {
        "instruction":"已知信息：\n'The process of artificially manipulating the genetic material of an organism so that it is modified or altered.'可被翻译为：对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。\n'The technique of introducing artificially isolated and modified genes into the genome of an organism and causing heritable modification of the traits of the organism due to the expression of the imported genes.'可被翻译为：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，引起生物体性状的可遗传性修饰的技术。\n'The process of synthesizing various compounds catalyzed by enzymes. This process can be carried out either in vivo or outside the body.'可被翻译为：由酶催化的各种化合物的合成过程。这个过程可以在生物体内进行，亦可以在体外进行。\n'A process in which a natural or chemically synthesized compound is added during fermentation to block the mutants and participate in the biosynthesis of new antibiotics.'可被翻译为：在发酵培养阻断变株时添加某种天然的或化学合成的化合物，参与生物合成以获得新抗生素的过程。\n\n根据上述已知信息，请将'The technique or method of synthesizing new compounds by replacing, adding, or deleting genes involved in the synthase of an organism's metabolic product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过对参与生物体某种代谢产物合成酶的基因进行替换、添加以及删除等操作，使其合成新的化合物的技术或方法。"
    },
    {
        "instruction":"已知信息：\n'A fluid whose shear stress (t) is proportional to the shear velocity (Q). Its flow properties can be expressed by the formula: t=ηD, where the proportional coefficient η is called the viscosity coefficient. For Newton fluids, the viscosity is constant at a certain temperature and does not change with the shear rate.'可被翻译为：切应力（t）与切变速度（Q）成正比的流体。其流动性质可用公式表示：t=ηD,式中的比例系数η称为黏滞系数。对于牛顿流体，黏度在一定温度下是常数，不随切变速度而变。\n'non-newtonian fluid'可被翻译为：非牛顿流体\n'newtonian fluid'可被翻译为：牛顿流体\n'apparent viscosity'可被翻译为：表观黏度\n\n根据上述已知信息，请将'The fluids that do not conform to Newton's formula mainly include polymer solutions and colloidal solutions. The ratio of shear stress and shear velocity of non-Newtonian fluid G\/D) is called the apparent viscosity, which is commonly expressed by %. Apparent viscosity is not only a function of temperature, but is also related to shear velocity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不符合牛顿公式的流体，主要有高分子溶液及胶体溶液等。非牛顿流体的切应力与切变速度的比值G\/D）称为表观黏度，常用%表示。表观黏度不仅是温度的函数，而且与切变速度有关。"
    },
    {
        "instruction":"已知信息：\n'The opening and closing of an ion channel is regulated by the potential difference between the two sides of the membrane.'可被翻译为：通道的开闭受膜两侧电位差调控的离子通道。\n'The transmembrane transport of a drug from one side with a high concentration to the other side with a low concentration.'可被翻译为：药物从浓度高的一侧向浓度低的一侧的跨膜转运。\n'A method for separating and analyzing substances by using the phenomenon of charged particles in electrolyte migrating in the opposite direction of charge under the action of electric field.'可被翻译为：利用电解质中带电粒子在电场作用下向电荷相反方向迁移的现象，对物质进行分离分析的方法。\n'membrane potential'可被翻译为：膜电位\n\n根据上述已知信息，请将'The potential difference between the two sides of the membrane due to the different types (or concentrations) of electrolytes leads to ion migration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"膜两侧因电解质种类（或浓度）不同而导致离子迁移时所产生的电位差。"
    },
    {
        "instruction":"已知信息：\n'(xi) Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.'可被翻译为：(xi) 调查导致药品投诉和质量缺陷的原因，并采取措施，防止类似质量缺陷再次发生\n'1. To identify existing or potential quality issues by analyzing complaints, recalls, deviations, findings of self-inspections or external inspections, monitoring trends of process performance and quality and quality data from other sources; when necessary, statistical approaches should be employed;'可被翻译为：（一）对投诉、召回、偏差、自检或外部检查结果、工艺性能和质量监测趋势以及其他来源的质量数据进行分析，确定已有和潜在的质量问题。必要时，应当采用适当的统计学方法。\n'10. Complaints about marketed products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence.'可被翻译为：（十）调查导致药品投诉和质量缺陷的原因，并采取措施，防止类似质量缺陷再次发生。\n'A systematic method of identifying and preventing product and process problems.'可被翻译为：识别和预防产品和过程问题的系统方法。\n\n根据上述已知信息，请将'2. To investigate causes related to the product, process and quality assurance system;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）调查与产品、工艺和质量保证系统有关的原因。"
    },
    {
        "instruction":"已知信息：\n'The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours.\nCompliance with aseptic gowning procedures should be confirmed by assessment and periodic reassessment at\nleast annually, and should involve both visual and microbial assessment (using monitoring locations such as\ngloved fingers, forearms, chest and hood (facemask \/ forehead). See paragraph 9.30 for the expected limits). The\nunsupervised access to the grade A and grade B areas where aseptic operations are or will be conducted should be\nrestricted to appropriately qualified personnel, who have passed the gowning assessment and have participated in\na successful APS.'可被翻译为：进入 A 级和 B 级区的人员应接受无菌更衣和无菌行为的培训。应通过评估和至少每年定期再评估来确认符合无菌更衣程序，并应包括目检和微生物评估（使用戴手套的手指、前臂、胸部和头罩（口罩\/额头）等监测位置。预期限度参见 9.30 节）。对于正在或即将进行无菌操作的 A 级和 B 级区，无监督进入应仅限于经过适当资质确认、已通过更衣评估并参与过成功的 APS 的人员。\n'Personnel gowning requirements.'可被翻译为：人员更衣要求。\n'Personnel monitoring must be performed after analysts conclude sterility testing and prior to exiting the aseptic clean room. The analyst shall use general media touch plates to monitor the sterile condition of their clean room attire and to ensure aseptic techniques were followed.'可被翻译为：化验员在结束无菌性检测之后，退出无菌洁净室之前，必须对人员进行监测。化 验员应使用通用培养基接触碟，对其洁净室服装的无菌条件进行监测，确保遵守 了无菌技术。\n'Use aseptic gowning procedure to don sterile uniform components.'可被翻译为：按照无菌更衣程序穿戴无菌服配件。\n\n根据上述已知信息，请将'Personnel gowning qualification should be performed by any analyst that enters the aseptic clean room. Personnel gowning qualification must consist of:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"进入无菌洁净室的任何分析员都应进行人员更衣资格确认。人员更衣资格必须包 括："
    },
    {
        "instruction":"已知信息：\n'The systematic application of quality management policies, procedures, and practices to the tasks of assessing, controlling, communicating, and reviewing risk. (ICH Q9)'可被翻译为：系统地应用质量管理策略、程序和规范进行风险的评估、控制、沟通和回顾。（ICH Q9）\n'A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）\n'An effective risk management system is integrated into all areas of the product life cycle with the aim to minimize microbial contamination and to ensure the quality of sterile products manufactured.'可被翻译为：将有效的风险管理系统纳入产品生命周期的各个方面，旨在尽可能减少微生物污染并确保所生产的无菌产品的质量。\n'A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle. (ICH Q9)'可被翻译为：贯穿产品生命周期的对药品质量风险进行评估、控制、沟通和回顾分析的系统化过程。(ICH Q9)\n\n根据上述已知信息，请将'A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是一套系统的、基于充分的科学知识和质量风险管理的研发方法，从预先确定的目标出发，强调对产品和工艺的理解以及工艺控制。"
    },
    {
        "instruction":"已知信息：\n'8. The application dossier is inconsistent with the original record, and has an impact on the result evaluation;'可被翻译为：8.申报资料与原始记录不一致且影响结果评价；\n'(IV)  There may be authenticity issues of the application dossiers for lot release or the samples;'可被翻译为：（四）批签发申请资料或者样品可能存在真实性问题的；\n'(IV) The registration application materials are obviously inconsistent with application items.'可被翻译为：（四）注册申报资料的内容与申报项目明显不符的；\n'(2) If the application dossiers contain errors that can be corrected on site, the applicant shall be allowed to make corrections on site;'可被翻译为：（二）申请资料存在可以当场更正的错误的，应当允许申请人当场更正；\n\n根据上述已知信息，请将'6. The application dossiers are inconsistent with the original records and affect the evaluation results;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.申报资料与原始记录不一致且影响结果评价；"
    },
    {
        "instruction":"已知信息：\n'The total amount of one or more enzymes of a microbial cell that convert one compound into another.'可被翻译为：微生物细胞的一种或多种酶将一种化合物转变为另一种化合物的总量。\n'The process by which microorganisms, such as bacteria and yeast, enzymatically degrade sugar molecules to produce energy in the absence of oxygen.'可被翻译为：细菌和酵母等微生物在无氧条件下，酶促降解糖分子产生能量的过程。\n'The process of fermentation to prepare microbial bodies and their metabolites.'可被翻译为：发酵制备微生物菌体及其代谢产物的流程。\n'In a series of enzymatic reactions, some intermediates or end products regulate the activity and synthesis of enzymes that catalyze the initial step of the reaction.'可被翻译为：酶促系列反应中，某些中间产物或终产物对催化起始步骤反应的酶活性和酶合成进行调节的作用。\n\n根据上述已知信息，请将'A series of reactions in which microorganisms, under the action of a series of biosynthetases, convert nutrients into final products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"微生物在其体内一系列生物合成酶作用下，将营养成分转变为终产物所经历的一系列反应过程。"
    },
    {
        "instruction":"已知信息：\n'A discipline that uses modern organic synthesis, structural analysis, physical organic chemistry, molecular biology, cell biology, and molecular pharmacology as means to discover small organic molecules with important biological activities and study their interactions with biological macromolecules.'可被翻译为：以现代有机合成、结构分析、物理有机化学、分子生物学、细胞生物学、分子药理学为手段，发现具有重要生物活性的有机小分子并研究其与生物大分子相互作用的学科。\n'Pharmacology that studies the biochemical and molecular biological mechanisms of drugs at various targets of action.'可被翻译为：研究药物在各类作用靶点上的生化与分子生物学机制的药理学。\n'An emerging discipline that uses chemical tools to study biological systems.'可被翻译为：利用化学工具来研究生物体系的-种新兴学科。\n'The study of the three-dimensional structure (including configuration and conformation) of biological macromolecules (such as proteins, nucleic acids, and polysaccharides) by physical and chemical methods and techniques, and the study of the relationship between structure and corresponding work and energy.'可被翻译为：以物理学、化学的方法和技术研究生物大分子（如蛋白质、核酸和多糖等分子）的三维结构（包括构型和构象），并研究结构与对应功 能的关系的学科。\n\n根据上述已知信息，请将'The interdisciplinary study of metal-containing biomolecules (e.g., metalloenzymes) and metal-biomolecular interactions (e.g., metal ion channels, metal drugs).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无机化学与生物化学的交叉学科，主要研究含金属的生物分子（如金属酶）、金属与生物分子的相互作用（如金属离子通道、金属药物）等。"
    },
    {
        "instruction":"已知信息：\n'For a newly developed in-vitro diagnostic reagent not yet listed in the classification catalogue, the applicant may directly apply for a class III in-vitro diagnostic reagent registration, or, after determining the class of the product in accordance with the classification rules and applying for class confirmation to the China Food and Drug Administration, apply for registration or for filing.'可被翻译为：对新研制的尚未列入体外诊断试剂分类目录的体外诊断试剂，申请人可以直接申请第三类体外诊断试剂产品注册，也可以依据分类规则判断产品类别向国家食品药品监督管理总局申请类别确认后，申请产品注册或者办理产品备案。\n'Where a class III medical device registration is directly applied for, China Food and Drug Administration shall determine the class according to its risk degree. Where a domestic medical device is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region or municipality directly under the central government where the applicant is located, for evaluation and approval. Where a medical device is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consists of its districts where the applicant is located, for filing.'可被翻译为：直接申请第三类医疗器械注册的，国家食品药品监督管理总局按照风险程度确定类别。境内医疗器械确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内医疗器械确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。\n'The product technical requirements for class I in-vitro diagnostic reagents shall be submitted to the food and drug regulatory department at the time of filing by filing entity. The product technical requirements for class II and class III in-vitro diagnostic reagents shall be approved by the food and drug regulatory department at the time of registration approval.'可被翻译为：第一类体外诊断试剂的产品技术要求由备案人办理备案时提交食品药品监督管理部门。第二类、第三类体外诊断试剂的产品技术要求由食品药品监督管理部门在批准注册时予以核准。\n'Article 56 Where major interest relationship between the applicant and others is directly involved in the application for in-vitro diagnostic reagent registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for in-vitro diagnostic reagent registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'可被翻译为：第五十六条 体外诊断试剂注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人依照法律、法规以及国家食品药品监督管理总局的有关规定享有申请听证的权利；对体外诊断试剂注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。\n\n根据上述已知信息，请将'Where a class III in-vitro diagnostic reagent registration is directly applied for, China Food and Drug Administration shall determine the class based on its risk degree. Where a domestic in-vitro diagnostic reagent is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region, or municipality directly under the central government where the applicant is located for evaluation and approval. Where a domestic in-vitro diagnostic reagent is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consisting of districts where the applicant is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"直接申请第三类体外诊断试剂注册的，国家食品药品监督管理总局按照风险程度确定类别。境内体外诊断试剂确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内体外诊断试剂确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。"
    },
    {
        "instruction":"已知信息：\n'regulatory impact analysis'可被翻译为：监管影响分析\n'Review or monitoring of output or results of the risk management process considering (if appropriate) new knowledge and experience about the risk.'可被翻译为：考虑到(如果合适的话)有关风险的新知识和经验，对风险管理过程的输出或结果进行评审或监控。\n'Regulatory：Regulation process description Applicable regulatory documentation'可被翻译为：法规：法规流程说明、适用法规文件\n'regulation'可被翻译为：监管\n\n根据上述已知信息，请将'Process of examining the probable impacts of a proposed regulation and of alternative policies to assist the policy development process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审查拟议法规和替代政策可能产生的影响，以协助政策制定过程的过程。"
    },
    {
        "instruction":"已知信息：\n'Secondly, scientific evaluation is reinforced to timely deal with risk warning signals. We established and improved the working mechanism of daily monitoring, weekly summarization and quarterly analysis. At the same time, we paid close attention to the domestic and foreign regulatory dynamics in close integration with our actual clinical medication practice, and continuously strengthened the analysis and evaluation of the ADR report data. According to the evaluation outputs, we timely released pharmacovigilance information. In 2019, we issued the Announcement on the Cessation of Production, Sale and Use of Furazolidone containing Compound Preparations, as well as 27 Announcements on the revision of drug package inserts, and 12 volumes of Pharmacovigilance Express. The functions of the early warning management platform were further optimized to realize early detection, response, investigation, and disposal of early warning signals to ensure effective protection of drug safety for the public.'可被翻译为：二是加强科学评价，及时处置风险预警信号。建立健全日监测、周汇总、季度分析工作机制，同时密切关注国内外监管动态，紧密结合临床用药实际，不断强化对药品不良反应报告数据的分析评价。根据评价结果，及时发布药品安全警示信息。2019年发布停止含呋喃唑酮复方制剂生产销售使用公告，发布药品说明书修订公告27期，发布《药物警戒快讯》12期。继续优化预警管理平台功能，对预警信号做到早发现、早应对、早调查、早处置，切实保障公众用药安全。\n'In 2018, the evaluation and disposal of risk signals for the monitoring of adverse events in medical devices were carried out in depth.We've strengthened the daily monitoring,early warning analysis and quarterly summary of national medical device adverse event reports. Based on the risk conditions,3 issues of Medical Device Adverse Event Information Notification and 6 Medical Device Pharmacovigilance Expresses were issued throughout the year. The intensive monitoring of adverse events in medical devices 13th Five-Year Plan continued to advance. The National Center for ADR Monitoring has organized inspections on key surveillance work. The relevant undertaking units proactively collected monitoring data to dig deeper into the risks of medical devices, and the relevant work saw steady progress.'可被翻译为：2018年，医疗器械不良事件监测风险信号评价处置工作深入开展。强化对全国医疗器械不良事件报告的日常监测、预警分析及季度汇总，根据发现的风险情况，全年共发布《医疗器械不良事件信息通报》3期、《医疗器械警戒快讯》6期。“十三五”医疗器械不良事件重点监测工作持续推进。国家药品不良反应监测中心组织对重点监测工作进行督查，相关承担单位主动收集监测数据，深入挖掘医疗器械风险，工作进展顺利。\n'Third, reinforce the principal responsibility of Marketing Authorization Holders for drug safety. In September2018, NMPA issued the Announcement onthe Direct Reporting of Adverse Reactions by Marketing Authorization Holders (Announcement No. 66 of 2018) and the Announcement on the Issuance of the Guidelines for the Collection and Reporting of Adverse Drug Reactions in Individual Cases (No. 131 of 2018), further reinforced the responsibility of MAHs for drug safety,and put forward specific requirements for monitoring, reporting, analysis and evaluation of the MAHs.'可被翻译为：三是夯实上市许可持有人药品安全主体责任。2018年9月，国家药品监督管理局发布《关于药品上市许可持有人直接报告不良反应事宜的公告》(2018年第66号)和《关于发布个例药品不良反应收集和报告指导原则的通告》（2018年第131号），进一步强化上市许可持有人药品安全主体责任，对上市许可持有人开展监测、报告、分析和评价提出具体要求。\n'Thirdly, the construction of standards is strengthened, and the transformation and implementation of ICH related guidance is promoted. The Guidance for Clinical Safety Literature Evaluation of Marketed Drugs(Interim) and Guidance for Compiling the Annual Pharmacovigilance Report by Marketing Authorization Holders (Interim) were issued to guide MAHs in monitoring, reporting, analysis and evaluation. We steadily promoted the transformation and implementation of E2B (R3: Clinical Safety Data Management - Data Elements for Transmission of Individual Case Safety Reports) of ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), and released the Regional Implementation Guidance for Individual Case Safety Reports E2B(R3). We promoted the application of the Medical Dictionary for Regulatory Activities(MedDRA), carried out disease term mapping research, strengthened the training for MAHs and monitoring institutions, and provide technical guarantee for full swing of ICH related Guidance.'可被翻译为：三是强化规范建设，推进ICH 相关指导原则转化实施。发布《上市药品临床安全性文献评价指导原则（试行）》《药品上市许可持有人药物警戒年度报告撰写指南（试行）》，指导持有人开展监测、报告、分析和评价工作。稳步推进国际人用药品注册技术协调会（ICH）E2B（R3）转化实施，发布《个例安全性报告E2B（R3）区域实施指南》；促进监管活动医学词典（MedDRA）应用，开展疾病术语映射研究，加强对持有人和监测机构的培训，为全面实施ICH相关指导原则提供技术保障。\n\n根据上述已知信息，请将'Second, conduct in-depth safety evaluation and timely address risk warning signals.Based on monitoring data analysis and evaluation results, in 2018, we've released a total of 33 announcements on the revision of drug package inserts; mandated the cessation of production, sales and use of Pyrithioxine Injections, Composite Terfenadine Tablets, Sulfisomidiae Tablets and Terfenadine, Ibuprofen and Pseudoephedrine Capsules, and issued 12volumes of Pharmacovigilance Express.We continued to optimize the early warning system and timely handled more than 150highly concerned ADR-events clustering signals, focusing on early detection, early response, early investigation and early disposal to ensure safety of public drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二是深入开展安全性评价，及时处置风险预警信号。根据监测数据分析评价结果，2018年共发布药品说明书修订公告33期、停止吡硫醇注射剂、特酚伪麻片、磺胺索嘧啶片和特洛伪麻胶囊生产销售使用、发布《药物警戒快讯》12期。继续优化预警系统，对重点关注的150余个药品不良反应事件聚集性信号及时进行处置，做到早发现、早应对、早调查、早处置，保障公众用药安全。"
    },
    {
        "instruction":"已知信息：\n'Validated loading patterns should be established for all sterilisation processes and load patterns should be subject to periodic revalidation. Maximum and minimum loads should also be considered as part of the overall load validation strategy.'可被翻译为：所有灭菌工艺都应建立经验证的装载模式，并且装载模式应定期进行再验证。最大装载和最小装载也应视为装载验证策略的一部分。\n'There should be mechanisms in place to detect a sterilisation cycle that does not conform to the validated parameters. Any failed sterilisation or sterilisation that deviated from the validated process (e.g. have longer or shorter phases such as heating cycles) should be investigated.'可被翻译为：应建立适当机制，发现不符合验证参数的灭菌循环。应对任何失败的灭菌或不符合经验证工艺过程的灭菌（例如加热循环等阶段较长或较短）进行调查。\n'Each heat sterilisation cycle should be recorded either electronically or by hardcopy, using equipment with\nsuitable accuracy and precision. The system should have safeguards and\/or redundancy in its control and\nmonitoring instrumentation to detect a cycle not conforming to the validated cycle parameter requirements and\nabort or fail this cycle (e.g. by the use of duplex\/double probes connected to independent control and monitoring\nsystems).'可被翻译为：每个加热灭菌循环应使用有适当准确度和精确度的设备进行记录，并形成电子或纸质记录。系统的控制和监测仪器中应有保障措施和\/或冗余，以检测不符合已验证参数的循环，并中止该循坏或判定该循环失败（例如，通过使用连接到独立控制和监测系统的双设备\/双探头）。\n' Validation of fluid cycles should include temperature, time and\/or Fo. Critical processing parameters should be subject to defined limits (including appropriate tolerances) and be confirmed as part of the sterilisation validation and routine cycle acceptance criteria.'可被翻译为：液体循环的验证应包括温度，时间和\/或 F0值。关键操作参数应符合规定的限度（包括适当的公差），并作为灭菌验证和常规循环可接受标准的一部分予以确认。\n\n根据上述已知信息，请将'The validity of the sterilizing process should be reviewed and verified at scheduled intervals based on risk.\nHeat sterilization cycles should be revalidated with a minimum frequency of at least annually for load patterns\nthat are considered worst case. Other load patterns should be validated at a frequency justified in the CCS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据风险按照预定的时间间隔审核和确认灭菌工艺的有效性。对于被认为是最差条件的装载模式，应至少每年一次定期开展加热灭菌周期的再验证。其它装载模式应以 CCS 中论证的频率进行验证。"
    },
    {
        "instruction":"已知信息：\n'The products subject to lot release shall be manufactured as per the process approved by the CFDA. Enterprises shall be responsible for the authenticity of the materials, records and data generated during the production and testing processes of the products subject to lot release. The materials for lot release shall be reviewed, signed and issued by the Qualified Person of the enterprise.'可被翻译为：批签发产品应当按照食品药品监管总局核准的工艺生产。企业对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经企业质量受权人审核并签发。\n'3. Implementation of the principal responsibilities of the marketing authorization holders, emphasizing life-cycle management requirements. Additional clauses provide that the drug marketing authorization holders should build up a complete production quality management system and deviation control; lot release products should be produced in accordance with approved processes and should meet national drug standards and drug registration standards; and the whole process of production should conform to drug GMP requirements. It is clarified that for products with quality problems or other safety hazards, the holders should take immediate measures such as stopping sales and use, and recalling defective products ,etc. At the same time, the handling measures for violations of laws and regulations in the lot release process are clearly defined in accordance with the law, to implement the requirement of strictest supervision and strictest punishment.'可被翻译为：三是落实上市许可持有人主体责任，强化全生命周期管理要求。增加规定药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理；批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准；生产全过程应当符合药品生产质量管理规范的要求。明确对存在质量问题或者其他安全隐患的产品，持有人应当采取停止销售、使用，召回缺陷产品等措施。同时，依法明确批签发过程中违法违规行为的处理措施，落实最严格监管和最严厉处罚要求。\n'Article 33 MAHs shall establish a marketing release procedure to audit drug products released by drug manufacturers. Drug products shall not be released until signed off by a qualified person and those that do not conform to national drug standards shall not be released.'可被翻译为：第三十三条 药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品进行审核，经质量受权人签字后方可放行。不符合国家药品标准的，不得放行。\n'Article 24 Engaging in drug manufacture activities shall comply with the GMP and the manufacturing process shall be in accordance with the national drug standards, drug registration specifications and the manufacturing process approved by drug regulatory departments. The site management file shall be submitted and continuously updated, the risk assessments and continuous improvements of the quality system operation shall be made to ensure a continuous compliance with statutory requirements throughout the whole process. Manufacturing and test records shall be complete and accurate. No fabrication or falsification is allowed.'可被翻译为：第二十四条 从事药品生产活动，应当遵守药品生产质量管理规范，按照国家药品标准、经药品监督管理部门核准的药品注册标准和生产工艺进行生产，按照规定提交并持续更新场地管理文件，对质量体系运行过程进行风险评估和持续改进，保证药品生产全过程持续符合法定要求。生产、检验等记录应当完整准确，不得编造和篡改。\n\n根据上述已知信息，请将'Lot release products shall be manufactured in accordance with the approved process and shall conform to the national drug standards and drug registration standards. The entire production process shall comply with the Good Manufacture Practice for Pharmaceutical Products. MAHs shall establish a complete production quality management system and continuously strengthen the management of deviation. MAHs shall be responsible for the authenticity of the materials, records and data generated during the production, testing and relevant processes of the lot release products. Lot release materials shall be reviewed, signed and issued by the qualified person of the MAHs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准。生产全过程应当符合药品生产质量管理规范的要求。药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理。药品上市许可持有人对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经药品上市许可持有人的质量受权人审核并签发。"
    },
    {
        "instruction":"已知信息：\n'Test Organism, Inoculum Preparation and Standardization'可被翻译为：微生物检测，接种准备和标定\n'microbiological assay'可被翻译为：微生物效价测定\n'test organism'可被翻译为：检定菌\n'strain identification'可被翻译为：菌种鉴别\n\n根据上述已知信息，请将'A standard strain used for microbiological assays and other tests.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于微生物测定和其他检查用的标准菌株。"
    },
    {
        "instruction":"已知信息：\n'Document specifying the quality management system of an organisation. (ISO 9000:2005)'可被翻译为：详细说明一个组织的质量管理体系的文件。(ISO 9000:2005)\n'(2) Formulate the management system documents in accordance with the analysis, and perform correspondingly. The contents of the management system documents comply with the requirements of laws, regulations and guidelines, and can cover the main processes of laboratory management and analysis item.'可被翻译为：(2) 制定与分析工作相适应的质量体系文件， 并遵照执行。质量体系文件的内容符合法律、法规和指导原则等的要求， 能覆盖实验室管理及分析项目的主要流程。\n'Section 4 Quality Management System Documents'可被翻译为：第四节 质量管理体系文件\n'Article 8: Quality Assurance is a part of the quality management system. The manufacturer should establish the Quality Assurance system with the support of a complete documentation system to ensure its effective operation.'可被翻译为：第八条 质量保证是质量管理体系的一部分。企业必须建立质量保证系统，同时建立完整的文件体系，以保证系统有效运行。\n\n根据上述已知信息，请将'1.A handbook that describes the various elements of the system for assuring the quality of the test results generated by a laboratory.\n2.A handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1–2.2).\n3.A document that includes the quality policy and objectives and describes the various elements of the QMS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述保证实验室产生的检测结果质量的系统的各种要素的手册。\n2.描述质量管理体系各种要素的手册，以保证实验室产生的检测结果的质量(见第一部分2.1-2.2节)。\n3.包括质量方针和目标并描述质量管理体系各要素的文件。"
    },
    {
        "instruction":"已知信息：\n'(V) The sales of drugs under special management and drugs with special management requirements by the State;'可被翻译为：（五）特殊管理的药品和国家有专门管理要求的药品的销售；\n'(X) Drugs with special management requirements by the State: drugs for which the State has adopted special regulatory measures, such as anabolic agents, peptide hormones, fixed dose combination containing special drugs, etc.'可被翻译为：（十）国家有专门管理要求的药品：国家对蛋白同化制剂、肽类激素、含特殊药品复方制剂等品种实施特殊监管措施的药品。\n'(VII) Provisions for drugs under special management;'可被翻译为：（七）特殊管理的药品的规定；\n'(III) Drugs under special management shall be handled in accordance with the relevant national provisions;'可被翻译为：（三）属于特殊管理的药品，按照国家有关规定处理；\n\n根据上述已知信息，请将'(V) Management of drugs under special management and drugs with special management requirements by the State;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）特殊管理的药品和国家有专门管理要求的药品的管理；"
    },
    {
        "instruction":"已知信息：\n'Article 155 This Law shall go into effect as of December 1, 2019.'可被翻译为：第一百五十五条 本法自2019年12月1日起施行。\n'Article 80  The Provisions shall be put into effect as of January 1, 2019.'可被翻译为：第八十条  本办法自2019年1月1日起施行。\n'Article 42 These Provisions shall go into effect as of December 1, 2022.'可被翻译为：第四十二条 本办法自2022年12月1日起施行。\n'This Announcement shall come into force on September 1, 2019.'可被翻译为：本公告自2019年9月1日起施行。\n\n根据上述已知信息，请将'Article 100 This Law shall be effective as of December 1, 2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 本法自2019年12月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'(2) have the premises, facilities, and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施和卫生环境；\n'(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施、设备和卫生环境；\n'(I) The management of the purchase, acceptance inspection, display and sales of drugs, and the management of storage and maintenance if a warehouse has been established;'可被翻译为：（一）药品采购、验收、陈列、销售等环节的管理，设置库房的还应当包括储存、养护的管理；\n'drug distribution'可被翻译为：药物分布\n\n根据上述已知信息，请将'(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；"
    },
    {
        "instruction":"已知信息：\n'oil-in-water emulsion'可被翻译为：水包油乳剂\n'The excipient substance of the main drug in the ointment is an important part of the formation and effect of the ointment.'可被翻译为：软膏剂中主药的赋形剂物质，是软膏剂形成和发挥药效的重要组成部分。\n'water-in-oil emulsion'可被翻译为：油包水乳剂\n'hydrophilic ointment'可被翻译为：亲水软膏\n\n根据上述已知信息，请将'Ointments made from oil-in-water (O\/W) emulsion matrix and water-soluble matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由水包油（O\/W）乳剂基质及水溶性基质制备而成的软膏。"
    },
    {
        "instruction":"已知信息：\n'(7) cooperate with the drug regulatory departments in extended inspection of the drug MAH and related parties;'可被翻译为：（七）配合药品监督管理部门对药品上市许可持有人及相关方的延伸检查；\n'Article 5 The organization being inspected shall provide cooperation, and shall not refuse, delay, deny or limit the unannounced inspection of drugs and medical devices organized by the food and drug regulatory departments.'可被翻译为：第五条 被检查单位对食品药品监督管理部门组织实施的药品医疗器械飞行检查应当予以配合，不得拒绝、逃避或者阻碍。\n'During the supervision and inspection, the drug regulatory department shall assign two or more inspectors to the inspected company, and the inspectors shall present the proof of law enforcement to the inspected company. The personnel of the drug regulatory department shall keep confidential of the known commercial secrets.'可被翻译为：在进行监督检查时，药品监督管理部门应当指派两名以上检查人员实施监督检查，检查人员应当向被检查单位出示执法证件。药品监督管理部门工作人员对知悉的商业秘密应当保密。\n'Article 105 Drug regulatory departments shall, in accordance with laws and regulations, supervise and inspect drug R&D activities and, when necessary, carry out extended inspection of entities and individuals providing products or services for drug R&D. Relevant entities and individuals shall provide cooperation and shall not refuse inspection or conceal information.'可被翻译为：第一百零五条 药品监督管理部门应当依照法律、法规的规定对药品研制活动进行监督检查，必要时可以对为药品研制提供产品或者服务的单位和个人进行延伸检查，有关单位和个人应当予以配合，不得拒绝和隐瞒。\n\n根据上述已知信息，请将'(5) Cooperating with the supervision and inspection of the drug regulatory department.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）配合药品监督管理部门的监督检查工作。"
    },
    {
        "instruction":"已知信息：\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'可被翻译为：第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。\n'Article 21 The medical device manufacturer shall keep detailed records on the handling of recalled medical devices, and report to the food and drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the medical device manufacturer is located. The records shall be kept up to 5 years after the expiration of the Medical Device Registration Certificate, and the handling records of the recall of Class I medical devices shall be kept for 5 years. Where product defects can be eliminated by warning, checking, repairing, relabeling, modifying and improving the instructions for use, software upgrade, replacement, and destruction, the above actions may be completed at the location of the product. The medical devices that need to be destroyed shall be destroyed under the supervision of the food and drug regulatory department.'可被翻译为：第二十一条 医疗器械生产企业对召回医疗器械的处理应当有详细的记录，并向医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门报告，记录应当保存至医疗器械注册证失效后5年，第一类医疗器械召回的处理记录应当保存5年。对通过警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、销毁等方式能够消除产品缺陷的，可以在产品所在地完成上述行为。需要销毁的，应当在食品药品监督管理部门监督下销毁。\n'The online drug sales enterprises shall keep complete records of qualification documents and electronic transactions of the suppliers. The online drug retailers selling prescription drugs shall also keep records of prescriptions, online pharmaceutical services, etc. The relevant records shall be kept for not less than 5 years, and not less than 1 year after the expiration of the drug.'可被翻译为：药品网络销售企业应当完整保存供货企业资质文件、电子交易等记录。销售处方药的药品网络零售企业还应当保存处方、在线药学服务等记录。相关记录保存期限不少于5年，且不少于药品有效期满后1年。\n\n根据上述已知信息，请将'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。"
    },
    {
        "instruction":"已知信息：\n'(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;'可被翻译为：（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n'Article 3 The registration of cosmetics and new cosmetic ingredients refers to the activity that a registrant submits a registration application in accordance with legal procedures and requirements, and the drug regulatory department reviews the safety and quality control of the cosmetics and new cosmetic ingredients applied for registration and decides whether it agrees to the application.'可被翻译为：第三条 化妆品、化妆品新原料注册，是指注册申请人依照法定程序和要求提出注册申请，药品监督管理部门对申请注册的化妆品、化妆品新原料的安全性和质量可控性进行审查，决定是否同意其申请的活动。\n'(III) Conducting product recall;'可被翻译为：（三）实施产品召回；\n\n根据上述已知信息，请将'(3) Assisting the registrants and filing persons in implementing the recall of cosmetics and new cosmetic ingredients;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）协助注册人、备案人实施化妆品、化妆品新原料召回工作；"
    },
    {
        "instruction":"已知信息：\n'Sterile  filtration  of liquids  should be validated  in  accordance with relevant Pharmacopeia requirements. Validation can be grouped by different strengths or variations of a product but should be done under worst-case conditions. The rationale for grouping should be justified and documented.'可被翻译为：液体的除菌过滤应按照相关药典要求进行验证。验证可以根据产品的不同规格或种类进行分组，但应在最差条件下进行。分组的基本依据应经过论证并用文件记录。\n'Assess and document the risks associated with the duration of filter use for the sterile filtration process for a given fluid.'可被翻译为：评估并记录与给定液体除菌过滤工艺中过滤器的使用时间相关的风险。\n'All sterilisation processes should be validated. Validation studies should take into account the product\ncomposition, storage conditions and maximum time between the start of the preparation of a product or material to\nbe sterilised and its sterilisation. Before any sterilisation process is adopted, its suitability for the product and\nequipment, and its efficacy in consistently achieving the desired sterilising conditions in all parts of each type of\nload to be processed should be validated notably by physical measurements and where appropriate by Biological Indicators (BI). For effective sterilisation, the whole of the product, and surfaces of equipment and components\nshould be subject to the required treatment and the process should be designed to ensure that this is achieved.'可被翻译为：所有灭菌工艺均应经过验证。验证研究应考虑产品成分、储存条件以及从待灭菌产品或物料的准备到其灭菌之间的最长时间。在釆用任何灭菌工艺之前，应验证该工艺与其产品和设备的适用性，以及该工艺的效能（即每种装载模式下的所有部位始终达到预期的灭菌效果），验证应主要通过物理测定，在适当情况下通过生物指示剂（BI）。为进行有效的灭菌，产品、设备和部件的表面都应进行必要的灭菌处理，灭菌过程的设计应确保实现有效灭菌。\n'During filter validation, wherever possible, the product to be filtered should be used for bacterial retention testing of the sterilising grade filter. Where the product to be filtered is not suitable for use in bacterial retention testing, a suitable surrogate product should be justified for use in the test. The challenge organism used in the bacterial retention test should be justified.'可被翻译为：在过滤器验证过程中，应尽可能使用待过滤产品进行除菌级过滤器的细菌截留测试。如果待过滤产品不适 合用于细菌截留测试，应使用合适的替代产品进行测试并说明原因。应论证用于细菌截留试验的挑战微生物的合理性。\n\n根据上述已知信息，请将'Conduct and document effective validation and qualification studies to demonstrate that the duration of filter use for a given  sterile  filtration process and for a given  fluid does not compromise performance of the final sterilising grade filter or filtrate quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"执行有效的验证和确认研究并进行记录，以证明给定液体和给定除菌过滤工艺中过滤器的使用时间不会影响最终除菌级过滤器的性能或滤液质量。"
    },
    {
        "instruction":"已知信息：\n'The CFDA shall, in accordance with the needs of lot release work, in a timely manner announce the selection criteria and conditions for added lot release institutions and the product varieties added by the lot release institutions.'可被翻译为：食品药品监管总局根据批签发工作需要，适时公布新增批签发机构及批签发机构扩增批签发品种的遴选标准和条件。\n'Article 32 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the CFDA before the end of March each year.'可被翻译为：第三十二条 批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向食品药品监管总局报告。\n'The lot release institutions designated by the CFDA shall be responsible for the acceptance, dossier review, on-site inspection and sample testing and making the decision on lot release in accordance with the law.'可被翻译为：食品药品监管总局指定的批签发机构负责批签发的受理、资料审核、现场核实、样品检验等工作，并依法作出批签发决定。\n'Article 4 The CFDA shall be in charge of lot release of biological products nationwide, specifies the scope of product varieties subject to lot release, designates lot release institutions, and guides the implementation of lot release.'可被翻译为：第四条 食品药品监管总局主管全国生物制品批签发工作，负责规定批签发品种范围，指定批签发机构，指导批签发工作的实施。\n\n根据上述已知信息，请将'Article 36 The CFDA shall establish a unified Information Management System for Lot Release, release the determination and adjustment by the lot release institutions and provide the lot release applicants with the searchable progress and conclusions of lot release, and summarize and disclose the lot release conclusion of the products with the lot release completed and handling decision of major issues and other information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十六条 食品药品监管总局建立统一的批签发信息管理系统，公布批签发机构确定及调整情况，向批签发申请人提供可查询的批签发进度、批签发结论，汇总公开已完成批签发的产品批签发结论以及重大问题处理决定等信息。"
    },
    {
        "instruction":"已知信息：\n't-test'可被翻译为：t检验\n'An indicator of statistical analysis that shows how closely two phenomena are related to each other.'可被翻译为：说明两个现象之间相互关系密切程度的统计分析指标。\n'The k2 distribution is used as the theoretical basis to determine whether the overall characteristics of the sample information obey the k2 distribution hypothesis testing method.'可被翻译为：以k2分布为理论依据，判断样本信息的总体特征是否服从k2分布的假设检验方法。\n'A statistical index that describes the degree of variation (difference) in the sampled measurements.'可被翻译为：描述抽样个体测值变异（差别）程度的统计指标。\n\n根据上述已知信息，请将'A statistical test to determine whether the difference between two means is significant by applying T-distribution theory to infer the probability of the difference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用t分布理论推断差异发生的概率，从而判定两个平均数的差异是否显著的一种统计学检验方法。"
    },
    {
        "instruction":"已知信息：\n'In a redundant filtration system (where a second redundant sterilising grade filter is present as a backup but the sterilising process is validated as only requiring one filter), post-use integrity test of the primary sterilising grade filter should be performed and if demonstrated to be integral, then a post-use integrity test of the redundant (backup) filter is not necessary. However, in the event of a failure of the post-use integrity test on the primary filter, post-use integrity test  on the  secondary (redundant) filter  should be performed, in conjunction with an investigation and risk assessment to determine the reason for the primary filter test failure.'可被翻译为：对于冗余过滤系统（存在第二个冗余除菌级过滤器作为备用过滤器，但灭菌工艺验证时仅用一个过滤器）， 应进行主除菌级过滤器的使用后完整性测试，如果证明该过滤器是完整的，则不需要对冗余（备用）过滤 器进行使用后完整性测试。但如果主过滤器的使用后完整性测试失败，应对二级（冗余）过滤器进行使用后完整性测试，同时进行调查和风险评估，确定主过滤器测试失败的原因。\n'Permit in-place integrity testing, of the 0.22 μm final sterilising grade filter, preferably as a closed system, both prior to, and following filtration as necessary. In-place integrity testing methods should be selected to avoid any adverse impact on the quality of the product.'可被翻译为：允许在必要时在过滤之前和之后对 0.22μm 最终除菌级过滤器进行在线完整性测试，最好作为密闭系统，应选择在线完整性测试方法， 以避免对产品质量产生任何不良影响。\n'Integrity testing of the product filling lines and filtration systems (as relevant).'可被翻译为：产品灌装线和过滤系统的完整性测试（如相关）。\n'Installed filter system leakage and integrity testing.'可被翻译为：已安装的过滤器系统的检漏和完整性测试。\n\n根据上述已知信息，请将'The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。"
    },
    {
        "instruction":"已知信息：\n'Stereoisomers that are mirror images of each other.'可被翻译为：互为镜像关系的立体异构体。\n'When a chiral compound molecule contains more than one asymmetric center, an excess of one diastereomer in the isomer mixture to the other diastereomers.'可被翻译为：手性化合物分子含有一个以上不对称中心时，异构体混合物中一个非对映体对其他非对映体的过量。\n'A diastereomer containing multiple chiral atoms in which only one chiral atom has a different configuration and the rest have the same configuration.'可被翻译为：含有多个手性原子的立体异构体中，只有一个手性原子的构型不同，其余的构型均相同的非对映体。\n'A stereoisomerism in which the atoms or atomic groups of organic molecules with a certain configuration are arranged in different ways in space due to the rotation or distortion of the carbon-carbon single bonds (rather than breaking the bonds).'可被翻译为：具有一定构型的有机物分子由于碳碳单键的旋转或扭曲（不是把键断开）而使得分子各原子或原子团在空间产生不同的排列方式的一种立体异构现象。\n\n根据上述已知信息，请将'For stereoisomers that have two or more asymmetric centers in a molecule and whose molecules are not mirror images of each other.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于分子中具有两个或多个不对称中心，并且其分子不互为镜像关系的立体异构体。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments shall conduct supervision and inspection on the vaccine quality during the process of the vaccine development, manufacture, storage, transportation, and immunization. The competent health departments shall conduct supervision and inspection on the implementation of the immunization planning system and immunization activities according to law.'可被翻译为：药品监督管理部门依法对疫苗研制、生产、储存、运输以及预防接种中的疫苗质量进行监督检查。卫生健康主管部门依法对免疫规划制度的实施、预防接种活动进行监督检查。\n'(1) having legally qualified pharmaceutical professionals, engineering professionals and the necessary technical workers, a legal representative, principal of the company, person in charge of production management (hereinafter referred to as \"production responsible person\"), the persons in charge of quality management (hereinafter referred to as \"quality responsible person\"), qualified persons and other relevant personnel complied with the conditions stipulated in the Drug Administration Law or the Vaccine Administration Law;'可被翻译为：（一）有依法经过资格认定的药学技术人员、工程技术人员及相应的技术工人，法定代表人、企业负责人、生产管理负责人（以下称生产负责人）、质量管理负责人（以下称质量负责人）、质量受权人及其他相关人员符合《药品管理法》《疫苗管理法》规定的条件；\n'Before administering vaccines, medical and healthcare professionals shall, in accordance with the prescribed guidance for immunization, examine the vaccine recipient's health status, immunization contraindication, check the immunization certificate, examine the appearance, lot number and expiration date of the vaccine and syringe, and verify the recipient's name and age and the vaccine's name, specifications, dose, injection site and route of administration. Vaccine administration shall only take place after confirmation of information on the recipient, the immunization certificate and the vaccine to be administered.'可被翻译为：医疗卫生人员在实施接种前，应当按照预防接种工作规范的要求，检查受种者健康状况、核查接种禁忌，查对预防接种证，检查疫苗、注射器的外观、批号、有效期，核对受种者的姓名、年龄和疫苗的品名、规格、剂量、接种部位、接种途径，做到受种者、预防接种证和疫苗信息相一致，确认无误后方可实施接种。\n'Article 57 Vaccine MAHs shall establish and improve quality management systems for whole life cycle of vaccines, formulate and implement vaccine post-marketing risk management plans, and conduct vaccine post-marketing studies to further verify the safety, effectiveness and quality management of vaccines.'可被翻译为：第五十七条 疫苗上市许可持有人应当建立健全疫苗全生命周期质量管理体系，制定并实施疫苗上市后风险管理计划，开展疫苗上市后研究，对疫苗的安全性、有效性和质量可控性进行进一步确证。\n\n根据上述已知信息，请将'For the dispatch of vaccines, there shall be at least two professionals especially responsible for the quality management and acceptance inspection of vaccines. Professionals shall have a bachelor's degree or above and intermediate professional and technical title or above in preventive medicine, pharmacy, microbiology or medicine, and have working experiences in vaccine management or techniques for more than 3 years.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从事疫苗配送的，还应当配备2名以上专业技术人员专门负责疫苗质量管理和验收工作。专业技术人员应当具有预防医学、药学、微生物学或者医学等专业本科以上学历及中级以上专业技术职称，并有3年以上从事疫苗管理或者技术工作经历。"
    },
    {
        "instruction":"已知信息：\n'Sonicate the test containers for 60 minutes (wattage range 150 – 480 watts) at 37°C ±1°C. Do not sonicate more tubes than can be vortexed within 15 minutes of completion of the sonication. Make sure the water in the sonicator covers the rinse solution in the 20 x 150 mm tubes. Do not allow the water in the sonicator to exceed 38°C.'可被翻译为：37°C ±1°C 超声测试容器60分钟（功率150-480瓦）。在超声处理完成后的15 分钟内，超声处理的管数不要超过可以涡旋的管数。确保超声装置里面的水覆盖20 x 150 mm试管中的淋洗溶液。不要让超声装置中的水温超过38°C。\n'Place all pieces into the 20 x 150 mm tube containing 15 mL of preheated (37°C ±1°C) 0.01% SLS rinse solution.'可被翻译为：将所有小片放入装有15ml预热（37°C ±1°C）0.01%SLS淋洗液的20 x 150 mm 试管。\n'Prepare the appropriate number of tubes (one tube for each device) and one as a negative \/ system control. Preheat in a water bath to 37°C ±1°C.'可被翻译为：制备适当数量的试管（每个器械一个试管）和一个阴性\/系统对照试管。水浴预 热至37°C ±1°C\n'During use, when the liquid level drops to the liquid outlet and stops, the last residual solution is then blown out.'可被翻译为：使用过程中液面降至流液口并静止时，随即将最后残留的溶液次吹出的吸管。\n\n根据上述已知信息，请将'Vortex the tubes for 30 – 60 seconds or until all pieces of the device are immersed in the rinse solution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"涡旋震摇试管30-60秒钟或直到器械的所有小块均浸入淋洗液。"
    },
    {
        "instruction":"已知信息：\n'In a prescribed release medium, the drug is released slowly and at a non-constant rate as required, and the frequency of administration is reduced by half or somewhat than that of the ordinary preparation compared with the corresponding ordinary preparation, and the patient's compliance is significantly increased.'可被翻译为：在规定释放介质中，按要求缓慢地非恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，且能显著增加患者的顺应性的制剂。\n'The speed and extent to which a drug dissolves from a sustained release, controlled release, or enteric-soluble preparation in a specified medium.'可被翻译为：药物在规定的介质中从缓释制剂、控释制剂或肠溶制剂溶出的速度和程度。\n'In the prescribed release medium, the drug is slowly released at or near a constant rate as required, and compared with the corresponding ordinary preparation, the frequency of administration is reduced by half or the frequency of administration is reduced compared with the ordinary preparation, the blood concentration is more stable than the sustained release preparation, and can significantly increase the patient's compliance.'可被翻译为：在规定释放介质中，按要求缓慢地恒速或接近恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，血药浓度比缓释制剂更加平稳，且能显著增加患者的顺应性的制剂。\n'controlled-release capsule'可被翻译为：控释胶囊\n\n根据上述已知信息，请将'Capsules that slowly release the drug at a non-constant rate or near constant rate in water or a prescribed release medium.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水中或规定的释放介质中缓慢地以非恒速或接近恒速释放药物的胶囊剂。"
    },
    {
        "instruction":"已知信息：\n'electronic signatures'可被翻译为：电子签名\n'(5) Digital signature means an electronic signature based upon cryptographic methods of originator authentication, computed by using a set of rules and a set of parameters such that the identity of the signer and the integrity of the data can be verified.'可被翻译为：数字签名系指利用发送者身份认证的私钥加密方法的电子签名，采用一套规则和一系列参数计算以核实签名者的身份及数据的完整性。\n'A signature in digital form (bio-metric or non-biometric) that represents the signatory. In legal terms, it is the equivalent of the handwritten signature of the signatory.'可被翻译为：代表签署人的数字形式的签名(生物特征或非生物特征)。在法律上，它相当于签字人的手写签名。\n'(c) Persons using electronic signatures shall, prior to or at the time of such use, certify to the agency that the electronic signatures in their system, used on or after August 20, 1997, are intended to be the legally binding equivalent of traditional handwritten signatures.'可被翻译为：使用电子签名前或期间应向主管部门证明1997年8月20日或之后再系统中使用的电子签名与传统手写签名具有同等的法律效力。\n\n根据上述已知信息，请将'(7) Electronic signature means a computer data compilation of any symbol or series of symbols executed, adopted, or authorized by an individual to be the legally binding equivalent of the individual's handwritten signature.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电子签名系指与手写签名具有相同法律效力，且由一个个体签署、采纳或授权的符号或一系列符号的计算机数据编制。"
    },
    {
        "instruction":"已知信息：\n'Article 94 The drug registration timeline mentioned in these Provisions is the longest time needed for drug registration acceptance, review, inspection, testing, approval, etc. The timeline for priority review and approval procedures shall be implemented in accordance with relevant provisions on priority review and approval.'可被翻译为：第九十四条 本办法所规定的时限是药品注册的受理、审评、核查、检验、审批等工作的最长时间。优先审评审批程序相关工作时限，按优先审评审批相关规定执行。\n'Article 157 Acceptance inspection shall be conducted for drugs under special management in accordance with relevant regulations.'可被翻译为：第一百五十七条 特殊管理的药品应当按照相关规定进行验收。\n'Article 1 In order to standardize the work process of drug registration inspection (hereinafter referred to as registration inspection), strengthen the connection between registration inspection and evaluation, and ensure the quality and efficiency of registration inspection, the Procedures is formulated in accordance with the Drug Registration Regulation and Drug Manufacture Regulation.'可被翻译为：第一条 为规范药品注册核查(以下简称注册核查)工作行为，加强注册核查与审评工作的衔接，保证注册核查工作质量和效率，根据《药品注册管理办法》《药品生产监督管理办法》,制定本程序。\n'(2) Drug registration applications accepted between the issuance and the implementation of the new Provisions shall be handled in accordance with the scope stipulated in the new Provisions and the Opinions on Encouraging Priority Review and Examination and procedures prescribed in the Opinions on Fueling Pharmaceutical Innovation via Prioritized Review & Approval (CFDA Department of Drug and Cosmetics Supervision [2017] No.126) .'可被翻译为：（二）新《办法》发布至实施前受理的药品注册申请，按照新《办法》规定的范围和《关于鼓励药品创新实行优先审评审批的意见》（食药监药化管〔2017〕126号）规定的程序执行。\n\n根据上述已知信息，请将'Article 14 Priority shall be given to registration inspection of the drugs in special approval procedures and priority evaluation and approval procedures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 特别审批程序、优先审评审批程序的品种，予以优先安排注册核查。"
    },
    {
        "instruction":"已知信息：\n'Article 49 Enterprises engaged in storage and transportation of refrigerated and frozen drugs shall be equipped with the following facilities and equipment:'可被翻译为：第四十九条 储存、运输冷藏、冷冻药品的，应当配备以下设施设备：\n'Article 28 Personnel engaged in the storage and transportation of drugs under special management and refrigerated and frozen drugs shall have received the training on relevant laws and regulations and professional knowledge, and shall not take up their posts until passing the assessment.'可被翻译为：第二十八条 从事特殊管理的药品和冷藏冷冻药品的储存、运输等工作的人员，应当接受相关法律法规和专业知识培训并经考核合格后方可上岗。\n'Article 104 Enterprises shall take necessary measures for heat preservation, or refrigeration and freezing during transportation in accordance with the temperature control requirements of drugs.'可被翻译为：第一百零四条 企业应当根据药品的温度控制要求，在运输过程中采取必要的保温或者冷藏、冷冻措施。\n'Article 75 For drugs conforming to receipt requirements, the receiving personnel shall place them in the corresponding area for quarantine according to the characteristics and requirements of the varieties, or set status identification, and notify relevant personnel for acceptance inspection. The refrigerated and frozen drugs shall be placed in the freezer for quarantine.'可被翻译为：第七十五条 收货人员对符合收货要求的药品，应当按品种特性要求放于相应待验区域，或者设置状态标志，通知验收。冷藏、冷冻药品应当在冷库内待验。\n\n根据上述已知信息，请将'Article 99 Specially-assigned personnel shall be responsible for the operations such as packaging and loading of refrigerated or frozen drugs, which shall conform to the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十九条 冷藏、冷冻药品的装箱、装车等项作业，应当由专人负责并符合以下要求："
    },
    {
        "instruction":"已知信息：\n'The process by which a drug is transported from one side of a biofilm to the other side of a biofilm with a higher concentration.'可被翻译为：药物从浓度低的一侧生物膜向浓度高的一侧的转运过程。\n'The motion state of two types of molecules, membrane lipids and membrane proteins. Is one of the basic characteristics of biofilm.'可被翻译为：膜脂和膜蛋白两类分子的运动状态。是生物膜的基本特征之一。\n'Non-fat soluble or very little fat soluble substances, with the help of carrier proteins or channel proteins on the cell membrane, along the concentration gradient and\/or along the potential gradient (potential difference) of the transport process through the cell membrane.'可被翻译为：非脂溶性或脂溶性很小的物质，借助于细胞膜上的运载蛋白或通道蛋白的帮助，顺浓度梯度和（或）顺电位梯度（电位差）通过细胞膜的转运过程。\n'Also known as \"water-soluble diffusion\". The transmembrane transport of a water-soluble polar or non-polar drug (molecular weight less than 100) with a diameter smaller than the membrane pore by means of hydrostatic or osmotic pressure on both sides of the membrane.'可被翻译为：又称\"水溶性扩散\"。直径小于膜孔的水溶性的极性或非极性药物（分子量小于100）,借助于膜两侧的流体静压或渗透压而进行的跨膜转运。\n\n根据上述已知信息，请将'The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。"
    },
    {
        "instruction":"已知信息：\n'In order to strengthen the supervision and administration of cosmetics labels, standardize the use of cosmetics labels and protect the legitimate rights and interests of consumers, according to the Regulations for the Supervision and Administration of Cosmetics, NMPA has drafted the Measures for the Administration of Cosmetics Labels (hereinafter referred to as the Measures),which are hereby promulgated. On May 31, matters related to implementation of the Measures are hereby announced as follows:'可被翻译为：为加强化妆品标签监督管理，规范化妆品标签使用，保障消费者合法权益，依据《化妆品监督管理条例》，国家药监局组织起草了《化妆品标签管理办法》（以下简称《办法》），现予公布。现就《办法》实施有关事宜公告如下：\n'NMPA Announcement on Issuing the Provisions for the Supervision and Administration of Children's Cosmetics'可被翻译为：国家药监局关于发布《儿童化妆品监督管理规定》的公告\n'NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of Cosmetics'可被翻译为：国家药监局关于发布《化妆品注册备案资料管理规定》的公告\n'NMPA Announcement on Issuing the Provisions for the Administration of Adverse Reaction Monitoring of Cosmetics'可被翻译为：国家药监局关于发布《化妆品不良反应监测管理办法》的公告\n\n根据上述已知信息，请将'NMPA Announcement on Issuance and Implementation of the Measures for the Administration of Cosmetics Labels'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布实施《化妆品标签管理办法》的公告"
    },
    {
        "instruction":"已知信息：\n'Where a drug distributor fails to report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension for rectification and be fined not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：药品经营企业未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处五万元以上五十万元以下的罚款。\n'Where a medical institution fails to report suspected adverse drug reactions, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：医疗机构未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，处五万元以上五十万元以下的罚款。\n'Article 73 In any of the following circumstances for MAHs, the drug regulatory departments above county level should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction:'可被翻译为：第七十三条  持有人有下列情形之一的，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 135 Where a drug MAH is ordered by the drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the Central Government to recall a drug but refuses, it shall be subject to a fine of not less than five times but not more than ten times the value of the drug to be recalled. If the illegal values are less than RMB 100,000, it shall be counted as RMB 100,000. In serious circumstances, drug approval documents, Drug Manufacturing Certificate, and Drug Distribution Certificate shall be revoked. The legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel shall be subject to a fine of not less than RMB 20,000 but not more than RMB 200,000. Where a drug manufacturer, drug distributor or medical institution refuses to cooperate in the recall, it shall be subject to a fine of not less than RMB 100,000 but not more than RMB 500,000.'可被翻译为：第一百三十五条 药品上市许可持有人在省、自治区、直辖市人民政府药品监督管理部门责令其召回后，拒不召回的，处应召回药品货值金额五倍以上十倍以下的罚款；货值金额不足十万元的，按十万元计算；情节严重的，吊销药品批准证明文件、药品生产许可证、药品经营许可证，对法定代表人、主要负责人、直接负责的主管人员和其他责任人员，处二万元以上二十万元以下的罚款。药品生产企业、药品经营企业、医疗机构拒不配合召回的，处十万元以上五十万元以下的罚款。\n\n根据上述已知信息，请将'Article 134 Where a drug MAH fails to monitor adverse drug reactions or report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension and be fined not less than RMB 100,000 but not more than RMB 1,000,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十四条 药品上市许可持有人未按照规定开展药品不良反应监测或者报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处十万元以上一百万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, approved by the State Council, the Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement &Use of Drugs as a Breakthrough in order to implement the decisions and plans of the CPC central Committee and the State Council on deepening the reform of the medical and health care systems and promote the interlocked reform of healthcare, health insurance, and pharmaceuticals. The Notice pointed out that it is necessary to promote the interlocked reform of healthcare, health insurance, and pharmaceuticals, magnify the effects of reform, and better address the problems complicating medical services to the people, the following policies and measures shall be implemented, covering 15 aspects:'可被翻译为：为贯彻落实党中央、国务院关于深化医药卫生体制改革的决策部署，推动各地加大力度持续深化医疗、医保、医药联动改革，2019年11月29日，经国务院同意，国务院深化医药卫生体制改革领导小组发布《关于以药品集中采购和使用为突破口 进一步深化医药卫生体制改革的若干政策措施》。通知指出要促进医疗、医保、医药联动，放大改革效应，更好推动解决群众看病就医问题。\n'General Office of the State Council Issued the Key Tasks for Deepening the Reform of the Pharmaceutical and Healthcare System in 2019'可被翻译为：国务院办公厅印发《深化医药卫生体制改革2019年重点工作任务》\n'1. Deepening the reform of state-led centralized procurement and use of drugs'可被翻译为：一、全面深化国家组织药品集中采购和使用改革\n'Recently, the General Office of the State Council issued the Key Tasks for Deepening the Reform of the Pharmaceutical and Healthcare System in 2019 (hereinafter referred to as the Tasks).'可被翻译为：近日，国务院办公厅印发《深化医药卫生体制改革2019年重点工作任务》（以下简称《任务》）。\n\n根据上述已知信息，请将'The State Council's Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement & Use of Drugs as a Breakthrough'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院深化医药卫生体制改革领导小组印发关于以药品集中采购和使用为突破口进一步深化医药卫生体制改革若干政策措施的通知"
    },
    {
        "instruction":"已知信息：\n'Article 82 Where an enterprise directly transfers the drugs in accordance with Article 69 herein, it may entrust the purchaser to conduct drug acceptance inspection. The purchaser shall conduct acceptance inspection on the drugs in strict accordance with the GSP and establish special acceptance inspection records for the directly transferred drugs. On the day of acceptance inspection, relevant information of acceptance inspection records shall be transmitted to the directly transferring enterprise.'可被翻译为：第八十二条 企业按本规范第六十九条规定进行药品直调的，可委托购货单位进行药品验收。购货单位应当严格按照本规范的要求验收药品，并建立专门的直调药品验收记录。验收当日应当将验收记录相关信息传递给直调企业。\n'Article 69 In case of special situations such as disasters, epidemic, emergencies or clinical emergency treatment, and other circumstances in conformity with the relevant national provisions, enterprises can purchase and sell drugs by means of direct transfer, and the drugs purchased will not be put into their own warehouse, but directly sent from the supplier to the purchaser. Special purchase records shall be established to ensure effective quality tracking and tracing.'可被翻译为：第六十九条 发生灾情、疫情、突发事件或者临床紧急救治等特殊情况，以及其他符合国家有关规定的情形，企业可采用直调方式购销药品，将已采购的药品不入本企业仓库，直接从供货单位发送到购货单位，并建立专门的采购记录，保证有效的质量跟踪和追溯。\n'Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.'可被翻译为：第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。\n'The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.'可被翻译为：随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。\n\n根据上述已知信息，请将'Where an enterprise directly transfers drugs in accordance with Article 69 herein, the supplier shall issue two copies of the same accompanying sheet (bill) at the time of ex-warehousing of the directly transferred drugs which shall be respectively sent to the directly transferring enterprise and the purchaser. The contents of the accompanying sheet (bill) shall comply with the requirements of Paragraph 2 of Article 73 herein and also indicate the name of the directly transferring enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"企业按照本规范第六十九条规定直调药品的，直调药品出库时，由供货单位开具两份随货同行单（票），分别发往直调企业和购货单位。随货同行单（票）的内容应当符合本规范第七十三条第二款的要求，还应当标明直调企业名称。"
    },
    {
        "instruction":"已知信息：\n'A substance that changes the genetic information of a strain by physical action.'可被翻译为：通过物理作用使菌种发生遗传信息改变的物质。\n'An effect that causes structural and\/or quantitative changes in the genetic material of prokaryotic or eukaryotic cells, or of experimental animals.'可被翻译为：受试样品引起原核或真核细胞、或实验动物遗传物质发生结构和（或）数量改变的效应。\n'A type of physical mutagen. The genetic information of the strain is altered by exposure to ultraviolet light.'可被翻译为：物理诱变剂的一种。用紫外线进行照射使菌种发生遗传信息改变。\n'The alteration of an organism's chromosomes or genes by physical or chemical mutagens.'可被翻译为：通过物理或化学诱变剂造成生物染色体或基因的改变而产生遗传性状的变异。\n\n根据上述已知信息，请将'A substance that causes the genetic information of a strain to be altered by chemical action.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学作用使菌种发生遗传信息改变的物质。"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Article 20 For vaccines which are used to respond to major public health emergencies or other vaccines which are urgently needed as identified by the competent health department under the State Council, the drug regulatory department under the State Council may grant conditional approval on registration application if benefits of those vaccines outweigh risks based on evaluation.'可被翻译为：第二十条 应对重大突发公共卫生事件急需的疫苗或者国务院卫生健康主管部门认定急需的其他疫苗，经评估获益大于风险的，国务院药品监督管理部门可以附条件批准疫苗注册申请。\n'Article 78 For drugs given conditional approval, MAHs shall adopt corresponding risk management measures and complete relevant studies within the stipulated period in accordance with regulations. Where MAHs are unable to complete the study within the stipulated period as required or are unable to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall handle the matter in accordance with the law, until the drug approval license is revoked.'可被翻译为：第七十八条 对附条件批准的药品，药品上市许可持有人应当采取相应风险管理措施，并在规定期限内按照要求完成相关研究；逾期未按照要求完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销药品注册证书。\n'Article 62 The drug regulatory department under the State Council may organize post-marketing evaluation of vaccine varieties based on the demand for disease prevention and control as well as the development of the vaccine industry. Where a vaccine variety is found to be significantly inferior to other vaccine varieties used for the prevention and control of the same disease in terms of product design, production process, safety, effectiveness or quality management, the drug registration certificates of all vaccines of the inferior variety shall be revoked and the corresponding national drug standards shall be abolished.'可被翻译为：第六十二条 国务院药品监督管理部门可以根据疾病预防、控制需要和疫苗行业发展情况，组织对疫苗品种开展上市后评价，发现该疫苗品种的产品设计、生产工艺、安全性、有效性或者质量可控性明显劣于预防、控制同种疾病的其他疫苗品种的，应当注销该品种所有疫苗的药品注册证书并废止相应的国家药品标准。\n\n根据上述已知信息，请将'Where further study is required when a vaccine's registration application is approved, the vaccine MAH shall complete the study within the prescribed time limit; where the study fails to be completed on time or fails to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall take actions in accordance with law up to revoke the vaccine's registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对批准疫苗注册申请时提出进一步研究要求的疫苗，疫苗上市许可持有人应当在规定期限内完成研究；逾期未完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销该疫苗的药品注册证书。"
    },
    {
        "instruction":"已知信息：\n'2. Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated \ndata (e.g. averages) is NMT 10%; and,'可被翻译为：所有测量所得（即毫米或吸光度）和计算所得数据（例如平均值）的相对标准偏差\n不得过 10%，且\n'2) Relative standard deviation for all measured and calculated data is NMT 10% and'可被翻译为：所有测量和计算所得数据的相对标准偏差应 NMT 10%，且\n'Uncertainty of the result of a measurement expressed as a standard deviation.'可被翻译为：用标准偏差表示的测量结果的不确定度。\n'The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.'可被翻译为：浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。\n\n根据上述已知信息，请将'Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated data (e.g. averages) is NMT 10%; and,'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有测量值（即，mm或吸光度）的相对标准偏差和计算所得数据（例如平均值） NMT10%；且"
    },
    {
        "instruction":"已知信息：\n'2) To be responsible for product release and to ensure that the production and testing of each batch of released products are in accordance with the related regulations, the registration requirements and specifications;'可被翻译为：2.承担产品放行的职责，确保每批已放行产品的生产、检验均符合相关法规、药品注册要求和质量标准；\n'1.Validation carried out during routine production of products intended for sale.\n2.Validation carried out during routine production of products intended for sale in exceptional circumstances when data from replicate production runs are unavailable because only a limited number of batches have been produced, batches are produced infrequently or batches are produced by a validated process that has been modified. Individual batches may be evaluated and released before completion of the validation exercise, based on thorough monitoring and testing of the batches.'可被翻译为：1.在拟销售产品的常规生产过程中进行的验证。\n2.在特殊情况下，在用于销售的产品的常规生产期间进行验证，当由于只生产了有限数量的批次、不经常生产批次或由已修改的经过验证的工艺生产批次而无法获得复制生产运行的数据时。在对批次进行全面监控和测试的基础上，可以在验证工作完成之前对单个批次进行评估和放行。\n'Article 288: The contract should specify the way in which the qualified person approving to release the batch for sale ensures that each batch has been manufactured and checked for compliance with the requirements of the Marketing Authorization.'可被翻译为：第二百八十八条 合同应当详细规定质量受权人批准放行每批药品的程序，确保每批产品都已按照药品注册的要求完成生产和检验。\n'(V)   Summary of batch production and testing records signed by the qualified person and affixed with the seal of the enterprise;'可被翻译为：（五）质量受权人签字并加盖企业公章的批生产及检验记录摘要；\n\n根据上述已知信息，请将'1.A person responsible for the release of batches of finished product for sale. In certain countries the batch documentation of a batch of finished product must be signed by an authorized person from the production department and the batch test results by an authorized person from the quality control department for batch release.\n2.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale.\n3.The person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n4.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale. In some good manufacturing practice (GMP) guides and legal texts, the term qualified person is used to describe analogous functions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.负责放行成批销售的成品的人。在某些国家，一批成品的批文件必须由生产部门的授权人员签字，批检测结果必须由质量控制部门的授权人员签字才能批放行。\n2.负责放行成批成品供销售的人员(在制造企业的关键人员中)。\n3.经国家监管机构认可的负责确保每批成品的生产、检测和放行符合该国现行法律法规的人员。\n4.负责放行成批成品供销售的人员(在制造企业的关键人员中)。在一些良好生产规范(GMP)指南和法律文本中，“合格人员”一词用于描述类似的功能。"
    },
    {
        "instruction":"已知信息：\n'Article 77 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions as well as raw data, and production site inspections according to the manufacturing processes and quality specifications provided by the applicant, and take samples of three consecutive batches of products, and send to the drug testing institutes for testing within five days starting from the date they accept an application.'可被翻译为：第七十七条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对研制情况和原始资料进行现场核查，并应当根据申请人提供的生产工艺和质量标准组织进行生产现场检查，现场抽取连续生产的3批样品，送药品检验所检验。\n'Article 41 The undertaking of drug manufacturing shall be subject to approval by the local drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the central government, and shall obtain a Drug Manufacturing Certificate. No one may manufacture drugs without the certificate.'可被翻译为：第四十一条 从事药品生产活动，应当经所在地省、自治区、直辖市人民政府药品监督管理部门批准，取得药品生产许可证。无药品生产许可证的，不得生产药品。\n'Article 58 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions and raw data, make preliminary review of the submitted dossiers, and provide review opinions within five days from the date it accepts an application. For the other drugs except biological products, samples of three production batches shall also be collected for testing, and a notice of specifications verification shall be issued to the drug testing institute.'可被翻译为：第五十八条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对临床试验情况及有关原始资料进行现场核查，对申报资料进行初步审查，提出审查意见。除生物制品外的其他药品，还需抽取3批样品，向药品检验所发出标准复核的通知。\n'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'可被翻译为：第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。\n\n根据上述已知信息，请将'Article 117 For supplementary applications of drug manufacturing technology transfer, altering formula or manufacturing process that may affect product quality, etc., the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall organize production site inspection, according to the attachment of the Letter of Approval for Drug Registration or the verified manufacturing process. Drug testing institutes shall conduct testing on samples of three batches of product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 对药品生产技术转让、变更处方和生产工艺可能影响产品质量等的补充申请，省、自治区、直辖市药品监督管理部门应当根据其《药品注册批件》附件或者核定的生产工艺，组织进行生产现场检查，药品检验所应当对抽取的3批样品进行检验。"
    },
    {
        "instruction":"已知信息：\n'Integrity testing of the product filling lines and filtration systems (as relevant).'可被翻译为：产品灌装线和过滤系统的完整性测试（如相关）。\n'Prior to product testing, the exterior of the unit container should be disinfected before transfer to the work station or HEPA filtered laminar flow hood. If the product container is not hermetically sealed do not soak the product container in a disinfection solution which may allow the ingress of bactericidal solution into the product.'可被翻译为：产品测试前，单元容器的外部应在转移到工作站或HEPA过滤层流罩之前进行消毒。 如果产品容器未密封，请勿将产品容器浸泡在消毒溶液中，否则灭菌溶液可能会渗 入产品中。\n'Any leaks from these systems that would present a risk to the product should be detectable (e.g. an indication system for leakage).'可被翻译为：对产品造成风险的系统泄漏应是可检岀的（例如泄漏指示系统）。\n'Use a material similar to the product under test. The control material must be of the same volume, and similarly packaged as the test product. Filter- sterilized and autoclaved Peptone water (USP Fluid A) may be useful for this purpose in many cases.'可被翻译为：在测试时使用与产品相似的物料。对照物料必须与测试产品有着相同的体 积和相似的包装。在许多情况下，过滤灭菌和高压灭菌的蛋白胨水（USP 流体 A）可用于此目的。\n\n根据上述已知信息，请将'If the system is flushed or integrity tested in-situ with a fluid other than the product, appropriate actions are taken to avoid any deleterious effect on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果使用产品之外的其他液体冲洗系统或进行在线完整性测试，应釆取适当措施避以免对产品质量的任何有害影响。"
    },
    {
        "instruction":"已知信息：\n'One of the mass spectrometry samplers. It is mainly used for solid samples and high boiling point liquid samples. Place the microgram (Rg) measure sample at the bottom of the capillary tube with closed end and insert it into the top of the injector rod.'可被翻译为：质谱进样器之一。主要用于固体样品及高沸点液体样品的进样。将微克(Rg)量样品置于末端封闭的毛细管底部，插入进样杆顶端。\n'The main part of the mass spectrometer is to separate the ions formed in the ion source according to the difference of the mass charge ratio, and receive and amplify the weak ion flow signal and send it to the display unit and computer data processing system to obtain the mass spectrum and data of the analyzed sample.'可被翻译为：质谱仪主体组成部分，将离子源中形成的离子按质荷比的差异进行分离并将这些微弱的离子流信号接收并放大后送至显示单元及计算机数据处理系统，得到被分析样品的质谱图及数据。\n'mass analyzer detector'可被翻译为：质量分析检测器\n'One of the methods of mass spectrometer introduction. The process is to load a little sample (several nanograms) with the tip of the direct injection rod and send it to the ion source after reducing pressure, and quickly heat it to vaporize and be ionized by the ion source.'可被翻译为：质谱仪导入方式之一。其过程是用直接进样杆尖端装上少许样品（几纳克）经减压后送入离子源，快速加热使之气化并被离子源离子化。\n\n根据上述已知信息，请将'One of the mass spectrometry sampler. It consists of a valve, a storage tank and a pinhole leak.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱进样器之一。由阀、贮槽和针孔漏组成。"
    },
    {
        "instruction":"已知信息：\n'(1) No application for registration renewal has been submitted prior to expiration of the term of validity;'可被翻译为：（一）有效期届满未提出再注册申请的；\n'(I) The registrant fails to submit the application for registration renewal within the specified period.'可被翻译为：（一）注册人未在规定期限内提出延续注册申请的；\n'If the application for renewal of registration is not submitted within the time limit, its application for renewal of registration will no longer be accepted.'可被翻译为：逾期未提出延续注册申请的，不再受理其延续注册申请。\n'Article 59 The following circumstances are not within the change of application items, registration application shall be conducted:'可被翻译为：第五十九条 下列情形不属于本章规定的变更申请事项，应当按照注册申请办理：\n\n根据上述已知信息，请将'(1) the application for re-registration is not made prior to the expiry date;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）有效期届满前未提出再注册申请的；"
    },
    {
        "instruction":"已知信息：\n'Any untoward medical occurrence that at any dose: \n- results in death, \n- is life-threatening, \n- requires inpatient hospitalization or prolongation of existing hospitalization, \n- results in persistent or significant disability\/incapacity, or \n- is a congenital anomaly\/birth defect (see the ICH Guideline for Clinical Safety Data Management: \nDefinitions and Standards for Expedited Reporting).[ICH E6(R1)]'可被翻译为：在任何剂量下发生的任何不良医疗事件：\n- 导致死亡\n- 危及生命\n- 需要住院治疗或延长现有住院治疗\n- 导致永久的或严重的残疾或功能损失，或\n- 治疗现有住院治疗永久的或严重的残疾或功能损失先天性异常\/出生缺陷\n（见 ICH 指导原则临床安全数据管理：加速报告的定义和标准）。[ICH E6 (R1) ]\n'Medical events that may not be immediately life -threatening or result in death or  hospitalisation, but may jeopardise the patient or may require intervention to prevent serious  outcomes; these events require medical and scientific judgement and fall under the expedited  reporting rules (see ICH E2A).'可被翻译为：可能不会立即危及生命、死亡或住院，但可能危害患者或可能需要干预以预防严重后果的医学事件；这些事件需要医学判断，符 合快速报告规则的类别（参见ICH E2A）。\n'Reactions resulting in one of the following harmful conditions due to the use of a drug: causing death; posing a life-threatening situation; causing cancer, teratogenicity, or congenital defects; leading to significant or permanent human injury or damage to organ function; resulting in hospitalization or prolonged hospital stay; causing other significant medical events, where failure to treat may lead to the aforementioned adverse reactions.'可被翻译为：因使用药品引起以下损害情形之一的反应：导致死亡；危及生命；致癌、致畸、致出生缺陷；导\n致显著的或者永久的人体伤残或者器官功能的损伤；导致住院或者住院时间延长；导致其他重要医学\n事件，如不进行治疗可能出现上述所列情况的不良反应。\n'The serious adverse event refers to event of death or serious deterioration of physical health during the clinical trial, including deadly illnesses or injuries, permanent defect in body structure or body function, and event where hospitalization or prolonged hospitalization, medical or surgical intervention is needed to avoid permanent defect to body structure or body function; and events that causes fetal distress, fetal death, or congenital anomalies or defects.'可被翻译为：严重不良事件，是指临床试验过程中发生的导致死亡或者健康状况严重恶化，包括致命的疾病或者伤害、身体结构或者身体功能的永久性缺陷、需住院治疗或者延长住院时间、需要进行医疗或者手术介入以避免对身体结构或者身体功能造成永久性缺陷；导致胎儿窘迫、胎儿死亡或者先天性异常、先天缺损等事件。\n\n根据上述已知信息，请将'Any untoward medical occurrence that at any dose: - results in death,   - is life -threatening,   - requires inpatient hospitali sation or prolongation of existing hospitali sation,   - results in persistent or significant disability\/incapacity,   or  - is a congenital anomaly\/birth defect   (see ICH E2A and ICH E6 ).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在任何剂量下发生的以下任何不良医学事件：\n- 导致死亡，\n- 危及生命，\n- 需要住院或者延长住院时间，\n- 导致永久性或显著的残疾\/功能丧失，\n或- 先天性异常\/出生缺陷\n（参见ICH E2A和ICH E6）。"
    },
    {
        "instruction":"已知信息：\n'Where any violation by a medical institution defined in the preceding paragraph is identified by the drug regulatory department, the case shall be transferred to the health administrative department at the same level for handling.'可被翻译为：药品监督管理部门发现医疗机构有前款规定行为之一的，应当移交同级卫生行政部门处理。\n'Where the health administrative departments make decision of administrative penalty for user facilities, it shall promptly notify the drug regulatory departments at the same level.'可被翻译为：卫生行政部门对使用单位作出行政处罚决定的，应当及时通报同级药品监督管理部门。\n'Where the health administrative department decides to give administrative penalty to a medical institution, the drug regulatory department at the same level shall be informed promptly.'可被翻译为：卫生行政部门对医疗机构作出行政处罚决定的，应当及时通报同级药品监督管理部门。\n'The drug regulatory departments at provincial level or above shall notify the annual reports to the health administrative departments at the same level.'可被翻译为：省级以上药品监督管理部门应当将年度报告情况通报同级卫生行政部门。\n\n根据上述已知信息，请将'In case of identifying any using unit having violations specified in preceding paragraph, the drug regulatory departments shall transfer the case to the health administrative departments at the same level for disposition.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门发现使用单位有前款规定行为的，应当移交同级卫生行政部门处理。"
    },
    {
        "instruction":"已知信息：\n'If the substance to be tested has many components or is under special circumstances, the substance can adopt the indication name related to the product or other substitute names.'可被翻译为：如果被测物组分较多或者有其他特殊情况，可以采用与产品相关的适应症名称或者其他替代名称。\n'(1) substitute narcotics, psychotropic substances, toxic drugs for medical use, radioactive drugs or pharmaceutical precursor chemicals for other drugs, or vice versa;'可被翻译为：（一）以麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品冒充其他药品，或者以其他药品冒充上述药品；\n'(2) a non-drug substance is substituted for a drug or one drug is substituted for another;'可被翻译为：（二）以非药品冒充药品或者以他种药品冒充此种药品；\n'First accurately add excess standard solution, so as to react with the measured substance or solid sample in the test solution, and then use another standard solution to titration the remaining standard solution method.'可被翻译为：先准确的加入过量标准溶液，使与试液中的待测物质或固体试样进行反应，再用另一种标准溶液滴定剩余的标准溶液的方法。\n\n根据上述已知信息，请将'2. Use the reference preparation substitute for the test preparation, use the test preparation substitute for the reference preparation or use product purchased in the market substitute for self-developed investigational drug, or otherwise use false investigational drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.以参比制剂替代试验制剂、以试验制剂替代参比制剂或者以市场购买药品替代自行研制的试验用药品， 以及以其他方式使用虚假试验用药品；"
    },
    {
        "instruction":"已知信息：\n'Most IVPT experiments report skin flux and the total cumulative amount of drug that has permeated into the receptor solution (or as a percentage of drug from the total applied dose). Depending on the purpose of the study, an evaluation of drug tissue distribution (amounts in the stratum corneum, viable epidermis, and dermis) and total mass balance may provide additional insights.'可被翻译为：大多数IVPT实验报告皮肤通量和渗透到受体溶液中的药物总累积量(或药物占总应用剂量的百分比)。根据研究的目的，对药物组织分布(角质层、活表皮和真皮层中的药物量)和总质量平衡的评估可能会提供额外的见解。\n'The flux (rate of drug permeation) should be calculated for each time point in units of mass\/area\/time (e.g., ng\/cm2\/h) on the y-axis versus time in the x-axis. The extent of drug permeation should also be reported in units of mass\/area (e.g., ng\/cm2) in the y-axis versus time in the x-axis—the slope of this curve can help determine the overall drug flux through the skin at different points in time. Drug levels in the viable epidermis and dermis can be reported as absolute mass amount (e.g., nanograms or micrograms) or concentration (e.g., nanograms or micrograms of drug per milligram of tissue [ng\/mg or µg\/ mg]).'可被翻译为：每个时间点的通量(药物渗透率)应以质量\/面积\/时间(例如，ng\/cm2\/h)为单位在y轴上与时间在x轴上进行计算。药物的渗透程度也应在y轴上以质量\/面积(例如，ng\/cm2)为单位报告，在x轴上以时间为单位报告——该曲线的斜率可以帮助确定在不同时间点通过皮肤的总体药物通量。活的表皮和真皮层中的药物水平可以用绝对质量(例如，纳克或微克)或浓度(例如，每毫克组织中药物的纳克或微克[ng\/mg或µg\/ mg])来报告。\n'The total volume of body fluid required when calculated according to the measured plasma drug concentration after the total amount of drugs in the body is to be balanced.'可被翻译为：体内药物总量待平衡后，按测得的血浆药物浓度计算时，所需要的体液总容积。\n'The amount of active ingredient contained in the test product per unit weight or volume.'可被翻译为：单位重量或容积的供试品中所含有效成分的量。\n\n根据上述已知信息，请将'Full mass balance results are generally reported as percentage of drug(s) in each compartment (e.g., stratum corneum, viable epidermis, dermis and receptor solution) relative to the total amount applied at the beginning of the experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"全质量守衡结果通常报告为每个部分(例如角质层、活表皮、真皮层和受体溶液)中药物相对于实验开始时施用的总量的百分比。"
    },
    {
        "instruction":"已知信息：\n'metabolism'可被翻译为：新陈代谢\n'A substance that is no longer used by the organism through a series of complex biochemical actions in the organism through metabolism.'可被翻译为：生物通过新陈代谢作用，在生物体内经过一系列复杂的生物化学作用所生成的最终不再被本生物体利用的物质。\n'The various forms of regulation that organisms continuously undergo during metabolism in order to adapt to changes in the internal and external environment.'可被翻译为：生物体在代谢过程中为适应内外环境的变化而不断进行的多种形式的调节。\n'In an organism, a nonheritable alteration resulting from the influence of its activities and environment; It often refers to the limited alteration of macromolecules such as proteins and nucleic acids by chemical or enzymatic means, and the modified molecules often produce changes in their properties and physiological effects.'可被翻译为：对于生物指受其活动和环境的影响而产生的非遗传性的改变；常指用化学或酶的手段对蛋白质、核酸这样的大分子进行有限的改变，被修饰的分子常产生性质和生理学作用的改变。\n\n根据上述已知信息，请将'For short, \"metabolism\". A general term for all ordered chemical changes in an organism, including both material metabolism and energy metabolism.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"简称\"代谢”。生物体内全部有序化学变化的总称，包括物质代谢和能量代谢两个方面。"
    },
    {
        "instruction":"已知信息：\n'(1) Employ at least two distinct identification components such as an identification code and password.'可被翻译为：至少采用两种不同的识别方式，例如识别码和密码。\n'(a) Each electronic signature shall be unique to one individual and shall not be reused by, or reassigned to, anyone else.'可被翻译为：每个电子签名应对应唯一的个体，且不应被他人重新使用或重新分配给他人。\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n'Uniqueness means that UDI shall comply with the requirements of device identification.'可被翻译为：唯一性，是指医疗器械唯一标识应当与医疗器械识别要求相一致。\n\n根据上述已知信息，请将'(a) Maintaining the uniqueness of each combined identification code and password, such that no two individuals have the same combination of identification code and password.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"保持每一组的识别码和密码的唯一性，即不存在两个个体拥有同组识别码和密码的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 75 To apply for the registration of a generic drug, the applicant shall fill the Application Form for Drug Registration, submit relevant dossiers and apply for production site inspection to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the applicant is located.'可被翻译为：第七十五条 申请仿制药注册，应当填写《药品注册申请表》，向所在地省、自治区、直辖市药品监督管理部门报送有关资料和生产现场检查申请。\n'Article 74 The generic drug shall have the identical active ingredients, route of administration, dosage form, strength and therapeutic effects with the registered drug. Where a drug has been produced by more than one manufacturer, the selection of registered drugs for comparative study shall be in accordance with relevant technical guidelines.'可被翻译为：第七十四条 仿制药应当与被仿制药具有同样的活性成份、给药途径、剂型、规格和相同的治疗作用。已有多家企业生产的品种，应当参照有关技术指导原则选择被仿制药进行对照研究。\n'Application for generic drugs refers to registration application for producing the drugs having existing national drug standard which is approved to be marketed by the State Food and Drug Administration, whereas the application for biological products shall be submitted as the process of new drug application.'可被翻译为：仿制药申请，是指生产国家食品药品监督管理局已批准上市的已有国家标准的药品的注册申请；但是生物制品按照新药申请的程序申报。\n'Article 72 Where an application for an import drug registration is approved first, the domestic application already approved for clinical trial of the drug may proceed along drug registration application, review and approval procedures; where regulations are conformed to, the State Food and Drug Administration shall approve the production of the drug; or, the applicant may withdraw the application, and submit a generic drug application. The other applications for the same drugs already accepted but not yet approved for clinical trials shall be returned; the registration of a generic drug may be applied for.'可被翻译为：第七十二条 进口药品注册申请首先获得批准后，已经批准境内申请人进行临床试验的，可以按照药品注册申报与审批程序继续办理其申请，符合规定的，国家食品药品监督管理局批准其进行生产；申请人也可以撤回该项申请，重新提出仿制药申请。对已经受理但尚未批准进行药物临床试验的其他同品种申请予以退回，申请人可以提出仿制药申请。\n\n根据上述已知信息，请将'Article 73 The applicant applying for registration of a generic drug shall be a drug manufacturer. The applied drug shall be within the production scope specified in the Drug Manufacturing Certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 仿制药申请人应当是药品生产企业，其申请的药品应当与《药品生产许可证》载明的生产范围一致。"
    },
    {
        "instruction":"已知信息：\n'The APS should assess all aseptic operations performed subsequent to the sterilisation and decontamination\ncycles of materials utilised in the process to the point where the container is sealed.'可被翻译为：APS 应评估从工艺所用物料的灭菌和清洁后到容器密封之间进行的所有无菌操作。\n'Environmental control, cleaning, sterilisation and monitoring of the critical extrusion, transfer and filling areas as relevant.'可被翻译为：关键挤压出区、转移区和灌装区的环境控制、清洁、灭菌和监测（如相关）。\n'Article 12 For reusable medical devices, treatment processes, including methods of cleaning, disinfection, packaging and sterilization, as well as times of reuse and other restrictions, shall be provided in instructions.'可被翻译为：第十二条 重复使用的医疗器械应当在说明书中明确重复使用的处理过程，包括清洁、消毒、包装及灭菌的方法和重复使用的次数或者其他限制。\n'The capability of the extrusion system to provide appropriate sterility assurance for the moulded container should   be   understood   and   validated.   The    sampling   frequency,   the   bioburden   and,   where   applicable, endotoxin\/pyrogen levels of the raw polymer should be defined and controlled within the PQS and considered in the CCS.'可被翻译为：应了解和验证挤出系统为成型容器提供适当的无菌保证的能力。聚合物原材料的取样频率、生物负载以及内毒素\/热原水平（如适用）应在 PQS 中定义和控制，并在 CCS 中予以考虑。\n\n根据上述已知信息，请将'Interventions requiring cessation of filling and\/or extrusion, moulding and sealing and, where required, re-sterilisation of the filling machine should be clearly defined and described in the filling procedure, and included in the APS as relevant (see paragraphs 9.34, 9.35 and 9.36).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"要求停止灌装和\/或挤出、模塑和密封，以及必要时灌装机再灭菌的干预措施，应在灌装程序中明确规定和描述，并包括在 APS 中（如相关）（参见第 9.34 、9.35 和 9.36 节）。"
    },
    {
        "instruction":"已知信息：\n'Drugs that constrict blood vessels and raise blood pressure. Divided into two categories according to their effects: (1) adrenergic receptor agonists, such as epinephrine, norepinephrine, dopamine, ephedrine, mehydroxyamine, etc., can raise blood pressure and can be used in the early stage of shock; (2) Angiotensin amines, that is, pressors and their derivatives, such as phrenopressin.'可被翻译为：使血管收缩而升高血压的药物。按其作用分为两类：①肾上腺素受体激动药，如肾上腺素、去甲肾上腺素、多巴胺、麻黄素、间羟胺等，可以升高血压，可用于休克早期；②血管紧张素胺，即增压素及其衍生物，如苯赖加压素。\n'Drugs that bind to adrenergic receptors and excite them to produce effects similar to those of epinephrine. It can cause vasoconstriction, increase blood pressure, dilate pupils, dilate bronchus, relax gastrointestinal muscle, accelerate heart rate, strengthen myocardial contractility and reduce mucosal secretion. Clinically, it is mainly used to raise pressure, relieve asthma, and reduce nasal mucosal congestion. Drugs include epinephrine, norepinephrine, mehydroxyamine and ephedrine.'可被翻译为：能与肾上腺素受体结合，并使其激动产生与肾上腺素相似作用的药物。可引起血管收缩、升高血压、散大瞳孔、舒张支气管、弛缓胃肠肌、加速心率、加强心肌收缩力以及减少黏膜分泌等作用。临床上主要应用于升压、平喘、减轻鼻黏膜充血等。药物有肾上腺素、去甲肾上腺素、间羟胺以及麻黄碱等。\n'Also known as \"blood pressure drugs\". A drug that lowers high blood pressure to normal. According to the action of the following categories: ① central antihypertensive drugs, such as clonidine; (2) adrenergic blockers, such as the β-blocker prozafolol, the α-blocker prazosin, the α and β-blocker labetalol: (3) drugs that affect sympathetic neurotransmitters, such as reservior; ④ ganglion blockers such as megamine, etc.; ⑤ calcium antagonists, such as nifedipine; ⑥ peripheral vasodilators, such as hydralazine; ⑦ Angiotensin-converting enzyme inhibitors, such as captopril; ⑧ Angiotensin II receptor blockers, such as losartan; ⑨ potassium channel openers, such as pyenadil; ⑩ diuretics, such as hydrochlorothiazide.'可被翻译为：又称\"降压药\"。能使高的血压下降至正常的药物。按作用分以下几种：①中枢性抗高血压药，如可乐定；②肾上腺素受体阻滞药，如β受体阻滞药普蔡洛尔、α受体阻滞药哌唑嗪、α和β受体阻滞药拉贝洛尔：③影响交感神经递质的药物，如利血平等；④神经节阻滞药，如美加明等；⑤钙拮抗剂，如硝苯地平等；⑥周围血管扩张药，如肼屈嗪等；⑦血管紧张素转换酶抑制剂，如卡托普利等；⑧血管紧张素II受体阻滞药，如氯沙坦等；⑨钾离子通道开放剂，如吡那地尔等；⑩利尿药，如氢氯噻嗪等。\n'Drugs that block the sympathetic ganglion's transmission of impulses and cause blood pressure to drop. Because the antihypertensive effect of this class of drugs is too fast and too strong, it is only used in some special cases, such as hypertensive crisis, aortic dissection aneurysm, and hypotension control in surgery. The applied drugs are camphimiphene, mecamine, hexamethonium bromide and so on.'可被翻译为：阻滞交感神经节对冲动的传递而引起血压下降的药物。由于本类药物降压作用过快过强，仅用于一些特殊情况，如高血压危象、主动脉夹层动脉瘤、外科手术中的控制低血压等。应用药物有樟磺咪芬、美卡明、六甲溴铵等。\n\n根据上述已知信息，请将'Medications used to correct low blood pressure, such as shock. These include alpha-agonist epinephrines and angiotensin amines that directly contraindicate blood vessels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以纠正血压过低(如休克)的治疗药物。包括具有α激动作用的肾上腺素类和直接收缩血管的血管紧张素胺。"
    },
    {
        "instruction":"已知信息：\n'drug information for consumer'可被翻译为：消费者用药信息\n'Information to the user provided on the package label or in the patient information leaflet.'可被翻译为：在包装标签或患者信息单张上提供给用户的信息。\n'Announcement of drug safety information shall be prompt, correct, comprehensive, and accompanied by necessary explanations to avoid misunderstanding.'可被翻译为：公布药品安全信息，应当及时、准确、全面，并进行必要的说明，避免误导。\n'patient education'可被翻译为：患者用药教育\n\n根据上述已知信息，请将'Drug information provided to the patient (consumer) in plain language and manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以通俗的语言和方式，向患者（消费者）提供的药物信息。"
    },
    {
        "instruction":"已知信息：\n'(4) If the application materials are incomplete or do not meet the requirements for format examination, the notification on correcting and supplementing materials of amendments shall be sent to the applicant on the spot or within five days, with all the content needs to be corrected or supplemented at one time. The application materials shall be deemed as accepted since the date of submission if there is no notification after the timeline.'可被翻译为：（四）申请材料不齐全或者不符合形式审查要求的，应当当场或者在五日内发给申请人补正材料通知书，一次性告知申请人需要补正的全部内容，逾期不告知的，自收到申请材料之日起即为受理；\n'(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;'可被翻译为：（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected one-off on site or within 5 working days. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容。逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申请资料之日起即为受理；\n\n根据上述已知信息，请将'(III) Where the application materials are incomplete or do not meet the preliminary review requirements, the applicants shall be informed one-off of all the supplements or corrections required within 5 workdays. Where the application is not informed, the application shall be deemed as accepted from the date the application materials are received.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）申报资料不齐全或者不符合形式审查要求的，应当在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'burden of disease'可被翻译为：疾病负担\n'A measure of the indirect cost or health benefit of disease in terms of the economic value to society of a healthy individual's remaining life.'可被翻译为：用健康个体的剩余生命对社会产生的经济价值来衡量疾病间接成本或健康效益的测量方法。\n'On the basis of health economics, the application of modern economic means, combined with epidemiology, decision science, statistics and other disciplines of research results, comprehensive analysis of the cost-benefit or effect of different drug treatment programs and utility evaluation of their economic differences.'可被翻译为：以卫生经济学为基础，应用现代经济学手段，结合流行病学、决策学、统计学等学科研究成果，全方位地分析不同药物治疗方案的成本效益或效果及效用评价其经济上差别的一门学科。\n'Biological effects that cause dysfunction, injury, illness, or death.'可被翻译为：引起功能紊乱、损伤、疾病或死亡的生物学效应。\n\n根据上述已知信息，请将'The socio-economic and population health effects of disease. It includes two aspects: epidemiological burden and economic burden of disease.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"疾病对社会经济及人群健康的影响。包括疾病的流行病学负担和经济负担两个方面。"
    },
    {
        "instruction":"已知信息：\n'solubility'可被翻译为：溶解度\n'The thermodynamic activity of the drug(s) present in a formulation will affect the rate and extent of skin permeation. It is prudent to understand the drug(s) solubility in the solvents\/excipients of interest, as well as in the formulation prototypes under evaluation.'可被翻译为：制剂中存在的药物的热力学活性将影响皮肤渗透的速率和程度。谨慎的做法是了解药物在所用的溶剂\/赋形剂中的溶解度，以及在评估中的原型制剂中的溶解度。\n'pharmaceutical excipients'可被翻译为：药用辅料\n'phase solubility analysis'可被翻译为：相溶解度分析\n\n根据上述已知信息，请将'information on solubility of active ingredients, excipients and vehicles;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"活性成分、辅料和载体的溶解度信息；"
    },
    {
        "instruction":"已知信息：\n'Article 56 The State implements a compensation system for adverse reactions of immunization. Where, during or after the immunization process, a vaccine recipient suffers from harm including death, severe disability, organ and tissue damage, etc., compensation shall be given thereto if these conditions are adverse reactions of immunization or the possibility cannot be ruled out. The scope of compensation is subject to catalogue management, and shall be adjusted based on the actual situations.'可被翻译为：第五十六条 国家实行预防接种异常反应补偿制度。实施接种过程中或者实施接种后出现受种者死亡、严重残疾、器官组织损伤等损害，属于预防接种异常反应或者不能排除的，应当给予补偿。补偿范围实行目录管理，并根据实际情况进行动态调整。\n'Suspected adverse reactions of immunization that have significant influence on the society including any death or severe disability of the vaccine recipient caused by immunization and suspected cluster adverse reactions of immunization shall be investigated and handled by the competent health departments and the drug regulatory departments of the people's government of the municipalities divided into districts and above as per their respective responsibilities.'可被翻译为：因预防接种导致受种者死亡、严重残疾，或者群体性疑似预防接种异常反应等对社会有重大影响的疑似预防接种异常反应，由设区的市级以上人民政府卫生健康主管部门、药品监督管理部门按照各自职责组织调查、处理。\n'Article 53 The State strengthens the monitoring on adverse reactions of immunization. The plan for monitoring adverse reactions of immunization shall be formulated by the competent health department under the State Council jointly with the drug regulatory department under the State Council.'可被翻译为：第五十三条 国家加强预防接种异常反应监测。预防接种异常反应监测方案由国务院卫生健康主管部门会同国务院药品监督管理部门制定。\n'(1) common reactions following immunization caused by the vaccine's intrinsic features;'可被翻译为：（一）因疫苗本身特性引起的接种后一般反应；\n\n根据上述已知信息，请将'Article 52 An adverse reaction of immunization is an adverse drug reaction that causes damage to the vaccine recipient's body tissue, organ and functions during or following the standard process of administering a qualified vaccine, for which no party involved is at fault.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 预防接种异常反应，是指合格的疫苗在实施规范接种过程中或者实施规范接种后造成受种者机体组织器官、功能损害，相关各方均无过错的药品不良反应。"
    },
    {
        "instruction":"已知信息：\n'Drugs that do not require a prescription from a medical practitioner or assistant medical practitioner and that consumers can judge, purchase and use on their own.'可被翻译为：不需要凭执业医师和执业助理医师处方，消费者可以自行判断、购买和使用的药品。\n'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'可被翻译为：这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。\n'(4) sale of drugs that have not been evaluated as required;'可被翻译为：（四）应当检验而未经检验即销售药品；\n'Drugs that can be purchased, dispensed and used only on the prescription of a medical practitioner or assistant medical practitioner.'可被翻译为：凭执业医师和执业助理医师处方方可购买、调配和使用的药品。\n\n根据上述已知信息，请将'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。"
    },
    {
        "instruction":"已知信息：\n'Standardized Generalized Markup Language. An ISO standard for describing structured information in a platform independent manner.'可被翻译为：标准通用标记语言。以平台无关的方式描述结构化信息的 ISO 标准。\n'An EDI Message consists of a set of segments, structured using an agreed standard, prepared in a computer readable format and \ncapable of being automatically and unambiguously processed.[EMA]'可被翻译为：EDI 信息由一组字段组成，使用商定的标准进行结构化，以计算机可读格式制备，并能够自动和明确处理。[EMA]\n'Electronic Standards for the Transfer of Regulatory Information'可被翻译为：监管信息电子传输标准\n'An information structure that represents the requirements for a set of messages.'可被翻译为：表示信息要求的信息结构。\n\n根据上述已知信息，请将'American Standard Code for Information Interchange. A specification for representing text as computer-readable information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"美国信息交换标准代码。将文本表示为计算机可读的信息规范。"
    },
    {
        "instruction":"已知信息：\n'An intervention that is an integral part of the aseptic process and is required for set-up, routine operation or monitoring (for example, aseptic assembly, container replenishment or environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'可被翻译为：是无菌工艺的一个组成部分，是设置、常规操作或监控所必需的干预(例如，无菌装配、容器补充或环境取样)。固有干预措施是无菌工艺执行的程序或作业指导书所要求的。\n'An intervention that is performed to correct or adjust an aseptic process during its execution. This may not occur at a set frequency in the routine aseptic process. Examples include clearing component jams, stopping leaks, adjusting sensors and replacing equipment components.'可被翻译为：在无菌工艺执行过程中为纠正或调整无菌工艺而进行的干预。这在常规无菌工艺中可能不会以规定的频率发生。例子包括清理组件堵塞，停止泄漏，调整传感器和更换设备组件。\n'Corrective  intervention  - An intervention that is performed to  correct or adjust  an aseptic process  during its execution.  These may not  occur at  a  set  frequency in the routine aseptic process. Examples  include  such as clearing component jams, stopping leaks, adjusting sensors, and replacing equipment components.'可被翻译为：纠正性干预：在执行过程中纠正或调整无菌工艺的干预措施。在常规无菌工艺中这些措施可能不会以固定的频率出现。例如清除成分堵塞、阻止泄漏、调整传感器和更换设备部件。\n'inherent intervention'可被翻译为：固有的干预\n\n根据上述已知信息，请将'Inherent interventions - An intervention that is an integral part of the aseptic process and is required for either set-up,  routine  operation  and\/or  monitoring  (e.g.  aseptic  assembly,  container  replenishment,  environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"固有性干预：无菌工艺不可或缺的、在组装、常规操作和\/或监测（例如无菌装配、容器补充、环境采样）中必须要进行的干预措施。关于无菌工艺执行的程序或工作指令要求固有干预。"
    },
    {
        "instruction":"已知信息：\n'To produce intermediates of certain products.'可被翻译为：生产某些产品的中间产物。\n'The process of using chemical methods to make simple substances, simple inorganic substances or simple organic compounds into more complex organic compounds.'可被翻译为：利用化学方法将单质、简单的无机物或简单的有机物制成比较复杂的有机物的过程。\n'A substance other than a starting material, intermediate, or solvent that is used in the manufacture of a new drug substance.'可被翻译为：一种与起始物、中间体或溶剂不同的物质，在新原料药的生产中使用。\n'Intermediates produced during the manufacture of a drug substance that can be used by downstream manufacturers for further processing into a drug substance.'可被翻译为：生产原料药过程中产生的可以被下游厂家用于进一步加工为原料药的中间产品。\n\n根据上述已知信息，请将'Something else, such as another compound, that is produced in the process of making one thing, such as a compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在制作生产某种物品（如某化合物）时附带产生的另外物品（如另一化合物）."
    },
    {
        "instruction":"已知信息：\n'Article 76  Where the drug regulatory departments, health administrative departments and monitoring agencies at all levels and their staff fail to fulfill   responsibilities in accordance with regulations, they shall be penalized in accordance with Article 72 and Article 74 of the Regulations for the Supervision and Administration of Medical Devices.'可被翻译为：第七十六条  各级药品监督管理部门、卫生行政部门、监测机构及其工作人员，不按规定履行职责的，依照《医疗器械监督管理条例》第七十二条和第七十四条的规定予以处理。\n'Article 74 In one of the following circumstances, punishment shall be imposed in accordance with provisions in Article 81 of the Regulations on Supervision and Administration of Medical Devices:'可被翻译为：第七十四条  有下列情形之一的，依照医疗器械监督管理条例第八十一条的规定处罚：\n'Article 29  Where an organization being inspected is to be given administrative penalty due to its illegal act(s), and has the circumstances such as refusing, delaying and denying supervision and inspection, or forging, destroying and concealing relevant evidential materials, heavier punishment(s) shall be given by the food and drug regulatory department in accordance with the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, the Regulations on the Supervision and Administration of Medical Devices and other relevant regulations.'可被翻译为：第二十九条 被检查单位因违法行为应当受到行政处罚，且具有拒绝、逃避监督检查或者伪造、销毁、隐匿有关证据材料等情形的，由食品药品监督管理部门按照《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》、《医疗器械监督管理条例》等有关规定从重处罚。\n'Article 34 The food and drug regulatory departments and their personnel who fail to perform their responsibilities for medical device supervision and administration, or abuse their powers or neglect their duties, in any of the following circumstances, the supervisory authority or the appointment and dismissal authority shall, according to the seriousness of the circumstances, give criticism and education, or give warning, demerit or major demerit to the persons directly in charge and other directly responsible persons according to law; if serious consequences are caused, demotion, removal or dismissal shall be given:'可被翻译为：第三十四条 食品药品监督管理部门及其工作人员不履行医疗器械监督管理职责或者滥用职权、玩忽职守，有下列情形之一的，由监察机关或者任免机关根据情节轻重，对直接负责的主管人员和其他直接责任人员给予批评教育，或者依法给予警告、记过或者记大过的处分；造成严重后果的，给予降级、撤职或者开除的处分：\n\n根据上述已知信息，请将'Article 18 Where the instructions and labels fail to comply with the Provisions, punishment shall be imposed by the food and drug regulatory departments at or above the county level according to stipulations of Article 67 of Regulations on Supervision and Administration of Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 说明书和标签不符合本规定要求的，由县级以上食品药品监督管理部门按照《医疗器械监督管理条例》第六十七条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'A distribution procedure to ensure that the oldest stock is distributed and\/or used before a newer and identical stock item is distributed and\/or used.'可被翻译为：一种分配程序，以确保在分发和\/或使用较新的和相同的库存项目之前分发和\/或使用最旧的库存。\n'A distribution procedure to ensure that the stock with the earliest expiry date is distributed and\/or utilized before an identical stock item with a later expiry date is distributed and\/or utilized.'可被翻译为：一种分配程序，以确保具有最早到期日的库存在具有较晚到期日的相同库存被分配和\/或使用之前被分配和\/或使用。\n'1.A distribution procedure that ensures the stock with the earliest expiry date is distributed and\/or used before an identical stock item with a later expiry date is distributed and\/or used; earliest expiry\/first out (EEFO) has a similar meaning.\n2.A distribution procedure that ensures that the stock with the earliest expiry date is distributed and\/or used before an identical stock item with a later expiry date is distributed and\/or used.'可被翻译为：1.一种分配程序，确保具有最早到期日的库存在具有较晚到期日的相同库存被分发和\/或使用之前被分发和\/或使用;最早到期\/先出(EEFO)也有类似的含义。\n2.一种分配程序，确保在分配和\/或使用截止日期最早的存货之前，先分配和\/或使用截止日期较晚的相同存货。\n'Article 108: All materials and products should be stored in an orderly fashion according to their nature, to permit batch segregation and stock rotation. Their dispensing and distribution should comply with the principle of first-in-first-out and first-expiry-first-out.'可被翻译为：第一百零八条 物料和产品应当根据其性质有序分批贮存和周转，发放及发运应当符合先进先出和近效期先出的原则。\n\n根据上述已知信息，请将'A distribution procedure to ensure that the oldest stock is distributed and\/or utilized before a newer and identical stock item is distributed and\/or utilized.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种分配程序，以确保较旧的库存在较新的和相同的库存项目分发和\/或使用之前被分发和\/或使用。"
    },
    {
        "instruction":"已知信息：\n'area under the concentration-time curve'可被翻译为：浓度-时间曲线下面积\n'concentration-time curve'可被翻译为：浓度-时间曲线\n'The ratio of the area under the concentration-time curve of the target organ or target tissue to the non-target tissue.'可被翻译为：靶器官或靶组织与非靶组织的浓度-时间曲线下面积的比值。\n'concentration-effect curve'可被翻译为：浓度-效应曲线\n\n根据上述已知信息，请将'1.Area Under the Curve\n2.Area under the concentration versus time curve'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线下面积；血药浓度-时间曲线下面积"
    },
    {
        "instruction":"已知信息：\n'Drugs that dilate the function of the pupil. Such as atropine, homatropine, topicamide, etc., often used for fundus examination and optometry.'可被翻译为：有扩大瞳孔功能的药物。如阿托品、后马托品、托吡卡胺等，常用于眼底检查和验光。\n'Also known as \"muscarinic receptor blocker two inhibition of muscarinic excited receptors, the main effect is to reduce glandular secretion, relax visceral smooth muscle, on the eye to cause dilation of mydriasis, increase intraocular pressure, regulate paralysis, relieve vagus nerve to the heart inhibition, expand small blood vessels, large doses can still stimulate the central nervous system drugs. Such as atropine and its analogs. Pirenzepine has no central effect and is mainly used to regulate the function of the digestive system.'可被翻译为：又称\"毒蕈碱受体阻滞药二抑制毒蕈碱所激动的受体，主要作用是减少腺体分泌，松弛内脏平滑肌，对眼引起扩瞳、升高眼内压、调节麻痹，解除迷走神经对心脏的抑制、扩张小血管，大剂量时尚可兴奋中枢神经系统的药物。如阿托品及其类似物。哌仑西平无中枢作用，主要用于调正消化系统的功能。\n'eye drop'可被翻译为：滴眼剂\n'Drugs that block the sympathetic ganglion's transmission of impulses and cause blood pressure to drop. Because the antihypertensive effect of this class of drugs is too fast and too strong, it is only used in some special cases, such as hypertensive crisis, aortic dissection aneurysm, and hypotension control in surgery. The applied drugs are camphimiphene, mecamine, hexamethonium bromide and so on.'可被翻译为：阻滞交感神经节对冲动的传递而引起血压下降的药物。由于本类药物降压作用过快过强，仅用于一些特殊情况，如高血压危象、主动脉夹层动脉瘤、外科手术中的控制低血压等。应用药物有樟磺咪芬、美卡明、六甲溴铵等。\n\n根据上述已知信息，请将'The drugs that can make the pupil shrink and the intraocular pressure drop after the application of local eye drops are mostly paracoleceptive agents. Including M receptor agonists and cholinesterase inhibitors, such as pilocarpine, physostigmine, etc., for glaucoma.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"局部滴眼应用后能使瞳孔缩小、眼压下降的药，多为拟副交感受神经药。包括M受体激动药及胆碱酯酶抑制药，如毛果芸香碱、毒扁豆碱等，用于青光眼。"
    },
    {
        "instruction":"已知信息：\n'Article 25 The registrant, filing entity, and contract manufacturer of medical devices shall, in compliance with the requirements of the Good Manufacturing Practice for medical devices, establish and improve the quality management system commensurate with the medical devices manufactured and maintain its effective operation, organize manufacturing in strict accordance with the registered or filed technical specifications for the products, and ensure that the medical devices released from the factory meet the mandatory standards and registered or filed technical specifications for the products.'可被翻译为：第二十五条  医疗器械注册人、备案人、受托生产企业应当按照医疗器械生产质量管理规范的要求，建立健全与所生产医疗器械相适应的质量管理体系并保持其有效运行，并严格按照经注册或者备案的产品技术要求组织生产，保证出厂的医疗器械符合强制性标准以及经注册或者备案的产品技术要求。\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n'Article 29 The registrant, filing entity or contract manufacturer of medical devices shall, based on the characteristics, technical process and requirements for manufacturing environment of the manufactured products, rationally equip and use of the facilities and equipment, strengthen the management of the facilities and equipment, and maintain their effective operation.'可被翻译为：第二十九条  医疗器械注册人、备案人、受托生产企业应当按照所生产产品的特性、工艺流程以及生产环境要求合理配备、使用设施设备，加强对设施设备的管理，并保持其有效运行。\n'Article 37 The registrant, filing entity and distributor of the medical devices shall strengthen training and management of the sales personnel, and assume legal liabilities for purchase or sale of medical devices of the sales personnel in the name of the enterprise.'可被翻译为：第三十七条  医疗器械注册人、备案人和经营企业应当加强对销售人员的培训和管理，对销售人员以本企业名义从事的医疗器械购销行为承担法律责任。\n\n根据上述已知信息，请将'Article 27 The registrant, filing entity or contract manufacturer of medical devices shall designate a management representative. The management representative is entrusted by the legal representative or principal responsible person with establishing, implementing and maintaining effective operation of the quality management system, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人、受托生产企业应当配备管理者代表。管理者代表受法定代表人或者主要负责人委派，履行建立、实施并保持质量管理体系有效运行等责任。"
    },
    {
        "instruction":"已知信息：\n'Manual aseptic processing— An aseptic process where the operator manually compounds, fills, places and \/or seals an open container with sterile product.'可被翻译为：手动无菌工艺：操作人员手动配制、灌装、放置和\/或密封无菌产品敞口容器的无菌工艺。\n'A process in which the entire preparation process is controlled under sterile conditions.'可被翻译为：把整个制备过程控制在无菌条件下进行的一种操作方法。\n'Staging and conveying of sterile primary packaging components in the aseptic filling line while not wrapped.'可被翻译为：未包裹的无菌内包装组件在无菌灌装线中的分段运输和传送。\n'Aseptic filling, sealing of containers such as ampoules, vial closure, transfer of open or partially stoppered vials.'可被翻译为：无菌灌装，容器密封（如安瓶、西林瓶密封），敞口或半压塞西林瓶的转移。\n\n根据上述已知信息，请将'An aseptic process whereby the operator manually compounds, fills, places or seals an open container with sterile product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"操作人员用无菌产品手动配制、填充、放置或密封一个开放容器的无菌过程。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'可被翻译为：2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。\n'(II) Number of registered grassroots users nationwide'可被翻译为：（二）全国注册基层用户数量\n'As of December 31, 2020, there were a total of 350,973 grassroots users (incl. registrants, distributors and using units) registered in the National Medical Device Adverse Event Monitoring Information System, covering 27,195 registrants (7.75%); 198,833 distributors (56.65%); and 124,945 using units (35.60%).'可被翻译为：截至2020年12月31日，在国家医疗器械不良事件监测信息系统中注册的基层用户（包括注册人、经营企业和使用单位）共350,973家，其中注册人27,195家，占用户总数的7.75%；经营企业198,833家，占用户总数的56.65%；使用单位124,945家，占用户总数的35.60%。\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n\n根据上述已知信息，请将'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。"
    },
    {
        "instruction":"已知信息：\n'sedimentation'可被翻译为：沉降\n'A solid substance trapped on the filter medium after the liquid passes through the filter.'可被翻译为：液体通过过滤器后截留于过滤介质上的固体物质。\n'The process by which solid or liquid particles suspended in a gas or liquid collide with each other to form larger particles due to Brownian motion, eddy currents, thermal effects, or sound waves.'可被翻译为：悬浮在气体或液体中的固体或液体微粒，由于布朗运动、涡流、热效应或声波等的作用，相互碰撞而团聚成较大颗粒的过程。\n'A viscous solid powder or liquid that condenses materials into particles or compresses them.'可被翻译为：可使物料聚结成颗粒或压缩成型的具有黏性的固体粉末或液体。\n\n根据上述已知信息，请将'The act of continuous settling of solid particles suspended in a liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"悬浮在液体中的固体颗粒的连续沉降的行为。"
    },
    {
        "instruction":"已知信息：\n'Sub culture SCD broth to general growth medium and incubate aerobically. Streak one plate; incubate aerobically at 22.5 ± 2.5 ºC.'可被翻译为：转接种SCD肉汤至通用生长培养基，并在有氧情况下培养。划线转接种一个培养 碟，在22.5 ± 2.5 ºC有氧情况下培养。\n'Record on Analyst's worksheets the day that the primary isolation media, Fluid Thioglycollate Broth (THIO), or Soybean-Casein Digest Broth (SCD) is turbid and inform supervisor. Streak tubes on the day they first appear positive and again at 14 days to determine the presence of other possible slow-growing (i.e., fungi) microorganisms.'可被翻译为：在化验员工作本上记录初始分离培养基、THIO或SCD混浊的情况并通知主管。当首 次发现阳性当天和第14天时在试管上划线，以确定是否有其它可能缓慢生长（例如真 菌）微生物。\n'Plates should be incubated for 48 hours at 35°C, and an additional 5 days at 25°C in order to detect mold contamination.'可被翻译为：平板应在35°C 培养48小时，然后在25°C 培养5天，以检查霉菌污染。\n'4. Hycheck slides and RODAC plates should promptly be incubated at 30-35ºC for 2 days and then 20 ºC -25 ºC for 5 days. Longer incubation times may be required when contaminants are suspected to be slow growing. Check plates daily for colony formation to minimize obscuring visualization of smaller colonies by over growth.'可被翻译为：立即将 Hycheck 条和 RODAC 碟在 30-35ºC 充分培养 2 天，然后在 20 ºC -25 ºC 培养5 天。如果容器可能导致生长缓慢，则可能需要更长时间。每天检查培养碟中菌群污染物情况，以减少较小菌落过分生长难以看清。\n\n根据上述已知信息，请将'All streaked plates are incubated for a period at least as long as required for growth in original isolation media (THIO or SCD) not to exceed seven days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有划线平板均培养原始分离培养基（THIO或SCD）生长所要求的相同时长，但不 得超过7天。"
    },
    {
        "instruction":"已知信息：\n'Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)'可被翻译为：药品注册核查要点与判定原则(药物临床试验)(试行)\n'3.《Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)》'可被翻译为：3. 药品注册核查要点与判定原则（药物临床试验）（试行）\n'In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.'可被翻译为：为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。\n'4.《Key Points and Determination Principles of Drug Registration Inspection(Pharmaceutical Development and Manufacturing Site) (Trial)》'可被翻译为：4. 药品注册核查要点与判定原则（药学研制和生产现场）（试行）\n\n根据上述已知信息，请将'2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）"
    },
    {
        "instruction":"已知信息：\n'pepsin chiral stationary phase'可被翻译为：胃蛋白酶手性固定相\n'A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis.'可被翻译为：以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。\n'human serum albumin chiral stationary phase'可被翻译为：人血清白蛋白手性固定相\n'ai-acid glycoprotein chiral stationary phase'可被翻译为：5酸性糖蛋白手性固定相\n\n根据上述已知信息，请将'A chiral stationary phase of protein prepared by N, v-dissuccinimide binding pepsin to aminopropyl silica gel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由N,V-二琥珀酰亚胺酯将胃蛋白酶结合在胺丙基硅胶上制备的一种蛋白质手性固定相。"
    },
    {
        "instruction":"已知信息：\n'IV. Under the leadership of the provincial Party Committee and the provincial government, the relevant administrative departments of each province should cooperate with and assist the people's government of the place of origin of Chinese crude drugs to achieve regulated development of Chinese crude drugs, such as improving the working mechanism for high-quality development of Chinese crude drugs industry; formulating the development plan for Chinese medicine materials industry; refining the incentive policies to promote the regulated development of Chinese crude drugs; establishing a standing book and credit archives for TCM manufacturers and their manufacturing bases to implement dynamic supervision; and establishing an information platform for regulated manufacturing and traceability for Chinese crude drugs. Provinces with a better basis for regulated and intensive manufacturing of Chinese crude drugs are encouraged to study and formulate implementation rules based on the actual development of Chinese crude drugs in the areas under their jurisdiction, and make active exploration and promotion, so as to accumulate experiences for further promotion of the GAP.'可被翻译为：四、各省相关管理部门在省委省政府领导下，配合和协助中药材产地人民政府做好中药材规范化发展工作，如完善中药材产业高质量发展工作机制；制定中药材产业发展规划；细化推进中药材规范化发展的激励政策；建立中药材生产企业及其生产基地台账和信用档案，实施动态监管；建立中药材规范化生产追溯信息化平台等。鼓励中药材规范化、集约化生产基础较好的省份，结合本辖区中药材发展实际，研究制定实施细则，积极探索推进，为本规范的深入推广积累经验。\n'V. The relevant administrative departments of each province should conduct inspection and provide technical guidance on the implementation and promotion of the GAP according to their responsibilities. Relevant authorities of Ministry of Agriculture and Rural Affairs should take the lead in providing guidance on the supply of seeds, seedlings and provenances of Chinese crude drugs, field management, use of pesticides and fertilizers, and pest control. Relevant authorities of the National Forestry and Grassland Administration should take the lead in providing guidance on ecological planting, wild cultivation and imitated wild cultivation of Chinese crude drugs, as well as planting and breeding of Chinese crude drugs under the management category of endangered plants. TCM regulatory authorities should work together to provide guidance on seeds and seeding, standardized planting, harvesting and processing, and ecological planting of Chinese crude drugs. The drug regulatory departments should carry out extended inspections on the corresponding manufacturers of Chinese crude drugs, and provide guidance on the requirements for medicinal use, processing in the place of origin and quality inspection.'可被翻译为：五、各省相关管理部门依职责对本规范的实施和推进进行检查和技术指导。农业农村部门牵头做好中药材种子种苗及种源提供、田间管理、农药和肥料使用、病虫害防治等指导。林业和草原部门牵头做好中药材生态种植、野生抚育、仿野生栽培，以及属于濒危管理范畴的中药材种植、养殖等指导。中医药管理部门协同做好中药材种子种苗、规范种植、采收加工以及生态种植等指导。药品监督管理部门对相应的中药材生产企业开展延伸检查，做好药用要求、产地加工、质量检验等指导。\n'In order to implement the Opinions of the CPC Central Committee and the State Council on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine, promote the regulated manufacturing of Chinese crude drugs, strengthen the quality control of Chinese crude drugs, and promote the high quality development of traditional Chinese medicine, the National Medical Products Administration, Ministry of Agriculture and Rural Affairs, National Forestry and Grassland Administration, and National Administration of Traditional Chinese Medicine formulated the Good Agricultural Practice (hereinafter referred to as the GAP)in accordance with the Drug Administration Law of the People's Republic of China and Law of the People's Republic of China on Traditional Chinese Medicine, which was promulgated and implemented on March 1, 2022, and the relevant issues are hereby announced as follows:'可被翻译为：为贯彻落实《中共中央 国务院关于促进中医药传承创新发展的意见》，推进中药材规范化生产，加强中药材质量控制，促进中药高质量发展，依据《中华人民共和国药品管理法》《中华人民共和国中医药法》，国家药监局、农业农村部、国家林草局、国家中医药局研究制定了《中药材生产质量管理规范》（以下称本规范），于2022年3月1日予以发布实施，并将有关事项公告如下：\n'Provincial drug regulatory departments should strengthen supervision and inspection, and when necessary, may carry out extended inspection on the corresponding TCM manufacturers that should use or mark the use of Chinese crude drugs that meet the GAP, with emphasis on whether they meet the GAPor not. In case of identifying any inconformity, the drug regulatory departments shall conduct severe investigation and punishment according to law, order the TCM manufacturer to make rectification within a prescribed time limit, cancel the labeling, etc., and disclose the information of corresponding manufacturers of Chinese crude drugs and their varieties of Chinese crude drugs, and notify the people’s government of the place of origin of Chinese crude drugs.'可被翻译为：省级药品监督管理部门应当加强监督检查，对应当使用或者标示使用符合本规范中药材的中药生产企业，必要时对相应的中药材生产企业开展延伸检查，重点检查是否符合本规范。发现不符合的，应当依法严厉查处，责令中药生产企业限期改正、取消标示等，并公开相应的中药材生产企业及其中药材品种，通报中药材产地人民政府。\n\n根据上述已知信息，请将'VI. The relevant administrative departments of each province should strengthen cooperation to form a joint force, jointly promote the regulated, standardized and intensive development of Chinese crude drugs, enhance publicity and training according to their responsibilities, and promote the implementation of the GAP. The relevant administrative departments of each province should strengthen the routine supervision during the implementation. In case identifying any major problems or suggestions on the improvement of major policies, please report to the corresponding management department of the State intime.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"六、各省相关管理部门应加强协作，形成合力，共同推进中药材规范化、标准化、集约化发展，按职责强化宣传培训，推动本规范落地实施。加强实施中日常监管，如发现存在重大问题或者有重大政策完善建议的，请及时报告国家相应的管理部门。"
    },
    {
        "instruction":"已知信息：\n'Imported starting materials should comply with importation regulations.'可被翻译为：进口原辅料应当符合国家相关的进口管理规定。\n'V. Registration (filing) forms for imported medical devices and domestically manufactured medical devices'可被翻译为：五、关于进口医疗器械和境内生产的医疗器械注册（备案）形式\n'Article 109 For the registration application of an import drug categorized as non-prescription drug, the application, review and approval procedures for import drugs shall apply, and the technological requirements shall be the same as those for the domestically produced non-prescription drugs.'可被翻译为：第一百零九条 进口的药品属于非处方药的，适用进口药品的申报和审批程序，其技术要求与境内生产的非处方药相同。\n'Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products.'可被翻译为：第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。\n\n根据上述已知信息，请将'For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。"
    },
    {
        "instruction":"已知信息：\n'Article 24 If the lot release institution believes that relevant data in the application dossiers needs to be verified or supplemented, it shall notify the lot release applicant of supplementing data in writing and specify the time limit for reply.'可被翻译为：第二十四条 批签发机构认为申请资料中的有关数据需要核对或者补充的，应当书面通知批签发申请人补正资料，并明确回复时限。\n'The lot release institution, under the premise of guaranteeing independence of dossier review, sample test and other technical review work, may communicate with the lot release applicant about specific problems requiring explanation in the lot release process.'可被翻译为：批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通。\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'Article 16 After receiving the application dossiers and samples, the lot release institution shall immediately verify and properly preserve the same after registration and signature confirmation by the two parties. If the lot release applicant cannot sign for confirmation on the spot, it shall submit a written commitment in advance.'可被翻译为：第十六条 批签发机构收到申请资料及样品后，应当立即核对，交接双方登记签字确认后，妥善保存。批签发申请人无法现场签字确认的，应当提前递交书面承诺。\n\n根据上述已知信息，请将'Article 24 The lot release institution, under the premise of guaranteeing independence of dossier review, sample testing and other technical review work, may communicate with the lot release applicant about specific issues requiring explanation in the lot release process. Verification can be carried out through telephone communication, written notice and other forms, and on-site verification can be carried out if necessary. If it is necessary for the lot release applicant to provide explanations or supplement materials, a written notice shall be given and the time limit for reply shall be specified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条    批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通核实。核实工作可通过电话沟通、书面通知等形式进行，必要时可开展现场核实。需要批签发申请人提供说明或者补充资料的，应当书面通知，并明确回复时限。"
    },
    {
        "instruction":"已知信息：\n'finished pharmaceutical product (FPP). A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more active pharmaceutical ingredients (APIs). In some cases, it may be in combination with a medical device.'可被翻译为：制剂成品（FPP） 经过了所有生产步骤包括包装在最终容器中并贴上标签的产品。一种FPP可包括一种或多种API。有时可能会与医疗器械的组合。\n'1.The product following purification, but before final formulation. It is obtained from a bulk harvest, and is kept in a single container and used in the preparation of the final dosage form.\n2.Any product that has completed all processing stages up to, but not including, final packaging.\n3.A product that has completed all processing stages up to, but not including, final packaging. (Reference to (should conform with) \"Good manufacturing practices for pharmaceutical products\")\n4.Any pharmaceutical product that has completed all processing stages up to, but not including, final packaging.\n5.Any product that has completed all processing stages, usually not including final packaging and labelling.'可被翻译为：1.净化后的产品，但在最终配方之前。它从批量收获中获得，并保存在单个容器中，用于制备最终剂型。\n2.任何已完成所有加工阶段直至但不包括最终包装的产品。\n3.成品:已完成直至但不包括最终包装的所有加工阶段的产品(参考(应符合)《药品生产质量管理规范》)\n4.任何已完成直至但不包括最终包装的所有加工阶段的药品。\n5.任何已完成所有加工阶段的产品，通常不包括最终包装和标签。\n'A product which has undergone all stages of production, including packaging in its final container.'可被翻译为：已完成所有生产操作步骤和最终包装的产品。\n'Production (example: finished pharmaceutical product):'可被翻译为：生产（例：制剂）\n\n根据上述已知信息，请将'A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。"
    },
    {
        "instruction":"已知信息：\n'For a filed medical device, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'可被翻译为：对备案的医疗器械，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。\n'Article 8 The food and drug regulatory department shall publicize relevant information on in-vitro diagnostic reagent registration and filing promptly in accordance with laws. The applicant can look up the approval progress and relevant results as well as the public can look up the result of approval.'可被翻译为：第八条 食品药品监督管理部门依法及时公布体外诊断试剂注册、备案相关信息。申请人可以查询审批进度和结果，公众可以查阅审批结果。\n'In-vitro diagnostic reagent filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.'可被翻译为：体外诊断试剂备案是备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。\n'Article 41 To apply for in-vitro diagnostic reagent registration, the applicant shall submit application materials to the food and drug regulatory department in accordance with relevant requirements.'可被翻译为：第四十一条 申请体外诊断试剂注册，申请人应当按照相关要求向食品药品监督管理部门报送申报资料。\n\n根据上述已知信息，请将'For a filed in-vitro diagnostic reagent, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对备案的体外诊断试剂，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。"
    },
    {
        "instruction":"已知信息：\n'For the filing of class I in-vitro diagnostic reagent, the filing entity may submit the product self-testing report.'可被翻译为：办理第一类体外诊断试剂备案的，备案人可以提交产品自检报告。\n'VI. Filing of Class I medical devices'可被翻译为：六、关于第一类医疗器械备案\n'Article 45 The registrant, filing entity, and contract manufacturer of medical devices shall conduct annual self-inspection of the operation of its quality management system, and submit self-inspection reports to the drug regulatory department of the place where it is located before the next March 31. The registrant or filing entity of imported medical devices shall entrust its agent to submit self-inspection report to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the agent is located.'可被翻译为：第四十五条  医疗器械注册人、备案人、受托生产企业应当每年对质量管理体系的运行情况进行自查，并于次年3月31日前向所在地药品监督管理部门提交自查报告。进口医疗器械注册人、备案人由其代理人向代理人所在地省、自治区、直辖市药品监督管理部门提交自查报告。\n'When necessary, inspection shall be carried out toward the registrant and filing entity of the medical devices.'可被翻译为：必要时，可以对医疗器械注册人、备案人开展检查。\n\n根据上述已知信息，请将'For the filing of class I medical device, the filing entity may submit the product self-testing report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理第一类医疗器械备案的，备案人可以提交产品自检报告。"
    },
    {
        "instruction":"已知信息：\n'Due to the conformation of the molecule leads to the influence on the physical properties, chemical reaction characteristics and biological activity.'可被翻译为：由于分子的构象导致对物理特性、化学反应特征和生物活性的影响。\n'conformational effect'可被翻译为：构象效应\n'The quantitative relationship between the structure of a series of compounds and their biological activity is investigated using theoretical calculations and statistical analysis methods.'可被翻译为：利用理论计算和统计分析方法研究系列化合物结构与生物活性之间所存在的定量关系。\n'A quantitative structure-activity relationship equation expressing the effects of physical and chemical parameters such as the electrical, stereoscopic, and hydrophobicity of a substituent on the biological activity.'可被翻译为：表达取代基的电性、立体效应和疏水性等物理化学参数对生物活性的影响的一种定量构效关系方程。\n\n根据上述已知信息，请将'According to the conformation distribution of the ground state and transition state of a compound, the influence on the physical and chemical behavior and biological activity of the compound is studied.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据一个化合物的基态、过渡态的构象分布，研究对该化合物物理、化学行为和生物活性的影响。"
    },
    {
        "instruction":"已知信息：\n'The entire process of a new drug from laboratory research to marketing and expansion of clinical application. It involves many disciplines such as pharmacy, pharmacology, toxicology, drug analysis, pharmacodynamics and clinical medicine.'可被翻译为：新药从实验室研究到上市、扩大临床应用的整个过程。涉及药剂学、药理学、毒理学、药物分析、药物动力及临床医学等诸多学科。\n'A test which is considered to be applicable to particular new drug substances or particular new drug products depending on their specific properties and\/or intended use.'可被翻译为：根据特定的原料药和制剂的特殊性质或用途而设定的检测。\n'A comprehensive applied technical discipline to study the preparation theory, production technology and quality control of drugs and their formulations, with the purpose of ensuring the effectiveness, safety and stability of drugs, and improving the compliance and bioavailability of drugs in clinical use.'可被翻译为：研究药物及其组方制剂的制备理论、生产技术和质量控制的综合应用技术学科，其目的在于保证药物有效性、安全性和稳定性，提高药物的临床使用的顺应性和生物利用度。\n'A general term for a report on the testing of starting materials, intermediates, active substances, excipients, reference substances and their finished products used in the manufacture of pharmaceutical products.'可被翻译为：对用于药品生产的起始物料、中间体、活性物质、辅料、标准物质及其成品的检测报告的通称。\n\n根据上述已知信息，请将'A series of laboratory studies carried out to prepare a proposed new drug for clinical trials. It includes synthetic process, extraction method, physicochemical properties and purity, prescription screening, preparation process, test method, quality index, stability, pharmacology and toxicology, animal pharmacokinetics, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为拟开发的新药用于临床试验而开展的一系列实验室研究工作的总称。包括合成工艺、提取方法、理化性质及纯度、处方筛选、制备工艺、检验方法、质量指标、稳定性、药理毒理、动物药动学等。"
    },
    {
        "instruction":"已知信息：\n'Article 58 If in violation of Paragraph 1 of Article 17, Article 18 and Paragraph 1 of Article 19 of these Provisions, the cosmetic manufacturer changes its licensing conditions, or needs to change the items stated on the License, but fails to apply for changes as the drug regulatory department issued former license shall order it to make rectification, give warning to it, and impose a fine of not less than RMB 10,000 and not more than RMB 30,000.'可被翻译为：第五十八条 违反本办法第十七条、第十八条第一款、第十九条第一款，化妆品生产企业许可条件发生变化，或者需要变更许可证载明的事项，未按规定申请变更的，由原发证的药品监督管理部门责令改正，给予警告，并处1万元以上3万元以下罚款。\n'Article 72 Where MAHs fail to carry out re-evaluation as required, conceal re-evaluation results, or fail to submit an application for cancellation as required, the drug regulatory departments at provincial level or above shall order them to make rectification and give a warning, and may impose a fine between 10,000 and 30,000 RMB.'可被翻译为：第七十二条  持有人未按照要求开展再评价、隐匿再评价结果、应当提出注销申请而未提出的，由省级以上药品监督管理部门责令改正，给予警告，可以并处1万元以上3万元以下罚款。\n'Article 57 If the registrant or filing person of new cosmetic ingredients violates the requirements of Article 21 of these Provisions, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall give an order for rectification; the person that refuses to do so shall be fined not less than 5,000 yuan but no more than 30,000 yuan.'可被翻译为：第五十七条 化妆品新原料注册人、备案人违反本办法第二十一条规定的，由省、自治区、直辖市药品监督管理部门责令改正；拒不改正的，处5000元以上3万元以下罚款。\n'Article 69 If Class III medical device distributors fail to handle change in enterprise name and person in charge of the enterprise as stipulated in these Provisions, the drug regulatory departments shall order rectification within prescribed time limit; for refusal to rectification, a fine of not less than 5,000 yuan and not more than 30,000 yuan shall be imposed.'可被翻译为：第六十九条  第三类医疗器械经营企业未按照本办法规定办理企业名称、法定代表人、企业负责人变更的，由药品监督管理部门责令限期改正；拒不改正的，处5000元以上3万元以下罚款。\n\n根据上述已知信息，请将'If in violation of Paragraph 2 of Article 19 of these Provisions, the person in charge of quality and safety and the reserved contact information are changed, without reporting to related department as required, the drug regulatory department issued former license shall order the applicant to make rectification; if refusing to make rectification, the department shall give warning, and impose a fine of not more than RMB 5,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"违反本办法第十九条第二款，质量安全负责人、预留的联系方式发生变化，未按规定报告的，由原发证的药品监督管理部门责令改正；拒不改正的，给予警告，并处5000元以下罚款。"
    },
    {
        "instruction":"已知信息：\n'The crude drug importers shall be the marketing authorization holders (MAHs) of Chinese patent medicines, manufacturers of TCMs and drug distributors with the business scope covering Chinese crude drugs or Prepared Slices within the territory of China.'可被翻译为：药材进口单位，应当是中国境内的中成药上市许可持有人、中药生产企业，以及具有中药材或者中药饮片经营范围的药品经营企业。\n'II. Manufacturers of prepared slices of Chinese crude drugs, marketing authorization holders of Chinese patent medicine are encouraged to build or jointly build manufacturers and manufacturing bases of Chinese crude drugs at the place of origin of Chinese crude drugs in accordance with the GAP, and extend the drug quality management system to the place of origin of Chinese crude drugs.'可被翻译为：二、鼓励中药饮片生产企业、中成药上市许可持有人等中药生产企业在中药材产地自建、共建符合本规范的中药材生产企业及生产基地，将药品质量管理体系延伸到中药材产地。\n'Announcement of the National Medical Products Administration, Ministry of Agriculture and Rural Affairs, National Forestry and Grassland Administration, and National Administration of Traditional Chinese Medicine on Issuing the Good Agricultural Practice for Chinese Crude Drugs'可被翻译为：国家药监局 农业农村部 国家林草局 国家中医药局关于发布《中药材生产质量管理规范》的公告\n'Enterprises exclusively or concurrently engaged in the production of drugs.'可被翻译为：生产药品的专营企业或者兼营企业。\n\n根据上述已知信息，请将'Chinese crude drugs manufacturers in this announcement include planting and breeding specialized cooperatives or cooperatives with the nature of an enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本公告所指中药材生产企业包括具有企业性质的种植、养殖专业合作社或联合社。"
    },
    {
        "instruction":"已知信息：\n'An indicator of statistical analysis that shows how closely two phenomena are related to each other.'可被翻译为：说明两个现象之间相互关系密切程度的统计分析指标。\n'A statistical test of whether and to what extent variables are correlated.'可被翻译为：对变量之间是否相关以及相关的程度如何所进行的统计检验。\n'The application of multivariate statistical techniques to analyse complex process data with potentially correlated variables. (Ph. Eur.)'可被翻译为：应用多变量统计技术分析具有潜在相关变量的复杂工艺数据。\n'In order to achieve the quantification of a specific component, a quantitative relationship between the variable and the response is established by multiplying a signal (K multiples, either the interference component or the component to be measured).'可被翻译为：是为了实现特定成分的定量，通过倍增某个信号（K倍数，可以是干扰成分，也可以是待测成分）的方式，来建立变量与响应之间的定量关系。\n\n根据上述已知信息，请将'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 73 Prescriptions dispensed by pharmacists or other drug professionals who are qualified in accordance with the law shall be checked, and no drugs listed in the prescriptions may be changed or substituted without authorization. The pharmacists shall refuse to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第七十三条 依法经过资格认定的药师或者其他药学技术人员调配处方，应当进行核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Article 58 Drug distributors shall retail drugs properly and include an accurate description of dosage and administration and precautions. Prescriptions for dispensing shall be checked, and no drugs listed in the prescription may be changed or substituted without authorization. Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第五十八条 药品经营企业零售药品应当准确无误，并正确说明用法、用量和注意事项；调配处方应当经过核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'prescription dispensing'可被翻译为：处方调剂\n'These are drugs supplied only in licensed pharmacies on the presentation of signed prescriptions issued by a licensed and registered medical practitioner, licensed and\/or registered dentist (for dental treatment only), and\/or licensed and\/or registered veterinarian (for animal treatment only), and the supply and dispensing of these drugs must be carried out by a pharmacist or under the supervision of a pharmacist. Prescription drugs are further subdivided into controlled drugs (narcotic drugs and psychotropic substances) and non- controlled drugs.'可被翻译为：这些药物仅在持牌药房供应，需出示由持牌和注册医生、持牌和\/或注册牙医(仅用于牙科治疗)和\/或持牌和\/或注册兽医(仅用于动物治疗)签发的签名处方，并且这些药物的供应和配药必须由药剂师或在药剂师的监督下进行。处方药又进一步细分为管制药物(麻醉药品和精神药物)和非管制药物。\n\n根据上述已知信息，请将'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。"
    },
    {
        "instruction":"已知信息：\n'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'可被翻译为：第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 40 If the drug regulatory departments, lot release institution, CFDI and their staff members constitute any of the following circumstances in the lot release work, sanctions shall be given to the directly responsible persons and  other directly responsible personnel by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条    药品监督管理部门、批签发机构、核查中心及其工作人员在批签发工作中有下列情形之一的，依法对直接负责的主管人员和其他直接责任人员给予处分；构成犯罪的，依法追究刑事责任：\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 162 Any drug regulatory department that constitutes any of the following circumstances in the process of drug registration shall be instructed by its superior administrative department or supervisory departments to make rectification, and administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第一百六十二条 药品监督管理部门在药品注册过程中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n\n根据上述已知信息，请将'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任："
    },
    {
        "instruction":"已知信息：\n'Article 49 During the drug review process, where on-site inspection is needed due to the circumstances such as the authenticity of the application dossiers is in doubt or reports with confirmed evidence are received, the CDE shall initiate for-cause inspection and, when necessary, sampling and testing shall be performed.'可被翻译为：第四十九条 药品审评中心在审评过程中，发现申报资料真实性存疑或者有明确线索举报等，需要现场检查核实的，应当启动有因检查，必要时进行抽样检验。\n'Article 58 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall organize to conduct on-site inspections of the drug research and development conditions and raw data, make preliminary review of the submitted dossiers, and provide review opinions within five days from the date it accepts an application. For the other drugs except biological products, samples of three production batches shall also be collected for testing, and a notice of specifications verification shall be issued to the drug testing institute.'可被翻译为：第五十八条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起5日内组织对临床试验情况及有关原始资料进行现场核查，对申报资料进行初步审查，提出审查意见。除生物制品外的其他药品，还需抽取3批样品，向药品检验所发出标准复核的通知。\n'Article 63 When carrying out on-site inspection, the drug regulatory department can make sample testing as needed.'可被翻译为：第六十三条  药品监督管理部门开展现场检查时，可以根据需要进行抽查检验。\n'Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process.'可被翻译为：第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。\n\n根据上述已知信息，请将'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。"
    },
    {
        "instruction":"已知信息：\n'Numerical factor used in a quantitative risk assessment to represent or allow for the extrapolation, uncertainty, or variability of an observed exposure concentration and its associated health outcome in a particular laboratory species or exposed population to an exposure concentration for the target population (for example, from animals to human patients and short-term exposure to chronic exposure) that would be associated with the same delivered dose. Adjustment factors can also be used when dealing with clinical data, e.g.  when a study population is not representative of the general population.'可被翻译为：定量风险评估中使用的数值因子，用于表示或允许在特定实验室物种或暴露人群中观察到的暴露浓度及其相关健康结果的外推、不确定性或可变性，这些暴露浓度将与相同的给药剂量相关(例如，从动物到人类患者以及从短期暴露到慢性暴露)。在处理临床数据时也可以使用调整因子，例如，当研究人群不能代表一般人群时。\n'A factor determined by professional judgment of a toxicologist and applied to bioassay data to relate that data safely to humans.'可被翻译为：毒理学家通过专业评判确定的一个独立因子，用于关联生物测定数据与人体安全性数据。\n'Since humans are more sensitive to the toxic reactions of most chemical poisons than animals, there are many uncertainties in the process of extrapolating the results of animal experiments to humans, which will cause errors. Especially in mg\/kg body weight to indicate the dose is even more so, so in the calculation, the experimental animal should not observe the harmful effect dose or observed harmful effect of the lowest dose to reduce a certain multiple to correct the error, to ensure safety.'可被翻译为：由于人对于大多数化学毒物的毒性反应要比动物敏感，在把动物实验结果向人外推的过程中，存在许多不确定因素，会造成误差。尤其是以mg\/kg体重表示剂量时更是如此，故在计算时，应该把实验动物的未观察到的有害作用剂量或观察到的有害作用的最低剂量缩小一定倍数来校正误差，确保安全。\n'An approach that focuses on the scientific understanding and measurement of chemical hazards as well as chemical exposures, and ultimately the risks associated with them. This term is often (and in this guideline) used synonymously with risk assessment.'可被翻译为：一种关注于科学认知和测定化学危险物和化学暴露量以及最终与之相关联风险的方法。该术语通常（并在本指南中）与风险评估同义使用。\n\n根据上述已知信息，请将'A factor set to eliminate the uncertainties involved in determining the adverse effects of an evaluated chemical on a large population by extrapolating data from animal trials to humans, or from small-population surveys. It is used to establish standards for the control of chemicals to ensure the safety of exposed populations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在以动物试验数据外推到人，或以小范围人群调查结果判断所评价的化学品对大范围人群的有害作用时，为排除所涉及的不确定因素而设定的系数。用于制定化学品控制标准，以保证接触人群的安全。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issued the Administrative Measures for Drug Quality Sampling Inspection'可被翻译为：国家药监局关于印发药品质量抽查检验管理办法的通知\n'To strengthen medical device administration and standardize the sampling inspection of medical device quality, NMPA has organized the revision of and released on March 13, 2020 the Administrative Measures for Sampling Inspection of Medical Device Quality. The Administrative Regulations on Quality Supervision and Sampling Inspection of Medical Devices (CFDA Department of Medical Device Supervision [2013] No. 212) and the Work Procedures for National Medical Device Sampling Inspection (CFDA General Office [2014] No. 213) issued by the former China Food and Drug Administration shall be repealed simultaneously.'可被翻译为：为加强医疗器械监督管理，规范医疗器械质量抽查检验工作，国家药监局于2020年3月13日组织修订并发布了《医疗器械质量抽查检验管理办法》。原国家食品药品监督管理总局发布的《医疗器械质量监督抽查检验管理规定》（食药监械监〔2013〕212号）和《国家医疗器械抽查检验工作程序》（食药监办〔2014〕213号）同时废止。\n'NMPA Issued the Notice on Strengthening the Supervision and Inspection of Sterile and Implantable Medical Devices'可被翻译为：国家药监局综合司关于加强无菌和植入性医疗器械监督检查的通知\n'NMPA Announcement on Issuing the Guidance for the Preparation of Annual Self-inspection Report of Medical Device Quality Management System'可被翻译为：关于发布医疗器械质量管理体系年度自查报告编写指南的通告\n\n根据上述已知信息，请将'NMPA Issued the Administrative Measures for Sampling Inspection of Medical Device Quality'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于印发医疗器械质量抽查检验管理办法的通知"
    },
    {
        "instruction":"已知信息：\n'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'可被翻译为：第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'Class III medical device distribution shall be subject to licensing management; Class II medical device distribution shall be subject to filing management, while Class I medical device distribution could be carried out without licensing or filing.'可被翻译为：经营第三类医疗器械实行许可管理，经营第二类医疗器械实行备案管理，经营第一类医疗器械不需要许可和备案。\n'Article 23 If an entity applies for Class III Medical Device Distribution License and files for Class II medical device distribution concurrently, or has obtained Class III Medical Device Distribution License when filing for Class II medical device distribution, then it may be exempted from submitting corresponding materials.'可被翻译为：第二十三条  同时申请第三类医疗器械经营许可和进行第二类医疗器械经营备案的，或者已经取得第三类医疗器械经营许可进行第二类医疗器械备案的，可以免予提交相应资料。\n'If the product is not managed as medical device in the country (region) where the applicant or filing entity is registered or the manufacture is carried out, the applicant or filing entity shall provide relevant proof documents, including the permission for distribution of sold product in the country (region) where the applicant or filing entity is registered or the manufacture is carried out.'可被翻译为：申请人或者备案人注册地或者生产地址所在国家（地区）未将该产品作为医疗器械管理的，申请人或者备案人需提供相关证明文件，包括注册地或者生产地址所在国家（地区）准许该产品上市销售的证明文件。\n\n根据上述已知信息，请将'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'The process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and\/or filtration into its components, and returning those not required to the donor.'可被翻译为：从献血者身上选择性地提取一种或多种血液成分的过程，通过离心和\/或过滤将其分离到其成分中，并将不需要的成分返回给献血者。\n'The liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and\/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.'可被翻译为：从含有抗凝剂的容器中收集的血液中分离细胞成分后，或在单采过程中通过抗凝血的连续过滤和\/或离心分离，用于进一步生产的人体血液的液体部分。\n'A person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.'可被翻译为：在同一血库按最低时间间隔定期捐献血液、血液成分或血浆的人。\n'blood collection'可被翻译为：血液采集\n\n根据上述已知信息，请将'The procedure whereby a single donation of blood is collected in an anticoagulant and\/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and\/or coagulation activation of the resulting blood donation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单次献血的血液在抗凝和\/或稳定溶液中收集的过程，在设计的条件下尽量减少微生物污染、细胞损伤和\/或由此产生的献血的凝血激活。"
    },
    {
        "instruction":"已知信息：\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n'Article 2 These Provisions shall apply to medical device manufacturing activities and its supervision and administration within the territory of the People’s Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械生产活动及其监督管理，应当遵守本办法。\n'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。\n'Article 2 These Provisions shall apply to medical device distribution activities and their supervision and administration within the territory of the People's Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械经营活动及其监督管理，应当遵守本办法。\n\n根据上述已知信息，请将'Article 3 The formulation and revision, implementation, supervision and administration of medical device standards within the territory of the People’s Republic of China shall conform to laws, administrative regulations and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 在中华人民共和国境内从事医疗器械标准的制修订、实施及监督管理，应当遵守法律、行政法规及本办法的规定。"
    },
    {
        "instruction":"已知信息：\n'(II) Class II products'可被翻译为：（二）第二类产品\n'(III) Class III products'可被翻译为：（三）第三类产品\n'(I) Class I products'可被翻译为：（一）第一类产品\n'Category 2 Products'可被翻译为：第二类产品\n\n根据上述已知信息，请将'Products not clearly defined as class I and class III products are class II products, mainly including:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除已明确为第一类、第三类的产品，其他为第二类产品，主要包括："
    },
    {
        "instruction":"已知信息：\n'ai-acid glycoprotein chiral stationary phase'可被翻译为：5酸性糖蛋白手性固定相\n'A polysaccharide chiral stationary phase using cellulose and amylose derived from different functional groups as stationary phases.'可被翻译为：一种利用不同官能团衍生化的纤维素和直链淀粉作为固定相的多聚糖手性固定相。\n'A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis.'可被翻译为：以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。\n'cellulose-based chiral stationary phase'可被翻译为：纤维素型手性固定相\n\n根据上述已知信息，请将'A chiral stationary phase of polymers prepared by coating phase and bonding phase of photoactive amino acids or pipercoic acid as chiral selective factors, which is mainly used for the analysis of amino acids and their derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以光活性氨基酸或哌可酸作为手性选择因子的涂渍相和键合相制备的，主要用于氨基酸及其衍生物分析的一种高聚物手性固定相。"
    },
    {
        "instruction":"已知信息：\n'pharmaceutical marketing'可被翻译为：医药营销学\n'A comprehensive applied technical discipline to study the preparation theory, production technology and quality control of drugs and their formulations, with the purpose of ensuring the effectiveness, safety and stability of drugs, and improving the compliance and bioavailability of drugs in clinical use.'可被翻译为：研究药物及其组方制剂的制备理论、生产技术和质量控制的综合应用技术学科，其目的在于保证药物有效性、安全性和稳定性，提高药物的临床使用的顺应性和生物利用度。\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n'The discipline that studies the specific problems of how to rationally select drugs and drug methods and formulate drug treatment plans in the prevention and treatment of diseases. Pharmacotherapeutics is the practice of pharmacological theory in clinical use of drugs.'可被翻译为：研究在疾病防治中如何合理地选择药物和用药方法及制定药物治疗方案等具体问题的学科。药物治疗学是药理学理论在临床用药的实践。\n\n根据上述已知信息，请将'An applied discipline that applies marketing principles, methods, and strategies to the study of the characteristics and needs of the pharmaceutical market, and how to provide pharmaceutical products and services to meet those needs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用市场营销学原理、方法和策略，研究医药市场特征、需求，以及如何提供医药产品和服务满足需求的一门应用性学科。"
    },
    {
        "instruction":"已知信息：\n'The additive or synergistic effect produced by the combination of drugs with identical properties of action.'可被翻译为：作用性质相同药物的联合应用，产生的相加或协同效应。\n'The combination of two drugs shows an effect significantly greater than the sum of the two.'可被翻译为：两药联合应用所显示的效应明显超过两者之和。\n'When at least two drugs are used at the same time or at a period of time apart, due to the reaction between drugs or drug-body-drug reaction, the original drug disposal process in the body, the sensitivity of tissues to drugs or the physical and chemical properties of drugs, and produce beneficial or adverse effects that are not found in a single drug.'可被翻译为：同时或相隔一段时间先后使用至少两种药物时，由于药物之间或药物-机体-药物之间的反应，改变了原来体内对药物的处置过程、组织对药物的感受性或药物的理化性质，而产生单种药物所没有的有益作用或不良作用。\n'The relationship between the chemical structure of a drug or other active substance and its physiological activity.'可被翻译为：药物或其他活性物质的化学结构与其生理活性之间的关系。\n\n根据上述已知信息，请将'The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种以上药物作用等于每一种化合物质单独作用的总和。"
    },
    {
        "instruction":"已知信息：\n'A WHO-type certificate of the form described in Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva,World Health Organization, 1998.'可被翻译为：在国际贸易中流通的药品质量WHO认证计划实施指南中所述形式的世卫组织类型证书。日内瓦，世界卫生组织，1998年。\n'9. WHO good manufacturing practices: guidelines on validation. Appendix 6. Guidelines on qualification. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).'可被翻译为：WHO GMP验证指南，WHO TRS1019附录3附录6确认指南，2019\n'certificate of pharmaceutical product'可被翻译为：医药产品证书\n'4. WHO good manufacturing practices: guidelines on validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).'可被翻译为：WHO GMP验证指南，WHO TRS1019附录3，2019\n\n根据上述已知信息，请将'A certificate of pharmaceutical product of the type defined in the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce* .\n\n*World Health Organization. WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva, World Health Organization, 2000 WHO\/EDM\/QSM\/2000.2.\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes. html).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在国际贸易中流通的药品质量世界卫生组织认证计划中定义的药品类型的证书*。\n\n*世界卫生组织。在国际贸易中流通的药品质量世界卫生组织认证计划。日内瓦，世界卫生组织，2000年，世界卫生组织\/EDM\/QSM\/2000.2。\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes。html)。"
    },
    {
        "instruction":"已知信息：\n'A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'可被翻译为：无菌加工区内产品和关键表面暴露在环境中的位置。\n'critical zone'可被翻译为：临界区域\n'Critical surfaces - Surfaces that may come directly into contact with, or directly affect, a sterile product or its containers or closures. Critical surfaces are rendered sterile prior to the start of the manufacturing operation, and sterility is maintained throughout processing.'可被翻译为：关键表面：可能直接接触或直接影响无菌产品或其容器或密封件的表面。关键表面在生产操作开始前已经过灭菌，并在整个工艺中保持无菌。\n'A surface that may come directly into contact with, or directly affect, a sterile product or its containers or closures. Critical surfaces are rendered sterile prior to the start of the manufacturing operation and sterility is maintained throughout processing.'可被翻译为：可能直接接触或直接影响无菌产品或其容器或封盖的表面。关键的表面在生产操作开始前被消毒，并在整个加工过程中保持无菌。\n\n根据上述已知信息，请将'Critical zone - A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"关键区：位于无菌工艺区内的、产品和关键表面暴露于其中的位置。"
    },
    {
        "instruction":"已知信息：\n'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'可被翻译为：具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。\n'Drugs that inhibit recurrent episodes of brain dysfunction caused by abnormal firing of brain cells. According to its mechanism of action can be divided into: ① sodium channel regulator; ② gamma-aminobutyric acid regulator; ③ excitatory amino acid receptor antagonists and excitatory amino acid release regulators; ④ anti-absence seizure agents related to ethansuxamine (selective calcium channel blockers); ⑤ other drugs whose mechanisms are not well defined.'可被翻译为：抑制由脑细胞异常放电引起的脑功能障碍反复发作的药物。按其作用机制可分为：①钠通道调节剂；②γ-氨基丁酸调节剂；③兴奋性氨基酸受体拮抗剂和兴奋性氨基酸释放调节剂；④与乙琥胺有关的抗失神发作药（选择性钙通道阻滞剂）；⑤其他机制尚不明确的药物。\n'Drugs that act like the endogenous transmitter of acetylcholine. Acts directly on choline receptors, such as acetylcholine and pilocarpine.'可被翻译为：作用类似乙酰胆碱内源性递质的药物。直接作用于胆碱受体，如乙酰胆碱和毛果芸香碱。\n'The role of drugs in enhancing the physiological and biochemical functions of the body.'可被翻译为：药物使机体生理生化功能增强的作用。\n\n根据上述已知信息，请将'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In accordance with degree of risks of the products and enterprise, the drug regulatory department shall make graded management of the registrant, filing entity or contract manufacturer of medical devices as well as dynamic adjustment.'可被翻译为：第四十八条  药品监督管理部门依据产品和企业的风险程度，对医疗器械注册人、备案人、受托生产企业实行分级管理并动态调整。\n'Article 53 The drug regulatory department shall implement risk classification management based on the operation of quality control system, post-filing supervision, and post-marketing supervision and inspection status of the filing persons, the domestic responsible person and the cosmetic manufacturer.'可被翻译为：第五十三条 药品监督管理部门根据备案人、境内责任人、化妆品生产企业的质量管理体系运行、备案后监督、产品上市后的监督检查情况等，实施风险分类分级管理。\n'Article 47 The drug regulatory department shall establish and improve a sound system for professional and specialized team of medical devices inspectors, and designate sufficient inspectors in accordance with the regulatory authority, industry scale and inspection task, etc., to guarantee the inspection needs effectively.'可被翻译为：第四十七条  药品监督管理部门应当建立健全职业化、专业化医疗器械检查员制度，根据监管事权、产业规模以及检查任务等，配备充足的检查员，有效保障检查工作需要。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall organize and implement graded supervision and administration, in accordance with the list of products under key regulation and the management condition of manufacturing quality of medical devices, as well as in combination with medical device adverse events, product complaint reports and enterprise credit status, etc.'可被翻译为：省、自治区、直辖市药品监督管理部门依据重点监管产品目录以及医疗器械生产质量管理状况，结合医疗器械不良事件、产品投诉举报以及企业信用状况等因素，组织实施分级监督管理工作。\n\n根据上述已知信息，请将'Article 47 The drug regulatory departments shall implement classified and graded management and make dynamic adjustment in accordance with quality management of the medical device distributors and degree of risk of the distributed medical device products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  药品监督管理部门根据医疗器械经营企业质量管理和所经营医疗器械产品的风险程度，实施分类分级管理并动态调整。"
    },
    {
        "instruction":"已知信息：\n'Article 63 Terms used in these Provisions are defined as follows:'可被翻译为：第六十三条 本办法下列用语的含义：\n'Article 3 The terms used in the Rules are defined as follows:'可被翻译为：第三条 本规则有关用语的含义是：\n'Article 17 The following terms are defined as follows:'可被翻译为：第十七条 本规则下列用语的含义：\n'3. Glossary'可被翻译为：术语\n\n根据上述已知信息，请将'Article 312: Glossary:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百一十二条 本规范下列术语（按汉语拼音排序）的含义是："
    },
    {
        "instruction":"已知信息：\n'Review and re-check results shall be fed back to MAHs. In case of any objection to the evaluation results of MAHs, MAHs may be required to carry out re-evaluation again.'可被翻译为：审核和复核结果应当反馈持有人。对持有人的评价结果存在异议的，可以要求持有人重新开展评价。\n'Article 56 In case of carrying out medical device re-evaluation, MAHs shall, based on the product safety and effectiveness information learned after products are marketed, clinical data and use experiences, re-evaluate the summary information, study data, clinical evaluation materials, product risk analysis materials, product technical requirements, instructions, labels and other technical data and content in original registration materials of medical devices.'可被翻译为：第五十六条  持有人开展医疗器械再评价，应当根据产品上市后获知和掌握的产品安全有效信息、临床数据和使用经验等，对原医疗器械注册资料中的综述资料、研究资料、临床评价资料、产品风险分析资料、产品技术要求、说明书、标签等技术数据和内容进行重新评价。\n'Article 60 Monitoring agencies shall review the re-evaluation reports by MAHs and submit the review opinions to the corresponding drug regulatory departments.'可被翻译为：第六十条  监测机构对收到的持有人再评价报告进行审核，并将审核意见报相应的药品监督管理部门。\n'Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.'可被翻译为：第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。\n\n根据上述已知信息，请将'Article 55 In case of any of following situations, MAHs shall voluntarily carry out re-evaluation and take corresponding measures based on re-evaluation conclusions:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十五条  有下列情形之一的，持有人应当主动开展再评价，并依据再评价结论，采取相应措施："
    },
    {
        "instruction":"已知信息：\n'Article 5    The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.'可被翻译为：第五条 药品说明书和标签的文字表述应当科学、规范、准确。非处方药说明书还应当使用容易理解的文字表述，以便患者自行判断、选择和使用。\n'Article 143 The drug insert sheet and label shall be provided by the applicant. The Center for Drug Evaluation of the State Food and Drug Administration shall review the contents thereof except the manufacturer information, and the State Food and Drug Administration shall review and approve the data when approving the drug production.'可被翻译为：第一百四十三条 药品说明书和标签由申请人提出，国家食品药品监督管理局药品审评中心根据申报资料对其中除企业信息外的内容进行审核，在批准药品生产时由国家食品药品监督管理局予以核准。\n'Provisions for Drug Insert Sheets and Labels'可被翻译为：药品说明书和标签管理规定\n'Article 145 The applicant shall print the insert sheets and labels according to the format and requirements established by the State Food and Drug Administration, and in conformity with the contents approved.'可被翻译为：第一百四十五条 申请人应当按照国家食品药品监督管理局规定的格式和要求、根据核准的内容印制说明书和标签。\n\n根据上述已知信息，请将'The applicant shall be responsible for making the drug insert sheet and label scientific, standard and accurate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请人应当对药品说明书和标签的科学性、规范性与准确性负责。"
    },
    {
        "instruction":"已知信息：\n'Article 28 If a medical device manufacturer violates laws, regulations and rules and causes defects in the marketed medical devices, administrative penalties shall be imposed according to law. For the manufacturer who has taken recall measures to initiatively eliminate or reduce the harmful consequences, the food and drug regulatory department shall impose a lighter or mitigated penalty according to the Law of the People's Republic of China on Administrative Penalty; for the manufacturer who has committed minor violations and made prompt corrections but has not caused any serious consequences, the punishment shall be exempted.'可被翻译为：第二十八条 医疗器械生产企业因违反法律、法规、规章规定造成上市医疗器械存在缺陷，依法应当给予行政处罚，但该企业已经采取召回措施主动消除或者减轻危害后果的，食品药品监督管理部门依照《中华人民共和国行政处罚法》的规定给予从轻或者减轻处罚；违法行为轻微并及时纠正，没有造成危害后果的，不予处罚。\n'Article 74 In any of the following circumstances for medical device distributing enterprises and user facility, the drug regulatory departments and the health administrative departments above county level according to their respective responsibilities should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction.'可被翻译为：第七十四条  医疗器械经营企业、使用单位有下列情形之一的，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 32 In case of identifying or knowing group adverse events of medical device, MAHs shall immediately suspend the production and sales, and notify user facility to immediately stop using relevant medical devices. At the same time, MAHs shall carry out investigation and self-inspection of production quality management system and report to the drug regulatory departments and monitoring agencies of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate and where the adverse events occur within 7 days.'可被翻译为：第三十二条  持有人发现或者获知其产品的群体医疗器械不良事件后，应当立即暂停生产、销售，通知使用单位停止使用相关医疗器械，同时开展调查及生产质量管理体系自查，并于7日内向所在地及不良事件发生地省、自治区、直辖市药品监督管理部门和监测机构报告。\n'Article 71 In any of the following circumstances for medical device distributing enterprises and user facility, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments and the health administrative departments above the county level according to their respective responsibilities should order to make correction and give warning, and a  fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production shall be ordered to stop until the relevant certificates are revoked by the original issuing authority:'可被翻译为：第七十一条  医疗器械经营企业、使用单位有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件：\n\n根据上述已知信息，请将'Article 75 MAHs, distributing enterprises and user facility report, investigate, evaluate and dispose medical device adverse events in accordance with the requirements of the Provisions to proactively eliminate or reduce serious consequence, they shall impose a lighter or mitigated punishment for the relevant violations in accordance with Law of the People's Republic of China on Administrative Penalties, and impose no punishment for those having mild violations and making timely correction without causing serious consequences but are not exempt from other legal liabilities according to laws.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十五条  持有人、经营企业、使用单位按照本办法要求报告、调查、评价、处置医疗器械不良事件，主动消除或者减轻危害后果的，对其相关违法行为，依照《中华人民共和国行政处罚法》的规定从轻或者减轻处罚。违法行为轻微并及时纠正，没有造成危害后果的，不予处罚，但不免除其依法应当承担的其他法律责任。"
    },
    {
        "instruction":"已知信息：\n'Cephalin that eliminates the acyl group on 7-amides.'可被翻译为：消去7-位酰胺基上酰基的头抱菌素。\n'penicillin'可被翻译为：青霉素\n'6-aminopenicillanic acid'可被翻译为：6-氨基青霉烷酸\n'Cephalosporin C with the 3-lateral chain acetyl removed.'可被翻译为：脱去3-位侧链乙酰基的头抱菌素C。\n\n根据上述已知信息，请将'Penicillin with the elimination of the 6-amide-superacyl group.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"消去6-位酰胺基上酰基的青霉素。"
    },
    {
        "instruction":"已知信息：\n'The monitoring  of grade A  should  demonstrate the maintenance  of aseptic processing  conditions  during critical operations. Monitoring should be performed at locations posing the highest risk of contamination to the sterile  equipment  surfaces,  containers,  closures  and  product.  The  selection  of  monitoring  locations  and  the orientation and positioning of sampling devices should be justified and appropriate to obtain reliable data from the critical zones.'可被翻译为：A 级区的监测应证明在关键操作中都维持了无菌工艺条件。监测位置应为对无菌设备表面、容器、密封件 和产品造成最高污染风险的位置。监测位置的选择以及取样装置的定位和放置应证明合理，适合从关键区域获取可靠的数据。\n'The adoption of suitable alternative monitoring  systems such as rapid methods should be considered by manufacturers in order to expedite the detection of microbiological contamination issues and to reduce the risk to product.  These  rapid   and  automated  microbial   monitoring  methods  may  be   adopted   after validation  has demonstrated their equivalency or superiority to the established methods.'可被翻译为：生产商应考虑釆用合适的替代监测系统（例如快速方法），以加速微生物污染问题的发现并降低对产品的风险。在通过验证证明对已建立的方法具有等效性或优越性后，可以采用这些快速或自动微生物监测方法。\n'3. Environmental monitoring- Types of equipment, calibration, operation and maintenance; surface, air, personnel and water; critical work areas for aseptically filled products (ISO 5, isolators, etc.); surface contact, surface sanitizer neutralizing media (e.g., TSA w\/ Lecithin & Polysorbate 80), observe sampling technique, sample must represent dynamic\/operational conditions, and trending\/CAPA.'可被翻译为：环境监测—设备类型、校验、操作和维护；表面、空气、人员和水；无菌灌装产品的关键工作区域（ISO 5 级，隔离器等）；表面接触，表面灭菌剂中和培养基（例如，TSA w\/卵磷脂和吐温 80）、观察取样技术、样品必须代表动态\/运行条件，以及趋势分析\/CAPA\n'Where aseptic operations are performed, microbial monitoring should be frequent using a combination of methods such as settle plates, volumetric air sampling, glove, gown and surface sampling (e.g. swabs and contact plates). The method of sampling used should be justified within the CCS and should be demonstrated not to have a detrimental impact on grade A and B airflow patterns. Cleanroom and equipment surfaces should be monitored\nat the end of an operation.'可被翻译为：当进行无菌操作时，应采用多种方法经常进行微生物监测，例如沉降碟、定量空气釆样、手套、洁净服和 表面采样（例如棉签擦拭和接触碟）。所使用的采样方法的合理性应在 CCS 中进行论证，并证明不会对 A级和 B 级的气流模式造成不利影响。在操作结束后应对洁净室和设备表面进行监测。\n\n根据上述已知信息，请将'Note 1: It should be noted that the types of monitoring methods listed in the table above are examples and other methods can be used provided they meet the intent of providing information across the whole of the critical process where product may be contaminated (e.g. aseptic line set-up, aseptic processing, filling and lyophilizer\nloading).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注 1：应注意，上表中列出的监测方法类型是示例，可以使用其它方法，只要这些方法满足相同目的，即在产品可能被污染是提供整个关键工艺过程的信息（例如无菌生产线组装、无菌工艺、灌装和冻干机上料）。"
    },
    {
        "instruction":"已知信息：\n'The sum total of the complete set of genes contained in an individual or cell.'可被翻译为：个体或细胞所含的全套基因的总和。\n'gene pool'可被翻译为：基因库\n'genetic information'可被翻译为：遗传信息\n'The phenomenon of making a large number of copies of specific genes (groups) under certain conditions.'可被翻译为：在一定条件下，把特定的基因（群）加以大量复制的现象。\n\n根据上述已知信息，请将'The sum of all the genes carried by all the individuals of a population.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个种群全部个体所带有的全部基因的总和。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department may require the drug manufacturer, distributor and user to stop selling and using the drug immediately if necessary.'可被翻译为：必要时，药品监督管理部门可以要求药品生产企业、经营企业和使用单位立即停止销售和使用该药品。\n'When necessary, the food and drug regulatory department may require the medical device manufacturers, distributors, and using units to immediately suspend the manufacture, sale and use, and inform the users to immediately suspend the use of the defective products.'可被翻译为：必要时，食品药品监督管理部门可以要求医疗器械生产企业、经营企业和使用单位立即暂停生产、销售和使用，并告知使用者立即暂停使用该缺陷产品。\n'Raw materials, excipients, packaging materials, and equipment used specifically for producing counterfeit or inferior drugs shall be confiscated.'可被翻译为：对生产者专门用于生产假药、劣药的原料、辅料、包装材料、生产设备予以没收。\n'Inspection agencies shall make recommendations on risk control where emergency measures may be required according to the degree of risks and scope involved that are identified in the inspection. The drug regulatory departments receiving the notification shall notify the lot release institution to disapprove or suspend the lot release for relevant products or all products of the lot release applicant and order the lot release applicant to make rectification.'可被翻译为：检查机构应当根据检查发现的风险程度和涉及范围，对可能需要采取紧急措施的，提出风险控制建议。接到通报的药品监督管理部门应当通知批签发机构对批签发申请人的相关产品或者所有产品不予批签发或者暂停批签发，并责令批签发申请人整改。\n\n根据上述已知信息，请将'Where the immediate packaging materials and containers are not up to standard, the drug regulatory department shall order a stop to the use of the materials and containers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对不合格的直接接触药品的包装材料和容器，由药品监督管理部门责令停止使用。"
    },
    {
        "instruction":"已知信息：\n'Changes in compatibility between drugs that are not conducive to application and treatment under certain conditions.'可被翻译为：在一定条件下，产生的不利于应用和治疗的合用药物之间的配伍变化。\n'When the drugs are compatible, chemical reactions occur, and the drugs have different degrees of deterioration or failure, reducing the efficacy or increasing side effects.'可被翻译为：药物配伍时，发生化学反应，而使药物产生不同程度的变质或失效，降低疗效或增加副作用。\n'compatibility of drugs'可被翻译为：药物配伍\n'The extent to which the nature and quality of a drug product are affected by the means and processes by which it is prepared.'可被翻译为：药品的性质和质量受制剂手段和过程影响的程度。\n\n根据上述已知信息，请将'Physical properties change when drugs are compatible, so that they can not meet the requirements of the preparation, reduce the efficacy or increase side effects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物配伍时发生的物理性质改变，因而得不到符合要求的制剂、降低疗效或增加副作用。"
    },
    {
        "instruction":"已知信息：\n'(i) This part does not apply to records required to be established or maintained by part 117 of this chapter. Records that satisfy the requirements of part 117 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第117部分要求建立或维护的记录。符合本章第117部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(k) This part does not apply to records required to be established or maintained by part 112 of this chapter. Records that satisfy the requirements of part 112 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第112部分要求建立或维护的记录。符合本章第112部分要求的同时 也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(j) This part does not apply to records required to be established or maintained by part 507 of this chapter. Records that satisfy the requirements of part 507 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第507部分要求建立或维护的记录。符合本章第507部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(n) This part does not apply to records required to be established or maintained by subpart O of part 1 of this chapter. Records that satisfy the requirements of subpart O of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第1部分的O部分要求建立或维护的记录。符合本章第1部分的O部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n\n根据上述已知信息，请将'(o) This part does not apply to records required to be established or maintained by part 121 of this chapter. Records that satisfy the requirements of part 121 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本部分不适用于根据本章第121部分要求建立或维护的记录。符合本章第121部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the \"Regulations on the Trial Implementation of Professional Titles for Health Technical Personnel,\" individuals who have obtained qualifications for pharmaceutical technical positions include Chief Pharmacist, Deputy Chief Pharmacist, Supervising Pharmacist, Pharmacist, and Pharmacy Technician.'可被翻译为：按照《卫生技术人员职务试行条例》规定，取得药学专业技术职务任职资格人员，包括主任药师、\n副主任药师、主管药师、药师和药士。\n'(1) The qualification, experience of the investigator and whether he\/she has sufficient time to participate in the clinical trial.'可被翻译为：（一）研究者的资格、经验以及是否有充分的时间参加该临床试验。\n'The clinical trial institution chosen shall be a qualified medical device clinical trial institution of which the facilities and conditions meet the requirement for safe and effective clinical trials. The investigator shall have the expertise, qualification and competencies and shall be trained to conduct the clinical trial.'可被翻译为：所选择的试验机构应当是经资质认定的医疗器械临床试验机构，且设施和条件应当满足安全有效地进行临床试验的需要。研究者应当具备承担该项临床试验的专业特长、资格和能力，并经过培训。\n'2. Investigators and clinical trial institutions designate qualified pharmacists or other personnel to manage investigational medicinal products.'可被翻译为：2.研究者和临床试验机构指派有资格的药师或其他人员管理试验用药品。\n\n根据上述已知信息，请将'(1) Having the professional technical titles and qualifications of deputy chief physician, associate professor and associate investigator in the clinical trial institution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）在该临床试验机构中具有副主任医师、副教授、副研究员等副高级以上相关专业技术职称和资质；"
    },
    {
        "instruction":"已知信息：\n'(3) Undertake technical guidance of medical device standards in each specialized field and assist in solving technical problems during the implementation of standards;'可被翻译为：（三）承担本专业领域医疗器械标准的技术指导工作，协助解决标准实施中的技术问题；\n'(2) Undertake the drafting, public consultation, technical review of medical device standards and other organizational work in each specialized field and be responsible for the technical contents and quality of the standards;'可被翻译为：（二）承担本专业领域医疗器械标准起草、征求意见、技术审查等组织工作，并对标准的技术内容和质量负责；\n'(5) Be responsible for the follow-up assessment of the implementation of medical device standards in each specialized field;'可被翻译为：（五）负责本专业领域医疗器械标准实施情况的跟踪评价;\n'(6) Undertake work relevant to medical device international standardization activities and foreign exchanges and cooperation;'可被翻译为：（六）承担医疗器械国际标准化活动和对外合作交流的相关工作；\n\n根据上述已知信息，请将'(6) Be responsible for the consultation and explanation on technical contents of the medical device standards in each specialized field;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）负责本专业领域医疗器械标准技术内容的咨询和解释;"
    },
    {
        "instruction":"已知信息：\n'Release of a drug (or drugs) at a time other than immediately following oral administration.'可被翻译为：口服后，药物在一定时间后才释放，而不是立即释放。\n'A preparation that does not release the drug immediately after administration. These include enteric-soluble preparations, colon-locating preparations, and pulsing preparations.'可被翻译为：在给药后不立即释放药物的制剂。包括肠溶制剂、结肠定位制剂和脉冲制剂。\n'Preparations that release no or little of the drug in a prescribed acidic medium and most or all of the drug in a pH6.8 phosphate buffer for the required amount of time.'可被翻译为：在规定的酸性介质中不释放或几乎不释放药物，而在要求的时间内，于pH6.8磷酸盐缓冲液中大部分或全部释放药物的制剂。\n'Products which are formulated to make the drug available over an extended period after administration.'可被翻译为：某种制剂，由于处方设计，在服用后，能使药物在一段时间内缓慢释放。\n\n根据上述已知信息，请将'A preparation that does not release the drug immediately, but releases the drug suddenly one or more times under certain conditions (such as after a certain time or under a certain pH or certain enzymes in body fluids).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不立即释放药物，而在某种条件下（如在体液中经过一定时间或一定pH或某些酶作用下）一次或多次突然释放药物的制剂。"
    },
    {
        "instruction":"已知信息：\n'The validation of the receptor sample analytical method should include relevant qualifications of dilution integrity, if applicable, as well as stability assessments with the highest relevant temperature in the receptor solution for the longest relevant duration; the highest relevant temperature may be warmer than the IVRT membrane surface temperature because the temperature of the receptor solution is often higher than the temperature at the surface of the membrane (e.g., the temperature of the receptor solution may be 34°C when the temperature of membrane surface is 32°C, so stability assessments with the IVRT receptor solution may be performed at 34°C for 6 hours; the temperature would be higher for an IVRT with a vaginal gel, for example).'可被翻译为：如适用，接收液中样品分析方法的验证应包括相关的稀释完整性确认，以及样品在最高相关温度的接收液中放置最长相关时间的稳定性评估；最高相关温度可以略高于IVRT膜表面温度，因为接收液的温度通常高于膜表面温度（例如，当膜表面温度为32℃时，接收液温度可能是34℃，因此，IVRT接收液的稳定性评估可以设定为34℃维持6小时；而在阴道凝胶制剂的IVRT研究中，温度会更高）。\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVPT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior and during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. Frozen biological membranes should be thawed at ambient temperature prior to assembling on the diffusion cells. Once mounted, the skin sections should be allowed to equilibrate to a physiologically relevant state of hydration and temperature (e.g., for 30 min at a membrane surface temperature of 32°).'可被翻译为：在IVPT开始运行之前，系统应在预先确定的实验条件下进行适当的平衡。在实验之前和实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。冷冻的生物膜应在室温下解冻，然后组装在扩散池上。一旦安装，皮肤切片应该被允许平衡到生理上相关的水合作用和温度状态(例如，在32°的膜表面温度下30分钟)。\n'The system should be appropriately equilibrated under the predefined experimental conditions prior to the beginning of the IVRT run. No air bubbles should be present in the receptor solution (under the membrane) immediately prior to, or during the experiment; if appropriate, the receptor solution can be degassed. The system temperature (including the membrane surface temperature and the circulating water bath temperature, if applicable) should be stable and well controlled. IVRT membranes can be presoaked with receptor solution prior to assembling in the diffusion cell or equilibrated with the receptor solution in situ within the diffusion cell prior to dosing (e.g., for 30 min at a membrane temperature of 32°) depending upon the method.'可被翻译为：在IVRT开始运行之前，系统应在预定的实验条件下适当地平衡。在实验前或实验过程中，受体溶液(膜下)中不应出现气泡;如果合适，受体溶液可以脱气。系统温度(包括膜表面温度和循环水浴温度，如适用)应稳定且控制良好。IVRT膜在装配于扩散池之前可以用受体溶液预浸泡，或者在给药之前用扩散池内的受体溶液原位平衡(例如，在32°的膜温度下30分钟)，具体取决于方法。\n'During the entire test, the nominal system conditions, like the temperature of the receptor solution, should be maintained so that the temperature at the membrane remains within specified parameters (e.g., 32 ± 1°) for the duration of the IVRT. The temperature control qualification is described under Equipment.'可被翻译为：在整个测试过程中，应保持标称系统条件，如受体溶液的温度，使膜上的温度在IVRT期间保持在规定的参数范围内(例如，32±1°)。温度控制鉴定在设备一节中描述。\n\n根据上述已知信息，请将'3. Stability of the temperature measured at the membrane surface (e.g., 32 ± 1°) across a relevant duration (e.g., 6 h for IVRT or 48 h for IVPT)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在相关持续时间内(例如，IVRT为6小时或IVPT为48小时)膜表面测量温度的稳定性(例如，32±1°)"
    },
    {
        "instruction":"已知信息：\n'Article 2 This Procedure is applicable to the domestic registration inspection of drug development site and manufacturing site organized by the National Medical Products Administration (NMPA). The Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) organizes the implementation of registration inspection work.'可被翻译为：第二条 国家药品监督管理局组织的在境内开展的药品研制、生产现场注册核查适用本程序。国家药品监督管理局食品药品审核查验中心(以下简称核查中心)组织实施注册核查工作。\n'Article 10 CFDI shall establish a quality management system related to registration inspection, formulate standard operating procedures for registration inspection and the corresponding Key Points and Determination Principles of Drug Registration Inspection, strengthen the construction of the inspector team, establish a registration inspection inspector database, and regulate the related work of registration inspection.'可被翻译为：第十条 核查中心建立注册核查相关质量管理体系，制定注册核查的标准操作程序及相应的《药品注册核查要点与判定原则》,加强检查员队伍建设，建立注册核查检查员库，规范注册核查有关工作。\n'Article 4 If the Center for Drug Evaluation of NMPA (hereinafter referred to as the CDE) decides to initiate a registration inspection during the review of a drug registration application, it shall notify the CFDI to conduct an inspection, provide relevant information required for the inspection, and at the same time inform the applicant and the relevant provincial authority where the applicant or the manufacturing site is located.'可被翻译为：第四条 国家药品监督管理局药品审评中心(以下简称药品审评中心) 在药品注册申请审评期间，决定启动注册核查的，通知核查中心组织实施核查，提供核查所需的相关材料，同时告知申请人以及申请人或者生产企业所在地省级局。\n'Article 9 CFDI and the institutions of drug evaluation, drug testing and others shall establish a joint mechanism for registration inspection, evaluation, and registration test, and strengthen communication, exchanges, and coordination to research and solve problems in the registration inspection work.'可被翻译为：第九条 核查中心与药品审评、药品检验等机构建立注册核查与审评、注册检验的工作衔接机制，并加强沟通和交流，共同协调、研究和解决注册核查工作中出现的问题。\n\n根据上述已知信息，请将'Article 18 CFDI explores the establishment of a caused-related registration inspection model based on information such as the drug product archives and institutional files of the NMPA; explores the application of off-site inspection methods based on the development of information management methods; continues to improve the system of technical guidelines for inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 核查中心基于国家药品监督管理局药品品种档案和机构档案等信息，探索建立基于风险的注册核查模式；基于信息化管理手段的发展，探索应用非现场的核查方式；持续完善核查相关技术指导原则体系。"
    },
    {
        "instruction":"已知信息：\n'A gas that, when packaged for transport, is partially liquid (or solid) at a temperature above –50 °C.'可被翻译为：一种气体，在包装运输时，在-50°C以上的温度下部分为液体(或固体)。\n'Any substance that is completely gaseous at 1.013 bar and +20 °C or has a vapour pressure exceeding 3 bar at +500 °C.'可被翻译为：在1.013 bar和+20°C时完全气态或在+500°C时蒸气压超过3bar的任何物质。\n'cryogenic gas'可被翻译为：低温气体\n'A gas that liquefies at 1.013 bar at temperatures below –150 °C .'可被翻译为：在低于-150°C的温度下在1.013巴液化的气体。\n\n根据上述已知信息，请将'A gas that, when packaged under pressure for transport, is entirely gaseous at –50 °C; this category includes all gases with a critical temperature less than or equal to –50 °C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种在压力下包装运输时，在-50℃时完全为气态的气体;这一类气体包括临界温度小于或等于-50℃的所有气体。"
    },
    {
        "instruction":"已知信息：\n'Gauze, Purified Cotton, Sutures and Surgical Dressings'可被翻译为：纱布、净化棉布、缝合线和外 科绷带\n'The USP method for analysis of surgical dressing\/cotton\/gauze (in packages) calls for a minimum quantity of 100 mg, to be tested in each medium. It is recommended that an entire unit shall be tested in each medium for individually packaged single-use articles.'可被翻译为：USP 分析手术敷料\/棉花\/纱布（包装内）的方法要求最少 100 mg，在每种培养基中进行 测试。对于单独包装的一次性用品，建议在每种培养基中对整个单元进行测试。\n'Finished medical devices may also be pooled into a composite sample and assayed for bacterial endotoxins. Testing for medical devices should be conducted using rinsing\/eluting and sampling techniques as described in ISO 10993-1 and ISO 10993-12, as also used for inhibition\/enhancement.'可被翻译为：成品组合器械可能亦会合并成组合样品进行细菌内毒素检测。器械的检测应该使用 ISO 10993-1 和 ISO 10993-12所述淋洗\/洗脱和取样技术，这也用于抑制\/增强。\n'IV. Biological test of medical devices'可被翻译为：四、关于医疗器械生物学试验\n\n根据上述已知信息，请将'Analysis of Medical Devices (ex. Purified Cotton, Gauze, Sutures and Surgical Dressings)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械的分析（除净化棉、纱布、缝合线和手术敷料外）"
    },
    {
        "instruction":"已知信息：\n'The following topics should be reviewed and evaluated by a microbiologist although some aspects will also be covered by the Consumer Safety Officer during the inspection.'可被翻译为：虽然消费品安全官员亦要检查有些问题，但在检查期间，微生物专家应查看并评价以下问题\n'A. Microbiological Issues for Inspection of Pharmaceutical Laboratories'可被翻译为：药物实验室检查的微生物问题\n'B. Microbiological Issues for Inspection of Pharmaceutical Manufacturing Facilities'可被翻译为：药品生产设施检查中的微生物问题\n'9. Laboratory Facility and Analytical Review'可被翻译为：实验写到设施和分析审核\n\n根据上述已知信息，请将'The following topics should be reviewed and evaluated during an inspection of a pharmaceutical microbiology laboratory.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在对药物微生物实验室进行检查期间应查看和评估以下方面："
    },
    {
        "instruction":"已知信息：\n'(3) Trail objective;'可被翻译为：（三）试验目的；\n'(4) Trail design;'可被翻译为：（四）试验设计；\n'Article 55 If the applicant or the inspected institution believes that there is a conflict of interest between the inspector and the inspection item they are engaged in, it may submit a withdrawal request with related reasons to CFDI before the end of the open meeting of the on-site inspection. If CFDI confirms that it is a situation that requires withdrawal, the relevant personnel shall be withdrawn.'可被翻译为：第五十五条 申请人或被核查单位认为核查人员与所从事的核查事项存在利益冲突的，可在现场核查首次会议结束前向核查中心提出回避要求及相关理由。经核查中心确认属于需要回避情形的，相关人员应当予以回避。\n'audit trail'可被翻译为：审计跟踪\n\n根据上述已知信息，请将'(5) Capital source and possible conflict of interest of the trail;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）试验的资金来源、可能的利益冲突；"
    },
    {
        "instruction":"已知信息：\n'In the conformation, the Angle of torsion (or dihedral Angle) between each of the more connected groups (or atoms) on two adjacent atoms is +90. To +150. The range may be between -150. To -90. Conformation between ranges.'可被翻译为：在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+90。至+150。范围间或在-150。至-90。范围间的构象。\n'Also known as the \"gaucheconformation\", in which the torsion Angle (or dihedral Angle) between the superior groups (or atoms) connected on each of the two adjacent atoms is +30. To +90. Between ranges, or at -90. To -30. Conformation between ranges.'可被翻译为：又称\"邻位交叉构象（gaucheconformation）\"在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+30。至+90。范围间，或在-90。至-30。范围间的构象。\n'Also known as \"eclipsedconformation\". In the conformation, the Angle of torsion (or dihedral Angle) between the superior groups (or atoms) connected on each of the two adjacent atoms is -30. To +30. Conformation between ranges.'可被翻译为：又称\"重叠构象（eclipsedconformation）\"。在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在-30。至+30。范围间的构象。\n'The Angle between two adjacent bonds in a molecule.'可被翻译为：分子中两个相邻化学键之间的夹角。\n\n根据上述已知信息，请将'Also known as \"staggeredconformation\" \\ In the conformation, the torsion Angle (or dihedral Angle) between the two adjacent atoms on each of the better connected groups (or atoms) is +150. To -150. Conformation between ranges.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"对位交叉构象（staggeredconformation）\\在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+150。至-150。范围间的构象。"
    },
    {
        "instruction":"已知信息：\n'nucleic acid drug'可被翻译为：核酸类药物\n'nucleic acid'可被翻译为：核酸\n'A biomacromolecule polymerized from nucleotide. Includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).'可被翻译为：由核昔酸聚合而成的生物大分子。包括脱氧核糖核酸(DNA)和核糖核酸(RNA)。\n'nucleotide'可被翻译为：核昔酸\n\n根据上述已知信息，请将'Nucleic acids, nucleotides, nucleotides, or bases having medicinal properties. Including its analogues, derivatives, or polymers of such analogues or derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有药用价值的核酸、核昔酸、核昔或者碱基的统称。包括其类似物、衍生物或这些类似物、衍生物的聚合物。"
    },
    {
        "instruction":"已知信息：\n'(III) Medical device adverse event monitoring information requiring regularly release;'可被翻译为：（三）需要定期发布的医疗器械不良事件监测信息；\n'(IV) Other medical device adverse event monitoring information that needs to be released in a unified manner.'可被翻译为：（四）认为需要统一发布的其他医疗器械不良事件监测信息。\n'V. Issuance of Pharmacovigilance Expresses on Medical Devices (omitted)'可被翻译为：五、医疗器械警戒快讯发布情况\n'(I)  Information on group adverse event of medical device;'可被翻译为：（一）群体医疗器械不良事件相关信息；\n\n根据上述已知信息，请将'IV. Release of medical device adverse event information notification (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、医疗器械不良事件信息通报发布情况（省略）"
    },
    {
        "instruction":"已知信息：\n'Article 62 Manufacturing of imported medical devices shall conform to relevant requirements for manufacturing of medical devices in China, and accept overseas inspection organized by NMPA. The agent shall be responsible for work related to coordinating and cooperating with overseas inspection.'可被翻译为：第六十二条  进口医疗器械的生产应当符合我国医疗器械生产相关要求，并接受国家药品监督管理局组织的境外检查。代理人负责协调、配合境外检查相关工作。\n'In order to further implement the Opinions on the Reform of Review and Approval System for Drugs and Medical Devices issued by the State Council and the Opinions on Deepening the Reform of Review and Approval System to Encourage Innovation of Drugs and Medical Devices issued by the General Office of the CPC Central Committee and the General Office of the State Council as well as there form of \"Streamline Administration,Delegate Power, Strengthen Regulation and Improve Services\", and optimize business environment requirements, comprehensively deepen reform of the review and approval system for medical devices, promote high quality development of the medical device industry, and better meet public health needs, on September 18, 2020, NMPA announced the following matters concerning the production of products with imported medical device registration certificates in domestic enterprises in China:'可被翻译为：为进一步贯彻落实国务院《关于改革药品医疗器械审评审批制度的意见》和中共中央办公厅、国务院办公厅印发的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》，落实“放管服”改革和优化营商环境要求，全面深化医疗器械审评审批制度改革，推动医疗器械产业高质量发展，更好地满足公众健康需求，现就已获进口医疗器械注册证产品在中国境内企业生产的有关事项公告如下：\n'To further unify the understanding of mandatory industry standards, and truly promote the implementation of mandatory industry standards of medical devices,in accordance with the Standardization Law of the People's Republic of China,the Regulations for the Supervision and Administration of Medical Devices,the Provisions for Mandatory National Standards and the Provisions for Medical Device Standards, on July 7, 2020, NMPA issued the notice on matters related to further strengthening management for mandatory industry standards of medical devices, requiring drug regulatory authorities at all levels to effectively maintain the legal status of mandatory industry standards,further improve the mandatory industry standard system, promote the drafting and implementation of mandatory industry standards, reinforce the publicity,implementation and training, standardize the implementation of mandatory industry standards, and reinforce the evaluation on implementation of mandatory industry standards.'可被翻译为：为进一步统一对强制性行业标准的认识，切实推进医疗器械强制性行业标准规范、有效实施，根据《中华人民共和国标准化法》《医疗器械监督管理条例》《强制性国家标准管理办法》和《医疗器械标准管理办法》，现就进一步加强医疗器械强制性行业标准管理有关事项通知：切实维护强制性行业标准的法律地位、进一步完善强制性行业标准体系、完善强制性行业标准起草和实施、加强强制性行业标准的宣贯培训、规范强制性行业标准的执行、强化强制性行业标准的实施评估。\n'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China'可被翻译为：国家药监局关于贯彻实施《中华人民共和国药品管理法》有关事项的公告\n\n根据上述已知信息，请将'NMPA issued the Announcement on Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于进口医疗器械产品在中国境内企业生产有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'For generic drugs or other products, drug registration inspection of the manufacturing site and\/or  pre-marketing GMP inspection shall be carried out based on risks, taking into consideration the circumstances such as whether Drug Manufacturing Certificate covering the corresponding manufacturing scope has been obtained and product of the same dosage form has been marketed,.'可被翻译为：对于仿制药等，根据是否已获得相应生产范围药品生产许可证且已有同剂型品种上市等情况，基于风险进行药品注册生产现场核查、上市前药品生产质量管理规范检查。\n'Work Procedure for Collaborative Drug Registration Inspection of Manufacturing Site and Pre-market Good Manufacturing Practice (GMP) Inspection (Trial)'可被翻译为：药品注册生产现场核查和上市前药品生产质量管理规范检查衔接工作程序(试行)\n'5.《Work Procedure for Collaborative Drug Registration Inspection of Manufacturing Site and Pre-market Good Manufacturing Practice (GMP) Inspection(Trial)》'可被翻译为：5. 药品注册生产现场核查和上市前药品生产质量管理规范检查衔接工作程序（试行）\n'Article 1 In order to standardize the work procedure for collaborative drug registration inspection of manufacturing site (hereinafter referred to as registration inspection) and Pre-market Good Manufacturing Practice (GMP) compliance inspection (hereinafter referred to as Pre-market GMP inspection), and to ensure the quality and efficiency of collaborative registration inspection and Pre-market GMP inspection, this Procedures is formulated in accordance with the Drug Administration Law of the People's Republic of China, Vaccine Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and Measures for Supervision and Administration of Drug Production.'可被翻译为：第一条 为规范药品注册生产现场核查(以下简称注册核查)和上市前药品生产质量管理规范符合性检查(以下简称上市前 GMP 检查) 的衔接，保证注册核查和上市前 GMP 检查同步实施工作的质量和效率， 根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》《药品注册管理办法》《药品生产监督管理办法》，制定本程序。\n\n根据上述已知信息，请将'Drug registration inspection of the manufacturing site and pre-marketing GMP inspection shall be carried out for innovative drugs, modified new drugs and biological products, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于创新药、改良型新药以及生物制品等，应当进行药品注册生产现场核查和上市前药品生产质量管理规范检查。"
    },
    {
        "instruction":"已知信息：\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected one-off on site or within 5 working days. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容。逾期不告知的，自收到申请资料之日起即为受理；\n'(4) If the application materials are incomplete or do not meet the requirements for format examination, the notification on correcting and supplementing materials of amendments shall be sent to the applicant on the spot or within five days, with all the content needs to be corrected or supplemented at one time. The application materials shall be deemed as accepted since the date of submission if there is no notification after the timeline.'可被翻译为：（四）申请材料不齐全或者不符合形式审查要求的，应当当场或者在五日内发给申请人补正材料通知书，一次性告知申请人需要补正的全部内容，逾期不告知的，自收到申请材料之日起即为受理；\n'(4) Where the dossier is incomplete or not conformed with the defined format, the applicant shall be informed on-site or within five days at once of what to be supplemented or corrected; if it is not informed to the applicant within the timeline, the application is regarded as accepted on the date the dossier is received; and'可被翻译为：（四）申报资料不齐全或者不符合法定形式的，应当当场或者在5日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；\n\n根据上述已知信息，请将'(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'Article 36 The inspection team shall submit the on-site inspection report, on-site inspection question sheet and related dossiers to CFDI within the prescribed time limit as required.'可被翻译为：第三十六条 核查组应当按照要求在规定时限内，将现场核查报告、现场核查问题表及相关材料报送核查中心。\n'Article 49 CFDI shall, within 40 days from the end of the on-site inspection, and within 20 days from the end of the on-site inspection for those included in the priority evaluation and approval procedures, complete the review of the inspection report, make the review conclusion, and report the registration inspection and inspection results to CDE.'可被翻译为：第四十九条 核查中心在现场核查结束之日起40日内、纳入优先审评审批程序的在现场核查结束之日起20日内，完成核查报告审核，作出审核结论，并将注册核查情况和核查结果反馈药品审评中心。\n'Article 40 CFDI shall send the on-site inspection report and the inspection and review conclusions and other dossiers to CDE within the prescribed time limit as required.'可被翻译为：第四十条 核查中心将现场核查报告和核查审核结论等材料按要求在规定时限内，送交药品审评中心。\n'If the problems found in the on-site inspection will affect the determination of the inspection conclusion, CFDI shall request the applicant in writing to provide feedback on the relevant issues within 20 days. If the problem only needs to be explained, the applicant shall be required in writing to submit dossiers within 5 days. After reviewing the feedback and explanations, CFDI shall inspect and review conclusion. If the applicant fails to submit feedback within the time limit, CFDI shall make the inspection and review conclusion based on the existing registration inspection status.'可被翻译为：认为现场核查发现的问题影响核查结论判定的，核查中心应当书面要求申请人于20日内对相关问题进行反馈，如涉及问题仅需进行解释说明的，书面要求申请人于5日内提交材料。核查中心对反馈及解释说明进行审核后，作出核查审核结论。申请人逾期未予反馈提交的，核查中心基于已有注册核查情况作出核查审核结论。\n\n根据上述已知信息，请将'Article 48 The inspection team shall submit the on-site inspection report and related dossiers to CFDI within 5 days after the completion of the on-site inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 核查组应当在现场核查结束之日起5日内，将现场核查报告及相关资料报送核查中心。"
    },
    {
        "instruction":"已知信息：\n'corrective and preventative actions'可被翻译为：纠正和预防措施\n'A system for implementing corrective and preventive actions resulting from an investigation of complaints, product rejections, non-conformances, recalls, deviations, audits, regulatory inspections and findings and trends from process performance and product quality monitoring.'可被翻译为：对投诉、产品拒收、不符合、召回、偏差、审核、法规检查以及过程性能和产品质量监控的发现和趋势进行调查后，实施纠正和预防措施的系统。\n'Determination and implementation of appropriate corrective measures.'可被翻译为：确定并实施适当的纠正措施。\n'Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)'可被翻译为：为消除已发现的违规或其他非期望状况的原因(所采取)的措施。注:采取纠正措施是为了防止(事情)再次发生，而采取预防措施是为了防止(事情)发生。 (ISO 9000:2005)\n\n根据上述已知信息，请将'Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"纠正措施和预防措施用于调查、理解和纠正偏差并预防其再次发生的系统。"
    },
    {
        "instruction":"已知信息：\n'A limit above (>) which an impurity should be qualified.'可被翻译为：为一限度，高于此限度的降解产物需界定其安全性。\n'identified impurity'可被翻译为：已鉴定的杂质\n'potential impurity'可被翻译为：潜在杂质\n'specified impurity'可被翻译为：指定杂质\n\n根据上述已知信息，请将'A limit above (>) which an impurity should be identified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为一限度，高于此限度的杂质需鉴定其结构。"
    },
    {
        "instruction":"已知信息：\n'A molecule with a symmetric element that overlaps with its own mirror image and has no chiral properties.'可被翻译为：分子中有对称元素，能与其自身镜像重合，没有手性的分子。\n'An asymmetric molecule that cannot overlap with its own mirror image and has the property of rotating the vibrational plane of polarized light.'可被翻译为：不能与自身的镜像相重叠，并具有使偏振光振动面旋转性质的不对称分子。\n'A compound having the same molecular formula but with a different arrangement of atoms.'可被翻译为：具有相同分子式而分子中原子排列不同的化合物。\n'For stereoisomers that have two or more asymmetric centers in a molecule and whose molecules are not mirror images of each other.'可被翻译为：对于分子中具有两个或多个不对称中心，并且其分子不互为镜像关系的立体异构体。\n\n根据上述已知信息，请将'A compound containing asymmetric atoms in a molecule, but which is not optically active because of the symmetry factor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在分子内虽然含有不对称原子，但因具有对称因素而使其不具有旋光性的化合物。"
    },
    {
        "instruction":"已知信息：\n'Cleaning - A process for removing contamination e.g. product residues or disinfectant residues.'可被翻译为：清洁：去除污染（如产品残留或消毒剂残留）的工艺。\n'A process for removing contamination (for example, product residues or disinfectant residues).'可被翻译为：清除污染(例如，产品残留物或消毒剂残留物)的过程。\n'Documented evidence to establish that cleaning procedures are removing residues to predetermined levels of acceptability, taking into consideration factors such as batch size, dosing, toxicology and equipment size.'可被翻译为：证明清洁程序将残留物去除到预定可接受水平的文件证据，同时考虑到诸如批量大小、剂量、毒理学和设备大小等因素。\n'Article 143: Cleaning validation should be performed in order to confirm the effectiveness of a cleaning procedure, to effectively prevent contamination and cross-contamination. In cleaning validation, a comprehensive consideration should include factors such as the use of the equipment, the detergents and disinfectants used, the sampling methods and locations, the relevant recovery rate of sampling, the nature and limit of residues, and the sensitivity of the testing method for residues.'可被翻译为：第一百四十三条 清洁方法应当经过验证，证实其清洁的效果，以有效防止污染和交叉污染。清洁验证应当综合考虑设备使用情况、所使用的清洁剂和消毒剂、取样方法和位置以及相应的取样回收率、残留物的性质和限度、残留物检验方法的灵敏度等因素。\n\n根据上述已知信息，请将'1.The ability of a cleaning procedure to effectively remove material, cleaning agent residue and microbial contamination.\n2.The factors that impact the ability to remove a residue from surfaces, including material of construction, the solubility of the material in different agents and the matrix of the material being cleaned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.清洗程序有效去除物料、清洗剂残留和微生物污染的能力。\n2.影响清除表面残留物能力的因素，包括建筑材料、材料在不同介质中的溶解度和被清洁材料的基质。"
    },
    {
        "instruction":"已知信息：\n'Vials should not be soaked due to the possibility of migration of disinfectant under the closure and into the product.'可被翻译为：不应浸泡西林瓶，因为消毒剂可能通过封盖处迁移，进入产品\n'4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided.'可被翻译为：4.对于涉及微生物限度、无菌等项目的标准，为避免样品污染，还应提供用于该检验的独立包装样品。\n'4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided.'可被翻译为：4.对于涉及微生物限度、无菌等项目的规范，为避免样品污染，还应提供用于该检验的独立包装样品。\n'For products which have been filled aseptically, samples should include containers filled at the beginning and end of the batch. Additional samples, e.g. taken after critical interventions should be considered based on risk.'可被翻译为：对于无菌灌装的产品，样品应包括在本批次灌装开始和结束时的容器。额外取样应根据风险进行考虑，例如在关键干预之后取样。\n\n根据上述已知信息，请将'Samples taken away from the packaging line should not be returned to prevent the products from mixups or contamination.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"样品从包装生产线取走后不应当再返还，以防止产品混淆或污染。"
    },
    {
        "instruction":"已知信息：\n'Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.'可被翻译为：第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。\n'Article 69 The drug regulatory department shall make known to the public contact information for accepting complaints and reports. Upon receipt of reports, the drug regulatory department shall make verification, handling and reply in a timely manner. If it is deemed authentic upon verification, the reporters shall be rewarded in accordance with relevant regulations.'可被翻译为：第六十九条  药品监督管理部门应当公布接受投诉、举报的联系方式。接到举报的药品监督管理部门应当及时核实、处理、答复。经查证属实的，应当按照有关规定对举报人给予奖励。\n'Article 61 The drug regulatory departments shall publish the contact information receiving complaints and reports. Upon receipt of reports, the drug regulatory departments shall make verification, handling and reply in a timely manner. If authentic upon verification, the drug regulatory departments shall reward the reporters in accordance with relevant regulations.'可被翻译为：第六十一条  药品监督管理部门应当公布接受投诉、举报的联系方式。接到举报的药品监督管理部门应当及时核实、处理、答复。经查证属实的，应当按照有关规定对举报人给予奖励。\n'Article 106 Drug regulatory departments shall list their email addresses and phone numbers to accept enquiries, complaints, and reports, and shall promptly reply, verify, and handle enquiries, complaints, and reports in accordance with the law. For verified reports, the whistleblower shall be rewarded in accordance with the relevant provisions.'可被翻译为：第一百零六条 药品监督管理部门应当公布本部门的电子邮件地址、电话，接受咨询、投诉、举报，并依法及时答复、核实、处理。对查证属实的举报，按照有关规定给予举报人奖励。\n\n根据上述已知信息，请将'Article 174 Enterprises shall publish the supervisory telephone number of food and drug regulatory department in their business premises, set up customer's book, and in a timely manner handle customer complaints of drug quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十四条 企业应当在营业场所公布食品药品监督管理部门的监督电话，设置顾客意见簿，及时处理顾客对药品质量的投诉。"
    },
    {
        "instruction":"已知信息：\n'Heating and cooling and hydraulic systems'可被翻译为：加热、冷却和液压系统\n'iii. Appropriate use of equipment operations substances, (lubricants, coolants, refrigerants, etc.) contacting products\/containers\/etc.'可被翻译为：适当使用与产品\/容器等接触的设备操作物质（润滑油、冷却剂、制剂剂等）\n'As far as practicable, equipment, fittings and services should be designed and installed so that operations, maintenance, and repairs can be performed outside the cleanroom. If maintenance has to be performed in the cleanroom, and the required standards of cleanliness and\/or asepsis cannot be maintained, then precautions such\nas restricting access to the work area to specified personnel, generation of clearly defined work protocols and maintenance procedures should be considered. Additional cleaning, disinfection and environmental monitoring should also be considered. If sterilisation of equipment is required, it should be carried out, wherever possible, after complete reassembly.'可被翻译为：设备及辅助装置和服务的设计和安装方式，应尽可能地使操作、维护和维修在洁净室外进行。如果必须在洁净室中进行维护，并且无法维持所要求的洁净和\/或无菌标准，则应当考虑预防措施，例如限制指定人员进入工作区，建立明确的工作方案和维护程序。还应考虑额外的清洁、消毒和环境监测。如果需要对设备进行灭菌，应尽可能在重新组装完成后灭菌\n'Environmental control and monitoring, both of the machine and the background in which it is placed.'可被翻译为：环境控制和监测，包括设备及其环境。\n\n根据上述已知信息，请将'Major items of equipment associated with hydraulic, heating and cooling systems should, where possible, be located outside the filling room. There should be appropriate controls to contain any spillage and\/or cross contamination associated with the system fluids.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"液压、加热和冷却系统相关的设备主要部分应尽可能位于灌装室外。应有适当的控制措施来处理与系统液体相关的任何泄漏和\/或交叉污染。"
    },
    {
        "instruction":"已知信息：\n'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'可被翻译为：一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。\n'non-clinical good laboratory practice'可被翻译为：药物非临床研究质量管理规范\n'Article 22 A pre-clinical drug study shall be in conformity with relevant requirements, among which the Good Laboratory Practice for Non-Clinical Laboratory Studies shall be implemented in the study of safety evaluation.'可被翻译为：第二十二条 药物临床前研究应当执行有关管理规定，其中安全性评价研究必须执行《药物非临床研究质量管理规范》。\n'I. Applicants are required to carry out the study in accordance with the ICH Guidelines as early as possible based on current technical requirements. For relevant studies that start 6 months after the issuance date of this Announcement(based on the time point of the trial record), the above ICH Guidelines shall apply.'可被翻译为：1. 申请人需在现行技术要求基础上，尽早按照ICH指导原则的要求开展研究。本公告发布之日起6个月后开始的相关研究（以试验记录时间点为准），适用上述ICH指导原则。\n\n根据上述已知信息，请将'Guidelines S5 (R3) and S11 shall be applicable to the non-clinical studies starting upon issuance of this Announcement. The designation of the starting date of nonclinical study shall be in accordance with the relevant provisions specified in the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"自本公告发布之日起开始的非临床研究适用S5（R3）和S11指导原则。非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'(2) Drugs that are urgently needed for public health, whose efficacy has been demonstrated by data in drug clinical trials and whose clinical values can be predicted;'可被翻译为：（二）公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的；\n'Article 26 Drugs used for the treatment of severe life-threatening diseases for which there is no effective treatment and drugs urgently needed for public health, where the drug clinical trial data have shown their efficacy and predictable clinical results, may be conditionally approved, and the relevant information should be stated in the drug approval license.'可被翻译为：第二十六条 对治疗严重危及生命且尚无有效治疗手段的疾病以及公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的，可以附条件批准，并在药品注册证书中载明相关事项。\n'Article 23 For drugs that are undergoing clinical trials which are to be used for the treatment of severe life-threatening diseases for which there is no effective treatment, where it is concluded from medical observation that such drugs are beneficial and comply with ethical principles, the drugs may, after review and obtaining informed consent, be used on other patients with the same condition within the clinical trial institutions that are conducting the trial.'可被翻译为：第二十三条 对正在开展临床试验的用于治疗严重危及生命且尚无有效治疗手段的疾病的药物，经医学观察可能获益，并且符合伦理原则的，经审查、知情同意后可以在开展临床试验的机构内用于其他病情相同的患者。\n'Article 59 During clinical trials, for innovative drugs or modified new drugs used for the prevention and treatment of serious life-threatening diseases or diseases that seriously affect the quality of life but no effective means of prevention and treatment is available, or significantly clinically superior over current treatments with sufficient evidence is demonstrated, the applicant may apply for the breakthrough therapy drug procedure.'可被翻译为：第五十九条 药物临床试验期间，用于防治严重危及生命或者严重影响生存质量的疾病，且尚无有效防治手段或者与现有治疗手段相比有足够证据表明具有明显临床优势的创新药或者改良型新药等，申请人可以申请适用突破性治疗药物程序。\n\n根据上述已知信息，请将'(1) Drugs used for treating serious life-threatening diseases for which no effective treatment is available, whose efficacy has been verified by data in drug clinical trials and whose clinical values can be predicted;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）治疗严重危及生命且尚无有效治疗手段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的；"
    },
    {
        "instruction":"已知信息：\n'Article 51 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue a acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十一条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n'Article 57 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十七条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n'Article 123 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers, and issue a acceptance notice of drug re-registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug re-registration application if requirements are not met.'可被翻译为：第一百二十三条 省、自治区、直辖市药品监督管理部门对申报资料进行审查，符合要求的，出具药品再注册申请受理通知书；不符合要求的，出具药品再注册申请不予受理通知书，并说明理由。\n'Article 111 The applicant shall fill in Supplementary Drug Application Form and submit relevant dossier and explanation to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the applicant is located. Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, with reasons, of drug registration application if requirements are not met.'可被翻译为：第一百一十一条 申请人应当填写《药品补充申请表》，向所在地省、自治区、直辖市药品监督管理部门报送有关资料和说明。省、自治区、直辖市药品监督管理部门对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n\n根据上述已知信息，请将'Article 76 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 省、自治区、直辖市药品监督管理部门对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。"
    },
    {
        "instruction":"已知信息：\n'batch culture'可被翻译为：分批培养\n'continuous culture production'可被翻译为：连续培养生产\n'In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.'可被翻译为：在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n\n根据上述已知信息，请将'Corresponding to batch culture. When the microorganisms were cultured in batch culture to the late exponential stage (logarithmic stage), on the one hand, they continuously flowed into the fresh medium at a certain speed; On the other hand, the culture after mixing is continuously flowed out of the incubator by overflow mode, so that it can continue to grow and produce metabolites for a long time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与分批培养相对应。当微生物以分批式培养方式培养到指数期（对数期）的后期时，一方面以一定速度连续流进新鲜培养基；另一方面经搅拌均匀后的培养物又经溢流方式不断流出培养器，从而使其能长时期进行连续生长和产生代谢产物的培养技术。"
    },
    {
        "instruction":"已知信息：\n'A continuous or discontinuous density gradient is formed with a certain medium in the centrifugal tube, and the cell suspension or homogenate is placed on the top of the medium, and the cells are stratified and separated by the action of gravity or centrifugal force field. This kind of separation can be divided into two kinds: rate zone centrifugation and equal density centrifugation. The commonly used media are chloride, sucrose and polysucrose.'可被翻译为：用一定的介质在离心管内形成一连续或不连续的密度梯度，将细胞混悬液或匀浆置于介质的顶部，通过重力或离心力场的作用使细胞分层、分离的方法。这类分离又可分为速率区带离心和等密度离心两种。常用的介质为氯化铭、蔗糖和多聚蔗糖。\n'density gradient centrifugation'可被翻译为：密度梯度离心\n'gradient centrifugation'可被翻译为：梯度离心\n'density gradient centrifugation method'可被翻译为：密度梯度离心法\n\n根据上述已知信息，请将'The centrifuged sample is placed in a medium with a gradient distribution for horizontal or vertical centrifugation. Commonly used media are sucrose and chlorination, the former need to be prepared in advance in the centrifuge tube continuous or discontinuous gradient, the latter is prepared into a certain concentration of solution, in the centrifuge process will form a continuous gradient.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被离心样品置于成梯度分布的介质中进行水平或垂直离心。常用的介质有蔗糖及氯化铭，前者需事先在离心管中配制好连续或不连续梯度，后者配成一定浓度溶液，在离心过程中会形成连续梯度。"
    },
    {
        "instruction":"已知信息：\n'Article 67 Filing for a class I in-vitro diagnostic reagent shall be conducted prior to production.'可被翻译为：第六十七条 第一类体外诊断试剂生产前，应当办理产品备案。\n'Article 6 Class I in-vitro diagnostic reagents are subject to filing administration and class II and class III in-vitro diagnostic reagents are subject to registration administration.'可被翻译为：第六条 第一类体外诊断试剂实行备案管理，第二类、第三类体外诊断试剂实行注册管理。\n'Article 84 The registration or filing unit of in-vitro diagnostic reagent shall be a single reagent or a single reagent kit. One registration or filing unit may include different packaging sizes.'可被翻译为：第八十四条 体外诊断试剂的注册或者备案单元应为单一试剂或者单一试剂盒，一个注册或者备案单元可以包括不同的包装规格。\n'Article 77 The filing certificate for class I medical device shall be arranged in the following form:'可被翻译为：第七十七条 第一类医疗器械备案凭证编号的编排方式为：\n\n根据上述已知信息，请将'Article 86 The filing certificate for class I in-vitro diagnostic reagent shall be arranged in the following form:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十六条 第一类体外诊断试剂备案凭证编号的编排方式为："
    },
    {
        "instruction":"已知信息：\n'Drugs that bind to adrenergic receptors and excite them to produce effects similar to those of epinephrine. It can cause vasoconstriction, increase blood pressure, dilate pupils, dilate bronchus, relax gastrointestinal muscle, accelerate heart rate, strengthen myocardial contractility and reduce mucosal secretion. Clinically, it is mainly used to raise pressure, relieve asthma, and reduce nasal mucosal congestion. Drugs include epinephrine, norepinephrine, mehydroxyamine and ephedrine.'可被翻译为：能与肾上腺素受体结合，并使其激动产生与肾上腺素相似作用的药物。可引起血管收缩、升高血压、散大瞳孔、舒张支气管、弛缓胃肠肌、加速心率、加强心肌收缩力以及减少黏膜分泌等作用。临床上主要应用于升压、平喘、减轻鼻黏膜充血等。药物有肾上腺素、去甲肾上腺素、间羟胺以及麻黄碱等。\n'Drugs to prevent and treat allergic diseases. These include antihistamines, such as diphenhydramine; Anaphylaxis mediators such as cyproheptyl; And other antiallergic agents, such as calcium salts, desensitizers, glucocorticoids, etc.'可被翻译为：防治变态反应性疾病的药物。包括抗组胺药，如苯海拉明；过敏反应介质阻释剂，如赛庚定；其他抗变态反应药，如钙盐、脱敏制剂、糖皮质激素等。\n'Drugs that increase mucus secretion and thin or break down phlegm, making it easy to cough up. Divided into irritating expectorants, such as chlorinated amines, and phlegm-dissolving drugs, such as acetylcysteine.'可被翻译为：增加黏液分泌，使痰液变稀或分解黏痰，易于咳出的药物。分为刺激性祛痰药，如氯化胺和黏痰溶解药，如乙酰半胱氨酸等。\n'A drug that competes with histamine receptors and blocks allergic reactions caused by histamine. There are histamine H1 blockers such as diphenhydramine, promethazine, cetirizine, etc.; And H2 blockers such as cimetidine.'可被翻译为：竞争组胺受体，阻滞组胺所引起过敏反应的药物。有组胺H1阻滞剂，如苯海拉明、异丙嗪、西替利嗪等；H2受体阻滞剂，如西咪替丁。\n\n根据上述已知信息，请将'Drugs that inhibit bronchospasm, improve lung ventilation, and prevent asthma symptoms. There are: beta-2 receptor agonists, such as salbutamol, etc.; Theophylline, such as theophylline, dihydroxypropylline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抑制支气管痉挛，改善肺通气，防治哮喘症状发作的药物。有：β2受体激动剂，如沙丁胺醇等；茶碱类，如茶碱，二羟丙茶碱。"
    },
    {
        "instruction":"已知信息：\n'Article 29 The registrant, filing entity or contract manufacturer of medical devices shall, based on the characteristics, technical process and requirements for manufacturing environment of the manufactured products, rationally equip and use of the facilities and equipment, strengthen the management of the facilities and equipment, and maintain their effective operation.'可被翻译为：第二十九条  医疗器械注册人、备案人、受托生产企业应当按照所生产产品的特性、工艺流程以及生产环境要求合理配备、使用设施设备，加强对设施设备的管理，并保持其有效运行。\n'The registrant, filing entity or contract manufacturer of medical devices shall establish procedures for purchasing, accepting and recording raw materials, to ensure authenticity, accuracy, integrity and traceability of related records.'可被翻译为：医疗器械注册人、备案人、受托生产企业应当建立原材料采购验收记录制度，确保相关记录真实、准确、完整和可追溯。\n'Article 25 The registrant, filing entity, and contract manufacturer of medical devices shall, in compliance with the requirements of the Good Manufacturing Practice for medical devices, establish and improve the quality management system commensurate with the medical devices manufactured and maintain its effective operation, organize manufacturing in strict accordance with the registered or filed technical specifications for the products, and ensure that the medical devices released from the factory meet the mandatory standards and registered or filed technical specifications for the products.'可被翻译为：第二十五条  医疗器械注册人、备案人、受托生产企业应当按照医疗器械生产质量管理规范的要求，建立健全与所生产医疗器械相适应的质量管理体系并保持其有效运行，并严格按照经注册或者备案的产品技术要求组织生产，保证出厂的医疗器械符合强制性标准以及经注册或者备案的产品技术要求。\n'Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.'可被翻译为：第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。\n\n根据上述已知信息，请将'The registrant, filing entity or contract manufacturer of medical devices are encouraged to establish information management system by advanced technical means, to strengthen management of the manufacturing process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励医疗器械注册人、备案人、受托生产企业采用先进技术手段，建立信息化管理系统，加强对生产过程的管理。"
    },
    {
        "instruction":"已知信息：\n'A process designed to remove or inactivate pyrogenic material (such as endotoxin) to a specified minimum quantity.'可被翻译为：去除或灭活致热物质(如内毒素)至规定最小量的过程。\n'Depyrogenation'可被翻译为：除热原\n'depyrogenation'可被翻译为：去除热原法\n'2. Depyrogenation- dry heat ovens for glass containers, wash\/rinse for stoppers, adequacy of validation using spiked endotoxin, recovery studies before depryrogenation, filtration and column applications'可被翻译为：去热源—用于玻璃容器的烘箱、用于塞子的清洗\/冲洗机、使用加标内毒素的充分性验证、去热原前的回收研究、过滤和色谱柱应用\n\n根据上述已知信息，请将'Depyrogenation - A process designed to remove or inactivate pyrogenic material (e.g. endotoxin) to a specified\nminimum quantity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除热原： 旨在将致热物质（例如内毒素）去除或灭活至规定最小量的过程。"
    },
    {
        "instruction":"已知信息：\n'agarose gel'可被翻译为：琼脂糖凝胶\n'A low-grade polymeric sugar consisting of 2 to 10 monosaccharides connected by glycoxi-bonds to form a straight or branched chain.'可被翻译为：由2〜10个单糖通过糖昔键连接形成直链或支链的低度聚合糖。\n'A polysaccharide consisting of multiple monosaccharides. Hemicellulose, AGAR, pectin, etc.'可被翻译为：多种单糖组成的多糖。如半纤维素、琼脂、果胶等。\n'Natural or synthetic chemical substances having a network structure. Such as crosslinked glucans, zeolites, etc., when used as chromatographic media, mixtures can be separated according to molecular size.'可被翻译为：具网状结构的天然或人工合成的化学物质。如交联葡聚糖、沸石等，当作为层析介质时，可按分子大小对混合物进行分级分离。\n\n根据上述已知信息，请将'After the charged AGAR is removed from the AGAR, the remaining neutral part of the charged group does not contain sulfonic acid group, carboxylic acid group, etc. The structure is a chain of polygalactose, easily soluble in boiling water, after cooling can rely on the hydrogen bond attraction between sugar groups to form a network structure of gel. The mesh size of the gel and the mechanical strength of the gel depend on the agarose concentration. It can be used as a molecular sieve and is often used for gel chromatography and electrophoresis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从琼脂中除去带电荷的琼脂胶后，剩下的不含磺酸基团、竣酸基团等带电荷基团的中性部分。结构是链状的聚半乳糖，易溶于沸水，冷却后可依靠糖基间的氢键引力形成网状结构的凝胶。凝胶的网孔大小和凝胶的机械强度取决于琼脂糖浓度。可作为分子筛，常用于凝胶层析和电泳。"
    },
    {
        "instruction":"已知信息：\n'2.2. Throughout development life cycle stages, transfers should be appropriate and proportionate to the phase of the development program to ensure product development knowledge is maintained and processes are appropriately controlled. This guideline should be applied when transferring the technology of manufacturing processes and analytical procedures relating to active pharmaceutical ingredients (APIs), isolated API intermediates, bulk drug products and finished pharmaceutical products (FPPs).'可被翻译为：在整个开发生命周期阶段，转移应适当，并与开发计划的阶段相称，从而确保产品开发知识得 到保存，工艺得到适当控制。在转移API、分离的API中间体、待包装制剂和制剂（FPP）有 关的生产工艺和分析方法技术转移时应使用本指南。\n'2.4. Although this document focuses on pharmaceutical products, the principles can also be applied to the transfer of production, related processes and controls for other products such as biopharmaceutical products, advanced therapy medicinal products\/cellular and gene therapy products, vaccines, medical devices and vector control products.'可被翻译为：虽然本文重点在于药品，但其原则应可应用于其它产品如生物制品、先进疗法药品\/细胞和基因疗法产品、疫苗、医疗器械和病媒控制产品的生产、相关工艺和控制的转移。\n'WHO guidelines on the transfer of technology in pharmaceutical manufacturing'可被翻译为：WHO药品生产技术转移指南\n'1.1. Technology transfer is a logical procedure that controls the transfer of any process, together with its documentation and professional expertise. Technology transfers may involve development, manufacturing and testing sites.'可被翻译为：技术转移是一个控制所有流程及其文件记录和专业经验的逻辑程序。技术转移可涉及开发、生产和检测场所。\n\n根据上述已知信息，请将'1.2. The transfer of production and control procedures of pharmaceutical products from one site to another may take place before or after obtaining regulatory marketing authorization Product transfer may therefore occur during development, during clinical trials, or for full-scale commercialization and commercial batch manufacturing. The level of rigor applied in the technology transfer should be commensurate with the respective product life cycle phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产和检测方法从一个场所转移至另一个场所可能会发生在在获得上市批准之前或之后。因此产品转移可能会在开发过程中、临床试验过程中或全面商业化及商业化批生产过程中发生。技术转移时的严格程序应与产品所处生命周期阶段相称。"
    },
    {
        "instruction":"已知信息：\n'c. RODAC\/Hycheck Sterility Control: Place an unused RODAC plate and\/or Hycheck plate within a sterile Whirl-pak® bag.'可被翻译为：RODAC\/Hycheck 无菌控制：将未使用的 RODAC 碟和\/或 Hycheck 碟放入无菌Whirl- pak®袋中。\n'e. Sterile Whirl-pak® bags'可被翻译为：无菌 Whirl-pak®袋\n'b. Swab\/Sponge Sterility Control: Place an intact unus ed swab (or sponge) unit into a sterile Whirl-pak® bag.'可被翻译为：棉签\/海绵无菌控制：将完整的未使用的棉签（或海绵）单元放入无菌 Whirl-pak®袋中。\n'a. Aseptic Technique Control: Place one (1) sterile Dacron or cotton swab into sterile water and place back into its sterile transport media solution. Place this negative control into a sterile Whirl- pak® bag.\nNote: This control may not be needed if the sponges and\/or swabs are received premoistened. There is no surface contact for this control.'可被翻译为：无菌技术控制：将一个无菌涤纶或棉签放入无菌水中，并放回其无菌输送培养基溶液中，将此阴性对照放入无菌 Whirl- pak®袋中。\n注：如果海绵和\/或棉签在收到之前就已蘸湿则不需要该控制。该控制没有表面接触。\n\n根据上述已知信息，请将'd. Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。"
    },
    {
        "instruction":"已知信息：\n'Article 3 When the CFDI coordinates the collaborative inspections with provincial authorities, both parties shall, in accordance with the regulatory requirements and their respective functions, follow the concept of risk management and work together to ensure the smooth collaboration between registration inspection and Pre-market GMP inspection.'可被翻译为：第三条 核查中心协调省级局同步实施检查工作时，双方应当根据法规要求和各自职能，遵循风险管理的理念，共同合作，保证注册核查与上市前GMP 检查的有机衔接。\n'Article 6 In accordance with the requirements and functions of laws and regulations, the CFDI and provincial authorities shall form inspection team in accordance with procedures to complete the drug registration inspection and Pre-market GMP inspection.'可被翻译为：第六条 根据法规要求和职能， 核查中心和省级局按程序组建检查组，完成药品注册现场核查和上市前 GMP 检查工作。\n'Article 21 If asked for Manufacturing Site Inspections, the applicant shall confirm within the prescribed time limit and submit the confirmation form to CFDI to clarify the circumstances under for this inspection; in the case of dynamic manufacturing on-site inspection, the production arrangement within the specified time limit shall also be confirmed.'可被翻译为：第二十一条 进行生产现场核查的品种，申请人应当在规定时限内，进行生产现场核查确认，向核查中心报送药品注册生产现场核查确认表，明确可接受生产现场核查的情况；需要进行动态生产现场核查的，还需确认在规定时限内的生产安排。\n'The CFDI and the provincial authority may form separate inspection teams or jointly form an inspection team. In principle, the registration inspection, and the Pre-market GMP inspection should be carried out in the same production period.'可被翻译为：核查中心和省级局可分别组建检查组， 或共同组建一个检查组。原则上注册核查与上市前 GMP 检查选择在同一生产周期内开展。\n\n根据上述已知信息，请将'Article 5 After confirming the inspection arrangements with the applicant taking consideration of the characteristics, processes, risks, etc. of the product, the CFDI shall work together with the provincial authorities to agree on the work arrangements to clarify the composition of the inspection team and the inspection time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 核查中心根据品种的特性、工艺、风险等情况，在与申请人沟通确认检查安排后，同省级局共同商定工作安排，明确检查组组成方式和检查时间。"
    },
    {
        "instruction":"已知信息：\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Article 183: There should be operation procedures and the associated records of actions taken and conclusions reached for:'可被翻译为：第一百八十三条 下述活动也应当有相应的操作规程，其过程和结果应当有记录：\n'Article 52 Personnel specially assigned shall be responsible for periodical inspection, cleaning and maintenance of the storage and transportation facilities\/equipment, and records and archives shall be established.'可被翻译为：第五十二条 储存、运输设施设备的定期检查、清洁和维护应当由专人负责，并建立记录和档案。\n'Article 153: Operation procedures should be followed for drafting, revision, review, approval, replacement or withdrawal, reproduction, storage and destruction of documents; and relevant records for distribution, withdrawal, reproduction and destruction of documents should be in place.'可被翻译为：第一百五十三条 文件的起草、修订、审核、批准、替换或撤销、复制、保管和销毁等应当按照操作规程管理，并有相应的文件分发、撤销、复制、销毁记录。\n\n根据上述已知信息，请将'Article 73: The documents and records for equipment procurement, installation, and qualification should be archived.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 应当建立并保存设备采购、安装、确认的文件和记录。"
    },
    {
        "instruction":"已知信息：\n'2.2 Drugs that contain known active ingredients with new dosage form (including new drug delivery system), new formulation process or new route of administration, and have significant clinical advantages.'可被翻译为：2.2含有已知活性成份的新剂型（包括新的给药系统）、新处方工艺、新给药途径，且具有明显临床优势的药品。\n'2.4 Drugs for new indications that contain known active ingredients.'可被翻译为：2.4含有已知活性成份的新适应症的药品。\n'constituents with known therapeutic activity'可被翻译为：具有已知治疗活性的成分\n'new active pharmaceutical ingredient'可被翻译为：新的活性药物成分\n\n根据上述已知信息，请将'2.3 New compound preparations that contain known active ingredients and havesignificant clinical advantages.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.3含有已知活性成份的新复方制剂，且具有明显临床优势。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'可被翻译为：第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。\n'Where it is specified in laws, regulations and guidelines as a major change or determined by MAHs as a major change, it shall be implemented after being approved in accordance with relevant provisions. For the change to lower the category after communicating with and reaching an agreement with the drug regulatory department, the application for filing or reporting shall be filed according to the agreed category of change management. For the changes of filing and reporting categories specified in laws, regulations and technical guidelines or defined by MAHs, those shall be submitted in accordance with relevant provisions.'可被翻译为：法律、法规、指导原则中明确为重大变更或持有人确定为重大变更的，应当按照有关规定批准后实施。与药品监管部门沟通并达成一致后降低变更管理类别的变更，应当按照达成一致的变更管理类别申报备案或报告。法律、法规、技术指导原则中明确为备案、报告管理的变更或持有人确定为备案、报告管理的变更，应当按照有关规定提出备案或报告。\n'Article 80 For MAHs shall report the following changes in annual reports:'可被翻译为：第八十条 以下变更，持有人应当在年度报告中报告：\n\n根据上述已知信息，请将'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。"
    },
    {
        "instruction":"已知信息：\n'All phases in the life of the product from the initial development through marketing until the product’s discontinuation. (ICH Q9)'可被翻译为：从最初的研发到上市直至撤市的产品生命中的所有阶段。（ICH Q9）\n'All stages of the product from its development, launch to market, till discontinuation.'可被翻译为：产品从最初的研发、上市直至退市的所有阶段。\n'1.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8 (4))\n2.All phases in the life of a medical device, from the initial conception to final decommissioning and disposal.\n3.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (4).'可被翻译为：1.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(ICH Q8 (4))\n2.医疗器械生命周期的所有阶段，从最初的构思到最终的退役和处置。\n3.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(4)。\n'11. Product life cycle'可被翻译为：产品生命周期\n\n根据上述已知信息，请将'All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个产品从开始研发到上市，直至产品终止上市的整个过程。"
    },
    {
        "instruction":"已知信息：\n'5. Chromatogram integration'可被翻译为：5.色谱积分\n'Change of the original integration of a chromatographic peak'可被翻译为：重新分析色谱峰。\n'In the chromatographic instrument, after the completion of the separation of the components, according to the qualitative and quantitative requirements of the chromatography, the original chromatographic signals and data are collected and processed, and the computer system is used to control the operation of the chromatographic instrument.'可被翻译为：在色谱仪器中，完成了组分的色谱分离后，按照色谱定性、定量要求，对原始色谱信号和数据进行采集、处理，并控制色谱仪器的操作的计算机系统。\n'chromatogram'可被翻译为：色谱图\n\n根据上述已知信息，请将'(1) Chromatogram adopts automatic integration; the same integration parameters are used in the same analysis batch. If reintegration and manual integration of chromatogram are adopted, record the reason of modification and retain the original and reintegrated chromatogram and data, which are consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) 色谱使用自动积分， 同一个分析批中采用相同的积分参数。如果色谱重积分和手动积分， 记录修改理由并保留原始和重积分的图谱和数据， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'hazardous substance'可被翻译为：有害物质\n'Red powder, soluble in alcohol, enzyme, benzene and glacial acetic acid, insoluble in water, used as acid-base indicator, pH8.5 (yellow) ~9.8 (green). It should be sealed and stored away from light.'可被翻译为：为红色粉末，能溶于醇、酶、苯和冰乙酸，不溶于水，用作酸碱指示剂，pH8.5（黄）~9.8（绿）。应密封避光保存。\n'A substance prone to chemical reactions in the presence of oxygen.'可被翻译为：遇到氧气易发生化学反应的物质。\n'hazardous product'可被翻译为：有害产品\n\n根据上述已知信息，请将'For dark yellow toxic gas. Dissolved in ethylene, tetrahydroyvean, etc., heated to 100 hours explosion; It decomposes rapidly in water and ethanol, and is relatively stable in ethyl-sweet wine. It is highly toxic and has a strong irritating effect on eyes and mucous membranes. It is an important methylation reagent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为深黄色有毒气体。溶于乙触、四氢吠喃等，加热至100工时爆炸；在水和乙醇中迅速分解，在乙醴中比较稳定。有剧毒，对眼睛和黏膜有强烈的刺激作用，为重要的甲基化试剂。"
    },
    {
        "instruction":"已知信息：\n'(1) drugs to be marketed in China for the first time;'可被翻译为：（一）首次在中国境内销售的药品；\n'Drugs produced abroad, registered in China and approved by the competent authorities of the State, enter China for sale and use.'可被翻译为：国外生产的药品，在中国注册、并经国家主管部门批准，进入中国销售和使用的药品。\n'Drugs that are first marketed.'可被翻译为：首次上市的药品。\n'(1) Drugs with the same active ingredients, indications, dosage forms and strengths as non-prescription drugs that have been marketed within the territory of the People's Republic of China;'可被翻译为：（一）境内已有相同活性成分、适应症（或者功能主治）、剂型、规格的非处方药上市的药品；\n\n根据上述已知信息，请将'(II) drugs to be marketed in China for the first time; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）首次在中国境内销售的药品；"
    },
    {
        "instruction":"已知信息：\n'Article 31 The registrant, filing entity or contract manufacturer of medical devices shall enhance purchase management, establish suppliers audit system, and evaluate the suppliers, to ensure that the purchased products and services conform to relevant regulations and requirements.'可被翻译为：第三十一条  医疗器械注册人、备案人、受托生产企业应当加强采购管理，建立供应商审核制度，对供应商进行评价，确保采购产品和服务符合相关规定要求。\n'Article 37 The registrant, filing entity and distributor of the medical devices shall strengthen training and management of the sales personnel, and assume legal liabilities for purchase or sale of medical devices of the sales personnel in the name of the enterprise.'可被翻译为：第三十七条  医疗器械注册人、备案人和经营企业应当加强对销售人员的培训和管理，对销售人员以本企业名义从事的医疗器械购销行为承担法律责任。\n'Article 36 If the registrant or filing entity of the medical devices entrusts the sale to other entities, they shall entrust the sale to medical device distributors conforming to conditions, and sign an entrustment agreement, specifying rights and obligations of both parties.'可被翻译为：第三十六条  医疗器械注册人、备案人委托销售的，应当委托符合条件的医疗器械经营企业，并签订委托协议，明确双方的权利和义务。\n'Article 32 The medical device distributors shall establish procedures for inspecting and recording incoming goods, and when purchasing medical devices, it shall inspect qualifications of the supplier, the Medical Device Registration Certificate, the filing information and qualification certificates. The inspection records of incoming goods shall be authentic, accurate, complete, and traceable. The inspection records of incoming goods shall include:'可被翻译为：第三十二条  医疗器械经营企业应当建立进货查验记录制度，购进医疗器械时应当查验供货企业的资质，以及医疗器械注册证和备案信息、合格证明文件。进货查验记录应当真实、准确、完整和可追溯。进货查验记录包括：\n\n根据上述已知信息，请将'Article 31 The medical device distributors shall purchase medical devices from medical device registrant, filing entity and distributor with legal qualification.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十一条  医疗器械经营企业应当从具有合法资质的医疗器械注册人、备案人、经营企业购进医疗器械。"
    },
    {
        "instruction":"已知信息：\n'The method of dispersing the drug in the solution of the material to form a suspension or emulsion, and then spraying the liquid into an inert hot air flow to shrink the droplets into spheres, and then drying to obtain microcapsules or microspheres.'可被翻译为：将药物分散在材料的溶液中形成混悬液或乳状液，再将此液喷入惰性热气流使液滴收缩成球形，进而干燥，得到微囊或微球的方法。\n'The use of natural or synthetic polymer materials as carrier materials, so that the drug dissolved or\/and dispersed in the polymer material, the formation of a skeleton type of tiny spherical entity.'可被翻译为：利用天然或合成的高分子材料为载体材料，使药物溶解或\/和分散在高分子材料中，形成的骨架型微小球状实体。\n'oil-in-water emulsion'可被翻译为：水包油乳剂\n'An emulsion in which water is the dispersing phase and oil is the dispersing medium.'可被翻译为：以水为分散相，以油为分散介质的乳剂。\n\n根据上述已知信息，请将'Drugs and natural polymer materials for the water phase, emulsifier oil phase stirring emulsification, the use of polymer solution itself surface tension to form a spherical emulsion, forming a stable oil-in-water emulsion, need to add chemical crosslinking agent, amine aldehyde condensation or aldol condensation reaction, preparation of powdered microspheres method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物和天然高分子材料为水相，与含乳化剂的油相搅拌乳化，在搅拌下利用高分子溶液本身的表面张力形成球形乳滴，形成稳定的油包水型乳状液，需加入化学交联剂，发生胺醛缩合或醇醛缩合反应，制得粉末状微球的方法。"
    },
    {
        "instruction":"已知信息：\n'A subdiscipline of toxicology that developed out of immunology and toxicology. The study of the harmful effects of foreign chemicals and physical factors on the body's immune system and their mechanisms.'可被翻译为：在免疫学和毒理学基础上发展起来的一个毒理学分支学科。主要研究外源化学物质和物理因素对机体免疫系统的有害作用及其机制。\n'The branch of toxicology that studies the effects and damage of exogenous chemicals on the plasma membrane components, biophysical functions, receptors, membranases, transport and metabolism of messenger substances, and messenger delivery processes in toxicology and pathology.'可被翻译为：研究外源化学物质对质膜的组成成分、生物物理功能、受体、膜酶、信使物质的转运与代谢和毒理病理学信使传递过程的影响与损伤的毒理学分支学科。\n'The discipline that studies the basic principles, rules, and evaluation methods of tissue and organ damage caused by the interaction of foreign chemicals with the body.'可被翻译为：研究外源化学物与机体交互作用导致组织器官损伤的基本原理、规律和评价方法的学科。\n'The discipline that studies the characteristics and mechanisms of the damaging effects of foreign chemicals on the kidney by using the basic methods and techniques of toxicology.'可被翻译为：利用毒理学的基本方法和技术，研究外源化学物对肾脏的损害作用特点及其机制的学科。\n\n根据上述已知信息，请将'The branch of toxicology that studies the damaging effects of foreign chemicals on the respiratory system, explores methods of detection, and elucidates mechanisms of damage. Its research is helpful for the diagnosis, treatment, prevention and mechanism of poisoning.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究外源化学物对呼吸系统的损害作用，探讨检测方法以及阐述损害机制的毒理学分支学科。其研究有助于对中毒的诊断、治疗、预防以及中毒机制的探讨。"
    },
    {
        "instruction":"已知信息：\n'Article 16 The State supports innovation in drug development which is guided by clinical value and has clear or specific therapeutic effect on human diseases, encourages research and development of new drugs with new therapeutic mechanisms, treats serious life-threatening or rare diseases, makes use of targeted and systemic regulatory interventions for humans, and promotes technological advancement in drug development.'可被翻译为：第十六条 国家支持以临床价值为导向、对人的疾病具有明确或者特殊疗效的药物创新，鼓励具有新的治疗机理、治疗严重危及生命的疾病或者罕见病、对人体具有多靶向系统性调节干预功能等的新药研制，推动药品技术进步。\n'Article 5 The State encourages research and development of new drugs, and protects the legitimate rights and interests of citizens, legal bodies and other institutions in research and development of new drugs.'可被翻译为：第五条 国家鼓励研究和创制新药，保护公民、法人和其他组织研究、开发新药的合法权益。\n'Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.'可被翻译为：第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n\n根据上述已知信息，请将'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。"
    },
    {
        "instruction":"已知信息：\n'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'可被翻译为：水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。\n'To minimize the risk of biofilm formation, sterilisation, disinfection or regeneration of water systems should be carried out according to a predetermined schedule and as a remedial action following out-of-limit or specification results. Disinfection of a water system with chemicals should be followed by a validated rinsing\/flushing procedure. Water should be tested after disinfection\/regeneration. Chemical testing results should be approved before the water system is returned to use and microbiological\/endotoxin results verified to be within specification and approved before batches manufactured using water from the system are considered for certification\/release.'可被翻译为：为最大程度降低生物膜形成的风险，应按照预定的时间表对水系统进行灭菌、消毒或再生，并作为超限或超标后的整改措施。用化学品对水系统进行消毒后，用经过验证的程序进行淋洗\/冲洗。应在消毒\/再生后进行水质检测。在水系统恢复使用之前，化学检验结果应得到批准，并且在使用该系统的水生产的批次得到认证\/放行之前，微生物\/内毒素结果应经过核实在质量标准范围内并得到批准。\n'Water systems should be qualified and validated to maintain the appropriate levels of physical, chemical and microbial control, taking the effect of seasonal variation into account.'可被翻译为：水系统应经过确认和验证，能维持适当的物理、化学和微生物控制水平，并考虑到季节变化的影响。\n'Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures.'可被翻译为：第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。\n\n根据上述已知信息，请将'Water flow should remain turbulent through the pipes in water distribution systems to minimize the risk of microbial adhesion, and subsequent biofilm formation. The flow rate should be established during qualification and be routinely monitored.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水流在水分配系统的管道中应保持湍流状态，以最大程度降低微生物粘附及随后生物膜形成的风险。应在确认过程中确定流速并进行日常监测。"
    },
    {
        "instruction":"已知信息：\n'A homogeneous suspension of the seed material derived from the master seed bank(s) at a finite passage level, dispensed in aliquots into individual containers for storage. All containers are treated identically and, once removed from storage, are not returned to the seed stock.'可被翻译为：从主种子库中提取的种子材料的均匀悬浮液，在有限传代水平上，等份分配到单独的容器中储存。所有容器的处理都是一样的，一旦从储存中取出，就不返回种子库。\n'spore suspension'可被翻译为：抱子悬浮液\n'disperse system'可被翻译为：分散体系\n'If the sample is an aqueous based product, the unit(s) should be shaken prior to transfer to work area to maximize microbial dispersement.'可被翻译为：如果样品是水基产品，应在转移到工作区之前摇动装置，以最大限度地分散微生物。\n\n根据上述已知信息，请将'A suspension formed when the seeds are dispersed by shaking them into a sterile liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将抱子转入无菌液体中振摇，使抱子分散后形成的悬浮液。"
    },
    {
        "instruction":"已知信息：\n'The absorption and distribution of drugs in the body Biotransformation and excretion.'可被翻译为：药物在体内的吸收分布生物转化和排泄。\n'Full name \"Pharmacokinetics\". It mainly studies the dynamic changes of the body's treatment of drugs, including the absorption, distribution, biotransformation and excretion processes of drugs in the body, especially the discipline of blood drug concentration changes with time.'可被翻译为：全称\"药物代谢动力学”。主要研究机体对药物的处置的动态变化，包括药物在机体内的吸收、分布、生物转化及排泄的过程，尤其是血药浓度随时间变化规律的学科。\n'The study of the absorption, distribution, metabolism, excretion and other processes of drugs and their dosage forms in the body, and the elucidation of the relationship between drug dosage forms, biological factors and efficacy.'可被翻译为：研究药物及其剂型在体内的吸收、分布、代谢、排泄等过程，阐明药物的剂型因素、机体生物因素和药效之间相互关系的一门学科。\n'toxicokinetics'可被翻译为：毒物代谢动力学\n\n根据上述已知信息，请将'The subject of quantitative study of the dynamic laws of the absorption, distribution, biotransformation and excretion of toxicants in the body over time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"定量研究毒物在体内吸收、分布、生物转化、排泄等过程随时间变化的动态规律的学科。"
    },
    {
        "instruction":"已知信息：\n'(1) The source of the test system used in the study should be clear and compliant with the related regulation, and the relevant supporting documentation for acquisition and characterization of the test system should be kept completely; documentation for assessing suitability of the test system should be kept completely.'可被翻译为：(1)研究所需实验系统的来源应清晰合规，应完整保存 实验系统购入(转入)、质量鉴定等相关证明性文件；应完整保留适用性评估资料。\n'2. The storage conditions of the test\/control articles should be in conformity with those specified in the study protocol or other supporting documents (such as instructions for use, certificates of analysis, etc.); records of monitoring storage conditions and handling unexpected events of the test\/control articles and their formulations during the study period should be retained completely;'可被翻译为：2.受试物\/对照品保存条件应符合试验方案或相关证明 性文件(如使用说明书、质检报告等)要求；应完整保留研 究期间受试物\/对照品及其制剂保存条件监测及异常情况处理记录；\n'3. The storage conditions of the test\/control articles and their formulations, biological samples, study files and specimens, etc. should be in conformity with those specified in the study protocol, SOPs or other operational instructions; records of corresponding environmental monitoring and handling of unexpected events in the course of the study should be retained completely.'可被翻译为：3.受试物\/对照品及其配制制剂、生物样本、研究档案和 标本等储存保管条件应符合试验方案及机构 SOP或其他试验操作文件要求；应完整保存研究开展期间相应环境控制数据以及异常情况处理等记录。\n'2. Records of use, cleaning, maintenance, testing, calibration, verification or validation, repair, handling of unexpected events and decommission of instruments and equipment used in the study during the study period should be retained completely; the testing time and items in the use records of instruments and equipment should be in line with that as required by the study;'可被翻译为：2.应完整保留研究期间所使用仪器设备的使用、清洁、 保养、测试、校准、确认或验证、维修、异常情况处理、报废等记录；仪器设备使用记录的时间及内容应与研究对应一致；\n\n根据上述已知信息，请将'1. The applicant and the testing facility under inspection should ensure that the original study materials retained are complete and can be provided for inspection in a timely manner, including an original copy of protocol, raw data, specimens, relevant testing reports, reserve samples of test\/control articles, an original copy of the final study report and other documentation related to the study;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.现场核查期间，申请人及被核查研究机构应确保研究 原始资料保存完整并能够及时提供、接受核查，包括试验方案的原件、原始数据、标本、相关检测报告、留样受试物和对照品、总结报告的原件以及研究有关的各种文件；"
    },
    {
        "instruction":"已知信息：\n'Article 69 Where a drug manufacturer does not conduct production of the new drug, for which an observation period is set, within two years from the date of the approval, the State Food and Drug Administration may approve the application of another drug manufacturer to produce the new drug and reset the observation period of the drug.'可被翻译为：第六十九条 药品生产企业对设立监测期的新药从获准生产之日起2年内未组织生产的，国家食品药品监督管理局可以批准其他药品生产企业提出的生产该新药的申请，并重新对该新药进行监测。\n'Article 70 Starting from the date a new drug enters the observation period, any other application for the clinical trial of the same drug already approved by the State Food and Drug Administration may proceed along drug registration application, review and approval procedures; where regulations are conformed to, the State Food and Drug Administration shall approve the production or importation of the same drug. The observations of the drugs produced by the domestic manufacturers should be conducted together with the drug already in the observation period.'可被翻译为：第七十条 新药进入监测期之日起，国家食品药品监督管理局已经批准其他申请人进行药物临床试验的，可以按照药品注册申报与审批程序继续办理该申请，符合规定的，国家食品药品监督管理局批准该新药的生产或者进口，并对境内药品生产企业生产的该新药一并进行监测。\n'Article 41 Drug manufacturers shall frequently examine the safety of their drug products and conduct intensive surveillance on drugs within the New Drug Observation Period and on imported drugs within 5 years after first importation, and they shall summarize, analyze, evaluate and report the monitoring data as required. For other drugs products, intensive surveillance shall be conducted voluntarily based on the drug safety information.'可被翻译为：第四十一条 药品生产企业应当经常考察本企业生产药品的安全性，对新药监测期内的药品和首次进口5年内的药品，应当开展重点监测，并按要求对监测数据进行汇总、分析、评价和报告；对本企业生产的其他药品，应当根据安全性情况主动开展重点监测。\n'Article 71 Starting from the date a new drug enters the observation period, other registration applications for the same drug shall no longer be accepted. The other applicants' applications for the same drug already accepted but not yet approved for clinical trials shall be returned; upon the expiration of the observation period of the drug, the registration of a generic or import drug may be applied for.'可被翻译为：第七十一条 新药进入监测期之日起，不再受理其他申请人的同品种注册申请。已经受理但尚未批准进行药物临床试验的其他申请人同品种申请予以退回；新药监测期满后，申请人可以提出仿制药申请或者进口药品申请。\n\n根据上述已知信息，请将'Article 66 In order to protect the public health, the State Food and Drug Administration may set an observation period for any new drug approved for production. The observation period of a new drug shall be no longer than five years from the date the drug is approved for production.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十六条 国家食品药品监督管理局根据保护公众健康的要求，可以对批准生产的新药品种设立监测期。监测期自新药批准生产之日起计算，最长不得超过5年。"
    },
    {
        "instruction":"已知信息：\n'A large percentage of small volume parenterals appear to be inhibitory to the LAL gel- clot method because of low pH, or some excipient \/ active component of the product. In order to expedite the neutralization of this interfering trait, determine the lowest product dilution overcoming the interference but still within the Maximum Valid Dilution (MVD). The detailed description of this protocol is delineated in LIB No. 2433 (July 25, 1980), “A condensed procedure for diluting product in determining compatibility with the Limulus Amebocyte Lysate test for endotoxin”. In addition, the use of neutralizers such as sodium laurel sulfate or PyrosperseTM has also been described (see references).'可被翻译为：由于其低pH值，或产品的有些辅料\/活性组份，很大比例的小容量注射剂显示出对 LAL凝胶方法的抑制性。为了加快对这种干扰特性的中和，要确定克服干扰但仍在 最大有效稀释度（MVD）内的最低产品稀释级别。该方案在LIB No. 2433 (19800725) “在确定与鲎变形细胞裂解物检测内毒素的相容性时稀释产品的浓缩程 序”中有详细说明。另外，使用中和剂如月桂基硫酸钠或PyrosperseTM（参见参考 资料）。\n'The Gel-Clot Method is a qualitative assay that detects Gram-negative bacterial endotoxin based upon a reaction between lysate and endotoxin which results in a firm clot formation. For samples with endotoxin, the endotoxin amount present in a test sample is calculated by diluting the sample to determine the assay endpoint where a clot does not form. If no clot forms in the verified dilution from the inhibition and enhancement testing, the sample does not contain detectable endotoxin.'可被翻译为：凝胶法是一种定性方法，基于裂解液与内毒素之间的反应形成稳定凝固形态检出革兰氏阴性 菌内毒素。对于含有内毒素的样本，检测样本上的内毒素数量是通过稀释样本至不会形成凝 胶的测试终点来计算的。如果在抑制和增强检测中经过验证的稀释倍数下未形成凝胶，则认 为样本不含有可检出内毒素。\n'It would be advisable when performing the repeat test from a composite mixture that, if remaining product is available and had been opened aseptically under controlled conditions, the repeat test be performed on the original individual units. It is strongly advised that the individual units be adequately shaken to assure that the endotoxin is re suspended back into solution before taking the sample test aliquot. If any of the original individual units fail the USP test at this point, the compendium does not allow any additional repeat testing unless the test can be proven not to be suitable as defined by the USP chapter.'可被翻译为：建议在执行组合混合物的重复检测时，如果有留样，且在受控环境下以无菌方式打 开，可采用原受检单元执行重复检测。强烈建议对单个单元进行足够震摇，以确保 内毒素在测试取样之前混回至溶液中。如果所有原始单元均在该点的USP检测不合格，则药典不允许复验，有USP章节证明该检测不适用者除外。\n'The Bacterial Endotoxin test does not directly address the issue of combining product units (compositing\/pooling). The risk of unit composites is that one unit (vial, ampoule, etc.) may have bacterial endotoxin contamination at a higher level but the dilution of this one unit with endotoxin-free units of product may reduce the detectable level of endotoxin below the sensitivity of the lysate or dilute the level of endotoxin below the acceptable monograph level. Therefore, when using a composite format for screening drug products for endotoxin it is important to adjust the MVD calculation to account for this reduced lysate sensitivity. Secondly, when compositing is performed for product screening, if a positive result is detected a repeat test is acceptable under the conditions stated by the Interpretation section of the USP chapter.'可被翻译为：细菌内毒素检测并未直接说明组合产品单元（组合\/混合）的问题。单元组合 的风险是一个单元（西林瓶、安瓿等）可能会有较高水平的细菌内毒素污染，而该 单元采用产品的无内毒素单元稀释后可能会将内毒素检出水平降低至鲎灵敏度水平 以下，或将内毒素水平稀释至低于可接受的各论水平以下。因此，如果使用组合形 式筛选产品的内毒素，调整该降低的鲎试剂灵敏度MVD计算非常重要。其次，如 果组合是在产品筛选时执行的，如果检出阳性结果，可接受按USP章节中的诠释 部分所声明条件下重复检测。\n\n根据上述已知信息，请将'When conflicting results occur within a test run, the analyst should consult USP Chapter<85> , Gel-Clot Limits Test, Interpretation, for guidance on repeat testing. As specified in Chapter<85> , if the test failure occurred at less than the maximum valid dilution (MVD), the test should be repeated using a greater dilution not exceeding the MVD. A record of this failure should be included in the laboratory results. If a test is performed at the MVD and an out-of- specification (OOS) test result occurs that cannot be attributed to testing error, continue product dilution until the actual endotoxin concentration can be calculated. These results should be recorded on your worksheets.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在同一次检测中得到相互矛盾的结果，化验员应遵守US<85>P“凝胶法限度测 试”结果诠释中的复测指导。正如第<85>章所述，如果低于MVD时检测结果不合 格，应使用不超过MVD的较大稀释倍数重复检测。该检测不合格结果记录要放在 实验室结果中。如果在MVD执行检测并得到不可归因于检测错误的OOS结果，则 要持续稀释产品直到实际内毒素浓度可计算为止。这些结果均应记录在你的工作表 中。"
    },
    {
        "instruction":"已知信息：\n'Cleanroom gowning should be performed in change rooms of an appropriate cleanliness grade to ensure\ngown cleanliness is maintained. Outdoor clothing including socks (other than personal underwear) should not be\nbrought into changing rooms leading directly to grade B and C areas. Single or two-piece facility trouser suits,\ncovering the full length of the arms and the legs, and facility socks covering the feet, should be worn before entry\nto change rooms for grades B and C. Facility suits and socks should not present a risk of contamination to the\ngowning area or processes.'可被翻译为：洁净室更衣应在适当洁净级别的更衣室进行，以确保维持工作服的洁净度。不得将包括袜子在内的便服（个\n人内衣除外）带入直接通往 B 级和 C 级区的更衣室。在进入 B 级和 C 级的更衣室之前，应穿着覆盖整个\n手臂和腿部的连体服或分体式工作服，以及覆盖脚部的工作袜。工作服和工作袜不应对更衣区或者工艺带\n来污染风险。\n'Grade D: Hair, beards and moustaches should be covered. A general protective suit and appropriately disinfected shoes or overshoes should be worn. Appropriate measures should be taken to avoid any ingress of contaminants from outside the clean area.'可被翻译为：D 级：应遮盖头发、胡须。应穿普通的防护服和适当消毒的鞋子或鞋套。应釆取适当措施，以避免洁净区\n外的污染引入本区。\n'Grade C: Hair, beards and moustaches should be covered. A single or two-piece trouser suit gathered at the wrists and with high neck and appropriately disinfected shoes or overshoes should be worn. They should minimize the shedding of fibres and particles.'可被翻译为：C 级：应遮盖头发、胡须。应穿手腕处可收紧的高领连体服或分体式工作服，并穿适当消毒的鞋或鞋套。这类服装应尽可能减少纤维和微粒的脱落。\n'Other characteristics, such as temperature and relative humidity, should be controlled within ranges that align with product\/processing\/personnel requirements and support maintenance of defined cleanliness standards (e.g. grade A or B).'可被翻译为：温度和相对湿度等检测项目应控制在符合产品\/工艺\/人员要求的范围内，并应能够用于维护规定的洁净标准（例如 A 级或 B 级）。\n\n根据上述已知信息，请将'A description of typical clothing required for each cleanliness grade is given below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"各洁净级别通常要求的着装说明如下："
    },
    {
        "instruction":"已知信息：\n'The Medical Device Distribution License applies the uniform format made by NMPA, and shall be printed by the department in charge of drug supervision and administration at the level of a city divided into districts.'可被翻译为：医疗器械经营许可证由国家药品监督管理局统一样式，由设区的市级负责药品监督管理的部门印制。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device manufacturing within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device manufacturing as required by NMPA.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械生产监督管理信息化建设和管理工作，按照国家药品监督管理局的要求统筹推进医疗器械生产监督管理信息共享。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n'The NMPA shall be responsible for making template of the Cosmetics Manufacturing License. The drug regulatory department of the province, autonomous region or municipality directly under the central government shall be responsible for printing, issuing and other management work of the cosmetics manufacturing license.'可被翻译为：国家药品监督管理局负责制定化妆品生产许可证式样。省、自治区、直辖市药品监督管理部门负责化妆品生产许可证的印制、发放等管理工作。\n\n根据上述已知信息，请将'The Medical Device Manufacturing License applies the uniform format made by NMPA, and shall be printed by the drug regulatory department of the province, autonomous region, or municipality directly under the central government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械生产许可证由国家药品监督管理局统一样式，由省、自治区、直辖市药品监督管理部门印制。"
    },
    {
        "instruction":"已知信息：\n'Article 65 The number of Cosmetics Manufacturing License is arranged as follows: X妆XXXXXXXX. Where, the first X refers to the abbreviation of the province, autonomous region, or municipality directly under the central government where the licensing department is located, the second to the fifth X refer to the licensing year in 4-digit, and the sixth to the ninth X refer to the licensing serial number in 4-digit.'可被翻译为：第六十五条 化妆品生产许可证编号的编排方式为：X妆XXXXXXXX。其中，第一位X代表许可部门所在省、自治区、直辖市的简称，第二位到第五位X代表4位数许可年份，第六位到第九位X代表4位数许可流水号。\n'Article 63 For the preparing, filling and canning of cosmetics contents, an entity shall obtain the Cosmetics Manufacturing License according to law. The manufacturing process of labeling shall be completed in the manufacturer of cosmetics that completes the last manufacturing process of contacting contents of cosmetics.'可被翻译为：第六十三条 配制、填充、灌装化妆品内容物，应当取得化妆品生产许可证。标注标签的生产工序，应当在完成最后一道接触化妆品内容物生产工序的化妆品生产企业内完成。\n'Article 5 The state exercises licensing management for the manufacturing of cosmetics. To engage in manufacturing of cosmetics, the Cosmetics Manufacturing License shall be obtained in accordance with the law.'可被翻译为：第五条 国家对化妆品生产实行许可管理。从事化妆品生产活动，应当依法取得化妆品生产许可证。\n'Article 26 If the registrant or the filing entity of cosmetics entrusts manufacturing of cosmetics, it shall entrust one that has obtained the manufacturing license for the relevant cosmetics, and shall supervise the whole manufacturing process of the entrusted enterprise, and be responsible for quality and safety of the cosmetics entrusted with manufacturing. The contract manufacturer shall have the corresponding manufacturing conditions, and organize manufacturing in accordance with the laws, regulations, mandatory national standards, technical specifications and contractual agreements, be responsible for the manufacturing and be supervised by the entrusting party.'可被翻译为：第二十六条 化妆品注册人、备案人委托生产化妆品的，应当委托取得相应化妆品生产许可的生产企业生产，并对其生产活动全过程进行监督，对委托生产的化妆品的质量安全负责。受托生产企业应当具备相应的生产条件，并依照法律、法规、强制性国家标准、技术规范和合同约定组织生产，对生产活动负责，接受委托方的监督。\n\n根据上述已知信息，请将'Article 15 The Cosmetics Manufacturing License shall be indicated with the license number, the manufacturer’s name, domicile, manufacturing address, unified social credit identifier, legal representative or responsible person, the manufacturing licensed items, expiry date, issuing authority and date of issuance, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 化妆品生产许可证应当载明许可证编号、生产企业名称、住所、生产地址、统一社会信用代码、法定代表人或者负责人、生产许可项目、有效期、发证机关、发证日期等。"
    },
    {
        "instruction":"已知信息：\n'(3) the handling of unqualified drugs;'可被翻译为：（三）药品质量不合格的处理情况；\n'Use of a medicine outside the scope of regulatory authorization.'可被翻译为：在监管授权范围之外使用药物。\n'(3) issue a Drug Manufacturing Certificate, Drug Distribution Certificate, or Pharmaceutical Preparation Certificate for Medical Institution to organizations which do not satisfy the criteria.'可被翻译为：（三）对不符合条件的单位颁发药品生产许可证、药品经营许可证或者医疗机构制剂许可证。\n'(4) sale of drugs that have not been evaluated as required;'可被翻译为：（四）应当检验而未经检验即销售药品；\n\n根据上述已知信息，请将'(3) selling drugs beyond the scope of the drug distribution certificate;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）超过药品经营许可范围销售药品的；"
    },
    {
        "instruction":"已知信息：\n'A uniform, stable mixture formed by the separation of one or more substances into another.'可被翻译为：一种或几种物质分散到另-种物质里，形成的均一的、稳定的混合物。\n'For example, the homogeneous product that solid or semi-solid preparations for oral or topical use are produced within the same blender by one blending prior to molding or filling should be regarded as one batch. The homogeneous product that liquid preparations for oral or topical use are produced by final mixing prior to filling (sealing) should be regarded as one batch.'可被翻译为：例如：口服或外用的固体、半固体制剂在成型或分装前使用同一台混合设备一次混合所生产的均质产品为一批；口服或外用的液体制剂以灌装（封）前经最后混合的药液所生产的均质产品为一批。\n'Contamination of raw materials and excipients (starting materials) or of a product with another material or product.'可被翻译为：不同原料、辅料及产品之间发生的相互污染。\n'The operation in which two or more materials are dispersed to a uniform state by mechanical means.'可被翻译为：用机械方法使两种或多种物料相互分散而达到均匀状态的操作。\n\n根据上述已知信息，请将'The blending of carry-over material from one grade of an excipient with another, usually due to a continuous process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常由于一个连续的过程，将一种等级的赋形剂的残留物质与另一种等级的赋形剂混合。"
    },
    {
        "instruction":"已知信息：\n'After review and approval, NMPA published the YY 0096-2019 Co-60 Teletherapy Unit and other 26 medical device industry standards, as well as the No. 1 amendment form for YY 0285.3-2017 Intravascular catheters—Sterile and single-use catheters—Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment (Annex omitted).'可被翻译为：经审查和批准，国家药监局发布了YY 0096-2019《钴-60远距离治疗机》和其他26项医疗器械行业标准，以及YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单于2019年5月31日。标准编号、名称、适用范围、实施日期和修改单内容见附件（附件略）。\n'On November 13, 2019, NMPA issued the Announcement on 21 Medical Device Industry Standards such as YY\/T 0464-2019 Single-Use Hemoperfutor and 1 Modification Order. For the codes, names, scope of application and implementation date of the standards, please see the attachment (omitted).'可被翻译为：2019年11月13日，国家药监局审定通过并发布了YY\/T 0464-2019《一次性使用血液灌流器》等21项医疗器械行业标准和YY\/T 0953-2015《医用羧甲基壳聚糖》医疗器械行业标准第1号修改单。标准编号、名称、适用范围和实施日期详见附件（省略）。\n'NMPA Issued 27 Medical Device Industry Standards (Covering YY 0096-2019 Co-60 Teletherapy Unit) and 1 Amendment Form'可被翻译为：关于发布YY 0096—2019《钴-60远距离治疗机》等27项医疗器械行业标准和1项修改单的公告\n'NMPA Announcement on the Issuance of 21 Medical Device Industry Standards such as YY \/ T 0464-2019 Single-Use Hemoperfutor and 1 Modification Order'可被翻译为：国家药监局关于发布YY\/T 0464-2019《一次性使用血液灌流器》等21项医疗器械行业标准和1项修改单的公告\n\n根据上述已知信息，请将'After review and approval, NMPA published the YY0096-2019 Co-60 Teletheraphy Unit and other 26 medical device industry standards, as well as the No.1 amendment form for YY0285.3-2017 Intravascular catheters-Sterile and single-use catheters-Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药检局于2019年5月31日发布了YY 0096-2019《钴-60远距离治疗机》等27项医疗器械行业标准和YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单已经审定通过。标准编号、名称、适用范围、实施日期和修改单内容见附件。"
    },
    {
        "instruction":"已知信息：\n'Article 126 In any of the following circumstances, a drug shall not be re-registered:'可被翻译为：第一百二十六条 有下列情形之一的药品不予再注册：\n'(1) not accepting a drug registration application that is in conformity with regulatory requirements;'可被翻译为：（一）对符合法定条件的药品注册申请不予受理的；\n'(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;'可被翻译为：（一）药品生产、经营企业违反本办法第六条规定的；\n'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'可被翻译为：销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n\n根据上述已知信息，请将'Where a drug manufacturer violates Item (IV) or (V) of the preceding paragraph, re-registration of relevant drugs shall be prohibited in accordance with requirements of the Provisions for Drug Registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产企业有前款规定第（四）项、第（五）项情形之一的，按照《药品注册管理办法》的规定对相应药品不予再注册。"
    },
    {
        "instruction":"已知信息：\n'Article 16 The organization being inspected and their related personnel shall, as required by the inspection team, timely specify person(s) responsible for the inspection site, open the relevant places or areas, cooperate with the inspection of related equipment and facilities, maintain normal production and operation conditions, provide true, valid and complete documents, records, receipts, vouchers, electronic data and other related materials, and truthfully answer the questions raised by the inspection team.'可被翻译为：第十六条 被检查单位及有关人员应当及时按照检查组要求，明确检查现场负责人，开放相关场所或者区域，配合对相关设施设备的检查，保持正常生产经营状态，提供真实、有效、完整的文件、记录、票据、凭证、电子数据等相关材料，如实回答检查组的询问。\n'Article 29 At the beginning of the on-site inspection, the inspection team shall preside over the open meeting, present the authorization certificate to the applicant and the inspected institution, notify the inspector composition, inspection purpose and scope, declare inspection precautions and inspection disciplines, etc., and inform the rights and obligations of the inspected institution.'可被翻译为：第二十九条 现场核查开始时，核查组应当主持召开首次会议，向申请人和被核查单位出示授权证明文件，通报核查人员组成、核查目的和范围，声明检查注意事项及检查纪律等，告知被核查单位的权利和义务。\n'Article 17 The inspection team shall record in detail the inspection time, place and site conditions, etc., make written records of findings, and collect or copy relevant documents, take photos\/videos of related articles such as equipment, facilities and material as well as site conditions, collect objects and inquire related personnel in accordance with the actual situations. The inquiry records shall include the name, position and conversation content of the personnel inquired, and shall be signed or fingerprinted page by page by the personnel.'可被翻译为：第十七条 检查组应当详细记录检查时间、地点、现场状况等；对发现的问题应当进行书面记录，并根据实际情况收集或者复印相关文件资料、拍摄相关设施设备及物料等实物和现场情况、采集实物以及询问有关人员等。询问记录应当包括询问对象姓名、工作岗位和谈话内容等，并经询问对象逐页签字或者按指纹。\n'Inspectors shall strictly abide by national laws, regulations, and work disciplines, have no conflicts of interest with the applicant and the inspected institution, earnestly perform their duties during the inspection, and conduct registration inspections impartially and honestly. The dossiers and information provided by the applicant and the inspected institution shall be kept confidential.'可被翻译为：检查员应当严格遵守国家法律法规和工作纪律，与申请人和被核查单位不存在利益冲突，核查期间认真履行职责，公正廉洁地从事注册核查工作。对申请人和被核查单位提供的资料、信息负保密责任。\n\n根据上述已知信息，请将'The inspected institution shall cooperate with the inspection team, open relevant venues, provide documents, records, electronic data, etc. required for the inspection in a timely manner, answer the inspection team's inquiries truthfully, and ensure the authenticity of the information provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位应当配合核查组工作，开放相关场地，及时提供核查所需的文件、记录、电子数据等，如实回答核查组的询问，保证所提供的资料真实。"
    },
    {
        "instruction":"已知信息：\n'The procedure requires that the test be conducted with a suitable volume of product. It is advisable to begin with at least 20 mL of product. Use the original product containers whenever possible or five sterile, capped bacteriological containers of suitable size into which a suitable volume of product has been transferred. If the diluted product exhibits antimicrobial properties, specific neutralizers may need to be incorporated into the diluents or the recovery media. For purposes of testing, products have been divided into four categories:'可被翻译为：程序要求用适量产品来进行测试，建议从至少20mL的产品开始。尽可能使用原来的产品容器， 或将合适体积的产品转移到 5 个合适尺寸的无菌细菌学容器。如果稀释的产品表现出抑菌性能， 则可能需要将特定的中和剂掺入稀释剂或恢复培养基中。根据测试的目的，产品分为四类：\n'The standard extracting, rinsing and soaking fluid for medical devices is pyrogen-free water. The analytical approach for testing medical devices is covered in USP. If the extraction fluid shows endotoxin interfering results, modification of testing may be necessary depending on the product configuration. Alternate diluents must be verified to not interfere with the endotoxin assay prior to use.'可被翻译为：医疗器械的标准萃取、淋洗和浸泡流体为无热源水。检测医疗器械的分析方法在USP 中写明。如果萃取流体显示出内毒素干扰结果，可能需要根据产品参数设置对检测进行 修改。替代稀释剂在使用前必须确认其不会干扰内毒素分析。\n'Prepare a 1% stock solution by placing one (1) gram of sodium lauryl sulfate (SLS) into a depyrogenated glass flask and add 99 ml of pyrogen-free water. Allow the SLS to fully dissolve. This should be followed by filtration through a 10,000 MW depyrogenation membrane filter into a pyrogen-free glass or plastic container.'可被翻译为：向除热源处理的玻璃瓶中加入1g月桂基硫酸钠（SLS），再加入99ml无热源水，制备1%贮备溶液。让SLS完全溶解。用10000MW除热源膜过滤至无热源玻璃或塑料容器中。\n'Use a material similar to the product under test. The control material must be of the same volume, and similarly packaged as the test product. Filter- sterilized and autoclaved Peptone water (USP Fluid A) may be useful for this purpose in many cases.'可被翻译为：在测试时使用与产品相似的物料。对照物料必须与测试产品有着相同的体 积和相似的包装。在许多情况下，过滤灭菌和高压灭菌的蛋白胨水（USP 流体 A）可用于此目的。\n\n根据上述已知信息，请将'When using commercially purchased pyrogen-free water for product dilutions, it is recommended to transfer a working volume from the original stock container to an individual pyrogen-free test tube or flask in order to minimize back contamination. Run a negative control for the working volume for each sample run.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果产品稀释使用的是商业化采购的无热源水，建议从原始存贮容器中转移工作用 体积的水至单个无热源试管或烧瓶中，以最大程度减少背景污染。每次检测样品时 均要使用工作体积的水进行阴性对照试验。"
    },
    {
        "instruction":"已知信息：\n'(5) not stating the reasons of non-acceptance or unapproval of a drug registration application by law; and'可被翻译为：（五）未依法说明不受理或者不批准药品注册申请理由的；\n'(1) not accepting a drug registration application that is in conformity with regulatory requirements;'可被翻译为：（一）对符合法定条件的药品注册申请不予受理的；\n'In any of the following circumstances, the drug registration application shall not be approved:'可被翻译为：药品注册申请有下列情形之一的，不予批准：\n'(I) The applicant fails to carry out Manufacturing Site Inspection within the prescribed time limit, or fails to accept on-site inspection within the prescribed time limit, except for the legitimate reasons of force majeure such as natural disaster or government acts;'可被翻译为：(一)除自然灾害、政府行为等不可抗力的正当理由外，申请人未在规定时限内进行生产现场核查确认，或者不能在规定时限内接受现场核查的；\n\n根据上述已知信息，请将'(5) The applicant refuses to accept drug registration inspection and testing or, without justifiable reasons, fails to accept drug registration inspection and testing within the specified timeline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）申请人拒绝接受或者无正当理由未在规定时限内接受药品注册核查、检验的；"
    },
    {
        "instruction":"已知信息：\n'The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalification should include at a minimum the following:'可被翻译为：洁净室和洁净空气设备的再确认应按照规定的程序定期执行。再确认应至少包括以下内容：\n'Requalification should be performed every 6–12 months, based on equipment usage, risk tolerance, and manufacturers recommendation. Requalification should also be performed if the system is relocated or undergoes a major repair.'可被翻译为：应根据设备使用情况、风险承受能力和制造商建议，每6-12个月进行一次再确认。如果系统重新安置或进行大修，也应进行重新确认。\n'Revalidation of a validated process, component, system, or analytical determination method for changes that may affect the final result.'可被翻译为：对经过验证的工艺、组分、系统或分析测定方法的可能影响最终结果的变更，再次进行的验证。\n'Article 142: Qualification or validation should be performed when there is a change in major factors influencing the product quality, including any change in starting materials, immediate packaging materials, production equipment and environment (or premises), manufacturing process or testing method, etc. Where necessary, the changes should be approved by drug regulatory departments.'可被翻译为：第一百四十二条 当影响产品质量的主要因素，如原辅料、与药品直接接触的包装材料、生产设备、生产环境（或厂房）、生产工艺、检验方法等发生变更时，应当进行确认或验证。必要时，还应当经药品监督管理部门批准。\n\n根据上述已知信息，请将'Appropriate requalification consisting of at least the above tests should also be carried out following completion of remedial action implemented to rectify an out of compliance equipment or facility condition or after changes to equipment, facility or processes as appropriate. The significance of a change should be determined through the change management process. Examples of changes to be considered include but are not limited to the following:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在纠正设备或设施缺陷而采取的整改措施完成后，或设备、设施或工艺的变更后，还应视情况进行上述检测进行适当的再确认。变更的重要性应通过变更管理程序确定。需要考虑的变更案例包括但不限于："
    },
    {
        "instruction":"已知信息：\n'f. <62> Microbiological Examination of Nonsterile products: Tests for Specified Microorganisms'可被翻译为：<62>非无菌药品的微生物检查\n'c. <1111> Microbiological Examination of Nonsterile Products: Acceptable Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use'可被翻译为：<1111>非无菌产品的微生物检查：药物制剂和药用物质的可接受标准\n'd. <60> Microbiological Examination of Nonsterile Products: Tests for Burkholderia cepacia complex'可被翻译为：<60>非无菌药品的微生物检查：洋葱伯克霍尔德菌复合物检测\n'Chapter 2: Microbial Examination of Non-Sterile Products'可被翻译为：第二章：非无菌药品的 微生物检查\n\n根据上述已知信息，请将'e. <61> Microbiological Examination of Nonsterile products: Microbial enumeration tests'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"<61>非无菌药品的微生物检查：微生物计数"
    },
    {
        "instruction":"已知信息：\n'7. Sufficient reference samples of starting materials and finished products are retained to permit future inspection and testing of the product when necessary, and that the finished product is retained in its final package unless exceptionally large packages are produced.'可被翻译为：（七）物料和最终包装的成品应当有足够的留样，以备必要的检查或检验；除最终包装容器过大的成品外，成品的留样包装应当与最终包装相同。\n'The status of starting or packaging materials, intermediate, bulk or finished products isolated physically or by other effective means whilst storing and awaiting a decision on their release or refusal before dispensing or marketing.'可被翻译为：指原辅料、包装材料、中间产品、待包装产品或成品，采用物理手段或其他有效方式将其隔离或区分，在允许用于投料生产或上市销售之前贮存、等待作出放行决定的状态。\n'(ii) Samples of starting materials, packaging materials, intermediate products, bulk products and finished products are taken by approved personnel and methods;'可被翻译为：(ii)原材料、包装材料、中间产品、散装产品、成品的取样人员和方法应经过批准；\n'1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.'可被翻译为：1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。\n\n根据上述已知信息，请将'A sample of a batch of starting material, packaging material, product contained in its primary packaging, or finished product that is stored for the purpose of being analysed, should the need arise. This may include storage in a suitable bulk container.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一批起始原料、包装材料、包含在其主要包装中的产品或成品的样品，如果需要，为分析目的而储存。这可能包括储存在合适的散装容器中。"
    },
    {
        "instruction":"已知信息：\n'Reactions resulting in one of the following harmful conditions due to the use of a drug: causing death; posing a life-threatening situation; causing cancer, teratogenicity, or congenital defects; leading to significant or permanent human injury or damage to organ function; resulting in hospitalization or prolonged hospital stay; causing other significant medical events, where failure to treat may lead to the aforementioned adverse reactions.'可被翻译为：因使用药品引起以下损害情形之一的反应：导致死亡；危及生命；致癌、致畸、致出生缺陷；导\n致显著的或者永久的人体伤残或者器官功能的损伤；导致住院或者住院时间延长；导致其他重要医学\n事件，如不进行治疗可能出现上述所列情况的不良反应。\n'hazardous drugs'可被翻译为：危害药品\n'Medications that, if used improperly, can cause serious harm to patients and may even pose a life-threatening risk.'可被翻译为：一旦使用不当发生用药错误，会对患者造成严重伤害，甚至会危及生命的药品。\n'Drugs with severe toxicity, therapeutic doses close to toxic doses, and improper use of which can cause poisoning or death.'可被翻译为：毒性剧烈、治疗剂量与中毒剂量相近，使用不当会致人中毒或死亡的药品。\n\n根据上述已知信息，请将'Medications that can pose occupational exposure risks or hazards, including those with genotoxic, carcinogenic, teratogenic effects, or those causing reproductive harm. Additionally, drugs with severe organ toxicity or other significant toxic effects at low doses fall into this category.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能产生职业暴露危险或者危害的药品，即具有遗传毒性、致癌性、致畸性，或者对生育有损害作\n用以及在低剂量下可产生严重的器官或其他方面毒性的药品。"
    },
    {
        "instruction":"已知信息：\n'Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.'可被翻译为：违反本办法第十八条第二款规定，药品零售企业在执业药师或者其他依法经过资格认定的药学技术人员不在岗时销售处方药或者甲类非处方药的，责令限期改正，给予警告；逾期不改正的，处以一千元以下的罚款。\n'Article 20    A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.'可被翻译为：第二十条 药品生产、经营企业不得以搭售、买药品赠药品、买商品赠药品等方式向公众赠送处方药或者甲类非处方药。\n'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'可被翻译为：这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。\n'The online drug retailers shall not directly display the package and label of prescription drugs on the main page and the home page of prescription drug sales. Before the prescription examination is passed, the enterprises shall not display the package inserts and other relevant information, or provide services related to the purchase of prescription drugs.'可被翻译为：药品网络零售企业在处方药销售主页面、首页面不得直接公开展示处方药包装、标签等信息。通过处方审核前，不得展示说明书等信息，不得提供处方药购买的相关服务。\n\n根据上述已知信息，请将'Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经营处方药和甲类非处方药的药品零售企业，执业药师或者其他依法经资格认定的药学技术人员不在岗时，应当挂牌告知，并停止销售处方药和甲类非处方药。"
    },
    {
        "instruction":"已知信息：\n'Article 17: The quality management department should participate in all quality related activities, and review all GMP related documents. The responsibilities of quality management personnel are not permitted to be delegated to personnel of other departments.'可被翻译为：第十七条 质量管理部门应当参与所有与质量有关的活动，负责审核所有与本规范有关的文件。质量管理部门人员不得将职责委托给其他部门的人员。\n'(XIX) Other responsibilities that shall be fulfilled by the quality management department.'可被翻译为：（十九）其他应当由质量管理部门履行的职责。\n'Article 123 The quality management department or quality management personnel of enterprises shall fulfill the following responsibilities:'可被翻译为：第一百二十三条 企业应当设置质量管理部门或者配备质量管理人员，履行以下职责：\n'Article 16 Enterprises shall set up a quality management department to effectively carry out quality management. The responsibilities of quality management department shall not be performed by other departments or personnel.'可被翻译为：第十六条 企业应当设立质量管理部门，有效开展质量管理工作。质量管理部门的职责不得由其他部门及人员履行。\n\n根据上述已知信息，请将'Article 17 The quality management department shall fulfill the following responsibilities:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 质量管理部门应当履行以下职责："
    },
    {
        "instruction":"已知信息：\n'Among the 5,574 applications requiring technical review, 4,459 were for chemical drugs, accounting for 80% of all those for technical reviews, and 300 and 815 were for TCMs and biologicals, respectively.'可被翻译为：需技术审评的5574件注册申请中，化药为4459件，占全部需技术审评的注册申请受理量的80%，中药和生物制品注册申请分别为300件和815件。\n'Of the applications with completed review, 6,624 were registered for chemical drugs, accounting for about 83%. The completion status of various types of drug registration applications in 2015-2018 is detailed in Figure 12.'可被翻译为：完成审评的申请中，化药注册申请为6624件，约占全部审评完成量的83%。2018年各类药品注册申请审评完成情况与近三年比较详见图12。\n'In 2019, 6,199 registration applications requiring technical review were accepted, increased by 11.21% as compared with those in 2018. Among them, 4,937 registration applications were for chemical drugs, increased by 10.72% as compared with those in 2018, accounting for 79.64% of the total number of registration applications requiring technical review; 257 registration applications were for TCMs, decreased by 14.33% as compared with those in 2018;1,005 registration applications were for biological products, increased by 23.3% as compared with those in 2018. The details of acceptance of registration applications for chemical drugs, TCMs and biological products requiring technical review in 2016-2019 are shown in Figure 2.'可被翻译为：2019年，受理需技术审评的注册申请6199件，较2018年增加11.21%，其中化学药注册申请为4937件，较2018年增长了10.72%，占全部需技术审评的注册申请受理量的79.64%；中药注册申请257件，较2018年降低了14.33%；生物制品注册申请1005件，较2018年增长了23.3%。2016-2019年需技术审评的化学药、中药和生物制品注册申请受理情况详见图2。\n'CDE completed the review of registration applications for 6,624 chemical drugs, including 843 clinical applications (IND and confirmatory trial), 206 NDAs, and 2,353 ANDAs. See Figure 14 for details of the various registration applications for chemical drugs that have been reviewed.'可被翻译为：药审中心完成审评的化药注册申请6624件，其中完成化药临床申请（IND和验证性临床）共843件，完成化药NDA 206件，完成化药ANDA 2353件。完成审评的化药各类注册申请情况详见图14。\n\n根据上述已知信息，请将'Among the 6,817 registration applications with completed technical review, 300 applications were for TCMs , 1104 applications were for biological products, and 5,413 applications were for chemical drugs (accounting for about 79% of all completed reviews).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"完成技术审评的6817件注册申请中，中药注册申请300件，生物制品注册申请1104件，化学药注册申请为5413件，化学药注册申请约占全部审评完成量的79%。"
    },
    {
        "instruction":"已知信息：\n'A comprehensive applied technical discipline to study the preparation theory, production technology and quality control of drugs and their formulations, with the purpose of ensuring the effectiveness, safety and stability of drugs, and improving the compliance and bioavailability of drugs in clinical use.'可被翻译为：研究药物及其组方制剂的制备理论、生产技术和质量控制的综合应用技术学科，其目的在于保证药物有效性、安全性和稳定性，提高药物的临床使用的顺应性和生物利用度。\n'The branch of pharmacy concerned with the research, production, storage, transportation, supply and use of drugs used by the armed forces to prevent and treat injuries caused by special and conventional weapons and diseases caused by special environment.'可被翻译为：关于军队防治特种和常规武器伤及特殊环境引发疾病所用药物的研究、生产、储运、供应和使用等的药学分支学科。\n'Research, design and selection of pharmaceutical industrial production pathway is a discipline, but also research, selection of appropriate intermediates and determine the synthesis route, process principles and industrial production process, to achieve the optimization of pharmaceutical production process of a discipline.'可被翻译为：研究、设计和选用药物工业生产途径的一门学科，也是研究、选用适宜的中间体和确定合成路线、工艺原理和工业生产过程，实现制药生产过程最优化的一门学科。\n'The entire process of a new drug from laboratory research to marketing and expansion of clinical application. It involves many disciplines such as pharmacy, pharmacology, toxicology, drug analysis, pharmacodynamics and clinical medicine.'可被翻译为：新药从实验室研究到上市、扩大临床应用的整个过程。涉及药剂学、药理学、毒理学、药物分析、药物动力及临床医学等诸多学科。\n\n根据上述已知信息，请将'The branch of pharmacy that studies the industrial production of drugs and provides scientific basis and technical support for the design of new drugs and dosage forms, the improvement of production technology and the improvement of product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究药品的工业化生产，为新药和新剂型的设计、生产工艺的改进和产品质量的提高提供科学依据和技术支持的药学分支学科。"
    },
    {
        "instruction":"已知信息：\n'The estimation of the risk associated with the identified hazards. (ICH Q9)'可被翻译为：与已识别的危害相关的风险评估。（ICH Q9）\n'The systematic use of information to identify potential sources of harm (hazards) referring to the risk question or problem description. (ICH Q9)'可被翻译为：参考风险问题或问题描述系统地利用信息来识别潜在的危害源（危害）。\n'hazard analysis'可被翻译为：危害分析\n'A systematic process of organizing information to support a risk decision to be made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards. (ICH Q9)'可被翻译为：一个系统的信息组织过程，以支持风险管理过程中的风险决策。包括危害的识别和与 危害物质暴露相关的分析和风险评估。（ICH Q9）\n\n根据上述已知信息，请将'A measure of the possible consequences of a hazard. (ICH Q9)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种危害所造成可能结果的量度。（ICH Q9）"
    },
    {
        "instruction":"已知信息：\n'In both iPSC and hESC lines, it is not unusual for clones ofabnormal karyotype to arise on extended passage and overgrow the culture. Thusanalysts should monitor cultures for such abnormal cells. Traditionally, thishas been performed by karyotypic studies of metaphase spreads of the cellsusing Giemsa staining.The occurrence of nondiploid cells, even at very low incidence,can be problematic. Guidance documents such as the 2009 International Stem CellBanking Initiative are helpful to determine if such cultures should be discarded.However, newer procedures such as array comparative genome hybridization andsingle-nucleotide polymorphism arrays provide much more detailed analysis ofgenetic stability and can be used in parallel with Giemsa banding to givegreater confidence in genetic stability.'可被翻译为：在iPSC和hESC品系中，异常核型克隆在传代和培养中过度生长中比较常见。因此，分析人员应监控此类异常细胞的培养。通常通过姬姆萨染色对分裂中期细胞进行核形分析。非二倍体细胞的出现，即使发生率很低，也可能是有问题的。诸如2009年国际干细胞银行倡议之类的指导文件有助于确定是否应该丢弃此类培养物。然而，诸如比较基因组杂交和单核苷酸多态性阵列之类的较新方法提供了对遗传稳定性的更详细的分析，并且可以与Giemsa谱带结合使用，从而对遗传稳定性具有更大的信心。\n'In order to check that a PSC line has not lost any of its stem cell characteristics during preservation, analysts should check expression of a number of key stem cell-related markers. One extensive study analyzed 59 hESC lines and a panel of 94 genes and resolved five stem cell-related molecules for which mRNA was expressed consistently in hESCs. These genes now are included in commercially available microfluidics gene cards that are specifically designed for investigating stem cell populations. If it is crucial to demonstrate that the PSCs have retained their pluripotency, then a number of characterization tests can be performed, including teratoma formation inimmune-deficient mice, formation of trilaminar embryoid bodies, and directed differentiation to demonstrate that the culture can produce representatives of each of the three germ layer tissues that are required to form all of the cells of the human body.'可被翻译为：为了检查PSC品系在保存过程中没有失去任何干细胞特性，分析人员应检查许多关键的干细胞标志物的表达。一项大量的研究分析了59个hESC系和94个基因组，并解析了hESCs 中mRNA表达的5个与干细胞相关的分子。现在，这些基因已包含在商业可购买的微流体基因数据库中，该数据库专门设计用于研究干细胞群体。如果证明PSC保留了其多能性是至关重要的，那么可以进行许多表型测试，包括免疫缺陷小鼠中的畸胎瘤形成、三层胚状体的形成以及定向分化，证明培养的PSC可以产生代表形成人体所有细胞所需的三个胚层组织。\n'Analysts should observe cell cultures on a regular basis. Cultures that exhibit high levels of differentiated cells should be discarded. An individual investigator or banking facility should have a quality control program that evaluates differentiation of cultures on a regular basis and develops threshold levels of acceptable differentiation in a culture. The protocol for harvesting followed by equilibration of the sample with CPAs should be carried out rapidly in order to minimize cell losses because of harvesting.'可被翻译为：操作人员应定期观察细胞培养情况，对于表现出高水平分化细胞应被丢弃。研究者或存储机构应该有一个质量控制程序，定期评估分化差异并制定可接受差异的阈值。为尽量减少因收获而造成的细胞损失，应迅速由CPAs平衡样品后实施收获。\n'In addition to the guidance given in the Key Elements of Cryopreservation Practice section, these additional points should be considered for animal cell line substrates:'可被翻译为：除了在低温保存实践部分的关键要素中给出的指导，对于动物细胞系底物，还应考虑以下几点：\n\n根据上述已知信息，请将'In addition to following good cell culture practices, analysts should note the availability of a specific guidance that contains principles and best practices in the procurement, banking, testing, and storage of hESCs for research purposes (see the ISCB 2009 reference in the Appendix). This guidance is useful for both iPSC and hESC lines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除了遵循良好的细胞培养规范外，分析人员应该还注意到一个具体的指南的可用性，其中包含用于研究目的hESCs的采购、存储机构、测试和存储的原则 (参见附录中的ISCB 2009参考)。本指南对iPSC和hESC都是实用的。"
    },
    {
        "instruction":"已知信息：\n'(1) To alter the dosage form of a non-prescription drug determined by the State Food and Drug Administration without changing the indications or functions, dosage and route of administration; or'可被翻译为：（一）经国家食品药品监督管理局确定的非处方药改变剂型，但不改变适应症或者功能主治、给药剂量以及给药途径的药品；\n'(3) New compound preparations composed of active ingredients of non-prescription drugs authorized by the NMPA;'可被翻译为：（三）使用国家药品监督管理局确定的非处方药的活性成份组成的新的复方制剂；\n'(2) To formulate a new fixed dose combination using active ingredients of non-prescription drugs determined by the State Food and Drug Administration.'可被翻译为：（二）使用国家食品药品监督管理局确定的非处方药活性成份组成的新的复方制剂。\n'Use of a medicine outside the scope of regulatory authorization.'可被翻译为：在监管授权范围之外使用药物。\n\n根据上述已知信息，请将'(2) Drugs developed by changing the dosage forms or strength of non-prescription drugs authorized by the NMPA without changing the indications, dosages or administration routes;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）经国家药品监督管理局确定的非处方药改变剂型或者规格，但不改变适应症（或者功能主治）、给药剂量以及给药途径的药品；"
    },
    {
        "instruction":"已知信息：\n'Article 299: A person should be designated as responsible for execution and coordination of recalls and should be supported by sufficient staff. This responsible person should be independent of the sales and marketing organization. If this person is not the Authorized Person, the latter should be made aware of any recall activity.'可被翻译为：第二百九十九条 应当指定专人负责组织协调召回工作，并配备足够数量的人员。产品召回负责人应当独立于销售和市场部门；如产品召回负责人不是质量受权人，则应当向质量受权人通报召回处理情况。\n'Article 304: The progress of the recall process should be recorded, and a final report should be issued, including the distributed and recalled quantities of the products, along with the reconciliation between them.'可被翻译为：第三百零四条 召回的进展过程应当有记录，并有最终报告。产品发运数量、已召回数量以及数量平衡情况应当在报告中予以说明。\n'Article 295: Each batch of product should have a distribution record. Based on the record, the sale of each batch should be traceable, when necessary, all the products should be able to be taken back timely, The distribution record should include information such as the product name, strength, batch number, quantity, customer name, address, and contact details, date of shipment, mode of transport, etc.'可被翻译为：第二百九十五条 每批产品均应当有发运记录。根据发运记录，应当能够追查每批产品的销售情况，必要时应当能够及时全部追回，发运记录内容应当包括：产品名称、规格、批号、数量、收货单位和地址、联系方式、发货日期、运输方式等。\n'(Ⅲ) Way and scope of disclosing the recall information;'可被翻译为：（三）召回信息的公布途径与范围；\n\n根据上述已知信息，请将'Article 302: The distribution records should be readily available to the person(s) responsible for recalls.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百零二条 产品召回负责人应当能够迅速查阅到药品发运记录。"
    },
    {
        "instruction":"已知信息：\n'Article 93 The State implements an essential drugs system to select essential drugs of appropriate quantities, better organize manufacturing and stockpile, improve the supply capacity for essential drugs, and satisfy the need for essential medications for disease prevention and treatment.'可被翻译为：第九十三条 国家实行基本药物制度，遴选适当数量的基本药物品种，加强组织生产和储备，提高基本药物的供给能力，满足疾病防治基本用药需求。\n'Article 95 The State implements an administration to supply a list of drugs in shortage. Detailed provisions shall be formulated by the competent health department under the State Council jointly with the drug regulatory department under the State Council.'可被翻译为：第九十五条 国家实行短缺药品清单管理制度。具体办法由国务院卫生健康主管部门会同国务院药品监督管理部门等部门制定。\n'Article 66 The State buildss vaccines into the stockpile of strategic materials, implementing the stockpile at the national and provincial levels.'可被翻译为：第六十六条 国家将疫苗纳入战略物资储备，实行中央和省级两级储备。\n'Article 94 The State establishes a drug supply monitoring system to promptly gather, compile, and analyze the supply information of drugs in shortage, implement advance drug shortage warnings, and take countermeasures.'可被翻译为：第九十四条 国家建立药品供求监测体系，及时收集和汇总分析短缺药品供求信息，对短缺药品实行预警，采取应对措施。\n\n根据上述已知信息，请将'Article 92 The State implements a drug stockpile system by the establishment of national and local drug stockpile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十二条 国家实行药品储备制度，建立中央和地方两级药品储备。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Drug regulatory departments at or above the provincial level shall regularly release information on ADR reporting and monitoring.'可被翻译为：第五十三条 省级以上药品监督管理部门应当定期发布药品不良反应报告和监测情况。\n'Article 3 The State implements an ADR reporting system. Drug manufacturers (including overseas pharmaceutical manufacturers of imported drugs), drug distributors and medical institutions shall report ADRs as regulated.'可被翻译为：第三条 国家实行药品不良反应报告制度。药品生产企业（包括进口药品的境外制药厂商）、药品经营企业、医疗机构应当按照规定报告所发现的药品不良反应。\n'Article 34 The National Center for ADR Monitoring shall analyze and evaluate ADR reports received and report to the SFDA and the Ministry of Health semiannually; once information indicating potential drug safety risks is identified, reports shall be submitted in a timely manner.'可被翻译为：第三十四条 国家药品不良反应监测中心应当对收到的药品不良反应报告进行分析、评价，每半年向国家食品药品监督管理局和卫生部报告，发现提示药品可能存在安全隐患的信息应当及时报告。\n'Article 1 These Provisions are formulated in accordance with the Drug Administration Law of the People's Republic of China and other relevant laws and regulations in order to reinforce the post-marketing supervision and administration of drugs, standardize adverse drug reaction (ADR) reporting and monitoring, control drug risks promptly and effectively, and ensure safety of drug use for the public.'可被翻译为：第一条 为加强药品的上市后监管，规范药品不良反应报告和监测，及时、有效控制药品风险，保障公众用药安全，依据《中华人民共和国药品管理法》等有关法律法规，制定本办法。\n\n根据上述已知信息，请将'Article 57 The contents and statistical data of ADR reports are the basis for strengthening drug regulation and providing guidance for rational drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 药品不良反应报告的内容和统计资料是加强药品监督管理、指导合理用药的依据。"
    },
    {
        "instruction":"已知信息：\n'ammonia nitrogen'可被翻译为：氨氮\n'nitrogen equilibrium'可被翻译为：氮平衡\n'amino nitrogen'可被翻译为：氨基氮\n'non-protein nitrogen'可被翻译为：非蛋白质氮\n\n根据上述已知信息，请将'Nitrogen in the medium in the form of ammonia and coil ions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"培养基中以氨与卷离子形式存在的氮。"
    },
    {
        "instruction":"已知信息：\n'(7) When the multicenter clinical trial ends, the investigator of each clinical trial institution shall respectively issue the clinical trial summary, examine and verify the summary and the case reports according to relevant regulations, and submit them to the coordinating investigator and the coordinating investigator shall collect them and complete the summary report.'可被翻译为：（七）多中心临床试验结束后，各临床试验机构研究者应当分别出具临床试验小结，连同病历报告表按规定经审核后交由协调研究者汇总完成总结报告。\n'Article 86 The clinical trial report shall be signed and dated by the investigator, and submitted to the sponsor after being issued with opinions, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第八十六条 临床试验报告应当由研究者签名、注明日期，经临床试验机构医疗器械临床试验管理部门审核出具意见、注明日期并加盖临床试验机构印章后交申办者。\n'Article 84 For a multicenter clinical trial, the clinical trial summaries of each sub-site shall include at least a summary of the clinical trial, clinical general information, information for the investigational medical device and the compared device, safety and effectiveness data sets, incidence rate of the adverse events, description of deviation from the protocol and the case report form.'可被翻译为：第八十四条 对于多中心临床试验，各分中心临床试验小结应当至少包括临床试验概况、临床一般资料、试验用医疗器械以及对照用医疗器械的信息描述、安全性和有效性数据集、不良事件的发生率以及处理情况、方案偏离情况说明等，并附病例报告表。\n'Article 57 For multicenter clinical trials, the sponsor shall organize to formulate standard operating procedures in accordance with the clinical trial protocol and organize the training about the clinical trial protocol and the use and maintenance of investigational medical device to all investigators involved, so as to ensure the consistency of the implementation of clinical trial protocol and the use of investigational medical device.'可被翻译为：第五十七条 对于多中心临床试验，申办者应当按照临床试验方案组织制定标准操作规程，并组织对参与试验的所有研究者进行临床试验方案和试验用医疗器械使用和维护的培训，确保在临床试验方案执行、试验用医疗器械使用方面的一致性。\n\n根据上述已知信息，请将'In a multicenter clinical trial, the summaries of each clinical trial of sub-site shall be signed and dated by the investigator of the corresponding center, and reviewed, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the center, and then submitted to the leading unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"多中心临床试验中，各分中心临床试验小结应当由该中心的研究者签名并注明日期，经该中心的医疗器械临床试验管理部门审核、注明日期并加盖临床试验机构印章后交牵头单位。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In case of discovering the following serious illegal acts, the operator of cosmetic e-commerce platform shall immediately suspend provision of e-commerce platform services for the marketers of cosmetics in the platform:'可被翻译为：第四十八条 化妆品电子商务平台经营者发现有下列严重违法行为的，应当立即停止向平台内化妆品经营者提供电子商务平台服务：\n'The operators of cosmetic e-commerce platform shall assume the responsibility for managing cosmetic marketers within the platform according to law, make daily inspection of the marketing behavior of the cosmetic marketers within the platform, urge the cosmetic marketers within the platform to perform obligations specified in the Regulations on Supervision and Administration of Cosmetics and these Provisions according to law. In case of discovering illegal marketing of cosmetics, the inspectors shall stop timely by necessary means of deleting, shielding and unlinking, etc. in accordance with the laws or with service agreement and trading provisions of the platform, and report to the drug regulatory department of the province, autonomous region or municipality directly under the central government of the place where it is located.'可被翻译为：化妆品电子商务平台经营者应当依法承担平台内化妆品经营者管理责任，对平台内化妆品经营者的经营行为进行日常检查，督促平台内化妆品经营者依法履行化妆品监督管理条例以及本办法规定的义务。发现违法经营化妆品行为的，应当依法或者依据平台服务协议和交易规则采取删除、屏蔽、断开链接等必要措施及时制止，并报告所在地省、自治区、直辖市药品监督管理部门。\n'If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.'可被翻译为：化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。\n'If the department in charge of drug supervision and administration requires the operators of cosmetic e-commerce platform to provide relevant information according to law due to the needs for supervision and inspection and case investigation, etc., the operator of cosmetics e-commerce platform shall provide assistance and cooperation.'可被翻译为：负责药品监督管理的部门因监督检查、案件调查等工作需要，要求化妆品电子商务平台经营者依法提供相关信息的，化妆品电子商务平台经营者应当予以协助、配合。\n\n根据上述已知信息，请将'If the cosmetic marketers within the platform are placed on a file for investigation or are initiated a public prosecution due to being suspected of crime related with quality and safety of cosmetics, and there are evidences proving that this might cause potential harm to human health, then the operators of cosmetic e-commerce platform could suspend provision of e-commerce platform services for the cosmetic marketers within the platform in accordance with the laws or with the service agreement and trading provisions of the platform.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因涉嫌化妆品质量安全犯罪被立案侦查或者提起公诉，且有证据证明可能危害人体健康的，化妆品电子商务平台经营者可以依法或者依据平台服务协议和交易规则暂停向平台内化妆品经营者提供电子商务平台服务。"
    },
    {
        "instruction":"已知信息：\n'Article 14 The documents for registration application or filing shall be in Chinese, where they are translated from a foreign language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving of the owner's permission to use the information.'可被翻译为：第十四条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。\n'Article 14 The cited literature of the dossier of drug registration shall indicate the title of works or the name, volume number, issue and page of the journal. Where the cited references are not published, an author's permission shall be provided. For foreign literatures, Chinese translation shall be provided as required.'可被翻译为：第十四条 药品注册所报送的资料引用文献应当注明著作名称、刊物名称及卷、期、页等；未公开发表的文献资料应当提供资料所有者许可使用的证明文件。外文资料应当按照要求提供中文译本。\n'Article 18 An applicant shall provide the information on patent and its ownership of the applicant or other parties in China, in respect of the drug applied for registration, its formula, manufacturing processes and\/or uses, etc. Where another party owns the patent in China, the applicant shall provide a statement of non-infringement. The drug regulatory department shall publish the information or the statement submitted by the applicant on its official website.'可被翻译为：第十八条 申请人应当对其申请注册的药物或者使用的处方、工艺、用途等，提供申请人或者他人在中国的专利及其权属状态的说明；他人在中国存在专利的，申请人应当提交对他人的专利不构成侵权的声明。对申请人提交的说明或者声明，药品监督管理部门应当在行政机关网站予以公示。\n'(I) The foreign-invested enterprise established by an imported medical device registrant in China shall, asthe registration applicant, submit the application for medical device registration in China to the corresponding drug regulatory authority. The content of the registration application, except the name, domicile and production address of the registrant, shall, in principle, be consistent with relevant items specified in the corresponding imported medical device registration certificate and its attachments.'可被翻译为：（一）进口医疗器械注册人在中国境内设立的外商投资企业作为注册申请人，向药品监督管理部门提交境内医疗器械注册申请。注册申请内容，除注册人名称、住所、生产地址外，原则上应当与所对应的进口医疗器械注册证及其附件载明的相关事项保持一致。\n\n根据上述已知信息，请将'Article 12 The documents for registration application or filing shall be in Chinese. Where they are translated from another language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving the owner’s permission to use the information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。"
    },
    {
        "instruction":"已知信息：\n'cloning efficiency'可被翻译为：克隆形成率\n'The ability of cells to divide and to form daughter cells.'可被翻译为：细胞分化以及形成子细胞的能力。\n'The ratio of the number of observed mutant cells to the number of surviving cells.'可被翻译为：所观察到的突变细胞数与存活细胞数之比值。\n'A group of contact cells growing from a single cell in a solid medium or on a surface.'可被翻译为：从单一的细胞在固体培养基内或表面生长出一群相接触的细胞。\n\n根据上述已知信息，请将'The efficiency of single cells to form clones. It is usually measured after seeding low numbers of cells in a suitable environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个细胞形成克隆的能力。通常将少量细胞接种于适宜的环境培养后测量。"
    },
    {
        "instruction":"已知信息：\n'When atoms form molecules, the atomic orbitals are linearly combined into molecular orbitals, which are called bonding orbitals if the energy of the constituent molecular orbitals is lower than the energy of the atomic orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若低于原子轨道的能量，则该分子轨道叫做成键轨道。\n'When atoms form molecules, the atomic orbitals are linearly combined into the component F orbitals, and the energy of the component molecular orbitals is equal to the energy of the atomic orbitals, then the molecular orbitals are called non-bonding orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分F轨道，组成的分子轨道的能量若等于原子轨道的能量，则该分子轨道叫做非键轨道。\n'A chemical bond between atoms that results from overlapping atomic orbitals of bonding electrons.'可被翻译为：原子间由于成键电子的原子轨道重叠而形成的化学键。\n'In molecular orbitals, the highest occupied orbital and the lowest unoccupied orbital are collectively called.'可被翻译为：分子轨道中，最高占据轨道和最低未占轨道的统称。\n\n根据上述已知信息，请将'When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。"
    },
    {
        "instruction":"已知信息：\n'A compound having a chemical structure similar to that of existing drug molecules.'可被翻译为：与现有药物分子在化学结构上具有相似性的化合物。\n'A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.'可被翻译为：与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。\n'Similarity of compounds to known drugs. A concept that is similar to a drug and affects the success of drug development, including the pharmaceutical properties of the lead compound, pharmacokinetic parameters, and drug safety.'可被翻译为：化合物与已知药物的相似性。表示某些类似于药物性质又影响药物开发成功与否的概念，内容包含先导化合物的药学性质、药动学参数和药物安全性等。\n'1.A substance, other than the active pharmaceutical ingredient, which has been appropriately evaluated for safety and is included in a drug delivery system to:—aid in the processing of the drug delivery system during its manufacture;\n—protect, support or enhance stability, bioavailability or patient acceptability;\n—assist in pharmaceutical product identification; or\n—enhance any other attribute of the overall safety and effectiveness of the drug during its storage or use.\n2.A substance, other than the active pharmaceutical ingredient (API), which has been appropriately evaluated for safety and is included in a medicines delivery system to:—aid in the processing of the medicines delivery system during its manufacture;\n—protect, support or enhance stability, bioavailability or patient acceptability;\n—assist in pharmaceutical product identification; or\n—enhance any other attribute of the overall safety and effectiveness of the medicine during its storage or use.'可被翻译为：1.一种非活性药物成分的物质，已经过适当的安全性评估，并包含在给药系统中，以在给药系统生产过程中辅助处理;\n-保护、支持或增强稳定性、生物利用度或患者可接受性;\n-协助药品鉴定;或\n-在储存或使用期间增强药物整体安全性和有效性的任何其他属性。\n2.一种非活性药物成分(API)的物质，已经过适当的安全性评估，并包含在药物输送系统中，以在药物输送系统生产过程中辅助处理;\n-保护、支持或增强稳定性、生物利用度或患者可接受性;\n-协助药品鉴定;或\n-在储存或使用期间增强药物整体安全性和有效性的任何其他属性。\n\n根据上述已知信息，请将'A compound having a structural characteristic necessary for the action of a drug. The compound is not metabolized or transformed in living organisms, avoiding the production of certain toxic metabolites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有发挥药物作用所必需的结构特征的化合物。该化合物在生物体内不发生代谢或转化，可避免产生某些毒性代谢产物。"
    },
    {
        "instruction":"已知信息：\n'Disordered arrangement of molecules having the same chemical structure.'可被翻译为：具有相同化学结构的分子间的无序排列。\n'The arrangement of all the atoms in a compound molecule in space.'可被翻译为：化合物分子中所有原子在空间的排布方式。\n'Molecules with the same chemical structure are arranged in an orderly manner.'可被翻译为：具有相同化学结构的分子按照一定方式的有序排列。\n'Representing the bonding form and spatial arrangement of all constituent atoms in a molecule.'可被翻译为：表示分子中全部构成原子的成键形式与空间排列。\n\n根据上述已知信息，请将'The mutual repulsion caused by the spatial arrangement of groups inside the molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子内部基团在空间排布造成的相互排斥作用。"
    },
    {
        "instruction":"已知信息：\n'To keep pace with the international technicalstandards for drug registration, NMPA has decided after research to apply 15 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guidelines, including the E1: Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-ThreateningConditions (see annex for details). The relevant matters are announced as follows:'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《E1：人群暴露程度：评估非危及生命性疾病长期治疗药物的临床安全性》等15个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'To align the technical standards for drug registration with international standards, the National Medical Products Administration has decided to adopt 13 ICH safety guidelines, including S1A: Need for Carcinogenicity Studies of Pharmaceuticals (see the attachment for further information). Items of the Announcement are as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用13个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'To keep pace with the international technical standards for drug registration, NMPA has decided to apply 11 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the Q2(R1): Validation of Analytical Procedures: Text and Methodology. The relevant matters are hereby announced as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'NMPA Released Announcement on the Application of 13 ICH Guidelines Including S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals'可被翻译为：国家药监局关于适用《S1A：药物致癌性试验必要性指导原则》等13个国际人用药品注册技术协调会指导原则的公告\n\n根据上述已知信息，请将'To keep pace with the international technical standards for drug registration, NMPA has decided after research to apply 13 ICH(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.The relevant matters are announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《S1A：药物致癌性试验必要性指导原则》等13个国际人用药品注册技术协调会（ICH）指导原则。现就有关事项公告如下。"
    },
    {
        "instruction":"已知信息：\n'A volumetric utensil for accurately removing a given volume of solution. It is a glass tube with two slender ends and an enlarged part in the middle. The bottom end of the tube is needle-shaped, and there is a ring mark in the upper part. The mark marks the volume of the liquid when the liquid is filled to the scale at the specified temperature and left to flow out naturally. The commonly used pipette has 50ml, 25ml, 20ml, 10ml, 5ml, 2ml, 1ml and other specifications.'可被翻译为：一种准确移取一定体积溶液的容量器皿。是一根两头细长而中间有膨大部分的玻璃管。管的最下端呈尖嘴状，在上部有一环形标线，该标线标示在指定的温度下把液体充满到刻度后，任其自然流出时流出液体的体积。常用的移液管有50ml、25ml、20ml、10ml、5ml、2ml、1ml等多种规格。\n'In acid-base titration analysis, a measuring glass dropper containing a standard alkali titration solution. The lower end is a latex tube containing glass beads.'可被翻译为：酸碱滴定分析中，盛放标准碱滴定液的定量玻璃滴管。下端为含有玻璃珠的乳胶管。\n'In volumetric analysis, a standard solution of known accurate concentrations used for sample determination.'可被翻译为：在容量分析中，用于样品测定的已知准确浓度的标准溶液。\n'For immersion cells, the volume of receptor solution to be filled in the dissolution vessel should be accurately measured with the appropriate volumetric glassware and transferred to the dissolution vessel.'可被翻译为：对于浸没池，应使用适当体积的玻璃器皿准确测量所用的受体溶液体积，并将其转移到溶出杯中。\n\n根据上述已知信息，请将'A graduated slender glass tube, the most basic instrument for titrating the volume of a solution in volumetric analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容量分析中滴定溶液的体积最基本的仪器，有刻度的细长玻璃管。"
    },
    {
        "instruction":"已知信息：\n'Article 41 Based on the on-site inspection issues and related dossiers submitted by the observers, the drug regulatory authorities of the provinces, autonomous regions, and municipalities directly under the Central Government shall, in accordance with their daily supervision duties, review and confirm the rectification of the issues found in the on-site inspection of the inspected institution, and conduct follow-up inspections when necessary, and inform the review results to CDE in a timely manner.'可被翻译为：第四十一条 根据观察员报送的现场核查问题及相关材料，省、自治区、直辖市药品监督管理部门依日常监管职责对被核查单位的现场核查发现问题整改情况进行审核确认，必要时进行跟踪检查，并将审核结果及时告知药品审评中心。\n'Article 49 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall, within its administrative region, be responsible for the supervision and administration of the drug MAHs, and manufacturers of drug products, chemical active drug ingredients and Prepared Slices.'可被翻译为：第四十九条 省、自治区、直辖市药品监督管理部门负责对本行政区域内药品上市许可持有人，制剂、化学原料药、中药饮片生产企业的监督管理。\n'Article 55 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall determine inspection frequency based on the drug varieties, dosage form, regulation categories, taking into account overall national situation of drug safety, drug safety risk warning information, major drug safety events and related investigations and handling information as well as the previous inspections, monitoring of adverse reactions, complaints and whistle-blowing.'可被翻译为：第五十五条 省、自治区、直辖市药品监督管理部门应当根据药品品种、剂型、管制类别等特点，结合国家药品安全总体情况、药品安全风险警示信息、重大药品安全事件及其调查处理信息等，以及既往检查、检验、不良反应监测、投诉举报等情况确定检查频次：\n'Article 53 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'可被翻译为：第五十三条 省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告以及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。\n\n根据上述已知信息，请将'Article 25 The drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government where the inspected institution is located shall select a drug regulatory officer as an observer to assist in the registration inspection work and be responsible for transferring the problems found in the registration inspection to the drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条 被核查单位所在地省、自治区、直辖市药品监督管理部门选派1名药品监督管理人员作为观察员协助注册核查工作，负责将注册核查发现的问题等转送给省、自治区、直辖市药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'The involved disciplines at an organization from where a designated product, process or method is expected to be transferred.'可被翻译为：指定的产品、过程或方法预计将从该组织转移，该组织所涉及的学科。\n'transfer of relevant information in production, including but not limited to processing and packaging and analytical procedure;'可被翻译为：生产相关信息的转移，包括但不仅限于工艺、包装和分析方法；\n'A logical procedure that controls the transfer of any product or process, including product or process knowledge, together with its documentation and professional expertise. Technology transfer may involve development, manufacturing or testing sites.'可被翻译为：控制任何产品或工艺(包括产品或工艺知识)及其文件和专业知识转让的逻辑程序。技术转让可能涉及开发、制造或测试场所。\n'arrangements are made for the documented technology transfer.'可被翻译为：技术转移工作有文件记录安排。\n\n根据上述已知信息，请将'The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组织中涉及的学科，其中指定的产品、过程或方法预计将被转移。"
    },
    {
        "instruction":"已知信息：\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n'Each lot of vaccines to be sold or imported shall be examined and tested in accordance with relevant technical requirements by lot release institutions designated by the drug regulatory department under the State Council. A qualified lot shall be granted a certificate for lot release of biological product; and a disqualified lot shall be given a notice of disapproval for lot release.'可被翻译为：每批疫苗销售前或者进口时，应当经国务院药品监督管理部门指定的批签发机构按照相关技术要求进行审核、检验。符合要求的，发给批签发证明；不符合要求的，发给不予批签发通知书。\n'Article 30 In the case that major quality risks of vaccines are identified during the process of lot release, lot release institutions shall in a timely manner report to the drug regulatory department under the State Council and the drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government.'可被翻译为：第三十条 批签发机构在批签发过程中发现疫苗存在重大质量风险的，应当及时向国务院药品监督管理部门和省、自治区、直辖市人民政府药品监督管理部门报告。\n'Article 29 The lot release institution shall make decision on lot release based on dossier review, sample testing or on-site inspection. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.'可被翻译为：第二十九条    批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。\n\n根据上述已知信息，请将'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。"
    },
    {
        "instruction":"已知信息：\n'l. <1223> Validation of alternative microbiological methods'可被翻译为：<1223>替代微生物方法的验证\n'The adoption of suitable alternative monitoring  systems such as rapid methods should be considered by manufacturers in order to expedite the detection of microbiological contamination issues and to reduce the risk to product.  These  rapid   and  automated  microbial   monitoring  methods  may  be   adopted   after validation  has demonstrated their equivalency or superiority to the established methods.'可被翻译为：生产商应考虑釆用合适的替代监测系统（例如快速方法），以加速微生物污染问题的发现并降低对产品的风险。在通过验证证明对已建立的方法具有等效性或优越性后，可以采用这些快速或自动微生物监测方法。\n'microbiological assay'可被翻译为：微生物效价测定\n'b. Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products (draft guidance, 2\/2008)'可被翻译为：基于生长快速微生物方法用于细胞和基因治疗产品无菌检测的验证（2008 年 2月，草案）\n\n根据上述已知信息，请将'Evaluation, Validation and Implementation of New Microbiological Testing Methods'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"新微生物检测方法的评估、验证和实施"
    },
    {
        "instruction":"已知信息：\n'ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet the appropriate specifications in order to ensure the requirements of the method or specification are met;'可被翻译为：确保QC具备所需的仪器，并经过确认。分析方法转移期间RU所用仪器应符合适当的标准，以确保满足方法要求或标准要求；\n'12.27. Analytical methods used to test pharmaceutical products, starting materials, packaging components and cleaning (residue) samples, if applicable, should be implemented at the testing laboratory before the testing of samples for process validation studies is performed by the RU. The transfer of the analytical procedure may be accomplished by several approaches such as confirmation testing, comparability testing between SU and RU results, co-validation between laboratories, or through a “paper-based knowledge” transfer. The strategy chosen should be risk-based and scientifically justifiable.'可被翻译为：在RU开始对工艺验证研究样品进行检测之前，应在检测实验室执行检测药品、起始物料、包装材料和清洁（残留）样品（如适用）所用的分析方法。分析方法的转移有几种方法，如确认性检测、SU与RU之间比较性检测结果、实验室之间协同验证，或者是通过“纸面知识”进行转移。应基于风险选择策略，策略应该可进行科学论证。\n'1.7. A technology transfer should include relevant documentation, data, information and knowledge from the SU in order to enable the RU to effectively perform the specified process or procedure in, for example, production and QC. A successful transfer of technology should result in proof that the RU can routinely reproduce the transferred product, process or procedure against a predefined set of specifications as agreed between the SU and RU.'可被翻译为：技术转移应包括来自SU的相关文件、数据、信息和知识，使得RU能够有效实施指定的工艺或方法，例如生产和QC。成功的技术转移应证明RU可以常规化地按SU与RU之间预定的标准生产出所转移的产品、工艺或方法。\n'12.23. During the transfer process, the RU should identify any differences in facilities, systems and capabilities and discuss these with the SU. The SU should cooperate with the RU to understand the potential impact and satisfactorily address this in order to assure equivalent product quality. based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop the relevant site operating procedures and documentation before the start of routine production.'可被翻译为：在转移过程中，RU应该找出设施、系统和能力方面的所有差异，并与SU进行讨论。SU应该与RU合作，了解潜在影响，并圆满解决这些问题，从而确保产品质量一致。基于从SU处收到的信息，RU应该考虑其自己生产和包装该产品达到所需标准的能力，应在开始常规生产之前建立相关的现场操作程序和文件。\n\n根据上述已知信息，请将'10.4. Production process and analytical procedures should be appropriately transferred to the RU following documented procedures. Where validation data exist, these should be included in the \ntransfer.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产工艺和分析方法应按照文件程序妥善转移至 RU 处。如果有验证数据，应该包括在转移中。"
    },
    {
        "instruction":"已知信息：\n'1.The act whereby the regulatory authority in one jurisdiction may take into account and give significant weight to – i.e. totally or partially rely upon – evaluations performed by another regulatory authority or trusted institution in reaching its own decision. The relying authority remains responsible and accountable for decisions taken, even when it relies on the decisions and information of others (25).\n2.An act whereby a regulatory authority in one jurisdiction may take into account or give significant weight to work performed by another regulator, or other trusted institution, in reaching its own decision.'可被翻译为：1.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或值得信赖的机构所进行的评估，并给予重大重视，即完全或部分依赖。依赖机构仍然对所做的决定负责，即使它依赖于他人的决定和信息(25)。\n2.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或其他受信任的机构所做的工作或给予重大重视的行为。\n'participating stringent regulatory authority'可被翻译为：参与的严格监管机构\n'A set of interrelated or interacting activities that use inputs to deliver an intended result. In the context of NRAs, the production and service provision processes should coincide with basic regulatory functions.'可被翻译为：一组相互关联或相互作用的活动，它们使用输入来交付预期的结果。在nra的背景下，生产和服务提供过程应与基本监管功能相一致。\n'reliance'可被翻译为：依赖\n\n根据上述已知信息，请将'Regulatory procedures facilitated by reliance, whereby a regulatory decision is solely or partially based on application of reliance. This usually involves some work by the national regulatory authority (NRA) that is practising reliance (see section 5.4 Risk-based approach). It is expected that use of reliance in these pathways will save resources and time as compared with standard pathways, while ensuring that the standards of regulatory oversight are maintained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"信赖促进了监管程序，即监管决定完全或部分基于信赖的应用。这通常涉及实施信赖的国家监管机构(NRA)的一些工作(见第5.4节基于风险的方法)。预计与标准途径相比，在这些途径中使用依赖将节省资源和时间，同时确保维持监管监督的标准。"
    },
    {
        "instruction":"已知信息：\n'Article 181: Operation procedures should include the title, code, version number, issuing department, effective date, distribution list, along with the dated signatures of author, reviewer and approver, the title, content, and change history.'可被翻译为：第一百八十一条 操作规程的内容应当包括：题目、编号、版本号、颁发部门、生效日期、分发部门以及制定人、审核人、批准人的签名并注明日期，标题、正文及变更历史。\n'Article 159: Records should be made at the time each activity related to the Provisions is taken and in such a way that activities concerning the manufacture, quality control and quality assurance of products are traceable. Sufficient space should be provided for data entering in the record. The record should be entered timely and truthfully, and the handwriting should be clear, legible and indelible.'可被翻译为：第一百五十九条 与本规范有关的每项活动均应当有记录，以保证产品生产、质量控制和质量保证等活动可以追溯。记录应当留有填写数据的足够空格。记录应当及时填写，内容真实，字迹清晰、易读，不易擦除。\n'Article 211: Checks should be carried out to ensure that any electronic code readers, label counters or similar devices are functioning correctly. Such checks should be recorded.'可被翻译为：第二百一十一条 应当对电子读码机、标签计数器或其他类似装置的功能进行检查，确保其准确运行。检查应当有记录。\n'Article 153: Operation procedures should be followed for drafting, revision, review, approval, replacement or withdrawal, reproduction, storage and destruction of documents; and relevant records for distribution, withdrawal, reproduction and destruction of documents should be in place.'可被翻译为：第一百五十三条 文件的起草、修订、审核、批准、替换或撤销、复制、保管和销毁等应当按照操作规程管理，并有相应的文件分发、撤销、复制、销毁记录。\n\n根据上述已知信息，请将'Article 182: Premises, equipment, materials, documents and records should have codes (or reference numbers). Operation procedures should be established for the numbering\/coding system to ensure the uniqueness of the codes (or reference numbers).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百八十二条 厂房、设备、物料、文件和记录应当有编号（或代码），并制定编制编号（或代码）的操作规程，确保编号（或代码）的唯一性。"
    },
    {
        "instruction":"已知信息：\n'The MAH shall establish a marketing release procedure to review the testing results and release documents of the product released by the drug manufacturers, and the drug products can be released only after signed off by qualified person.'可被翻译为：药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品检验结果和放行文件进行审核，经质量受权人签字后方可上市放行。\n'Drug manufacturers shall establish drug release procedures and specify the release standards and criteria. Drug products that meet the standards and criteria shall be released upon signature by the qualified person.'可被翻译为：药品生产企业应当建立药品出厂放行规程，明确出厂放行的标准、条件。符合标准、条件的，经质量受权人签字后方可放行。\n'Article 37 Drug manufacturers shall establish standard procedures for drug release by clarifying the release specification and conditions, and review the quality testing results, key manufacturing records and deviation control and conduct quality testing for the drugs. Only the drugs with qualified specification and conditions as well as the signature of the qualified person can be released.'可被翻译为：第三十七条 药品生产企业应当建立药品出厂放行规程，明确出厂放行的标准、条件，并对药品质量检验结果、关键生产记录和偏差控制情况进行审核，对药品进行质量检验。符合标准、条件的，经质量受权人签字后方可出厂放行。\n'Lot release products shall be manufactured in accordance with the approved process and shall conform to the national drug standards and drug registration standards. The entire production process shall comply with the Good Manufacture Practice for Pharmaceutical Products. MAHs shall establish a complete production quality management system and continuously strengthen the management of deviation. MAHs shall be responsible for the authenticity of the materials, records and data generated during the production, testing and relevant processes of the lot release products. Lot release materials shall be reviewed, signed and issued by the qualified person of the MAHs.'可被翻译为：批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准。生产全过程应当符合药品生产质量管理规范的要求。药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理。药品上市许可持有人对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经药品上市许可持有人的质量受权人审核并签发。\n\n根据上述已知信息，请将'Article 33 MAHs shall establish a marketing release procedure to audit drug products released by drug manufacturers. Drug products shall not be released until signed off by a qualified person and those that do not conform to national drug standards shall not be released.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十三条 药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品进行审核，经质量受权人签字后方可放行。不符合国家药品标准的，不得放行。"
    },
    {
        "instruction":"已知信息：\n'Environmental monitoring data and trend data generated for classified areas should be reviewed as part of product batch certification\/release. A written procedure should be available that describes the actions to be taken when data from environmental monitoring are found out of trend or exceeding the established limits. For products with short shelf life, the environmental data for the time of manufacture may not be available; in these cases, the compliance should include a review of the most recent available data. Manufacturers of these products  should\nconsider the use of rapid\/alternative methods.'可被翻译为：洁净区的环境监测数据和趋势分析数据应作为产品批次认证\/放行的一部分进行审核。应提供一份书面程序，描述当发现环境监测数据超趋势或超出既定限度时应釆取的措施。对于货架期较短的产品，可能无法获得生产时的环境数据；在这些情况下，符合性应包括对最新可用数据的审核。这些产品的生产商应考虑使用\n快速\/替代方法。\n'Article 187: For each product batch, checks on yields and reconciliation of quantities should be carried out to ensure that there are no discrepancies outside of the acceptable limits. If a discrepancy is found, investigations should be performed to find out the reason, and the batch can only be released after it has been made clear that no potential quality risks exist.'可被翻译为：第一百八十七条 每批产品应当检查产量和物料平衡，确保物料平衡符合设定的限度。如有差异，必须查明原因，确认无潜在质量风险后，方可按照正常产品处理。\n'Note: Where the manufacturing process results in sub-batches (e.g. for terminally sterilised products) then sterility samples from each sub-batch should be taken and a sterility test for each sub-batch performed. Consideration should also be given to performing separate testing for other finished product tests.'可被翻译为：注：如果生产过程中出现了亚批（例如最终灭菌产品），则应从每个亚批中取样，并对每个亚批进行无菌\n检验。还应考虑对其它成品检验项目进行单独检验。\n'For some products it may not be possible to obtain a sterility test result prior to release because the shelf life of the product is too short to allow completion of a sterility test. In these cases, the additional considerations of design of the process and additional monitoring and\/or alternative test methods required to mitigate the identified risks should be assessed and documented.'可被翻译为：对于某些产品，可能无法在放行前获得无菌检验结果，因为产品的货架期太短而来不及获得无菌检验的结 果。在这些情况下，应考采用虑额外的工艺设计以及额外监测和\/或替代检验方法来缓解已识别风险，并对此进行评估并记录。\n\n根据上述已知信息，请将'All non-conformities, such as sterility test failures, environmental monitoring excursions or deviations from established procedures should be adequately investigated before certification\/release of the batch. The\ninvestigation should determine the potential impact upon process and product quality and whether any other processes or batches are potentially impacted. The reason for including or excluding a product or batch from the\nscope of the investigation should be clearly justified and recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有不合格情况应在批次认证\/放行之前充分调查，例如无菌检验不通过、环境监测异常或偏离既定程序的偏差等。调查中，应确定不合格情况对工艺和产品质量的潜在影响，以及是否有可能影响任何其它工艺或批次。某一产品或批次纳入调查范围或排除在外的理由应予以明确说明并记录。"
    },
    {
        "instruction":"已知信息：\n'Provisions for Drug Recall'可被翻译为：药品召回管理办法\n'The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.'可被翻译为：《药品流通监督管理办法》于2006年12月8日经国家食品药品监督管理局局务会审议通过，现予公布，自2007年5月1日起施行。\n'The State Food and Drug Administration shall supervise the management of recall of drugs across the country.'可被翻译为：国家食品药品监督管理局监督全国药品召回的管理工作。\n'Article 9 The State Food and Drug Administration and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall establish the drug recall information disclosure system and publicize information about drugs with safety hazards and recall of drugs to the society in an effective way.'可被翻译为：第九条 国家食品药品监督管理局和省、自治区、直辖市药品监督管理部门应当建立药品召回信息公开制度，采用有效途径向社会公布存在安全隐患的药品信息和药品召回的情况。\n\n根据上述已知信息，请将'The Provisions for Drug Recall was deliberated and adopted by the executive meeting of the State Food and Drug Administration on December 6, 2007 and now is issued. These Provisions shall go into effect as of the date of promulgation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品召回管理办法》于2007年12月6日经国家食品药品监督管理局局务会审议通过，现予公布，自公布之日起施行。"
    },
    {
        "instruction":"已知信息：\n'An applicant who is approved to carry out clinical trials of drugs shall be the sponsor of drug clinical trials (hereinafter referred to as the sponsor).'可被翻译为：申请人获准开展药物临床试验的为药物临床试验申办者（以下简称申办者）。\n'The applicant shall be responsible for the quality of the drugs used for clinical trials.'可被翻译为：申请人对临床试验用药物的质量负责。\n'Article 26 When the drug clinical trial application is approved, the sponsor shall formulate the corresponding drug clinical trial protocols and have them reviewed and approved by the ethics committee before carrying out the subsequent phases of clinical trial, and submit the corresponding protocols and supporting dossiers on the CDE website.'可被翻译为：第二十六条 获准开展药物临床试验的，申办者在开展后续分期药物临床试验前，应当制定相应的药物临床试验方案，经伦理委员会审查同意后开展，并在药品审评中心网站提交相应的药物临床试验方案和支持性资料。\n'Article 27 For a drug approved for clinical trials, where an indication is to be added or the drug is to be used in combination with other drug(s), the applicant shall file a new drug clinical trial application to the CDE, and after approval shall the new drug clinical trial be conducted.'可被翻译为：第二十七条 获准开展药物临床试验的药物拟增加适应症（或者功能主治）以及增加与其他药物联合用药的，申请人应当提出新的药物临床试验申请，经批准后方可开展新的药物临床试验。\n\n根据上述已知信息，请将'Article 34 When a drug clinical trial is approved, the applicant shall select institutions for the clinical trial from those certified for conducting drug clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 药物临床试验批准后，申请人应当从具有药物临床试验资格的机构中选择承担药物临床试验的机构。"
    },
    {
        "instruction":"已知信息：\n'A class of inactive endogenous peptides synthesized in the liver and present in most body fluids. Converted by enzymolysis into active kinin, which is involved in inflammation, blood clotting, and complement reaction.'可被翻译为：在肝中合成并存在于绝大多数体液的一类无活性内源性肽类。经酶解作用转变成活性的激肽，后者与炎症、血液凝固、补体反应等有关。\n'bradykinin'可被翻译为：缓激肽\n'A product made from human blood plasma.'可被翻译为：由人血浆为原料而制备的制品。\n'An immunoglobulin produced by plasma cells differentiated from B cells under the stimulation of antigenic substances and capable of specific binding reactions with corresponding antigens.'可被翻译为：机体在抗原物质刺激下，由B细胞分化成的浆细胞所产生的、可与相应抗原发生特异性结合反应的免疫球蛋白。\n\n根据上述已知信息，请将'A precursor substance of kinin in the body. Produced in the liver, it is -plasma 012-globulin.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"体内激肽的前体物质。产生于肝脏，是-种血浆012-球蛋白。"
    },
    {
        "instruction":"已知信息：\n'Article 132 Items and personal belongings irrelevant to drug distribution activities shall not be stored in the storage and display areas of drugs. There shall be no action in the working areas that may affect the quality and safety of drugs.'可被翻译为：第一百三十二条 在药品储存、陈列等区域不得存放与经营活动无关的物品及私人用品，在工作区域内不得有影响药品质量和安全的行为。\n'(I) Such drugs shall be stored in special places clearly marked and effectively isolated, and shall not be sold;'可被翻译为：（一）存放于标志明显的专用场所，并有效隔离，不得销售；\n'(XII) Items irrelevant to storage management shall not be stored in the storage area of drugs.'可被翻译为：（十二）药品储存作业区内不得存放与储存管理无关的物品。\n'(X) Facilities and equipment for the storage of drugs such as shelves and trays shall be kept clean without damage or stacking of sundries;'可被翻译为：（十）储存药品的货架、托盘等设施设备应当保持清洁，无破损和杂物堆放；\n\n根据上述已知信息，请将'(XI) The unapproved personnel shall not enter the storage area, and the personnel in storage area shall not have any action affecting the quality and safety of drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）未经批准的人员不得进入储存作业区，储存作业区内的人员不得有影响药品质量和安全的行为；"
    },
    {
        "instruction":"已知信息：\n'As of January 1, 2022, for the registration application of cosmetics for spot correcting, whitening and preventing hair loss, registration persons shall submit the human efficacy test report conforming to the requirements in accordance with the Rules.'可被翻译为：自2022年1月1日起，申请祛斑美白、防脱发化妆品注册时，注册申请人应当按照规定，提交符合要求的人体功效试验报告。\n'For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed prior to May 1, 2021, registration persons shall submit the human efficacy test report prior to May 1, 2023.'可被翻译为：2021年5月1日前申请并取得注册的祛斑美白、防脱发化妆品，注册人应当在2023年5月1日前补充提交人体功效试验报告。\n'For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed between May 1 and December 31, 2021, registration persons shall submit the human efficacy test report conforming to the requirements prior to May 1, 2022.'可被翻译为：2021年5月1日至12月31日期间申请并取得注册的祛斑美白、防脱发化妆品，注册人应当于2022年5月1日前补充提交符合要求的人体功效试验报告。\n'In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs'可被翻译为：ANDA申请中递交的外用药物产品体外释放（IVRT）研究\n\n根据上述已知信息，请将'IV. Efficacy evaluation and test report of cosmetics for spot correcting, whitening and preventing hair loss'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、关于祛斑美白和防脱发化妆品功效评价检验报告"
    },
    {
        "instruction":"已知信息：\n'According to the normal usage, dosage of the drug to prevent, diagnose or treat the disease process, occurred in the therapeutic purpose unrelated harmful reactions.'可被翻译为：按正常用法、用量应用药物预防、诊断或治疗疾病过程中，发生于治疗目的无关的有害反应。\n'Also known as \"dose-related adverse reactions\". Adverse reactions that are closely related to dosage. Predictable.'可被翻译为：又称\"剂量相关性不良反应\"。与剂量密切相关的不良反应。可预测。\n'therapeutic effect'可被翻译为：治疗作用\n'A pharmacological effect occurring at a therapeutic dose independent of the therapeutic effect.'可被翻译为：在治疗剂量下出现的，和治疗作用无关的药理效应。\n\n根据上述已知信息，请将'The adverse reactions that occur after the therapeutic effect of drugs are the consequences of the therapeutic effect itself under the therapeutic dose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物治疗作用之后出现的不良反应，是治疗剂量下治疗作用本身带来的后果。"
    },
    {
        "instruction":"已知信息：\n'Article 10 The persons undertaking registration or filing for medical devices shall have corresponding specialized knowledge and be familiar with the laws, rules, regulations and technical requirements of the administration on registration or filing of medical devices.'可被翻译为：第十条 办理医疗器械注册或者备案事务的人员应当具有相应的专业知识，熟悉医疗器械注册或者备案管理的法律、法规、规章和技术要求。\n'Article 11 The persons undertaking registration or filing for in-vitro diagnostic reagents shall have corresponding specialized knowledge and be familiar with the laws, rules, regulations and technical requirements of the administration on registration or filing of in-vitro diagnostic reagent.'可被翻译为：第十一条 办理体外诊断试剂注册或者备案事务的人员应当具有相应的专业知识，熟悉医疗器械注册或者备案管理的法律、法规、规章和技术要求。\n'Pharmaceutical professional and technical personnel who have received academic education in pharmacy and are engaged in drug dispensing, preparation, testing, production and other work, and have been recognized as qualified according to law.'可被翻译为：受过药学专业学历教育，从事药物调剂、制备、检定、生产等工作，并依法经资格认定的药学专业技术人员。\n'Legally qualified pharmacists or other pharmaceutical professionals shall be responsible for the drug management, prescription examination and dispensing, and guidance of rational use of drugs.'可被翻译为：依法经过资格认定的药师或者其他药学技术人员负责本企业的药品管理、处方审核和调配、合理用药指导等工作。\n\n根据上述已知信息，请将'The persons who handle the application for drug registration shall have professional knowledge and be familiar with the laws and regulations on, and the technical requirements for, drug registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理药品注册申请事务的人员应当具有相应的专业知识，熟悉药品注册的法律、法规及技术要求。"
    },
    {
        "instruction":"已知信息：\n'Article 80 MAHs shall monitor for adverse reactions of marketed drugs, take the initiative to collect, track and analyze information on suspected adverse drug reactions, and promptly take risk control measures for drugs for which risks are identified.'可被翻译为：第八十条 药品上市许可持有人应当开展药品上市后不良反应监测，主动收集、跟踪分析疑似药品不良反应信息，对已识别风险的药品及时采取风险控制措施。\n'Drug MAHs and drug manufacturers shall make constant investigations into quality, efficacy and adverse reactions of their drugs. Once suspected adverse reactions are discovered, they shall be reported in a timely manner as required.'可被翻译为：药品上市许可持有人、药品生产企业应当经常考察本单位的药品质量、疗效和不良反应。发现疑似不良反应的，应当及时按照要求报告。\n'The State establishes the pharmacovigilance system to monitor, detect, assess and control adverse reactions or other harmful reactions related to use of drugs.'可被翻译为：国家建立药物警戒制度，对药品不良反应及其他与用药有关的有害反应进行监测、识别、评估和控制。\n'(4) information on pharmacovigilance department, personnel and system establishment, as well as information on the monitoring, identification, assessment and control of suspected adverse drug reactions;'可被翻译为：（四）药物警戒机构、人员、制度制定情况以及疑似药品不良反应监测、识别、评估、控制情况；\n\n根据上述已知信息，请将'(3) They shall have the abilities to monitor and evaluate adverse reactions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）有不良反应监测与评价的能力。"
    },
    {
        "instruction":"已知信息：\n'Article 158: Documents should be regularly reviewed and revised. When a document has been revised, systems should exist to prevent inadvertent use of superseded documents. Distributed documents in use should be the approved current version. Those superseded and outdated documents should not be accessible in operating area except for archiving.'可被翻译为：第一百五十八条 文件应当定期审核、修订；文件修订后，应当按照规定管理，防止旧版文件的误用。分发、使用的文件应当为批准的现行文本，已撤销的或旧版文件除留档备查外，不得在工作现场出现。\n'Article 32 The drafting, revision, review, approval, distribution and retention as well as the amendment, revocation, replacement and destruction of documents, shall be conducted in accordance with the documentation control operating procedures, and relevant records shall be kept.'可被翻译为：第三十二条 文件的起草、修订、审核、批准、分发、保管，以及修改、撤销、替换、销毁等应当按照文件管理操作规程进行，并保存相关记录。\n'Article 55 Validation shall be carried out in accordance with the pre-determined and approved scheme; the validation report shall be reviewed and approved. Validation documents shall be archived.'可被翻译为：第五十五条 验证应当按照预先确定和批准的方案实施，验证报告应当经过审核和批准，验证文件应当存档。\n'Article 54 Enterprises shall form validation control documents in accordance with relevant validation management systems, including validation schemes, reports, evaluations, deviation handling and preventive measures, etc.'可被翻译为：第五十四条 企业应当根据相关验证管理制度，形成验证控制文件，包括验证方案、报告、评价、偏差处理和预防措施等。\n\n根据上述已知信息，请将'Article 34 Enterprises shall periodically review and revise the documents, and the documents used shall be current valid versions. Documents that have been abolished or invalid shall not appear on the work site unless they are kept for reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 企业应当定期审核、修订文件，使用的文件应当为现行有效的文本，已废止或者失效的文件除留档备查外，不得在工作现场出现。"
    },
    {
        "instruction":"已知信息：\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n'Article 16 Procedures for the formulation and revision of medical device standards include standards project initiation, drafting, public consultation, technical review, approval and issuance, reexamination and abolishment, etc. The specific stipulations shall be formulated by China Food and Drug Administration.'可被翻译为：第十六条 医疗器械标准制修订程序包括标准立项、起草、征求意见、技术审查、批准发布、复审和废止等。具体规定由国家食品药品监督管理总局制定。\n'Article 12 China Food and Drug Administration shall, based on the demands of medical device standardization, establish technical committees on medical device standardization upon approval in accordance with laws.'可被翻译为：第十二条 国家食品药品监督管理总局根据医疗器械标准化工作的需要，经批准依法组建医疗器械标准化技术委员会。\n'Article 6 China Food and Drug Administration shall develop the medical device standards plan, establish the working mechanism for medical device standards administration and improve the medical device standards administration system in accordance with laws.'可被翻译为：第六条 国家食品药品监督管理总局依法编制医疗器械标准规划，建立医疗器械标准管理工作制度，健全医疗器械标准管理体系。\n\n根据上述已知信息，请将'Article 2 Medical device standards stated in these Provisions refer to the unified technical requirements for the research and development, manufacturing, distribution, use, supervision and administration of medical devices which are formulated and revised by China Food and Drug Administration as per its duties and issued in accordance with the legal procedures so as.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 本办法所称医疗器械标准，是指由国家食品药品监督管理总局依据职责组织制修订，依法定程序发布，在医疗器械研制、生产、经营、使用、监督管理等活动中遵循的统一的技术要求。"
    },
    {
        "instruction":"已知信息：\n'Article 21 An enterprise to be engaged in Class II medical device distribution shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions (except Item (7)) to complete the distribution filing, and obtain the filing number.'可被翻译为：第二十一条  从事第二类医疗器械经营的，经营企业应当向所在地设区的市级负责药品监督管理的部门备案，并提交符合本办法第十条规定的资料（第七项除外），即完成经营备案，获取经营备案编号。\n'To engage in manufacturing of Class II and Class III medical devices, an entity shall obtain approval from the drug regulatory department of the local province, autonomous region, or municipality directly under the central government, and acquire Medical Device Manufacturing License according to law; to engage in manufacturing of Class I medical devices, an entity shall handle medical device manufacturing filing formalities at the local department in charge of drug supervision and administration at the level of a city divided into districts.'可被翻译为：从事第二类、第三类医疗器械生产活动，应当经所在地省、自治区、直辖市药品监督管理部门批准，依法取得医疗器械生产许可证；从事第一类医疗器械生产活动，应当向所在地设区的市级负责药品监督管理的部门办理医疗器械生产备案。\n'Article 10 An enterprise to be engaged in the manufacturing of Class II or III medical devices shall apply for a manufacturing license to the drug regulatory department of the province, autonomous region, or municipality directly under the central government where it is located, and shall submit the following materials:'可被翻译为：第十条  在境内从事第二类、第三类医疗器械生产的，应当向所在地省、自治区、直辖市药品监督管理部门申请生产许可，并提交下列材料：\n'Article 23 In case of changes in manufacturing filing contents of Class I medical devices, the applicant shall submit materials related with such changes as stipulated in Article 10 of these Provisions to the former filing department within 10 working days, and if necessary, the drug regulatory department may carry out on-site inspection as stipulated in Article 22 of these Provisions.'可被翻译为：第二十三条  第一类医疗器械生产备案内容发生变化的，应当在10个工作日内向原备案部门提交本办法第十条规定的与变化有关的材料，药品监督管理部门必要时可以依照本办法第二十二条的规定开展现场核查。\n\n根据上述已知信息，请将'Article 22 An enterprise to be engaged in manufacturing Class I medical devices shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions to complete the manufacturing filing, and obtain the filing number. Where the medical device filing entities manufacture Class I medical devices by themselves, they may handle the manufacturing filing together with the product filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  从事第一类医疗器械生产的，应当向所在地设区的市级负责药品监督管理的部门备案，在提交本办法第十条规定的相关材料后，即完成生产备案，获取备案编号。医疗器械备案人自行生产第一类医疗器械的，可以在办理产品备案时一并办理生产备案。"
    },
    {
        "instruction":"已知信息：\n'cylinder bundle'可被翻译为：筒包\n'cylinder'可被翻译为：油缸\n'Aseptic assembly of filling equipment.'可被翻译为：灌装设备的无菌装配。\n'A device in which two or more materials are dispersed to a uniform state by mechanical means.'可被翻译为：用机械方法使两种或多种物料相互分散而达到均匀状态的设备。\n\n根据上述已知信息，请将'An assembly of cylinders that are fastened together, interconnected by a manifold, transported and used as a unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种钢瓶的组合，它们被固定在一起，通过歧管相互连接，作为一个整体运输和使用。"
    },
    {
        "instruction":"已知信息：\n'(2) Where an application item is not subject to the jurisdiction of the concerned departments by law, it shall be decided not to accept the application in time and informed to the applicant to apply to the relevant administrative departments;'可被翻译为：（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；\n'(IV) Where an application is not within the functions and duties of the department, the applicant shall be notified immediately of unacceptance.'可被翻译为：（四）申请事项不属于本部门职权范围的，应当即时告知申请人不予受理。\n'(1)  For those application items that are not within its duties, the relevant department may make a prompt decision of non-acceptance and inform the applicant to resubmit the application to the applicable administrative agency;'可被翻译为：（一）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；\n'(2) Where an application item is not subject to the jurisdiction of the relevant authorities in accordance with the law, a decision of rejection shall be made in time and the applicant shall be informed to apply to the relevant authorities;'可被翻译为：（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请。\n\n根据上述已知信息，请将'(4) If the subject matter of the application does not fall within the scope of this administrative authority, a decision of not accepting the application shall be made immediately, and the applicant shall be notified of applying to relevant administrative authority.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请事项不属于本行政机关职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政部门申请。"
    },
    {
        "instruction":"已知信息：\n'If an investigation finds that the conduct of the analysis included errors or events that caused the test specimens to be contaminated by the lab environment, the Sterility Test result would be invalid, and the substandard laboratory practice should be corrected to prevent this problem from recurring. For more information on how to judge investigational findings to make this evaluation, see Section XI.C1.and 2 of FDA’s guidance on Sterile Drug Products Produced by Aseptic Processing for principles and expectations for investigating a sterility positive.'可被翻译为：如果调查发现分析过程有可能导致受试样本被环境污染的错误或事件，则无菌性测 试结果可能无效，应纠正不合格的实验室作法，从而防止发生该问题。如何判断调 查发现，进行该评价的更多信息参见FDA指南《采用无菌工艺生产的无菌药品》 中无菌阳性的调查原则和要求。\n'Determine whether equipment malfunctioned or was not operated properly. If a malfunction occurred, determine whether it was likely to cause the contamination. Determine if monitoring records and any checklists or logs indicate that the ISO 5 environment was in good state of control (serious environmental quality or equipment repair issues) at the time of the sterility test. Be aware of the most likely failure modes in the equipment (e.g., laminar flow hood, glovebox, or isolator) used.'可被翻译为：确定是否设备故障，或操作不当。如果发生故障，确定是否可能导致污染。确定在 无菌测试时监测记录和检查清单或日志是否显示ISO5环境处于良好的受控状态 （严重环境质量或设备维修问题）。了解所用设备（例如，层流罩、手套箱或隔离 器）的最可能失效模式。\n'Determine whether there were any anomalies or deviations from the analytical method. Adherence to method should be verified at the time of analysis, and any major breach of sterility test procedure should also be documented at that time. If any method breaches occurred, determine whether it was likely to cause the contamination. Be aware of any possible weaknesses in the test method (e.g., kit, manifold, etc.) used.'可被翻译为：确定是否有异常或分析方法偏差。核查分析时是否遵守检验方法，严重违反无菌检 测程序的情况亦要即时记录。如果发现违背方法的情况，确定是否有可能导致污染。 了解所用检测方法（例如，检测盒，歧管等）中是否有任何可能弱点。\n'a. Check environmental monitoring (EM) data taken from production areas and the testing environment (i.e., S-T-A, settling plates, RODAC, etc.) for microbial contamination that matches the microbe isolated from the finished product sterility test'可被翻译为：检查从生产区域和测试环境（即 STA，沉降碟，RODAC 等）采集的环境监测（EM）数据中微生物污染情况与从成品无菌检测中分离出来的微生物是否相符\n\n根据上述已知信息，请将'Determine whether there was adverse environmental data. Note that a negative control failure, on its own, is not necessarily cause for invalidating a result. If a negative control was contaminated, consider whether the microbe identified is similar to, or the same as, the sterility test isolate and also consider whether there are other adverse environmental trends.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定是否有不良环境数据。注意阴性控制失败其本身并不一定导致结果无效。如果 阴性对照受到污染，考虑所鉴别的微生物是否类似或相同于无菌测试分离物，同时 考虑是否有其它不良环境趋势。"
    },
    {
        "instruction":"已知信息：\n'2019 China Cancer Immunotherapy Workshop Successfully Held'可被翻译为：2019中国肿瘤免疫治疗会议成功举办\n'The China Cancer Immunotherapy Workshop has been successfully held for five consecutive years with rising social attention and influence. The Workshop has provided an important academic exchange platform for Chinese and foreign drug regulatory authorities, academia and industry, promoting the exchange of professional knowledge and experience in the field of cancer immunotherapy. It has played a positive role in promoting international exchanges and cooperation in the field of drug regulation and enhancing innovation and development in the field of cancer immunotherapy.'可被翻译为：中国肿瘤免疫治疗会议已连续成功举办了5届，社会关注度和影响力不断扩大，会议为中外药品监管机构、学术界、企业界搭建了一个重要学术交流平台，促进了肿瘤免疫治疗领域的专业知识和经验交流，为推动我国药品监管领域的国际交流合作和肿瘤免疫治疗领域创新发展发挥了积极的作用。\n'In the Workshop, Dr. Ronald Levy, who is the Member of US National Academy of Sciences, Member of US National Academy of Medicine, professor of Stanford University, was specially invited to deliver a keynote speech entitled In Situ Therapeutic Vaccination and share the experience and views on clinical research progress. Prof.Lieping Chen of Yale University, Prof. Xuetao Cao of Nankai University, Prof.Yilong Wu, Prof. Jun Zhu and other famous experts also shared their latest achievements in the field of cancer immunotherapy and put forward their views from the perspective of clinical research and patient needs.'可被翻译为：本次会议特别邀请了美国国家科学院院士、美国国家医学院院士、斯坦福大学罗纳德•莱维(Ronald Levy)教授，发表了题为“原位治疗性疫苗”的主旨演讲，分享了原位治疗性疫苗临床研究进展等方面的经验与看法。耶鲁大学陈列平教授、南开大学校长曹雪涛院士、我国著名肿瘤领域专家吴一龙教授、朱军教授等也分享了肿瘤免疫治疗领域的最新成果，从临床研究和患者需求的角度提出了观点和经验。\n'More than 50 Chinese and foreign leading experts in the field of cancer immunotherapy, including US FDA, EMA, CDE, CAHON delivered speeches on the current status and hot topics of cancer immunotherapy and interactively communicated with the participants.'可被翻译为：美国FDA、欧盟药品监管机构、国家药品监督管理局药品审评中心、美国华裔血液及肿瘤专家学会等50余位中外肿瘤免疫治疗学术界顶尖专家针对当前肿瘤免疫治疗的现状和热点进行演讲，并与参会代表进行互动交流。国内外学术机构代表、从事肿瘤免疫治疗临床研究的专家学者和生物制药企业代表参加了会议。\n\n根据上述已知信息，请将'2019 China Cancer Immunotherapy Workshop was successfully held on June 29-30, 2019 in Tianjin, China. The Workshop was organized by China Center for Food and Drug International Exchange(CCFDIE),in cooperation with the Center for Drug Evaluation(CDE) of National Medical Products Administration(NMPA), Chinese American Hematologist and Oncologist Network(CAHON) and School of Medicine Tsinghua University.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年6月29日至6月30日，由中国食品药品国际交流中心(CCFDIE)主办，药品审评中心(CDE)、美国华裔血液及肿瘤专家学会(CAHON)和清华大学医学院协办的2019中国肿瘤免疫治疗会议在天津成功举办。"
    },
    {
        "instruction":"已知信息：\n'The process of the exchange and recombination of DNA fragments resulting from the breaking and joining of different DNA strands to form new DNA molecules.'可被翻译为：由于不同DNA链的断裂和连接而产生DNA片段的交换和重新组合，形成新DNA分子的过程。\n'dna open-circular'可被翻译为：DNA开环\n'Single or double strand scissions in the DNA.'可被翻译为：DNA的单链或双链被切断。\n'A unit, such as plasmid DNA, that is capable of independent replication.'可被翻译为：能够进行独立复制的单位，如质粒DNA等。\n\n根据上述已知信息，请将'If one of the two strands of plasmid DNA breaks in one or more places, the molecule can spin around, removing tension from the strand and forming a relaxed circular molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果质粒DNA两条链中有一条链发生-处或多处断裂，分子就能旋转而消除链的张力，形成松弛型的环状分子。"
    },
    {
        "instruction":"已知信息：\n'Media used for testing needs to be tested for growth promotion by inoculating the medium with appropriate microorganisms. It is preferable that test microorganisms be chosen for growth promotion testing (Section D).'可被翻译为：用于测试的培养基需要通过用适当微生物的培养基接种来测试促菌生长能力。最好选择测试微 生物用于促菌生长能力试验（D部分）。\n'The selected nutrient media should be capable of growing a designated group of reference microorganisms as described by the relevant pharmacopeia and suitably representative local isolates.'可被翻译为：所选的营养培养基应能够支持相关药典中的指定菌种以及具适当代表性的本地环境菌的生长。\n'Solid media tested for growth promotion is to be set up using the method that will be used to analyze the product (pour plate or spread plate) to determine a microbial plate count (CFU) which must be ≥ 50% of the microorganism inoculum’s calculated value.'可被翻译为：为了确定微生物平板计数（CFU）必须大于等于（≥）微生物接种菌计算值的50%，应使用准备 用于分析产品的方法（倾注平板法或平板涂布法）制作用于促菌生长能力试验的固体培养基。\n'Media used for product testing should be quality control tested according to the related Pharmacopeia before use. Media used for environmental monitoring and APS should be tested for growth promotion before use, using a scientifically justified and designated group of reference microorganisms  and including suitably representative local isolates. Media  quality  control testing  should normally be performed by the end user. Any reliance on outsourced testing or supplier testing of media should be justified and transportation and shipping conditions\nshould be thoroughly considered in this case.'可被翻译为：用于产品检验的培养基在使用前应根据相关药典进行质量控制测试。用于环境监测和 APS 的培养基在使用 前应使用经过科学论证的指定菌种，并包括具适当代表性的本地环境菌进行促生长试验。培养基质量控制 测试通常应由终端使用者进行。任何培养基委托检验或供应商检验都应经过论证，并且在这种情况下，应彻底考虑运输和发运条件。\n\n根据上述已知信息，请将'Both prepared and purchased media must meet the requirements of the USP growth promotion test of aerobes, anaerobes and fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无论是制备的还是购买的培养基均应满足USP的需氧菌、厌氧菌和真菌促生长测试 要求。"
    },
    {
        "instruction":"已知信息：\n'environmental control system'可被翻译为：环境控制体系\n'Environmental Control'可被翻译为：环境控制\n'Environmental & process monitoring'可被翻译为：环境监测和工艺监测\n'2. The monitoring of manufacturing environment and plant hygiene;'可被翻译为：（二）监督厂区卫生状况；\n\n根据上述已知信息，请将'Environmental control and monitoring, both of the machine and the background in which it is placed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"环境控制和监测，包括设备及其环境。"
    },
    {
        "instruction":"已知信息：\n'Article 20 During the safety monitoring period, registrants and filing persons of new cosmetic ingredients may use the new cosmetic ingredient to produce cosmetics.'可被翻译为：第二十条 安全监测的期限内，化妆品新原料注册人、备案人可以使用该化妆品新原料生产化妆品。\n'Article 19 New cosmetic ingredients that have been registered or filed shall follow a safety monitoring system. The period of safety monitoring is 3 years, starting from the date when cosmetics using new cosmetic ingredients for the first time are registered or filed.'可被翻译为：第十九条 已经取得注册、完成备案的化妆品新原料实行安全监测制度。安全监测的期限为3年，自首次使用化妆品新原料的化妆品取得注册或者完成备案之日起算。\n'Article 51 Where progress in scientific research, risks monitoring on cosmetics safety and evaluation shows that there are safety risks in certain cosmetic ingredients, and such risks could be eliminated by setting the use scope and conditions of ingredients, such use restrictions and conditions of ingredients should be clarified in the inventory of existing cosmetic ingredients.'可被翻译为：第五十一条 根据科学研究的发展、化妆品安全风险监测和评价等，发现化妆品原料存在安全风险，能够通过设定原料的使用范围和条件消除安全风险的，应当在已使用的化妆品原料目录中明确原料限制使用的范围和条件。\n'(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;'可被翻译为：（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；\n\n根据上述已知信息，请将'Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。"
    },
    {
        "instruction":"已知信息：\n'7. Method description, modifications, and verification along with recording of sample results and appropriate review and evaluation by management'可被翻译为：方法描述、修改和确认，以及样品结果的记录和管理人员的适当审核与评价\n'provide approved procedures used in testing; and'可被翻译为：提供检测中所用的已批准的检测方法；以及\n'2. There should be records for the receipt of laboratory reagents, solutions and culture media, the date of receipt should be indicated on the container where necessary.'可被翻译为：（二）应当有接收试剂、试液、培养基的记录，必要时，应当在试剂、试液、培养基的容器上标注接收日期。\n'documentation (including information to be supplied with the results, and report forms to be used, if any);'可被翻译为：文件（包括应与结果一起提供的信息和准备使用的报告表格，如有）\n\n根据上述已知信息，请将'provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"提供可记录接收样品并采用批准的检测方法按所需标准检测样品，并报告、记录和整合数据，确定其结果（批准、拒收、隔离）的文件系统；"
    },
    {
        "instruction":"已知信息：\n'A sterilizing preparation made of medicine for injection into the body.'可被翻译为：药物制成的供注入人体内的灭菌制剂。\n'sterile preparation'可被翻译为：灭菌制剂\n'flame sterilization'可被翻译为：火焰灭菌\n'Sterilisation by heat'可被翻译为：加热灭菌\n\n根据上述已知信息，请将'A sterilizing preparation for ulcers, burns, and trauma sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于溃疡、烧伤及外伤部位的灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 40 For an accepted registration application, the applicant may, prior to the administrative permission decision is made, withdraw the registration application and relevant materials, and give reasons to the food and drug regulatory department which accepted the application.'可被翻译为：第四十条 对于已受理的注册申请，申请人可以在行政许可决定作出前，向受理该申请的食品药品监督管理部门申请撤回注册申请及相关资料，并说明理由。\n'Article 169 Where there is any of the following circumstances, the State Food and Drug Administration shall withdraw the drug approval number, and announce to the public:'可被翻译为：第一百六十九条 具有下列情形之一的，由国家食品药品监督管理局注销药品批准文号，并予以公布：\n'(6) the drug approval documents shall be withdrawn in accordance with the provisions of the Drug Administration Law;'可被翻译为：（六）按照《药品管理法》的规定应当撤销药品批准证明文件的；\n'Article 50 For an accepted registration application, the applicant may, prior to the administrative permission decision is made, withdraw the registration application and relevant materials, and give reasons to the food and drug regulatory department which accepted the application.'可被翻译为：第五十条 对于已受理的注册申请，申请人可以在行政许可决定作出前，向受理该申请的食品药品监督管理部门申请撤回注册申请及相关资料，并说明理由。\n\n根据上述已知信息，请将'Article 159 In any of the circumstances prescribed in Article 69 of the Administrative Permission Law, the State Food and Drug Administration may withdraw the relevant drug approval documents upon the request of any interest party or according to its responsibilities and authorities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十九条 有《行政许可法》第六十九条规定情形的，国家食品药品监督管理局根据利害关系人的请求或者依据职权，可以撤销有关的药品批准证明文件。"
    },
    {
        "instruction":"已知信息：\n'Assembly of closed and sterilised SUS using intrinsic sterile connection devices.'可被翻译为：使用内部无菌连接装置组装已密封和已灭菌的 SUS。\n'Appropriate measures should be in place to ensure the integrity of components used in aseptic connections. The means by which this is achieved should be determined and captured in the CCS. Appropriate system integrity tests should be considered when there is a risk of compromising product sterility.  Supplier assessment should include the collation of data in relation to potential failure modes that may lead to a loss of system sterility.'可被翻译为：应釆取适当的措施确保无菌连接所用组件的完整性。应在 CCS 中确定并记录实现方式。如果存在影响产品 无菌性的风险，应考虑适当的系统完整性测试。供应商评价应包括收集整理与可能导致系统丧失无菌性的潜在失效模式相关的数据。\n'Where materials, equipment, components and ancillary items are sterilised in sealed packaging or containers, the packaging should be qualified for minimizing the risk of particulate, microbial, endotoxin\/pyrogen or chemical contamination, and for compatibility with the selected sterilisation method. The packaging sealing process should be validated. The validation should consider the integrity of the sterile protective barrier system, the maximum hold time before sterilisation and the maximum shelf life assigned to the sterilised items. The integrity of the sterile protective barrier system for each of the sterilised items should be checked prior to use.'可被翻译为：如果物料、设备、组分和辅助用品在密封包装或容器中灭菌，包装应经过确认，以最大限度减少微粒、微生物、内毒素\/热原或化学污染的风险，并与所选灭菌方法兼容。包装密封工艺应经过验证。验证应考虑无菌保护屏障系统的完整性、灭菌前的最长保持时间以及被灭菌物品的最长有效期。应在使用前检查每种被灭菌物品的无菌保护屏障系统的完整性。\n'It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).'可被翻译为：确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。\n\n根据上述已知信息，请将'SUS  should  be  designed  to  maintain  integrity  throughout  processing  under  the  intended  operational conditions. Attention to the structural integrity of the single use components is necessary where these may be exposed to more extreme conditions (e.g. freezing and thawing processes) either during routine processing or transportation.  This  should  include verification that intrinsic  sterile  connection  devices  (both heat  sealed and mechanically sealed) remain integral under these conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SUS 的设计应能在预期操作条件和持续时间内保持完整性。在日常加工或运输过程可能出现暴露于极端条 件（例如冻融过程）的情况，有必要注意一次性组件的结构完整性。这应包括确认内部无菌连接装置（热密封和机械密封）在这些条件下保持完整。"
    },
    {
        "instruction":"已知信息：\n'(2) biological products and radioactive pharmaceuticals; and'可被翻译为：（二）生物制品、放射性药品；\n'radiopharmaceutical product'可被翻译为：放射性药物的产品\n'3. Biological products'可被翻译为：3.生物制品注册申请受理情况\n'For the purpose of this document, this term is defined in the same way as in the IAEA\/WHO guideline on good manufacturing practices for radiopharmaceutical products (3), as any pharmaceutical product that, when ready for use, contains one or more radionuclides (radioactive isotopes) included for medicinal purposes.'可被翻译为：就本文件而言，该术语的定义与国际原子能机构\/WHO《放射性药品良好生产规范》指南中的定义相同(3)，即在准备使用时含有一种或多种用于医疗目的的放射性核素(放射性同位素)的任何药品。\n\n根据上述已知信息，请将'(3) Biological products, radiopharmaceuticals and in-vitro diagnostic reagents regulated as drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）生物制品、放射性药品和按照药品管理的体外诊断试剂；"
    },
    {
        "instruction":"已知信息：\n'A secondary chemical reference substance is a substance whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than  for a primary chemical reference substance. Although this definition may apply inter alia to some substances termed “working standards”, part B of these guidelines is intended to apply to secondary reference substances supplied as “official”, e.g. regional\/national standards, and not to manufacturers’ or other laboratories’ working standards.'可被翻译为：二级化学标准物质是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质。虽然该定义可特别适用于一些被称为“工作标准”的物质，但本指南B部分旨在适用于作为“官方”提供的二级标准物质，例如区域\/国家标准，而不适用于制造商或其他实验室的工作标准。\n'A substance whose characteristics are assigned and\/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance.Note: Often referred to as an “in-house” working standard.'可被翻译为：通过与主要标准物质比较而确定和\/或校准其特性的物质。二级标准物质的表征和测试范围可能小于一级标准物质。注:通常被称为“内部”工作标准。\n'secondary chemical reference substance'可被翻译为：二级化学参比物质\n'Primary chemical reference substances are substances that are widely acknowledged to have the appropriate qualities within a specified context, and whose assigned content when used as a (mostly as an assay) standard is accepted without requiring comparison to another chemical substance (7).'可被翻译为：主要化学标准物质是在特定环境中被广泛认可具有适当质量的物质，其指定含量在用作(主要是作为分析)标准时被接受，而无需与另一种化学物质进行比较(7)。\n\n根据上述已知信息，请将'Secondary chemical reference substances (also called working standards) are substances whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than for a primary chemical reference substance (7).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二级化学标准物质(也称为工作标准品)是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质(7)。"
    },
    {
        "instruction":"已知信息：\n'(Ⅰ) Fail to establish the drug recall system, drug quality assurance system and adverse drug reaction monitoring system according to these Provisions;'可被翻译为：（一）未按本办法规定建立药品召回制度、药品质量保证体系与药品不良反应监测系统的；\n'(III) Failing to cooperate with drug regulatory departments and monitoring agencies in relevant investigation of medical device adverse events and control measures to be taken.'可被翻译为：（三）不配合药品监督管理部门和监测机构开展的医疗器械不良事件相关调查和采取的控制措施的。\n'(3) failing to establish and maintain records of vaccine reception, purchase, storage, distribution, supply, inoculation, and disposal as required;'可被翻译为：（三）未按照规定建立并保存疫苗接收、购进、储存、配送、供应、接种、处置记录；\n'(3) the drug manufacturer has failed to appoint a dedicated Qualified Person to fulfill drug release responsibilities;'可被翻译为：（三）药品生产企业未配备专门质量受权人履行药品出厂放行责任；\n\n根据上述已知信息，请将'(3) fails to establish and implement a drug tracking system as required;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未按照规定建立并实施药品追溯制度；"
    },
    {
        "instruction":"已知信息：\n'Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.'可被翻译为：第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：\n'Article 19 The importation of drugs in urgent clinical needs, drugs for donation purpose, samples or comparator products required for new drug research and drug registration and so on shall apply for approval from the State Food and Drug Administration, and shall go through the formalities of importation record filing in accordance with Article 16 of the Provisions by presenting the Import Drug Approval issued by the State Food and Drug Administration.'可被翻译为：第十九条 进口临床急需药品、捐赠药品、新药研究和药品注册所需样品或者对照药品等，必须经国家食品药品监督管理局批准，并凭国家食品药品监督管理局核发的《进口药品批件》，按照本办法第十六条的规定，办理进口备案手续。\n'Article 13 An applicant for importation record filing shall fill in the Application for Testing of Import Drugs, present the original Import Drug License (or Pharmaceutical Product License) (in original or duplicate), additionally the original Import License for narcotic drugs and psychotropic substances when importing them, and submit other relevant materials (with two photocopies each) of the drug to be imported to the local drug regulatory department at ports of entry:'可被翻译为：第十三条 办理进口备案，报验单位应当填写《进口药品报验单》，持《进口药品注册证》（或者《医药产品注册证》）（正本或者副本）原件，进口麻醉药品、精神药品还应当持麻醉药品、精神药品《进口准许证》原件，向所在地口岸药品监督管理局报送所进口品种的有关资料一式两份：\n'The State Food and Drug Administration shall make a review and approval decision based on the general opinion. An Import Drug License shall be issued if regulations are conformed to. For a drug applied for registration by a drug manufacturer in Hong Kong, Macao or Taiwan of China, its application shall be handled in reference to the application procedures for import drug registration. If requirements are met, a Pharmaceutical Product License shall be issued; if requirements are not met, a Disapproval Notice shall be issued with reasons.'可被翻译为：国家食品药品监督管理局依据综合意见，做出审批决定。符合规定的，发给《进口药品注册证》。中国香港、澳门和台湾地区的制药厂商申请注册的药品，参照进口药品注册申请的程序办理，符合要求的，发给《医药产品注册证》；不符合要求的，发给《审批意见通知件》，并说明理由。\n\n根据上述已知信息，请将'Article 5 An importer may go through the formalities of importation record filing and port testing of drugs to be imported only after it has obtained the Import Drug License (or Pharmaceutical Product License) or Import Drug Approval issued by State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 进口药品必须取得国家食品药品监督管理局核发的《进口药品注册证》（或者《医药产品注册证》），或者《进口药品批件》后，方可办理进口备案和口岸检验手续。"
    },
    {
        "instruction":"已知信息：\n'5. All changes of the process or testing methods;'可被翻译为：（五）生产工艺或检验方法等的所有变更；\n'Article 254: CAPA implementation should be recorded and retained by the quality management department.'可被翻译为：第二百五十四条 实施纠正和预防措施应当有文件记录，并由质量管理部门保存。\n'5) To review and approve all quality related changes;'可被翻译为：5.审核和批准所有与质量有关的变更；\n'(v) A review of all changes carried out to the processes or analytical methods;'可被翻译为：(v)对工艺或分析方法的所有变更进行回顾；\n\n根据上述已知信息，请将'5. To record all changes during CAPA implementation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）对实施纠正和预防措施过程中所有发生的变更应当予以记录。"
    },
    {
        "instruction":"已知信息：\n'Settle plates should be exposed for the duration of operations and changed as required after a maximum of 4 hours. Exposure time should be based on recovery studies and should not allow desiccation of the media used.'可被翻译为：沉降碟应在操作期间暴露，并在最多 4 小时后按需要更换。暴露时间应基于回收率研究，并且避免所所用培养基干燥。\n'(a)  Settle plates should be exposed in grade A and B areas for the duration of operations (including equipment set-up)  and  changed  as required after  a maximum  of 4 hours  (exposure time  should be based  on validation including recovery studies and it should not have any negative effect on the suitability of the media used).'可被翻译为：沉降碟应在操作期间（包括设备安装）暴露在 A 级和 B 级区，并在最多 4 小时后按要求更换（暴露时间应基于验证，包括回收研究，不应对所用培养基的适用性产生任何负面影响）。\n'Plastic Petri dishes containing an effective non-selective medium (based on test requirements) are exposed in the hood for a period not to exceed four hours during the analysis. After four hours, plates should be replaced to continue monitoring (as appropriate).'可被翻译为：含有效非选择性培养的塑料培养皿（根据检测要求）检测期间暴露在层流罩下不 应超过4小时。4小时之后，替换进行持续监测（适当时）。\n'Plates should be incubated for 48 hours at 35°C, and an additional 5 days at 25°C in order to detect mold contamination.'可被翻译为：平板应在35°C 培养48小时，然后在25°C 培养5天，以检查霉菌污染。\n\n根据上述已知信息，请将'Individual settle plates may be exposed for less than 4 hours.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个沉降碟的暴露时间可以少于 4 小时。"
    },
    {
        "instruction":"已知信息：\n'Article 6 Manufacturers and marketers of cosmetics shall establish, in accordance with the law, documentation system for the check and test of purchases, and product sales record, and other systems, to ensure traceability of the products.'可被翻译为：第六条 化妆品生产经营者应当依法建立进货查验记录、产品销售记录等制度，确保产品可追溯。\n'(6) having a management system for guaranteeing the quality and safety of the cosmetics.'可被翻译为：（六）有保证化妆品质量安全的管理制度。\n'For entrusted manufacturing of cosmetics, the documentation for the check and test of purchases of raw materials and packaging materials contacted with cosmetics could be kept by the contract manufacturer.'可被翻译为：委托生产化妆品的，原料以及直接接触化妆品的包装材料进货查验等记录可以由受托生产企业保存。\n'(2) They shall have a quality management system that corresponds with the cosmetics for which registration or filing is done; and'可被翻译为：（二）有与申请注册、进行备案化妆品相适应的质量管理体系；\n\n根据上述已知信息，请将'Manufacturers and marketers of cosmetics are encouraged to adopt information technology to collect and store information on manufacturing and marketing, and establish a traceability system for quality and safety of cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励化妆品生产经营者采用信息化手段采集、保存生产经营信息，建立化妆品质量安全追溯体系。"
    },
    {
        "instruction":"已知信息：\n'dust removal'可被翻译为：除尘\n'extract air'可被翻译为：抽气\n'Article 53: Operation areas where dust is generated (e.g. during sampling, weighing, mixing and packaging of dry materials and products) should be kept under relatively negative pressure, and specific measures should be taken to avoid dust diffusion and cross-contamination, and to facilitate cleaning.'可被翻译为：第五十三条 产尘操作间（如干燥物料或产品的取样、称量、混合、包装等操作间）应当保持相对负压或采取专门的措施，防止粉尘扩散、避免交叉污染并便于清洁。\n'A process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.'可被翻译为：在一个区域内容纳产品、灰尘或污染物，防止其泄漏到另一个区域的过程或设备。\n\n根据上述已知信息，请将'1.Air extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n2.Air extraction point located so that it effectively captures dust near its source.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.抽气除尘，抽气点尽量靠近粉尘源。\n2.排风点的位置使它能有效地在其源头附近捕获灰尘。"
    },
    {
        "instruction":"已知信息：\n'This test is performed to validate that a filter can remove bacteria from a gas or liquid. The test is usually performed using a standard organism, such as Brevundimonas diminuta, at a minimum concentration of 107 colony-forming units\/cm2'可被翻译为：进行这种测试是为了验证过滤器可以从气体或液体中去除细菌。该测试通常使用标准生物进行，如微小Brevundimonas，最低浓度为107菌落形成单位\/cm2\n'bacterial retention testing'可被翻译为：细菌残留测试\n'During filter validation, wherever possible, the product to be filtered should be used for bacterial retention testing of the sterilising grade filter. Where the product to be filtered is not suitable for use in bacterial retention testing, a suitable surrogate product should be justified for use in the test. The challenge organism used in the bacterial retention test should be justified.'可被翻译为：在过滤器验证过程中，应尽可能使用待过滤产品进行除菌级过滤器的细菌截留测试。如果待过滤产品不适 合用于细菌截留测试，应使用合适的替代产品进行测试并说明原因。应论证用于细菌截留试验的挑战微生物的合理性。\n'A filter that, when appropriately validated, will remove a defined microbial challenge from a fluid or gas producing a sterile effluent. Usually such filters have a pore size equal to or less than 0.22 micrometres (µm).'可被翻译为：一种过滤器，经过适当验证后，将从产生无菌流出物的流体或气体中去除特定的微生物挑战。通常这种过滤器的孔径等于或小于0.22微米(µm)。\n\n根据上述已知信息，请将'Bacterial retention testing - This test is performed to validate that a filter can remove bacteria from a gas or liquid. The  test  is  usually  performed  using  a  standard  organism,  such  as  Brevundimonas  diminuta  at  a  minimum concentration of 107 Colony Forming Units\/cm2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"细菌截留试验：进行该试验是为了验证过滤器可以去除气体或液体中的细菌。该试验通常采用标准微生物进行，例如最低浓度 107 CFU\/cm2 的缺陷短波单孢菌（Brevundimonas diminuta）。"
    },
    {
        "instruction":"已知信息：\n'The on-site inspection question sheet shall be signed by all members of the inspection team, observers, and the person in charge of the inspected, and shall be affixed with the official seal of the inspected institution.'可被翻译为：现场核查问题表应当由核查组全体成员、观察员、被核查单位负责人签名，并加盖被核查单位公章。\n'The inspection team shall record in written form the acts of refusing and evading inspection by the organization being inspected, order it to make rectification and timely report to the food and drug regulatory departments organizing the conduction of the unannounced inspection. Where the organization being inspected fails to make rectification after being ordered, and causes the failure of the  inspection, the inspection conclusion shall be determined as not complying with the relevant good practice on quality management or other relevant requirements'可被翻译为：检查组对被检查单位拒绝、逃避检查的行为应当进行书面记录，责令改正并及时报告组织实施飞行检查的食品药品监督管理部门；经责令改正后仍不改正、造成无法完成检查工作的，检查结论判定为不符合相关质量管理规范或者其他相关要求。\n'The inspected institution shall confirm the feedback from the inspection team, and may put forward different opinions, explanations, and explanations if there is any objection. The inspection team shall make further verification and make necessary adjustments to the relevant content of the on-site inspection report and the on-site inspection question sheet based on the inspection situation.'可被翻译为：被核查单位应当对核查组反馈的情况进行确认，有异议的，可提出不同意见、作出解释和说明。核查组应当就此予以进一步核实，并结合核实情况对现场核查报告、现场核查问题表相关内容进行必要调整。\n'Where any of the following circumstances exists, the organization being inspected shall be regarded as refusing, delaying and denying inspection:'可被翻译为：被检查单位有下列情形之一的，视为拒绝、逃避检查：\n\n根据上述已知信息，请将'If the inspected institution refuses to sign and seal, the inspection team shall indicate it in the on-site inspection report. The inspected institution shall give another written explanation on the refusal of signature and seal, which shall be signed by the person in charge of the inspected institution and stamped with the official seal of the inspected institution and submitted to the inspection team.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位拒绝签字盖章的，核查组应当在现场核查报告中予以注明。被核查单位应当就拒绝签字盖章情况另行书面说明，由被核查单位负责人签字，并加盖被核查单位公章交核查组。"
    },
    {
        "instruction":"已知信息：\n'accountability'可被翻译为：问责制\n'1.The term transparency means: — defining policies and procedures in writing and publishing the written documentations; and — giving reasons for decisions to the public (see also accountability above).\n2.Defining policies and procedures in writing and publishing the written documentation, and giving reasons for decisions to the public.'可被翻译为：1.“透明度”一词是指:-以书面形式确定政策和程序，并公布书面文件;以及-向公众提供决策的理由(另见上文的问责制)。\n2.以书面形式确定政策和程序并公布书面文件，向公众说明作出决定的理由。\n'An exchange of data between individuals or entities outside the traditional organizational boundaries, to achieve a common goal in terms of better policies and to deliver better services. This may mean that one party is disclosing information while the other is collecting the information or both parties are mutually disclosing and collecting information.'可被翻译为：在传统组织边界之外的个人或实体之间交换数据，以实现更好的政策和提供更好的服务方面的共同目标。这可能意味着一方在披露信息的同时另一方在收集信息，或者双方在相互披露和收集信息。\n'1.The act whereby the regulatory authority in one jurisdiction may take into account and give significant weight to – i.e. totally or partially rely upon – evaluations performed by another regulatory authority or trusted institution in reaching its own decision. The relying authority remains responsible and accountable for decisions taken, even when it relies on the decisions and information of others (25).\n2.An act whereby a regulatory authority in one jurisdiction may take into account or give significant weight to work performed by another regulator, or other trusted institution, in reaching its own decision.'可被翻译为：1.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或值得信赖的机构所进行的评估，并给予重大重视，即完全或部分依赖。依赖机构仍然对所做的决定负责，即使它依赖于他人的决定和信息(25)。\n2.一个司法管辖区的监管机构在做出自己的决定时，可能会考虑到另一个监管机构或其他受信任的机构所做的工作或给予重大重视的行为。\n\n根据上述已知信息，请将'The obligation to account for one's conduct and actions, ussually to an individual or group, but ultimately to the public. Both individuals and organizations may be accountable. There is some overlap between accountability and transparency (see transparency).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对自己的行为和行为负责的义务，通常是对个人或团体负责，但最终是对公众负责。个人和组织都有责任。问责制和透明度之间有一些重叠(见透明度)。"
    },
    {
        "instruction":"已知信息：\n'A document containing the information as set out in Appendix 1 of the guidelines that is validated and issued for a specific product by the competent authority of the exporting country and intended for use by the competent authority in the importing country or - in the absence of such an authority - by the drug procurement authority (see also section 3.5 of the guidelines). Transmission of product certificate: see sections 3.8 and 4.9 of the guidelines.Validity of product certificate: see section 3.9 of the guidelines.When to request a product certificate: see section 3.5 of the guidelines.'可被翻译为：包含指南附录1中所列信息的文件，由出口国主管部门对特定产品进行验证和签发，供进口国主管部门使用，或者在没有此类主管部门的情况下，供药品采购主管部门使用(另见指南第3.5节)。产品证书的传递:见指南第3.8节和4.9节。产品证书有效期:见指南第3.9节。何时申请产品证书:见指南第3.5节。\n'A document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.'可被翻译为：一种或一组文件，规定原料及其数量和包装材料，以及生产规定数量的成品所需的程序和注意事项的说明，以及加工说明，包括过程控制。\n'A document or set of documents established with the purpose to produce a specified quantity of a finished product, which include the manufacturing formula, processing and packaging instructions, and specify the quantities of starting and packaging materials, process parameters and conditions, a processing description (including in-process controls), and precautions, etc.'可被翻译为：为生产特定数量的成品而制定的一个或一套文件，包括生产处方、生产操作要求和包装操作要求，规定原辅料和包装材料的数量、工艺参数和条件、加工说明（包括中间控制）、注意事项等内容。\n'The document prepared by some national regulatory authorities that summarizes the technical \nbasis on which the product has been licensed (see section 4.7 of the guidelines and \nexplanatory note 9 of the Product Certificate contained in Appendix 1).'可被翻译为：一些国家监管部门准备的总结技术的文件\n产品获得许可的依据(见指南第4.7节和\n附录1中产品证书的解释性说明9)。\n\n根据上述已知信息，请将'A document containing the information (as set out in Appendix 1 of these Guidelines) that is validated and issued for a specific starting material by the competent authority of the exporting country and intended for use by the competent authority in the importing country or in the absence of such an authority by, for example, the manufacturer of the finished product when exporting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一份包含信息的文件(如本指南附录1所述)，由出口国主管当局就特定起始材料进行验证和签发，供进口国主管当局使用，或在没有此类当局的情况下，供成品制造商在出口时使用。"
    },
    {
        "instruction":"已知信息：\n'A constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing\/manufacturing.'可被翻译为：一种血液成分(红细胞、白细胞、血小板、低温沉淀和血浆)，可通过各种分离方法制备，并在可直接用于治疗目的或用于进一步加工\/制造的条件下制备。\n'Any therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.'可被翻译为：从人类血液中提取的任何治疗物质，包括全血、血液成分和血浆来源的药品。\n'A product made from human blood plasma.'可被翻译为：由人血浆为原料而制备的制品。\n'A substance that is produced by or extracted from a biological source and for which a combination of physicochemical-biological testing and the production process and its control is needed for its characterization and the determination of its quality.'可被翻译为：由生物源生产或从生物源中提取的物质，对其进行物化生物学试验、生产过程及其控制相结合，以表征和确定其质量。\n\n根据上述已知信息，请将'A biological material including, but not limited to, blood, serum, plasma and urine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种生物材料，包括但不限于全血、血清、血浆和尿液。"
    },
    {
        "instruction":"已知信息：\n'A single variable, usually a scale of ordered categorical ratings, which integrates objective variables and the investigator's overall impression about the state or change in state of a subject.'可被翻译为：是指将客观指标和研究者对受试者的状态或状态变化\n的总体印象综合起来所设定的一个单一指标，通常是一个有\n序分类量表。\n'A model that describes the measurement relationship between the observed variable and the latent variable.'可被翻译为：描述观测变量与潜变量之间的测量关系的模型。\n'The degree to which the Quality of Life scale measures results reliably or reproducibly.'可被翻译为：生存质量量表测量结果的可靠程度或可重复程度。\n'measurement model'可被翻译为：测量模型\n\n根据上述已知信息，请将'The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指一个指标（如量表）测量它所预期测量的内容的程\n度。"
    },
    {
        "instruction":"已知信息：\n'A signal for which an evaluation was completed during the reporting interval.'可被翻译为：在报告期内完成评估的信号。\n'Test Procedure and Interpretation of Data'可被翻译为：检测方法和数据解释\n'audit of a trial'可被翻译为：一次审判的审计\n'(II) After checking the original record and data of the study process, confirm on-site, and confirm through inspection, if there is no problem identified or the problem identified does not constitute the circumstances mentioned above, the inspection is determined as \"Pass\". Among which, the identified problem may have impact on data quality and reliability, which needs special attention in the review.'可被翻译为：(二) 对研究过程中原始记录和数据进行核实、实地确认， 未发现问题或发现的问题不构成以上不通过情形的， 核查认定为“通过”。其中发现的问题对数据质量和可靠性可能有影响的， 需审评重点关注。\n\n根据上述已知信息，请将'The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalising the planned analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指在试验完成（最后一位受试者的最后一次观察）到揭盲这段时间内对数据的检查和评价，旨在最终确定分析计划。"
    },
    {
        "instruction":"已知信息：\n'A VDC consists of two compartments (a donor compartment and a receptor compartment with a sampling arm) separated by a membrane and held together by a clamp, screw top, or other means (see Figures 1–5). The VDC body (i.e., donor and receptor compartment with associated cell structures like the sampling arm and water jacket, if present) is usually made from borosilicate glass, although different materials may be used to manufacture the body and other parts of the VDC assembly. Other diffusion cells that are similar in design principles and features to those depicted in Figures 1–3 can generally be used.'可被翻译为：VDC由两个隔室(供体隔室和带采样臂的受体隔室)组成，隔室由膜隔开，并通过夹钳、螺旋顶或其他方式连接在一起(见图1-5)。VDC主体(即，供体和受体隔室与相关的池体结构，如采样臂和水套，如果存在)通常由硼硅酸盐玻璃制成，尽管可以使用不同的材料来制造主体和VDC组件的其他部分。通常可以使用与图1-3所示扩散池在设计原理和特征上相似的其他扩散池。\n'Immersion cells should match the description of one of the instruments listed in this chapter. Other designs can be used with sufficient scientific justification so long as they consist of a donor compartment separated from a receptor compartment by a membrane.'可被翻译为：浸没池应符合本章所列仪器的描述。其他设计也可以有充分的科学依据，只要它们是由一层膜将供体隔室与受体隔室隔开的。\n'The operating principles and specific test procedures differ among the various equipment; relevant procedures from the manufacturer may be used for installation, operation, and performance qualifications. The laboratory qualification of each diffusion cell should, at minimum, include: (1) measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounte; (2) the empirically measured volume of the receptor solution compartment\/vessel for each diffusion cell; (3) the stability of the temperature measured at the membrane surface (e.g., at 32°C ± 1°C), or just below the membrane, across a relevant duration (e.g., 6 hours); and (4) the rate of stirring or agitation, as applicable.'可被翻译为：每种设备的操作原理和特定测试方法均不相同；可根据生产商提供的相关规程进行安装、操作和性能确认。每个扩散池的实验室确认内容，至少应包括：1）测定供给室和接收室之间膜安装位置的孔口扩散面积；2）测量每个接收室的容积；3）在相关研究期间（如，6小时），测定膜表面或膜下温度（如，32℃±1℃）的稳定性；和4）如适用，测定搅拌速率。\n'Model A VDC are intended to have the membrane prepared and the dosing performed as part of the assembly of the cell top, which is separate from the cell bottom of the Model A VDC. In this model, the unique design and operation of the Model A VDC, as defined by the manufacturer, should be taken into consideration along with requirements of the test method. This method should not be used with conventional VDC designs like VDC models B and C.'可被翻译为：A型VDC的目的是将膜的制备和给药作为池体顶部组装的一部分进行，池体顶部与A型VDC的池体底部分开。在本模型中，应考虑制造商定义的A型VDC的独特设计和操作，以及测试方法的要求。这种方法不应用于传统的VDC设计，如VDC模型B和C。\n\n根据上述已知信息，请将'The VDC, immersion cells, and FDC should match the general descriptions provided below and may have design variations of the types shown among specific examples illustrated in Figures 1–5 for VDCs, Figures 6 and 7 for immersion cells, or Figures 8–10 for FDCs. The VDC, immersion cell, and FDC components should be manufactured with inert materials that do not adsorb, absorb, bind, or react with the analyte. The diffusion cell and its components should not alter the amount of diffusing drug that is measured, either by adsorbing, absorbing, binding, or reacting with the drug, or by releasing drug that was adsorbed, absorbed, bound, or reacted with in a previous experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDC、浸没池和FDC应符合下面提供的一般描述，并且可以在图1-5所示的VDC、图6和图7所示的浸没池或图8-10所示的FDC的具体示例中具有不同的设计类型。VDC、浸没池和FDC组件应使用惰性材料制造，这些材料不会吸附、吸收、结合或与分析物发生反应。扩散池及其组件不应通过吸附、吸收、结合或与药物反应，或通过释放先前实验中吸附、吸收、结合或与之反应的药物来改变所测量的扩散药物的量。"
    },
    {
        "instruction":"已知信息：\n'Article 73 The investigator shall ensure that the clinical trial data is accurately, completely, clearly and promptly entered in the case report form. The case report form shall be signed by the investigator; any change in the data shall be signed and dated by the investigator and meanwhile clear and identifiable original records shall be kept.'可被翻译为：第七十三条 研究者应当保证将临床试验数据准确、完整、清晰、及时地载入病例报告表。病例报告表由研究者签署姓名，任何数据的更改均应当由研究者签名并标注日期，同时保留原始记录，原始记录应当清晰可辨识。\n'Article 78 Upon the completion of the clinical trial, the investigator shall ensure that the records and reports are completed. At the same time, the investigator shall also ensure that the number of investigational medical devices received is consistent with that of the used, discarded or returned devices, and ensure that the remaining investigational medical devices are properly handled, recorded and documented.'可被翻译为：第七十八条 临床试验结束时，研究者应当确保完成各项记录、报告。同时，研究者还应当确保收到的试验用医疗器械与所使用的、废弃的或者返还的数量相符合，确保剩余的试验用医疗器械妥善处理并记录存档。\n'The case report form refers to the document designed in accordance with the clinical trial protocol, which is used to record all the information and data of every subject during the trial.'可被翻译为：病例报告表，是指按照临床试验方案所规定设计的文件，用以记录试验过程中获得的每个受试者的全部信息和数据。\n'Article 83 The investigator shall verify or confirm the safety and effectiveness of the investigational medical device in accordance with the design requirements of the clinical trial protocol and complete the clinical trial report. The clinical trial report of a multicenter clinical trial shall include the summaries of each clinical trial of the sub-site.'可被翻译为：第八十三条 研究者应当按照临床试验方案的设计要求，验证或者确认试验用医疗器械的安全性和有效性，并完成临床试验报告。多中心临床试验的临床试验报告应当包含各分中心的临床试验小结。\n\n根据上述已知信息，请将'Article 80 In the clinical trial, the investigator shall ensure that any observation and finding are recorded in the correct and complete manner and that the case report form is carefully filled out. Records shall include at least:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 在临床试验中，研究者应当确保将任何观察与发现均正确完整地予以记录，并认真填写病例报告表。记录至少应当包括："
    },
    {
        "instruction":"已知信息：\n'Article 19 MAHs, distributing enterprises and secondary medical institutions or above shall register as the users of the National Medical Device Adverse Events Monitoring Information System, voluntarily maintain the user information and report medical device adverse events. MAHs shall continuously track and handle monitoring information; in case of any change in product registration information, MAHs shall update the information in the system immediately.'可被翻译为：第十九条  持有人、经营企业和二级以上医疗机构应当注册为国家医疗器械不良事件监测信息系统用户，主动维护其用户信息，报告医疗器械不良事件。持有人应当持续跟踪和处理监测信息；产品注册信息发生变化的，应当在系统中立即更新。\n'In case of identifying or knowing any suspected medical device adverse event, medical device distributing enterprises and user facility shall notify MAHs and report it through the National Medical Device Adverse Events Monitoring Information System. In case of having no conditions for online report temporarily, MAHs shall report to local monitoring agency above county level in paper form. The monitoring agency shall make online reporting on their behalf.'可被翻译为：医疗器械经营企业、使用单位发现或者获知可疑医疗器械不良事件的，应当及时告知持有人，并通过国家医疗器械不良事件监测信息系统报告。暂不具备在线报告条件的，应当通过纸质报表向所在地县级以上监测机构报告，由监测机构代为在线报告。\n'Article 32 In case of identifying or knowing group adverse events of medical device, MAHs shall immediately suspend the production and sales, and notify user facility to immediately stop using relevant medical devices. At the same time, MAHs shall carry out investigation and self-inspection of production quality management system and report to the drug regulatory departments and monitoring agencies of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate and where the adverse events occur within 7 days.'可被翻译为：第三十二条  持有人发现或者获知其产品的群体医疗器械不良事件后，应当立即暂停生产、销售，通知使用单位停止使用相关医疗器械，同时开展调查及生产质量管理体系自查，并于7日内向所在地及不良事件发生地省、自治区、直辖市药品监督管理部门和监测机构报告。\n'Article 20 MAHs shall release the contact information such as telephone, correspondence address, email and fax, designate the contact person, and voluntarily collect the adverse event information from medical device distributing enterprises, user facility and users; In case of identifying or knowing any suspected medical device adverse event, MAHs shall report and evaluate the medical device adverse event directly through the National Medical Device Adverse Events Monitoring Information System and submit investigation report of group adverse events of medical device as well as periodic risk evaluation report.'可被翻译为：第二十条  持有人应当公布电话、通讯地址、邮箱、传真等联系方式，指定联系人，主动收集来自医疗器械经营企业、使用单位、使用者等的不良事件信息；对发现或者获知的可疑医疗器械不良事件，持有人应当直接通过国家医疗器械不良事件监测信息系统进行医疗器械不良事件报告与评价，并上报群体医疗器械不良事件调查报告以及定期风险评价报告等。\n\n根据上述已知信息，请将'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。"
    },
    {
        "instruction":"已知信息：\n'Article 119 Where drug use institutions use counterfeit drugs or inferior drugs, they shall be punished in accordance with the provisions on the sale of counterfeit drugs and inferior drugs. In serious circumstances, and if the legal representative, the principal responsible persons, the persons directly in charge, and other directly responsible persons as well as other responsible personnel have a medical license, the medical license shall be revoked.'可被翻译为：第一百一十九条 药品使用单位使用假药、劣药的，按照销售假药、零售劣药的规定处罚；情节严重的，法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n'Where leading members, drug purchasers, physicians, and pharmacists of a medical institution receives rake-offs or other improper gains from a drug MAH, drug manufacturer, drug distributor, or its agent, the competent health departments or the said medical institution shall impose punishment and confiscate the illegal income. In serious circumstances, their licenses to practice shall be revoked.'可被翻译为：医疗机构的负责人、药品采购人员、医师、药师等有关人员收受药品上市许可持有人、药品生产企业、药品经营企业或者代理人给予的财物或者其他不正当利益的，由卫生健康主管部门或者本单位给予处分，没收违法所得；情节严重的，还应当吊销其执业证书。\n'Article 145 Where a drug regulatory department or its designated drug professional and technical institutions participate in drug manufacturing and business activities, it shall be ordered by its higher-level competent administrative department to make correction, and its illegal income shall be confiscated. In serious circumstances, the persons directly in charge and other directly responsible persons shall be punished in accordance with the law.'可被翻译为：第一百四十五条 药品监督管理部门或者其设置、指定的药品专业技术机构参与药品生产经营活动的，由其上级主管机关责令改正，没收违法收入；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予处分。\n'Article 147 Where a drug regulatory department commits any of the following acts in violation of this Law, the relevant permit shall be revoked, and the persons directly in charge and other directly responsible persons shall be punished in accordance with the law:'可被翻译为：第一百四十七条 违反本法规定，药品监督管理部门有下列行为之一的，应当撤销相关许可，对直接负责的主管人员和其他直接责任人员依法给予处分：\n\n根据上述已知信息，请将'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。"
    },
    {
        "instruction":"已知信息：\n'Method of sterilization in saturated steam, boiling water, or circulating steam.'可被翻译为：在饱和蒸汽、沸水或流通蒸汽中进行灭菌的方法。\n'boiling sterilization'可被翻译为：煮沸灭菌\n'Sterilisation by heat'可被翻译为：加热灭菌\n'Method of sterilization by flame or dry hot air.'可被翻译为：用火焰或干热空气进行灭菌的方法。\n\n根据上述已知信息，请将'The method of sterilization by heating the articles to be sterilized in boiling water.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"把待灭菌物品放入沸水中加热灭菌的方法。"
    },
    {
        "instruction":"已知信息：\n'adverse drug reaction (adr)'可被翻译为：药物不良反应\n'Adverse reactions not mentioned in the drug product labeling. If the nature, severity, consequences, or frequency of an adverse reaction differs from or is more severe than what is described in the product labeling, it should be handled according to the new adverse reaction information.'可被翻译为：药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者\n频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。\n'For drugs that have been verified as causing serious ADRs, drug manufacturers shall promptly inform the health professionals, patients and the public of the ADRs and information on rational drug use by various effective means; measures such as revising labels and package inserts, suspension of production, sales and use, and recall shall be taken to reduce and prevent the recurrence of ADRs. For drugs causing significant adverse reactions, drug manufacturers shall voluntarily apply for canceling the approval documents.'可被翻译为：药品生产企业对已确认发生严重不良反应的药品，应当通过各种有效途径将药品不良反应、合理用药信息及时告知医务人员、患者和公众；采取修改标签和说明书，暂停生产、销售、使用和召回等措施，减少和防止药品不良反应的重复发生。对不良反应大的药品，应当主动申请注销其批准证明文件。\n'ADR\/ADE (adverse drug event)reporting'可被翻译为：药品不良反应\/事件报告情况\n\n根据上述已知信息，请将'(IV) A new ADR refers to any adverse reaction that is not listed on the package insert. An ADR that is listed but is in consistent with or more severe than that described on the package insert in nature, severity, outcome and frequency shall be handled as a new ADR.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）新的药品不良反应，是指药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。"
    },
    {
        "instruction":"已知信息：\n'Article 78 Acceptance inspection personnel shall inspect and check the appearance, package, label, package insert and relevant supporting documents of the sampled drugs one by one; after the acceptance inspection, the intact samples taken shall be put back into the original packaging box, sealed and marked.'可被翻译为：第七十八条 验收人员应当对抽样药品的外观、包装、标签、说明书以及相关的证明文件等逐一进行检查、核对；验收结束后，应当将抽取的完好样品放回原包装箱，加封并标示。\n'When taking samples, the drugs shall be prevented from deterioration due to pollution, moisture absorption, weathering or oxidation. Samples taken for testing shall be promptly placed in sealed containers (plastic bags, cans or ground-glass flask).'可被翻译为：（二）抽样时应当防止药品污染吸潮、风化、氧化而变质。抽取的检验样品应当迅速放入密闭容器中（塑料袋、铁罐或磨口玻璃瓶）。\n'Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection.'可被翻译为：第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。\n'(III) After sampling, the opened package shall be sealed, and the quantity and date of sampling shall be indicated on the package.'可被翻译为：（三）抽样后，应当将开启之包装封固，并在包装上注明抽样数量及日期。\n\n根据上述已知信息，请将'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。"
    },
    {
        "instruction":"已知信息：\n'In the 2018 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women.Reports of pediatric patients under 14 years of age accounted for 9.8%; reports of elderly patients over the age of 65 accounted for27.7% (Figure 5).'可被翻译为：2018年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者的报告占9.8%；65岁以上老年患者的报告占27.7%（图5）。\n'Patients involved in the ADR\/ADE reports'可被翻译为：药品不良反应\/事件报告涉及患者情况\n'MAHs, pharmaceutical distributors and medical institutions constitute the responsible units for ADR \/ ADE reporting. As per source-specific statistics of ADR\/ADE reports in 2019, a lion's share of 88.1 percent came from medical institutions; while a share of 6.6 percent, 5.2 percent, and 0.1 percent came from pharmaceutical distributors, MAHs, individuals and other sources, respectively (Figure 3).'可被翻译为：持有人、经营企业和医疗机构是药品不良反应报告的责任单位。按照报告来源统计，2019年来自医疗机构的报告占88.1%；来自经营企业的报告占6.6%；来自持有人的报告占5.2%；来自个人及其他报告者的报告占0.1%（图3）。\n'In 2020, the National ADR Monitoring Network received a total of 830,000 ADR\/ADE reports of the varieties included in the National Essential Drugs List (2018 Edition), of which 88,000 were reports of serious ADRs\/ADEs, accounting for 10.6%. Reports involving chemical drugs and biological products account for 88.1% and those involving traditional Chinese medicines account for 11.9%.'可被翻译为：2020年全国药品不良反应监测网络共收到《国家基本药物目录（2018年版）》收载品种的不良反应\/事件报告83.0万份，其中严重报告8.8万份，占10.6%。报告涉及化学药品和生物制品占88.1%，中成药占11.9%。\n\n根据上述已知信息，请将'In the 2019 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women. Reports of pediatric patients under 14 years of age accounted for 10.2 percent; and reports of elderly patients over 65 accounted for 29.1 percent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者占10.2%；65岁及以上老年患者占29.1%。"
    },
    {
        "instruction":"已知信息：\n'CDE reviewed and approved the marketing of 10 varieties of Class 1 innovative drugs, and 58 varieties of imported brand-name drugs (including new indications).'可被翻译为：审评通过上市1类创新药10个品种，审评通过进口原研药58个品种（含新适应症）。\n'CDE accepted 75 applications for registration of Class 5.1 imported chemical brand name drugs (involving 50 varieties), and85 applications for registration of imported innovative drugs (incl. 42 varieties). The indications for innovative drugs are mainly focused on anti-tumor, circulatory and digestive systems.'可被翻译为：药审中心受理5.1类化药进口原研药注册申请75件（涉及50个品种），受理1类进口创新药注册申请85件（涉及42个品种），创新药的适应症主要集中在抗肿瘤、循环系统和消化系统领域。\n'CDE has accepted a total of 700 applications(involving 319 varieties, increased by 20.8% as compared with those in 2018) for the registration of Class 1 innovative drugs(the number of varieties of chemical drugs is based on the statistical analysis of active ingredients, while the varieties of TCMs and biological products are all counted by their generic names, the same below), covering 302 INDs (increased by 26.4% as compared with those in 2018) and 17 NDAs (decreased by 8 varieties as compared with those in 2018) for Class 1 innovative drugs.'可被翻译为：药审中心受理1类创新药注册申请共700件（319个品种），（化学药的品种数以活性成分统计，中药和生物制品的品种数均以药品通用名称统计，下同），品种数较2018年增长了20.8%。其中，受理1类创新药的新药临床试验（IND）申请302个品种，较2018年增长了26.4%；受理1类创新药的新药上市申请（NDA）17个品种，较2018年减少了8个品种。\n'CDE accepted 448 applications for the registration of domestically-produced Class1 innovative drugs (involving 222 varieties),of which 403 were for INDs (involving 198varieties), and 45 were for NDAs (involving24 varieties). As per drug-specific statistics,323 applications were for chemical drugs(involving 115 varieties), 2 for TCMs(involving 1 variety), and 123 biologicals(involving 106 varieties). The indications of innovative drugs are mainly concentrated in the field of anti-tumor and endocrine systems,and digestive systems.'可被翻译为：药审中心受理国产1类创新药注册申请448件（涉及222个品种），其中受理临床申请403件（涉及198个品种），上市申请45件（涉及24个品种）。按药品类型统计，化药323件（涉及115个品种），中药2件（涉及1个品种），生物制品123件（涉及106个品种），创新药的适应症主要集中在抗肿瘤、内分泌系统和消化系统领域。\n\n根据上述已知信息，请将'CDE reviewed and approved the marketing of 9 varieties of Class 1 innovative drugs, and67 varieties of imported brand-name drugs.For details, see Annexes 1 and 2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审评通过上市1类创新药9个品种，审评通过进口原研药67个品种，具体品种详见附件1、2。"
    },
    {
        "instruction":"已知信息：\n'The holding time for sterilised equipment, components, and containers before use and during filling\/assembly.'可被翻译为：已灭菌设备、组分和容器在使用前和灌装\/装配过程中的保持时间。\n'Maximum permitted holding times for sterile product and equipment exposed during the aseptic process.'可被翻译为：无菌产品和设备在无菌工艺中的最长允许保留时间。\n'The holding time for sterilised product prior to filling.'可被翻译为：已灭菌产品在灌装前的保持时间。\n'Cleaning-in-place and sterilisation-in-place of equipment as necessary.'可被翻译为：必要时对设备进行在线清洁和在线灭菌。\n\n根据上述已知信息，请将'The holding time between equipment, component, and container cleaning, drying and sterilisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设备、组件和容器清洁、干燥和灭菌之间的保持时间。"
    },
    {
        "instruction":"已知信息：\n'For drugs marketed overseas but not marketed in China, technical requirements for clinical trials to support its marketing in China should be established in compliance with the basic logic of clinical evaluation and on the basis of full evaluation of clinical demand of Chinese patients, clinical safety and effectiveness of overseas originator drugs, influences of racial factors as well as the need of benefit\/risk evaluation in Chinese patients.'可被翻译为：境外已上市境内未上市药品的临床技术要求，应遵循临床评价基本逻辑，在充分评价中国患者临床需求、境外原研药品临床安全性和有效性、以及种族因素影响的基础上，基于中国患者获益\/风险评估的需要，确定其在境内上市需开展的临床试验技术要求。\n'For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.'可被翻译为：对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。\n'For adding new dosage form (with clinical advantage), new administration route, new usage and dosage approved overseas but not in China for approved indications of drugs marketed in China, and each domestically marketed single drug in a new compound drug marketed overseas but not marketed in China, when the following conditions are met simultaneously, reduction or exemption of clinical trials can be considered according to the evaluation of overseas clinical trial data : ①Data of completed clinical trials of marketed originator drugs indicates that benefits of the drug for Chinese patients outweigh the risks, and there is no significant impact of racial factors compared with data in foreign populations; ②The overseas clinical trial data of new dosage form, new administration route, new usage and dosage or new compound of the drug can be used to fully evaluate its safety and effectiveness.'可被翻译为：对于境内已上市药品增加境外已批准境内未批准的新剂型（有临床优势的）、新给药途径、新用法用量，用于境内已上市药品已批准适应症的情形，以及境外已上市境内未上市新复方药品中各单药均已在境内上市的情形，在同时满足以下条件时，可考虑基于境外临床试验数据评价情况，减或免临床试验：①已上市原研药品完成的临床试验数据显示，该药品用于中国患者的获益大于风险，且与境外人群数据相比未见明显种族因素的影响；②递交的该药物新剂型、新给药途径、新用法用量，或新复方的境外临床试验数据可用于充分评价其安全性和有效性。\n'As for the requirements for clinical trials of generic drugs marketed overseas but not marketed in China, they should be determined after comprehensive consideration of two factors including clinical evaluation results and pharmaceutics of originator drugs.'可被翻译为：对于境外已上市境内未上市药品的仿制药的临床试验要求，需结合原研药品临床评价结果及制剂学两个方面的因素综合考虑后确定。\n\n根据上述已知信息，请将'If a new indication that has been approved overseas but not in China is added to drugs marketed domestically, besides complying with the above-mentioned basic logic of clinical evaluation and clinical trial requirements, analysis should be based on cases because multi-dimensional complicated factors of diseases and drugs are involved. It is suggested to communicate with regulatory authorities before application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于境内已上市药品增加境外已批准境内未批准的新适应症的情形，除应遵循上述临床评价基本逻辑和临床试验要求外，因涉及疾病和药物等多维度复杂因素，应具体问题具体分析，建议申报前与监管机构进行沟通。"
    },
    {
        "instruction":"已知信息：\n'Development of a cryopreservation process for a clinical cell therapy must consider the consequences for the product, the patient, and the overall feasibility of the therapy. For the cell product, the manufacturer must ensure that expected cell losses because of cryopreservation and thaw occur in a manner that is reasonably predictable and must ensure that the final product administered to the patient will meet specifications for cell number, viability, and functional characteristics.'可被翻译为：开发用于临床细胞治疗的冷冻保存过程必须考虑对产品、病人和治疗整体可行性的影响。对于细胞产品,制造商必须确保由于低温贮藏和解冻产生的预期细胞损失是合理的可预见的，并且必须确保患者使用的最终产品符合细胞数量、生存能力和功能特征的规范。\n'If cells areharvested with plasma present, samples should be properly processed with ananticoagulant to prevent clotting. In addition, some cells are prone toclumping or aggregation when centrifuged, and some cell products may exhibitexcessive damage or loss of one or more populations within the product. Cellsharvested from adherent or nonadherent culture may include substantial numbersof dead or fragile cells. Therefore, centrifugation and wash steps should beoptimized and specific for the product's cellular contents, suspension volume,suspension medium, and container, along with appropriate evaluation of thecellular product before and after these manipulations. Prefreeze processingshould not result in cells that are stressed (e.g., cells that demonstrateelevated early apoptotic markers or temperature-shock responses) before thestart of the freezing process, or cell losses will be higher than expected.'可被翻译为：如果收获的细胞中含有血浆，则应使用抗凝剂对样品进行适当处理来防止凝聚。此外，某些细胞在离心时易于结团或聚集，而一些细胞可能对其中的一个或多个种群表现出过度的损伤或损失。从贴壁或非贴壁培养中收获的细胞可能包括大量死细胞或比较脆弱的细胞。因此，应优化离心和洗涤步骤，并针对产品的细胞含量、悬浮液体积、悬浮介质和容器等进行优化，并在操作前后对细胞产品进行适当评估。在冻存过程开始之前，预冷冻处理不应导致细胞受到压力（例如，表现出早期凋亡标志物升高或温度休克反应的细胞），否则细胞损失将高于预期。\n'Cellpreservation methods are used to ensure product stability during hold, storage,and transport steps for a wide range of human cell-based products (additionalinformation is found in <1046>). Cells can bepreserved in liquid suspension for up to a few days, but quantitative andqualitative changes in the cellular product invariably occur over time.Although preservation in the frozen state also affects the cellular product, itallows more predictable preservation of specific product characteristics overmuch longer time intervals.'可被翻译为：细胞保存方法用于确保产品在各种人体细胞产品在保存、存储和运输过程中的稳定性（有关其他信息，请参见<1046>）。细胞可以在液体悬浮液中保存几天，但是随着时间的推移，细胞产物的定量和定性会发生变化。尽管在冷冻状态下保存对细胞也会有影响，但是它可以在更长时间内维持和预测细胞产品的特性。\n'Transport of cryopreserved cell therapyproducts usually is accomplished by using dry shippers containing absorbentmaterial that can be charged with liquid nitrogen to maintain vapor-phasetemperatures for up to 2 weeks if properly charged. Data loggers are used todocument the temperature history during transport. These shipping containersand procedures must be validated before cell therapy products for clinical useare shipped in the containers.'可被翻译为：冻存的细胞治疗产品的运输通常是通过使用含有吸附材料的干燥的运输箱来完成的，这种材料可以添加液氮，从而保持气相温度长达2周。数据记录仪用于记录运输过程中的温度历史记录。在装运临床的细胞治疗产品之前，这些装运容器和程序必须要经过验证。\n\n根据上述已知信息，请将'Although bedside thawing of cell therapy products before infusion has been a common clinical practice, the use of trained personnel in a controlled laboratory environment is now recognized asthe preferred method for thawing because it allows a more standardized process and a higher degree of control when staff must respond to a container failure,which may require product salvage in a more sterile environment. Product thawing typically is done by immersion in 37° water baths and using over wrap bags to minimize product loss and contamination in case of primary container failure. Bags may be gently kneaded during thaw to reduce temperature gradients across the bag and to accelerate thawing. The product is removed from the water bath when some ice is still present in the product but the majority of the product is thawed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尽管在输液前在床边对细胞治疗产品进行解冻是一种常见的临床过程，但现在公认受过培训的人员在受控实验室环境中解冻是首选的方案。因为这样可以使工作人员在无菌环境中通过更标准化的操作过程和更高程度的控制细胞解冻过程，并对容器故障作出响应来产品回收。解冻通常是通过浸37°水浴中并使用复温袋来完成的，以便在主容器发生故障的情况下将产品损失和污染降至最低。解冻过程中可以轻轻揉捏袋子，降低袋子上的温度梯度并加速解冻。当产品中仍然存在一些冰而大部分产品已经解冻后，将产品从水浴中取出。"
    },
    {
        "instruction":"已知信息：\n'5) Approved master manufacturing documents and operation procedures;'可被翻译为：5.经批准的工艺规程和操作规程；\n'1) To ensure that products are produced and stored according to approved master manufacturing documents in order to obtain the required quality;'可被翻译为：1.确保药品按照批准的工艺规程生产、贮存，以保证药品质量；\n'Article 169: Master manufacturing documents should not be changed without authorization. When revision is needed, they should be revised, reviewed and approved according to relevant operation procedures.'可被翻译为：第一百六十九条 工艺规程不得任意更改。如需更改，应当按照相关的操作规程修订、审核、批准。\n'(2) Management for review of the product formula, manufacturing process and material supplier, etc.;'可被翻译为：（二）产品配方、生产工艺、物料供应商等的审核管理；\n\n根据上述已知信息，请将'1. The review and approval of master manufacturing documents, procedures, etc;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）审核和批准产品的工艺规程、操作规程等文件；"
    },
    {
        "instruction":"已知信息：\n'Article 34 If the registrant, the filing entity and the contract manufacturer of cosmetics have suspended manufacturing for more than 1 year consecutively, it shall make comprehensive internal audit before the manufacturing is resumed, and can resume the manufacturing only after confirming that the requirements are met. The internal audit and rectification conditions shall be reported to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located within 10 workings days from date of resumption of manufacturing.'可被翻译为：第三十四条 化妆品注册人、备案人、受托生产企业连续停产1年以上，重新生产前，应当进行全面自查，确认符合要求后，方可恢复生产。自查和整改情况应当在恢复生产之日起10个工作日内向所在地省、自治区、直辖市药品监督管理部门报告。\n'Where a comprehensive on-site inspection is required due to changes in manufacturing licensed items, etc., if the manufacturer conforms to requirements upon on-site inspection by the drug regulatory department of the province, autonomous region or municipality directly under the central government, a new Cosmetics Manufacturing License shall be issued with the license number unchanged, and the validity period thereof will be recalculated from the date of issuance.'可被翻译为：因生产许可项目等的变更需要进行全面现场核查，经省、自治区、直辖市药品监督管理部门现场核查并符合要求的，颁发新的化妆品生产许可证，许可证编号不变，有效期自发证之日起重新计算。\n'Article 18 In case of changes in the manufacturing licensed items, or changes in the manufacturing facilities and equipment that may affect the product quality and safety, or workshops are newly built, rebuilt or expanded on the original cosmetic manufacturing premises, cosmetics manufacturers shall apply to the drug regulatory department issued former license for change before manufacturing, and submit documents related to the change as specified in Article 10 of these Provisions. The drug regulatory department issued former license shall conduct the review, and make a decision on whether granting approval for change or not within 30 workings days upon acceptance of the application for change, and keep record on duplicate of the Cosmetics Manufacturing License. If it needs to make on-site inspection, it shall be handled as specified in Article 12 of these Provisions.'可被翻译为：第十八条 生产许可项目发生变化，可能影响产品质量安全的生产设施设备发生变化，或者在化妆品生产场地原址新建、改建、扩建车间的，化妆品生产企业应当在投入生产前向原发证的药品监督管理部门申请变更，并依照本办法第十条的规定提交与变更有关的资料。原发证的药品监督管理部门应当进行审核，自受理变更申请之日起30个工作日内作出是否准予变更的决定，并在化妆品生产许可证副本上予以记录。需要现场核查的，依照本办法第十二条的规定办理。\n'Article 53 If the sample testing results of the cosmetics are non-conforming, the registrant and the filing entity of cosmetics shall, in accordance with the Regulations on Supervision and Administration of Cosmetics, stop manufacturing immediately, recall the cosmetics having entered the market for sale, inform relevant marketers and consumers of stopping marketing and use, and make internal audit in accordance with the Paragraph 2 of Article 33 of these Provisions, and then make rectification.'可被翻译为：第五十三条 化妆品抽样检验结果不合格的，化妆品注册人、备案人应当依照化妆品监督管理条例第四十四条的规定，立即停止生产，召回已经上市销售的化妆品，通知相关经营者和消费者停止经营、使用，按照本办法第三十三条第二款的规定开展自查，并进行整改。\n\n根据上述已知信息，请将'Where changes occur in the manufacturing conditions are discovered upon internal audit, so that the conditions no longer meet the requirements of Good Manufacturing Practice for cosmetics, the registrant, the filing entity and the contract manufacturer of cosmetics shall immediately take measures for rectification; upon discovering that the quality and safety of cosmetics may be affected, they shall immediately stop the manufacturing and report the matter to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located. Manufacturing can be resumed only upon removal of the risk factors affecting the quality and safety. The drug regulatory department of the province, autonomous region or municipality directly under the central government may organize on-site inspection based on actual conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经自查发现生产条件发生变化，不再符合化妆品生产质量管理规范要求的，化妆品注册人、备案人、受托生产企业应当立即采取整改措施；发现可能影响化妆品质量安全的，应当立即停止生产，并向所在地省、自治区、直辖市药品监督管理部门报告。影响质量安全的风险因素消除后，方可恢复生产。省、自治区、直辖市药品监督管理部门可以根据实际情况组织现场检查。"
    },
    {
        "instruction":"已知信息：\n'An enveloped single-stranded, RNA virus that is the causative agent of hepatitis C.'可被翻译为：丙型肝炎病毒一种包膜单链RNA病毒，是丙型肝炎的病原体\n'A non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.'可被翻译为：一种非包膜单链RNA病毒，是甲型肝炎的病原体。\n'An enveloped single-stranded RNA virus that is the causative agent of West Nile fever.'可被翻译为：一种包膜单链RNA病毒，是西尼罗河热的病原体。\n'The antigen on the periphery of the hepatitis B virus.'可被翻译为：乙型肝炎病毒周围的抗原。\n\n根据上述已知信息，请将'An enveloped double-stranded DNA virus that is the causative agent of hepatitis B.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种包膜双链DNA病毒，是乙型肝炎的病原体。"
    },
    {
        "instruction":"已知信息：\n'A distinctive combination of numbers and\/or letters which specifically identifies a batch.'可被翻译为：用于识别一个特定批的具有唯一性的数字和（或）字母的组合。\n'A set of numbers or letters plus numbers used to identify the \"lot\". Used to trace and review the manufacturing history of the drug.'可被翻译为：用于识别''批”的一组数字或字母加数字。用以追溯和审查该药品的生产历史。\n'(viii) Records of manufacture including distribution which enable the complete history of a batch to be traced are retained in a comprehensible and accessible form;'可被翻译为：(viii)批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；\n'7. Records of manufacture and distribution, which enable the complete history of a batch to be traced, are retained in a comprehensible and accessible form.'可被翻译为：（七）批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；\n\n根据上述已知信息，请将'A unique combination of numbers, letters, and\/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以标明一个批次的数字、字母和\/或符号的唯一组合，从中可以确定生产和分销的历史。"
    },
    {
        "instruction":"已知信息：\n'Article 45 MAHs of the medical device varieties under intensive surveillance shall, in accordance with requirements in intensive surveillance project of medical devices, carry out relevant works, voluntarily collect the adverse event reports of products and relevant risk information, write risk evaluation report and submit the report to authorities organizing the intensive surveillance project as required.'可被翻译为：第四十五条  医疗器械重点监测品种涉及的持有人应当按照医疗器械重点监测工作方案的要求开展工作，主动收集其产品的不良事件报告等相关风险信息，撰写风险评价报告，并按要求报送至重点监测工作组织部门。\n'Article 14 MAHs shall carry out continuous research on the medical devices already marketed, evaluate the risks, assume the responsibilities of medical device adverse event monitoring, take effective control measures based on the analysis and evaluation results, and fulfill the following main obligations:'可被翻译为：第十四条  持有人应当对其上市的医疗器械进行持续研究，评估风险情况，承担医疗器械不良事件监测的责任，根据分析评价结果采取有效控制措施，并履行下列主要义务：\n'MAHs of innovative medical devices shall, within the first registration cycle, submit analysis, evaluation and summary report of product adverse event monitoring to national monitoring agency every half a year. In case of identifying any possible serious defects of a medical device, national monitoring agency shall promptly report to National Medical Products Administration.'可被翻译为：创新医疗器械持有人应当在首个注册周期内，每半年向国家监测机构提交产品不良事件监测分析评价汇总报告。国家监测机构发现医疗器械可能存在严重缺陷的信息，应当及时报国家药品监督管理局。\n'Article 10 The medical device manufacturers shall establish and improve a medical device quality management system as well as a medical device adverse events monitoring system in accordance with regulations, collect and record medical device quality complaint information and medical device adverse events information, analyze the collected information, and investigate and assess possible defects.'可被翻译为：第十条 医疗器械生产企业应当按照规定建立健全医疗器械质量管理体系和医疗器械不良事件监测系统，收集、记录医疗器械的质量投诉信息和医疗器械不良事件信息，对收集的信息进行分析，对可能存在的缺陷进行调查和评估。\n\n根据上述已知信息，请将'Article 47 MAHs of innovative medical devices shall strengthen voluntary monitoring of innovative medical devices, formulate product monitoring plans, voluntarily collect relevant adverse event reports and product complaint information, and carry out investigation, analysis and evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  创新医疗器械持有人应当加强对创新医疗器械的主动监测，制定产品监测计划，主动收集相关不良事件报告和产品投诉信息，并开展调查、分析、评价。"
    },
    {
        "instruction":"已知信息：\n'Root cause analysis of procedural, process or equipment failure is performed in such a way that the risk to product is correctly identified and understood so that suitable corrective and preventive actions (CAPA) are implemented.'可被翻译为：对程序、工艺或设备失败进行根本原因分析，正确识别和理解产品风险，从而实施适当的纠正和预防措施（CAPA）\n'Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence'可被翻译为：纠正措施和预防措施用于调查、理解和纠正偏差并预防其再次发生的系统。\n'corrective and preventative actions'可被翻译为：纠正和预防措施\n'An investigation to determine the most probable root cause(s).'可被翻译为：进行调查，确定最可能的根本原因。\n\n根据上述已知信息，请将'Prevention mechanisms - trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预防机制——趋势分析、详细调查、确定根本原因、纠正和预防措施（CAPA）以及对全面调查工具的需求。"
    },
    {
        "instruction":"已知信息：\n'A liposome consisting of lipids whose phase transition temperature is slightly higher than body temperature. Its drug release is temperature-sensitive.'可被翻译为：由相转变温度稍高于体温的脂质组成的脂质体。其药物的释放对温度具有敏感性。\n'membrane fluidity'可被翻译为：膜流动性\n'liposome'可被翻译为：脂质体\n'phase transition temperature'可被翻译为：相变温度\n\n根据上述已知信息，请将'The temperature at which a phase transition occurs in the liposome membrane. When the temperature increases, the acyl side bonds in the bilayer of liposome change from ordered to disordered, from colloidal to liquid crystal, and the cross section of the membrane increases, the thickness decreases, and the fluidity increases.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"脂质体膜发生相态转变的温度。当温度升高时，脂质体双分子层中酰基侧键可从有序排列变为无序排列，由胶晶变为液晶态，膜的横切面增加、厚度减少、流动性增加等。"
    },
    {
        "instruction":"已知信息：\n'To further unify the understanding of mandatory industry standards, and truly promote the implementation of mandatory industry standards of medical devices,in accordance with the Standardization Law of the People's Republic of China,the Regulations for the Supervision and Administration of Medical Devices,the Provisions for Mandatory National Standards and the Provisions for Medical Device Standards, on July 7, 2020, NMPA issued the notice on matters related to further strengthening management for mandatory industry standards of medical devices, requiring drug regulatory authorities at all levels to effectively maintain the legal status of mandatory industry standards,further improve the mandatory industry standard system, promote the drafting and implementation of mandatory industry standards, reinforce the publicity,implementation and training, standardize the implementation of mandatory industry standards, and reinforce the evaluation on implementation of mandatory industry standards.'可被翻译为：为进一步统一对强制性行业标准的认识，切实推进医疗器械强制性行业标准规范、有效实施，根据《中华人民共和国标准化法》《医疗器械监督管理条例》《强制性国家标准管理办法》和《医疗器械标准管理办法》，现就进一步加强医疗器械强制性行业标准管理有关事项通知：切实维护强制性行业标准的法律地位、进一步完善强制性行业标准体系、完善强制性行业标准起草和实施、加强强制性行业标准的宣贯培训、规范强制性行业标准的执行、强化强制性行业标准的实施评估。\n'Pursuant to the Opinions of the General Office of the CPC Central Committee and the General Office of the State Council on Deepening the Reform of Review &Approval System to Encourage Innovation in Drugs and Medical Devices (General Office [2017] No. 42), to orderly promote the electronic application of medical device registration, on July 10, 2019, NMPA issued the Announcement on the Requirements for Relevant Electronic Application Dossiers of Medical Devices, to regulate the submission of relevant dossiers.'可被翻译为：为落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》（厅字〔2017〕42号）的要求，有序推进医疗器械注册电子申报工作，2019年7月10日，国家药监局发布了《关于医疗器械电子申报有关资料要求的通告》，规范相关档案的提交。\n'The revised Regulations for the Supervision and Administration of Medical Devices (State Council Order No. 739, hereinafter referred to as the Regulations) will be implemented as of June 1, 2021. NMPA is organizing the formulation and revision of supporting regulations, normative documents and technical guidances, which will be released one after another in accordance with procedures. The matters related to implementation of the new Regulations are hereby announced as follows:'可被翻译为：新修订的《医疗器械监督管理条例》（国务院令第739号，以下简称新《条例》），将于2021年6月1日起施行。国家药监局正在组织制修订配套规章、规范性文件和技术指导原则等，将按照程序陆续发布。现就贯彻实施新《条例》有关事项公告如下：\n'As per the Opinions of the General Office of the CPC Central Committee and the General Office of the State Council on Deepening the Reform of Review & Approval System to Encourage Innovation in Drugs and Medical Devices (General Office [2017]No. 42), in conjunction with the roll out of electronic application of medical device registration, according to the Provisions for Medical Device Registration (former CFDA Decree No. 4) and the requirements of other documents, NMPA organized the formulation of the Requirements for Filing Review of Registration Items of Medical Device Products (Interim), which has been released on July 10, 2019, and shall enter into force as from September 1, 2019.'可被翻译为：为贯彻落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》（厅字〔2017〕42号），配合医疗器械注册电子申报工作的开展，根据《医疗器械注册管理办法》（原国家食品药品监督管理总局令第4号）和其他文件要求，国家药品监督管理局组织制定了《医疗器械产品注册项目立卷审查要求（试行）》，已于2019年7月10日发布，自2019年9月1日起生效。\n\n根据上述已知信息，请将'Unless otherwise specified in the standard documents issued and implemented by NMPA, a medical device with the application already accepted for registration before implementation of the new standards can be reviewed and approved according to original provisions where the mandatory standards cited in the product technical requirements have changed. As of the date of implementation of the new standards, enterprises shall fully implement the new standards and their products shall meet the requirements of the new standards.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于申请注册的医疗器械，其产品技术要求中引用的强制性标准发生变化的，除国家药监局在发布实施标准文件中另有规定外，在新标准实施之日前受理注册的，可以按照原标准进行审评审批。自新标准实施之日起，企业应当全面实施新标准，产品应当符合新标准要求。"
    },
    {
        "instruction":"已知信息：\n'Rules for Labels of Prepared Slices of Chinese Crude Drugs Issued by China NMPA'可被翻译为：国家药监局关于发布《中药饮片标签管理规定》的公告\n'Annex: The Rules for Labels of Prepared Slices of Chinese Crude Drugs'可被翻译为：附件：中药饮片标签管理规定\n'As per the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and the regulations on postmarketing supervision of pharmaceuticals, NMPA uniformly formulated the formats of Drug Production License and other Certificates. To standardize the formats and renewal of the drug administrative licenses, on August 7, 2019, NMPA issued the Notice on Enabling the New Version of the Drug Production License and other Certificates, and notified the relevant matters as follows:'可被翻译为：根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》及有关药品上市后监管的法规规定，国家药品监督管理部门统一制定《药品生产许可证》等许可证书样式。为规范药品行政许可证明文件样式和换发工作，国家药监局于2019年8月7日发布了关于启用新版《药品生产许可证》等许可证书的通知，并将有关事宜通知如下：\n'To implement the provisions of the Drug Administration Law of the People's Republic of China, in accordance with the requirements of the Guiding Opinions of the China National Drug Administration on the Construction of Drug Information Traceability System (CNDA Department of Drug Supervision [2018] No. 35) and other documents, NMPA organized the formulation of the Basic Data Sets for Traceability of Drug Marketing Authorization Holders and Manufacturers, Basic Data Sets for Traceability of Drug Distributors, Basic Data Sets for Traceability of Drug Using Units, Basic Data Sets for Traceable Drugs for Consumers, and Basic Technical Requirements for Traceability Data Exchange of Drugs, which were issued on March 11, 2020, and effective as of the issuing date.'可被翻译为：为贯彻落实《中华人民共和国药品管理法》的规定，按照《国家药品监督管理局关于药品信息溯源系统建设的指导意见》(国家药品监督管理局[2018]35号)等文件要求，国家药监局组织编制了《药品上市许可持有人和生产企业溯源基本数据集》。《药品经营企业可追溯性基本数据集》、《使用单位可追溯性基本数据集》、《消费者可追溯性药品基本数据集》、《药品可追溯性数据交换基本技术要求》于2020年3月11日发布，自发布之日起施行。\n\n根据上述已知信息，请将'To further standardize the regulation on labels of prepared slices of Chinese crude drugs, in accordance with laws, administrative regulations and provisions including the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Insert Sheets and Labels, the NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024. The labeling of expiration date according to the Rules shall be implemented since August 1, 2025.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步规范中药饮片标签的管理，根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》《药品说明书和标签管理规定》等法律、行政法规和规章，国家药监局组织制定了《中药饮片标签管理规定》，现予发布，自2024年8月1日起施行，其中，保质期的标注自2025年8月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'Article 12 National monitoring agencies shall be responsible for receiving medical device adverse events information reported by MAHs, distributing enterprises and user facility, assume relevant technical works related to medical device adverse event monitoring and re-evaluation nationwide; be responsible for the construction, maintenance and information management of national network and database of monitoring information of medical device adverse event, organize to develop technical specifications and guidelines, organize the investigation, evaluation and feedback of relevant adverse events information of the medical devices approved by the NMPA to be registered, summarize, analyze and guide relevant adverse events information of the medical devices approved by local drug regulatory departments above municipal level to be registered or filed, and investigate and evaluate group adverse events of medical device that have great influence nationwide and cause severe injuries or death and other serious consequences.'可被翻译为：第十二条  国家监测机构负责接收持有人、经营企业及使用单位等报告的医疗器械不良事件信息，承担全国医疗器械不良事件监测和再评价的相关技术工作；负责全国医疗器械不良事件监测信息网络及数据库的建设、维护和信息管理，组织制定技术规范和指导原则，组织开展国家药品监督管理局批准注册的医疗器械不良事件相关信息的调查、评价和反馈，对市级以上地方药品监督管理部门批准注册或者备案的医疗器械不良事件信息进行汇总、分析和指导，开展全国范围内影响较大并造成严重伤害或者死亡以及其他严重后果的群体医疗器械不良事件的调查和评价。\n'Article 8 The NMPA shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation nationwide, organize the investigation and handling of group adverse events of medical device that has great influence nationwide and causes severe injuries or death and other serious consequences jointly with the Health Administrative Departments of the State Council, and take emergency control measures according to law.'可被翻译为：第八条  国家药品监督管理局负责全国医疗器械不良事件监测和再评价的监督管理工作，会同国务院卫生行政部门组织开展全国范围内影响较大并造成严重伤害或者死亡以及其他严重后果的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。\n'National monitoring agencies shall carry out comprehensive analysis on adverse event reports of the medical devices approved by the NMPA to be registered or filed and quarterly reports submitted by all the provinces, autonomous regions and municipalities directly under the central government, and if necessary, propose recommendations on supervisory measures to the NMPA.'可被翻译为：国家监测机构应当对国家药品监督管理局批准注册或者备案的医疗器械的不良事件报告和各省、自治区、直辖市药品监督管理部门的季度报告进行综合分析，必要时向国家药品监督管理局提出监管措施建议。\n'Article 5 National Medical Products Administration (hereinafter referred to as the NMPA) shall establish the National Medical Device Adverse Event Monitoring Information System and strengthen the construction of medical device adverse event monitoring information network and database.'可被翻译为：第五条  国家药品监督管理局建立国家医疗器械不良事件监测信息系统，加强医疗器械不良事件监测信息网络和数据库建设。\n\n根据上述已知信息，请将'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。"
    },
    {
        "instruction":"已知信息：\n'Studies designed to increase the rate of chemical degradation and physical change of a drug by using exaggerated storage conditions as part of the formal stability testing programme. The data thus obtained, in addition to those derived from real-time stability studies, may be used to assess longer-term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'可被翻译为：作为正式稳定性试验计划的一部分，通过使用夸张的储存条件来提高药物的化学降解和物理变化速度的研究。由此获得的数据，除了来自实时稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估在标签存储条件之外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。\n'Studies designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated storage conditions as part of the formal stability studies. Data from these studies, in addition to long term stability studies, can be used to assess longer term chemical effects at non-accelerated conditions and to evaluate the effect of short term excursions outside the label storage conditions such as might occur during shipping. Results from accelerated testing studies are not always predictive of physical changes.'可被翻译为：加速试验是通过使用超常的贮存条件来加速原料药或制剂的化学降解或物理变化。它是正式的稳定性研究的一部分。除了长期稳定性研究外，从这些研究中得到的数据也可以评估在非加速条件下更长时间内的化学变化以及评价在短期偏离标签上所注明的储存条件，如运输过程中可能遇到的情况时的影响，加速试验研究的结果有时不能预示物理变化。\n'1.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the re- test period (or shelf-life) of an API or the shelf-life of an FPP.\n2.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the retest period (or shelf life) of an active pharmaceutical ingredient or the shelf life of a finished pharmaceutical product.'可被翻译为：1.根据规定的稳定性协议，对主要批次和\/或承诺批次进行长期和加速(和中间)研究，以确定或确认API或FPP的复测期(或保质期)。\n2.根据规定的稳定性方案对主要批次和\/或承诺批次进行的长期和加速(和中间)研究，以确定或确认活性药物成分的复测期(或保质期)或成品药品的保质期。\n'Studies designed to increase the rate of chemical or physical degradation of a drug by using degradation reactions and predicting the shelf-life under normal storage conditions. The design of accelerated studies may include elevated temperature (e.g., 37-49°C and up to 50- 55°C), high humidity and light.Only a provisional shelf-life may be established on the basis of these studies. Therefore, accelerated studies should always be supplemented by real-time studies under expected storage conditions.'可被翻译为：通过降解反应和预测药物在正常储存条件下的保质期来提高药物化学或物理降解速度的研究。加速研究的设计可能包括高温(例如，37-49°C和高达50- 55°C)、高湿度和光照。在这些研究的基础上，只能建立临时的保质期。因此，在预期的储存条件下，加速研究应始终辅以实时研究。\n\n根据上述已知信息，请将'Studies designed to increase the rate of chemical degradation and physical change of an API or FPP by  using exaggerated storage conditions as part of the stability testing programme. The data thus obtained, in addition to those derived from long-term stability studies, may be used to assess longer term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过使用夸张的储存条件作为稳定性测试程序的一部分，旨在增加API或FPP的化学降解和物理变化速率的研究。由此获得的数据，除了来自长期稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估标签存储条件外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。"
    },
    {
        "instruction":"已知信息：\n'A solid preparation made of drugs and excipients filled in hollow capsules in an appropriate form.'可被翻译为：药物及辅料以适当形式填装于空心胶囊中制成的固体制剂。\n'A solid preparation made of drugs and excipients in an appropriate form by pressing (or dropping) sealed in soft sacs.'可被翻译为：药物及辅料以适当形式通过压制法（或滴制法）密封于软质囊材中而制成的固体制剂。\n'A solid preparation made of a drug and a suitable excipient in a round or shaped form.'可被翻译为：药物和适宜的辅料混匀压制而成的圆片状或异形片状的固体制剂。\n'A capsule shell used in the preparation of capsules.'可被翻译为：用于制备胶囊剂的囊壳。\n\n根据上述已知信息，请将'A solid preparation prepared by filling a hollow capsule or sealing in a soft capsule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物及辅料填装于空心胶囊或密封于软质囊材中制得的固体制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 18 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第十八条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'The State encourages and guides the operation of retail drug chains. The headquarters of a retail drug chain shall establish a unified quality management system and perform management responsibilities for the business activities of the chain retailers.'可被翻译为：国家鼓励、引导药品零售连锁经营。从事药品零售连锁经营活动的企业总部，应当建立统一的质量管理制度，对所属零售企业的经营活动履行管理责任。\n'Article 180 The GSP provides basic requirements for quality management of drug distribution. Specific requirements for enterprise informatization management, automatic monitoring of temperature and humidity for drug storage and transportation, drug acceptance inspection management, drug cold chain logistics management, and retail chain management shall be separately formulated by the National Medical Products Administration (NMPA) in the form of appendixes.'可被翻译为：第一百八十条 本规范为药品经营质量管理的基本要求。对企业信息化管理、药品储运温湿度自动监测、药品验收管理、药品冷链物流管理、零售连锁管理等具体要求，由国家食品药品监督管理总局以附录方式另行制定。\n'Article 53 The undertaking of drug distribution activities shall comply with the GSP.A quality management system for drug distribution shall be established and improved, to ensure that the whole chain of drug distribution continuously complies with statutory requirements.'可被翻译为：第五十三条 从事药品经营活动，应当遵守药品经营质量管理规范，建立健全药品经营质量管理体系，保证药品经营全过程持续符合法定要求。\n\n根据上述已知信息，请将'Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。"
    },
    {
        "instruction":"已知信息：\n'electrical conductivity'可被翻译为：电导率\n'A technique for measuring the relationship between the electrical properties of a substance and its temperature at a programmed temperature. It is often used to measure resistance, conductance, and capacitance.'可被翻译为：在程序控制温度下，测量物质的电学特性与温度关系的技术。常用于测量电阻、电导和电容。\n'A physical quantity indicating the degree of diffusion of the molecules of a substance.'可被翻译为：表示物质分子扩散程度的物理量。\n'The molar concentration of each ion in a solution multiplied by the square of the valence number of the ion yields half of the sum of the terms, usually expressed as \/. Expresses the degree to which the ions in the solution are electrically strong or weak.'可被翻译为：溶液中每种离子的质量摩尔浓度乘以该离子的价数的平方所得诸项之和的一半，通常以\/表示。表达了溶液中离子的电性强弱的程度。\n\n根据上述已知信息，请将'The reciprocal of resistivity. Is a physical indicator of the electrical conductivity of a substance. The greater the conductivity, the stronger the material conductivity, the smaller the resistance, on the contrary, the worse the conductivity, the greater the resistance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电阻率的倒数。是表示物质导电性能的物理指标。电导率越大则物质导电性能越强，电阻就越小，反之导电性能越差，电阻越大。"
    },
    {
        "instruction":"已知信息：\n'Article 280: The contract giver is responsible for assessing the contract acceptor, via on-site audit of the conditions, technical levels and quality management status, to confirm its competence to carry out the contracted operations, and to ensure the compliance with the Provisions.'可被翻译为：第二百八十条 委托方应当对受托方进行评估，对受托方的条件、技术水平、质量管理情况进行现场考核，确认其具有完成受托工作的能力，并能保证符合本规范的要求。\n'Article 292: The contract should define that the contract acceptor has the obligation to accept the inspection conducted by drug regulatory department.'可被翻译为：第二百九十二条 委托检验合同应当明确受托方有义务接受药品监督管理部门检查。\n'Article 289: The contract should describe clearly who is responsible for purchasing materials, testing and releasing materials, undertaking production and quality controls (including in-process controls), and who has responsibility for sampling and analysis.'可被翻译为：第二百八十九条 合同应当规定何方负责物料的采购、检验、放行、生产和质量控制（包括中间控制），还应当规定何方负责取样和检验。\n'When necessary, inspection shall be carried out toward the contract manufacturer.'可被翻译为：必要时，可以对受托生产企业开展检查。\n\n根据上述已知信息，请将'Article 291: The contract should clearly define that the contract giver can conduct on-site inspection or audit to the contract acceptor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百九十一条 合同应当明确规定委托方可以对受托方进行检查或现场质量审计。"
    },
    {
        "instruction":"已知信息：\n'iv. Cleaning procedures and cleaning validation'可被翻译为：清洁程序和清洁验证\n'Points to Consider for Cleaning Validation'可被翻译为：清洁验证考量要点\n'Article 143: Cleaning validation should be performed in order to confirm the effectiveness of a cleaning procedure, to effectively prevent contamination and cross-contamination. In cleaning validation, a comprehensive consideration should include factors such as the use of the equipment, the detergents and disinfectants used, the sampling methods and locations, the relevant recovery rate of sampling, the nature and limit of residues, and the sensitivity of the testing method for residues.'可被翻译为：第一百四十三条 清洁方法应当经过验证，证实其清洁的效果，以有效防止污染和交叉污染。清洁验证应当综合考虑设备使用情况、所使用的清洁剂和消毒剂、取样方法和位置以及相应的取样回收率、残留物的性质和限度、残留物检验方法的灵敏度等因素。\n'cleaning verification'可被翻译为：清洁验证\n\n根据上述已知信息，请将'The cleaning process should be validated to be able to:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"清洁程序应进行验证，确保其能够："
    },
    {
        "instruction":"已知信息：\n'Article 152 The State Food and Drug Administration shall make the review and approval decision within 20 days; where a decision cannot be made within 20 days, another ten days may be extended with the approval of the State Food and Drug Administration head in charge, and the applicant shall be informed of the reason of the time extended.'可被翻译为：第一百五十二条 国家食品药品监督管理局应当在20日内作出审批决定；20日内不能作出决定的，经主管局领导批准，可以延长10日，并应当将延长时限的理由告知申请人。\n'Article 40 The NMPA shall, within 20 working days from the date of receiving the technical evaluation conclusions, review the legality, standardization and completeness of the technical evaluation procedures and conclusions, and decide whether to approve registration.'可被翻译为：第四十条 国家药品监督管理局应当自收到技术审评结论之日起20个工作日内，对技术审评程序和结论的合法性、规范性以及完整性进行审查，并作出是否准予注册的决定。\n'Article 26 After receiving the recommendations for on-site inspection, the CFDI shall conduct on-site inspection within 20 days.'可被翻译为：第二十六条 核查中心接到现场检查建议后，应当在20日内进行现场检查。\n'Article 14 The provincial drug regulatory department shall make a decision of approval or disapproval within 20 days upon the acceptance of the application. For those meeting the requirements, a one-time approval document for importation of crude drugs shall be issued. The time for testing and submission of supplementary materials shall not be counted in the timeline for approval.'可被翻译为：第十四条 省级药品监督管理部门应当自受理申请之日起20日内作出准予或者不予批准的决定。对符合要求的，发给一次性进口药材批件。检验、补充资料期限不计入审批时限。\n\n根据上述已知信息，请将'Article 100 A decision on administrative approval shall be made within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 行政审批决定应当在二十日内作出。"
    },
    {
        "instruction":"已知信息：\n'(16) Medical device with measuring functions'可被翻译为：（十六）具有计量测试功能的医疗器械\n'Any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination, for human beings, for one or more of the specific medical purpose(s) of: ■■ diagnosis, prevention, monitoring, treatment or alleviation of disease; ■■ diagnosis, monitoring, treatment, alleviation of or compensation for an injury; investigation, replacement, modification or support of the anatomy or of a physiological process; ■■ supporting or sustaining life; ■■ control of conception; ■■ disinfection of medical devices; ■■ providing information by means of in vitro examination of specimens derived from the human body, and which does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human body, but which may be assisted in its intended function by such means (1).'可被翻译为：任何仪器、仪器、器具、机器、器具、植入物、体外使用试剂、软件、材料或其他类似或相关物品，制造商打算单独或组合用于人类，用于一种或多种特定医疗目的:■■诊断、预防、监测、治疗或减轻疾病;■■诊断、监测、治疗、减轻或者赔偿伤害;解剖或生理过程的调查、替换、修改或支持;■支持或维持生命;■■控制受孕;■■医疗器械消毒;■■通过对来自人体的标本进行体外检查来提供信息，这些标本不能通过药理学、免疫学或代谢手段在人体中或在人体上达到其主要预期作用，但可以通过这些手段辅助其预期功能(1)。\n'The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (7).'可被翻译为：评估和分析与医疗器械有关的临床数据，以验证器械在按制造商预期使用时的临床安全性和性能(7)。\n'Any systematic investigation or study in or on one or more human subjects, undertaken to assess the safety and\/or performance of a medical device (7).'可被翻译为：为评估医疗器械的安全性和\/或性能而对一个或多个人类受试者进行的系统调查或研究(7)。\n\n根据上述已知信息，请将'A medical device intended to measure the physiological, pathological and anatomic parameters or make quantitative determination on the energies\/substances entering or leaving the human body. The measuring results shall be accurately quantified, and the accuracy of such results may have obvious effects on patient's health and safety.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种用于测定生理、病理、解剖参数，或者定量测定进出人体的能量或物质的医疗器械，其测量结果需要精确定量，并且该结果的准确性会对患者的健康和安全产生明显影响。"
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance of medical device registration, and further improve the quality of registration review, the NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《视力筛查仪注册技术审查指导原则》和《乳腺X射线系统注册技术审查指导原则》，并于6月24日发布。\n'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'可被翻译为：国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products'可被翻译为：国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of X-ray Image Guided Systems for Radiotherapy and Guidelines for Technical Review of the Registration of Positron Emission \/ X-Ray Computed Tomography Systems.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《用于放射治疗的X射线图像引导系统注册技术审查指导原则》和《正电子发射\/X射线计算机断层成像系统注册技术审查指导原则》。\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.'可被翻译为：第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。\n'Article 73: The documents and records for equipment procurement, installation, and qualification should be archived.'可被翻译为：第七十三条 应当建立并保存设备采购、安装、确认的文件和记录。\n'Article 84: Production equipment should be cleaned according to detailed operation procedures.'可被翻译为：第八十四条 应当按照详细规定的操作规程清洁生产设备。\n'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'可被翻译为：第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。\n\n根据上述已知信息，请将'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。"
    },
    {
        "instruction":"已知信息：\n'Manufacturers of Prepared Slices shall fulfill relevant obligations of drug MAHs and ensure the manufacturing of Prepared Slices continuously complies with regulatory requirements.'可被翻译为：中药饮片生产企业应当履行药品上市许可持有人的相关义务，确保中药饮片生产过程持续符合法定要求。\n'Prepared Slices may be released from the factory and sold only if they conform to the national drug standards or the processing standards formulated by the drug regulatory department of the province, autonomous region or municipality directly under the Central Government.'可被翻译为：中药饮片符合国家药品标准或者省、自治区、直辖市药品监督管理部门制定的炮制规范的，方可出厂、销售。\n'(IX) Management of prescription audit, dispensing and checking of Prepared Slices;'可被翻译为：（九）中药饮片处方审核、调配、核对的管理；\n'(III) Those distributing Prepared Slices shall have equipment for storing such drugs and prescription dispensing;'可被翻译为：（三）经营中药饮片的，有存放饮片和处方调配的设备；\n\n根据上述已知信息，请将'(IV) For the sales of Prepared Slices, they shall be accurately weighed, and the customers shall be informed of the decocting and administration methods and corresponding precautions. The provision of decoction services for Prepared Slices shall conform to the relevant national provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）销售中药饮片做到计量准确，并告知煎服方法及注意事项；提供中药饮片代煎服务，应当符合国家有关规定。"
    },
    {
        "instruction":"已知信息：\n'The adverse event refers to an adverse medical event that occurs during the clinical trial, no matter whether it is related to the investigational medical devices.'可被翻译为：不良事件，是指在临床试验过程中出现的不利的医学事件，无论是否与试验用医疗器械相关。\n'The serious adverse event refers to event of death or serious deterioration of physical health during the clinical trial, including deadly illnesses or injuries, permanent defect in body structure or body function, and event where hospitalization or prolonged hospitalization, medical or surgical intervention is needed to avoid permanent defect to body structure or body function; and events that causes fetal distress, fetal death, or congenital anomalies or defects.'可被翻译为：严重不良事件，是指临床试验过程中发生的导致死亡或者健康状况严重恶化，包括致命的疾病或者伤害、身体结构或者身体功能的永久性缺陷、需住院治疗或者延长住院时间、需要进行医疗或者手术介入以避免对身体结构或者身体功能造成永久性缺陷；导致胎儿窘迫、胎儿死亡或者先天性异常、先天缺损等事件。\n'Article 30 Where safety issues or other risks are observed during drug clinical trials, the sponsor shall promptly modify the clinical trial protocol, suspend or terminate the clinical trial, and report the case to the CDE.'可被翻译为：第三十条 药物临床试验期间，发现存在安全性问题或者其他风险的，申办者应当及时调整临床试验方案、暂停或者终止临床试验，并向药品审评中心报告。\n'(2) the clinical trial sponsor fails to promptly adjust the clinical trial plan, suspends or terminates clinical trial protocol, or fails to report to the drug regulatory department of the State Council during drug clinical trial, upon discovery of safety issues or other risks;'可被翻译为：（二）药物临床试验期间，发现存在安全性问题或者其他风险，临床试验申办者未及时调整临床试验方案、暂停或者终止临床试验，或者未向国务院药品监督管理部门报告；\n\n根据上述已知信息，请将'(14) Adverse events found in the clinical trial and the handling;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十四）临床试验中发现的不良事件以及其处理情况；"
    },
    {
        "instruction":"已知信息：\n'Provisions for Supervision of Drug Distribution'可被翻译为：药品流通监督管理办法\n'Article 47    The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.'可被翻译为：第四十七条 本办法自2007年5月1日起施行。自本办法施行之日起，1999年8月1日实施的国家药品监督管理局《药品流通监督管理办法（暂行）》（国家药品监督管理局第7号令）同时废止。\n'1. As form the implementation of the newly revised Drug Administration Law, unless the promulgation of relevant supportive departmental regulations stated otherwise, the Regulations on Drug Distribution License (Former CFDA Order No. 6) and the Provisions for Supervision of Drug Distribution (Formerly CFDA Order No. 26) remains valid and, where their provisions are inconsistent with the Drug Administration Law, the latter shall prevail.'可被翻译为：一、作为新修订的《药品管理法》施行以来，在相关配套部门规章发布前，《药品经营许可证管理办法》（原国家食品药品监督管理局局令第6号）和《药品流通监督管理办法》（原国家食品药品监督管理局局令第26号）继续有效，其中规定与《药品管理法》不一致的，以后者为准。\n'Provisions for the Supervision and Administration of Drug Manufacturing'可被翻译为：药品生产监督管理办法\n\n根据上述已知信息，请将'Provisions for Supervision of Drug Distribution(SFDA Decree No.26)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品流通监督管理办法》（局令第26号）"
    },
    {
        "instruction":"已知信息：\n'controlled vocabulary (cv)'可被翻译为：受控词汇\n'In a hierarchical medical dictionary, for example MedDRA, the included term is the lowest level of dictionary term to which the investigator description is coded. The preferred term is the level of grouping of included terms typically used in reporting frequency of occurrence. For example, the investigator text “Pain in the left arm” might be coded to the included term “Joint pain”, which is reported at the preferred term level as “Arthralgia”.'可被翻译为：在分层级医学词典中，例如 MedDRA，收录术语是词典\n术语的最低层级，以研究者的描述进行编码。首选术语是收录术语的分组层级，通常用于报告发生率。例如，研究者写的是“左臂疼痛”，收录术语编码为：“关节疼痛”，在首选术语层级上报告为“关节痛”。\n'An organization currently engaged in establishing, populating on an initial basis or maintaining controlled vocabularies (ISO). For example, EDQM, ICH, \nIHTSDO.'可被翻译为：目前参与建立、在初步基础上填入或维护受控词汇（ISO）的组织。 例如，EDQM、ICH、IHTSDO。\n'A method of indexing a piece of information multiple times in a document. Pharmacology centered on the study of the effects of drugs on mental activity.'可被翻译为：一个文件中对某个信息多次提及时采用的一种索引方式。以研究药物对精神活动作用为中心内容的药理学。\n\n根据上述已知信息，请将'A controlled vocabulary is an established list of standardized terminology for use in indexing and retrieval of information. CVs are established lists of \npreferred terms for cataloguing or indexing information (for example as descriptors in databases). CVs can address issues of synonyms or \nstandardised headings. Sample CVs: MedDRA, ISO country codes, EDQM Routes of Administration, etc.)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受控词汇表（CV）是一张已确定的标准术语表，用于信息的索引和检索。CV 是已确定的首选术语表，用于分类和索引信息（类似于数据库中的描述符）。CV可以解决同义词或标准化标题的问题。（CV 样例：MedDRA、ISO 国家代码、EDQM 给药途径等。）"
    },
    {
        "instruction":"已知信息：\n'Describes a process step, process condition, test requirement, or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.'可被翻译为：用以描述某个为保证药品符合要求而确立的应当被控制在预先确定的标准范围内的工艺步骤、工艺条件、试验要求或其他有关的参数或项目。\n'A processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product.'可被翻译为：系统内的加工参数或部件，其操作、接触、数据控制、报警或故障将对产品质量产生间接影响或无影响。\n'A process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure the process produces the desired quality.'可被翻译为：指其波动会影响到产品关键质量属性而应该被监测或控制的工艺参数，以确保能生产出预期质量的产品。\n'A process parameter which could have an impact on the critical quality attribute.'可被翻译为：可能对关键质量属性产生影响的工艺参数。\n\n根据上述已知信息，请将'1.Describes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n2.Having the potential to impact on product quality or performance in a  significant way.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述必须控制在预定标准内的工艺步骤、工艺条件、测试要求或其他相关参数或项目，以确保原料药符合其规格。\n2.有可能对产品质量或性能产生重大影响的。"
    },
    {
        "instruction":"已知信息：\n'Article 39 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of technical evaluation, and deal with it respectively according to the following circumstances:'可被翻译为：第三十九条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理：\n'Article 15 If the evaluation conclusion is disapproval, the technical assessment agency shall notify the applicant and explain the reasons. If disagreements exist, the applicant may apply for re-evaluation within 20 working days from the date of receiving the evaluation conclusion. The content of the re-evaluation is limited to the original application items and application dossiers.'可被翻译为：第十五条 技术审评结论为审评不通过的，技术审评机构应当告知申请人并说明理由。申请人有异议的，可以自收到技术审评结论之日起20个工作日内申请复核。复核的内容仅限于原申请事项以及申请资料。\n'(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval.'可被翻译为：（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。\n'Article 47 During the process of registration technical evaluation, the technical assessment agency may notify the inspection agency to carry out on-site inspection as needed. Domestic on-site inspections should be completed within 45 working days, and overseas on-site inspections should be implemented in accordance with relevant provisions on overseas inspections. The time for on-site inspection is not included in the time limit of technical evaluation.'可被翻译为：第四十七条 技术审评机构在注册技术审评过程中，可以根据需要通知审核查验机构开展现场核查。境内现场核查应当在45个工作日内完成，境外现场核查应当按照境外核查相关规定执行。现场核查所用时间不计算在审评时限之内。\n\n根据上述已知信息，请将'Article 14 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of the technical evaluation, and deal with it separately according to the following circumstances:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理："
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 5, 2020 the Guidelines for Technical Review of the Registration of Colloidal Gold Immunochromatographic Analyzers, Guidelines for Technical Review of the Registration of Follicle stimulating Hormone Detection Reagents, Guidelines for Technical Review of the Registration of Creatinine Detection Reagents, Guidelines for Technical Review of the Registration of Antinuclear Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Antithyroid Peroxidase Antibody Assay Reagents, Guidelines for Technical Review of the Registration of Glycated Albumin Assay Reagents, and the Guidelines for Technical Review of the Registration of Total Bile Acid Assay Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月5日发布了《胶体金免疫层析分析仪注册技术审查指导原则》《促卵泡生成素检测试剂注册技术审查指导原则》《肌酐检测试剂注册技术审查指导原则》《抗核抗体检测试剂注册技术审查指导原则》《抗甲状腺过氧化物酶抗体测定试剂注册技术审查指导原则》《糖化白蛋白测定试剂注册技术审查指导原则》和《总胆汁酸测定试剂注册技术审查指导原则》。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on January 18, 2021 the Guidelines for Technical Review of the Registration of Mycoplasma Pneumoniae IgM\/IgG Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Cryptococcus Capsular Polysaccharide Antigen Detection Reagents, and Guidelines for Technical Review of the Registration of Hereditary Hearing Loss Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《肺炎支原体IgM\/IgG抗体检测试剂注册技术审查指导原则》《隐球菌荚膜多糖抗原检测试剂注册技术审查指导原则》和《遗传性耳聋相关基因突变检测试剂注册技术审查指导原则》，于2021年1月18日予以发布。\n'NMPA Issued Four Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase and Others'可被翻译为：国家药监局关于发布天门冬氨酸氨基转移酶测定试剂等4项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on November 1, 2019 the Guidelines for Technical Review of the Registration of Embryo Replacement Catheter in Assisted Reproduction, Guidelines for Technical Review of the Registration of Methods for the Determination and Identification of Known Leachables in Medical Devices ,and the Guidelines for Technical Review of the Registration and Application of Cardiopulmonary Bypass System Extracorporeal Circulation Tubes.'可被翻译为：为加强对医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年11月1日组织制定并发布了《辅助生殖用胚胎移植导管注册技术审查指导原则》《医疗器械已知可沥滤物测定方法验证及确认注册技术审查指导原则》《心肺转流系统 体外循环管道注册申报技术审查指导原则》。\n\n根据上述已知信息，请将'To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of and released on October 29, 2019 the Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase, Guidelines for Technical Review of the Registration of Total Cholesterol Assay Reagents, Guidelines for the Technical Review of Registration of Uric Acid Determination Reagents, and Guidelines for Technical Review of the Registration of Urea Determination Reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年10月29日组织制定并发布了《天门冬氨酸氨基转移酶测定试剂注册技术审查指导原则》《总胆固醇测定试剂注册技术审查指导原则》《尿酸测定试剂注册技术审查指导原则》和《尿素测定试剂注册技术审查指导原则》。"
    },
    {
        "instruction":"已知信息：\n'(II) Concealing, missing to report or submitting false report;'可被翻译为：（二）瞒报、漏报、虚假报告的；\n'(1) Providing fake filing documents;'可被翻译为：（一）备案时提交虚假资料的；\n'(2) concealing information, giving false information, delaying reporting, giving incomplete report of vaccine safety incidents;'可被翻译为：（二）瞒报、谎报、缓报、漏报疫苗安全事件；\n'(III) Concealing, missing to report or submitting false report;'可被翻译为：（三）瞒报、漏报、虚假报告的；\n\n根据上述已知信息，请将'(2) providing false information or conceal authentic condition on purpose;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）故意提供虚假信息或者隐瞒真实情况；"
    },
    {
        "instruction":"已知信息：\n'Precision in the laboratory. That is, the influence of varying factors such as different time, different analysts, different instruments and equipment on the measurement results.'可被翻译为：实验室内的精密度。即不同时间、不同分析人员、不同仪器设备等变动因素对测定结果的影响。\n'Reproducibility expresses precision between laboratories.'可被翻译为：再现性表示实验室之间的精确性。\n'The degree of closeness of the measured value to the nominal or known true value under prescribed conditions (or as measured by a particular method). In this document accuracy is expressed as percent of the nominal value.Accuracy (%) = (Measured Value\/Nominal Value) × 100'可被翻译为：在指定条件下（或以特定方法测量）测得值与标示值或已知真实值的接近程度。在本文中，准缺度表示为标示值的百分数。准确度(%）=（测得值\/标示值）×100\n'Closeness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).'可被翻译为：在相同的测量条件下，同一测量的连续测量结果之间的一致性(改编自ISO)。\n\n根据上述已知信息，请将'1.The degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations — different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n2.The degree of agreement among individual results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.当程序重复应用于均匀样本的多个采样时，单个结果之间的一致程度。精密度通常表示为相对标准偏差，可以在三个层面上考虑:重复性(在短时间内相同操作条件下的精密度)、中间精密度(在实验室变化范围内——不同的日期、不同的分析人员或不同的设备)和再现性(实验室之间的精密度)。\n2.一致性:个别结果之间的一致程度"
    },
    {
        "instruction":"已知信息：\n'The process by which drugs or their metabolites are excreted from the body and the process by which drugs are biotransformed.'可被翻译为：体内药物或其代谢产物排出体外的过程以及药物生物转化的过程。\n'A substance that is no longer used by the organism through a series of complex biochemical actions in the organism through metabolism.'可被翻译为：生物通过新陈代谢作用，在生物体内经过一系列复杂的生物化学作用所生成的最终不再被本生物体利用的物质。\n'A measure of the rate at which a drug is eliminated by the body.'可被翻译为：机体消除药物速率的一种表示方法。\n'A group in a drug molecule that determines the pharmacokinetic properties of a drug and influences the internal processes of drug absorption, distribution, metabolism, and excretion.'可被翻译为：药物分子中决定药物药动学性质，影响药物吸收、分布、代谢和排泄等体内过程的基团。\n\n根据上述已知信息，请将'Prone to metabolizing inactivated drugs. A class of drugs that are rapidly excreted from the body after a step transformation into inactive metabolites in a controlled metabolic pathway and metabolic rate after the completion of the therapeutic effect in order to achieve separation of activity and toxicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容易代谢失活的药物。在完成治疗作用后以可控的代谢途径和代谢速率，经一步转化为无活性的代谢产物迅速排出体外，以便实现活性和毒性分离的一类药物。"
    },
    {
        "instruction":"已知信息：\n'Anticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.'可被翻译为：TTSPP在运输过程中可能暴露的预期环境温度变化和持续时间。\n'temperature excursion'可被翻译为：超温\n'The temperature range listed on the TTSPP label, and within the regulatory documentation, for long-term storage.'可被翻译为：TTSPP标签上列出的温度范围，以及监管文件内，用于长期储存。\n'The acceptable variations in temperature and relative humidity of storage facilities for formal stability studies. The equipment should be capable of controlling the storage condition within the ranges defined in this guideline. The actual temperature and humidity (when controlled) should be monitored during stability storage. Short term spikes due to opening of doors of the storage facility are accepted as unavoidable. The effect of excursions due to equipment failure should be addressed, and reported if judged to affect stability results. Excursions that exceed the defined tolerances for more than 24 hours should be described in the study report and their effect assessed.'可被翻译为：在正式稳定性研究中，对放置设备的温度和相对湿度的可接受的偏差。该设备应能将放置条件控制在本指导原则规定的范围内。在稳定性放置期间应监控温度和湿度（当需控制时）。由于开启放置设备的门而导致的短期偏离认为是不可避免的。应记录设备失控而导致的偏离的影响，如已证明影响稳定性结果，则需报告。超过允许偏差24小时的偏离，应在研究报告中说明并评估其影响。\n\n根据上述已知信息，请将'An excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and\/or transport. Temperature ranges for storage and transport may be the same or different; they are determined by the product manufacturer, based on stability data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"TTSPP暴露在超出规定的储存和\/或运输范围的温度下的偏移事件。储存和运输的温度范围可能相同，也可能不同;由产品生产厂家根据稳定性数据确定。"
    },
    {
        "instruction":"已知信息：\n'1.The practice of pharmacy aimed at providing and promoting the best use of drugs and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist's prime concern at all times.\n2.The practice of pharmacy aimed at providing and promoting the best use of medicines and other health-care services and products by patients and members of the public. It requires that the welfare of the patient is the pharmacist’s prime concern at all times.'可被翻译为：1.药剂学旨在为病人和公众提供和促进药物及其他保健服务和产品的最佳使用的药学实践。它要求药剂师在任何时候都以病人的福利为首要考虑。\n2.旨在为病人和公众提供和促进药品及其他保健服务和产品的最佳利用的药学实践。它要求药剂师在任何时候都以病人的福利为首要考虑。\n'The process of pharmacists providing patients with guidance on rational drug use, disseminating knowledge about appropriate medication practices, and offering pharmaceutical services aims to elevate patients' understanding of medications. This, in turn, enhances medication adherence, reduces the occurrence of medication errors, and safeguards the quality and safety of healthcare.'可被翻译为：药师对患者提供合理用药指导、普及合理用药知识等药学服务的过程，以提高患者用药知识水平，\n提高用药依从性，降低用药错误发生率，保障医疗质量和医疗安全。\n'A prescription made by pharmacists and physicians in consultation according to clinical needs and approved by the pharmaceutical Administration committee. It can be prepared or packaged in large quantities in advance to facilitate clinical use and shorten the waiting time for patients to take medicine.'可被翻译为：由药师和医师根据临床需要协商，经药事管理委员会批准所制定的处方。可事先大量制备或分装，方便临床使用和缩短患者取药等候时间。\n'medication record'可被翻译为：药历\n\n根据上述已知信息，请将'A record established by a pharmacist of a patient's treatment or prevention of a disease in order to ensure the safety and effectiveness of a drug. It includes professional activities that affect the outcome of the patient's prognosis (protocol development, implementation, efficacy, adverse reaction observation, evaluation, adjustment, patient education). Available in both paper and electronic form.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为保证用药安全有效，由药师建立的患者治疗或预防疾病进行药物治疗过程的记录。包括为影响患者预后结果的专业活动（方案制定，实施，疗效、不良反应观察，评价、调整，患者教育）等内容。有纸质和电子两种形式。"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.'可被翻译为：经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。\n'Article 66 For a conditionally approved drug, the MAH shall take appropriate risk management measures after the drug is marketed and complete relevant studies including drug clinical trials as requested and submit supplementary applications within the specified timeline.'可被翻译为：第六十六条 对附条件批准的药品，持有人应当在药品上市后采取相应的风险管理措施，并在规定期限内按照要求完成药物临床试验等相关研究，以补充申请方式申报。\n'Article 24 For the review and approval category, MAHs shall submit a supplementary application to CDE, submit the study data in accordance with relevant regulations and technical guidelines for change, and implement it after approval. The specific timeline shall be implemented in accordance with the relevant provisions of the Provisions for Drug Registration.'可被翻译为：第二十四条 审批类变更应当由持有人向药审中心提出补充申请，按照有关规定和变更技术指导原则提交研究资料，经批准后实施。具体工作时限按照《药品注册管理办法》有关规定执行。\n\n根据上述已知信息，请将'Where the Drug Approval License and its attachments require the MAH to carry out relevant post-marketing studies, the MAH shall complete the studies within the specified timeline and submit a supplementary application, filing or report as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册证书及附件要求持有人在药品上市后开展相关研究工作的，持有人应当在规定时限内完成并按照要求提出补充申请、备案或者报告。"
    },
    {
        "instruction":"已知信息：\n'The lot release institutions designated by the CFDA shall be responsible for the acceptance, dossier review, on-site inspection and sample testing and making the decision on lot release in accordance with the law.'可被翻译为：食品药品监管总局指定的批签发机构负责批签发的受理、资料审核、现场核实、样品检验等工作，并依法作出批签发决定。\n'The NMPA shall, in accordance with the needs of lot release, in a timely manner announce the selection criteria, procedures and conditions for added lot release institutions and the product varieties added by the lot release institutions.'可被翻译为：国家药品监督管理局根据批签发工作需要，适时公布新增批签发机构及批签发机构扩增批签发品种的评定标准、程序和条件。\n'Article 7 The lot release institutions and the product varieties subject to lot release in their charge shall be determined by the NMPA.'可被翻译为：第七条    批签发机构及其所负责的批签发品种由国家药品监督管理局确定。\n'Article 5 The NMPA shall establish a risk-based regulation system for the products subject to lot release. If necessary, on-site inspection may be carried out to validate the authenticity and reliability of the application dossiers for lot release.'可被翻译为：第五条    国家药品监督管理局对批签发产品建立基于风险的监督管理体系。必要时，可以通过现场核实验证批签发申请资料的真实性、可靠性。\n\n根据上述已知信息，请将'The lot release institutions designated by the NMPA shall be responsible for the acceptance, dossier review, and sample testing and the decision-making on lot release in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的批签发机构负责批签发的受理、资料审核、样品检验等工作，并依法作出批签发决定。"
    },
    {
        "instruction":"已知信息：\n'semi-permeable containers'可被翻译为：半渗透性容器\n'impermeable containers'可被翻译为：不透水的容器\n'A container, usually cylindrical, suitable for liquid or solid pharmaceutical dosage forms; generally for use in a specially designed apparatus (e.g. a prefilled syringe).'可被翻译为：一种容器，通常为圆柱形，适用于液体或固体药物剂型;一般用于专门设计的器具中(如预充注射器)。\n'A multi-dose container consisting of two layers, usually provided with perforations, suitable for \ncontaining single doses of solid or semi-solid preparations. Blisters are excluded.'可被翻译为：由两层组成的多剂量容器，通常有穿孔，适用于\n装有单剂量固体或半固体制剂的容器。排除水疱。\n\n根据上述已知信息，请将'Containers that provide a permanent barrier to the passage of gases or solvents, e.g. sealed aluminium tubes for semisolids, sealed glass ampoules for solutions and luminium\/aluminium blisters for solid dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为气体或溶剂的通过提供永久屏障的容器，例如，用于半固体的密封铝管，用于溶液的密封玻璃安瓿和用于固体剂型的铝\/铝泡罩。"
    },
    {
        "instruction":"已知信息：\n'Article 56 If the medical device registrant and the contract manufacturer are not in the same province, autonomous region or municipality directly under the central government, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant of medical devices is located shall be responsible for carrying out supervision and inspection of the registrant’s performance of its legal duties such as operation of quality management system, adverse events monitoring and product recall, etc., and if relevant conditions of the contract manufacturer, the drug regulatory department of the place where the contract manufacturer is located shall make cooperation.'可被翻译为：第五十六条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市的，医疗器械注册人所在地省、自治区、直辖市药品监督管理部门负责对注册人质量管理体系运行、不良事件监测以及产品召回等法定义务履行情况开展监督检查，涉及受托生产企业相关情况的，受托生产企业所在地药品监督管理部门应当配合。\n'Article 57 If the registrant and the contract manufacturer of medical devices are not in the same province, autonomous region or municipality directly under the central government, and the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer is located needs to carry out cross-region inspection, it could also make inspection by means of joint inspection and entrusted inspection, etc.'可被翻译为：第五十七条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门需要跨区域开展检查的，可以采取联合检查、委托检查等方式进行。\n'Article 59 If suspicious illegal acts is found in cross-region inspection, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer of medical devices is located shall make investigation and handling according to their own duties. The handling condition of the illegal acts shall be promptly informed to the related drug regulatory department.'可被翻译为：第五十九条  在跨区域检查中发现可能存在违法行为的，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当依据各自职责进行调查处理。违法行为处理情况应当及时通报相关药品监督管理部门。\n'Article 49 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall formulate annual supervision and inspection plan for manufacturing of medical devices, determine the key points of supervision and administration of medical devices, specify the inspection frequency and coverage, and make comprehensive use of multiple means such as supervision and inspection, key inspection, follow-up inspection, for-cause inspection and special inspection, etc. to strengthen supervision and administration.'可被翻译为：第四十九条  省、自治区、直辖市药品监督管理部门应当制定年度医疗器械生产监督检查计划，确定医疗器械监督管理的重点，明确检查频次和覆盖范围，综合运用监督检查、重点检查、跟踪检查、有因检查和专项检查等多种形式强化监督管理。\n\n根据上述已知信息，请将'Article 58 If it is found in cross-region inspection that there is defect with the enterprise quality management system, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer of medical devices is located shall, in accordance with their respective duties, urge relevant enterprises to make prompt rectification in place as required, and inform the inspection and rectification conditions to related drug regulatory department in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  跨区域检查中发现企业质量管理体系存在缺陷的，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当依据各自职责，督促相关企业严格按照要求及时整改到位，并将检查以及整改情况及时通报相关药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'Note that the linearity of release rates across different strengths of the product (which assesses the specificity of the IVRT method, with a minimum r2 value ≥ 0.95) is fundamentally different and has different scientific considerations than the linearity of the release rate for a single strength of the product across the range of the sampling times (which assesses the IVRT method’s ability to monitor the steady state release kinetics of the active ingredient, with a minimum r2 value ≥ 0.97). Despite the potential for different scientific considerations to impact the linearity of the IVRT results in each context, for well-developed and suitably controlled IVRT methods, the r2 value ≥ 0.99 is routinely observed in both contexts.'可被翻译为：需要注意的是，产品不同规格释放速率的线性关系（评估IVRT方法的专属性，要求r2≥0.95）与同一规格产品在不同采样时间点获得的释放速率线性关系（评估IVRT方法监控活性成分稳态释放动力学的能力，要求r2≥0.97）具有根本不同的科学考虑。尽管基于不同的科学考虑因素，可能会影响IVRT结果的线性关系，但对于经过良好的开发和适当控制的IVRT方法，在两者的背景下，通常都能满足r2≥0.99的要求。\n'It is unconventional for IVRT sampling times to be selected within a study duration of less than 4 hours. This may occur in situations where the fixed product dose was depleted to such a great extent by 4 hours that the release kinetics were no longer linear thereafter (when plotted vs. the square root of time). In such instances, it would be appropriate to explain the efforts that were made to optimize the IVRT method (e.g., using a different diffusion cell equipment that allowed for a larger product dose to be used) so that the sustained steady state release kinetics could potentially be characterized over a conventional IVRT duration of 4 to 6 hours.'可被翻译为：通常情况下，所选的IVPT取样时长不应少于4小时。但是，对于某些特定类型的制剂，如果在大于4小时后，因产品剂量消耗非常大，之后的时间点不能呈线性关系（以释放量对时间的平方根作图）。在这种情况下，应该阐述为优化IVRT方法所做的努力（例如，使用不同的扩散池设备，以便可以采用更大的产品上样量），确保在4～6小时内呈现持续稳态释放动力学。\n'The selection of the receptor solution is guided by the solubility of the drug substance(s) in potential solvents\/solvent combinations. Most commonly, combinations of aqueous and alcoholic\/organic solvents are used, and the solubility of the drug in the receptor solution should exceed the highest sample concentration in the IVRT study, ideally by an order of magnitude,  but demonstrably sufficient to facilitate a linear (steady state) release rate for the duration of the study (even when evaluating a relatively higher release rate of a formulation that is 150% of the nominal reference strength).'可被翻译为：受体溶液的选择取决于原料药在潜在溶剂\/溶剂组合中的溶解度。最常见的是，使用水溶剂和酒精\/有机溶剂的组合，并且药物在受体溶液中的溶解度应超过IVRT研究中的最高样品浓度，理想情况下要超过一个数量级，但要证明足以促进研究期间的线性(稳态)释放率(即使评估一个相对较高的释放率，即标称参考剂量强度的150%)。\n'The reason for selecting the composition of the receptor solution used for the IVRT study should be explained. The solubility of the drug in the IVRT receptor solution should be empirically determined in triplicate, to illustrate that the solubility of the drug in the receptor solution exceeds the highest sample concentration in the IVRT pivotal study, ideally by an order of magnitude, but demonstrably sufficient to facilitate a linear (steady state) release rate for the duration of the study (even when evaluating the relatively higher release rate of a formulation that is 150% of the nominal strength of the RS during the IVRT method validation).'可被翻译为：应解释在IVRT研究中选择接收介质组成的理由。药物在接收介质中的溶解度，应进行三次重复检测经验确定，以说明药物在接收介质中的溶解度超过IVRT正式研究中药物的最大浓度，理想值应该是一个数量级或者是足以确切促成研究期间释放速率的线性关系（即使在IVRT方法验证期间评估相对较高的释放率，即RS的标称规格的150%）。\n\n根据上述已知信息，请将'When utilizing an appropriately selected receptor solution, membrane, equipment, dose, and sampling duration (as well as other potential method parameters) the release rate of the drug should be linear (when plotted as the amount of drug released versus the square root of time) and reproducible. The amount of drug product in the donor compartment should ensure that dose depletion does not occur to an extent that alters the linear (steady state) release kinetics during the duration of the test (i.e., a pseudo-infinite dose amount should be utilized). Excessive dose depletion is characterized by a nonlinear region in the plotted cumulative amount of drug released curve (when plotted as the amount of drug released versus the square root of time).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当使用适当选择的受体溶液、膜、设备、剂量和取样时间(以及其他潜在的方法参数)时，药物的释放速度应该是线性的(当绘制为药物释放量与时间的平方根时)并且可重复。给药室中的药物用量应确保在试验过程中，剂量消耗不会达到改变线性(稳态)释放动力学的程度(即，应使用伪无限剂量)。过量剂量消耗的特征是在绘制的药物累积释放量曲线中出现一个非线性区域(当绘制为药物释放量与时间的平方根时)。"
    },
    {
        "instruction":"已知信息：\n'The addition of fresh liquid at a similar flow rate during fermentation.'可被翻译为：在发酵过程中一边补入新鲜料液，一边以相近的流速放料。\n'continuous culture production'可被翻译为：连续培养生产\n'Nutrients added continuously or intermittently during fermentation culture.'可被翻译为：在发酵培养过程中连续或间断性地添加的营养物质。\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n\n根据上述已知信息，请将'In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。"
    },
    {
        "instruction":"已知信息：\n'(III) Failing to submit evaluation outcome reports or submit investigation reports of group adverse events of medical device in accordance with the time limits;'可被翻译为：（三）未按照时限要求报告评价结果或者提交群体医疗器械不良事件调查报告的；\n'(I) Failing to voluntarily collect and report medical device adverse events according to the time limits;'可被翻译为：（一）未主动收集并按照时限要求报告医疗器械不良事件的；\n'(V)  Failing to voluntarily maintain user information, or fail to continuously track and dispose monitoring information;'可被翻译为：（五）未主动维护用户信息，或者未持续跟踪和处理监测信息的；\n'(X)  Failing to release contact information and voluntarily collect the information of adverse events;'可被翻译为：（十）未公布联系方式、主动收集不良事件信息的；\n\n根据上述已知信息，请将'(III) Failing to keep the records of adverse event monitoring or preserve the records for insufficient duration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未保存不良事件监测记录或者保存年限不足的；"
    },
    {
        "instruction":"已知信息：\n'minimum required dilution (mrd)'可被翻译为：最低需求稀释度\n'A parameter demonstrating that the method can appropriately analyse samples at a concentration exceeding the ULOQ of the calibration curve without influence of prozone (hook) effect and that the measured concentrations are not affected by dilution within the calibration range in LBAs'可被翻译为：证明LBA方法可以适用于分析浓度超过校正曲线ULOQ浓度的样品而没有前区（钩状）效应，并且测量浓度不受校正范围内稀释影响的参数。\n'dilution factor'可被翻译为：稀释因子\n'Diluting the unknown sample [U3] in this manner ensures a detection limit within the linear portion of the standard curve. For example, if the median reference standard [S3] has a \nconcentration of 10.0 ug\/mL, the unknown sample [U3] will also be diluted to a concentration \nof 10.0 ug\/mL. See Diagram 1 for an example of one independent test run for the Plate Method \nand placement of the standard curve and unknown sample onto triplicate agar plates.'可被翻译为：未知样品【U3】的稀释方式应确保检测限在标准曲线线性范围内。例如，如果中值标准品【S3】的浓度为 10.0 µg\/mL，则未知样品 【U3】 也会稀释到 10.0 µg\/mL 的浓度。碟法一次独立测试中将一式三份标准曲线和未知样品放置到琼脂平板上的示例参见图 1。\n\n根据上述已知信息，请将'The initial dilution factor by which biological samples are diluted with buffer solution for the analysis by LBAs. The MRD may not necessarily be the ultimate dilution but should be identical for all samples including calibration standards and QCs. However, samples may require further dilution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于 LBA 分析，生物样品以缓冲液稀释的最初稀释因子。MRD可能不是最终稀释，但应对所有样品保持一致，包括校正标样和QC样品。然而样品可能需要进一步稀释。"
    },
    {
        "instruction":"已知信息：\n'reaction rate'可被翻译为：反应速率\n'rate constant'可被翻译为：速度常数\n'specific reaction rate'可被翻译为：特异反应比速\n'A class of constant-rate reactions in which the rate of reaction is independent of the concentration of the reactants.'可被翻译为：反应速率与反应物浓度无关的一类恒速反应。\n\n根据上述已知信息，请将'Also known as \"reaction rate constant\". The speed at which a chemical reaction proceeds is expressed as a decrease in the concentration of the reactant or an increase in the concentration of the product per unit time. In general, when the temperature is fixed, the specific rate of the reaction is constant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"反应速率常数”。化学反应进行的快慢，用单位时间内反应物浓度的减少或生成物浓度的增加量来表示。一般来说，当温度一定时，特异反应比速为常数。"
    },
    {
        "instruction":"已知信息：\n'(II) verifying the original Certificate of Analysis for release and Certificate of Origin;'可被翻译为：（二）核查出厂检验报告书和原产地证明原件；\n'(IV) the actual place of production indicated in the Certificate of Origin is not in conformity with the place of origin specified in the Import Drug License (or the Pharmaceutical Product License), or the Certificate of Origin issued by a regional organization fails to indicate the place of origin as specified in the Import Drug License (or the Pharmaceutical Product License);'可被翻译为：（四）原产地证明所标示的实际生产地与《进口药品注册证》（或者《医药产品注册证》）规定的产地不符的，或者区域性国际组织出具的原产地证明未标明《进口药品注册证》（或者《医药产品注册证》）规定产地的；\n'(I) the importer fails to provide the original Import Drug License (or the Pharmaceutical Product License) (in original or duplicate), or the Import Drug Approval, or the original Import License for narcotic drugs and psychotropic substances;'可被翻译为：（一）不能提供《进口药品注册证》（或者《医药产品注册证》）（正本或者副本）、《进口药品批件》或者麻醉药品、精神药品的《进口准许证》原件的；\n'(III) photocopies of the Certificate of Origin;'可被翻译为：（三）原产地证明复印件；\n\n根据上述已知信息，请将'(I) the original Certificate of Analysis for release and Certificate of Origin is not provided, or the original copy provided is inconsistent with the photocopies submitted at the time of importation record filing;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）未提供出厂检验报告书和原产地证明原件，或者所提供的原件与申报进口备案时的复印件不符的；"
    },
    {
        "instruction":"已知信息：\n'ADR\/ADE county reporting ratio marks an important indicator for measuring the balanced development and coverage of ADR monitoring in China. The proportion of county-level reports of ADRs\/ADEs in China in 2018 was 97.9%.'可被翻译为：药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2018年全国药品不良反应\/事件县级报告比例为97.9%。\n'4. Proportion of ADR\/ADE reports at county level *'可被翻译为：4.药品不良反应\/事件县级报告比例\n'In 2018, the National ADR Monitoring Network received 495,000 new and serious ADR\/ADE reports, accounting for 33.1% of the total number reported in the same period.The steady growth of the proportion of new and serious ADR\/ADE reports indicates a constant upclimbing of the availability of ADR reports in China.'可被翻译为：2018年全国药品不良反应监测网络收到新的和严重药品不良反应\/事件报告49.5万份；新的和严重药品不良反应\/事件报告占同期报告总数的33.1%。新的和严重药品不良反应\/事件报告比例持续增加，显示我国药品不良反应报告可利用性持续增加。\n'In 2020, the China National ADR Monitoring Network received 1.676 million copies of ADR\/ADE Reports. From 1999 to 2020, the National ADR Monitoring Network received a total of 16.87 million copies of ADR\/ADE Reports.'可被翻译为：2020年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》167.6万份。1999年至2020年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,687万份。\n\n根据上述已知信息，请将'The ratio of ADR\/ADE reports at county level constitutes one of the important indicators to measure the balanced development and coverage of ADR monitoring in China. In 2019, 97.4 percent of county-level regions across China reported ADRs\/ADEs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2019年全国97.4%的县级地区报告了药品不良反应\/事件。"
    },
    {
        "instruction":"已知信息：\n'description of manufacturing steps (narrative and process maps or flow charts, and\/or master batch records), including the qualification of in-processing hold times and conditions, the order and method of raw material addition and bulk transfers between processing steps;'可被翻译为：生产步骤描述（叙述性和工艺流程图，和\/或批记录母本），包括中间体保存时长和条件的确认，原料加入和散装物料在不同工艺步骤之间的转移\n'Article 172: A batch processing record should be based on the relevant parts of the currently approved master manufacturing documents. Such records should be designed to avoid transcription errors. The record should carry the product name, dosage form, strength and batch number on every page.'可被翻译为：第一百七十二条 批生产记录应当依据现行批准的工艺规程的相关内容制定。记录的设计应当避免填写差错。批生产记录的每一页应当标注产品的名称、规格和批号。\n'Article 173: The master batch processing records should be reviewed and approved by the heads of production and quality management. The reproduction and issuance should be managed and recorded according to operation procedures, and only one copy of reproduced master records can be issued for the manufacture of each batch.'可被翻译为：第一百七十三条 原版空白的批生产记录应当经生产管理负责人和质量管理负责人审核和批准。批生产记录的复制和发放均应当按照操作规程进行控制并有记录，每批产品的生产只能发放一份原版空白批生产记录的复制件。\n'Article 171: A batch processing record should be kept for each batch of product so that the production history and quality related status of that batch can be traced.'可被翻译为：第一百七十一条 每批产品均应当有相应的批生产记录，可追溯该批产品的生产历史以及与质量有关的情况。\n\n根据上述已知信息，请将'Batch manufacturing: Master of executed batch record; Scale up information; Risk assessment; Critical process parameters; In-process control specification; Scale up protocol and report; Process validation'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批生产： 已执行的批记录、放大信息、风险评估、关键工艺参数、中控标准、放大方案和报告、工艺验证"
    },
    {
        "instruction":"已知信息：\n'The medical device standards plan projects that are approved by China Food and Drug Administration shall be released to the public. The national standards plan project shall be submitted to the competent standardization administrative department under the State Council for approval and assignment; the industry standards plan project shall be approved and assigned by China Food and Drug Administration.'可被翻译为：国家食品药品监督管理总局审核通过的医疗器械标准计划项目，应当向社会公示。国家标准计划项目送国务院标准化行政主管部门批准下达；行业标准计划项目由国家食品药品监督管理总局批准下达。\n'Article 22 The Center for Medical Device Standardization Administration shall submit the reviewed medical device standards draft for approval and review conclusions to China Food and Drug Administration for examination. Medical device national standards passing the examination shall be submitted to the competent standardization administrative department under the State Council for approval and issuance; for medical device industry standards passing the examination, China Food and Drug Administration shall determine and announce the date and requirements for their implementation.'可被翻译为：第二十二条 医疗器械标准管理中心将审核通过后的医疗器械标准报批稿及审核结论等报送国家食品药品监督管理总局审查。审查通过的医疗器械国家标准送国务院标准化行政主管部门批准、发布；审查通过的医疗器械行业标准由国家食品药品监督管理总局确定实施日期和实施要求，以公告形式发布。\n'(3) Undertake administration of the technical committees on medical device standardization pursuant to law;'可被翻译为：（三）依法承担医疗器械标准化技术委员会的管理工作；\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n\n根据上述已知信息，请将'Medical device national standards and industry standards shall be disclosed in accordance with the relevant regulations of the competent standardization administrative department under the State Council for public reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械国家标准、行业标准按照国务院标准化行政主管部门的相关规定进行公开，供公众查阅。"
    },
    {
        "instruction":"已知信息：\n'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Article 56 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十六条 医疗器械延续注册申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Article 66 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十六条 体外诊断试剂延续注册申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Chapter V    Other Provisions'可被翻译为：第五章 其他规定\n\n根据上述已知信息，请将'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'3. County-level coverage. In 2019, the county-level coverage rate for reporting of suspected medical device adverse events in China was 96.70 percent, up by 0.80 percentage points YOY (Figure 3).'可被翻译为：3.县级覆盖率。2019年，我国可疑医疗器械不良事件报告的县级覆盖率为96.70%，比上年增加0.80个百分点（图3）。\n'Figure 2 Comparison of the number of suspected medical device adverse events reported per million people across China from2014 to 2018'可被翻译为：2018年，我国每百万人口平均可疑医疗器械不良事件报告数为305份，与2017年相比增长23份(图2)。\n'3. County-level coverage In 2018, the county-level coverage of suspected medical device adverse events in China was 95.9% (Figure 3) .(II) Number of registered grassroots users nationwide As of December 31, 2018, there were a total of 275,715 grassroots user units (including manufacturing enterprises, operating companies and users) registered in the National Medical Device Adverse Event'可被翻译为：3.县级覆盖率\n'1. Number of Medical Device Adverse Event Reports in China'可被翻译为：1.全国医疗器械不良事件报告数量\n\n根据上述已知信息，请将'Figure 3 County-level coverage of suspected medical device adverse event reports from 2015to 2018 in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2018年，我国可疑医疗器械不良事件报告的县级覆盖率为95.9%(图3 )。"
    },
    {
        "instruction":"已知信息：\n'(I) Determine the legal qualification of supplier;'可被翻译为：（一）确定供货单位的合法资格；\n'(V) Provisions on qualification of supplier, purchaser, sales personnel of supplier and purchasing personnel of purchaser;'可被翻译为：（五）供货单位、购货单位、供货单位销售人员及购货单位采购人员等资格审核的规定；\n'(III) Being responsible for the audit of the qualification certificates of suppliers and their sales personnel;'可被翻译为：（三）负责对供货单位及其销售人员资格证明的审核；\n'Article 64 Enterprises shall validate and retain the following information about the sales personnel of supplier:'可被翻译为：第六十四条 企业应当核实、留存供货单位销售人员以下资料：\n\n根据上述已知信息，请将'(III) Validate the legal qualification of sales personnel of supplier;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）核实供货单位销售人员的合法资格；"
    },
    {
        "instruction":"已知信息：\n'antifungal drug'可被翻译为：抗真菌药\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'可被翻译为：治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。\n'Bacteria or fungi that are easily inhibited or killed by a particular drug.'可被翻译为：易于被某种药物抑制或杀死的细菌或真菌。\n\n根据上述已知信息，请将'Medications to treat or prevent fungal infections. For superficial fungal infections, there are Terbuchofen and some topical antifungals; Amphotericin and fluorocytosine are suitable for deep fungal infections; Azole antifungals have antibacterial effects on both superficial and deep fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防真菌感染的药物。适用于浅表真菌感染的有特比蔡芬及一些外用抗真菌药；适用于深部真菌感染的有两性霉素和氟胞嘧啶；唑类抗真菌药对浅表和深部真菌都有抗菌作用。"
    },
    {
        "instruction":"已知信息：\n'The operation of removing dissolved gases from the mobile phase in liquid chromatographic analysis. To prevent dissolved gases from forming bubbles in the flow tank of the pump or detector.'可被翻译为：液相色谱分析中除去流动相中溶解气体的操作。以免溶解的气体在泵或检测器的流通池中形成气泡。\n'An instrument for the detection of separated components on a chromatographic column. For analysis, such as by capillary electrophoresis or capillary electrochromatography, the polyimide coating is removed at a certain position at the outlet of the capillary tube and used as a detection pool for detection.'可被翻译为：在色谱柱上对获得分离的组分进行检测的仪器。如采用毛细管电泳法或毛细管电色谱法进行分析时，就是在毛细管出口端的某个位置，除去聚酰亚胺涂层后作为检测池进行检测。\n'The early term for capillary gas chromatography refers to gas chromatography using open tube columns (including wall coated open column and carrier coated open column). The types of open column include wall coated open column, carrier coated open column, porous layer open column and immobilized phase open column. Injection methods include shunt injection, no shunt injection and column head injection.'可被翻译为：早期对于毛细管气相色谱的称谓，指使用开管柱(包括涂壁开管柱和涂载体开管柱)的气相色谱法。开管柱的类型有涂壁开管柱、涂载体开管柱、多孔层开管柱和固定化相开管柱等。进样方式有分流进样、无分流进样 和柱头进样等。\n'An interface that is combined with an ionization device. With the spray probe as the sample channel, the effluent after the chromatograph column flows through the stainless steel capillary in the center of the spray probe at the flow rate of l~2ml\/min, forming an aerosol, and is heated violently by the heating tube before the capillary outlet, the solvent evaporates rapidly, and the volume expands rapidly after ejecting the capillary tube at supersonic speed. Thus forming a mist mixture composed of tiny droplets, particles and vapors.'可被翻译为：一种与电离装置结合在一起的接口。以喷雾探针为进样渠道，色谱柱后流出物以l~2ml\/min流速，经过喷雾探针中心部位的不锈钢毛细管流入，形成气溶胶，并在毛细管出口前被加热管剧烈加热，其溶剂迅速蒸发，体积迅速膨胀后以超音速喷出毛细管，从而形成由微小液滴、粒子和蒸气组成的雾状混合物。\n\n根据上述已知信息，请将'In capillary chromatography, a stream of air introduced at the exit of a capillary column. Its role is to reduce the dead volume behind the column, improve the column efficiency, meet the best gas flow rate of the detector, in order to improve the sensitivity of the detector.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"毛细管色谱分析中，在毛细管柱的出口端引入的一路气流。其作用是减少柱后的死体积，改善柱效，满足检测器的最佳气体流速，以提高检测器的灵敏度。"
    },
    {
        "instruction":"已知信息：\n'Article 46 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall organize supervision and inspection regarding supervision and administration of medical device distribution in the administrative areas.'可被翻译为：第四十六条  省、自治区、直辖市药品监督管理部门组织对本行政区域的医疗器械经营监督管理工作进行监督检查。\n'Article 64 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall formulate supervision and inspection plan on medical device adverse event within the administrative region, and explicitly define inspection work focus and supervise the implementation.'可被翻译为：第六十四条  省、自治区、直辖市药品监督管理部门应当制定本行政区域的医疗器械不良事件监测监督检查计划，确定检查重点，并监督实施。\n'Article 49 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall formulate annual supervision and inspection plan for manufacturing of medical devices, determine the key points of supervision and administration of medical devices, specify the inspection frequency and coverage, and make comprehensive use of multiple means such as supervision and inspection, key inspection, follow-up inspection, for-cause inspection and special inspection, etc. to strengthen supervision and administration.'可被翻译为：第四十九条  省、自治区、直辖市药品监督管理部门应当制定年度医疗器械生产监督检查计划，确定医疗器械监督管理的重点，明确检查频次和覆盖范围，综合运用监督检查、重点检查、跟踪检查、有因检查和专项检查等多种形式强化监督管理。\n'Article 9 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation within their respective administrative regions, organize the investigation and handling of group adverse events of medical device that occurs within their respective administrative regions jointly with the health administrative departments at the same level and relevant authorities, and take emergency control measures according to law.'可被翻译为：第九条  省、自治区、直辖市药品监督管理部门负责本行政区域内医疗器械不良事件监测和再评价的监督管理工作，会同同级卫生行政部门和相关部门组织开展本行政区域内发生的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。\n\n根据上述已知信息，请将'Article 44 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government may, in accordance with the requirements for supervision and administration of medical device within their respective administrative regions, carry out provincial intensive surveillance project on Class II medical devices registered and Class I medical devices filed within their respective administrative regions by referring to Article 43 of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十四条  省、自治区、直辖市药品监督管理部门可以根据本行政区域内医疗器械监管工作需要，参照本办法第四十三条规定，对本行政区内注册的第二类和备案的第一类医疗器械开展省级医疗器械重点监测工作。"
    },
    {
        "instruction":"已知信息：\n'(3) disturbing or obstructing vaccines-related investigation on illegal or criminal acts or safety incidents;'可被翻译为：（三）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；\n'(4) failing to conduct post-marketing research, or failing to establish institutions and equip staff as required to actively collect, track and analyze adverse reactions of suspected vaccination;'可被翻译为：（四）未按照规定开展上市后研究，或者未按照规定设立机构、配备人员主动收集、跟踪分析疑似预防接种异常反应；\n'(3) concealing information, giving false information, delaying reporting or giving incomplete reporting of vaccine safety incidents;'可被翻译为：（三）瞒报、谎报、缓报、漏报疫苗安全事件；\n'(4) entrusting vaccine manufacturing without authorization;'可被翻译为：（四）委托生产疫苗未经批准；\n\n根据上述已知信息，请将'(4) disturbing or obstructing vaccine-related investigation on illegal acts or safety incidents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；"
    },
    {
        "instruction":"已知信息：\n'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'可被翻译为：（二）库房内墙、顶光洁，地面平整，门窗结构严密；\n'Article 148 A warehouse shall have the following facilities and equipment:'可被翻译为：第一百四十八条 仓库应当有以下设施设备：\n'Article 47 A warehouse shall be equipped with the following facilities and equipment:'可被翻译为：第四十七条 库房应当配备以下设施设备：\n'Article 44 The site selection, design, layout, construction, reconstruction and maintenance of warehouse shall meet the requirements for drug storage, so as to prevent the contamination, cross contamination, mix-ups and errors of drugs.'可被翻译为：第四十四条 库房的选址、设计、布局、建造、改造和维护应当符合药品储存的要求，防止药品的污染、交叉污染、混淆和差错。\n\n根据上述已知信息，请将'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。"
    },
    {
        "instruction":"已知信息：\n'A method of separating the components of a liquid by means of the selectivity of the membrane, driven by pressure.'可被翻译为：以压力为推动力，依靠膜的选择性将液体中的组分进行分离的方法。\n'By using the size of the pore size of the microporous membrane, the particles larger than the pore size of the solution are retained to reach the process of solution clarification or separation.'可被翻译为：利用微孔膜孔径的大小，使溶液中大于膜孔径的微粒截留达到溶液澄清或分离的过程。\n'Under the pressure drive, the solvent in the solution (such as water) enters the low-pressure side of the membrane through the semi-permeable membrane in the opposite direction of natural penetration, so as to achieve an effective separation process.'可被翻译为：在压力驱动下溶液中的溶剂（如水）以与自然渗透相反的方向通过半透膜进入膜的低压侧，从而达到有效分离的过程。\n'microporous membrane'可被翻译为：微孔滤膜\n\n根据上述已知信息，请将'The process of separating a solid membrane from a solution containing particles by using pressure as a driving force. When the solution passes through the microporous membrane, suspended matter (colloids, bacteria) and larger microspheres are trapped and removed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以压力为推动力，过滤含有微粒的溶液的固体膜分离过程。当溶液通过微孔膜后，悬浮物（胶体、细菌）和粒径较大的微球被截留而被除去。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments at the level of the municipality consisting of districts or county level shall be responsible for medical device-related adverse event monitoring within their respective administrative regions.'可被翻译为：设区的市级和县级药品监督管理部门负责本行政区域内医疗器械不良事件监测相关工作。\n'Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.'可被翻译为：第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。\n'Article 9 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation within their respective administrative regions, organize the investigation and handling of group adverse events of medical device that occurs within their respective administrative regions jointly with the health administrative departments at the same level and relevant authorities, and take emergency control measures according to law.'可被翻译为：第九条  省、自治区、直辖市药品监督管理部门负责本行政区域内医疗器械不良事件监测和再评价的监督管理工作，会同同级卫生行政部门和相关部门组织开展本行政区域内发生的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。\n'Article 23 Provincial monitoring agencies shall carry out comprehensive analysis on adverse event reports of the medical devices registered or filed within local administrative regions, propose recommendations on supervisory measures for identified risks, and report to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government and national monitoring agencies within 30 days at each quarter end.'可被翻译为：第二十三条  省级监测机构应当对本行政区域内注册或者备案的医疗器械的不良事件报告进行综合分析，对发现的风险提出监管措施建议，于每季度结束后30日内报所在地省、自治区、直辖市药品监督管理部门和国家监测机构。\n\n根据上述已知信息，请将'The monitoring agencies at the level of the municipality consisting of districts or county level shall assist in carrying out technical works related to medical device adverse event monitoring within their respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设区的市级和县级监测机构协助开展本行政区域内医疗器械不良事件监测相关技术工作。"
    },
    {
        "instruction":"已知信息：\n'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the IMS, and apply to the lot release institution under jurisdiction for lot release in the place where the MAH applying for lot release is located or the import port is set.'可被翻译为：第十三条    按照批签发管理的生物制品，批签发申请人在生产、检验完成后，应当在生物制品批签发管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品上市许可持有人所在地或者拟进口口岸所在地批签发机构设置情况，向相应属地的批签发机构申请批签发。\n'(I)  Application Form for Lot Release of Biological Products;'可被翻译为：（一）生物制品批签发申请表；\n'Article 14 The lot release applicant shall propose a sampling application to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government or the sampling institutions designated thereby by virtue of the Application Form for Lot Release of Biological Products; sampling personnel shall organize on-site sampling within 5 days, and seal the samples. The lot release applicant shall be responsible for delivering the sealed samples under the stipulated conditions to the lot release institution to handle registration for lot release, and shall submit lot release application dossiers at the same time.'可被翻译为：第十四条    批签发申请人凭生物制品批签发申请表向省、自治区、直辖市药品监督管理部门或者其指定的抽样机构提出抽样申请，抽样人员在5日内组织现场抽样，并将所抽样品封存。批签发申请人将封存样品在规定条件下送至批签发机构办理批签发登记，同时提交批签发申请资料。\n'Article 11 Before the initial application for lot release of the new biological product approved for marketing, the lot release applicant shall register and file in the Information Management System for Lot Release. The following materials shall be submitted for registration:'可被翻译为：第十一条 新批准上市的生物制品首次申请批签发前，批签发申请人应当在批签发信息管理系统内登记建档。登记时应当提交以下资料：\n\n根据上述已知信息，请将'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the Information Management System for Lot Release, and apply to the lot release institution under jurisdiction for lot release in the place where the drug manufacturer applying for lot release is located or the place where the port at which the drug is to be imported is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十三条 按照批签发管理的生物制品在生产、检验完成后，批签发申请人应当在批签发信息管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品生产企业所在地或者拟进口口岸所在地，向相应属地的批签发机构申请批签发。"
    },
    {
        "instruction":"已知信息：\n'A graduated slender glass tube, the most basic instrument for titrating the volume of a solution in volumetric analysis.'可被翻译为：容量分析中滴定溶液的体积最基本的仪器，有刻度的细长玻璃管。\n'A general term for a sample solution used in direct analytical determination.'可被翻译为：直接分析测定用的样品溶液的通称。\n'Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer.'可被翻译为：标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。\n'In volumetric analysis, a standard solution of known accurate concentrations used for sample determination.'可被翻译为：在容量分析中，用于样品测定的已知准确浓度的标准溶液。\n\n根据上述已知信息，请将'In acid-base titration analysis, a measuring glass dropper containing a standard alkali titration solution. The lower end is a latex tube containing glass beads.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"酸碱滴定分析中，盛放标准碱滴定液的定量玻璃滴管。下端为含有玻璃珠的乳胶管。"
    },
    {
        "instruction":"已知信息：\n'Article 47 If the drug MAH is an oversea enterprise, it shall authorize a legal person within the territory of China to perform the obligations set forth in the Drug Administration Law and these Regulations, and to provide cooperation for overseas inspections.'可被翻译为：第四十七条 药品上市许可持有人为境外企业的，应当指定一家在中国境内的企业法人，履行《药品管理法》与本办法规定的药品上市许可持有人的义务，并负责协调配合境外检查工作。\n'Article 64 An overseas drug manufacturer of imported drugs may authorize its representative office or its agency within the territory of China to fulfill the obligations for ADR reporting and monitoring in accordance with the requirements of these Provisions for drug manufacturers.'可被翻译为：第六十四条 进口药品的境外制药厂商可以委托其驻中国境内的办事机构或者中国境内代理机构，按照本办法对药品生产企业的规定，履行药品不良反应报告和监测义务。\n'Article 14 Where the MAH or drug manufacturer within the territory of China makes internal change on the manufacturing sites, or the MAH within the territory of China makes change on their manufacturers (including change of contract manufacturers, addition of contract manufacturers, change of self-production by MAH to contract manufacturer, and change of contract manufacturing to self-manufacturing), MAH (drug manufacturers) shall conduct study, evaluation and necessary verification in accordance with the requirements in the Provisions for the Supervision and Administration of Drug Manufacture and relevant technical guidelines for changes, and file an application for changing the Drug Manufacturing Certificate with the local provincial drug regulatory department and submit relevant dossiers.'可被翻译为：第十四条 境内持有人或药品生产企业内部变更生产场地、境内持有人变更生产企业（包括变更受托生产企业、增加受托生产企业、持有人自行生产变更为委托生产、委托生产变更为自行生产）的，持有人（药品生产企业）应当按照《药品生产监督管理办法》及相关变更技术指导原则要求进行研究、评估和必要的验证，向所在地省级药品监管部门提出变更《药品生产许可证》申请并提交相关资料。\n'Article 15 Where the overseas MAH changes the drug manufacturing site and the new manufacturing site is still overseas, it shall conduct study, evaluation and necessary verification in accordance with relevant technical guidelines and submit supplementary application or filing to CDE.'可被翻译为：第十五条 境外持有人变更药品生产场地且变更后生产场地仍在境外的，应按照相关技术指导原则进行研究、评估和必要的验证，向药审中心提出补充申请或备案。\n\n根据上述已知信息，请将'Article 48 Where the manufacturing site of a drug MAH is outside the territory of China, it shall organize manufacturing according to the Drug Administration Law and these Regulations and provide cooperation for overseas inspections.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 药品上市许可持有人的生产场地在境外的，应当按照《药品管理法》与本办法规定组织生产，配合境外检查工作。"
    },
    {
        "instruction":"已知信息：\n'Article 97: Water treatment plants and distribution systems should be designed, constructed, operated and maintained so as to ensure that water for pharmaceutical use meets the defined specifications. They should not be operated beyond their designed capacity.'可被翻译为：第九十七条 水处理设备及其输送系统的设计、安装、运行和维护应当确保制药用水达到设定的质量标准。水处理设备的运行不得超出其设计能力。\n'To minimize the risk of biofilm formation, sterilisation, disinfection or regeneration of water systems should be carried out according to a predetermined schedule and as a remedial action following out-of-limit or specification results. Disinfection of a water system with chemicals should be followed by a validated rinsing\/flushing procedure. Water should be tested after disinfection\/regeneration. Chemical testing results should be approved before the water system is returned to use and microbiological\/endotoxin results verified to be within specification and approved before batches manufactured using water from the system are considered for certification\/release.'可被翻译为：为最大程度降低生物膜形成的风险，应按照预定的时间表对水系统进行灭菌、消毒或再生，并作为超限或超标后的整改措施。用化学品对水系统进行消毒后，用经过验证的程序进行淋洗\/冲洗。应在消毒\/再生后进行水质检测。在水系统恢复使用之前，化学检验结果应得到批准，并且在使用该系统的水生产的批次得到认证\/放行之前，微生物\/内毒素结果应经过核实在质量标准范围内并得到批准。\n'Regular ongoing chemical and microbial monitoring of water systems should be performed to ensure that the water continues to meet compendial expectations. Alert levels should be based on the initial qualification data and thereafter periodically reassessed on data obtained during subsequent re-qualifications, routine monitoring, and investigations. Review of ongoing monitoring data should be carried out to identify any adverse trend in system performance. Sampling programmes should reflect the requirements of the CCS and should include all outlets and points of use, at a specified interval, to ensure that representative water samples are obtained for analysis on a\nregular basis. Sample plans should be based on the qualification data, should consider the potential worst case sampling locations and should ensure that at least one representative sample is included every day of the water that is used for manufacturing processes.'可被翻译为：应对水系统定期进行化学和微生物监测，确保水始终满足药典要求。警戒限应基于初次确认数据设置，并根据后续再确认、日常监测和调查中获得的数据进行定期再评估。应对持续监测数据进行回顾，及时发现系统性能的任何不良趋势。取样计划应反映 CCS 的要求，涵盖所有出口和用水点，并规定时间间隔，以确保定期获取有代表性的水样用于分析。取样计划应基于确认数据制定，考虑潜在最差条件取样点，并应确保每天至少包括一个具有代表性的生产工艺用水样品。\n'7. Water purification and delivery system: vulnerability of distillation process, RO, deionizers, cartridge filters, etc.; UV lights, dead legs, biofilm; corrosion (heat exchangers); waterborne microorganisms (nanobacteria) and endotoxin production; cold system problems,disinfection problems'可被翻译为：水的纯化和输送系统：蒸馏工艺、RO、去离子器、筒式过滤器等的易损性；紫外灯、死管、生物膜；腐蚀（热交换器）；水生微生物（纳米细菌）和内毒素的生长；冷却系统问题，消毒问题\n\n根据上述已知信息，请将'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。"
    },
    {
        "instruction":"已知信息：\n'The design of open isolators should ensure grade A conditions with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：开放式隔离器的设计通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A级条件。\n'Airflow direction test and visualisation.'可被翻译为：气流方向测试和可视化。\n'Airflows determined by air pressure difference profiles correlated with the heat distribution and penetration studies.'可被翻译为：通过与热分布和热渗透研究相关的空气压差曲线确定的气流。\n'The design of closed isolators should ensure grade A conditions with adequate protection for exposed products during processing. Airflow may not be fully unidirectional in closed isolators where simple operations are conducted. However, any turbulent airflow should not increase risk of contamination of the exposed product.\nWhere processing lines are included in closed isolators, grade A conditions should be ensured with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：封闭式隔离器的设计通过工艺过程中充分保护暴露产品保证 A 级条件。在进行简单操作的封闭式隔离器中，气流可能不是完全单向的。然而，任何湍流不应增加暴露产品的污染风险。当生产线包含在封闭式隔离器中时，应通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A 级条件。\n\n根据上述已知信息，请将'Airflow pattern studies should be performed at the interfaces of open isolators to demonstrate the absence of air ingress.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应在开放式隔离器的接口处进行气流流型研究，以证明没有空气进入。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on the Revision of the Package Insert of the Propranolol Tablets'可被翻译为：国家药监局关于修订普萘洛尔片剂说明书的公告\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of[Adverse reactions], [Contraindications]and [Precautions] in the package inserts of Metoclopramide. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对甲氧氯普胺说明书【不良反应】、【禁忌】、【注意事项】等项目进行统一修订。现将有关事项公告如下：\n'In accordance with the results of adverse drug reaction assessment, to further guarantee the safety of people in the use of drug, the NMPA decided to revise such items as [Adverse reactions], [Contraindications]and [Precautions] in the package inserts of antiviral syrup, capsules, soft capsules, pills(concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid, and granules. The relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。现将有关事项公告如下：\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对注射用生长抑素说明书【不良反应】、【注意事项】、【药物相互作用】等项目进行统一修订。现将有关事项公告如下：\n\n根据上述已知信息，请将'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Precautions]in the package inserts of propranolol tablets. Relevant issues are hereby announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对普萘洛尔片剂说明书【注意事项】等项目进行统一修订。现将有关事项公告如下："
    },
    {
        "instruction":"已知信息：\n'Article 10 The people's governments at or above the county level shall incorporate the work of drug safety into the economic and social development plans of the people at their levels, and include funds for drug safety in their government budgets, strengthen the capacity-building of drug administration, and provide safeguards for drug safety work.'可被翻译为：第十条 县级以上人民政府应当将药品安全工作纳入本级国民经济和社会发展规划，将药品安全工作经费列入本级政府预算，加强药品监督管理能力建设，为药品安全工作提供保障。\n'Article 5 The State encourages research and development of new drugs, and protects the legitimate rights and interests of citizens, legal bodies and other institutions in research and development of new drugs.'可被翻译为：第五条 国家鼓励研究和创制新药，保护公民、法人和其他组织研究、开发新药的合法权益。\n'Article 9 The local people's governments at or above the county level shall be responsible for the work of drug administration in their administrative areas. They shall lead, organize, and coordinate the work of drug administration within their respective administrative areas as well as the response to drug safety emergencies. They shall establish and improve the drug administration work mechanism and an information-sharing system.'可被翻译为：第九条 县级以上地方人民政府对本行政区域内的药品监督管理工作负责，统一领导、组织、协调本行政区域内的药品监督管理工作以及药品安全突发事件应对工作，建立健全药品监督管理工作机制和信息共享机制。\n'Article 1 In order to strengthen the supervision and administration of drug manufacturing and standardize drug manufacturing activities, these Provisions has been formulated according to laws and administrative regulations, such as the Drug Administration Law of the People's Republic of China (hereinafter referred to as the \"Drug Administration Law\"), Traditional Chinese Medicine Law of the People's Republic of China, Vaccine Administration Law of the People's Republic of China (hereinafter referred to as the \"Vaccine Administration Law\"), Administrative Licensing Law of the People's Republic of China and Regulations for Implementation of Drug Administration Law of the People's Republic of China.'可被翻译为：第一条 为加强药品生产监督管理，规范药品生产活动，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）、《中华人民共和国中医药法》、《中华人民共和国疫苗管理法》（以下简称《疫苗管理法》）、《中华人民共和国行政许可法》、《中华人民共和国药品管理法实施条例》等法律、行政法规，制定本办法。\n\n根据上述已知信息，请将'Article 15 Entities and individuals that have made significant contributions to drug development, manufacturing, distribution, use and supervision and administration shall be commended and rewarded by the people's government and its relevant departments at or above the county level in accordance with the relevant provisions of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 县级以上人民政府及其有关部门对在药品研制、生产、经营、使用和监督管理工作中做出突出贡献的单位和个人，按照国家有关规定给予表彰、奖励。"
    },
    {
        "instruction":"已知信息：\n'Different forms of administration prepared to suit therapeutic or preventive needs.'可被翻译为：为适应治疗或预防的需要而制备的不同给药形式。\n'The different forms of administration of a drug used in the prevention and treatment of a disease are new forms of a drug that have a certain function.'可被翻译为：在防治疾病的过程中所采用的药物的不同给药形式，是具有某种功能的药物新剂型。\n'The selection or adjustment of therapeutic drugs, dosage, usage, frequency of administration and course of administration according to the patient's condition and individual situation.'可被翻译为：针对患者的病情和个体化情况所选择或调整的治疗药物、剂量、用法、给药频次及给药疗程。\n'When preparing drug preparations, medical institutions shall perform their duties in accordance with the approved process, and the required active drug ingredients, excipients, and packaging materials shall comply with medicinal requirements.'可被翻译为：医疗机构配制制剂，应当按照经核准的工艺进行，所需的原料、辅料和包装材料等应当符合药用要求。\n\n根据上述已知信息，请将'Specific varieties of different forms of administration prepared to meet the needs of treatment or prevention in accordance with the standards approved by the pharmacopoeia or the pharmaceutical administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药典或药政管理部门批准的标准，为适应治疗或预防的需要而制备的不同给药形式的具体品种。"
    },
    {
        "instruction":"已知信息：\n'Article 81 Enterprises shall keep inventory records, and in a timely manner warehouse and register the drugs that are qualified in the acceptance inspection; those failed in the acceptance inspection shall not be warehoused and shall be instead handled by the quality management department.'可被翻译为：第八十一条 企业应当建立库存记录，验收合格的药品应当及时入库登记；验收不合格的，不得入库，并由质量管理部门处理。\n'Article 39 Enterprises shall establish records related to drug purchase, acceptance inspection, maintenance, sales, ex-warehousing check, return after sales and return after purchase, transportation, temperature and humidity monitoring during storage and transportation, and disposal of unqualified drugs and make them authentic, complete, accurate, effective and traceable.'可被翻译为：第三十九条 企业应当建立药品采购、验收、养护、销售、出库复核、销后退回和购进退出、运输、储运温湿度监测、不合格药品处理等相关记录，做到真实、完整、准确、有效和可追溯。\n'Article 72 Enterprises shall, in accordance with the prescribed procedures and requirements, receive and inspect the arrived drugs lot by lot, so as to prevent unqualified drugs from being warehoused.'可被翻译为：第七十二条 企业应当按照规定的程序和要求对到货药品逐批进行收货、验收，防止不合格药品入库。\n'Article 91 Invoices shall be truthfully issued for drugs sold by enterprises, ensuring the consistency among invoice, accounts, goods and amount.'可被翻译为：第九十一条 企业销售药品，应当如实开具发票，做到票、账、货、款一致。\n\n根据上述已知信息，请将'Article 88 Enterprises shall periodically carry out inventory check of drugs and ensure consistency between the accounts and goods.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十八条 企业应当对库存药品定期盘点，做到账、货相符。"
    },
    {
        "instruction":"已知信息：\n'multicomponent spectrophotometry'可被翻译为：多组分光谱分析\n'A method for simultaneous determination of multicomponent mixtures. When the absorption curves of components A and B have first order absorption points, the determination using the wavelength at which these absorption points are located simplifies the processing of the results.'可被翻译为：用于同时测定多组分混合物的一种方法。当组分A和B的吸收曲线有一等吸收点时,利用此等吸收点所处的波长进行测定，可简化结果处理。\n'A spectrophotometric method for calculating the elimination of coexisting components by selecting three suitable wavelengths.'可被翻译为：一种通过选择3个合适的波长，经过计算消除共存组分的分光光度法。\n'The qualitative and quantitative analysis of a chemical substance is carried out by using some corresponding quantitative relationship between a physical or chemical signal and a substance to be measured in the analysis system.'可被翻译为：利用某一物理或化学信号与分析体系中某一待测物质存在的某种对应数量关系，对该化学物质进行定性、定量分析。\n\n根据上述已知信息，请将'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'When the availability of a given dosage form of a drug is calculated at 100%, the percentage of other dosage forms of that drug that are absorbed at the same dose.'可被翻译为：某药物指定剂型的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。\n'A drug dose that is often repeated or continuously injected intravenously in order to maintain a steady-state blood drug concentration within the therapeutic range.'可被翻译为：在治疗范围内为维持稳态血药浓度，常多次重复服用或连续静脉滴注的药物剂量。\n'The degree to which the drug is absorbed into the body after oral administration.'可被翻译为：口服给药后药物在机体中被吸收的程度。\n'The drug contains the same active ingredient in the same concentration, dosage form, and route of administration.'可被翻译为：药品含有相同的活性成分并且浓度、剂型及给药途径也相同。\n\n根据上述已知信息，请将'The percentage of other dosage forms of a drug that can be absorbed at the same dose when the intravenous availability of a drug is calculated at 100%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某药物静脉注射的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。"
    },
    {
        "instruction":"已知信息：\n'3. The preparation, storage and use of the laboratory reagents, solutions and culture media should follow the relevant requirements or instructions. In special cases, the laboratory reagents should be identified or tested upon reception or before use.'可被翻译为：（三）应当按照相关规定或使用说明配制、贮存和使用试剂、试液和培养基。特殊情况下，在接收或使用前，还应当对试剂进行鉴别或其他检验。\n'The procedure requires that the test be conducted with a suitable volume of product. It is advisable to begin with at least 20 mL of product. Use the original product containers whenever possible or five sterile, capped bacteriological containers of suitable size into which a suitable volume of product has been transferred. If the diluted product exhibits antimicrobial properties, specific neutralizers may need to be incorporated into the diluents or the recovery media. For purposes of testing, products have been divided into four categories:'可被翻译为：程序要求用适量产品来进行测试，建议从至少20mL的产品开始。尽可能使用原来的产品容器， 或将合适体积的产品转移到 5 个合适尺寸的无菌细菌学容器。如果稀释的产品表现出抑菌性能， 则可能需要将特定的中和剂掺入稀释剂或恢复培养基中。根据测试的目的，产品分为四类：\n'Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer.'可被翻译为：标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。\n'In volumetric analysis, a standard solution of known accurate concentrations used for sample determination.'可被翻译为：在容量分析中，用于样品测定的已知准确浓度的标准溶液。\n\n根据上述已知信息，请将'8. Laboratory volumetric glassware, reagents, solutions, reference standards and culture media should be tested;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）应当对实验室容量分析用玻璃仪器、试剂、试液、对照品以及培养基进行质量检查。"
    },
    {
        "instruction":"已知信息：\n'1. The review and approval of master manufacturing documents, procedures, etc;'可被翻译为：（一）审核和批准产品的工艺规程、操作规程等文件；\n'project management (for the review process)'可被翻译为：项目管理(用于审核过程)\n'(ii) A review of critical in-process controls and finished product results;'可被翻译为：(ii)对关键过程控制和成品检验结果进行回顾；\n'management review'可被翻译为：管理评审\n\n根据上述已知信息，请将'(2) Management for review of the product formula, manufacturing process and material supplier, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）产品配方、生产工艺、物料供应商等的审核管理；"
    },
    {
        "instruction":"已知信息：\n'A solid substance that effectively adsorbs some of its components from a gas or liquid.'可被翻译为：能有效地从气体或液体中吸附其中某些成分的固体物质。\n'adsorption'可被翻译为：吸附\n'The phenomenon in which the surface of a substance (mainly a solid substance) absorbs molecules or ions in the surrounding medium (liquid or gas).'可被翻译为：物质（主要是固体物质）表面吸住周围介质（液体或气体）中的分子或离子现象。\n'The  interaction  between  the  product  and  product  contact  surface  (such  as  adsorption,  or  leachables  and extractables).'可被翻译为：产品与产品接触表面之间的相互作用（例如吸附，或浸出物&溶出物）。\n\n根据上述已知信息，请将'A substance adsorbed from a solution or gas phase to the surface of another substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从溶液或气相中被吸附至另一物质表面的物质。"
    },
    {
        "instruction":"已知信息：\n'The phenomenon of having some genes from one parent and some genes from a descendant of a different parent. The combination of genes in a recombinant offspring is different from that of either parent. Higher organisms can recombine by free combination or exchange. Lower organisms may recombine by transformation, conjugation, or transduction.'可被翻译为：产生出部分基因来自一个亲本、部分基因来自遗传性不同的另一个亲本的后代的现象。重组后代的基因组合不同于双亲中的任何一个。高等生物可以用自由结合或者交换的方法进行重组。低等生物可以用转化、接合或者转导的方法进行重组。\n'An autonomously replicating, circular, extrachromosomal DNA element. It usually carries a few genes, some of which confer resistance to various antibiotics; such resistance is often used to discriminate between organisms that contain the plasmid and those that do not.'可被翻译为：一种自主复制的圆形染色体外DNA元件。它通常携带几个基因，其中一些基因赋予了对各种抗生素的抗性;这种耐药性通常被用来区分含有质粒和不含质粒的生物体。\n'The process by which a change in the structure of a gene results in a stable, heritable change in the genotype of a cell, virus, or microbe.'可被翻译为：基因的结构发生改变而导致细胞、病毒或微生物的基因型发生稳定的、可遗传的变化的过程。\n'(1) Groups of individuals or genetically identical organisms derived from a common ancestor, producing the same molecules (DNA, RNA), cells through asexual reproduction. (2) Also known as an \"asexual line\". A group of molecules, cells, or individuals of identical genetic makeup and their constituent parts. (3) The process of inserting a specific gene or DNA sequence into a carrier molecule using in vitro recombination technology.'可被翻译为：（1）来自同一个祖先、经过无性繁殖所产生相同的分子（DNA、RNA）、细胞的群体或遗传学上相同生物个体。（2）又称\"无性繁殖系”。遗传组成完全相同的分子、细胞或个体及其组成的一个群体。（3）利用体外重组技术将某特定的基因或DNA序列插入载体分子的操作过程。\n\n根据上述已知信息，请将'Also known as \"free genes\". A genetic structure that exists in a cell either in a free state or in conjunction with a chromosome. Their presence confers certain genetic traits on the cell, but their absence does not cause the cell to die.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"游离基因\"。在细胞中或以游离态、或以与染色体相结合的状态存在着的遗传结构。其存在给细胞带来一定的遗传性状，但它们的缺失并不会造成细胞的死亡。"
    },
    {
        "instruction":"已知信息：\n'A substance that changes an enzyme from inactive to active or increases its activity.'可被翻译为：使酶从无活性变为有活性或使酶活性增加的物质。\n'The part of an enzyme molecule that causes a chemical change in the substrate.'可被翻译为：酶分子中促使底物发生化学变化的部位。\n'A substance that acts on or affects the active center or essential group of an enzyme, resulting in the decrease or loss of enzyme activity and thus reducing the rate of enzymatic reaction. Can be divided into reversible inhibitors and irreversible inhibitors.'可被翻译为：作用于或影响酶的活性中心或必需基团导致酶活性下降或丧失而降低酶促反应速率的物质。可分为可逆抑制剂和不可逆抑制剂。\n'Any of several organic substances of small molecular weight that are loosely bound to enzyme proteins and are essential for catalytic activity.'可被翻译为：某些为催化活性所必需的、与酶蛋白疏松结合的小分子量的有机物质。\n\n根据上述已知信息，请将'A non-protein component of an enzyme required for its activity. It can promote the activation of enzymes and reactants, and can be divided into coenzymes and coenzymes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种酶的活性所需要的一种非蛋白质成分。能促进酶及反应物进入活化状态，分辅基和辅酶。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Article 66 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十六条 体外诊断试剂延续注册申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Article 56 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十六条 医疗器械延续注册申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Chapter VI Acceptance and Withdrawal of Application, Decision of Review and Dispute Resolution'可被翻译为：第六章 受理、撤回申请、审批决定和争议解决\n\n根据上述已知信息，请将'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；\n'(II) Failing to be equipped with the organization and personnel corresponding to the products to carry out the relevant medical device adverse event monitoring work as required;'可被翻译为：（二）未按照要求配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作的；\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n'(I)  Establishing a medical device quality management system that incorporates medical device adverse event monitoring and re-evaluation working mechanism;'可被翻译为：（一）建立包括医疗器械不良事件监测和再评价工作制度的医疗器械质量管理体系；\n\n根据上述已知信息，请将'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'Article 61 Purchase activities of an enterprise shall meet the following requirements:'可被翻译为：第六十一条 企业的采购活动应当符合以下要求：\n'Article 169 Dispensing sales of drugs shall meet the following requirements:'可被翻译为：第一百六十九条 药品拆零销售应当符合以下要求：\n'Article 165: Specifications for materials should include, if applicable:'可被翻译为：第一百六十五条 物料的质量标准一般应当包括：\n'Article 164: There should be appropriately authorized and dated specifications for materials and finished products; where appropriate, they should be also available for intermediate or bulk products.'可被翻译为：第一百六十四条 物料和成品应当有经批准的现行质量标准；必要时，中间产品或待包装产品也应当有质量标准。\n\n根据上述已知信息，请将'Article 161 The display of products shall meet the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十一条 药品的陈列应当符合以下要求："
    },
    {
        "instruction":"已知信息：\n'Article 197: Measures should be taken to avoid, as far as possible, contamination and cross-contamination during production, for example:'可被翻译为：第一百九十七条 生产过程中应当尽可能采取措施，防止污染和交叉污染，如：\n'12.40. To minimize the risk of contamination and cross-contamination, adequate cleaning procedures should be followed.'可被翻译为：为尽可能降低污染和交叉污染的风险，应严格遵守清洁程序。\n'Article 76: Appropriate washing and cleaning equipment should be chosen and used in order not to be a source of contamination.'可被翻译为：第七十六条 应当选择适当的清洗、清洁设备，并防止这类设备成为污染源。\n'Article 71: The design, selection, installation, adaption and maintenance of equipment should be suitable for its intended use, minimize the risk of contamination, cross-contamination, mixups or errors, and facilitate operation, cleaning, maintenance, as well as disinfection or sterilization if necessary.'可被翻译为：第七十一条 设备的设计、选型、安装、改造和维护必须符合预定用途，应当尽可能降低产生污染、交叉污染、混淆和差错的风险，便于操作、清洁、维护，以及必要时进行的消毒或灭菌。\n\n根据上述已知信息，请将'Article 198: Measures to prevent contamination and cross-contamination should be checked regularly and evaluated for their suitability and effectiveness.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百九十八条 应当定期检查防止污染和交叉污染的措施并评估其适用性和有效性。"
    },
    {
        "instruction":"已知信息：\n'In case of identifying or knowing any suspected medical device adverse event, medical device distributing enterprises, user facility shall promptly notify MAHs. Any event causing death shall be reported within 7 days and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days through the National Medical Device Adverse Events Monitoring Information System.'可被翻译为：医疗器械经营企业、使用单位发现或者获知可疑医疗器械不良事件的，应当及时告知持有人。其中，导致死亡的还应当在7日内，导致严重伤害、可能导致严重伤害或者死亡的在20日内，通过国家医疗器械不良事件监测信息系统报告。\n'Article 29 After reporting medical device adverse events or knowing relevant medical device adverse events through the National Medical Device Adverse Events Monitoring Information System, MAHs shall carry out subsequent investigation, analysis and evaluation as required. The evaluation results of the events causing death shall be reported to local provincial monitoring agencies where MAHs locate within 30 days and the evaluation results of the events causing severe injuries or possibly causing severe injuries or death shall be reported to local provincial monitoring agencies where MAHs locate within 45 days. If the MAH has any new identification or notification of event information and evaluation results, it shall submit a supplementary report as required.'可被翻译为：第二十九条  持有人在报告医疗器械不良事件后或者通过国家医疗器械不良事件监测信息系统获知相关医疗器械不良事件后，应当按要求开展后续调查、分析和评价，导致死亡的事件应当在30日内，导致严重伤害、可能导致严重伤害或者死亡的事件应当在45日内向持有人所在地省级监测机构报告评价结果。对于事件情况和评价结果有新的发现或者认知的，应当补充报告。\n'Article 27 The overseas MAHs of imported medical devices and the MAHs exporting domestic medical devices abroad shall voluntarily collect the adverse events of the products occurred abroad. For the adverse events causing or possibly causing severe injuries or death, the agents designated by overseas MAHs and the MAHs of domestically-produced medical devices shall report within 30 days upon the date of identification or notification.'可被翻译为：第二十七条  进口医疗器械的境外持有人和在境外销售国产医疗器械的持有人，应当主动收集其产品在境外发生的医疗器械不良事件。其中，导致或者可能导致严重伤害或者死亡的，境外持有人指定的代理人和国产医疗器械持有人应当自发现或者获知之日起30日内报告。\n'Article 26 In case of identifying any medical device adverse event causing or possibly causing severe injuries or death, other units and individuals other than MAHs, distributing enterprises and user facility shall  report to either monitoring agencies or MAHs, distributing enterprises or the medical institutions providing treatment, and provide relevant medical records if necessary.'可被翻译为：第二十六条  除持有人、经营企业、使用单位以外的其他单位和个人发现导致或者可能导致严重伤害或者死亡的医疗器械不良事件的，可以向监测机构报告，也可以向持有人、经营企业或者经治的医疗机构报告，必要时提供相关的病历资料。\n\n根据上述已知信息，请将'Article 25 In case of identifying or knowing any suspected medical device adverse event, MAHs shall immediately investigate the cause. Any event causing death shall be reported within 7 days; and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条  持有人发现或者获知可疑医疗器械不良事件的，应当立即调查原因，导致死亡的应当在7日内报告；导致严重伤害、可能导致严重伤害或者死亡的应当在20日内报告。"
    },
    {
        "instruction":"已知信息：\n'excipient'可被翻译为：贝武形剂\n'Name and Dosages Form of the Product'可被翻译为：产品名称与剂型\n'A solid preparation made of drugs and excipients filled in hollow capsules in an appropriate form.'可被翻译为：药物及辅料以适当形式填装于空心胶囊中制成的固体制剂。\n'A pharmaceutical product type that contains a drug substance, generally, in association with excipients.'可被翻译为：含有原液并通常与辅料放在一起的一种药品类型。\n\n根据上述已知信息，请将'For complete composition including excipients, see attached[Not disclosed to the public]'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"包括辅料在内的完整处方组成（可附表）[不对外公开]"
    },
    {
        "instruction":"已知信息：\n'It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).'可被翻译为：确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。\n'The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with\ndirect or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and\nperformed in grade A with a grade B background. Where an isolator is used, the background should be in\naccordance with paragraph 4.20'可被翻译为：与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定\n'Aseptic manipulations (including non-intrinsic sterile connection devices) should be minimized through the\nuse of engineering design solutions such as preassembled and sterilised equipment. Whenever feasible, product\ncontact piping and equipment should be pre-assembled, and sterilised in place.'可被翻译为：应通过使用预装配并灭菌的设备等工程设计方案，尽量减少无菌操作（包括非固有无菌连接装置）。与产品接触的管道和设备应尽可能预装配并在线灭菌。\n'For materials, equipment, components and ancillary items that are not a direct or indirect product contact part\nand are necessary for aseptic processing but cannot be sterilised, an effective and validated disinfection and\ntransfer process should be in place. These items, once disinfected, should be protected to prevent recontamination.\nThese items, and others representing potential routes of contamination, should be included in the environmental\nmonitoring programme.'可被翻译为：对于不直接或间接接触产品，并且是无菌工艺所必需但不能灭菌的物料、设备、组件和辅助用品，应建立有效且经验证的消毒和转移程序。消毒后应采取保护措施，防止物品再污染。这些物品以及代表潜在污染途径的其它因素应包含在环境监测计划中。\n\n根据上述已知信息，请将'For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the product passes through, such as filling needles or pumps. Indirect product contact parts are equipment parts that do not contact the product, but may come into contact with other sterilised surfaces, the\nsterility of which is critical to the overall product sterility (e.g. sterilised items such as stopper bowls and guides, and sterilised components).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于无菌工艺，直接和间接接触产品的部件应进行灭菌。直接接触产品的部件是指产品通过的部件，例如灌装针或泵。间接接触产品的部件是不接触产品的设备部件，但可能与其它灭菌表面接触，其无菌性对整个产品的无菌性至关重要（例如胶塞桶和导槽等已灭菌物品，以及已灭菌组件）。"
    },
    {
        "instruction":"已知信息：\n'In order to implement the E2B (R3) Regional Implementation Guide for Individual Case Safety Reports (hereinafter referred to as the Regional Implementation Guide), the Center for Drug Evaluation has completed the upgrade of the pharmacovigilance system during clinical trials, which was put into trial operation on January 1, 2022. Applicants shall complete the system configuration in a timely manner, and implement E2B(R3) in accordance with the Regional Implementation Guide no later than July 1,2022.'可被翻译为：为实施《个例安全性报告E2B(R3)区域实施指南》（以下简称区域实施指南），药审中心已完成对临床试验期间药物警戒系统升级改造，已于2022年1月1日上线试运行。申请人应及时完成系统配置,并按照区域实施指南要求实施E2B(R3),时间不得晚于2022年7月1日。\n'Thirdly, the construction of standards is strengthened, and the transformation and implementation of ICH related guidance is promoted. The Guidance for Clinical Safety Literature Evaluation of Marketed Drugs(Interim) and Guidance for Compiling the Annual Pharmacovigilance Report by Marketing Authorization Holders (Interim) were issued to guide MAHs in monitoring, reporting, analysis and evaluation. We steadily promoted the transformation and implementation of E2B (R3: Clinical Safety Data Management - Data Elements for Transmission of Individual Case Safety Reports) of ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), and released the Regional Implementation Guidance for Individual Case Safety Reports E2B(R3). We promoted the application of the Medical Dictionary for Regulatory Activities(MedDRA), carried out disease term mapping research, strengthened the training for MAHs and monitoring institutions, and provide technical guarantee for full swing of ICH related Guidance.'可被翻译为：三是强化规范建设，推进ICH 相关指导原则转化实施。发布《上市药品临床安全性文献评价指导原则（试行）》《药品上市许可持有人药物警戒年度报告撰写指南（试行）》，指导持有人开展监测、报告、分析和评价工作。稳步推进国际人用药品注册技术协调会（ICH）E2B（R3）转化实施，发布《个例安全性报告E2B（R3）区域实施指南》；促进监管活动医学词典（MedDRA）应用，开展疾病术语映射研究，加强对持有人和监测机构的培训，为全面实施ICH相关指导原则提供技术保障。\n'I. The guidelines below shall be adopted from the issue date of this Announcement: E2F: Development Safety Update Report and E2F: Example DSUR – Phase III Investigational Drug，E5 (R1): Ethnic Factors in the Acceptability of Foreign Clinical Data and E5 Q&A (R1) and E17: General Principle on Planning and Designing Multi-Regional Clinical Trials.'可被翻译为：一、本公告发布之日起适用《E2F：研发期间安全性更新报告》及《E2F示例》、《E5（R1）：接受国外临床试验数据的种族因素》及《E5问答（R1）》和《E17：多区域临床试验计划与设计的一般原则》。\n'NMPA Promulgated the Guidelines for Clinical Safety Literature Evaluation of Marketed Drugs (Interim)'可被翻译为：国家药监局发布《上市药品临床安全性文献评价指导原则（试行）》\n\n根据上述已知信息，请将'Notice of the Center for Drug Evaluation of NMPA on the Applicability of E2B (R3) Regional Implementation Guide to Individual Case Safety Reports during Drug Clinical Trials'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心药物临床试验期间个例安全性报告适用E2B(R3)区域实施指南的通知"
    },
    {
        "instruction":"已知信息：\n'Section 5 Facilities and Equipment'可被翻译为：第五节 设施与设备\n'(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;'可被翻译为：（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；\n'Chapter 5 Equipment'可被翻译为：第五章 设  备\n'a detailed description of facility requirements and equipment;'可被翻译为：详细的场所和设备要求描述；\n\n根据上述已知信息，请将'(5) the list of main facilities and equipment for distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）主要经营设施、设备目录；"
    },
    {
        "instruction":"已知信息：\n'good review practices (grevp)'可被翻译为：良好审查做法(GRevP)\n'The planning, organization and resources to achieve a complete and high quality review of an application within a specified time frame.'可被翻译为：在规定的时间范围内对一个应用程序进行完整和高质量的审查的计划、组织和资源。\n'(I)Overview of accomplished review & approval'可被翻译为：（一）审评审批总体完成情况\n'review strategy'可被翻译为：复习策略\n\n根据上述已知信息，请将'The important GRevP elements for Ras to implement in order to achieve successful review outcomes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了获得成功的评审结果，Ras需要实施的重要GRevP元素。"
    },
    {
        "instruction":"已知信息：\n'1.7. A technology transfer should include relevant documentation, data, information and knowledge from the SU in order to enable the RU to effectively perform the specified process or procedure in, for example, production and QC. A successful transfer of technology should result in proof that the RU can routinely reproduce the transferred product, process or procedure against a predefined set of specifications as agreed between the SU and RU.'可被翻译为：技术转移应包括来自SU的相关文件、数据、信息和知识，使得RU能够有效实施指定的工艺或方法，例如生产和QC。成功的技术转移应证明RU可以常规化地按SU与RU之间预定的标准生产出所转移的产品、工艺或方法。\n'12.48. A technology transfer report should be prepared, based on the data and information obtained during the project. The supportive data should be kept and be accessible.'可被翻译为：应根据项目期间获得的数据和资料编写一份技术转让报告。支持性数据应保存并便于查阅。\n'technology transfer report. A documented summary of a specific technology transfer project listing procedures, acceptance criteria, results achieved and conclusions.'可被翻译为：技术转移报告：一份列出了程序、可接受标准、达成结果和结论的专用技术转移项目总结文件\n'5.16. The execution of the technology transfer project should be documented in a report which is supported by the relevant data.'可被翻译为：技术转移项目的执行应记录在一份报告中，并有相关数据支持。\n\n根据上述已知信息，请将'Records should be maintained for the activities performed during the technology transfer process (e.g. a technology transfer report). The report content should reflect the protocol and SOPs that were followed. The report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU, and the final conclusions of the transfer. Changes, deviations, investigations and relevant appropriate actions taken should be recorded. The SU should provide all the relevant supportive documents with data, results and other relevant information to facilitate a successful transfer of technology and also comparison of data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应保存技术转移过程中所执行活动的记录（例如，技术转移报告）。报告内容应反映出所遵守的方案和SOP。报告应总结转移的范围、SU和RU所得的关键参数，以及转移的最终结论。变更、偏差、调查和所采取的相关恰当措施均应有记录。SU应提供所有相关支持性文件及数据、结果和其它相关信息，以使得技术转移获得成功，同时还要对数据进行比较。"
    }
]